<SEC-DOCUMENT>0001019687-13-004492.txt : 20131119
<SEC-HEADER>0001019687-13-004492.hdr.sgml : 20131119
<ACCEPTANCE-DATETIME>20131119161234
ACCESSION NUMBER:		0001019687-13-004492
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131119
DATE AS OF CHANGE:		20131119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oculus Innovative Sciences, Inc.
		CENTRAL INDEX KEY:			0001367083
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680423298
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33216
		FILM NUMBER:		131230114

	BUSINESS ADDRESS:	
		STREET 1:		1129 N. MCDOWELL BLVD.
		CITY:			PETALUMA
		STATE:			CA
		ZIP:			94954
		BUSINESS PHONE:		707-782-0792

	MAIL ADDRESS:	
		STREET 1:		1129 N. MCDOWELL BLVD.
		CITY:			PETALUMA
		STATE:			CA
		ZIP:			94954
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>oculus_10q-093013.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 12pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Wingdings">&thorn;</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the quarterly period ended September 30, 2013</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>or</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 95%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to ___<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Commission File Number 001-33216</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-align: center; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>68-0423298</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.2pt 0 0; text-align: center">(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.2pt 0 0; text-align: center">incorporation&nbsp;or&nbsp;organization)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.2pt 0 0; text-align: center">(I.R.S&nbsp;Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 3.2pt 0 0; text-align: center">Identification&nbsp;No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>1129 North McDowell Blvd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Petaluma, CA 94954</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address of principal executive offices) (Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(707) 283-0550</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
&nbsp;No&nbsp; </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;No&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 45%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font: 10pt Wingdings 2">&pound;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 42%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated filer</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font: 10pt Wingdings 2">&pound;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font: 10pt Wingdings 2">&pound;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font: 10pt Wingdings">&thorn;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp; </FONT><FONT STYLE="font-family: Wingdings">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
&nbsp;No&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of November 15, 2013, the
number of shares outstanding of the registrant&rsquo;s common stock, $0.0001 par value, was 6,644,764.</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART I &mdash; FINANCIAL INFORMATION</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1. </B>Financial Statements</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Balance Sheets</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Comprehensive Loss</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Cash Flows</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes to Condensed Consolidated Financial Statements</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2. </B>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 3. </B>Quantitative and Qualitative Disclosures About Market Risk</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 4. </B>Controls and Procedures</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART II &mdash; OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1. </B>Legal Proceedings</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1A. </B>Risk Factors</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2. </B>Unregistered Sales of Equity Securities and Use of Proceeds</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 3. </B>Defaults Upon Senior Securities</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 4. </B>Mine Safety Disclosures (Not applicable.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 5. </B>Other Information</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 6. </B>Exhibits</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">32</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>PART I. FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1. Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(In thousands, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt; text-indent: -10pt">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt; width: 66%">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,190</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">7,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,424</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,707</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Inventories, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">749</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">992</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">549</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">935</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,912</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">987</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">159</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">187</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,882</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,565</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt; text-indent: -10pt">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">808</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">699</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Current portion of cash settlement liability (See Note 3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Current portion of long-term debt, net of debt discount of $430 (unaudited) and $521 at September 30, 2013 and March 31, 2013, respectively</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">573</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,259</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,127</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,619</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Long-term debt, net of debt discount of $45 (unaudited) and $248 at September 30, 2013 and March 31, 2013, respectively, less current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">519</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">676</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Cash settlement liability, less current portion (See Note 3)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">193</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,332</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,484</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Convertible preferred stock, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized, none issued and outstanding at September 30, 2013 (unaudited) and March 31, 2013,&nbsp;&nbsp;respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Common stock, $0.0001&nbsp;par value; 14,285,715&nbsp;shares authorized, 6,633,694 and 6,583,150&nbsp;shares issued and outstanding at September 30, 2013 (unaudited) and March 31, 2013, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,482</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,816</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,077</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,991</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(140,856</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(137,745</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,550</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,081</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,882</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,565</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">The accompanying footnotes are an integral
part of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Consolidated Statements of Comprehensive
Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(In thousands, except per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended<BR>
    September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended<BR> September
    30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 32%; text-indent: -10pt; padding-left: 20pt">Product</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,456</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,890</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">6,177</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">7,674</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Product licensing fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">830</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Service</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">236</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">454</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,089</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,526</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,461</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,577</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Cost of revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,080</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Service</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">181</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">332</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">413</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total cost of revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,384</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,326</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,493</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,705</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,045</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Selling, general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,093</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,504</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,351</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 30pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,017</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,302</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,396</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,271</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(817</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,397</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,312</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(188</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(280</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(438</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(568</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Gain (loss) due to change in fair value of common stock (See Note 3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(210</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">(Loss) gain due to change in fair value of derivative instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(397</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(39</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(67</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(46</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,399</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,519</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,111</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,074</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Preferred stock deemed dividend</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss available to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,399</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,519</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,111</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,136</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss per common share: basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.47</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.47</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Weighted-average number of shares used in per common share calculations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,631</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,659</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,625</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,587</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Other comprehensive loss, net of tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,399</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,519</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,111</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,074</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(86</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Other comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,386</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,400</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,197</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,075</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part
of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Condensed Consolidated Statements of Cash
Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(In thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months&nbsp;Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(3,111</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(1,074</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">941</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Change in fair value of derivative liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(850</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Loss due to change in fair value of common stock (See Note 3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Non-cash interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Foreign currency transaction gains</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(738</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(705</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Inventories, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Accrued expenses and other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Deferred revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(791</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,479</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net cash (used in) provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,454</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,292</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Purchases of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(338</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(62</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Long-term deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(143</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(312</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(205</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Proceeds from issuance of common stock, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,925</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Proceeds from the issuance of convertible preferred stock, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">907</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Proceeds from the exercise of common stock options and warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(780</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Principal payments on long-term debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net cash (used in) provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,918</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,874</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Effect of exchange rate on cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net (decrease) increase cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,710</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,959</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Cash and cash equivalents, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,351</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Cash and cash equivalents, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,190</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,310</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Supplemental disclosure of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">143</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">265</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Non-cash operating and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Warrants issued as derivative liabilities in connection with registered direct offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,347</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part
of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OCULUS INNOVATIVE SCIENCES, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Consolidated Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 1.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Organization and Summary of Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Organization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oculus Innovative Sciences, Inc. (the &ldquo;Company&rdquo;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of
Delaware in December 2006. The Company&rsquo;s principal office is located in Petaluma, California. The Company is a global healthcare
company that designs, produces, and markets prescription and non-prescription products in 27 countries. It is pioneering innovative
products for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets. The Company&rsquo;s primary
focus is on its proprietary technology platform called Microcyn&reg; Technology. This technology is based on electrically charged
oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens). Several Microcyn&reg;
Technology tissue care products are designed to treat infections and enhance healing while reducing the need for antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective as of the open of business on April
1, 2013, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every 7 shares of common
stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse
stock split. Instead, each resulting fractional share of common stock was rounded up to one whole share. The reverse stock split
reduced the number of shares of the Company&rsquo;s common stock outstanding from 46,080,513 to 6,583,150. The total number of
authorized shares of common stock was also proportionally decreased by a ratio of 1:7 and the par value per share of the common
stock continued to be $0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All common shares and per share amounts contained
in the condensed consolidated financial statements have been retroactively adjusted to reflect a 1 for 7 reverse stock split, effective
April 1, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed
consolidated financial statements as of September 30, 2013 and for the three and six months then ended have been prepared in
accordance with the accounting principles generally accepted in the United States of America for interim financial
information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange
Commission (&ldquo;SEC&rdquo;) and on the same basis as the Company prepares its annual audited consolidated financial
statements. The unaudited condensed consolidated balance sheet as of September 30, 2013, the condensed consolidated
statements of comprehensive loss for the three and six months ended September 30, 2013 and 2012, and the condensed
consolidated statements of cash flows for the six months ended September 30, 2013 and 2012 are unaudited, but include all
adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation
of the financial position, operating results and cash flows for the periods presented. The results for the three and six
months ended September 30, 2013 are not necessarily indicative of results to be expected for the year ending March 31, 2014
or for any future interim period. The condensed consolidated balance sheet at March 31, 2013 has been derived from audited
consolidated financial statements. However, it does not include all of the information and notes required by accounting
principles generally accepted in the United States of America for complete consolidated financial statements.
The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements for the year ended March 31, 2013, and notes thereto included in the Company&rsquo;s annual report on Form 10-K,
which was filed with the SEC on June 25, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries, Aquamed Technologies, Inc. (&ldquo;Aquamed&rdquo;), Oculus
Technologies of Mexico S.A. de C.V. and Oculus Innovative Sciences Netherlands, B.V. and Ruthigen, Inc. (&ldquo;Ruthigen&rdquo;).
All significant intercompany accounts and transactions have been eliminated in consolidation. Aquamed has no current operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities
at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs
related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company&rsquo;s
deferred taxes,&nbsp;the valuation of equity and derivative instruments, and debt discounts and the estimated amortization periods
of upfront licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. The allowance
for uncollectible accounts receivable balances amounted to $9,000 and $22,000, which are included in accounts receivable, net in
the accompanying September 30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively. The reserve for excess
and obsolete inventory balances amounted to $76,000 and $170,000, which are included in inventories, net in the accompanying September
30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified
for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the Company&rsquo;s
previously reported net loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Net Loss per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for
the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include
the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the
&ldquo;treasury stock&rdquo; and/or &ldquo;if converted&rdquo; methods as applicable. The computation of basic net loss per share
for the three and six months ended September 30, 2013 and 2012 (adjusted if applicable for the reverse stock split effective April
1, 2013) excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options to purchase common stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">1,229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">988</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Warrants to purchase common stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,547</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,517</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Common Stock Purchase Warrants and Other Derivative Financial
Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies common stock purchase
warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or
net-share settlement, or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement
or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to
net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty
a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions
as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to
determine whether a change in classification between assets and liabilities is required. The Company determined that its freestanding
derivatives, which principally consist of warrants to purchase common stock, satisfied the criteria for classification as equity
instruments at September 30, 2013, other than certain warrants that contain reset provisions and certain warrants that require
net-cash settlement that the Company classified as derivative liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value of Financial Assets and Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable, inventory, accounts payable and accrued liabilities are carried at cost, which management believes
approximates fair value due to the short-term nature of these instruments. The fair value of capital lease obligations and equipment
loans approximates their carrying amounts as a market rate of interest is attached to their repayment. The Company measures the
fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable
inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&nbsp;1&nbsp;&mdash;
quoted prices in active markets for identical assets or liabilities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&nbsp;2&nbsp;&mdash;
quoted prices for similar assets and liabilities in active markets or inputs that are observable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&nbsp;3&nbsp;&mdash;
inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Financial liabilities measured at fair value on a recurring basis
are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities. For
fair value measurements categorized within Level 3 of the fair value hierarchy, the Company&rsquo;s accounting and finance department,
who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of
the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company&rsquo;s
accounting and finance department and are approved by the Chief Financial Officer.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Level 3 Valuation Techniques</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 financial liabilities consist of the
derivative liabilities for which there is no current market for these securities such that the determination of fair value requires
significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are
analyzed each period based on changes in estimates or assumptions and recorded as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option valuation
model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates transaction
details such as the Company&rsquo;s stock price, contractual terms, maturity, risk free rates, as well as volatility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A significant decrease in the volatility or
a significant decrease in the Company&rsquo;s stock price, in isolation, would result in a significantly lower fair value measurement.
Changes in the values of the derivative liabilities are recorded in &ldquo;(Loss) gain due to change in fair value of derivative
instruments&rdquo; in the Company&rsquo;s condensed consolidated statements of comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2013, there were no transfers
in or out of Level 3 from other levels in the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Subsequent Events</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events
or transactions occurring through the date the condensed consolidated financial statements were issued (Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2011-05, <I>Comprehensive Income (Topic 220):
Presentation of Comprehensive Income</I>. This guidance improves the comparability, consistency and transparency of financial reporting
and increases the prominence of items reported in other comprehensive income.&nbsp; In December 2011, the FASB issued ASU No. 2011-12,
<I>Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive
Income in ASU 2011-05</I>. ASU 2011-12 defers the requirement that companies present reclassification adjustments for each component
of Accumulated Other Comprehensive Income in both net income and Other Comprehensive Income on the face of the financial statements.
All other requirements in ASU No. 2011-05 are not affected by ASU No. 2011-12, including the requirement to report comprehensive
income either in a single continuous financial statement or in two separate but consecutive financial statements.&nbsp; While the
adoption of this standard required the Company to change the format of its condensed consolidated financial statements, it did
not have a material impact on the Company&rsquo;s consolidated financial position and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB has issued ASU No. 2013-11, <I>Income
Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or
a Tax Credit Carryforward Exists</I> (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that
an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a
reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except
as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available
at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result
from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and
the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in
the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective
for fiscal years, and interim periods within those years, beginning after <FONT STYLE="color: black">December 15, 2013</FONT>.
For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after
<FONT STYLE="color: black">December 15, 2014</FONT>. Early adoption is permitted. The amendments should be applied prospectively
to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this
standard is not expected to have a material impact on the Company&rsquo;s condensed consolidated financial position and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards that have been issued
or proposed by the FASB, SEC and/or other standards-setting bodies that do not require adoption until a future date are not expected
to have a material impact on the condensed consolidated financial statements upon adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 2.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liquidity and Financial Condition</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reported a net loss
of $3,111,000 for the six months ended September 30, 2013. At September 30, 2013 and March 31, 2013, the
Company&rsquo;s accumulated deficit amounted to $140,856,000 and $137,745,000, respectively. The Company had working capital
of $2,175,000 and $6,407,000 as of September 30, 2013 and March 31, 2013, respectively. The Company expects the need to raise
additional capital from external sources in order to continue the longer term efforts contemplated under its business plan
and repay its outstanding notes payable obligations. The Company expects to continue incurring losses for the foreseeable
future and may need to raise additional capital to pursue its product development initiatives, penetrate markets for the sale
of its products and continue as a going concern. Upon the closing of the intended initial public offering by the
Company&rsquo;s subsidiary, Ruthigen, Inc., the Company will be repaid for certain costs incurred and advanced related to
Ruthigen&rsquo;s initial public offering and certain other agreed-upon expenses, pursuant to the terms of the separation
agreement the Company entered into with Ruthigen (See Note 4). At September 30, 2013, these costs amounted to $911,000, of
which $824,000 is reported as deferred offering costs in the accompanying condensed consolidated balance sheet and $87,000
was reported as selling, general and administrative expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently anticipates that
its cash and cash equivalents will be sufficient to meet its working capital requirements to continue its sales and marketing
and research and development efforts through at least October 1, 2014. However, in order to execute the Company&rsquo;s
long-term Microcyn&reg; product development strategy and to penetrate new and existing markets, the Company may need to raise
additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and
potentially reduce operating expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the Company has
access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or
other means; however, the Company has not secured any commitment for new financing at this time, nor can it provide any
assurance that the Ruthigen initial public offering will be completed or that other new financings will be available on
commercially acceptable terms, if needed. If the Company is unable to secure additional capital, it may be required to
curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its
cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 3.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Condensed Consolidated Balance Sheets</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Inventories</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories consisted of the following (in
thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Raw materials</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">835</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,162</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: inventory allowances</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(76</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">749</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">992</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Notes Payable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Venture Lending &amp; Leasing&nbsp;V, Inc.
and Venture Lending &amp; Leasing&nbsp;VI, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2010, the Company entered into a
loan and security agreement and a supplement to the loan and security agreement with Venture Lending &amp; Leasing V, Inc. (&ldquo;VLL5&rdquo;)
to borrow up to an aggregate of $3,000,000 (collectively, the &ldquo;VLL5 Agreements&rdquo;). On May 3, 2010, the Company borrowed
$2,000,000 on the first tranche and on November 17, 2010, the Company borrowed $1,000,000 on the second tranche.&nbsp;&nbsp;The
loan is secured by all assets of the Company excluding intellectual property under certain circumstances. Related to the first
tranche, the Company made eight monthly interest-only payments of $16,660 through December 1, 2010. Thereafter, the Company made
interest and principal payments of $75,000 per month through June 1, 2013. Related to the second tranche, the Company paid monthly
interest only payments of $8,330 through May 1, 2012. Thereafter, the Company made interest and principal payments of $37,500 per
month through November 1, 2013. The Company made a final balloon payment related to the first tranche of $132,000 prior to the
June 1, 2013 deadline, and made a final balloon payment related to the second tranche of $66,000 on or prior to November 1, 2013.
The effective interest rate on the first and second tranche is 13.3%.&nbsp;During the three months ended September 30, 2013 and
2012, the Company made interest payments of $7,000 and $50,000, respectively, and principal payments of $24,000 and $288,000, respectively.
During the six months ended September 30, 2013 and 2012, the Company made interest payments of $27,000 and $109,000, respectively,
and principal payments of $556,000 and $566,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the VLL5 Agreements, the
Company issued two warrants to Venture Lending &amp; Leasing V, LLC, a Delaware limited liability company (&ldquo;LLC5&rdquo;),
which, in the aggregate, had a total put option cash value of $750,000 (the &ldquo;VLL5 Warrants&rdquo;). The $750,000 cash value
of the VLL5 Warrants was recorded as a cash settlement liability and a corresponding amount of $750,000 was recorded as a discount
on the note payable.&nbsp; The discount is being accreted to non-cash interest expense over the term of the loan using the effective
interest method.&nbsp; During the three months ended September 30, 2013 and 2012, the Company recorded $24,000 and $63,000, respectively,
of non-cash interest expense related to the loans.&nbsp;During the six months ended September 30, 2013 and 2012, the Company recorded
$90,000 and $125,000, respectively, of non-cash interest expense related to the loans.&nbsp;The remaining balance of the loans
amounted to $138,000 at September 30, 2013, which is included in the current portion of long-term debt, net of debt discount in
the accompanying condensed consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2011, the Company entered into
a loan and security agreement and a supplement to the loan and security agreement with Venture Lending &amp; Leasing&nbsp;VI, Inc.
(&ldquo;VLL6&rdquo;) to borrow up to an aggregate of up to $2,500,000 (collectively, the &ldquo;VLL6 Agreements&rdquo;).&nbsp;
The VLL6 Agreements provided for a first tranche of $1,500,000 and, upon meeting certain financial milestones, a second tranche
of $1,000,000.&nbsp;The loan is secured by the assets of the Company including intellectual property. On June 29, 2011, the Company
borrowed $1,500,000 on the first tranche. On September 30, 2011, the Company met the financial milestones to borrow the second
tranche. On November 10, 2011, the Company borrowed the second tranche.&nbsp;&nbsp;The cash interest or &ldquo;streaming&rdquo;
rate on the loan is 10%. In connection with the first tranche, for the first nine months, the Company made monthly interest-only
payments set at $12,500 through March 1, 2012. The Company now makes principal and interest payments of $56,250 per month through
September 1, 2014. Additionally, the Company will make a final balloon payment of $116,505 on September 29, 2014. In connection
with the second tranche, for the first nine months, the Company made monthly interest-only payments set at $8,333 through August
31, 2012. The Company now makes principal and interest payments of $37,500 per month through February 1, 2015. Additionally, the
Company will make a final balloon payment of $77,670 on February 1, 2015, resulting in an effective interest rate of 13%. During
the three months ended September 30, 2013 and 2012, the Company made interest payments of $53,000 and $75,000, respectively and
made principal payments of $228,000 and $148,000, respectively. During the six months ended September 30, 2013 and 2012, the Company
made interest payments of $114,000 and $151,000, respectively and made principal payments of $449,000 and $266,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the VLL6 Agreements, the
Company issued a warrant to Venture Lending &amp; Leasing VI, LLC (individually referred to as &ldquo;LLC6&rdquo; and collectively
referred to with LLC5 as &ldquo;WTI&rdquo;) for the purchase of 32,332 shares of its common stock at a purchase price per share
equal to $11.592. Once the Company became eligible to draw the second tranche of the loan, the Company was required to issue a
second warrant to LLC6 with coverage equal to $62,500 for the purchase of additional shares of the Company&rsquo;s common stock
at a strike price equal to the 10-day volume-weighted average price (&ldquo;VWAP&rdquo;) ending on the trading day prior to the
date the Company satisfied the second tranche milestones. On September 30, 2011, the Company met the second tranche milestones
and the Company issued the second warrant for the purchase of 5,586 shares of its common stock at a purchase price per share equal
to $11.189. On November 10, 2011, the Company borrowed the second tranche and therefore the Company became obligated to issue
a third warrant to LLC6 with coverage equal to $62,500 for the purchase of additional shares of its common stock at a strike price
equal to the 10-day VWAP ending on the trading day prior to the borrowing date of the second tranche. In connection with borrowing
the second tranche, the Company issued the third warrant for the purchase of 5,884 shares of its common stock at a purchase price
per share equal to $10.623. The three warrants issued to LLC6 are hereinafter collectively referred to as the &ldquo;VLL6 Warrants,&rdquo;
and had a total put option cash value, in the aggregate, of $1,250,000. The Company recorded the $1,250,000 cash value of the
VLL6 Warrants as a cash settlement liability and a corresponding amount of $1,250,000 was recorded as a discount on the note payable.
The discount is being accreted to non-cash interest expense over the term of the loan using the effective interest method. For
the three months ended September 30, 2013 and 2012, the Company recorded $104,000 and $91,000 of non-cash interest related to
the loan, respectively. For the six months ended September 30, 2013 and 2012, the Company recorded $204,000 and $178,000 of non-cash
interest related to the loan, respectively. The remaining balance of the discount on the loan amounted to $474,000 at September
30, 2013.&nbsp;The remaining balance of the loan amounted to $1,367,000 at September 30, 2013, of which $821,000 is included in
the current portion of long-term debt in the accompanying condensed consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2012, the Company entered into
respective letter agreements with VLL5 and VLL6 to amend the repayment terms of its outstanding debt obligations. Prior to the
execution of these agreements, LLC5 and LLC6 held an aggregate of 79,517 warrants (adjusted for the reverse stock split effective
April 1, 2013) to purchase common stock, which, in the aggregate, had a total put option cash value of $2,000,000 (the &ldquo;Cash
Settlement Liability&rdquo;) and was included in long term liabilities on the Company&rsquo;s condensed consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On that same day, the Company also entered
into a stock purchase agreement with WTI for the issuance to WTI of shares of its common stock having an aggregate grant date fair
market value of $3,500,000, or approximately $5.67 per post-split share, in exchange for LLC5&rsquo;s agreement to surrender the
VLL5 Warrants, and LLC6&rsquo;s agreement to surrender the VLL6 Warrants, and the surrender by WTI of the accompanying Cash Settlement
Liability. Accordingly, on November 1, 2012, the Company issued an aggregate of 617,284 restricted shares of its post-split common
stock (the &ldquo;Shares&rdquo;) to WTI, pursuant to the terms of the stock purchase agreement. The VLL5 Warrants and the VLL6
Warrants were surrendered on October 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If at any time between October 30, 2012 through
either March 31, 2014 or July 31, 2015 (the &ldquo;Settlement Dates&rdquo;) WTI sells the Shares, then the proceeds from the sale
of the Shares will be applied as follows (the &ldquo;Grace Period&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period, the fair value of the proceeds received will be retained by WTI as consideration for surrendering the Cash Settlement Liability, up to a maximum value of $2,000,000.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period, any additional proceeds received from the sale of the Shares in excess of $2,000,000 (approximately $3.22 per share) but up to $3,500,000 (approximately $5.67 per share) will be applied by WTI as a prepayment of a portion of the then outstanding debt based on the terms of the stock purchase agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period, any additional proceeds received from the sale of the Shares in excess of $3,500,000 (approximately $5.67 per share) up to $4,500,000 (approximately $7.28 per share) shall be the sole possession and property of WTI, in accordance with the terms of the stock purchase agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period for value in excess of $4,500,000 (approximately $6.72 per share), 50% of the amount of the proceeds in excess of the $4,500,000 will be the sole possession and property of WTI and 50% of the amount of the proceeds shall be applied as a prepayment of a portion of the then outstanding debt based on the terms of the stock purchase agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period for value less than $2,000,000 (approximately $3.22 per share), the Company is required to make a cash payment to WTI until the total Cash Settlement Liability of $2,000,000 has been settled (&ldquo;Cash Shortfall&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Shares are not sold during the Grace
Period, then the then fair value of the stock is to be determined at either of the Settlement Dates and the repayment of the Cash
Settlement Liability, prepayment of outstanding, distribution of gains from the sale of the Shares, or calculation of the Cash
Shortfall will consummate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2012, upon the issuance of the
Shares, the Company recorded a prepayment of $2,000,000 and $1,500,000 net against the Cash Settlement Liability and the outstanding
notes payable, respectively, on that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2013 and June 30, 2013, the
Shares had not yet been sold by WTI and the fair value of the Shares at September 30, 2013 and June 30, 2013 amounted to $1,691,000
and $1,592,000 (approximately $2.74 and $2.58 per share), respectively. Accordingly, in connection with the increase in fair market
value of the Shares, the Company recorded a gain on the fair value in the amount of $99,000, which is included in the accompanying
condensed consolidated statements of comprehensive loss for the three months ended September 30, 2013. The fair value of the Shares
at March 31, 2013 amounted to $1,901,000 ($3.08 per share). Accordingly, in connection with the decrease in fair market value
of the Shares from March 31, 2013 to September 30, 2013, the Company recorded a loss on the fair value in the amount of $210,000,
which is included in the accompanying condensed consolidated statements of comprehensive loss for the six months ended September
30, 2013. The fair value of the Shares will continue to be marked to market with any gain or loss recorded in the statement of
comprehensive loss until either the Shares are sold by the holder or the Settlement Dates, whichever is earlier. As of September
30, 2013, the net Cash Settlement Liability was $309,000, of which $116,000 is included in the current portion of the Cash Settlement
Liability on the accompanying condensed consolidated balance sheet. As of September 30, 2013, the $1,691,000 fair value of the
Shares has been recorded as a prepayment against the Cash Settlement Liability on the accompanying condensed consolidated balance
sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 4.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Commitments and Contingencies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Legal Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2006, the Company received a written
communication from the grantor of a license to an earlier version of its technology indicating that such license was terminated
due to an alleged breach of the license agreement by the Company. The license agreement extends to its use of the technology in
Japan only. While the Company does not believe that the grantor&rsquo;s revocation is valid under the terms of the license agreement
and no legal claim has been threatened to date, the Company cannot provide any assurance that the grantor will not take legal action
to restrict its use of the technology in the licensed territory. While the Company's management does not anticipate that the outcome
of this matter is likely to result in a material loss, there can be no assurance that if the grantor pursues legal action, such
legal action would not have a material adverse effect on its consolidated financial position or results of comprehensive loss.
The Company has not accrued a loss reserve for this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2011, the Company received notice
of a lawsuit filed in Mexico by Cesar Mangotich Pacheco and Prodinnv, S.A. de C.V. represented by Cesar Mangotich Pacheco. The
lawsuit appears to allege conversion of assets, tortious interference and defamation, among other claims. The Company is currently
evaluating the lawsuit, conferring with local counsel and translating the documents it has received. The Company&rsquo;s preliminary
assessment is that the lawsuit is completely without merit and intends to vigorously defend its position. The Company has not accrued
a loss reserve for this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, from time to time, is involved
in legal matters arising in the ordinary course of its business including matters involving proprietary technology. While management
believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of
business for which the Company is or could become involved in litigation, will not have a material adverse effect on its business,
financial condition or results of comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Employment Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2013, the Company had
employment agreements in place with five of its key executives. The agreements provide, among other things, for the payment of
nine to twenty-four months of severance compensation for terminations under certain circumstances. With respect to these agreements,
at September 30, 2013, potential severance amounted to $1,843,000 and aggregated annual salaries amounted to $1,310,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Commercial Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 26, 2009, the Company entered into
a commercial agreement with VetCure, Inc., a California corporation, to market and sell the Company&rsquo;s Microcyn&reg; Technology-based
animal healthcare products branded as Vetericyn&reg;. VetCure, Inc. later changed its name to Vetericyn, Inc. This agreement was
amended on February 24, 2009, July 24, 2009, June 1, 2010, and November 1, 2010. Pursuant to the agreement, the Company provides
Vetericyn, Inc. with bulk product and Vetericyn, Inc. bottles, packages, and sells Microcyn&reg; Technology-based animal healthcare
products branded as Vetericyn&reg;. The Company receives a fixed amount for each bottle of Vetericyn&reg; sold by Vetericyn, Inc.
At the time of these 2009 transactions, Vetericyn, Inc. was wholly-owned by Robert Burlingame, who was also a director of the Company
at that time. Mr. Burlingame resigned from the Company&rsquo;s board of directors on February 10, 2010.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 15, 2009, the Company entered
a commercial agreement with V&amp;M Industries, Inc., a California corporation, to market and sell certain of the Company&rsquo;s
Microcyn&reg; over-the-counter liquid and gel products. V&amp;M Industries, Inc. subsequently changed its name to Innovacyn, Inc.
On June 1, 2010, September 1, 2010, and November 1, 2010, the Company amended this agreement granting Innovacyn, Inc. the exclusive
right to sell certain of its over-the-counter products. At the time of the 2009 transaction, V&amp;M Industries, Inc. was wholly-owned
by Robert Burlingame, who was also a director of the Company at that time. Mr. Burlingame resigned from&nbsp;the Company&rsquo;s&nbsp;board
of directors on February 10, 2010. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2011, Vetericyn, Inc. and Innovacyn,
Inc. began to share profits with the Company related to the Vetericyn&reg; and Microcyn&reg; over-the-counter sales, resulting
in the Company receiving about a 30% royalty of net revenue. During the three months ended September 30, 2013 and 2012, the Company
recorded revenue related to these agreements in the amounts of $1,289,000 and $1,229,000, respectively. During the six months ended
September 30, 2013 and 2012, the Company recorded revenue related to these agreements in the amounts of $2,030,000 and $2,365,000,
respectively. The revenue is recorded in product revenues in the accompanying condensed consolidated statements of comprehensive
loss. At September 30, 2013 and March 31, 2013, the Company had outstanding accounts receivable of $801,000 and $264,000, respectively,
related to Innovacyn, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2012, the Company, along with
its Mexican subsidiary and manufacturer Oculus Technologies of Mexico S.A. de C.V., entered into a license, exclusive distribution
and supply agreement with More Pharma Corporation, S. de R.L. de C.V. (&ldquo;More Pharma&rdquo;) (the &ldquo;License Agreement&rdquo;).
For a one-time payment of $500,000, the Company granted More Pharma an exclusive license, with the right to sublicense under certain
conditions and with the Company&rsquo;s consent, to all of the Company&rsquo;s proprietary rights related to certain of its pharmaceutical
products for human application that utilize the Company&rsquo;s Microcyn&reg; Technology within Mexico. For an additional one-time
payment of $3,000,000, the Company also agreed to appoint More Pharma as the exclusive distributor of certain of its products in
Mexico for the term of the agreement. Additionally, the Company granted More Pharma an exclusive license to certain of the Company&rsquo;s
then-held trademarks in exchange for a payment of $100,000. The Company has the ability to terminate the agreement if certain annual
purchase minimums are not met. The term of the agreement is twenty-five years from the effective date of August 15, 2012. The term
of the License Agreement will automatically renew after the twenty-five year term for successive two year terms as long as More
Pharma has materially complied with any and all of the obligations under the License Agreement, including but not limited to, meeting
the minimum purchase requirements set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, on August 9, 2012, the Company
entered into an exclusive distribution and supply agreement with More Pharma (the &ldquo;Distribution Agreement&rdquo;). For a
one-time payment of $1,500,000, the Company granted More Pharma exclusive ability to market and sell certain of its pharmaceutical
products for human application that utilize the Company&rsquo;s Microcyn&reg; Technology. The Company also appointed More Pharma
as its exclusive distributor, with the right to execute sub-distribution agreements under certain conditions and with the Company&rsquo;s
consent, within the following countries: Antigua &amp; Barbuda, Argentina, Aruba &amp; Curacao, Bahamas, Barbados, Belize, Bolivia,
Bonaire, Brazil, British Guyana, British Islands, Cayman Islands, Chile, Colombia, Cuba, Dominica, Dominican Republic, Ecuador,
El Salvador, French Guyana, Grenada, Guadalupe, Guatemala, Haiti, Honduras, Jamaica, Martinique, Nicaragua, Paraguay, Peru, St.
Bartolome, St. Vincent &amp; Grenades, Surinam, Trinidad &amp; Tobago, Turks &amp; Caicos Islands, Uruguay, Venezuela and Virgin
Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is recognizing the $5,100,000 related
to the License Agreement and the Distribution Agreement as revenue on a straight line basis consistent with the Company&rsquo;s
historical experience with contracts with similar terms, which is typically over three to five years of the contract. Additionally,
the Company capitalized $214,000 of its transaction costs related to the License Agreement and the Distribution Agreement, which
will be amortized by the Company as expense on a straight line basis consistent with the related revenue recognition practices.
At September 30, 2013 and March 31, 2013, the Company had outstanding accounts receivable of $717,000 and $580,000, respectively,
due from More Pharma. During three months ended September 30, 2013 and 2012, the Company recognized $378,000 and $183,000, respectively,
related to the amortization of the upfront fees received in the transaction. During six months ended September 30, 2013 and 2012,
the Company recognized $752,000 and $183,000, respectively, related to the amortization of the upfront fees received in the transaction.
The Company recognizes product sales on a sell-through basis as More Pharma sells products through to its customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Ruthigen, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s wholly owned subsidiary,
Ruthigen, Inc., was incorporated in the State of Nevada on January 18, 2013, and reincorporated from Nevada to Delaware on September
25, 2013. Ruthigen has established offices in Santa Rosa, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 2, 2013, the Company entered into
a separation agreement with Ruthigen that contains key provisions relating to the Company&rsquo;s ongoing relationship with Ruthigen,
and more specifically governs its relationship with Ruthigen following the completion of Ruthigen&rsquo;s intended initial public
offering. The Company previously announced its entry into a license and supply agreement and a shared services agreement with Ruthigen.
Each of these agreements has been entered into in the overall context of the separation of the Company&rsquo;s business and its
novel biotechnology business into two separate, publicly-traded companies. The effective date for all three agreements is the closing
date of Ruthigen&rsquo;s intended initial public offering, if any should occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>License and Supply Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the license and supply agreement, the Company agreed to exclusively license certain of its proprietary technology to Ruthigen
to enable Ruthigen&rsquo;s research and development and commercialization of the newly discovered RUT58-60, and any improvements
to it, in the United States, Canada, European Union and Japan, referred to as the Territory, for certain invasive procedures in
human treatment as defined in the license and supply agreement.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
October 9, 2013, the Company entered into Amendment No. 1 to the license and supply agreement, which amended the second milestone
event set forth in Section 7.1 of the license and supply agreement. On November 6, 2013, the Company entered into Amendment No.
2 to the license and supply agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the
license and supply agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the license
and supply agreement. All other terms and conditions of the license and supply agreement remain unmodified and in full force and
effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The license and supply agreement provides Ruthigen
with the exclusive option, exercisable within the first five years following the effective date of the agreement, to expand the
license to certain other therapeutic indications upon payment of a license expansion fee of $10 million within the first two years
following the effective date of the agreement or, after the two&ndash;year period, the same fee plus certain out-of-pocket costs
the Company may incur in developing products for any of the indications. Additionally, the Company will be prohibited from using
the licensed proprietary technology to sell products that compete with Ruthigen&rsquo;s products within the Territory, and Ruthigen
cannot sell any device or product that competes with the Company&rsquo;s products being sold or developed as of the effective date
of the license and supply agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ruthigen will be required to make a total
of $5,000,000 in milestone payments to the Company for the first product only, as follows: upon completion of
Ruthigen&rsquo;s first meeting with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen&rsquo;s
first pivotal clinical trial and upon first patient enrollment in Ruthigen&rsquo;s second pivotal clinical trial. In
addition, as further consideration under the agreement, Ruthigen will be required to make royalty payments to the Company
based on Ruthigen&rsquo;s annual net sales of the product from the date of first commercial sale to the date that Ruthigen
ceases to commercialize the product, which percentage royalty rate will vary between 3% and 20% and will increase based on
various net sales thresholds and will differ depending on the country in which the sales are made. Ruthigen also agreed to
purchase certain research and development and manufacturing equipment from the Company for approximately $3 million following
the completion of Ruthigen&rsquo;s intended initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Shared Services Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also entered into a shared services
agreement with Ruthigen that would take effect upon the completion of Ruthigen&rsquo;s proposed initial public offering, if any
should occur, pursuant to which it will provide Ruthigen with general services, including general accounting, human resources,
laboratory personnel and shared R&amp;D resources while Ruthigen plans to establish an independent facility and systems. As a wholly
owned subsidiary of the Company, Ruthigen will be financed by the Company until the completion of the proposed initial public offering,
if any should occur, and after such event, Ruthigen would become responsible for its own expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Separation Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a separation agreement
with Ruthigen that contains key provisions relating to its ongoing relationship with Ruthigen following the completion of Ruthigen&rsquo;s
intended initial public offering. The separation agreement takes effect upon the closing of Ruthigen&rsquo;s intended initial public
offering and terminates on the earlier of 8.5 years following the closing of the offering, or when the parties mutually agree to
terminate it. The separation agreement also contains a series of restrictions on the Company&rsquo;s ability to transfer the Ruthigen
shares it owns. The Company is restricted from transferring any of the Ruthigen shares it owns during the first year (the &ldquo;lock
up period&rdquo;) immediately following Ruthigen&rsquo;s intended initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the one-year lock up period,
transfers by the Company of the Ruthigen shares it owns must be conducted with the consent of Ruthigen&rsquo;s board of
directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed
requirements include that the transfers must be in private placement transactions, the purchase price discount may not exceed
certain percentages depending on the transferee, the amount of shares transferred in a given transfer (or series of transfers
comprising a single transaction) may not exceed the greater of 5% of Ruthigen&rsquo;s outstanding shares or $1.5 million in
net proceeds to the Company, as well as certain other requirements set forth in the separation agreement. In addition to the
prescribed manner for the Company to conduct transfers described above, if, following a minimum of 41.5 months following the
closing of Ruthigen&rsquo;s initial public offering have lapsed under the separation agreement and the Company has not
consummated transfers of the Ruthigen shares it owns resulting in at least $3.8 million in net proceeds to the Company, then
the Company has a one-time transfer and registration right to transfer the Ruthigen shares it owns in an amount equal to the
difference between $3.8 million and the Ruthigen shares transferred by the Company pursuant to the separation agreement as of
the time the Company elects to exercise its one-time right. Transfers conducted using this one-time right must be conducted
with the consent of Ruthigen&rsquo;s board of directors or within the prescribed requirements for such transfers set forth in
the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the
amount of shares transferred may not exceed $3.8 million in net proceeds to the Company, as well as certain other
requirements set forth in the separation agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The separation agreement also provides for
certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether
and how many Ruthigen shares the Company transfers. The majority of the material restrictions and obligations contained in the
separation agreement lapse if and when the Company and its subsidiaries (other than Ruthigen) own less than 19.9% of the outstanding
shares of Ruthigen&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The separation agreement also sets forth the
methodology for the allocation of the operational and offering related expenses incurred prior to and in connection with Ruthigen&rsquo;s
intended initial public offering for which Ruthigen is required to reimburse the Company. Ruthigen will also reimburse the Company
for expenses such as salaries and benefits advanced or paid on Ruthigen&rsquo;s behalf, or for Ruthigen&rsquo;s benefit, during
a transition period following the closing of Ruthigen&rsquo;s intended initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The separation agreement provides that each
party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against the other
party. This includes an indemnification by the Company to Ruthigen related to obligations that the Company has under certain loan
and security agreements entered into by the Company with Venture Lending &amp; Leasing V, Inc. and Venture Lending &amp; Leasing
VI, Inc. The separation agreement also provides that, so long as the Company shall maintain a directors&rsquo; and officers&rsquo;
insurance program covering the past and present officers and directors of the Company, the program shall be standard in the Company&rsquo;s
industry and the Company shall not exclude any former director of the Company from any insurance policy coverage if such coverage
is made available to the Company&rsquo;s then existing directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 5.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholders&rsquo; Equity</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Common Stock Issued to Non-Employees
For Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2009, the Company entered into
an agreement with Advocos LLC, a contract sales organization that serves as part of the Company&rsquo;s sales force, for the sale
of the Company&rsquo;s wound care products in the United States. Pursuant to the agreement, the Company agreed to pay the contract
sales organization a monthly fee and potential bonuses that will be based on achievement of certain levels of sales. The Company
agreed to issue the contract sales organization cash or shares of common stock as compensation for its services. During the three
months ended September 30, 2013 and 2012, the Company issued 8,139 and 3,728 shares of common stock, respectively, in connection
with this agreement. During the six months ended September 30, 2013 and 2012, the Company issued 38,447 and 14,392 shares of common
stock, respectively, in connection with this agreement. The Company has determined that the fair value of the common stock, which
was calculated as shares were issued, was more readily determinable than the fair value of the services rendered. Accordingly,
the Company recorded the fair value of the stock as compensation expense. During the three months ended September 30, 2013
and 2012, the Company recorded $22,000 and $20,000 of expense related to this agreement, respectively. During the six months ended
September 30, 2013 and 2012, the Company recorded $134,000 and $112,000 of expense related to this agreement, respectively. The
expense was recorded as selling, general and administrative expense in the accompanying condensed consolidated statements of comprehensive
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 17, 2009, the Company entered into
an agreement with Windsor Corporation.&nbsp; Windsor Corporation provides financial advisory services to the Company. Pursuant
to the agreement, the Company agreed to pay Windsor Corporation, on a quarterly basis, cash or common stock as compensation for
services provided.&nbsp; The Company determined that the fair value of the common stock was more readily determinable than the
fair value of the services rendered. Accordingly, the Company recorded the fair value of the stock as compensation expense.
During the six months ended September 30, 2013, the Company issued 12,097 shares of common stock.&nbsp;During the six months ended
September 30, 2013, the Company recorded $49,000 of stock compensation expense related to this agreement. Additionally, during
the three months ended September 30, 2013, the Company accrued $30,000 of expense for services provided which was settled with
shares of common stock on October 2, 2013 (See Note 10). The expense was recorded as selling, general and administrative expense
in the accompanying condensed consolidated statements of comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 6.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock-Based Compensation</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based awards
exchanged for employee services at the estimated grant date fair value of the award. The Company amortizes the fair value of employee
stock options on a straight-line basis over the requisite service period of the awards.&nbsp;&nbsp;Compensation expense includes
the impact of an estimate for forfeitures for all stock options. The estimated forfeiture rates used during the six months ended
September 30, 2013 ranged from 1.63% to 4.77%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Employee stock-based compensation expense is as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Three&nbsp;Months</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Six Months</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: left; padding-left: 10pt; text-indent: -10pt">Cost of service revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">66</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Selling, general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">221</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">349</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">484</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Total stock-based compensation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">296</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">372</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">483</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">680</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2013, there were
unrecognized compensation costs of $1,403,000 related to stock options which are expected to be recognized, over a
weighted-average amortization period of 2.54 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimated the fair value of employee
stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line
basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated using
the following weighted-average assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><B>Three&nbsp;Months</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><B>Ended</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><B>September 30,</B></P></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><B>Six Months</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><B>Ended</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><B>September 30,</B></P></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2012</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2012</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Expected life</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-right: 1.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.89 years</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-right: 1.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.85 years</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-right: 1.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.89 years</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding-right: 1.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.85 years</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; width: 32%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.42%</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.73%</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.42%</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.73%</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dividend yield</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.00%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.00%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.00%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.00%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Volatility</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">86%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">88%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">86%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">88%</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair value of options granted</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.10</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.76</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.10</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.76</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected term of stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the
approach prescribed by the Securities and Exchange Commission's Staff Accounting Bulletin No. 110 for &ldquo;plain vanilla&rdquo;
options. The expected stock price volatility for the Company&rsquo;s stock options was determined by examining the historical volatility
of the Company and the historical volatilities of the Company&rsquo;s industry peers. The Company will continue to analyze the
stock price volatility and expected term assumptions as more data for the Company&rsquo;s common stock and exercise patterns become
available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the
expected term of the Company&rsquo;s stock options. The expected dividend assumption is based on the Company&rsquo;s history and
expectation of dividend payouts. The Company estimates forfeitures based on historical experience and reduces compensation expense
accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of all option activity as of September
30, 2013 and changes during the six months then ended is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of<BR> Shares <BR>(in thousands)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR> Average<BR> Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR> Average<BR> Contractual&nbsp; <BR>Term</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; padding-left: 10pt; text-indent: -10pt">Outstanding at March&nbsp;31, 2013</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">975</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">15.08</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Options forfeited or expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(81</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15.86</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Outstanding at September&nbsp;30, 2013</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,229</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11.72</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.42</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Exercisable at September&nbsp;30, 2013</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">816</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15.32</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.35</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Options available for grant as of September&nbsp;30, 2013</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">848</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price of the stock options and the underlying fair value of the Company&rsquo;s common stock
($2.74) for stock options that were in-the-money as of September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company did not capitalize any cost associated with stock-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No income tax benefit has been recognized related
to stock-based compensation expense and no tax benefits have been realized from exercised stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues new shares of common stock upon exercise of stock
options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 7.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income Taxes</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company completed a study during the year
ended March 31, 2013 to assess whether a change in control had occurred or whether there have been multiple changes of control
since the Company&rsquo;s formation.&nbsp; The Company determined, based on the results of the study, no change in control occurred
for purposes of Internal Revenue Code section 382. &nbsp;In addition, the Company is not aware of any changes in ownership during
the six months ended September 30, 2013 that would result in a change in control under Internal Revenue Code section 382.&nbsp;
The Company, after considering all available evidence, fully reserved against its deferred tax assets since it is more likely than
not that such benefits will not be realized in future periods. The Company incurred losses for both financial reporting and income
tax purposes for the six months ended September 30, 2013. Accordingly, the Company is continuing to fully reserve for its deferred
tax assets. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could
affect the realization of their future benefit. If it is determined in future periods that portions of the Company&rsquo;s deferred
income tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of certain realization requirements
of Accounting Standards Codification Topic 718, the Company&rsquo;s deferred tax assets and liabilities do not include certain
deferred tax assets at September 30, 2013 that arose directly from tax deductions related to equity compensation in excess of compensation
recognized for financial reporting purposes.&nbsp;&nbsp;Equity will be increased by approximately $533,000 if and when such deferred
tax assets are ultimately realized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 8.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Segment and Geographic Information</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates revenues from tissue
care products which are sold into the human and animal healthcare markets and the Company also generates revenues from laboratory
testing services which are provided to medical device manufacturers. The Company operates a single segment business for product
sales which consists of three geographical sales territories as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Three&nbsp;Months</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Six&nbsp;Months</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%">U.S.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,898,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,898,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,221,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,931,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mexico</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,862,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,776,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,240,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Europe and Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">603,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">504,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,010,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">909,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,853,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,264,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,007,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,080,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30, 2013
and 2012, the Company received licensing revenues of $397,000 and $374,000, respectively. Such revenues are included in the Company&rsquo;s
calculation of product revenues and are reflected in the table above under the respective geographic region where such licensing
revenues were earned. For the six months ended September 30, 2013 and 2012, the Company received licensing revenues of $830,000
and $406,000, respectively. Such revenues are included in the Company&rsquo;s calculation of product revenues and are reflected
in the table above under the respective geographic region where such licensing revenues were earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s service revenues amounted
to $236,000 and $262,000 for the three months ended September 30, 2013 and 2012, respectively, and the Company&rsquo;s service
revenues amounted to $454,000 and $497,000 for the six months ended September 30, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 9.&nbsp;</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Significant Customer Concentrations</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30, 2013,
one customer represented 33% of net revenue and one customer represented 32% of net revenue. For the three months ended September
30, 2012, one customer represented 27% of net revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ended September 30, 2013,
one customer represented 37% of net revenue and one customer represented 27% of net revenue. For the six months ended September
30, 2012, one customer represented 28% of net revenue.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2013, one customer represented
33%, one customer represented 30%, and one customer represented 11% of the net accounts receivable balance. At March 31, 2013,
one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Note 10.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Subsequent Events</B> &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Common Stock Issued to Non-Employee For
Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 2, 2013, the Company issued 11,070
shares of common stock, with a value of $30,000, to Windsor Corporation in consideration for services provided during the three
months ended September 30, 2013. The Company registered the issuance under its previously filed and currently effective shelf registration
statement on Form S-3 (File No. 333-171411) and the related prospectus supplement dated and filed on October 2, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Amendments No. 1 and No. 2 to the License and Supply Agreement
with Ruthigen, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 9, 2013, the Company
entered into Amendment No. 1 to the License and Supply Agreement with the Company&rsquo;s wholly owned subsidiary, Ruthigen,
Inc. Pursuant to the terms of the License and Supply Agreement, Ruthigen is required to make milestone payments to the
Company upon certain milestone events. Amendment No. 1 amended the second milestone event set forth in Section 7.1 of the
License and Supply Agreement. On November 6, 2013, the Company entered into Amendment No. 2 to the License and Supply
Agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the License and Supply
Agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the License and Supply
Agreement. Pursuant to the terms of Amendment No. 2, Ruthigen will be required to make a total of $5,000,000 in milestone
payments to the Company for the first product only, as follows: upon completion of Ruthigen&rsquo;s first meeting with the
U.S. Food and Drug Administration (FDA) following completion of Ruthigen&rsquo;s first pivotal clinical trial and upon first
patient enrollment in Ruthigen&rsquo;s second pivotal clinical trial. Ruthigen also agreed to purchase certain research and
development and manufacturing equipment from the Company for approximately $3 million following the completion of
Ruthigen&rsquo;s intended initial public offering. All other terms and conditions of the License and Supply Agreement remain
unmodified and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following discussion of our financial
condition and results of</I> <I>operations should be read in conjunction with the condensed consolidated</I> <I>financial statements
and notes to those statements included elsewhere in this</I> <I>Quarterly Report on Form 10-Q as of September 30, 2013 and our
audited</I> <I>consolidated financial statements for the year ended March 31, 2013 included in</I> <I>our Annual Report on Form
10-K, filed with the Securities and Exchange</I> <I>Commission on June 25, 2013.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This report contains forward-looking statements
within the meaning of the</I> <I>Private Securities Litigation Reform Act of 1995. When used in this report, the</I> <I>words &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;</I>
<I>&ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;potential,&rdquo; &ldquo;expect,&rdquo;
&ldquo;predict,&rdquo;</I> <I>&ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;proposal,&rdquo; and similar</I> <I>expressions are intended to identify forward-looking
statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Forward-looking statements are subject to
risks and uncertainties that</I> <I>could cause our actual results to differ materially from those projected. These</I> <I>risks
and uncertainties include, but are not limited to the risks described in</I> <I>our Annual Report on Form 10-K including: our ability
to become profitable; the effect of the general decline in the economy on our business; the progress and</I> <I>timing of our development
programs and regulatory approvals for our products; the</I> <I>benefits and effectiveness of our products; the ability of our products
to meet</I> <I>existing or future regulatory standards; the progress and timing of clinical trials</I> <I>and physician studies;
our expectations related to the use of our cash reserves; our</I> <I>expectations and capabilities relating to the sales and marketing
of our current</I> <I>products and our product candidates; our ability to gain sufficient reimbursement from third-party payors;
our ability to compete with other companies that</I> <I>are developing or selling products that are competitive with our products;
the</I> <I>establishment of strategic partnerships for the development or sale of products; the risk our research and development
efforts do not lead to new products; the</I> <I>timing of commercializing our products; our</I> <I>ability to penetrate markets
through our sales force, distribution network,</I> <I>and</I> <I>strategic business partners to gain a foothold in the market and
generate attractive margins; the expansion of our</I> <I>sales force and distribution network; the ability to attain specified
revenue goals</I> <I>within a specified time frame, if at all, or to reduce costs; the outcome of</I> <I>discussions with the U.S.
Food and Drug Administration, or FDA, and other regulatory agencies; the content and timing of</I> <I>submissions to, and decisions
made by, the FDA and other regulatory agencies,</I> <I>including demonstrating to the satisfaction of the FDA the safety and efficacy
of our</I> <I>products; our ability to manufacture sufficient amounts of our product candidates</I> <I>for clinical trials and
products for commercialization activities; our ability to</I> <I>protect our intellectual property and operate our business without
infringing on the</I> <I>intellectual property of others; our ability to continue to expand our intellectual</I> <I>property portfolio;
our expectations about the outcome of litigation and</I> <I>controversies with third parties; the risk we may need to indemnify
our distributors or other third parties; our ability to attract and retain qualified</I> <I>directors, officers and employees;
our expectations relating to the concentration of</I> <I>our revenue from international sales; our ability to expand to and commercialize</I>
<I>products in markets outside the wound care market; and the impact of the</I> <I>Sarbanes-Oxley Act of 2002 and any future changes
in accounting regulations or</I> <I>practices in general with respect to public companies. These forward-looking statements speak
only as of</I> <I>the date hereof. We expressly disclaim any obligation or undertaking to release</I> <I>publicly any updates or
revisions to any forward-looking statements contained</I> <I>herein to reflect any change in our expectations with regard thereto
or any</I> <I>change in events, conditions or circumstances on which any such statement is</I> <I>based, except as required by
law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investors and others should note that we announce
material financial information using our company website (<U>www.oculusis.com</U>), our investor relations website (<U>ir.oculusis.com</U>),
SEC filings, press releases, public conference calls and webcasts. Information about Oculus, our business, and our results of
operations may also be announced by posts on the following social media channels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oculus corporate blog (http://oculusis.com/dialogue/)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oculus Facebook page (www.facebook.com/oculusinnovativesciences)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dan McFadden&rsquo;s Twitter feed (http://twitter.com/dmcfaddenocls).
Mr. McFadden is the Vice President of Public and Investor Relations of our Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information that we post on these social
media channels could be deemed to be material information. Therefore, we encourage investors, the media, and others interested
in Oculus to review the information that we post on these social media channels. These social media channels may be updated from
time to time on Oculus&rsquo; investor relations website. The information on or accessible through our websites and social media
channels is not incorporated by reference in this Quarterly Report on Form 10-Q.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a global healthcare company that designs,
produces, and markets prescription and non-prescription products in 27 countries. We are pioneering innovative products for the
dermatology, surgical, advanced wound and tissue care, and animal healthcare markets. Our primary focus is on the commercialization
of our proprietary technology platform called Microcyn&reg; Technology. This technology is based on electrically charged oxychlorine
small molecules designed to target a wide range of organisms that cause disease (pathogens). These organisms include viruses, fungi,
spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant <I>Staphylococcus aureus</I>, or MRSA, and vancomycin-resistant
<I>Enterococcus,</I> or VRE, as well as <I>Clostridium difficile,</I> or C. diff, a highly contagious bacteria spread by human
contact. Several Microcyn&reg; Technology tissue care products are designed to treat infections and enhance healing while reducing
the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection
is a critical step in wound healing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have the necessary regulatory approvals
to market Microcyn&reg; as a drug or as a medical device with an antimicrobial or wound healing indication in the United States.
Through our wholly owned subsidiary, Ruthigen, Inc., we expect to apply to the U.S. Food and Drug Administration, or FDA, for clearance
as an antimicrobial drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outside the United States, our Microcyn&reg;
Technology products have a CE Mark device approval in Europe for debriding, irrigating and moistening acute and chronic wounds
in comprehensive wound treatment through potential local antimicrobial effect in the wound bed and creating a moist environment.
In Mexico, we are approved as a drug for antiseptic and were granted a Mexican patent for the use of our novel antimicrobial surgical
solution in the treatment and prevention of peritonitis. In India, our technology has a drug license for cleaning and debriding
in wound management.&nbsp;&nbsp;In China, we have obtained a medical device approval by the State Food and Drug Administration
for reducing the propagation of microbes in wounds and creating a moist environment for wound healing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we do not have the necessary regulatory
clearance for an antimicrobial or wound healing indication in the United States, several factors, including our global product
experience, clinical and laboratory testing, physician-led clinical studies based on our technology and scientific papers authored
about our technology, suggest that our Microcyn&reg; Technology may help reduce a wide range of pathogens in acute and chronic
wounds, while curing or improving infection, and concurrently enhancing wound healing through modes of action unrelated to the
treatment of infection. These physician-led clinical studies suggest that our Microcyn&reg; Technology is safe, easy to use and
complementary to many existing treatment methods in wound care. Physician-led clinical studies and usage of our products in the
United States suggest that our 510(k) cleared products may shorten hospital stays, lower aggregate patient care costs and, in certain
cases, reduce the need for systemic antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common methods of controlling infection, including
topical antiseptics and antibiotics, have proven to be only moderately effective in combating infection in the wound bed. However,
topical antiseptics tend to inhibit the healing process due to their toxicity and may require specialized preparation or handling.
The use of antibiotics can lead to the emergence of resistant bacteria, such as MRSA and VRE. Systemic antibiotics may be less
effective in controlling infection in patients with disorders affecting circulation, such as diabetes, which are commonly associated
with chronic wounds. As a result, no single treatment is used across all types of wounds and stages of healing and we believe Microcyn&reg;
Technology can fill a niche in the skin care and chronic/acute wound care markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe Microcyn&reg; Technology is a stable,
anti-infective therapeutic that treats infections and enhances wound healing through increased blood flow to the wound bed and
reduction of chronic inflammation. Also, we believe Microcyn&reg; Technology provides significant advantages over current methods
of care in the treatment of a wide range of chronic and acute wounds throughout all stages of treatment. These stages include cleaning,
debridement, prevention and treatment of infections and wound healing. We believe that unlike antibiotics, antiseptics, growth
regulators and other advanced wound care products, Microcyn&reg; Technology is a stable wound care solution that is as safe as
saline, and also treats infection while simultaneously accelerating wound healing. Also, unlike most antibiotics, we believe Microcyn&reg;
Technology does not target specific strains of bacteria, a practice which has been shown to promote the development of resistant
bacteria. In addition, our products are shelf stable, non-toxic, require no special preparation and are easy to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our goal is to become a worldwide leader as
the standard of care in the treatment and irrigation of open wounds and skin care. We currently have, and intend to seek additional,
regulatory clearances and approvals to market our Microcyn-based products worldwide. In July 2004, we first began selling Microdacyn60&trade;
in Mexico after receiving approval from the Mexican Ministry of Health, for use as an antiseptic, disinfectant and sterilant. Since
then, physicians and scientists in the United States, Europe, India, Pakistan, China and Mexico have conducted more than 40 clinical
and scientific studies of Microcyn&reg; Technology,&nbsp;generating data suggesting that the technology is non-irritating to healthy
tissue, reduces microbial load, accelerates wound healing, reduces pain, shortens treatment time and may have the potential to
reduce costs to healthcare providers and patients. Most of these studies were not intended to be rigorously designed or controlled
clinical trials and, as such, did not have all of the controls required for clinical trials used to support a new drug application
submission to the FDA, nor did the studies include blinding, randomization, predefined clinical end points, use of placebo and
active control groups or U.S.&nbsp;Good Clinical Practice (GCP) requirements. We used the data generated from certain of these
studies to support our CE Mark application with the European Union for certification of our Microcyn&reg; Technology products for
wound cleaning and reduction of microbial load in the European Economic Area. We received a Class II CE Mark in November 2004,
subsequently upgraded to a Class III CE Mark in early 2013, and have also received additional international approvals in China,
Canada, Mexico, India and select Latin America, Asian and Middle East countries. To date, our Microcyn-based products have received
seven FDA 510(k) clearances in the United States. Many of these clearances are for use as a medical device in wound cleaning, or
debridement, lubricating, moistening and dressing, including traumatic wounds and acute and chronic dermal lesions. We have also
received FDA clearance for use in dermatology for management of atopic dermatitis and radiation dermatitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate revenue through established and
scalable commercial operations including manufacturing in Mexico and the United States, and product sales via our domestic and
international strategic business partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We launched sales of Microcyn&reg; Technology
products in October 2008 and our initial sales were in the podiatry market in the United States. In the second quarter of 2009,
we expanded our sales efforts to include wound care centers, hospitals, nursing homes, urgent care clinics and home healthcare,
utilizing a contract sales organization to aid our sales force. We continue to seek opportunities to expand the applicability of
our products into current and new markets. Our products are primarily purchased by, among others, hospitals, physicians, nurses,
and other healthcare practitioners who are the primary caregivers to patients, both human and animal, being treated for acute or
chronic wounds or undergoing surgical procedures as well as to dermatologists for treatment of various skin afflictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">We currently make Microcyn-based human
advanced wound and tissue care products available, both as prescription and over-the-counter products, under our seven 510(k) clearances
in the United States, primarily through a combination of partnerships with Advocos LLC, a specialty U.S.&nbsp;contract sales organization,
and in collaboration with such partners as Amneal Enterprises and Eloquest Healthcare, Inc., a subsidiary of Ferndale Pharma, Inc.,&nbsp;as
described in greater detail below. We commercialized a family of Microcyn&reg; products for advanced wound care sold through a
contract sales force and by Eloquest Healthcare, and have commercialized Microcyn&reg; products for dermatology through a partnership
with Quinnova Pharmaceuticals.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">Through our animal healthcare partner Innovacyn,
Inc.,&nbsp;we currently make available Microcyn&reg; Technology-based animal healthcare products, designed specifically for the
care of horses, dogs, cats, exotic pets and farm/ranch animals and branded as Vetericyn&reg;, in the United States and Europe.
We are currently introducing Vetericyn&reg;-branded products into Canada and Asia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to our current product registration
and approvals, we intend to pursue additional regulatory approvals in Europe, China, India, Latin America, Asia, Middle East and
Mexico for additional Microcyn&reg; Technology-based products and plan to initiate commercialization upon obtaining these approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Animal Healthcare</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 26, 2009, we entered into a commercial
agreement with VetCure, Inc., a California corporation, to market and sell our Microcyn&reg; Technology-based animal healthcare
products branded as Vetericyn&reg; products. VetCure, Inc. later changed its name to Vetericyn, Inc. This agreement was amended
on February 24, 2009, July 24, 2009, June 1, 2010, and November 1, 2010. Pursuant to the agreement, we provide Vetericyn, Inc.
with bulk product and Vetericyn, Inc. bottles, packages, and sells Microcyn&reg; Technology-based animal healthcare products branded
as Vetericyn&reg;. We receive a fixed amount for each bottle of Vetericyn&reg; sold by Vetericyn, Inc. At the time of these 2009
transactions, Vetericyn, Inc. was wholly-owned by Robert Burlingame, who was also a director of our Company at that time. Mr. Burlingame
resigned from our board of directors on February 10, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 15, 2009, we entered a commercial
agreement with V&amp;M Industries, Inc., a California corporation, to market and sell certain of our Microcyn over-the-counter
liquid and gel products. V&amp;M Industries, Inc. subsequently changed their name to Innovacyn, Inc. &nbsp;On June 1, 2010, September
1, 2010, and November 1, 2010, we amended this agreement granting Innovacyn, Inc. the exclusive right to sell certain of our over-the-counter
products. At the time of the 2009 transaction, V&amp;M Industries, Inc. was wholly-owned by Robert Burlingame, who was also a director
of our Company at that time. Mr. Burlingame resigned from our board of directors on February 10, 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, on July 1, 2011, Vetericyn, Inc.
and Innovacyn, Inc. began to share profits with us related to the Vetericyn&reg; and Microcyn&reg; over-the-counter sales, resulting
in our receipt of about a 30% royalty of net revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Dermatology</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2011, we announced the formation
of a broad multi-year collaboration with Amneal Enterprises.&nbsp;Amneal Enterprises is an affiliation of independent pharmaceutical
marketing, discovery and development companies.&nbsp;&nbsp;As a part of this collaboration, Quinnova Pharmaceuticals, Inc., an
Amneal alliance member, licensed, with a $500,000 prepayment and ongoing double-digit royalties, the U.S. and Canadian rights to
the Microcyn-based dermatology atopic dermatitis hydrogel that received FDA clearance in February 2011. Future prescription dermatology
products can also be licensed for additional upfront payments.&nbsp;&nbsp;In addition, Quinnova&nbsp;agreed to co-promote the current
prescription Microcyn-based wound care products to podiatry professionals in the United States and Canada. Quinnova has a sales
force of over 35 people, selling to dermatologists and podiatrists with a complete line of dermatology products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently derive a significant portion
of our revenues from our dermatology products, which are sold in partnership with Quinnova. We anticipate our presence in the
market to continue to grow. Quinnova launched the Atrapro<SUP>TM</SUP> family of products formulated from our Microcyn&reg; Technology
platform in late February 2012. In partnership with Quinnova, we now market the following products.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Atrapro&trade; Antipruritic Hydrogel,
a non-oily, quick drying gel designed for the relief of pain, burning and itching associated with various dermatoses (pruritus),
which may include the treatment of atopic dermatitis and radiation dermatitis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Atrapro&trade; Dermal Spray with Preservatives,
a non-cytotoxic, non-irritating, and non-sensitizing spray for the management via debridement of wounds such as partial- and full-thickness
wounds, post-surgical wounds, first- and second-degree burns, and grafted and donor sites.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A convenience kit for the treatment of
various dermatoses which packages together Quinnova&rsquo;s Neosalus&reg; Cream with Proderm Technology&reg; and Atrapro&trade;
Antipruritic Hydrogel, a product based on our Microcyn&reg; Technology.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also sold the
option to exclusively sell and distribute our proprietary Microcyn-based acne drug candidate to AmDerma Pharmaceuticals, LLC, an
Amneal alliance member, for a one-time non-refundable payment of $500,000.&nbsp;On June 23, 2011, AmDerma exercised its option
to license rights to the drug candidate. On June 21, 2012, we entered into a collaboration agreement with AmDerma. Pursuant to
the agreement, AmDerma is responsible for the development of a Microcyn-based acne drug candidate in the United States, including
all activities required to gain regulatory approvals. AmDerma will also be responsible for all costs. Additionally, within one
year of the first commercial sale by AmDerma, AmDerma shall identify at least one secondary indication that AmDerma will develop.
If AmDerma declines to pursue such secondary indication, then the right to develop such secondary indication will revert back to
us. We granted AmDerma an exclusive, royalty-bearing perpetual license in the United States and India, with the right to sublicense
and subcontract in certain circumstances, and a right of first refusal to expand the territory of the license to include the European
Union, Canada, Brazil, and Japan. We retained rights to the &ldquo;rest of world.&rdquo; Additionally, we agreed to credit $250,000
of the option payment of $500,000 against future milestone payments in the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Acute Care in U.S. Hospitals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2011, we entered into a multi-year
licensing agreement with Eloquest Healthcare, Inc., a subsidiary of Ferndale Pharma Group, Inc. Under this agreement, we granted
Eloquest Healthcare an exclusive license to market certain Microcyn-based wound care products under the Microcyn brand to hospitals,
ambulatory surgical and acute care centers in the United States. In March 2012, Ferndale/ Eloquest launched a family of Microcyn-based
wound care products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Critical Care</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 22, 2011, we entered into an agreement
to license the exclusive global rights to a unique endotracheal tube, or ETT, from the National Institutes of Health. We believe
the ETT represents a potential breakthrough technology in mitigating ventilator-associated pneumonia. Under the licensing agreement,
we paid a nonrefundable royalty of $20,000, and agreed to pay minimum annual royalties of $5,000, and additional royalties based
off of net sales from use of the license. The patent term of the ETT expires on March 15, 2025. The ETT requires a device clearance
in the United States and we expect to obtain such clearance in the near future. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>International Sales and Marketing by Our
Strategic Business Partners</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Europe</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently rely on exclusive agreements with
country-specific distributors for the sale of Microcyn-based products in Europe, including Italy, the Netherlands, Germany, Czech
Republic, Slovakia, Sweden, Norway, Switzerland, Poland, Finland and Denmark. In July 2013, we added two new partners in the European
Union to sell our Dermacyn&reg; family of products in Finland and Serbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>People&rsquo;s Republic of China</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 28, 2011, we entered into an agreement
with Tianjin Ascent Import and Export Company, Ltd., a distributor in China, to sell certain of our liquid products, which are
currently sold under the product name &ldquo;Microcyn&rdquo; in the United States, into the People&rsquo;s Republic of China. Pursuant
to the agreement, we received a $350,000 non-refundable upfront payment from the distributor in return for exclusivity to sell
these liquid products for the first contract year. In order to maintain exclusivity in subsequent years, the distributor will need
to meet minimum purchase requirements each contract year. The initial term of the contract is for five years and is cancellable
if certain conditions are not met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 26, 2011, we entered into an agreement
with Shanghai Sunvic Technology Co. Ltd., a distributor in China, to sell certain of our gel products, which are currently sold
under the product name &ldquo;Microcyn&rdquo; in the United States, into the People&rsquo;s Republic of China. The initial term
of the contract is for five years and is cancellable if certain conditions are not met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Mexico, South and Central America, and the
Caribbean</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2012, we, along with our Mexican
subsidiary and manufacturer Oculus Technologies of Mexico S.A. de C.V., entered into a license, exclusive distribution and supply
agreement with More Pharma Corporation, S. de R.L. de C.V. (&ldquo;More Pharma&rdquo;). For a one-time payment of $500,000, we
granted More Pharma an exclusive license, with the right to sublicense under certain conditions and with our consent, to all of
our proprietary rights related to certain of our pharmaceutical products for human application that utilize our Microcyn&reg; Technology
within Mexico. For an additional one-time payment of $3,000,000, we also agreed to appoint More Pharma as the exclusive distributor
of certain of our products in Mexico for the term of the agreement. Additionally, we granted More Pharma an exclusive license to
certain of our then-held trademarks in exchange for a payment of $100,000. The term of the agreement is twenty-five years from
the effective date of August 15, 2012. The term of the license agreement will automatically renew after the twenty-five year term
for successive two year terms as long as More Pharma has materially complied with any and all of the obligations under the license
agreement, including but not limited to, meeting the minimum purchase requirements set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2012, we also entered into an
exclusive distribution and supply agreement with More Pharma. For a one-time payment of $1,500,000, we granted More Pharma exclusive
ability to market and sell certain of our pharmaceutical products for human application that utilize our Microcyn&reg; Technology.
We also appointed More Pharma as our exclusive distributor, with the right to execute sub-distribution agreements under certain
conditions and with our consent, within the following countries: Antigua &amp; Barbuda, Argentina, Aruba &amp; Curacao, Bahamas,
Barbados, Belize, Bolivia, Bonaire, Brazil, British Guyana, British Islands, Cayman Islands, Chile, Colombia, Cuba, Dominica, Dominican
Republic, Ecuador, El Salvador, French Guyana, Grenada, Guadalupe, Guatemala, Haiti, Honduras, Jamaica, Martinique, Nicaragua,
Paraguay, Peru, St. Bartolome, St. Vincent &amp; Grenades, Surinam, Trinidad &amp; Tobago, Turks &amp; Caicos Islands, Uruguay,
Venezuela and Virgin Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2013, we obtained, in close collaboration
with our global partner More Pharma, new regulatory approvals for Microcyn&reg;-based antiseptic products, under the brand name
Microdacyn&reg;, in Panama and El Salvador. More Pharma intends to begin commercialization of these new antiseptic products in
both countries in the summer of 2013, and to continue to expand product offerings of Microcyn-based products into the other countries
of South and Central America, and the Caribbean in the near future. In July 2013, we were granted a Mexican patent for the use
of our novel antimicrobial surgical solution in the treatment and prevention of peritonitis. The term of the patent expires in
2027 and will allow More Pharma the opportunity to pursue a new drug candidate in Latin America. More Pharma has also received
regulatory approval to market our Microdacyn60&reg; family of products in Honduras.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&ldquo;Rest of World&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In India, we entered into an exclusive agreement
with Alkem Laboratories, a large pharmaceutical company in India, for the sale of Microcyn-based products in India and Nepal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Throughout the rest of the world, we intend
to use strategic partners and distributors who have a significant sales, marketing and distribution presence in their respective
countries. We have established partners and distribution channels for our wound care products in Bangladesh, Pakistan, Singapore,
United Arab Emirates, Jordan, Kuwait, Yemen, Iraq, Malaysia, Indonesia and Saudi Arabia. We have also received approval to launch
a new Microcyn-based medical device in Indonesia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2013, we announced that our Singapore
business partner, Dyamed Biotech Pte. Ltd, is initiating the rollout of five new Microcyn&reg; Technology-based products in Singapore
and Malaysia, both in the hospital and consumer markets. The five products, which include Dermacyn&trade; BabyGuard, Dermacyn DermaGuard,
Dermacyn SkinGuard Solution, Dermacyn SkinGuard Hydrogel and Dermacyn Wound Care Hydrogel, will be rolled out sequentially and
all products are expected to be commercialized by year&rsquo;s end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2013, we obtained new regulatory approvals
in Dubai, United Arab Emirates, Kuwait, and Iraq for three new Microcyn&reg;-based consumer products: Face Cool&trade;, a hydrogel
for the treatment of acne and various dermatoses; Baby Cool&trade;, a hydrogel for treatment of baby rash; and Lady Cool&trade;,
a feminine hygiene wash. All products are targeted to be launched in the fall of 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ruthigen, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
wholly owned subsidiary, Ruthigen, Inc., was incorporated in the State of Nevada on January 18, 2013, </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">and
reincorporated from Nevada to Delaware on September 25, 2013. Ruthigen has established offices in Santa Rosa, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 2, 2013, we entered into a separation
agreement with Ruthigen that contains key provisions relating to our ongoing relationship with Ruthigen, and more specifically
governs our relationship with Ruthigen following the completion of Ruthigen&rsquo;s intended initial public offering. We previously
announced our entry into a license and supply agreement and a shared services agreement with Ruthigen. Each of these agreements
has been entered into in the overall context of Ruthigen&rsquo;s separation from our Company. The effective date for all three
agreements is the closing date of Ruthigen&rsquo;s intended initial public offering, if any should occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>License and Supply Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the license and supply agreement, we agreed to exclusively license certain of our proprietary technology to Ruthigen to enable
Ruthigen&rsquo;s research and development and commercialization of the newly discovered RUT58-60, and any improvements to it, in
the United States, Canada, European Union and Japan, referred to as the Territory, for certain invasive procedures in human treatment
as defined in the license and supply agreement.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">On October 9, 2013,
we entered into Amendment No. 1 to the license and supply agreement, which amended the second milestone event set forth in Section
7.1 of the license and supply agreement. On November 6, 2013, we entered into Amendment No. 2 to the license and supply agreement
with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the license and supply agreement and to
amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the license and supply agreement. All other
terms and conditions of the license and supply agreement remain unmodified and in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The license and supply agreement provides Ruthigen
with the exclusive option, exercisable within the first five years following the effective date of the agreement, to expand the
license to certain other therapeutic indications upon payment of a license expansion fee of $10 million within the first two years
following the effective date of the agreement or, after the two&ndash;year period, the same fee plus certain out-of-pocket costs
we may incur in developing products for any of the indications. Additionally, we will be prohibited from using the licensed proprietary
technology to sell products that compete with Ruthigen&rsquo;s products within the Territory, and Ruthigen cannot sell any device
or product that competes with our products being sold or developed as of the effective date of the license and supply agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ruthigen will be required to make a total
of $5,000,000 in milestone payments to us for the first product only, as follows: upon completion of Ruthigen&rsquo;s first
meeting with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen&rsquo;s first pivotal clinical
trial and upon first patient enrollment in Ruthigen&rsquo;s second pivotal clinical trial. In addition, as further
consideration under the agreement, Ruthigen will be required to make royalty payments to us based on Ruthigen&rsquo;s annual
net sales of the product from the date of first commercial sale to the date that Ruthigen ceases to commercialize the
product, which percentage royalty rate will vary between 3% and 20% and will increase based on various net sales thresholds
and will differ depending on the country in which the sales are made. Ruthigen also agreed to purchase certain research and
development and manufacturing equipment from us for approximately $3 million following the completion of Ruthigen&rsquo;s
intended initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Shared Services Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">We also entered into a shared services agreement
with Ruthigen that would take effect upon the completion of Ruthigen&rsquo;s proposed initial public offering, if any should occur,
pursuant to which we will provide Ruthigen with general services, including general accounting, human resources, laboratory personnel
and shared R&amp;D resources while Ruthigen plans to establish an independent facility and systems. As a wholly owned subsidiary
of our Company, Ruthigen will be financed by us until the completion of the proposed initial public offering, if any should occur,
and after such event, Ruthigen would become responsible for its own expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><I>Separation Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Effectiveness and Term</I> &ndash; On
August 2, 2013, we entered into a separation agreement with Ruthigen that contains key provisions relating to our
ongoing relationship with Ruthigen, and more specifically governs our relationship with Ruthigen following the completion
of Ruthigen&rsquo;s intended initial public offering. Because we will continue to own, at least initially, the majority
of Ruthigen&rsquo;s outstanding common stock following Ruthigen&rsquo;s intended initial public offering, the
separation agreement contains certain limitations on our ability to control various aspects of Ruthigen&rsquo;s business and
operations in order for Ruthigen to operate as independently as possible from us to unlock the value proposition of RUT58-60,
which Ruthigen expects to result in financial gain to us and Ruthigen, if Ruthigen is successful. The separation agreement
takes effect upon the closing of Ruthigen&rsquo;s intended initial public offering and terminates 8.5 years following the
closing of Ruthigen&rsquo;s intended initial public offering, unless the parties mutually agree to terminate it earlier, and,
as a general matter, most of the material restrictions and obligations contained in the separation agreement lapse when we
and our subsidiaries (other than Ruthigen) own less than 19.9%, or the ownership threshold for purposes of the agreement, of
the outstanding shares of Ruthigen&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Expense Allocation and
Reimbursement</I> &ndash; The separation agreement sets forth the methodology for the allocation of the operational and
offering related expenses incurred prior to and in connection with Ruthigen&rsquo;s intended initial public offering for
which Ruthigen is required to reimburse us. Ruthigen will also reimburse us for expenses such as salaries and benefits
advanced or paid on Ruthigen&rsquo;s behalf, or for Ruthigen&rsquo;s benefit, during a transition period following the
closing of Ruthigen&rsquo;s intended initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Marketing and
Transfer Restrictions</I> &ndash; In order for the parties to control the flow of the Ruthigen shares held by us into the
market to attempt to minimize price volatility and instability in the trading market for Ruthigen&rsquo;s shares, the
separation agreement contains a series of restrictions on our ability to transfer the Ruthigen shares we own. As a general
matter, transfers of the Ruthigen shares we own are primarily expected to be conducted through private marketing efforts in
private placement transactions, except in the cases prescribed in the separation agreement. For example, we are restricted
from engaging in marketing efforts related to the transfer of the Ruthigen shares we own and we are required to refer
indications of interest from third parties regarding the transfer of the Ruthigen shares we own to Ruthigen, in each case,
except during certain prescribed periods set forth in the separation agreement. With respect to transfer restrictions, we are
restricted from transferring any of the Ruthigen shares we own during the one-year lock up period immediately following
Ruthigen&rsquo;s intended initial public offering. Following the one-year lock up period, transfers by us of the Ruthigen
shares we own must be conducted with the consent of Ruthigen&rsquo;s board of directors or within the prescribed requirements
for such transfers set forth in the separation agreement. These prescribed requirements include that the transfers must be in
private placement transactions, that the purchase price discount may not exceed 15% or 20% of the prevailing market price
depending on the type of transferee, the amount of shares transferred in a given transfer (or series of transfers comprising
a single transaction) may not exceed the greater of 5% of Ruthigen&rsquo;s outstanding shares or $1.5 million in net proceeds
to us, as well as certain other requirements set forth in the separation agreement. Ruthigen has also agreed to assist us
in consummating transfers of the Ruthigen shares we own, because Ruthigen expects to be well-informed as to where the
investor demand for Ruthigen&rsquo;s shares resides and Ruthigen believes its involvement may be beneficial to us and the
trading market for Ruthigen&rsquo;s shares. In addition to the prescribed manner for us to conduct transfers described above,
if, following a minimum of 41.5 months following the closing of Ruthigen&rsquo;s intended initial public offering, we have
not consummated transfers of the Ruthigen shares we own resulting in at least $3.8 million in net proceeds to us, then we
have a one-time transfer and registration right to transfer the Ruthigen shares we own in an amount equal to the difference
between $3.8 million and the net proceeds received by us resulting from transfers of the Ruthigen shares we own as of the
time we elect to exercise our one-time right. Transfers conducted using this one-time right must be conducted with the
consent of Ruthigen&rsquo;s board of directors or within the prescribed requirements for such transfers set forth in the
separation agreement, including, for example, that the purchase price discount may not exceed 30% of the prevailing market
price, the amount of shares transferred may not exceed $3.8 million in net proceeds to us, as well as certain other
requirements set forth in the separation agreement. The separation agreement also provides for certain cooling off periods
between marketing attempts and/or successful transfers, the length of which are dependent upon whether and how many Ruthigen
shares we transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Distribution</I> - Ruthigen believes that
a distribution of Ruthigen shares by us to our shareholders would be advantageous to the market for Ruthigen&rsquo;s shares by
increasing liquidity, would accelerate Ruthigen&rsquo;s ability to become independent from us by decreasing our ownership of Ruthigen&rsquo;s
common stock and would be beneficial for our stockholders who would have a direct opportunity to participate in the Ruthigen value
proposition.&nbsp;We have advised Ruthigen that, following the completion of Ruthigen&rsquo;s intended initial public offering
and subject to the expiration of any applicable lock-up periods or other agreements we have or may have with Ruthigen, we do not
have any near term plans to distribute the Ruthigen shares held by us to our stockholders. The decision to conduct any such distribution
is at the sole discretion of our board of directors. There is no assurance that such a distribution will ever occur. However, pursuant
to the separation agreement, we have agreed, from time to time, to retain investment bankers and tax advisors to re-evaluate the
advisability of conducting a plan of distribution of the Ruthigen shares we own and Ruthigen has agreed to register any shares
that we may distribute in the future. Presently, it is expected that any potential distribution will be taxable to our Company
and our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Registration Rights</I> &ndash; The separation
agreement provides us with certain &ldquo;piggy back&rdquo; registration rights if Ruthigen proposes to publicly register any
of its common stock following the completion of Ruthigen&rsquo;s intended initial public offering, subject to certain conditions
and limitations, including cut back rights in the discretion of Ruthigen&rsquo;s board of directors. In addition, following transfers
by us of the Ruthigen shares, we have certain demand registration rights requiring Ruthigen to register all of the Ruthigen shares
we have transferred. In addition, as described under &ldquo;<I>Marketing and Transfer Restrictions</I>&rdquo; above, if, following
a minimum of 41.5 months following the closing of Ruthigen&rsquo;s intended initial public offering have lapsed under the separation
agreement and we have not consummated transfers of the Ruthigen shares we own resulting in at least $3.8 million in net proceeds
to us, then we have a one-time transfer and registration right that requires Ruthigen, subject to certain conditions and limitations,
to register the difference between $3.8 million and the Ruthigen shares transferred by us pursuant to the separation agreement
as of the time we elect to exercise our one-time right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Standstill</I> &ndash; We have agreed that,
subject to the ownership threshold, we shall not, and shall not act in concert with any person to, make or participate in a solicitation
of proxies or powers of attorney or similar rights to vote any of the Ruthigen shares we own or to deposit the Ruthigen shares
we own in a voting trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Restrictions Relating to Debt</I> &ndash;
We have agreed that, subject to the ownership threshold, we shall disclose in writing the existence of the transfer and other restrictions
involving the Ruthigen shares we own, which are set forth in the separation agreement, to potential lenders in the context of our
potential negotiations to incur debt in the future, where such debt would be collateralized by the Ruthigen shares we own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>WTI Loans</I> &ndash; Ruthigen&rsquo;s
primary assets serve as collateral under certain loan and security agreements, or the WTI loan agreements, between us and
Venture Lending &amp; Leasing V, Inc. and Venture Lending &amp; Leasing VI, Inc. The separation agreement provides that if we
default under the WTI loan agreements and Ruthigen is required to make payments or transfer its assets to Venture Lending
&amp; Leasing V, Inc. and Venture Lending &amp; Leasing VI, Inc. on our behalf, then Ruthigen is not required to make
payments that it may owe to us until such time as we reimburse Ruthigen or Ruthigen is otherwise made whole after having met
our obligations under the WTI loan agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Voting</I> &ndash; We have agreed that,
subject to the ownership threshold, we shall vote or consent all of the Ruthigen shares we own in the same manner as the majority
of the minority holders of Ruthigen&rsquo;s common stock (non-Oculus holders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Equity Plan, Oculus Equity and Corporate
Governance</I> &ndash; We and Ruthigen have agreed on the principal terms of Ruthigen&rsquo;s equity incentive plan, including
the formula for the number of shares reserved under the plan, the vesting schedule of awards under the plan, timing, size and award
type of the initial grants to be made following the closing of Ruthigen&rsquo;s intended initial public offering, and the formula
for the evergreen refresh provision and other share caps on certain types of awards and future equity plans. The separation agreement
clarifies that options for common stock of our Company held by employees and directors of Ruthigen shall continue to vest as long
as the individuals continue in service to Ruthigen. In addition, the separation agreement provides that Ruthigen&rsquo;s restated
articles of incorporation and bylaws for purposes of operating as a public company will contain provisions for a staggered board
of directors and plurality voting for the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Indemnification &ndash; </I>The
separation agreement provides that each party will indemnify, defend and hold harmless the other party and its affiliates for
third party claims asserted against the other party, and that we will indemnify, defend and hold harmless Ruthigen and
its affiliates from and against any and all direct losses relating to the WTI loan agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Directors&rsquo; and Officers&rsquo; Insurance</I>
&ndash; The separation agreement provides that, so long as we shall maintain a directors&rsquo; and officers&rsquo; insurance program
covering the past and present officers and directors of our Company, the program shall be standard in our industry and if there
is a change to the program, then we shall provide prior notice.&nbsp; In addition, we have agreed not to exclude any former Oculus
director from any insurance policy coverage if such coverage is made available to our Company&rsquo;s then existing directors and
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Miscellaneous</I> &ndash; The separation
agreement also contains customary provisions regarding confidentiality, access to information, books and records, dispute resolution
and the release of claims that pre-date the effective date of the separation agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NVN Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We established a nutritional products division
in the beginning of 2012 to expand our product pipeline. NVN Therapeutics is based in Sacramento, California. This division aims
to develop and manufacture medical foods that combine the best of science and nature to create products that provide patients with
natural healthcare therapies. This division is currently focused on the development of products for the women&rsquo;s health markets.
Our primary medical food product, Glucorein&trade; PCOS, was launched and is intended for the dietary management of Polycystic
Ovary Syndrome (PCOS). PCOS afflicts approximately 10% of women of reproductive age and is thought to be one of the leading causes
of female infertility and the most frequent endocrine problem in women of reproductive age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competition in this segment is generally
from other consumer and healthcare manufacturers. Competitive factors include consumer advertising, formulation, packaging, scientific
innovation, intellectual property, price and availability of product forms. A significant aspect of competition is the search for
ingredient innovations. The introduction of new products by competitors, changes in medical practices and procedures, and regulatory
changes can result in product obsolescence. In addition, private label and local manufacturers' products may increase competitive
pressure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contract Testing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also operate a microbiology contract testing laboratory division
that provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs,
as well as testing on our products and potential products. Our testing laboratory complies with U.S. Current Good Manufacturing
Practices (CGMPs) and Quality Systems Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Comparison of Three Months Ended September 30, 2013 and 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total revenues were $4,089,000 for the three months ended September
30, 2013, as compared to $4,526,000 for the same period in the prior year. Product revenues for the three months ended September
30, 2013 were down 10% from the same period in the prior year with reported decreases in revenues in Mexico, China and India, partially
offset by increases in revenues in Europe, Middle East and Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product revenue in the United States for the
three months ended September 30, 2013 was essentially flat when compared to the same period in the prior year, with higher reported
sales in dermatology, wound care and animal healthcare segments, offset by declines in sales related to the discontinuation of
our partnerships with Union Springs Pharmaceuticals and Onset Pharmaceuticals. We recorded revenue in the amounts of $1,289,000
and $1,229,000, for the three months ended September 30, 2013 and 2012, respectively, from our partner Innovacyn, Inc., with a
6% increase for the three months ended September 30, 2013 over the same period in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue in Mexico for the three months ended
September 30, 2013 decreased $510,000, or 27%, when compared to the same period in the prior year. The decrease in revenue was
attributed to our transaction with More Pharma, our exclusive distributor in Mexico, which closed in August 2012. The impact of
the transaction resulted in increased unit sales for the three months ended September 30, 2012 to existing customers prior to the
close of the transaction, as well as sales made directly to More Pharma. Similar sales did not incur in the three months ended
September 30, 2013. Further, the higher unit volume growth of 21% for the three months ended September 30, 2013 and the recognition
of $378,000 related to the amortization of upfront fees paid by More Pharma was more than offset by a 52% reduction in the average
overall sales price per unit. Finally, due to the transfer of our sales function in Mexico to More Pharma, our related operating
expenses in Mexico were $678,000 lower for the three months ended September 30, 2013 than reported for the same period in the prior
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue in Europe and Rest of World for the
three months ended September 30, 2013 increased $99,000, or 20%, as compared to the same period in the prior year, with increases
in sales in Europe, Middle East and Singapore, partially offset by decreases in China and India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows our product revenues
by geographic region:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Three Months<BR> Ended&nbsp;September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: left">United States</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,898,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,898,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;%</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mexico</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,862,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(510,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27)%</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Europe and Rest of World</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">603,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">504,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20%</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,853,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,264,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(411,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10)%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Licensing revenues were $397,000 and
$374,000 for the three months ended September 30, 2013 and 2012, respectively. These amounts are included in our calculation of
product revenues and are reflected in the table above under the respective geographic region where such licensing revenues were
earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Service revenues for the three months ended
September 30, 2013 decreased $26,000 when compared to the same period in the prior year due to a decrease in the number of tests
provided by our services business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Gross Profit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We reported gross profit related to our products
of $2,650,000, or 69% of product revenues, during the three months ended September 30, 2013, compared to a gross profit of $3,172,000,
or 74% of product revenues, for the same period in the prior year. Licensing revenues are included in our calculation of product
revenues and gross profit for the quarters ended September 30, 2013 and 2012.&nbsp;Gross margins for the three months ended September
30, 2013 were down due to the decline of margins in Mexico related to the More Pharma transaction, partially offset by higher gross
margins in the United States and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expense increased
$370,000 to $883,000 for the three months ended September 30, 2013, compared to $513,000 for the same period in the prior year,
due to $495,000 of expenses incurred by our wholly owned subsidiary, Ruthigen, Inc. for certain costs including costs related to
preclinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our research and development expenses
to decrease over the next few quarters as we expect to incur lower expenses related to Ruthigen after its intended initial public
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Selling, General and Administrative Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expense
decreased $411,000, or 12%, to $3,093,000 during the three months ended September 30, 2013, as compared to $3,504,000 for the same
period in the prior year. The decrease for the three months ended September 30, 2013 was primarily due to a reduction in selling
expenses in Mexico of $678,000 and lower non-Ruthigen expenses in the United States, including $199,000 of stock compensation charges,
despite an increase in overall Ruthigen expenses of $499,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our selling, general and administrative
expenses to decrease in the next period as we expect expenses related to Ruthigen to decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Expense and Interest Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense decreased $92,000 during the
three months ended September 30, 2013 to $188,000, as compared to $280,000 for the same period in the prior year. The decrease
for the three months ended September 30, 2013 related to a decrease of $26,000 of non-cash interest expense and a $66,000 reduction
of cash interest incurred during the quarter. The cash and non-cash interest is primarily related to borrowings from Venture Lending
&amp; Leasing V, Inc. and Venture Lending &amp; Leasing VI, Inc.&nbsp;and these amounts will continue to decrease as our outstanding
debt moves closer to maturity. Interest income for the three months ended September 30, 2013 showed no material change as compared
to the same period in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Expense, Net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other expense, net increased $13,000 to $39,000
for the three months ended September 30, 2013, compared to other expense, net of $26,000 for the same period in the prior year.
The change in other expense, net for the three months ended September 30, 2013 was primarily related to foreign exchange gains
and losses and tax expenses.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Derivative Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2012, we recorded a decrease in the fair value of our derivative liabilities of $397,000 and as a result, we recorded this amount
as a non-cash loss. The change in the fair value of our derivative liabilities for the three months ended September 30, 2012 was
primarily the result of increases in our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value of Common Stock Issued with
Stock Purchase Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2013, we recorded a gain of $99,000 on the fair value of common stock issued pursuant to the terms of a stock purchase agreement
we entered into with Venture Lending &amp; Leasing V, LLC and Venture Lending &amp; Leasing VI, LLC on October 30, 2012 for the
issuance to the entities of shares of our common stock having an initial aggregate fair market value equal to $3,500,000. This
gain was attributed to an increase in our stock price of $2.58 at June 30, 2013 to $2.74 at September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Net Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the three months ended September
30, 2013 was $1,399,000, a decrease of $120,000, as compared to net loss of $1,519,000 for the same period in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Comparison of Six Months Ended September
30, 2013 and 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total revenues were $7,461,000 for the six
months ended September 30, 2013, as compared to $8,577,000 for the same period in the prior year. Product revenues for the six
months ended September 30, 2013 were down 13% from the same period in the prior year with reported decreases in revenues in the
United States, Mexico and Middle East, partially offset by increases in revenues in Europe, China, India and Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product revenue in the United States for the
six months ended September 30, 2013 decreased $710,000, or 18%, as compared to the same period in the prior year due to decline
in sales in the animal healthcare market and other markets. We recorded revenue from our partner Innovacyn, Inc. in the amounts
of $2,030,000 and $2,365,000 for the six months ended September 30, 2013 and 2012, respectively. Although we experienced revenue
growth for the animal healthcare market in the quarter ended September 30, 2013, our revenue recoded for the six months ended September
30, 2013 was lower as compared to the same period in the prior year due to a decline in revenue recorded in the quarter ended June
30, 2013 related to the late winter storms in the East and Midwest. The decline in revenue for the six months ended September 30,
2013 attributed to other products was partially due to a decrease in sales related to the discontinuation of our partnerships with
Union Springs Pharmaceuticals and Onset Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue in Mexico for the six months ended
September 30, 2013 decreased $464,000, or 14%, when compared to the same period in the prior year. The decrease in revenue was
attributed to our transaction with More Pharma, our exclusive distributor in Mexico, which closed in August 2012. The impact of
the transaction resulted in increased unit sales for the six months ended September 30, 2012 to existing customers prior to the
close of the transaction, as well as sales made directly to More Pharma. Similar sales did not incur in the six months ended September
30, 2013. Further, the higher unit volume growth of 35% for the six months ended September 30, 2013 and the recognition of $752,000
related to the amortization of upfront fees paid by More Pharma was more than offset by about a 49% reduction in the average overall
sales price per unit. Finally, due to the transfer of our sales function in Mexico to More Pharma, our related operating expenses
in Mexico were $1,072,000 lower than reported for the same period in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue in Europe and Rest of World for the
six months ended September 30, 2013 increased $101,000, or 11%, as compared to the same period in the prior year, with increases
in sales in Europe, China, India, and Singapore, partially offset by decreases in Middle East.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table shows our product revenues by geographic region:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Six Months<BR> Ended&nbsp;September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 32%; text-align: left">United States</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,221,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,931,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(710,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">(18)%</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mexico</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,776,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,240,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(464,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14)%</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Europe and Rest of World</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,010,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">909,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">101,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11%</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,007,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,080,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,073,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(13)%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Licensing revenues were $830,000 and $406,000
for the six months ended September 30, 2013 and 2012, respectively. These amounts are included in our calculation of product revenues
and are reflected in the table above under the respective geographic region where such licensing revenues were earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Service revenues for the six months ended September
30, 2013 decreased $43,000 when compared to the same period in the prior year due to a decrease in the number of tests provided
by our services business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Gross Profit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We reported gross profit related to our Microcyn&reg;
products of $4,783,000, or 68% of product revenues, during the six months ended September 30, 2013, compared to a gross profit
of $6,000,000, or 74% of product revenues, for the same period in the prior year. Licensing revenues are included in our calculation
of product revenues and gross profit for the six months ended September 30, 2013 and 2012.&nbsp;Gross margins for the six months
ended September 30, 2013 were down due to the decline of margins in Mexico related to the More Pharma transaction, partially offset
by higher gross margins in the United States and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expense increased
$345,000 to $1,390,000 for the six months ended September 30, 2013, compared to $1,045,000 for the same period in the prior year,
with $670,000 of expenses incurred by our wholly owned subsidiary Ruthigen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our research and development expense
will decrease over the next few quarters as we expect to incur lower expenses related to Ruthigen after its intended initial public
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Selling, General and Administrative Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expense
decreased $439,000, or 7%, to $5,912,000 during the six months ended September 30, 2013, as compared to $6,351,000 for the same
period in the prior year. The decrease for the six months ended September 30, 2013 was primarily due to a reduction in selling
expenses in Mexico of $1,072,000 and $212,000 in stock compensation charges, partially offset by higher costs of $801,000 related
to Ruthigen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect selling, general and administrative
expenses to decrease in the next period as we expect expenses related to Ruthigen to decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Expense and Interest Income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense decreased $130,000 during
the six months ended September 30, 2013 to $438,000 as compared to $568,000 for the same period in the prior year. The decrease
for the six months ended September 30, 2013 related to a decrease of $9,000 of non-cash interest expense, and a decrease of $121,000
of cash interest during the period. The cash and non-cash interest is primarily related to borrowings from Venture Lending &amp;
Leasing V, Inc. and Venture Lending &amp; Leasing VI, Inc.&nbsp;and these amounts will continue to decrease as our outstanding
debt moves closer to maturity.&nbsp;Interest income for the six months ended September 30, 2013 showed no material change as compared
to the same period in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other Expense, Net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other expense, net increased $21,000 to $67,000
for the six months ended September 30, 2013, compared to other expense, net of $46,000 for the same period in the prior year. The
change in other expense, net for the six months ended September 30, 2013 was primarily due to foreign exchange gains and losses
and tax expenses.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Derivative Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30, 2012,
we recorded an increase in the fair value of our derivative liabilities of $850,000 and as a result, we recorded this amount as
a non-cash gain. The change in the fair value of our derivative liability for the six months ended September 30, 2012 was primarily
the result of decreases in our stock price and the issuance of warrants in connection with our registered direct offering that
closed on April 22, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value of Common Stock Issued with
Stock Purchase Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended September 30, 2013,
we recorded a loss of $210,000 on the fair value of common stock issued pursuant to the terms of a stock purchase agreement we
entered into with Venture Lending &amp; Leasing V, LLC and Venture Lending &amp; Leasing VI, LLC on October 30, 2012 for the issuance
to the entities of shares of our common stock having an initial aggregate fair market value equal to $3,500,000. This loss was
attributed to a decrease in our stock price of $3.08 at March 31, 2013 to $2.74 at September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Net Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the six months ended September
30, 2013 was $3,111,000 as compared to net loss of $1,074,000 for the same period in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We reported a net loss of $3,111,000
for the six months ended September 30, 2013. At September 30, 2013, our accumulated deficit amounted to $140,856,000. We
had working capital of $2,175,000 as of September 30, 2013. We expect the need to raise additional capital from external
sources in order to continue the longer term efforts contemplated under our business plan and repay our outstanding notes
payable obligations. We expect to continue incurring losses for the foreseeable future and may need to raise additional
capital to pursue our product development initiatives, to penetrate markets for the sale of our products and continue as a
going concern. We cannot provide any assurances that we will be able to raise additional capital. Our management believes
that we have access to capital resources through possible public or private equity offerings, debt financings,
corporate collaborations or other means, if needed; however, we have not secured any commitment for new financing at this
time, nor can we provide any assurance that the Ruthigen initial public offering will be completed or that other new
financings will be available on commercially acceptable terms, if needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Sources of Liquidity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2013, we had cash and cash
equivalents of $3,190,000. Since our inception, substantially all of our operations have been financed through sales of equity
securities. Other sources of financing that we have used to date include our revenues, as well as various loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Since October 1, 2011, substantially all of our operations have
been financed through the following transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">proceeds of $222,000 received from the exercise of common stock purchase
warrants and options;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">proceeds of $2,500,000 received from the issuance of a debt instrument
in the year ended March 31, 2012;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">net proceeds of $1,894,000 received from a registered direct offering
of common stock on December 28, 2011;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">net proceeds of $2,797,000 received from a registered direct offering
on April 22, 2012; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">net proceeds of $3,052,000 received from an underwritten offering on
March 12, 2013.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2013, we had cash and cash
equivalents of $3,190,000, compared to $7,900,000 at March 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities during
the six months ended September 30, 2013 was $2,454,000, primarily due to our net loss of $3,111,000 for the period. Additionally,
we had non-cash transactions during the six months ended September 30, 2013, including: $666,000 of stock-based compensation expenses;
a $210,000 loss on the fair value adjustment of common stock issued to Venture Lending &amp; Leasing V, LLC and Venture Lending
&amp; Leasing VI, LLC in connection with the stock purchase agreement dated October 30, 2012; and non-cash interest of $294,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by operating activities
during the six months ended September 30, 2012 was $3,292,000 primarily due to the receipt of a $5,100,000 upfront payment from
More Pharma offset by our net loss of $1,074,000 for the period. Additionally, we had non-cash transactions during the six months
ended September 30, 2012, including $941,000 of stock-based compensation expenses, an $850,000 gain on the fair value adjustment
of our derivative liabilities, and non-cash interest of $303,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities was $312,000 for the six
months ended September 30, 2013, primarily due to $338,000 related to equipment purchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities was $205,000
for the six months ended September 30, 2012, consisting of $62,000 related to equipment purchases and $143,000 related to long-term
prepaid expenses associated with the More Pharma transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in financing activities was $1,918,000
for the six months ended September 30, 2013, and consisted of principal payments on debt in the amount of $1,138,000 and $780,000
of deferred offering costs related to the intended initial public offering of our subsidiary, Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities was
$1,874,000 for the six months ended September 30, 2012. During the six months ended September 30, 2012, we received net proceeds
of $2,832,000 from our April 2012 registered direct offering of common and preferred stock. The offering proceeds were offset by
principal payments on the debt in the amount of $974,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operating Capital and Capital Expenditure
Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We reported a net loss of $3,111,000 for the
six months ended September 30, 2013. At September 30, 2013, our accumulated deficit amounted to $140,856,000, and at March 31,
2013, our accumulated deficit amounted to $137,745,000. At September 30, 2013, our working capital amounted to $2,175,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect the need to raise additional
capital from external sources in order to continue the longer term efforts contemplated under our business plan and repay our
outstanding notes payable obligations. We expect to continue incurring losses for the foreseeable future and may need to
raise additional capital to pursue our product development initiatives and to penetrate markets for the sale of our products.
Upon the closing of the intended initial public offering by our subsidiary, Ruthigen, Inc., we will be repaid for certain
costs incurred and advanced related to Ruthigen&rsquo;s initial public offering and certain other agreed-upon expenses,
pursuant to the terms of the separation agreement we entered into with Ruthigen. At September 30, 2013, these costs amounted
to $911,000, of which $824,000 is reported as deferred offering costs in the accompanying condensed consolidated balance
sheet and $87,000 was reported as selling, general and administrative expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order for us to potentially commercialize
Microcyn&reg; as a drug product in the United States, we must conduct clinical trials, which can be costly. Therefore, commencement
of such pivotal clinical trials will be delayed until we find a strategic partner to assist with funding. Without a strategic partner
or additional capital, our pivotal clinical trials will be delayed for a period of time that is currently indeterminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future funding requirements will depend
on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the scope, rate of progress and cost of our clinical trials and other
research and development activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">future clinical trial results;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms and timing of any collaborative, licensing and other arrangements
that we may establish;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the cost and timing of regulatory approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the cost and delays in product development as a result of any changes
in regulatory oversight applicable to our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the cost and timing of establishing sales, marketing and distribution
capabilities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the effect of competing technological and market developments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the cost of filing, prosecuting, defending and enforcing any patent
claims and other intellectual property rights; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which we acquire or invest in businesses, products and
technologies.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires our management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities
at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs
related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to our deferred
taxes, the valuation of equity and derivative instruments, debt discounts and the estimated amortization periods of upfront licensing
fees received from customers. Periodically, we evaluate and adjust estimates accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 3.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Quantitative and Qualitative Disclosures About Market Risk</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a smaller reporting company, we are electing
scaled disclosure reporting obligations and therefore are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 4.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Controls and Procedures</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) <B><I>Evaluation of Disclosure Controls
and Procedures</I></B>. We maintain &ldquo;disclosure controls and procedures,&rdquo; as such term is defined in Rule 13a-15(e)
under the Securities Exchange Act of 1934, or the Exchange Act, that are designed to ensure that information required to be disclosed
by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time
periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated
to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that
disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the disclosure controls and procedures are met. Accordingly, our disclosure controls and procedures have
been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management
was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and
procedures. The design of any disclosure controls and procedures is also based, in part, upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the supervision and with the participation
of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our
disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report.
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls
and procedures are effective at the reasonable assurance level for the quarter ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) <B><I>Changes in Internal Controls.</I></B>
There&nbsp;were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended September
30, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II.  OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Legal Proceedings</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2006, we received a written communication
from the grantor of a license to an earlier version of our technology indicating that such license was terminated due to an alleged
breach of the license agreement by us. The license agreement extends to our use of the technology in Japan only. While we do not
believe that the grantor&rsquo;s revocation is valid under the terms of the license agreement and no legal claim has been threatened
to date, we cannot provide any assurance that the grantor will not take legal action to restrict our use of the technology in the
licensed territory. While our management does not anticipate that the outcome of this matter is likely to result in a material
loss, there can be no assurance that if the grantor pursues legal action, such legal action would not have a material adverse effect
on our consolidated financial position or results of comprehensive loss. We have not accrued a loss reserve for this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2011, we received notice of a lawsuit
filed in Mexico by Cesar Mangotich Pacheco and Prodinnv, S.A. de C.V. represented by Cesar Mangotich Pacheco. The lawsuit appears
to allege conversion of assets, tortious interference and defamation, among other claims. We are currently evaluating the lawsuit,
conferring with local counsel and translating the documents we have received. Our preliminary assessment is that the lawsuit is
completely without merit and intend to vigorously defend our position. We have not accrued a loss reserve for this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Company, on occasion, may be involved in
legal matters arising in the ordinary course of our business including matters involving proprietary technology. While management
believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or
could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 1A.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risk Factors</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes from risk
factors previously disclosed in our annual report on Form 10-K for the fiscal year ended March&nbsp;31, 2013, as filed with the
SEC on June&nbsp;25, 2013, except as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to maintain compliance
with the continued listing standards as set forth in the Nasdaq Listing Rules, our common stock could be delisted from The Nasdaq
Capital Market, and if this were to occur, then the price and liquidity of our common stock, and our ability to raise additional
capital may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is currently listed on The
Nasdaq Capital Market. Continued listing of a security on The Nasdaq Capital Market is conditioned upon compliance with certain
continued listing requirements and continued listing standards set forth in the Nasdaq Listing Rules for Nasdaq Capital Market
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As reported in our Form 10-Q for the quarter
ended September 30, 2013, our stockholders&rsquo; equity was approximately $1,550,000. Under Nasdaq Listing Rule 5550(b)(1), we
are required to maintain a minimum of $2,500,000 in stockholders&rsquo; equity. We anticipate the receipt of a letter from the
Listing Qualifications staff of The Nasdaq Stock Market LLC that we will notify us of our non-compliance and grant us a certain
period to regain compliance with the Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this 10-Q, there is no effect
on the listing or trading of our common stock. However, there can be no assurance that we will be able to regain compliance with
Listing Rule 5550(b)(1) or the other compliance alternatives under Listing Rule 5550(b). In the event we do not regain compliance
with the Listing Rule prior to the expiration of the compliance period, if one is granted, we will likely receive written notification
that our securities are subject to delisting, at which time we may appeal the delisting determination to a Hearings Panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are not able to regain compliance with
the continued listing standards as set forth in the Nasdaq Listing Rules for Nasdaq Capital Market companies, our common stock
will be delisted from The Nasdaq Capital Market and an associated decrease in liquidity in the market for our common stock may
occur. In addition, the delisting of our common stock could materially adversely affect our access to the capital markets, and
any limitation on liquidity or reduction in the price of our common stock could materially adversely affect our ability to raise
capital on terms acceptable to us or at all. Delisting from The Nasdaq Capital Market could also result in the potential loss of
confidence by our business partners and suppliers, the loss of institutional investor interest and fewer business development opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the intended initial public offering
by our subsidiary, Ruthigen, Inc. is not successful, then we will not be repaid certain deferred offerings costs advanced to Ruthigen,
which may be substantial. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the separation agreement
we entered into with our subsidiary, Ruthigen, Inc., upon the closing of the intended initial public offering by Ruthigen, we will
be repaid for certain costs incurred and advanced related to Ruthigen&rsquo;s initial public offering and certain other agreed-upon
expenses. At September 30, 2013, these costs, which we expect to be repaid, amounted to $911,000, of which $824,000 is reported
as deferred offering costs in our accompanying condensed consolidated balance sheet and $87,000 was reported as selling, general
and administrative expense. Ruthigen&rsquo;s intended initial public offering may be delayed or may not occur at all. In such case,
we may not be reimbursed for such costs and expenses. In the event such reimbursement is delayed or never occurs, we will not receive
cash that might have otherwise been deployed to grow our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 2.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Unregistered Sales of Equity Securities and Use of Proceeds</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 24, 2013, we issued 8,139
shares of common stock to Advocos, LLC as compensation for services provided, and such shares were valued at $22,000. We
relied on the Section 4(a)(2) exemption from securities registration under the federal securities laws for transactions not
involving any public offering. No advertising or general solicitation was employed in offering the securities. The securities
were issued to an accredited investor. The securities were offered for investment purposes only and not for the purpose of
resale or distribution, and the transfer thereof was appropriately restricted by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 3.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-right: 1.6pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Default Upon Senior Securities</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We did not default upon any senior securities
during the quarter ended September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 4.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Mine Safety Disclosures</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 5.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other Information</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Amendments No. 1 and No. 2 to the License and Supply Agreement
with Ruthigen, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 9, 2013, we entered into
Amendment No. 1 to the License and Supply Agreement with our wholly owned subsidiary, Ruthigen, Inc. Pursuant to the terms of
the License and Supply Agreement, Ruthigen is required to make milestone payments to us upon certain milestone events.
Amendment No. 1 amended the second milestone event set forth in Section 7.1 of the License and Supply Agreement. On November
6, 2013, we entered into Amendment No. 2 to the License and Supply Agreement with Ruthigen to further amend the certain
milestone events set forth in Section 7.1 of the License and Supply Agreement and to amend the terms of the manufacturing
equipment purchases set forth in Section 6.13 of the License and Supply Agreement. Pursuant to the terms of Amendment No. 2,
Ruthigen will be required to make a total of $5,000,000 in milestone payments to us for the first product only, as follows:
upon completion of Ruthigen&rsquo;s first meeting with the U.S. Food and Drug Administration (FDA) following completion of
Ruthigen&rsquo;s first pivotal clinical trial and upon first patient enrollment in Ruthigen&rsquo;s second pivotal clinical
trial. Ruthigen also agreed to purchase certain research and development and manufacturing equipment from us for
approximately $3 million following the completion of Ruthigen&rsquo;s intended initial public offering. All other terms and
conditions of the License and Supply Agreement remain unmodified and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Letter Agreement with Venture Lending &amp;
Leasing V, Inc. and Venture Lending &amp; Leasing VI, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 6, 2013, we entered into a letter
agreement with Venture Lending &amp; Leasing V, Inc. and Venture Lending &amp; Leasing VI, Inc. (collectively, the &ldquo;Lenders&rdquo;).
We previously entered into a certain Loan and Security Agreement and Supplement thereto, both dated as of May 1, 2010 (together,
the &ldquo;VLL5 Loan Agreement&rdquo;), with Venture Lending &amp; Leasing V, Inc., as lender. We also entered into a certain Loan
and Security Agreement and Supplement thereto, both dated as of June 29, 2011 (together, the &ldquo;VLL6 Loan Agreement&rdquo;
and referred to with the VLL5 Loan Agreement, as the &ldquo;Loan Agreements&rdquo;). Pursuant to the letter agreement, we agreed
to, prior to the pricing of Ruthigen&rsquo;s intended initial public offering, cause a bank to issue, on our behalf, one or more
irrevocable standby letters of credit for our account in favor of Lenders, in form and substance reasonably satisfactory to Lenders,
in a total amount equal to all scheduled payments of principal and interest payable under the Loan Agreements at the time of execution
of such letter of credit, to secure all of our obligations under the Loan Agreements. The letter of credit shall be maintained
in effect for the period from the date of issuance and continuing until the date that all of our obligations under the Loan Agreements
have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item 6.</B></FONT></TD>
    <TD STYLE="width: 90%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibits</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Exhibit&nbsp;Index</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding-right: 0.8pt; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 0.8pt; width: 88%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc. (included as Exhibit 3.1 of the Company&rsquo;s Annual Report on Form&nbsp;10-K filed June 20, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc. (included as Exhibit A in the Company&rsquo;s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Bylaws, as Amended of Oculus Innovative Sciences, Inc., effective November 3, 2010 (included as Exhibit 3.3 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November 4, 2010, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended (included as Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Specimen Common Stock Certificate (included as Exhibit 4.1 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock of Oculus Innovative Sciences, Inc. (included as Exhibit 4.4 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock of Oculus Innovative Sciences, Inc. (included as Exhibit 4.5 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock of Oculus Innovative Sciences, Inc. (included as Exhibit 4.11 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.5</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock of Oculus Innovative Sciences, Inc. (included as Exhibit 4.12 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.6</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock of Oculus Innovative Sciences, Inc. (included as Exhibit&nbsp;10.3 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed August&nbsp;13, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.7</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Warrant to Purchase Common Stock of Oculus Innovative Sciences, Inc. (included as Exhibit&nbsp;4.1 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed March&nbsp;28, 2008, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.8</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant for April 2009 offering (included as Exhibit&nbsp;4.15 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-158539) declared effective on July 24, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.9</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrant issued to Dayl Crow, dated March&nbsp;4, 2009 (included as Exhibit 4.16 to the Company&rsquo;s Annual Report on Form 10-K filed June 11, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.10</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant for July 2009 offering (included as Exhibit 4.15 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-158539), as amended, declared effective on July 24, 2009, and incorporated herein by reference)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.11</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant for April 2012 offering (included as Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.12</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012 (included as Exhibit 4.2 to the Company&rsquo;s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.13</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Underwriters Warrant to be issued to the Underwriters in connection with the March 2013 Offering (included as Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, filed March 7, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors (included as Exhibit 10.1 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Oculus Innovative Sciences, Inc. 2006 Stock Incentive Plan and related form stock option plan agreements (included as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed May 2, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office Lease Agreement, dated October&nbsp;26, 1999, between Oculus Innovative Sciences, Inc. and RNM Lakeville, L.P. (included as Exhibit&nbsp;10.7 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to Office Lease Agreement, dated September&nbsp;15, 2000, between Oculus Innovative Sciences, Inc. and RNM Lakeville L.P. (included as Exhibit&nbsp;10.8 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 2 to Office Lease Agreement, dated July&nbsp;29, 2005, between Oculus Innovative Sciences, Inc. and RNM Lakeville L.P. (included as Exhibit&nbsp;10.9 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 88%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No.&nbsp;3 to Office Lease Agreement, dated August&nbsp;23, 2006, between Oculus Innovative Sciences, Inc. and RNM Lakeville L.P. (included as Exhibit&nbsp;10.23 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No.&nbsp;4 to Office Lease Agreement, dated September&nbsp;13, 2007, by and between Oculus Innovative Sciences, Inc. and RNM Lakeville L.P. (included as Exhibit 10.43 to the Company&rsquo;s Annual Report on Form&nbsp;10-K filed June 13, 2008, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office Lease Agreement, dated May&nbsp;18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish) (included as Exhibit&nbsp;10.10 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch) (included as Exhibit&nbsp;10.11 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Office Lease Agreement, effective February&nbsp;15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch) (included as Exhibit 10.44 to the Company&rsquo;s Annual Report on Form&nbsp;10-K filed June 13, 2008, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Director Agreement (included as Exhibit&nbsp;10.20 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.12</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Framework Agreement, dated June 16, 2005, by and among Javier Orozco Gutierrez, Quimica Pasteur, S de R.L., Jorge Paulino Hermosillo Martin, Oculus Innovative Sciences, Inc. and Oculus Technologies de Mexico, S.A. de C.V. (included as Exhibit 10.25 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mercantile Consignment Agreement, dated June 16, 2005, between Oculus Technologies de Mexico, S.A. de C.V., Quimica Pasteur, S de R.L. and Francisco Javier Orozco Gutierrez (included as Exhibit 10.26 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Partnership Interest Purchase Option Agreement, dated June&nbsp;16, 2005, by and between Oculus Innovative Sciences, Inc. and Javier Orozco Gutierrez (included as Exhibit&nbsp;10.27 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Termination of Oculus Innovative Sciences, Inc. and Oculus Technologies de Mexico, S.A. de C.V.&rsquo;s Agreements with Quimica Pasteur, S de R.L. by Jorge Paulino Hermosillo Martin (translated from Spanish) (included as Exhibit&nbsp;10.28 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Termination of Oculus Innovative Sciences, Inc. and Oculus Technologies de Mexico, S.A. de C.V.&rsquo;s Agreements with Quimica Pasteur, S de R.L. by Francisco Javier Orozco Gutierrez (translated from Spanish) (included as Exhibit&nbsp;10.29 to the Company&rsquo;s Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-135584), as amended, declared effective on January&nbsp;24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement by and between Oculus Innovative Sciences, Inc. and Robert Burlingame, dated January&nbsp;26, 2009 (included as Exhibit&nbsp;10.1 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed January&nbsp;29, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.18</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Revenue Sharing Distribution Agreement by and between Oculus Innovative Sciences, Inc. and VetCure, Inc., dated January&nbsp;26, 2009 (included as Exhibit&nbsp;10.3 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed January&nbsp;29, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.19</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement by and between Oculus Innovative Sciences, Inc. and accredited investors, dated February&nbsp;6, 2009 (refiled as Exhibit 10.32 to the Company&rsquo;s Quarterly Report on Form&nbsp;10-Q filed November 4, 2010, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.20</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement by and between Oculus Innovative Sciences, Inc., Robert Burlingame and Seamus Burlingame, dated February 24, 2009 (included as Exhibit&nbsp;10.4 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed February&nbsp;27, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.21</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to Revenue Sharing Distribution Agreement by and between Oculus Innovative Sciences, Inc. and VetCure, Inc., dated February&nbsp;24, 2009 (included as Exhibit&nbsp;10.5 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed February&nbsp;27, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.22</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Microcyn U.S. Commercial Launch Agreement by and between Oculus Innovative Sciences, Inc. and Advocos, dated April&nbsp;24, 2009 (included as Exhibit 10.53 to the Company&rsquo;s Annual Report on Form 10-K filed June 11, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.23</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No.&nbsp;5 to Office Lease Agreement by and between Oculus Innovative Sciences, Inc. and RNM Lakeville, LLC, dated May&nbsp;18, 2009 (included as Exhibit 10.54 to the Company&rsquo;s Annual Report on Form 10-K filed June 11, 2009, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.24</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Loan and Security Agreement between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing V, Inc., dated May 1, 2010 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed May 6, 2010, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.25</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Supplement to the Loan and Security Agreement between Oculus Innovative Sciences, Inc., and Venture Lending &amp; Leasing V, Inc., dated May 1, 2010 (included as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed May 6, 2010, and incorporated herein by reference).</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 88%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amendment No. 2 to Revenue Sharing,
Partnership and Distribution Agreement between Oculus Innovative Sciences, Inc. and Vetericyn, Inc., dated July 24, 2009 (refiled
as Exhibit 10.44 to the Company&rsquo;s Quarterly Report on Form 10-Q/A for the quarter ended September 30, 2010 filed April 29,
2011, and incorporated herein by reference).</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.27&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amendment No. 3 to Revenue Sharing,
Partnership and Distribution Agreement between Oculus Innovative Sciences, Inc. and Vetericyn, Inc., dated June 1, 2010 (refiled
as Exhibit 10.44 to the Company&rsquo;s Quarterly Report on Form 10-Q/A for the quarter ended June&nbsp;30, 2010&nbsp;filed April
29, 2011, and incorporated herein by reference).</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.28&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amendment No. 1 to Exhibit A to the
Revenue Sharing Distribution Agreement and to the Revenue Sharing, Partnership and Distribution Agreement as Revised and Amended,
June 1, 2010, dated September 1, 2010 (included as Exhibit 10.46 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November
4, 2010, and incorporated herein by reference).</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"></TD>
    <TD STYLE="padding-right: 0.8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Continuous Offering Program Agreement
between Oculus Innovative Sciences, Inc. and Rodman &amp; Renshaw, LLC, dated September 3, 2010 (included as Exhibit 10.1 to the
Company&rsquo;s&nbsp;Current Report on Form 8-K filed September 17, 2010, and incorporated herein by reference).</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Distribution Agreement between Oculus
Innovative Sciences, Inc. and Tianjin Ascent Import and Export Company, Ltd., dated January 28, 2011 (included as Exhibit 10.47
to the Company&rsquo;s Quarterly Report on Form 10-Q filed February 4, 2011, and incorporated herein by reference).&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exclusive Sales and Distribution Agreement
between Oculus Innovative Sciences, Inc. and Quinnova Pharmaceuticals, Inc., dated February 14, 2011 (included as Exhibit 10.1
to the Company&rsquo;s&nbsp;Current Report on Form 8-K filed February 18, 2011, and incorporated herein by reference).</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 1.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exclusive Co-Promotion Agreement between Oculus Innovative Sciences, Inc. and Quinnova Pharmaceuticals, Inc., dated February 14, 2011 (included as Exhibit 10.2 to the Company&rsquo;s&nbsp;Current Report on Form 8-K filed February 18, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Product Option Agreement between Oculus Innovative Sciences, Inc. and AmDerma Pharmaceuticals, LLC, dated February 14, 2011 (included as Exhibit 10.3 to the Company's Current Report on&nbsp;Form 8-K filed February 18, 2011, and incorporated herein by reference).&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 6 to Office Lease Agreement by and between Oculus Innovative Sciences, Inc. and RNM Lakeville, L.P., dated April 26, 2011 (included as Exhibit 10.52 to the Company&rsquo;s Annual Report on Form 10-K filed June 3, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.35</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Loan and Security Agreement between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing VI, Inc., dated June 29, 2011 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed July 6, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.36</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Supplement to the Loan and Security Agreement between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing VI, Inc., dated June 29, 2011 (included as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K filed July 6, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.37</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to the Loan and Security Agreement and Supplement to the Loan and Security Agreement between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing V, Inc., dated June 29, 2011 (included as Exhibit 10.4 to the Company&rsquo;s Current Report on Form 8-K filed July 6, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.38</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intellectual Property Security Agreement between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing VI, Inc., dated June 29, 2011 (included as Exhibit 10.5 to the Company&rsquo;s Current Report on Form 8-K filed July 6, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.39</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intellectual Property Security Agreement between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing V, Inc., dated June 29, 2011 (included as Exhibit 10.6 to the Company&rsquo;s Current Report on Form 8-K filed July 6, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.40&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Distribution Agreement between Oculus Innovative Sciences, Inc. and Shanghai Sunvic Technology Co. Ltd., dated June 26, 2011 (included as Exhibit 10.58 to the Company&rsquo;s Quarterly Report on Form 10-Q filed August 4, 2011 and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.41</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Oculus Innovative Sciences, Inc. 2011 Stock Incentive Plan (included as Exhibit A in the Company&rsquo;s Definitive Proxy Statement on Schedule 14A filed July 29, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.42</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement by and between the Company and the Purchasers, dated April 22, 2012 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.43&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patent License Agreement-Exclusive between Oculus Innovative Sciences, Inc. and agencies of the United States Public Health Service within the Department of Health and Human Services, dated August 22, 2011 (included as Exhibit 10.60 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November 3, 2011, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.44&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaboration Agreement between Oculus Innovative Sciences, Inc. and AmDerma Pharmaceuticals, LLC, dated June 21, 2012 (included as Exhibit 10.53 to the Company&rsquo;s Annual Report on Form 10-K filed June 21, 2012 and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.45&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License, Exclusive Distribution and Supply Agreement by and between Oculus Innovative Sciences, Inc. and Oculus Technologies of Mexico, S.A. de C.V., and, More Pharma Corporation, S. de R.L. de C.V., dated August 9, 2012 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed August 15, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.46&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exclusive Distribution and Supply Agreement by and between Oculus Innovative Sciences, Inc. and Oculus Technologies of Mexico, S.A. de C.V., and, More Pharma Corporation, S. de R.L. de C.V., dated August 9, 2012 (included as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed August 15, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.47</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lease by and between Oculus Innovative Sciences, Inc. and KCKMC Properties, LLP for the property located at 3045 65th Street, Suite 13, Sacramento, CA 95820, dated October 31, 2011 (included as Exhibit 10.56 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November 8, 2012, and incorporated herein by reference).</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.48</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; width: 88%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Lease dated August 30, 2012 by and between Oculus Innovative Sciences, Inc. and KCKMC Properties, LLC for the property located at 3045 65th Street, Suite 13, Sacramento, CA 95820, dated September 6, 2012 (included as Exhibit 10.57 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November 8, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.49</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 7 to Office Lease Agreement by and between Oculus Innovative Sciences, Inc. and 1125-1137 North McDowell, LLC, dated October 10, 2012 (included as Exhibit 10.58 to the Company&rsquo;s Quarterly Report on Form 10-Q filed November 8, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.50</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock Purchase Agreement by and between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing V, LLC and Venture Lending &amp; Leasing VI, LLC, dated October 30, 2012 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed November 1, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.51</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Letter Agreement by and between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing V, Inc., dated October 30, 2012 (included as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed November 1, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.52</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Letter Agreement by and between Oculus Innovative Sciences, Inc. and Venture Lending &amp; Leasing VI, Inc., dated October 30, 2012 (included as Exhibit 10.3 to the Company&rsquo;s Current Report on Form 8-K, filed November 1, 2012, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.53</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer of Employment Letter between Oculus Innovative Sciences, Inc. and Sameer Harish, effective as of February 1, 2013 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed February 4, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.54</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between Ruthigen, Inc. and Hojabr Alimi, dated March 21, 2013 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed March 22, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.55&dagger;&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License and Supply Agreement by and between Oculus Innovative Sciences, Inc. and Ruthigen, Inc., dated May 23, 2013 (refiled as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K/A, filed September 24, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.56</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shared Services Agreement by and between Oculus Innovative Sciences, Inc. and Ruthigen, Inc., dated May 23, 2013 (included as Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed June 7, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.57</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Offer of Employment Letter between Oculus Innovative Sciences, Inc. and Sameer Harish, dated May 23, 2013 (included as Exhibit 10.4 to the Company&rsquo;s Current Report on Form 8-K, filed June 7, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.58</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between Oculus Innovative Sciences, Inc. and Hojabr Alimi, dated January 1, 2004 (included as Exhibit 10.14 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.59</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between Oculus Innovative Sciences, Inc. and Jim Schutz, dated January 1, 2004 (included as Exhibit 10.15 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.60</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between Oculus Innovative Sciences, Inc. and Robert Miller, dated June 1, 2004 (included as Exhibit 10.16 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.61</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between Oculus Innovative Sciences, Inc. and Jim Schutz, dated June 20, 2013 (included as Exhibit 10.68 to the Company&rsquo;s Annual Report on Form 10-K, filed June 25, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.62</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between Oculus Innovative Sciences, Inc. and Robert Miller, dated June 20, 2013&nbsp;&nbsp;(included as Exhibit 10.69 to the Company&rsquo;s Annual Report on Form 10-K, filed June 25, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.63</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Separation Agreement by and between Oculus Innovative Sciences, Inc. and Ruthigen, Inc., dated August 2, 2013 (included as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed August 8, 2013, and incorporated herein by reference).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.64*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to License and Supply Agreement by and between Oculus Innovative Sciences, Inc. and Ruthigen, Inc., dated October 9, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.65*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 2 to License and Supply Agreement by and between Oculus Innovative Sciences, Inc. and Ruthigen, Inc., dated November 6, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.66*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Letter Agreement by and between Oculus Innovative Sciences, Inc., Venture Lending &amp; Leasing V, Inc., and Venture Lending &amp; Leasing VI, Inc., dated November 6, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1*</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS*#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH*#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL*#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation Linkbase.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF*#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition Linkbase.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB*#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Label Linkbase.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE*#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation Linkbase.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="width: 97%; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Confidential treatment has been granted with respect to certain portions of this agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&dagger;&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Confidential treatment has been requested with respect to certain portions of this agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">#</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OCULUS INNOVATIVE SCIENCES, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;&nbsp;November 19, 2013</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jim Schutz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jim Schutz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;&nbsp;November 19, 2013</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Robert Miller</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert Miller</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer and Principal Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 7pt 0 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.64
<SEQUENCE>2
<FILENAME>oculus_10q-ex1064.htm
<DESCRIPTION>AMENDMENT NO. 1 TO LICENSE AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.64</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDMENT NO. 1 TO LICENSE AND SUPPLY AGREEMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This AMENDMENT NO. 1 TO
LICENSE AND SUPPLY AGREEMENT (this &ldquo;<U>Amendment</U>&rdquo;) is made and entered into as of October 9, 2013 and shall become
effective upon the closing of an IPO (as defined in the License Agreement). This Amendment amends that certain License and Supply
Agreement dated as of May 23, 2013 (the &ldquo;<U>License Agreement</U>&rdquo;), by and between Ruthigen, Inc., a Delaware corporation
(&ldquo;<U>Ruthigen</U>&rdquo;) and Oculus Innovative Sciences, Inc., a Delaware corporation (&ldquo;<U>Oculus</U>&rdquo;). Capitalized
terms used and not defined herein shall have the meanings given to them in the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">WHEREAS, Section
15.13 of the License Agreement provides that the License Agreement may be amended, if such amendment is reduced to writing and
signed by the authorized officers of both Parties to the License Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties
wish to amend the second milestone event listed in Section 7.1 of the License Agreement as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
in consideration of the mutual covenants, agreements and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 4.5pt; text-align: justify; text-indent: 0.5in">1.&#9;<U>Amendment
to Second Milestone Event</U>. The second milestone event set forth in Section 7.1 of the License Agreement is hereby deleted in
its entirety and the following inserted in lieu thereof:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">2.</TD>
    <TD STYLE="width: 34%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">Upon first clinical trial site selection for the Phase I/II&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 29%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">One Million Dollars ($1,000,000)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 4.5pt; text-align: justify; text-indent: 0.5in">2.&#9;<U>Effect
of this Amendment</U>. Except as specifically amended as set forth herein, each term and condition of the License Agreement shall
continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 4.5pt; text-align: justify; text-indent: 0.5in">3.&#9;<U>Governing
Law</U>. This Amendment shall be governed by and construed in accordance with the laws in force in the State of California, without
giving effect to the choice of laws provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 4.5pt; text-align: justify; text-indent: 0.5in">4.&#9;<U>Counterparts;
Facsimile Signatures</U>. This Amendment may be executed or consented to in counterparts, each of which shall be deemed an original
and all of which taken together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile
or electronically and, upon such delivery, the facsimile or electronically transmitted signature will be deemed to have the same
effect as if the original signature had been delivered to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 4.5pt; text-align: center"><U>[Remainder of page intentionally
left blank</U>.]</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
Parties have caused this Amendment No. 1 to License and Supply Agreement to be duly executed and delivered by their proper and
duly authorized officers as of the day and year first above written.</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%; padding: 0.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>OCULUS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>OCULUS INNOVATIVE SCIENCES INC.
</B></P></TD>
    <TD STYLE="padding: 0.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>RUTHIGEN</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>RUTHIGEN, INC.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">By: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>/s/ James Schutz</U></TD>
    <TD STYLE="padding: 0.75pt; text-align: justify">By: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>/s/ Hojabr Alimi</U> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">Name: <U>James Schutz</U> </TD>
    <TD STYLE="padding: 0.75pt; text-align: justify">Name: <U>Hojabr Alimi</U> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">Title: &nbsp;&nbsp;<U>Chief Executive Officer</U> </TD>
    <TD STYLE="padding: 0.75pt; text-align: justify">Title: &nbsp;&nbsp;<U>Chief Executive Officer</U> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">Date: &nbsp;&nbsp;<U>10/9/13</U></TD>
    <TD STYLE="padding: 0.75pt; text-align: justify">Date: &nbsp;<U>10/9/13</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.65
<SEQUENCE>3
<FILENAME>oculus_10q-ex1065.htm
<DESCRIPTION>AMENDMENT NO. 2 TO LICENSE AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.65</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 2 TO LICENSE AND SUPPLY
AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This AMENDMENT NO.
2 TO LICENSE AND SUPPLY AGREEMENT (this &ldquo;<U>Amendment</U>&rdquo;) is made and entered into as of November 6, 2013 and shall
become effective upon the closing of an IPO (as defined in the License Agreement). This Amendment amends that certain License and
Supply Agreement dated as of May 23, 2013, as amended from time to time (the &ldquo;<U>License Agreement</U>&rdquo;), by and between
Ruthigen, Inc., a Delaware corporation (&ldquo;<U>Ruthigen</U>&rdquo;) and Oculus Innovative Sciences, Inc., a Delaware corporation
(&ldquo;<U>Oculus</U>&rdquo;). Capitalized terms used and not defined herein shall have the meanings given to them in the License
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Section 15.13
of the License Agreement provides that the License Agreement may be amended, if such amendment is reduced to writing and signed
by the authorized officers of both Parties to the License Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties
entered into Amendment No. 1 to License and Supply Agreement on October 9, 2013;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties
now wish to amend certain sections of the License Agreement as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the mutual covenants, agreements and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">1.&#9;<U>Amendment
to Milestones</U>. The table listing the Milestone Events and Milestone Payments under the License Agreement, which is set forth
in Section 7.1 of the License Agreement, is hereby deleted in its entirety and the following table listing the Milestone Events
and Milestone Payments under the License Agreement is inserted in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%; border: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <td style="width: 54%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><b>Milestone Event</b></td>
    <td style="width: 39%; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><b>Milestone Payment</b></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">1.</td>
    <td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Upon completion of Ruthigen&rsquo;s first meeting with the FDA following completion of Ruthigen&rsquo;s first pivotal clinical trial </td>
    <td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Three Million Dollars ($3,000,000)</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">2.</td>
    <td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Upon first patient enrollment in Ruthigen&rsquo;s second pivotal clinical trial</td>
    <td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Two Million Dollars ($2,000,000)</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-indent: 0.5in">2.&#9;<U>Amendment to Manufacturing
Equipment Purchases</U>. The introductory lead-in language and subsection (a) of Section 6.13 of the License Agreement is hereby
deleted in its entirety and the following language is inserted in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;6.13 &#9;<U>Manufacturing
Equipment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ruthigen shall purchase
and pay in full for (i) at least One Million Dollars ($1,000,000) of Manufacturing Equipment, upon the Effective Date; (ii) at
least One Million Two Hundred Fifty Thousand Dollars ($1,250,000) of additional Manufacturing Equipment, within thirty (30) days
following the Effective Date; and (iii) at least Seven Hundred Fifty Thousand Dollars ($750,000) of additional Manufacturing Equipment,
within forty five (45) days following the Effective Date (collectively, the &ldquo;<U>Equipment Purchase Price</U>&rdquo;). In
each case, Oculus shall deliver the Manufacturing Equipment to Ruthigen, at Ruthigen&rsquo;s expense, within sixty (60) days of
receipt of payment therefor or at such other time as the Parties agree upon orally or in writing.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">3.&#9;<U>Effect
of this Amendment</U>. Except as specifically amended as set forth herein, each term and condition of the License Agreement shall
continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">4.&#9;<U>Governing
Law</U>. This Amendment shall be governed by and construed in accordance with the laws in force in the State of California, without
giving effect to the choice of laws provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">5.&#9;<U>Counterparts;
Facsimile Signatures</U>. This Amendment may be executed or consented to in counterparts, each of which shall be deemed an original
and all of which taken together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile
or electronically and, upon such delivery, the facsimile or electronically transmitted signature will be deemed to have the same
effect as if the original signature had been delivered to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center"><U>[Remainder of page intentionally
left blank</U>.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Parties have caused this Amendment No. 2 to License and Supply Agreement to be duly executed and delivered by their proper
and duly authorized officers as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="3" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>OCULUS<BR>
<BR>
</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>OCULUS INNOVATIVE SCIENCES INC.</b></P></td>
    <TD STYLE="width: 50%; padding: 0.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RUTHIGEN <BR></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RUTHIGEN, INC.</b></P></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt; text-align: justify">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">By: <u>/s/ James Schutz</u></td>
    <TD STYLE="padding: 0.75pt; text-align: justify">By: <u>/s/ Hojabr Alimi</u></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">Name: <u>James Schutz</u> </td>
    <TD STYLE="padding: 0.75pt; text-align: justify">Name: <u>Hojabr Alimi</u> </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">Title: <u>Chief Executive Officer</u> </td>
    <TD STYLE="padding: 0.75pt; text-align: justify">Title: <u>Chief Executive Officer</u> </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0.75pt; text-align: justify">Date: <u>November 6, 2013</u></td>
    <TD STYLE="padding: 0.75pt; text-align: justify">Date: <u>November 6, 2013</u></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr>
    <td></td></tr>
</table>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.66
<SEQUENCE>4
<FILENAME>oculus_10q-ex1066.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.66</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Oculus Innovative Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">1129 North McDowell Boulevard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Petaluma, CA 94954</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">November 6, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>VIA EMAIL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Venture Lending &amp; Leasing V, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Venture Lending &amp; Leasing VI, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">104 La Mesa Drive, Suite 102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Portola Valley, CA 94028</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Re: <U>Letter of Credit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Reference is hereby made
to (i) that certain Loan and Security Agreement and Supplement thereto, both dated as of May 1, 2010 (together, as the same has
been and may be amended, supplemented, extended, renewed or otherwise modified from time to time, the &ldquo;<U>VLL5 Loan Agreement</U>&rdquo;),
between Oculus Innovative Sciences, Inc., a Delaware corporation (&ldquo;<U>Borrower</U>&rdquo;), and Venture Lending &amp; Leasing
V, Inc., as lender (&ldquo;<U>VLL5</U>&rdquo;), and (ii) that certain Loan and Security Agreement and Supplement thereto, both
dated as of June 29, 2011 (together, as the same has been and may be amended, supplemented, extended, renewed or otherwise modified
from time to time, the &ldquo;<U>VLL6 Loan Agreement</U>&rdquo; and sometimes referred to herein individually with the VLL5 Loan
Agreement, as a &ldquo;<U>Loan Agreement</U>&rdquo; and together, as the &ldquo;<U>Loan Agreements</U>&rdquo;), between Borrower
and Venture Lending &amp; Leasing VI, Inc., as lender (&ldquo;<U>VLL6</U>&rdquo; and sometimes referred to herein individually
with the VLL5, as a &ldquo;<U>Lender</U>&rdquo; and together, as &ldquo;<U>Lenders</U>&rdquo;). Except where the context otherwise
requires, or unless this letter agreement (this &ldquo;<U>Letter Agreement</U>&rdquo;) otherwise provides, all words and expressions
defined in the Loan Agreements when used or referred to in this Letter Agreement shall have the same meanings as those provided
for in the Loan Agreements. For the purposes of clarity, the definition of &ldquo;<U>Collatera</U>l&rdquo; shall have the meaning
as set forth in the waiver agreement (the &ldquo;<U>Waiver</U>&rdquo;) made by and between the Lenders and the Borrower on August
10, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Borrower previously notified
Lenders that Borrower&rsquo;s wholly owned subsidiary, Ruthigen, Inc., a Delaware corporation (&ldquo;<U>Ruthigen</U>&rdquo;),
intends to consummate an initial underwritten public offering of Ruthigen&rsquo;s equity interests (the &ldquo;<U>Ruthigen Shares</U>&rdquo;)
pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission under the federal Securities
Act of 1933, as amended (the &ldquo;<U>IPO</U>&rdquo;). All Ruthigen Shares issued on or after the date hereof to parties other
than Borrower are hereinafter referred to as the &ldquo;<U>Applicable Ruthigen Shares</U>.&rdquo; To the extent that the Applicable
Ruthigen Shares constitute Collateral for the Obligations under the Loan Agreements and the other Loan Documents, it is a condition
precedent to the IPO that the Applicable Ruthigen Shares be free and clear of Lenders&rsquo; Liens thereon in order to consummate
the IPO. In order to facilitate the IPO, Borrower and each of Lenders agree to the terms and conditions set forth in this Letter
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Prior to the pricing of the IPO, Wells Fargo Bank, N.A and its successors and assigns (&ldquo;<U>Wells
Fargo</U>&rdquo;) shall issue one or more irrevocable standby letters of credit for Borrower&rsquo;s account in favor of Lenders,
in form and substance reasonably satisfactory to Lenders (individually and collectively, the &ldquo;<U>Letter of Credit</U>&rdquo;),
in a total amount equal to all scheduled payments of principal and interest payable under the Loan Agreements at the time of execution
of such Letter of Credit, to secure all of the Borrower&rsquo;s Obligations under the Loan Agreements. The Letter of Credit shall
be maintained in effect for the period from the date of issuance and continuing until the date that all of the Borrower&rsquo;s
Obligations under the Loan Agreements have been paid in full. Lenders are willing to accept such Letter of Credit as a condition
to continuing the credit accommodations outstanding under the Loan Agreements and in consideration of the release and discharge
by Lenders of all Liens which they have or have had in any or all of the Applicable Ruthigen Shares pursuant to the provisions
of the Loan Agreements. Such waiver shall be given by Lenders concurrently with Lenders&rsquo; receipt of such Letter of Credit,
in form substantially similar to <U>Exhibit A</U> attached hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Borrower hereby covenants and agrees that Borrower will take all action within its power and authority
necessary or desirable to keep the Letter of Credit in full force and effect. Borrower further agrees that it will take all action
within its power and authority necessary or desirable to cause Wells Fargo to pay in accordance with the terms and provisions of
the Letter of Credit upon the occurrence of an Event of Default that gives rise to a contractual or legal right to draw upon the
Letter of Credit. In furtherance of the foregoing, Borrower agrees that the Letter of Credit shall be honored by Wells Fargo upon
the occurrence of such Event of Default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Each of Lenders hereby covenants and agrees that (a) such Lender will draw upon such Letter of
Credit only following the occurrence of an Event of Default and in accordance with the terms of the Loan Agreements, and (b) Borrower
has the right to reduce the amount subject to such Letter of Credit as it pays down the Obligations owed under the Loan Agreements,
however in no event will the Letter of Credit be less than the Obligations. Borrower hereby acknowledges and agrees that each Lender
is entering into this Letter Agreement in material reliance upon the ability of such Lender to draw upon the Letter of Credit upon
the occurrence of any Event of Default. If an Event of Default occurs, either Lender may, without notice to Borrower, draw upon
the Letter of Credit, in part or in whole. Borrower agrees not to interfere in any way with payment to either Lender of the proceeds
of the Letter of Credit, either prior to or following a draw by either Lender of any portion of the Letter of Credit. No condition
or term of the Loan Documents shall be deemed to render the Letter of Credit conditional to justify the issuer of the Letter of
Credit in failing to honor a drawing upon such Letter of Credit in a timely manner. Borrower agrees and acknowledges that (i)&nbsp;the
Letter of Credit constitutes a separate and independent contract between each Lender and the Wells Fargo, (ii)&nbsp;Borrower is
not a third party beneficiary of such contract, (iii)&nbsp;Borrower has no property interest whatsoever in the Letter of Credit
or the proceeds thereof, and (iv)&nbsp;in the event Borrower becomes a debtor under any chapter of the Bankruptcy Code, neither
Borrower, any trustee, nor Borrower&rsquo;s bankruptcy estate shall have any right to restrict or limit either Lender&rsquo;s claim
and/or rights to the Letter of Credit and/or the proceeds thereof by application of any provision of the U.&nbsp;S.&nbsp;Bankruptcy
Code or otherwise.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Letter Agreement
constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof,
and there are no other agreements, understandings, representations or understandings, other than those expressly stated in this
Letter Agreement. Except as expressly amended by this Letter Agreement, the Loan Agreements and the other Loan Documents remain
unamended and in full force and effect. All legal fees and costs incurred by Lenders in connection with the preparation, negotiation
and execution hereof shall be reimbursed by Borrower upon demand. This Letter Agreement may be executed in any number of counterparts,
including counterparts transmitted by facsimile or electronic transmission, each of which shall be an original, but all of which
together shall constitute one and the same instrument; signature pages may be detached from multiple separate counterparts and
attached to a single counterpart so that all signature pages are physically attached to the same document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">[<I>Remainder of page intentionally
left blank; signature page follows.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please indicate your agreement
to the foregoing by executing and returning a copy of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5in">OCULUS INNOVATIVE SCIENCES, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5in">By: <U>/s/ Jim Schutz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5in">Name:&nbsp;&nbsp;<U>Jim Schutz</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5in">Title:&nbsp;&nbsp;&nbsp;&nbsp;<U>Chief Executive Officer</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Acknowledged and agreed as of the date set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">VENTURE LENDING &amp; LEASING V, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Maurice Werdegar</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name: <U>Maurice Werdegar</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title: <U>President and CEO</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">VENTURE LENDING &amp; LEASING VI, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Maurice Werdegar</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name: <U>Maurice Werdegar</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title: <U>President and CEO</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Venture Lending &amp; Leasing V, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Venture Lending &amp; Leasing VI, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">104 La Mesa Drive, Suite 102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Portola Valley, CA 94028</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">________________, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Via Email</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Oculus Innovative Sciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1129 North McDowell Boulevard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Petaluma, CA 94954</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>Re:</B></TD><TD><B>Release of Certain Conditions Applicable to Ruthigen, Inc.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Reference is hereby made
to (i) that certain Loan and Security Agreement and Supplement thereto, both dated as of May 1, 2010 (as the same has been and
may be amended, supplemented, extended, renewed or otherwise modified from time to time, the &ldquo;<U>VLL5 Loan Agreement</U>&rdquo;),
between Oculus Innovative Sciences, Inc., a Delaware corporation (&ldquo;<U>Borrower</U>&rdquo;), and Venture Lending &amp; Leasing
V, Inc., as lender (&ldquo;<U>VLL5</U>&rdquo;), and (ii) that certain Loan and Security Agreement and Supplement thereto, both
dated as of June 29, 2011 (as the same has been and may be amended, supplemented, extended, renewed or otherwise modified from
time to time, the &ldquo;<U>VLL6 Loan Agreement</U>&rdquo; and sometimes referred to herein individually with the VLL5 Loan Agreement,
as a &ldquo;<U>Loan Agreement</U>&rdquo; and together, as the &ldquo;<U>Loan Agreements</U>&rdquo;), between Borrower and Venture
Lending &amp; Leasing VI, Inc., as lender (&ldquo;<U>VLL6</U>&rdquo; and sometimes referred to herein individually with the VLL5,
as a &ldquo;<U>Lender</U>&rdquo; and together, as &ldquo;<U>Lenders</U>&rdquo;). Except where the context otherwise requires, or
unless this letter (this &ldquo;<U>Agreement</U>&rdquo;) otherwise provides, all words and expressions defined in the Loan Agreements
when used or referred to in this Agreement shall have the same meanings as those provided for in the Loan Agreements. For the purposes
of clarity, the definition of &ldquo;<U>Collatera</U>l&rdquo; shall have the meaning as set forth in the waiver agreement (the
&ldquo;<U>Waiver</U>&rdquo;) made by and between the Lenders and the Borrower on August 10, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Initial Underwritten Public Offering
of Ruthigen, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Borrower has notified Lenders
that Borrower&rsquo;s wholly owned subsidiary, Ruthigen, Inc., a Delaware corporation (&ldquo;<U>Ruthigen</U>&rdquo;), desires
to consummate an initial underwritten public offering of Ruthigen&rsquo;s equity interests (the &ldquo;<U>Ruthigen Shares</U>&rdquo;)
pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission under the federal Securities
Act of 1933, as amended (the &ldquo;<U>IPO</U>&rdquo;). All Ruthigen Shares issued on or after the date hereof to parties other
than Borrower are hereinafter referred to as the &ldquo;<U>Applicable Ruthigen Shares</U>.&rdquo; To the extent that the Applicable
Ruthigen Shares constitute Collateral for the Obligations under the Loan Agreements and the other Loan Documents, it is a condition
precedent to the IPO that the Applicable Ruthigen Shares be free and clear of Lenders&rsquo; Liens thereon in order to consummate
the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order to facilitate
the IPO, Borrower wishes to obtain the release of all Lenders&rsquo; Liens on the Applicable Ruthigen Shares that Borrower granted
to Lenders pursuant to the Loan Agreements, if any. Subject to the final sentence of this paragraph, each Lender hereby releases
and discharges all Liens which it has or has had in any or all of the Applicable Ruthigen Shares pursuant to the provisions of
the Loan Agreements, including without limitation Section 2.10(a). Each Lender agrees to execute and deliver (and authorize the
execution and delivery of), prior to the pricing of the IPO and from time to time thereafter, all UCC financing statement amendments
and other documents and instruments, in form and substance reasonably satisfactory to Borrower (collectively, the &ldquo;<U>Release
Documentation</U>&rdquo;), and to take all other action as Borrower may from time to time reasonably request, to release and discharge
any Liens that such Lender may have had or may have in any of the Applicable Ruthigen Shares; <U>provided, however</U>, that any
and all such Release Documentation and such other documents related thereto and prepared in connection with the transactions contemplated
by this Agreement shall be prepared, filed and recorded at Borrower&rsquo;s sole cost and expense. Nothing in this Agreement shall
be deemed to be a release of Lenders&rsquo; Liens on the Collateral, as defined in the Loan Agreements and amended by the Waiver,
other than the Applicable Ruthigen Shares which are hereby included as an additional exclusion from the definition of &ldquo;Collateral&rdquo;
in the Loan Agreements as amended by the Waiver, including, without limitation, (A) any Ruthigen Shares owned by Borrower that
are not included in the IPO and (B) any Ruthigen Shares Borrower subsequently acquires after the IPO. This Agreement shall become
effective upon execution by Lenders and Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Waiver of Issuance of Applicable Ruthigen
Shares</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Lenders hereby waive Section
6.14(b) with respect to the issuance of the Applicable Ruthigen Shares on or after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Consent for Exclusive License of Certain
Intellectual Property to Ruthigen, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Borrower has also entered
into a license and supply agreement with Ruthigen (the &ldquo;<U>License Agreement</U>&rdquo;), which will become effective upon
the closing of the transaction contemplated by subsection (i) of the definition of IPO. Pursuant to the License Agreement, Borrower
has agreed to exclusively license certain of its proprietary technology to Ruthigen to enable Ruthigen&rsquo;s research and development
and commercialization of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada, European Union
and Japan (the &ldquo;<U>Territory</U>&rdquo;) for certain invasive procedures in human treatment as defined in the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As part of its condition
to undertake its agreements to make certain advances of money and to extend certain financial accommodations to Borrower, the Lenders
required the execution of Intellectual Property Security Agreements by and between Borrower and each respective Lender, each dated
June 29, 2011 (the &ldquo;<U>IP Agreements</U>&rdquo;), whereby Borrower granted to the Lenders a security interest in substantially
all of Borrower&rsquo;s intellectual property whether presently existing or hereafter acquired. By the terms of the IP Agreements,
the VLL5 Loan Agreement, and the VLL6 Loan Agreement, Borrower is prohibited from entering into agreement to exclusively license
or sell its intellectual property. In order to allow Borrower to pursue such exclusive licensing of certain of its intellectual
property to Ruthigen, the Lenders are willing to waive such covenants in consideration of Borrower&rsquo;s continued commitment
to pay off the indebtedness outstanding under the VLL5 Loan Agreement and under the VLL6 Loan Agreement in a timely manner. Each
Lender has agreed to waive the provisions of Section 6.5 (Sale of Assets) of each respective Loan Agreement solely as to Borrower&rsquo;s
anticipated entry into the License Agreement with Ruthigen, whereby Borrower intends to exclusively license certain of its proprietary
technology to Ruthigen to enable Ruthigen&rsquo;s research and development and commercialization of the newly discovered RUT58-60,
and any improvements to it, in the Territory for certain invasive procedures in human treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Therefore, pursuant to
this Agreement, the following sentence shall be added to the end of the definition of &ldquo;Collateral&rdquo; of the Loan Agreements,
as amended by the Waiver, as an additional exclusion from the definition of &ldquo;Collateral&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><BR>
&ldquo;and (viii) upon the closing date of the proposed initial underwritten public offering of Ruthigen, Inc., if any should occur,
exclusive license of certain of Borrower&rsquo;s proprietary technology to Ruthigen to enable Ruthigen&rsquo;s research and development
and commercialization of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada, European Union
and Japan for certain invasive procedures in human treatment pursuant to the License and Supply Agreement between Borrower and
Ruthigen, Inc., dated May 23, 2013, and as such may be subsequently amended.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Therefore, pursuant to
this Agreement, the following sentence shall be added to the end of the definition of &ldquo;Collateral&rdquo; in the last paragraph
of Section 1 of the IP Agreements, as amended by the Waiver, as an additional exclusion from the definition of &ldquo;Collateral&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><BR>
&ldquo;and (x) upon the closing date of the proposed initial underwritten public offering of Ruthigen, Inc., if any should occur,
exclusive license of certain of Grantor&rsquo;s proprietary technology to Ruthigen to enable Ruthigen&rsquo;s research and development
and commercialization of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada, European Union
and Japan for certain invasive procedures in human treatment pursuant to the License and Supply Agreement between Grantor and Ruthigen,
Inc., dated May 23, 2013, and as such may be subsequently amended.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>General Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Agreement shall become
effective upon execution by Lenders and Borrower. For avoidance of doubt, each Lender hereby consents to the Transfer (as defined
in Section 6.5 of the applicable Loan Agreement) of the Applicable Ruthigen Shares on the terms and conditions set forth herein.
Except as specifically amended by this Agreement, the Loan Agreements and the other Loan Documents and Security Documents shall
remain in full force and effect and are hereby ratified and confirmed. The execution, delivery and performance of this Agreement
shall not, except as expressly provided herein, constitute a waiver of any provision of the Loan Agreements or any of the other
Loan Documents or Security Documents. Without limiting the generality of the provisions of Section 9.3 of the Loan Agreements,
the consent set forth above shall be limited precisely as written solely for the purpose of permitting Borrower to Transfer the
Applicable Ruthigen Shares and for the purposes of permitting Borrower to consummate the transactions contemplated by the License
Agreement without violating the provisions of the Loan Agreements, including without limitation Sections 6.5, 6.14, 7.1(h) or 7.1(i)
thereof, and this Agreement does not constitute, nor should it be construed as, a waiver of compliance by Borrower with respect
to (i) Sections&nbsp;6.5, 6.14, 7.1(h) and 7.1(i) of the Loan Agreements in any other instance or (ii)&nbsp;any other term, provision
or condition of the Loan Agreements or any other instrument or agreement referred to therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Agreement may be executed
in any number of counterparts, including counterparts transmitted by facsimile or electronic transmission, each of which shall
be an original, but all of which together shall constitute one and the same instrument; signature pages may be detached from multiple
separate counterparts and attached to a single counterpart so that all signature pages are physically attached to the same document.
This Agreement is the only agreement between the parties with respect to its subject matter, and there are no other agreements,
understandings, representations or understandings other than those expressly stated in this Agreement. Borrower shall pay all costs
and expenses in connection with the transactions contemplated by this Agreement, and the negotiation and documentation hereof.
THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED
IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CALIFORNIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">[<I>Remainder of page intentionally
left blank; signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>LENDERS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>VENTURE LENDING &amp; LEASING V, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name:______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title:_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>VENTURE LENDING &amp; LEASING VI, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name:______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title:_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>BORROWER:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>OCULUS INNOVATIVE SCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name:______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title:_______________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>oculus_10q-ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Jim Schutz, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">1. I have reviewed this
quarterly report on Form 10-Q of Oculus Innovative Sciences, Inc. for the quarter ended September 30, 2013;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4. The registrant&rsquo;s
other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(d) Disclosed in this
report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5. The registrant&rsquo;s
other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(b) Any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jim Schutz</FONT></TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: November 19, 2013</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jim Schutz</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>oculus_10q-ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Robert Miller, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">1. I have reviewed this
quarterly report on Form 10-Q of Oculus Innovative Sciences, Inc. for the quarter ended September 30, 2013;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by
this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4. The registrant&rsquo;s
other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(d) Disclosed in this
report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5. The registrant&rsquo;s
other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(b) Any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Robert Miller</FONT></TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: November 19, 2013</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert Miller</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">(Principal Financial Officer and Principal Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>oculus_10q-ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of
Oculus Innovative Sciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), do hereby certify, to such officers&rsquo;
knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Quarterly Report on Form 10-Q for the quarter
ended September 30, 2013 (the &ldquo;Form 10-Q&rdquo;) of the Company fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects,
the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: November 19, 2013</FONT></TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jim Schutz</FONT></TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">Jim Schutz</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 4pt 0 0">(Principal Executive Officer)</P></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: November 19, 2013</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Robert Miller</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">Robert Miller</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 0">(Principal Financial Officer and Principal Accounting Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>ocls-20130930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: oculus_10q%2D093013.xfr; Date: 2013%2D11%2D18T18:51:34 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:ocls="http://oculus.com/20130930">
    <link:schemaRef xlink:href="ocls-20130930.xsd" xlink:type="simple" />
    <xbrli:context id="From2013-04-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_USMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:USMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_USMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:USMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_MexicoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:MexicoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_MexicoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:MexicoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_EuropeOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:EuropeOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_EuropeOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:EuropeOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_CustomerOneMember_custom_RevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_InnovacynMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:InnovacynMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_MorePharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:MorePharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_VLL5AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_VLL5AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_VLL6AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_VLL6AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_VLL5WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_VLL5WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_VLL5WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_VLL6WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_VLL6WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_VLL6WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_custom_InnovacynMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:InnovacynMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_custom_MorePharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:MorePharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_USMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:USMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_USMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:USMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_MexicoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:MexicoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_MexicoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:MexicoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_EuropeOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:EuropeOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_EuropeOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">ocls:EuropeOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_SecondCustomerMember_custom_RevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:SecondCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_FinishedGoodsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ocls:FinishedGoodsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_custom_FinishedGoodsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ocls:FinishedGoodsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_VLL5AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_VLL5AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_VLL5WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_VLL5WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL5WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_VLL6AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_VLL6AgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6AgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_VLL6WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_VLL6WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocls:VLL6WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_InnovacynMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:InnovacynMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_InnovacynMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:InnovacynMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_InnovacynMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:InnovacynMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_InnovacynMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:InnovacynMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_MorePharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:MorePharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_MorePharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:MorePharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_MorePharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:MorePharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_MorePharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:MorePharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_AdvocosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocls:AdvocosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_AdvocosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocls:AdvocosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-09-30_custom_AdvocosMember892848837">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocls:AdvocosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_AdvocosMember892848837">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocls:AdvocosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_WindsorMember892848837">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocls:WindsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-09-30_custom_WindsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocls:WindsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30_custom_SecondCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:SecondCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30_custom_CustomerOneMember_custom_RevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_SecondCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:SecondCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_custom_SecondCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:SecondCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_custom_ThirdCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:ThirdCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_custom_ThirdCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">ocls:ThirdCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2013-04-01to2013-09-30">Oculus Innovative Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2013-04-01to2013-09-30">0001367083</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2013-04-01to2013-09-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2013-04-01to2013-09-30">2013-09-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2013-04-01to2013-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2013-04-01to2013-09-30">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2013-04-01to2013-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2013-04-01to2013-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2013-04-01to2013-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2013-04-01to2013-09-30">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2013-04-01to2013-09-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2013-04-01to2013-09-30">2014</dei:DocumentFiscalYearFocus>
    <us-gaap:Assets contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">8882000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">12565000</us-gaap:Assets>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">159000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">187000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DeferredOfferingCosts contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">824000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">44000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">987000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">6912000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">11534000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">549000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">935000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">749000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">992000</us-gaap:InventoryNet>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">2424000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">1707000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Liabilities contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">7332000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">8484000</us-gaap:Liabilities>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">519000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">676000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1883000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">2619000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">4737000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">5127000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">573000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">1259000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">2322000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">2320000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">699000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">703000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1027000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">808000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">8882000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">12565000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">4081000</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">-140856000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">-137745000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">-3077000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">-2991000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">145482000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">144816000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">1000</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-09-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-09-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">14285715</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">14285715</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">6633694</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">6583150</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">6633694</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">6583150</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InventoryGross contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">825000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">1162000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2013-09-30_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" unitRef="USD" decimals="-3">591000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2013-03-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" unitRef="USD" decimals="-3">835000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2013-09-30_custom_FinishedGoodsMember" unitRef="USD" decimals="-3">234000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="AsOf2013-03-31_custom_FinishedGoodsMember" unitRef="USD" decimals="-3">327000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">76000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">170000</us-gaap:InventoryValuationReserves>
    <ocls:DebtDiscountLongtermPortionOfLongtermDebt contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">45000</ocls:DebtDiscountLongtermPortionOfLongtermDebt>
    <ocls:DebtDiscountLongtermPortionOfLongtermDebt contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">248000</ocls:DebtDiscountLongtermPortionOfLongtermDebt>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-03-31" unitRef="USD" xsi:nil="true" />
    <ocls:CashSettlementLiabilityNoncurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">193000</ocls:CashSettlementLiabilityNoncurrent>
    <ocls:CashSettlementLiabilityNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">62000</ocls:CashSettlementLiabilityNoncurrent>
    <ocls:CashSettlementLiabilityCurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">116000</ocls:CashSettlementLiabilityCurrent>
    <ocls:CashSettlementLiabilityCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">37000</ocls:CashSettlementLiabilityCurrent>
    <ocls:DebtDiscountCurrentPortionOfLongtermDebt contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">430000</ocls:DebtDiscountCurrentPortionOfLongtermDebt>
    <ocls:DebtDiscountCurrentPortionOfLongtermDebt contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">521000</ocls:DebtDiscountCurrentPortionOfLongtermDebt>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Oculus Innovative Sciences, Inc. (the&#13;&amp;#147;Company&amp;#148;) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the&#13;laws of the State of Delaware in December 2006. The Company&amp;#146;s principal office is located in Petaluma, California. The Company&#13;is a global healthcare company that designs, produces, and markets prescription and non-prescription products in 27 countries.&#13;It is pioneering innovative products for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets.&#13;The Company&amp;#146;s primary focus is on its proprietary technology platform called Microcyn&amp;#174; Technology. This technology is&#13;based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens).&#13;Several Microcyn&amp;#174; Technology tissue care products are designed to treat infections and enhance healing while reducing the need&#13;for antibiotics.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective as of the open of business&#13;on April 1, 2013, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every 7 shares of&#13;common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the&#13;reverse stock split. Instead, each resulting fractional share of common stock was rounded up to one whole share. The reverse stock&#13;split reduced the number of shares of the Company&amp;#146;s common stock outstanding from 46,080,513 to 6,583,150. The total number&#13;of authorized shares of common stock was also proportionally decreased by a ratio of 1:7 and the par value per share of the common&#13;stock continued to be $0.0001.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All common shares and per share amounts&#13;contained in the condensed consolidated financial statements have been retroactively adjusted to reflect a 1 for 7 reverse stock&#13;split, effective April 1, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The accompanying&#13;unaudited condensed consolidated financial statements as of September 30, 2013 and for the three and six months then ended have&#13;been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial&#13;information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission&#13;(&amp;#147;SEC&amp;#148;) and on the same basis as the Company prepares its annual audited consolidated financial statements. The unaudited&#13;condensed consolidated balance sheet as of September 30, 2013, the condensed consolidated statements of comprehensive loss for&#13;the three and six months ended September 30, 2013 and 2012, and the condensed consolidated statements of cash flows for the six&#13;months ended September 30, 2013 and 2012 are unaudited, but include all adjustments, consisting only of normal recurring adjustments,&#13;which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for&#13;the periods presented. The results for the three and six months ended September 30, 2013 are not necessarily indicative of results&#13;to be expected for the year ending March 31, 2014 or for any future interim period. The condensed consolidated balance sheet at&#13;March 31, 2013 has been derived from audited consolidated financial statements. However, it does not include all of the information&#13;and notes required by accounting principles generally accepted in the United States of America for complete consolidated financial&#13;statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial&#13;statements for the year ended March 31, 2013, and notes thereto included in the Company&amp;#146;s annual report on Form 10-K, which&#13;was filed with the SEC on June 25, 2013.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial&#13;statements include the accounts of the Company and its wholly owned subsidiaries, Aquamed Technologies, Inc. (&amp;#147;Aquamed&amp;#148;),&#13;Oculus Technologies of Mexico S.A. de C.V. and Oculus Innovative Sciences Netherlands, B.V. and Ruthigen, Inc. (&amp;#147;Ruthigen&amp;#148;).&#13;All significant intercompany accounts and transactions have been eliminated in consolidation. Aquamed has no current operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of condensed consolidated&#13;financial statements in conformity with accounting principles generally accepted in the United States of America requires management&#13;to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities&#13;at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting&#13;periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs&#13;related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company&amp;#146;s&#13;deferred taxes,&amp;#160;the valuation of equity and derivative instruments, and debt discounts and the estimated amortization periods&#13;of upfront licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. The allowance&#13;for uncollectible accounts receivable balances amounted to $9,000 and $22,000, which are included in accounts receivable, net in&#13;the accompanying September 30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively. The reserve for excess&#13;and obsolete inventory balances amounted to $76,000 and $170,000, which are included in inventories, net in the accompanying September&#13;30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior period amounts have been&#13;reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the&#13;Company&amp;#146;s previously reported net loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes basic net loss per&#13;share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding&#13;for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would&#13;include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock&#13;using the &amp;#147;treasury stock&amp;#148; and/or &amp;#147;if converted&amp;#148; methods as applicable. The computation of basic net loss&#13;per share for the three and six months ended September 30, 2013 and 2012 (adjusted if applicable for the reverse stock split effective&#13;April 1, 2013) excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; padding-left: 9pt; text-indent: -9pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;988&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,529&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Common Stock Purchase Warrants and Other Derivative&#13;Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies common stock purchase&#13;warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or&#13;net-share settlement, or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement&#13;or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to&#13;net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty&#13;a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions&#13;as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to&#13;determine whether a change in classification between assets and liabilities is required. The Company determined that its freestanding&#13;derivatives, which principally consist of warrants to purchase common stock, satisfied the criteria for classification as equity&#13;instruments at September 30, 2013, other than certain warrants that contain reset provisions and certain warrants that require&#13;net-cash settlement that the Company classified as derivative liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Assets&#13;and Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments, including cash&#13;and cash equivalents, accounts receivable, inventory, accounts payable and accrued liabilities are carried at cost, which management&#13;believes approximates fair value due to the short-term nature of these instruments. The fair value of capital lease obligations&#13;and equipment loans approximates their carrying amounts as a market rate of interest is attached to their repayment. The Company&#13;measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or&#13;paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly&#13;transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes&#13;the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair&#13;value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level&amp;#160;1&amp;#160;&amp;#151; quoted&#13;prices in active markets for identical assets or liabilities&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level&amp;#160;2&amp;#160;&amp;#151; quoted&#13;prices for similar assets and liabilities in active markets or inputs that are observable&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level&amp;#160;3&amp;#160;&amp;#151; inputs&#13;that are unobservable (for example, cash flow modeling inputs based on assumptions)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Financial liabilities measured at fair value on a recurring&#13;basis are summarized below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 liabilities are valued using&#13;unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities.&#13;For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company&amp;#146;s accounting and finance&#13;department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination&#13;of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company&amp;#146;s&#13;accounting and finance department and are approved by the Chief Financial Officer.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Level 3 Valuation Techniques&lt;/u&gt;:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 financial liabilities consist&#13;of the derivative liabilities for which there is no current market for these securities such that the determination of fair value&#13;requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy&#13;are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option&#13;valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates&#13;transaction details such as the Company&amp;#146;s stock price, contractual terms, maturity, risk free rates, as well as volatility.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A significant decrease in the volatility&#13;or a significant decrease in the Company&amp;#146;s stock price, in isolation, would result in a significantly lower fair value measurement.&#13;Changes in the values of the derivative liabilities are recorded in &amp;#147;(Loss) gain due to change in fair value of derivative&#13;instruments&amp;#148; in the Company&amp;#146;s condensed consolidated statements of comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2013, there were&#13;no transfers in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has evaluated subsequent events&#13;or transactions occurring through the date the condensed consolidated financial statements were issued (Note 10).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In June 2011,&#13;the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update (&amp;#147;ASU&amp;#148;) No. 2011-05,&#13;&lt;i&gt;Comprehensive Income (Topic 220): Presentation of Comprehensive Income&lt;/i&gt;. This guidance improves the comparability, consistency&#13;and transparency of financial reporting and increases the prominence of items reported in other comprehensive income.&amp;#160; In&#13;December 2011, the FASB issued ASU No. 2011-12, &lt;i&gt;Deferral of the Effective Date for Amendments to the Presentation of Reclassifications&#13;of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05&lt;/i&gt;. ASU 2011-12 defers the requirement that companies present&#13;reclassification adjustments for each component of Accumulated Other Comprehensive Income in both net income and Other Comprehensive&#13;Income on the face of the financial statements. All other requirements in ASU No. 2011-05 are not affected by ASU No. 2011-12,&#13;including the requirement to report comprehensive income either in a single continuous financial statement or in two separate&#13;but consecutive financial statements.&amp;#160; While the adoption of this standard required the Company to change the format of its&#13;condensed consolidated financial statements, it did not have a material impact on the Company&amp;#146;s consolidated financial position&#13;and results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The FASB&#13;has issued ASU No. 2013-11, &lt;i&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss&#13;Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists&lt;/i&gt; (a consensus of the FASB Emerging Issues Task Force).&#13;The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented&#13;in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss,&#13;or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax&#13;credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional&#13;income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not&#13;require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax&#13;benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The&#13;amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after &lt;font style="color: black"&gt;December&#13;15, 2013&lt;/font&gt;. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years,&#13;beginning after &lt;font style="color: black"&gt;December 15, 2014&lt;/font&gt;. Early adoption is permitted. The amendments should be applied&#13;prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption&#13;of this standard is not expected to have a material impact on the Company&amp;#146;s condensed consolidated financial position and&#13;results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Accounting standards&#13;that have been issued or proposed by the FASB, SEC and/or other standards-setting bodies that do not require adoption until a&#13;future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories consisted of the following&#13;(in thousands):&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;591&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;835&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;234&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;327&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,162&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Less: inventory allowances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(170&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Venture Lending &amp;#38; Leasing&amp;#160;V,&#13;Inc. and Venture Lending &amp;#38; Leasing&amp;#160;VI, Inc.&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 1, 2010, the Company entered into&#13;a loan and security agreement and a supplement to the loan and security agreement with Venture Lending &amp;#38; Leasing V, Inc. (&amp;#147;VLL5&amp;#148;)&#13;to borrow up to an aggregate of $3,000,000 (collectively, the &amp;#147;VLL5 Agreements&amp;#148;). On May 3, 2010, the Company borrowed&#13;$2,000,000 on the first tranche and on November 17, 2010, the Company borrowed $1,000,000 on the second tranche.&amp;#160;&amp;#160;The&#13;loan is secured by all assets of the Company excluding intellectual property under certain circumstances. Related to the first&#13;tranche, the Company made eight monthly interest-only payments of $16,660 through December 1, 2010. Thereafter, the Company made&#13;interest and principal payments of $75,000 per month through June 1, 2013. Related to the second tranche, the Company paid monthly&#13;interest only payments of $8,330 through May 1, 2012. Thereafter, the Company made interest and principal payments of $37,500 per&#13;month through November 1, 2013. The Company made a final balloon payment related to the first tranche of $132,000 prior to the&#13;June 1, 2013 deadline, and made a final balloon payment related to the second tranche of $66,000 on or prior to November 1, 2013.&#13;The effective interest rate on the first and second tranche is 13.3%.&amp;#160;During the three months ended September 30, 2013 and&#13;2012, the Company made interest payments of $7,000 and $50,000, respectively, and principal payments of $24,000 and $288,000, respectively.&#13;During the six months ended September 30, 2013 and 2012, the Company made interest payments of $27,000 and $109,000, respectively,&#13;and principal payments of $556,000 and $566,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the VLL5 Agreements,&#13;the Company issued two warrants to Venture Lending &amp;#38; Leasing V, LLC, a Delaware limited liability company (&amp;#147;LLC5&amp;#148;),&#13;which, in the aggregate, had a total put option cash value of $750,000 (the &amp;#147;VLL5 Warrants&amp;#148;). The $750,000 cash value&#13;of the VLL5 Warrants was recorded as a cash settlement liability and a corresponding amount of $750,000 was recorded as a discount&#13;on the note payable.&amp;#160; The discount is being accreted to non-cash interest expense over the term of the loan using the effective&#13;interest method.&amp;#160; During the three months ended September 30, 2013 and 2012, the Company recorded $24,000 and $63,000, respectively,&#13;of non-cash interest expense related to the loans.&amp;#160;During the six months ended September 30, 2013 and 2012, the Company recorded&#13;$90,000 and $125,000, respectively, of non-cash interest expense related to the loans.&amp;#160;The remaining balance of the loans&#13;amounted to $138,000 at September 30, 2013, which is included in the current portion of long-term debt, net of debt discount in&#13;the accompanying condensed consolidated balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 29, 2011, the Company entered&#13;into a loan and security agreement and a supplement to the loan and security agreement with Venture Lending &amp;#38; Leasing&amp;#160;VI,&#13;Inc. (&amp;#147;VLL6&amp;#148;) to borrow up to an aggregate of up to $2,500,000 (collectively, the &amp;#147;VLL6 Agreements&amp;#148;).&amp;#160;&#13;The VLL6 Agreements provided for a first tranche of $1,500,000 and, upon meeting certain financial milestones, a second tranche&#13;of $1,000,000.&amp;#160;The loan is secured by the assets of the Company including intellectual property. On June 29, 2011, the Company&#13;borrowed $1,500,000 on the first tranche. On September 30, 2011, the Company met the financial milestones to borrow the second&#13;tranche. On November 10, 2011, the Company borrowed the second tranche.&amp;#160;&amp;#160;The cash interest or &amp;#147;streaming&amp;#148;&#13;rate on the loan is 10%. In connection with the first tranche, for the first nine months, the Company made monthly interest-only&#13;payments set at $12,500 through March 1, 2012. The Company now makes principal and interest payments of $56,250 per month through&#13;September 1, 2014. Additionally, the Company will make a final balloon payment of $116,505 on September 29, 2014. In connection&#13;with the second tranche, for the first nine months, the Company made monthly interest-only payments set at $8,333 through August&#13;31, 2012. The Company now makes principal and interest payments of $37,500 per month through February 1, 2015. Additionally, the&#13;Company will make a final balloon payment of $77,670 on February 1, 2015, resulting in an effective interest rate of 13%. During&#13;the three months ended September 30, 2013 and 2012, the Company made interest payments of $53,000 and $75,000, respectively and&#13;made principal payments of $228,000 and $148,000, respectively. During the six months ended September 30, 2013 and 2012, the Company&#13;made interest payments of $114,000 and $151,000, respectively and made principal payments of $449,000 and $266,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the VLL6 Agreements,&#13;the Company issued a warrant to Venture Lending &amp;#38; Leasing VI, LLC (individually referred to as &amp;#147;LLC6&amp;#148; and collectively&#13;referred to with LLC5 as &amp;#147;WTI&amp;#148;) for the purchase of 32,332 shares of its common stock at a purchase price per share&#13;equal to $11.592. Once the Company became eligible to draw the second tranche of the loan, the Company was required to issue a&#13;second warrant to LLC6 with coverage equal to $62,500 for the purchase of additional shares of the Company&amp;#146;s common stock&#13;at a strike price equal to the 10-day volume-weighted average price (&amp;#147;VWAP&amp;#148;) ending on the trading day prior to the&#13;date the Company satisfied the second tranche milestones. On September 30, 2011, the Company met the second tranche milestones&#13;and the Company issued the second warrant for the purchase of 5,586 shares of its common stock at a purchase price per share equal&#13;to $11.189. On November 10, 2011, the Company borrowed the second tranche and therefore the Company became obligated to issue a&#13;third warrant to LLC6 with coverage equal to $62,500 for the purchase of additional shares of its common stock at a strike price&#13;equal to the 10-day VWAP ending on the trading day prior to the borrowing date of the second tranche. In connection with borrowing&#13;the second tranche, the Company issued the third warrant for the purchase of 5,884 shares of its common stock at a purchase price&#13;per share equal to $10.623. The three warrants issued to LLC6 are hereinafter collectively referred to as the &amp;#147;VLL6 Warrants,&amp;#148;&#13;and had a total put option cash value, in the aggregate, of $1,250,000. The Company recorded the $1,250,000 cash value of the VLL6&#13;Warrants as a cash settlement liability and a corresponding amount of $1,250,000 was recorded as a discount on the note payable.&#13;The discount is being accreted to non-cash interest expense over the term of the loan using the effective interest method. For&#13;the three months ended September 30, 2013 and 2012, the Company recorded $104,000 and $91,000 of non-cash interest related to the&#13;loan, respectively. For the six months ended September 30, 2013 and 2012, the Company recorded $204,000 and $178,000 of non-cash&#13;interest related to the loan, respectively. The remaining balance of the discount on the loan amounted to $474,000 at September&#13;30, 2013.&amp;#160;The remaining balance of the loan amounted to $1,367,000 at September 30, 2013, of which $821,000 is included in&#13;the current portion of long-term debt in the accompanying condensed consolidated balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 30, 2012, the Company entered&#13;into respective letter agreements with VLL5 and VLL6 to amend the repayment terms of its outstanding debt obligations. Prior to&#13;the execution of these agreements, LLC5 and LLC6 held an aggregate of 79,517 warrants (adjusted for the reverse stock split effective&#13;April 1, 2013) to purchase common stock, which, in the aggregate, had a total put option cash value of $2,000,000 (the &amp;#147;Cash&#13;Settlement Liability&amp;#148;) and was included in long term liabilities on the Company&amp;#146;s condensed consolidated balance sheets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On that same day, the Company also entered&#13;into a stock purchase agreement with WTI for the issuance to WTI of shares of its common stock having an aggregate grant date fair&#13;market value of $3,500,000, or approximately $5.67 per post-split share, in exchange for LLC5&amp;#146;s agreement to surrender the&#13;VLL5 Warrants, and LLC6&amp;#146;s agreement to surrender the VLL6 Warrants, and the surrender by WTI of the accompanying Cash Settlement&#13;Liability. Accordingly, on November 1, 2012, the Company issued an aggregate of 617,284 restricted shares of its post-split common&#13;stock (the &amp;#147;Shares&amp;#148;) to WTI, pursuant to the terms of the stock purchase agreement. The VLL5 Warrants and the VLL6&#13;Warrants were surrendered on October 30, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If at any time between October 30, 2012&#13;through either March 31, 2014 or July 31, 2015 (the &amp;#147;Settlement Dates&amp;#148;) WTI sells the Shares, then the proceeds from&#13;the sale of the Shares will be applied as follows (the &amp;#147;Grace Period&amp;#148;):&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 96%; padding-right: 0.8pt; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;If and when the Shares are sold by WTI during the Grace Period, the fair value of the proceeds received will be retained by WTI as consideration for surrendering the Cash Settlement Liability, up to a maximum value of $2,000,000.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(b)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;If and when the Shares are sold by WTI during the Grace Period, any additional proceeds received from the sale of the Shares in excess of $2,000,000 (approximately $3.22 per share) but up to $3,500,000 (approximately $5.67 per share) will be applied by WTI as a prepayment of a portion of the then outstanding debt based on the terms of the stock purchase agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(c)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;If and when the Shares are sold by WTI during the Grace Period, any additional proceeds received from the sale of the Shares in excess of $3,500,000 (approximately $5.67 per share) up to $4,500,000 (approximately $7.28 per share) shall be the sole possession and property of WTI, in accordance with the terms of the stock purchase agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(d)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;If and when the Shares are sold by WTI during the Grace Period for value in excess of $4,500,000 (approximately $6.72 per share), 50% of the amount of the proceeds in excess of the $4,500,000 will be the sole possession and property of WTI and 50% of the amount of the proceeds shall be applied as a prepayment of a portion of the then outstanding debt based on the terms of the stock purchase agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(e)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;If and when the Shares are sold by WTI during the Grace Period for value less than $2,000,000 (approximately $3.22 per share), the Company is required to make a cash payment to WTI until the total Cash Settlement Liability of $2,000,000 has been settled (&amp;#147;Cash Shortfall&amp;#148;).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the Shares are not sold during the&#13;Grace Period, then the then fair value of the stock is to be determined at either of the Settlement Dates and the repayment of&#13;the Cash Settlement Liability, prepayment of outstanding, distribution of gains from the sale of the Shares, or calculation of&#13;the Cash Shortfall will consummate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 30, 2012, upon the issuance&#13;of the Shares, the Company recorded a prepayment of $2,000,000 and $1,500,000 net against the Cash Settlement Liability and the&#13;outstanding notes payable, respectively, on that date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2013 and June 30, 2013,&#13;the Shares had not yet been sold by WTI and the fair value of the Shares at September 30, 2013 and June 30, 2013 amounted to $1,691,000&#13;and $1,592,000 (approximately $2.74 and $2.58 per share), respectively. Accordingly, in connection with the increase in fair market&#13;value of the Shares, the Company recorded a gain on the fair value in the amount of $99,000, which is included in the accompanying&#13;condensed consolidated statements of comprehensive loss for the three months ended September 30, 2013. The fair value of the Shares&#13;at March 31, 2013 amounted to $1,901,000 ($3.08 per share). Accordingly, in connection with the decrease in fair market value of&#13;the Shares from March 31, 2013 to September 30, 2013, the Company recorded a loss on the fair value in the amount of $210,000,&#13;which is included in the accompanying condensed consolidated statements of comprehensive loss for the six months ended September&#13;30, 2013. The fair value of the Shares will continue to be marked to market with any gain or loss recorded in the statement of&#13;comprehensive loss until either the Shares are sold by the holder or the Settlement Dates, whichever is earlier. As of September&#13;30, 2013, the net Cash Settlement Liability was $309,000, of which $116,000 is included in the current portion of the Cash Settlement&#13;Liability on the accompanying condensed consolidated balance sheet. As of September 30, 2013, the $1,691,000 fair value of the&#13;Shares has been recorded as a prepayment against the Cash Settlement Liability on the accompanying condensed consolidated balance&#13;sheet.&lt;/p&gt;</us-gaap:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2006, the Company received a&#13;written communication from the grantor of a license to an earlier version of its technology indicating that such license was terminated&#13;due to an alleged breach of the license agreement by the Company. The license agreement extends to its use of the technology in&#13;Japan only. While the Company does not believe that the grantor&amp;#146;s revocation is valid under the terms of the license agreement&#13;and no legal claim has been threatened to date, the Company cannot provide any assurance that the grantor will not take legal action&#13;to restrict its use of the technology in the licensed territory. While the Company's management does not anticipate that the outcome&#13;of this matter is likely to result in a material loss, there can be no assurance that if the grantor pursues legal action, such&#13;legal action would not have a material adverse effect on its consolidated financial position or results of comprehensive loss.&#13;The Company has not accrued a loss reserve for this matter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2011, the Company received&#13;notice of a lawsuit filed in Mexico by Cesar Mangotich Pacheco and Prodinnv, S.A. de C.V. represented by Cesar Mangotich Pacheco.&#13;The lawsuit appears to allege conversion of assets, tortious interference and defamation, among other claims. The Company is currently&#13;evaluating the lawsuit, conferring with local counsel and translating the documents it has received. The Company&amp;#146;s preliminary&#13;assessment is that the lawsuit is completely without merit and intends to vigorously defend its position. The Company has not accrued&#13;a loss reserve for this matter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company, from time to time, is involved&#13;in legal matters arising in the ordinary course of its business including matters involving proprietary technology. While management&#13;believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of&#13;business for which the Company is or could become involved in litigation, will not have a material adverse effect on its business,&#13;financial condition or results of comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&lt;i&gt;Employment&#13;Agreements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;As of September&#13;30, 2013, the Company had employment agreements in place with five of its key executives. The agreements provide, among other&#13;things, for the payment of nine to twenty-four months of severance compensation for terminations under certain circumstances.&#13;With respect to these agreements, at September 30, 2013, potential severance amounted to $1,843,000 and aggregated annual salaries&#13;amounted to $1,310,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Commercial Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 26, 2009, the Company entered&#13;into a commercial agreement with VetCure, Inc., a California corporation, to market and sell the Company&amp;#146;s Microcyn&amp;#174;&#13;Technology-based animal healthcare products branded as Vetericyn&amp;#174;. VetCure, Inc. later changed its name to Vetericyn, Inc.&#13;This agreement was amended on February 24, 2009, July 24, 2009, June 1, 2010, and November 1, 2010. Pursuant to the agreement,&#13;the Company provides Vetericyn, Inc. with bulk product and Vetericyn, Inc. bottles, packages, and sells Microcyn&amp;#174; Technology-based&#13;animal healthcare products branded as Vetericyn&amp;#174;. The Company receives a fixed amount for each bottle of Vetericyn&amp;#174; sold&#13;by Vetericyn, Inc. At the time of these 2009 transactions, Vetericyn, Inc. was wholly-owned by Robert Burlingame, who was also&#13;a director of the Company at that time. Mr. Burlingame resigned from the Company&amp;#146;s board of directors on February 10, 2010.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 15, 2009, the Company entered&#13;a commercial agreement with V&amp;#38;M Industries, Inc., a California corporation, to market and sell certain of the Company&amp;#146;s&#13;Microcyn&amp;#174; over-the-counter liquid and gel products. V&amp;#38;M Industries, Inc. subsequently changed its name to Innovacyn, Inc.&#13;On June 1, 2010, September 1, 2010, and November 1, 2010, the Company amended this agreement granting Innovacyn, Inc. the exclusive&#13;right to sell certain of its over-the-counter products. At the time of the 2009 transaction, V&amp;#38;M Industries, Inc. was wholly-owned&#13;by Robert Burlingame, who was also a director of the Company at that time. Mr. Burlingame resigned from&amp;#160;the Company&amp;#146;s&amp;#160;board&#13;of directors on February 10, 2010. &amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 1, 2011, Vetericyn, Inc. and&#13;Innovacyn, Inc. began to share profits with the Company related to the Vetericyn&amp;#174; and Microcyn&amp;#174; over-the-counter sales,&#13;resulting in the Company receiving about a 30% royalty of net revenue. During the three months ended September 30, 2013 and 2012,&#13;the Company recorded revenue related to these agreements in the amounts of $1,289,000 and $1,229,000, respectively. During the&#13;six months ended September 30, 2013 and 2012, the Company recorded revenue related to these agreements in the amounts of $2,030,000&#13;and $2,365,000, respectively. The revenue is recorded in product revenues in the accompanying condensed consolidated statements&#13;of comprehensive loss . At September 30, 2013 and March 31, 2013, the Company had outstanding accounts receivable of $801,000&#13;and $264,000, respectively, related to Innovacyn, Inc.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 9, 2012, the Company, along&#13;with its Mexican subsidiary and manufacturer Oculus Technologies of Mexico S.A. de C.V., entered into a license, exclusive distribution&#13;and supply agreement with More Pharma Corporation, S. de R.L. de C.V. (&amp;#147;More Pharma&amp;#148;) (the &amp;#147;License Agreement&amp;#148;).&#13;For a one-time payment of $500,000, the Company granted More Pharma an exclusive license, with the right to sublicense under certain&#13;conditions and with the Company&amp;#146;s consent, to all of the Company&amp;#146;s proprietary rights related to certain of its pharmaceutical&#13;products for human application that utilize the Company&amp;#146;s Microcyn&amp;#174; Technology within Mexico. For an additional one-time&#13;payment of $3,000,000, the Company also agreed to appoint More Pharma as the exclusive distributor of certain of its products in&#13;Mexico for the term of the agreement. Additionally, the Company granted More Pharma an exclusive license to certain of the Company&amp;#146;s&#13;then-held trademarks in exchange for a payment of $100,000. The Company has the ability to terminate the agreement if certain annual&#13;purchase minimums are not met. The term of the agreement is twenty-five years from the effective date of August 15, 2012. The term&#13;of the License Agreement will automatically renew after the twenty-five year term for successive two year terms as long as More&#13;Pharma has materially complied with any and all of the obligations under the License Agreement, including but not limited to, meeting&#13;the minimum purchase requirements set forth therein.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, on August 9, 2012, the&#13;Company entered into an exclusive distribution and supply agreement with More Pharma (the &amp;#147;Distribution Agreement&amp;#148;).&#13;For a one-time payment of $1,500,000, the Company granted More Pharma exclusive ability to market and sell certain of its pharmaceutical&#13;products for human application that utilize the Company&amp;#146;s Microcyn&amp;#174; Technology. The Company also appointed More Pharma&#13;as its exclusive distributor, with the right to execute sub-distribution agreements under certain conditions and with the Company&amp;#146;s&#13;consent, within the following countries: Antigua &amp;#38; Barbuda, Argentina, Aruba &amp;#38; Curacao, Bahamas, Barbados, Belize, Bolivia,&#13;Bonaire, Brazil, British Guyana, British Islands, Cayman Islands, Chile, Colombia, Cuba, Dominica, Dominican Republic, Ecuador,&#13;El Salvador, French Guyana, Grenada, Guadalupe, Guatemala, Haiti, Honduras, Jamaica, Martinique, Nicaragua, Paraguay, Peru, St.&#13;Bartolome, St. Vincent &amp;#38; Grenades, Surinam, Trinidad &amp;#38; Tobago, Turks &amp;#38; Caicos Islands, Uruguay, Venezuela and Virgin&#13;Islands.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is recognizing the $5,100,000&#13;related to the License Agreement and the Distribution Agreement as revenue on a straight line basis consistent with the Company&amp;#146;s&#13;historical experience with contracts with similar terms, which is typically over three to five years of the contract. Additionally,&#13;the Company capitalized $214,000 of its transaction costs related to the License Agreement and the Distribution Agreement, which&#13;will be amortized by the Company as expense on a straight line basis consistent with the related revenue recognition practices.&#13;At September 30, 2013 and March 31, 2013, the Company had outstanding accounts receivable of $717,000 and $580,000, respectively,&#13;due from More Pharma. During three months ended September 30, 2013 and 2012, the Company recognized $378,000 and $183,000, respectively,&#13;related to the amortization of the upfront fees received in the transaction. During six months ended September 30, 2013 and 2012,&#13;the Company recognized $752,000 and $183,000, respectively, related to the amortization of the upfront fees received in the transaction.&#13;The Company recognizes product sales on a sell-through basis as More Pharma sells products through to its customers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Other Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Ruthigen, Inc.&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#146;s wholly owned subsidiary,&#13;Ruthigen, Inc., was incorporated in the State of Nevada on January 18, 2013, and reincorporated from Nevada to Delaware on September&#13;25, 2013. Ruthigen has established offices in Santa Rosa, California.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 2, 2013, the Company entered&#13;into a separation agreement with Ruthigen that contains key provisions relating to the Company&amp;#146;s ongoing relationship with&#13;Ruthigen, and more specifically governs its relationship with Ruthigen following the completion of Ruthigen&amp;#146;s intended initial&#13;public offering. The Company previously announced its entry into a license and supply agreement and a shared services agreement&#13;with Ruthigen. Each of these agreements has been entered into in the overall context of the separation of the Company&amp;#146;s business&#13;and its novel biotechnology business into two separate, publicly-traded companies. The effective date for all three agreements&#13;is the closing date of Ruthigen&amp;#146;s intended initial public offering, if any should occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;License and Supply Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the license and supply agreement,&#13;the Company agreed to exclusively license certain of its proprietary technology to Ruthigen to enable Ruthigen&amp;#146;s research&#13;and development and commercialization of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada,&#13;European Union and Japan, referred to as the Territory, for certain invasive procedures in human treatment as defined in the license&#13;and supply agreement. On October 9, 2013, the Company entered into Amendment No. 1 to the license and supply agreement, which amended&#13;the second milestone event set forth in Section 7.1 of the license and supply agreement. On November 6, 2013, the Company entered&#13;into Amendment No. 2 to the license and supply agreement with Ruthigen to further amend the certain milestone events set forth&#13;in Section 7.1 of the license and supply agreement and to amend the terms of the manufacturing equipment purchases set forth in&#13;Section 6.13 of the license and supply agreement. All other terms and conditions of the license and supply agreement remain unmodified&#13;and in full force and effect.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The license and supply agreement provides&#13;Ruthigen with the exclusive option, exercisable within the first five years following the effective date of the agreement, to expand&#13;the license to certain other therapeutic indications upon payment of a license expansion fee of $10 million within the first two&#13;years following the effective date of the agreement or, after the two&amp;#150;year period, the same fee plus certain out-of-pocket&#13;costs the Company may incur in developing products for any of the indications. Additionally, the Company will be prohibited from&#13;using the licensed proprietary technology to sell products that compete with Ruthigen&amp;#146;s products within the Territory, and&#13;Ruthigen cannot sell any device or product that competes with the Company&amp;#146;s products being sold or developed as of the effective&#13;date of the license and supply agreement.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Ruthigen will be required to make a&#13;total of $5,000,000 in milestone payments to the Company for the first product only, as follows: upon completion of&#13;Ruthigen&amp;#146;s first meeting with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen&amp;#146;s first&#13;pivotal clinical trial and upon first patient enrollment in Ruthigen&amp;#146;s second pivotal clinical trial. In addition, as&#13;further consideration under the agreement, Ruthigen will be required to make royalty payments to the Company based on&#13;Ruthigen&amp;#146;s annual net sales of the product from the date of first commercial sale to the date that Ruthigen ceases to&#13;commercialize the product, which percentage royalty rate will vary between 3% and 20% and will increase based on various net&#13;sales thresholds and will differ depending on the country in which the sales are made. Ruthigen also agreed to purchase&#13;certain research and development and manufacturing equipment from the Company for approximately $3 million following the&#13;completion of Ruthigen&amp;#146;s intended initial public offering.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Shared Services Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also entered into a shared&#13;services agreement with Ruthigen that would take effect upon the completion of Ruthigen&amp;#146;s proposed initial public offering,&#13;if any should occur, pursuant to which it will provide Ruthigen with general services, including general accounting, human resources,&#13;laboratory personnel and shared R&amp;#38;D resources while Ruthigen plans to establish an independent facility and systems. As a wholly&#13;owned subsidiary of the Company, Ruthigen will be financed by the Company until the completion of the proposed initial public offering,&#13;if any should occur, and after such event, Ruthigen would become responsible for its own expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Separation Agreement&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a separation&#13;agreement with Ruthigen that contains key provisions relating to its ongoing relationship with Ruthigen following the completion&#13;of Ruthigen&amp;#146;s intended initial public offering. The separation agreement takes effect upon the closing of Ruthigen&amp;#146;s&#13;intended initial public offering and terminates on the earlier of 8.5 years following the closing of the offering, or when the&#13;parties mutually agree to terminate it. The separation agreement also contains a series of restrictions on the Company&amp;#146;s&#13;ability to transfer the Ruthigen shares it owns. The Company is restricted from transferring any of the Ruthigen shares it owns&#13;during the first year (the &amp;#147;lock up period&amp;#148;) immediately following Ruthigen&amp;#146;s intended initial public offering.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following the one-year lock up&#13;period, transfers by the Company of the Ruthigen shares it owns must be conducted with the consent of Ruthigen&amp;#146;s board&#13;of directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed&#13;requirements include that the transfers must be in private placement transactions, the purchase price discount may not exceed&#13;certain percentages depending on the transferee, the amount of shares transferred in a given transfer (or series of transfers&#13;comprising a single transaction) may not exceed the greater of 5% of Ruthigen&amp;#146;s outstanding shares or $1.5 million in&#13;net proceeds to the Company, as well as certain other requirements set forth in the separation agreement. In addition to the&#13;prescribed manner for the Company to conduct transfers described above, if, following a minimum of 41.5 months following the&#13;closing of Ruthigen&amp;#146;s initial public offering have lapsed under the separation agreement and the Company has not&#13;consummated transfers of the Ruthigen shares it owns resulting in at least $3.8 million in net proceeds to the Company, then&#13;the Company has a one-time transfer and registration right to transfer the Ruthigen shares it owns in an amount equal to the&#13;difference between $3.8 million and the Ruthigen shares transferred by the Company pursuant to the separation agreement as of&#13;the time the Company elects to exercise its one-time right. Transfers conducted using this one-time right must be conducted&#13;with the consent of Ruthigen&amp;#146;s board of directors or within the prescribed requirements for such transfers set forth in&#13;the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the&#13;amount of shares transferred may not exceed $3.8 million in net proceeds to the Company, as well as certain other&#13;requirements set forth in the separation agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The separation agreement also provides&#13;for certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether&#13;and how many Ruthigen shares the Company transfers. The majority of the material restrictions and obligations contained in the&#13;separation agreement lapse if and when the Company and its subsidiaries (other than Ruthigen) own less than 19.9% of the outstanding&#13;shares of Ruthigen&amp;#146;s common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The separation agreement also sets forth&#13;the methodology for the allocation of the operational and offering related expenses incurred prior to and in connection with Ruthigen&amp;#146;s&#13;intended initial public offering for which Ruthigen is required to reimburse the Company. Ruthigen will also reimburse the Company&#13;for expenses such as salaries and benefits advanced or paid on Ruthigen&amp;#146;s behalf, or for Ruthigen&amp;#146;s benefit, during&#13;a transition period following the closing of Ruthigen&amp;#146;s intended initial public offering.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The separation agreement provides that&#13;each party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against&#13;the other party. This includes an indemnification by the Company to Ruthigen related to obligations that the Company has under&#13;certain loan and security agreements entered into by the Company with Venture Lending &amp;#38; Leasing V, Inc. and Venture Lending&#13;&amp;#38; Leasing VI, Inc. The separation agreement also provides that, so long as the Company shall maintain a directors&amp;#146; and&#13;officers&amp;#146; insurance program covering the past and present officers and directors of the Company, the program shall be standard&#13;in the Company&amp;#146;s industry and the Company shall not exclude any former director of the Company from any insurance policy&#13;coverage if such coverage is made available to the Company&amp;#146;s then existing directors and officers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock Issued to Non-Employees&#13;For Services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 24, 2009, the Company entered&#13;into an agreement with Advocos LLC, a contract sales organization that serves as part of the Company&amp;#146;s sales force, for the&#13;sale of the Company&amp;#146;s wound care products in the United States. Pursuant to the agreement, the Company agreed to pay the&#13;contract sales organization a monthly fee and potential bonuses that will be based on achievement of certain levels of sales. The&#13;Company agreed to issue the contract sales organization cash or shares of common stock as compensation for its services. During&#13;the three months ended September 30, 2013 and 2012, the Company issued 8,139 and 3,728 shares of common stock, respectively, in&#13;connection with this agreement. During the six months ended September 30, 2013 and 2012, the Company issued 38,447 and 14,392 shares&#13;of common stock, respectively, in connection with this agreement. The Company has determined that the fair value of the common&#13;stock, which was calculated as shares were issued, was more readily determinable than the fair value of the services rendered.&#13;Accordingly, the Company recorded the fair  value of the stock as compensation expense. During the three months ended September&#13;30, 2013 and 2012, the Company recorded $22,000 and $20,000 of expense related to this agreement, respectively. During the six&#13;months ended September 30, 2013 and 2012, the Company recorded $134,000 and $112,000 of expense related to this agreement, respectively.&#13;The expense was recorded as selling, general and administrative expense in the accompanying condensed consolidated statements of&#13;comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 17, 2009, the Company entered&#13;into an agreement with Windsor Corporation.&amp;#160; Windsor Corporation provides financial advisory services to the Company. Pursuant&#13;to the agreement, the Company agreed to pay Windsor Corporation, on a quarterly basis, cash or common stock as compensation for&#13;services provided.&amp;#160; The Company determined that the fair value of the common stock was more readily determinable than the&#13;fair value of the services rendered. Accordingly, the Company recorded the fair  value of the stock as compensation expense.&#13;During the six months ended September 30, 2013, the Company issued 12,097 shares of common stock.&amp;#160;During the six months ended&#13;September 30, 2013, the Company recorded $49,000 of stock compensation expense related to this agreement. Additionally, during&#13;the three months ended September 30, 2013, the Company accrued $30,000 of expense for services provided which was settled with&#13;shares of common stock on October 2, 2013 (See Note 10). The expense was recorded as selling, general and administrative expense&#13;in the accompanying condensed consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for share-based&#13;awards exchanged for employee services at the estimated grant date fair value of the award. The Company amortizes the fair value&#13;of employee stock options on a straight-line basis over the requisite service period of the awards.&amp;#160;&amp;#160;Compensation expense&#13;includes the impact of an estimate for forfeitures for all stock options. The estimated forfeiture rates used during the six months&#13;ended September 30, 2013 ranged from 1.63% to 4.77%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Employee stock-based compensation expense is as follows (in&#13;thousands):&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&amp;#160;Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Cost of service revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;56&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;78&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;130&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Selling, general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;221&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;349&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;484&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;296&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;372&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;483&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;680&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2013, there were&#13;unrecognized compensation costs of $1,403,000 related to stock options which are  expected to be recognized over a&#13;weighted-average amortization period of 2.54 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimated the fair value&#13;of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized&#13;on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options&#13;was estimated using the following weighted-average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Three&amp;#160;Months&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.89 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.85 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.89 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.85 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1.42%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.73%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1.42%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.73%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;86%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;88%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;86%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;88%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Fair value of options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The expected term of stock options represents&#13;the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the&#13;approach prescribed by the Securities and Exchange Commission's Staff Accounting Bulletin No. 110 for &amp;#147;plain vanilla&amp;#148;&#13;options. The expected stock price volatility for the Company&amp;#146;s stock options was determined by examining the historical volatility&#13;of the Company and the historical volatilities of the Company&amp;#146;s industry peers. The Company will continue to analyze the&#13;stock price volatility and expected term assumptions as more data for the Company&amp;#146;s common stock and exercise patterns become&#13;available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the&#13;expected term of the Company&amp;#146;s stock options. The expected dividend assumption is based on the Company&amp;#146;s history and&#13;expectation of dividend payouts. The Company estimates forfeitures based on historical experience and reduces compensation expense&#13;accordingly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of all option activity as of&#13;September 30, 2013 and changes during the six months then ended is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&amp;#160;of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&amp;#160; &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at March&amp;#160;31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;335&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options forfeited or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(81&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at September&amp;#160;30, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable at September&amp;#160;30, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options available for grant as of September&amp;#160;30, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;848&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated&#13;as the difference between the exercise price of the stock options and the underlying fair value of the Company&amp;#146;s common stock&#13;($2.74) for stock options that were in-the-money as of September 30, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company did not capitalize any cost associated with stock-based&#13;compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;No income tax benefit has been recognized&#13;related to stock-based compensation expense and no tax benefits have been realized from exercised stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company issues new shares of common stock upon exercise&#13;of stock options.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company completed a study during&#13;the year ended March 31, 2013 to assess whether a change in control had occurred or whether there have been multiple changes of&#13;control since the Company&amp;#146;s formation.&amp;#160; The Company determined, based on the results of the study, no change in control&#13;occurred for purposes of Internal Revenue Code section 382. &amp;#160;In addition, the Company is not aware of any changes in ownership&#13;during the six months ended September 30, 2013 that would result in a change in control under Internal Revenue Code section 382.&amp;#160;&#13;The Company, after considering all available evidence, fully reserved against its deferred tax assets since it is more likely than&#13;not that such benefits will not be realized in future periods. The Company incurred losses for both financial reporting and income&#13;tax purposes for the six months ended September 30, 2013. Accordingly, the Company is continuing to fully reserve for its deferred&#13;tax assets. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could&#13;affect the realization of their future benefit. If it is determined in future periods that portions of the Company&amp;#146;s deferred&#13;income tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result of certain realization requirements&#13;of Accounting Standards Codification Topic 718, the Company&amp;#146;s deferred tax assets and liabilities do not include certain&#13;deferred tax assets at September 30, 2013 that arose directly from tax deductions related to equity compensation in excess of compensation&#13;recognized for financial reporting purposes.&amp;#160;&amp;#160;Equity will be increased by approximately $533,000 if and when such deferred&#13;tax assets are ultimately realized.&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company generates revenues from tissue&#13;care products which are sold into the human and animal healthcare markets and the Company also generates revenues from laboratory&#13;testing services which are provided to medical device manufacturers. The Company operates a single segment business for product&#13;sales which consists of three geographical sales territories as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&amp;#160;Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Six&amp;#160;Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;U.S.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,898,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,898,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,931,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Mexico&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,352,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,862,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,776,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,240,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Europe and Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;603,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;504,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,010,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;909,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,853,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7,007,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,080,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three months ended September&#13;30, 2013 and 2012, the Company received licensing revenues of $397,000 and $374,000, respectively. Such revenues are included in&#13;the Company&amp;#146;s calculation of product revenues and are reflected in the table above under the respective geographic region&#13;where such licensing revenues were earned. For the six months ended September 30, 2013 and 2012, the Company received licensing&#13;revenues of $830,000 and $406,000, respectively. Such revenues are included in the Company&amp;#146;s calculation of product revenues&#13;and are reflected in the table above under the respective geographic region where such licensing revenues were earned.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#146;s service revenues&#13;amounted to $236,000 and $262,000 for the three months ended September 30, 2013 and 2012, respectively, and the Company&amp;#146;s&#13;service revenues amounted to $454,000 and $497,000 for the six months ended September 30, 2012 and 2011, respectively.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three months ended September&#13;30, 2013, one customer represented 33% of net revenue and one customer represented 32% of net revenue. For the three months ended&#13;September 30, 2012, one customer represented 27% of net revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the six months ended September 30,&#13;2013, one customer represented 37% of net revenue and one customer represented 27% of net revenue. For the six months ended September&#13;30, 2012, one customer represented 28% of net revenue.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2013, one customer represented&#13;33%, one customer represented 30%, and one customer represented 11% of the net accounts receivable balance. At March 31, 2013,&#13;one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Common Stock Issued to Non-Employee&#13;For Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 2, 2013, the Company issued&#13;11,070 shares of common stock, with a value of $30,000, to Windsor Corporation in consideration for services provided during the&#13;three months ended September 30, 2013. The Company registered the issuance under its previously filed and currently effective shelf&#13;registration statement on Form S-3 (File No. 333-171411) and the related prospectus supplement dated and filed on October 2, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Amendments No. 1 and No. 2 to the License and Supply Agreement&#13;with Ruthigen, Inc.&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 9, 2013, the Company&#13;entered into Amendment No. 1 to the License and Supply Agreement with the Company&amp;#146;s wholly owned subsidiary, Ruthigen,&#13;Inc. Pursuant to the terms of the License and Supply Agreement, Ruthigen is required to make milestone payments to the&#13;Company upon certain milestone events. Amendment No. 1 amended the second milestone event set forth in Section 7.1 of&#13;the License and Supply Agreement. On November 6, 2013, the Company entered into Amendment No. 2 to the License and&#13;Supply Agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the License and&#13;Supply Agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the License and&#13;Supply Agreement. Pursuant to the terms of Amendment No. 2, Ruthigen will be required to make a total of $5,000,000 in&#13;milestone payments to the Company for the first product only, as follows: upon completion of Ruthigen&amp;#146;s first meeting&#13;with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen&amp;#146;s first pivotal clinical trial and&#13;upon first patient enrollment in Ruthigen&amp;#146;s second pivotal clinical trial. Ruthigen also agreed to purchase certain&#13;research and development and manufacturing equipment from the Company for approximately $3 million following the completion&#13;of Ruthigen&amp;#146;s intended initial public offering. All other terms and conditions of the License and Supply Agreement&#13;remain unmodified and in full force and effect.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ocls:OrganizationTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Oculus Innovative Sciences, Inc. (the&#13;&amp;#147;Company&amp;#148;) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the&#13;laws of the State of Delaware in December 2006. The Company&amp;#146;s principal office is located in Petaluma, California. The Company&#13;is a global healthcare company that designs, produces, and markets prescription and non-prescription products in 27 countries.&#13;It is pioneering innovative products for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets.&#13;The Company&amp;#146;s primary focus is on its proprietary technology platform called Microcyn&amp;#174; Technology. This technology is&#13;based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens).&#13;Several Microcyn&amp;#174; Technology tissue care products are designed to treat infections and enhance healing while reducing the need&#13;for antibiotics.&lt;/p&gt;</ocls:OrganizationTextBlock>
    <ocls:ReverseStockSplitTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective as of the open of business&#13;on April 1, 2013, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every 7 shares of&#13;common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the&#13;reverse stock split. Instead, each resulting fractional share of common stock was rounded up to one whole share. The reverse stock&#13;split reduced the number of shares of the Company&amp;#146;s common stock outstanding from 46,080,513 to 6,583,150. The total number&#13;of authorized shares of common stock was also proportionally decreased by a ratio of 1:7 and the par value per share of the common&#13;stock continued to be $0.0001.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All common shares and per share amounts&#13;contained in the condensed consolidated financial statements have been retroactively adjusted to reflect a 1 for 7 reverse stock&#13;split, effective April 1, 2013.&lt;/p&gt;</ocls:ReverseStockSplitTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial&#13;statements include the accounts of the Company and its wholly owned subsidiaries, Aquamed Technologies, Inc. (&amp;#147;Aquamed&amp;#148;),&#13;Oculus Technologies of Mexico S.A. de C.V. and Oculus Innovative Sciences Netherlands, B.V. and Ruthigen, Inc. (&amp;#147;Ruthigen&amp;#148;).&#13;All significant intercompany accounts and transactions have been eliminated in consolidation. Aquamed has no current operations.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of condensed consolidated&#13;financial statements in conformity with accounting principles generally accepted in the United States of America requires management&#13;to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities&#13;at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting&#13;periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs&#13;related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company&amp;#146;s&#13;deferred taxes,&amp;#160;the valuation of equity and derivative instruments, and debt discounts and the estimated amortization periods&#13;of upfront licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. The allowance&#13;for uncollectible accounts receivable balances amounted to $9,000 and $22,000, which are included in accounts receivable, net in&#13;the accompanying September 30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively. The reserve for excess&#13;and obsolete inventory balances amounted to $76,000 and $170,000, which are included in inventories, net in the accompanying September&#13;30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:Reclassifications contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior period amounts have been&#13;reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the&#13;Company&amp;#146;s previously reported net loss.&lt;/p&gt;</us-gaap:Reclassifications>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes basic net loss per&#13;share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding&#13;for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would&#13;include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock&#13;using the &amp;#147;treasury stock&amp;#148; and/or &amp;#147;if converted&amp;#148; methods as applicable. The computation of basic net loss&#13;per share for the three and six months ended September 30, 2013 and 2012 (adjusted if applicable for the reverse stock split effective&#13;April 1, 2013) excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; padding-left: 9pt; text-indent: -9pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;988&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,529&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Common Stock Purchase Warrants and Other Derivative&#13;Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies common stock purchase&#13;warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or&#13;net-share settlement, or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement&#13;or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to&#13;net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty&#13;a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions&#13;as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to&#13;determine whether a change in classification between assets and liabilities is required. The Company determined that its freestanding&#13;derivatives, which principally consist of warrants to purchase common stock, satisfied the criteria for classification as equity&#13;instruments at September 30, 2013, other than certain warrants that contain reset provisions and certain warrants that require&#13;net-cash settlement that the Company classified as derivative liabilities.&lt;/p&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Assets&#13;and Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments, including cash&#13;and cash equivalents, accounts receivable, inventory, accounts payable and accrued liabilities are carried at cost, which management&#13;believes approximates fair value due to the short-term nature of these instruments. The fair value of capital lease obligations&#13;and equipment loans approximates their carrying amounts as a market rate of interest is attached to their repayment. The Company&#13;measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or&#13;paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly&#13;transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes&#13;the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair&#13;value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level&amp;#160;1&amp;#160;&amp;#151; quoted&#13;prices in active markets for identical assets or liabilities&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level&amp;#160;2&amp;#160;&amp;#151; quoted&#13;prices for similar assets and liabilities in active markets or inputs that are observable&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level&amp;#160;3&amp;#160;&amp;#151; inputs&#13;that are unobservable (for example, cash flow modeling inputs based on assumptions)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Financial liabilities measured at fair value on a recurring&#13;basis are summarized below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 liabilities are valued using&#13;unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities.&#13;For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company&amp;#146;s accounting and finance&#13;department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination&#13;of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company&amp;#146;s&#13;accounting and finance department and are approved by the Chief Financial Officer.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 100%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Level 3 Valuation Techniques&lt;/u&gt;:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 financial liabilities consist&#13;of the derivative liabilities for which there is no current market for these securities such that the determination of fair value&#13;requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy&#13;are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the Black-Scholes option&#13;valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates&#13;transaction details such as the Company&amp;#146;s stock price, contractual terms, maturity, risk free rates, as well as volatility.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A significant decrease in the volatility&#13;or a significant decrease in the Company&amp;#146;s stock price, in isolation, would result in a significantly lower fair value measurement.&#13;Changes in the values of the derivative liabilities are recorded in &amp;#147;(Loss) gain due to change in fair value of derivative&#13;instruments&amp;#148; in the Company&amp;#146;s condensed consolidated statements of comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2013, there were&#13;no transfers in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has evaluated subsequent events&#13;or transactions occurring through the date the condensed consolidated financial statements were issued (Note 10).&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2013-04-01to2013-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; padding-left: 9pt; text-indent: -9pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;988&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 9pt; text-indent: -9pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrants to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,529&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2013-04-01to2013-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;591&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;835&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;234&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;327&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;825&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,162&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Less: inventory allowances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(170&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2013-04-01to2013-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&amp;#160;Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Six&amp;#160;Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;U.S.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,898,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,898,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,221,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,931,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Mexico&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,352,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,862,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2,776,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,240,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Europe and Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;603,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;504,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,010,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;909,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,853,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4,264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7,007,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,080,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2013-11-15" unitRef="Shares" decimals="INF">6644764</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">3190000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="-3">3351000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">7900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-09-30" unitRef="USD" decimals="-3">8310000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-3197000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">-1400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-1075000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">-1386000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-86000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">119000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">13000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-3111000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">-1519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-1074000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">-1399000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">6625</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-07-01to2012-09-30" unitRef="Shares" decimals="INF">4659</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-04-01to2012-09-30" unitRef="Shares" decimals="INF">4587</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-07-01to2013-09-30" unitRef="Shares" decimals="INF">6631</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-04-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-07-01to2012-09-30" unitRef="USDPShares" decimals="INF">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-04-01to2012-09-30" unitRef="USDPShares" decimals="INF">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-07-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-3111000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">-1519000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-2136000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">-1399000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherNonoperatingExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">67000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">26000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">46000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">39000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">438000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">280000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">568000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">188000</us-gaap:InterestExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-2397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">-817000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-1312000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">-1271000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">7302000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">4017000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">7396000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">3976000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">5912000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">3504000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">6351000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">3093000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">1390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">513000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">1045000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GrossProfit contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">4905000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">3200000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">6084000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">2705000</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">2556000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">1326000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">2493000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">1384000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfServices contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">332000</us-gaap:CostOfServices>
    <us-gaap:CostOfServices contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">234000</us-gaap:CostOfServices>
    <us-gaap:CostOfServices contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">413000</us-gaap:CostOfServices>
    <us-gaap:CostOfServices contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">181000</us-gaap:CostOfServices>
    <us-gaap:CostOfGoodsSold contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">2224000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">1092000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">2080000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">1203000</us-gaap:CostOfGoodsSold>
    <us-gaap:Revenues contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">7461000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">4526000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">8577000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">4089000</us-gaap:Revenues>
    <us-gaap:SalesRevenueServicesNet contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">454000</us-gaap:SalesRevenueServicesNet>
    <us-gaap:SalesRevenueServicesNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">262000</us-gaap:SalesRevenueServicesNet>
    <us-gaap:SalesRevenueServicesNet contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">497000</us-gaap:SalesRevenueServicesNet>
    <us-gaap:SalesRevenueServicesNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">236000</us-gaap:SalesRevenueServicesNet>
    <us-gaap:LicensesRevenue contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">830000</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">374000</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">406000</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">397000</us-gaap:LicensesRevenue>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">6177000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">3890000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">7674000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">3456000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-07-01to2013-09-30_custom_InnovacynMember" unitRef="USD" decimals="-3">1289000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-07-01to2012-09-30_custom_InnovacynMember" unitRef="USD" decimals="-3">1229000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-04-01to2012-09-30_custom_InnovacynMember" unitRef="USD" decimals="-3">2365000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-04-01to2013-09-30_custom_InnovacynMember" unitRef="USD" decimals="-3">2030000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-07-01to2013-09-30_custom_MorePharmaMember" unitRef="USD" decimals="-3">378000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-07-01to2012-09-30_custom_MorePharmaMember" unitRef="USD" decimals="-3">183000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2012-04-01to2012-09-30_custom_MorePharmaMember" unitRef="USD" decimals="-3">183000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet contextRef="From2013-04-01to2013-09-30_custom_MorePharmaMember" unitRef="USD" decimals="-3">752000</us-gaap:SalesRevenueGoodsNet>
    <ocls:WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">0</ocls:WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering>
    <ocls:WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">2347000</ocls:WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering>
    <us-gaap:InterestPaid contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">143000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">265000</us-gaap:InterestPaid>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-4710000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">4959000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-26000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-2000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-1918000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">1874000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">1138000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">974000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">907000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">1925000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-312000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-205000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">26000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-143000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">338000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">62000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-2454000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">3292000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-791000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">4479000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">76000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-71000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">225000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-28000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">369000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">84000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-215000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-70000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">738000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">705000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">5000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">-7000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:OtherNoncashExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">294000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">303000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2013-04-01to2013-09-30_custom_VLL5WarrantsMember" unitRef="USD" decimals="-3">90000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2012-04-01to2012-09-30_custom_VLL5WarrantsMember" unitRef="USD" decimals="-3">125000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2013-04-01to2013-09-30_custom_VLL6WarrantsMember" unitRef="USD" decimals="-3">204000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2012-04-01to2012-09-30_custom_VLL6WarrantsMember" unitRef="USD" decimals="-3">178000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2013-07-01to2013-09-30_custom_VLL5WarrantsMember" unitRef="USD" decimals="-3">24000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2012-07-01to2012-09-30_custom_VLL5WarrantsMember" unitRef="USD" decimals="-3">63000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2013-07-01to2013-09-30_custom_VLL6WarrantsMember" unitRef="USD" decimals="-3">104000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="From2012-07-01to2012-09-30_custom_VLL6WarrantsMember" unitRef="USD" decimals="-3">91000</us-gaap:OtherNoncashExpense>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">-397000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">850000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ShareBasedCompensation contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">666000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">941000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-04-01to2013-09-30_custom_WindsorMember" unitRef="USD" decimals="-3">49000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">136000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">136000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">1229000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">335000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">816000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2013-09-30" unitRef="Shares" decimals="INF">848000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-09-30" unitRef="USDPShares" decimals="INF">11.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">15.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2013-04-01to2013-09-30" unitRef="USDPShares" decimals="INF">2.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2013-04-01to2013-09-30" unitRef="USDPShares" decimals="INF">15.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2013-09-30" unitRef="USDPShares" decimals="INF">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2013-04-01to2013-09-30">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2013-04-01to2013-09-30">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">483000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30_us-gaap_CostOfSalesMember" unitRef="USD" decimals="-3">56000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-04-01to2012-09-30_CostOfSalesMember" unitRef="USD" decimals="-3">66000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">78000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-04-01to2012-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-04-01to2013-09-30_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-04-01to2012-09-30_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">484000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30_us-gaap_CostOfSalesMember" unitRef="USD" decimals="-3">30000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-07-01to2012-09-30_us-gaap_CostOfSalesMember" unitRef="USD" decimals="-3">34000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">45000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-07-01to2012-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">63000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-07-01to2013-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-07-01to2012-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-04-01to2013-09-30" unitRef="Shares" decimals="INF">2547000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-04-01to2013-09-30_StockOptionMember" unitRef="Shares" decimals="INF">1229000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-04-01to2012-09-30" unitRef="Shares" decimals="INF">2517000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-04-01to2012-09-30_StockOptionMember" unitRef="Shares" decimals="INF">988000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-04-01to2013-09-30_WarrantMember" unitRef="Shares" decimals="INF">1318000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-04-01to2012-09-30_WarrantMember" unitRef="Shares" decimals="INF">1529000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ocls:EstimatedForfeitureRates contextRef="From2013-04-01to2013-09-30_us-gaap_MaximumMember" unitRef="Percent" decimals="INF">.0477</ocls:EstimatedForfeitureRates>
    <ocls:EstimatedForfeitureRates contextRef="From2013-04-01to2013-09-30_us-gaap_MinimumMember" unitRef="Percent" decimals="INF">.0163</ocls:EstimatedForfeitureRates>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1403000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2013-04-01to2013-09-30">P2Y6M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-04-01to2013-09-30" unitRef="Percent" decimals="INF">.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-07-01to2012-09-30" unitRef="Percent" decimals="INF">.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-04-01to2012-09-30" unitRef="Percent" decimals="INF">.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-07-01to2013-09-30" unitRef="Percent" decimals="INF">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-04-01to2013-09-30" unitRef="Percent" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-07-01to2012-09-30" unitRef="Percent" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-09-30" unitRef="Percent" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-07-01to2013-09-30" unitRef="Percent" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-04-01to2013-09-30" unitRef="Percent" decimals="INF">.86</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-07-01to2012-09-30" unitRef="Percent" decimals="INF">.88</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-04-01to2012-09-30" unitRef="Percent" decimals="INF">.88</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-07-01to2013-09-30" unitRef="Percent" decimals="INF">0.86</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2013-04-01to2013-09-30" unitRef="USDPShares" decimals="INF">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2012-07-01to2012-09-30" unitRef="USDPShares" decimals="INF">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2012-04-01to2012-09-30" unitRef="USDPShares" decimals="INF">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2013-07-01to2013-09-30" unitRef="USDPShares" decimals="INF">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <ocls:WorkingCapital contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">2175000</ocls:WorkingCapital>
    <ocls:WorkingCapital contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">6407000</ocls:WorkingCapital>
    <ocls:GainLossDueToChangeInFairValueOfCommonStock contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-210000</ocls:GainLossDueToChangeInFairValueOfCommonStock>
    <ocls:GainLossDueToChangeInFairValueOfCommonStock contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">0</ocls:GainLossDueToChangeInFairValueOfCommonStock>
    <ocls:GainLossDueToChangeInFairValueOfCommonStock contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">0</ocls:GainLossDueToChangeInFairValueOfCommonStock>
    <ocls:GainLossDueToChangeInFairValueOfCommonStock contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">99000</ocls:GainLossDueToChangeInFairValueOfCommonStock>
    <us-gaap:DividendsPreferredStock contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="-3">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">1062000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:DividendsPreferredStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">16000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">9000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2013-03-31" unitRef="USD" decimals="-3">22000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InterestAndDebtExpense contextRef="From2012-04-01to2012-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">109000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-04-01to2013-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">27000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-04-01to2013-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">114000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2012-04-01to2012-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">151000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-07-01to2013-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">7000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2012-07-01to2012-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">50000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-07-01to2013-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">53000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2012-07-01to2012-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">75000</us-gaap:InterestAndDebtExpense>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-04-01to2012-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">566000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-04-01to2013-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">556000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-04-01to2013-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">449000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-04-01to2012-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">266000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-07-01to2013-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">24000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-07-01to2012-09-30_custom_VLL5AgreementsMember" unitRef="USD" decimals="-3">288000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-07-01to2013-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">228000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-07-01to2012-09-30_custom_VLL6AgreementsMember" unitRef="USD" decimals="-3">148000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:LongTermDebt contextRef="AsOf2013-09-30_custom_VLL5WarrantsMember" unitRef="USD" decimals="-3">138000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2013-09-30_custom_VLL6WarrantsMember" unitRef="USD" decimals="-3">1367000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2013-09-30_custom_VLL6WarrantsMember" unitRef="USD" decimals="-3">474000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:OtherCommitment contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1843000</us-gaap:OtherCommitment>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent contextRef="AsOf2013-09-30" unitRef="USD" decimals="-3">1310000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:AccountsReceivableGross contextRef="AsOf2013-09-30_InnovacynMember" unitRef="USD" decimals="-3">801000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="AsOf2013-09-30_MorePharmaMember" unitRef="USD" decimals="-3">717000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="AsOf2013-03-31_custom_InnovacynMember" unitRef="USD" decimals="-3">264000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="AsOf2013-03-31_custom_MorePharmaMember" unitRef="USD" decimals="-3">580000</us-gaap:AccountsReceivableGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-07-01to2013-09-30_custom_AdvocosMember" unitRef="Shares" decimals="INF">8139</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2012-07-01to2012-09-30_custom_AdvocosMember" unitRef="Shares" decimals="INF">3728</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2012-04-01to2012-09-30_custom_AdvocosMember892848837" unitRef="Shares" decimals="INF">14392</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-04-01to2013-09-30_custom_AdvocosMember892848837" unitRef="Shares" decimals="INF">38447</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-04-01to2013-09-30_custom_WindsorMember" unitRef="Shares" decimals="INF">12097</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-07-01to2013-09-30_custom_AdvocosMember" unitRef="USD" decimals="-3">22000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-07-01to2012-09-30_custom_AdvocosMember" unitRef="USD" decimals="-3">20000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2012-04-01to2012-09-30_custom_AdvocosMember892848837" unitRef="USD" decimals="-3">112000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-04-01to2013-09-30_custom_AdvocosMember892848837" unitRef="USD" decimals="-3">134000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-07-01to2013-09-30_custom_WindsorMember892848837" unitRef="USD" decimals="-3">30000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-04-01to2013-09-30">P5Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-07-01to2012-09-30">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-04-01to2012-09-30">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-07-01to2013-09-30">P5Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-04-01to2012-09-30_custom_CustomerOneMember_custom_RevenueMember" unitRef="Percent" decimals="INF">.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-04-01to2013-09-30_custom_CustomerOneMember" unitRef="Percent" decimals="INF">.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-04-01to2013-09-30_custom_SecondCustomerMember_custom_RevenueMember" unitRef="Percent" decimals="INF">.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-07-01to2013-09-30_custom_CustomerOneMember" unitRef="Percent" decimals="INF">.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-07-01to2013-09-30_custom_SecondCustomerMember" unitRef="Percent" decimals="INF">.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-07-01to2012-09-30_custom_CustomerOneMember_custom_RevenueMember" unitRef="Percent" decimals="INF">.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;In June 2011,&#13;the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update (&amp;#147;ASU&amp;#148;) No. 2011-05,&#13;&lt;i&gt;Comprehensive Income (Topic 220): Presentation of Comprehensive Income&lt;/i&gt;. This guidance improves the comparability, consistency&#13;and transparency of financial reporting and increases the prominence of items reported in other comprehensive income.&amp;#160; In&#13;December 2011, the FASB issued ASU No. 2011-12, &lt;i&gt;Deferral of the Effective Date for Amendments to the Presentation of Reclassifications&#13;of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05&lt;/i&gt;. ASU 2011-12 defers the requirement that companies present&#13;reclassification adjustments for each component of Accumulated Other Comprehensive Income in both net income and Other Comprehensive&#13;Income on the face of the financial statements. All other requirements in ASU No. 2011-05 are not affected by ASU No. 2011-12,&#13;including the requirement to report comprehensive income either in a single continuous financial statement or in two separate&#13;but consecutive financial statements.&amp;#160; While the adoption of this standard required the Company to change the format of its&#13;condensed consolidated financial statements, it did not have a material impact on the Company&amp;#146;s consolidated financial position&#13;and results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The FASB&#13;has issued ASU No. 2013-11, &lt;i&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss&#13;Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists&lt;/i&gt; (a consensus of the FASB Emerging Issues Task Force).&#13;The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented&#13;in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss,&#13;or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax&#13;credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional&#13;income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not&#13;require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax&#13;benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The&#13;amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after &lt;font style="color: black"&gt;December&#13;15, 2013&lt;/font&gt;. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years,&#13;beginning after &lt;font style="color: black"&gt;December 15, 2014&lt;/font&gt;. Early adoption is permitted. The amendments should be applied&#13;prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption&#13;of this standard is not expected to have a material impact on the Company&amp;#146;s condensed consolidated financial position and&#13;results of operations.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Accounting standards&#13;that have been issued or proposed by the FASB, SEC and/or other standards-setting bodies that do not require adoption until a&#13;future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The Company reported&#13;a net loss of $3,111,000 for the six months ended September 30, 2013. At September 30, 2013 and March 31, 2013, the Company&amp;#146;s&#13;accumulated deficit amounted to $140,856,000 and $137,745,000, respectively. The Company had working capital of $2,175,000 and&#13;$6,407,000 as of September 30, 2013 and March 31, 2013, respectively. The Company expects the need to raise additional capital&#13;from external sources in order to continue the longer term efforts contemplated under its business plan and repay its outstanding&#13;notes payable obligations. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional&#13;capital to pursue its product development initiatives, penetrate markets for the sale of its products and continue as a going&#13;concern. Upon the closing of the intended initial public offering by the Company&amp;#146;s subsidiary, Ruthigen, Inc., the Company&#13;will be repaid for certain costs incurred and advanced related to Ruthigen&amp;#146;s initial public offering and certain other agreed-upon&#13;expenses, pursuant to the terms of the separation agreement the Company entered into with Ruthigen (See Note 4). At September&#13;30, 2013, these costs amounted to $911,000, of which $824,000 is reported as deferred offering costs in the accompanying condensed&#13;consolidated balance sheet and $87,000 was reported as selling, general and administrative expense.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The Company currently&#13;anticipates that its cash and cash equivalents will be sufficient to meet its working capital requirements to continue its sales&#13;and marketing and research and development efforts through at least October 1, 2014. However, in order to execute the Company&amp;#146;s&#13;long-term Microcyn&amp;#174; product development strategy and to penetrate new and existing markets, the Company may need to raise&#13;additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially&#13;reduce operating expenditures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Management believes&#13;that the Company has access to capital resources through possible public or private equity offerings, debt financings, corporate&#13;collaborations or other means; however, the Company has not secured any commitment for new financing at this time, nor can it&#13;provide any assurance that the Ruthigen initial public offering will be completed or that other new financings will be available&#13;on commercially acceptable terms, if needed. If the Company is unable to secure additional capital, it may be required to curtail&#13;its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/font&gt;&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2013-04-01to2013-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&amp;#160;Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Cost of service revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;56&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;78&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;130&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Selling, general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;221&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;349&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;484&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;296&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;372&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;483&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;680&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2013-04-01to2013-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Three&amp;#160;Months&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expected life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.89 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.85 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.89 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5.85 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1.42%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.73%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1.42%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.73%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;86%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;88%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;86%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;88%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #EEEEEE"&gt;&#13;    &lt;td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Fair value of options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;4.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2013-04-01to2013-09-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&amp;#160;of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&amp;#160;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&amp;#160; &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at March&amp;#160;31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;335&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options forfeited or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(81&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding at September&amp;#160;30, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,229&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable at September&amp;#160;30, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#150;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options available for grant as of September&amp;#160;30, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;848&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <ocls:ConcentrationRiskPercentage2 contextRef="AsOf2013-03-31_CustomerOneMember" unitRef="Percent" decimals="INF">.34</ocls:ConcentrationRiskPercentage2>
    <ocls:ConcentrationRiskPercentage2 contextRef="AsOf2013-09-30_custom_CustomerOneMember" unitRef="Percent" decimals="INF">.33</ocls:ConcentrationRiskPercentage2>
    <ocls:ConcentrationRiskPercentage2 contextRef="AsOf2013-09-30_custom_SecondCustomerMember" unitRef="Percent" decimals="INF">.30</ocls:ConcentrationRiskPercentage2>
    <ocls:ConcentrationRiskPercentage2 contextRef="AsOf2013-03-31_custom_SecondCustomerMember" unitRef="Percent" decimals="INF">.26</ocls:ConcentrationRiskPercentage2>
    <ocls:ConcentrationRiskPercentage2 contextRef="AsOf2013-09-30_custom_ThirdCustomerMember" unitRef="Percent" decimals="INF">.11</ocls:ConcentrationRiskPercentage2>
    <ocls:ConcentrationRiskPercentage2 contextRef="AsOf2013-03-31_custom_ThirdCustomerMember" unitRef="Percent" decimals="INF">.15</ocls:ConcentrationRiskPercentage2>
    <ocls:BasisOfPresentationPolicyTextBlock contextRef="From2013-04-01to2013-09-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;The accompanying&#13;unaudited condensed consolidated financial statements as of September 30, 2013 and for the three and six months then ended have&#13;been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial&#13;information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission&#13;(&amp;#147;SEC&amp;#148;) and on the same basis as the Company prepares its annual audited consolidated financial statements. The unaudited&#13;condensed consolidated balance sheet as of September 30, 2013, the condensed consolidated statements of comprehensive loss for&#13;the three and six months ended September 30, 2013 and 2012, and the condensed consolidated statements of cash flows for the six&#13;months ended September 30, 2013 and 2012 are unaudited, but include all adjustments, consisting only of normal recurring adjustments,&#13;which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for&#13;the periods presented. The results for the three and six months ended September 30, 2013 are not necessarily indicative of results&#13;to be expected for the year ending March 31, 2014 or for any future interim period. The condensed consolidated balance sheet at&#13;March 31, 2013 has been derived from audited consolidated financial statements. However, it does not include all of the information&#13;and notes required by accounting principles generally accepted in the United States of America for complete consolidated financial&#13;statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial&#13;statements for the year ended March 31, 2013, and notes thereto included in the Company&amp;#146;s annual report on Form 10-K, which&#13;was filed with the SEC on June 25, 2013.&lt;/font&gt;&lt;/p&gt;</ocls:BasisOfPresentationPolicyTextBlock>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="0">7007000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-04-01to2013-09-30_USMember" unitRef="USD" decimals="0">3221000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-04-01to2012-09-30_USMember" unitRef="USD" decimals="0">3931000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-04-01to2013-09-30_MexicoMember" unitRef="USD" decimals="0">2776000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-04-01to2012-09-30_MexicoMember" unitRef="USD" decimals="0">3240000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-04-01to2013-09-30_EuropeOtherMember" unitRef="USD" decimals="0">1010000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-04-01to2012-09-30_EuropeOtherMember" unitRef="USD" decimals="0">909000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">4264000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="0">8080000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">3853000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-07-01to2013-09-30_custom_USMember" unitRef="USD" decimals="0">1898000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-07-01to2012-09-30_custom_USMember" unitRef="USD" decimals="0">1898000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-07-01to2013-09-30_custom_MexicoMember" unitRef="USD" decimals="0">1352000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-07-01to2012-09-30_custom_MexicoMember" unitRef="USD" decimals="0">1862000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2013-07-01to2013-09-30_custom_EuropeOtherMember" unitRef="USD" decimals="0">603000</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-07-01to2012-09-30_custom_EuropeOtherMember" unitRef="USD" decimals="0">504000</us-gaap:OtherSalesRevenueNet>
    <ocls:DeferredOfferingCosts1 contextRef="From2013-04-01to2013-09-30" unitRef="USD" decimals="-3">-780000</ocls:DeferredOfferingCosts1>
    <ocls:DeferredOfferingCosts1 contextRef="From2012-04-01to2012-09-30" unitRef="USD" decimals="-3">0</ocls:DeferredOfferingCosts1>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ocls-20130930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: oculus_10q%2D093013.xfr; Date: 2013%2D11%2D18T18:51:34 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9ag5o7xRiXhun8uCZndcWauPucOdxZR/+ZlBsGxybQmKLyQssfE8DyDVx8k2cc8P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:ocls="http://oculus.com/20130930" elementFormDefault="qualified" targetNamespace="http://oculus.com/20130930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://oculus.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000006 - Disclosure - 1. Organization and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/LiquidityAndFinancialCondition" id="LiquidityAndFinancialCondition">
	  <link:definition>00000007 - Disclosure - 2. Liquidity and Financial Condition</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000008 - Disclosure - 3. Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000009 - Disclosure - 4. Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000010 - Disclosure - 5. Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/Stock-BasedCompensation" id="Stock-BasedCompensation">
	  <link:definition>00000011 - Disclosure - 6. Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000012 - Disclosure - 7. Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SegmentAndGeographicInformation" id="SegmentAndGeographicInformation">
	  <link:definition>00000013 - Disclosure - 8. Segment and Geographic Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SignificantCustomerConcentrations" id="SignificantCustomerConcentrations">
	  <link:definition>00000014 - Disclosure - 9. Significant Customer Concentrations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000015 - Disclosure - 10. Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000016 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000017 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" id="CondensedConsolidatedBalanceSheetsTables">
	  <link:definition>00000018 - Disclosure - 3. Condensed Consolidated Balance Sheets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/Stock-BasedCompensationTables" id="Stock-BasedCompensationTables">
	  <link:definition>00000019 - Disclosure - 6. Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SegmentAndGeographicInformationTables" id="SegmentAndGeographicInformationTables">
	  <link:definition>00000020 - Disclosure - 8. Segment and Geographic Information (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" id="PotentiallyDilutiveSecuritesTableDetails">
	  <link:definition>00000021 - Disclosure - 1. Potentially Dilutive Securites Table (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative">
	  <link:definition>00000022 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" id="LiquidityAndFinancialConditionNarrative">
	  <link:definition>00000023 - Disclosure - 2. Liquidity and Financial Condition (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/InventoriesDetails" id="InventoriesDetails">
	  <link:definition>00000024 - Disclosure - 3. Inventories (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/NotesPayableNarrative" id="NotesPayableNarrative">
	  <link:definition>00000025 - Disclosure - 3. Notes Payable (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/CommitmentsAndContingenciesNarrative" id="CommitmentsAndContingenciesNarrative">
	  <link:definition>00000026 - Disclosure - 4. Commitments and Contingencies (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000027 - Disclosure - 5. Stockholders' Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/Stock-BasedCompensationDetails" id="Stock-BasedCompensationDetails">
	  <link:definition>00000028 - Disclosure - 6. Stock-Based Compensation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/OptionAssumptionsDetails" id="OptionAssumptionsDetails">
	  <link:definition>00000029 - Disclosure - 6. Option Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/OptionsOutstandingDetails" id="OptionsOutstandingDetails">
	  <link:definition>00000030 - Disclosure - 6. Options Outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/Stock-BasedCompensationNarrative" id="Stock-BasedCompensationNarrative">
	  <link:definition>00000031 - Disclosure - 6. Stock-Based Compensation (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SegmentAndGeographicInformationDetails" id="SegmentAndGeographicInformationDetails">
	  <link:definition>00000032 - Disclosure - 8. Segment and Geographic Information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SegmentAndGeographicInformationNarrative" id="SegmentAndGeographicInformationNarrative">
	  <link:definition>00000033 - Disclosure - 8. Segment and Geographic Information (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" id="SignificantCustomerConcentrationsNarrative">
	  <link:definition>00000034 - Disclosure - 9. Significant Customer Concentrations (Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ocls-20130930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ocls-20130930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ocls-20130930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ocls-20130930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="ocls_WarrantsWithoutFixedSettlementProvisionsMember" name="WarrantsWithoutFixedSettlementProvisionsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_WarrantsWithNetCashSettlementProvisionsMember" name="WarrantsWithNetCashSettlementProvisionsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_HojabrAlimiMember" name="HojabrAlimiMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_StockBasedCompensationExpenseMember" name="StockBasedCompensationExpenseMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_USMember" name="USMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_MexicoMember" name="MexicoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_EuropeAndOtherMember" name="EuropeAndOtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ModificationIncrementalFairValueMember" name="ModificationIncrementalFairValueMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_PreModificationMember" name="PreModificationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_EuropeOtherMember" name="EuropeOtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_VentureLendingLeasingMember" name="VentureLendingLeasingMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ShareBasedCompensationMember" name="ShareBasedCompensationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CustomerThreeMember" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_UsefulLifeMember" name="UsefulLifeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CustomerAMember" name="CustomerAMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CustomerBMember" name="CustomerBMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Plan1999Member" name="Plan1999Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Plan2000Member" name="Plan2000Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Plan2003Member" name="Plan2003Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Plan2004Member" name="Plan2004Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Plan2006Member" name="Plan2006Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Plan2011Member" name="Plan2011Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_OneCustomerMember" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_SecondCustomerMember" name="SecondCustomerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ThirdCustomerMember" name="ThirdCustomerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Note100kMember" name="Note100kMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Note57kMember" name="Note57kMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Note40kMember" name="Note40kMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Note27kMember" name="Note27kMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Note141kMember" name="Note141kMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_Note155kMember" name="Note155kMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_VLL5AgreementsMember" name="VLL5AgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_VLL6AgreementsMember" name="VLL6AgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_LLC6Member" name="LLC6Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CommercialAgreementsMember" name="CommercialAgreementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CollaborationAgreementMember" name="CollaborationAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ShanghaiSunvicMember" name="ShanghaiSunvicMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_MorePharmaMember" name="MorePharmaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_InnovacynMember" name="InnovacynMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_AdvocosMember" name="AdvocosMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_WindsorMember" name="WindsorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_NetgainMember" name="NetgainMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_WroldwideFinancialMember" name="WroldwideFinancialMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_VLL5WarrantsMember" name="VLL5WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_VLL6WarrantsMember" name="VLL6WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_WTIMember" name="WTIMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_FinishedGoodsMember" name="FinishedGoodsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_RevenueMember" name="RevenueMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CashSettlementLiabilityCurrent" name="CashSettlementLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_CashSettlementLiabilityNoncurrent" name="CashSettlementLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_DebtDiscountCurrentPortionOfLongtermDebt" name="DebtDiscountCurrentPortionOfLongtermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_DebtDiscountLongtermPortionOfLongtermDebt" name="DebtDiscountLongtermPortionOfLongtermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_GainLossDueToChangeInFairValueOfCommonStock" name="GainLossDueToChangeInFairValueOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_DeferredOfferingCosts1" name="DeferredOfferingCosts1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" name="WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_LiquidityAndFinancialConditionAbstract" name="LiquidityAndFinancialConditionAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_OrganizationTextBlock" name="OrganizationTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ReverseStockSplitTextBlock" name="ReverseStockSplitTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_BasisOfPresentationPolicyTextBlock" name="BasisOfPresentationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_DebtInstrumentDomain" name="DebtInstrumentDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_StockbasedCompensationDetailsTextAbstract" name="StockbasedCompensationDetailsTextAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_StockOptionsAbstract" name="StockOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_EstimatedForfeitureRates" name="EstimatedForfeitureRates" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_AccountsReceivableAbstract" name="AccountsReceivableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_ConcentrationRiskPercentage2" name="ConcentrationRiskPercentage2" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ocls_IncreaseDecreaseInDeferredOfferingCosts" name="IncreaseDecreaseInDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ocls-20130930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: oculus_10q%2D093013.xfr; Date: 2013%2D11%2D18T18:51:34 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oculus.com/role/DocumentAndEntityInformation" xlink:href="ocls-20130930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/BalanceSheets" xlink:href="ocls-20130930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/BalanceSheetsParenthetical" xlink:href="ocls-20130930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StatementsOfComprehensiveLoss" xlink:href="ocls-20130930.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StatementsOfCashFlows" xlink:href="ocls-20130930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/LiquidityAndFinancialCondition" xlink:href="ocls-20130930.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ocls-20130930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CommitmentsAndContingencies" xlink:href="ocls-20130930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StockholdersEquity" xlink:href="ocls-20130930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensation" xlink:href="ocls-20130930.xsd#Stock-BasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/IncomeTaxes" xlink:href="ocls-20130930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformation" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SignificantCustomerConcentrations" xlink:href="ocls-20130930.xsd#SignificantCustomerConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SubsequentEvents" xlink:href="ocls-20130930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" xlink:href="ocls-20130930.xsd#CondensedConsolidatedBalanceSheetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationTables" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationTables" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" xlink:href="ocls-20130930.xsd#PotentiallyDilutiveSecuritesTableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" xlink:href="ocls-20130930.xsd#LiquidityAndFinancialConditionNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/InventoriesDetails" xlink:href="ocls-20130930.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/NotesPayableNarrative" xlink:href="ocls-20130930.xsd#NotesPayableNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CommitmentsAndContingenciesNarrative" xlink:href="ocls-20130930.xsd#CommitmentsAndContingenciesNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StockholdersEquityDetailsNarrative" xlink:href="ocls-20130930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationDetails" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OptionAssumptionsDetails" xlink:href="ocls-20130930.xsd#OptionAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OptionsOutstandingDetails" xlink:href="ocls-20130930.xsd#OptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationNarrative" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationDetails" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationNarrative" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" xlink:href="ocls-20130930.xsd#SignificantCustomerConcentrationsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CashSettlementLiabilityCurrent" xlink:label="loc_oclsCashSettlementLiabilityCurrent" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_oclsCashSettlementLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CashSettlementLiabilityNoncurrent" xlink:label="loc_oclsCashSettlementLiabilityNoncurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_oclsCashSettlementLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaapSalesRevenueGoodsNet" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapSalesRevenueGoodsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaapSalesRevenueServicesNet" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapSalesRevenueServicesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostOfGoodsAndServicesSold" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfServices" xlink:label="loc_us-gaapCostOfServices" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostOfGoodsAndServicesSold" xlink:to="loc_us-gaapCostOfServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:label="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="1200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:label="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" />
      <link:calculationArc order="1300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_IncreaseDecreaseInDeferredOfferingCosts" xlink:label="loc_oclsIncreaseDecreaseInDeferredOfferingCosts" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_oclsIncreaseDecreaseInDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000006 - Disclosure - 1. Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/LiquidityAndFinancialCondition" xlink:title="00000007 - Disclosure - 2. Liquidity and Financial Condition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000008 - Disclosure - 3. Condensed Consolidated Balance Sheets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - 4. Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - 5. Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensation" xlink:title="00000011 - Disclosure - 6. Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - 7. Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformation" xlink:title="00000013 - Disclosure - 8. Segment and Geographic Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SignificantCustomerConcentrations" xlink:title="00000014 - Disclosure - 9. Significant Customer Concentrations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - 10. Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000017 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" xlink:title="00000018 - Disclosure - 3. Condensed Consolidated Balance Sheets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationTables" xlink:title="00000019 - Disclosure - 6. Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationTables" xlink:title="00000020 - Disclosure - 8. Segment and Geographic Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" xlink:title="00000021 - Disclosure - 1. Potentially Dilutive Securites Table (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:title="00000022 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" xlink:title="00000023 - Disclosure - 2. Liquidity and Financial Condition (Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/InventoriesDetails" xlink:title="00000024 - Disclosure - 3. Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/NotesPayableNarrative" xlink:title="00000025 - Disclosure - 3. Notes Payable (Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/CommitmentsAndContingenciesNarrative" xlink:title="00000026 - Disclosure - 4. Commitments and Contingencies (Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000027 - Disclosure - 5. Stockholders' Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationDetails" xlink:title="00000028 - Disclosure - 6. Stock-Based Compensation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/OptionAssumptionsDetails" xlink:title="00000029 - Disclosure - 6. Option Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/OptionsOutstandingDetails" xlink:title="00000030 - Disclosure - 6. Options Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationNarrative" xlink:title="00000031 - Disclosure - 6. Stock-Based Compensation (Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationDetails" xlink:title="00000032 - Disclosure - 8. Segment and Geographic Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationNarrative" xlink:title="00000033 - Disclosure - 8. Segment and Geographic Information (Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" xlink:title="00000034 - Disclosure - 9. Significant Customer Concentrations (Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ocls-20130930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: oculus_10q%2D093013.xfr; Date: 2013%2D11%2D18T18:51:34 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oculus.com/role/DocumentAndEntityInformation" xlink:href="ocls-20130930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/BalanceSheets" xlink:href="ocls-20130930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/BalanceSheetsParenthetical" xlink:href="ocls-20130930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StatementsOfComprehensiveLoss" xlink:href="ocls-20130930.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StatementsOfCashFlows" xlink:href="ocls-20130930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/LiquidityAndFinancialCondition" xlink:href="ocls-20130930.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ocls-20130930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CommitmentsAndContingencies" xlink:href="ocls-20130930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StockholdersEquity" xlink:href="ocls-20130930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensation" xlink:href="ocls-20130930.xsd#Stock-BasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/IncomeTaxes" xlink:href="ocls-20130930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformation" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SignificantCustomerConcentrations" xlink:href="ocls-20130930.xsd#SignificantCustomerConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SubsequentEvents" xlink:href="ocls-20130930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" xlink:href="ocls-20130930.xsd#CondensedConsolidatedBalanceSheetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationTables" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationTables" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" xlink:href="ocls-20130930.xsd#PotentiallyDilutiveSecuritesTableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" xlink:href="ocls-20130930.xsd#LiquidityAndFinancialConditionNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/InventoriesDetails" xlink:href="ocls-20130930.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/NotesPayableNarrative" xlink:href="ocls-20130930.xsd#NotesPayableNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CommitmentsAndContingenciesNarrative" xlink:href="ocls-20130930.xsd#CommitmentsAndContingenciesNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StockholdersEquityDetailsNarrative" xlink:href="ocls-20130930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationDetails" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OptionAssumptionsDetails" xlink:href="ocls-20130930.xsd#OptionAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OptionsOutstandingDetails" xlink:href="ocls-20130930.xsd#OptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationNarrative" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationDetails" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationNarrative" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" xlink:href="ocls-20130930.xsd#SignificantCustomerConcentrationsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000006 - Disclosure - 1. Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/LiquidityAndFinancialCondition" xlink:title="00000007 - Disclosure - 2. Liquidity and Financial Condition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000008 - Disclosure - 3. Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - 4. Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - 5. Stockholders' Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensation" xlink:title="00000011 - Disclosure - 6. Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - 7. Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformation" xlink:title="00000013 - Disclosure - 8. Segment and Geographic Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SignificantCustomerConcentrations" xlink:title="00000014 - Disclosure - 9. Significant Customer Concentrations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - 10. Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000017 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" xlink:title="00000018 - Disclosure - 3. Condensed Consolidated Balance Sheets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationTables" xlink:title="00000019 - Disclosure - 6. Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationTables" xlink:title="00000020 - Disclosure - 8. Segment and Geographic Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" xlink:title="00000021 - Disclosure - 1. Potentially Dilutive Securites Table (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:title="00000022 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" xlink:title="00000023 - Disclosure - 2. Liquidity and Financial Condition (Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/InventoriesDetails" xlink:title="00000024 - Disclosure - 3. Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaapPublicUtilitiesInventoryAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:label="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_FinishedGoodsMember" xlink:label="loc_oclsFinishedGoodsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_oclsFinishedGoodsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/NotesPayableNarrative" xlink:title="00000025 - Disclosure - 3. Notes Payable (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtInstrumentDomain" xlink:label="loc_oclsDebtInstrumentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_oclsDebtInstrumentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtInstrumentDomain" xlink:label="loc_oclsDebtInstrumentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_oclsDebtInstrumentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL5AgreementsMember" xlink:label="loc_oclsVLL5AgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL5AgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL5WarrantsMember" xlink:label="loc_oclsVLL5WarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL5WarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL6AgreementsMember" xlink:label="loc_oclsVLL6AgreementsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL6AgreementsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL6WarrantsMember" xlink:label="loc_oclsVLL6WarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL6WarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNoncashExpense_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_190" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/CommitmentsAndContingenciesNarrative" xlink:title="00000026 - Disclosure - 4. Commitments and Contingencies (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_InnovacynMember" xlink:label="loc_oclsInnovacynMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsInnovacynMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_MorePharmaMember" xlink:label="loc_oclsMorePharmaMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsMorePharmaMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCommitment_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="loc_us-gaapAccountsReceivableGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableGross_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaapSalesRevenueGoodsNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalesRevenueGoodsNet_140" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000027 - Disclosure - 5. Stockholders' Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AdvocosMember" xlink:label="loc_oclsAdvocosMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_oclsAdvocosMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WindsorMember" xlink:label="loc_oclsWindsorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_oclsWindsorMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationDetails" xlink:title="00000028 - Disclosure - 6. Stock-Based Compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/OptionAssumptionsDetails" xlink:title="00000029 - Disclosure - 6. Option Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/OptionsOutstandingDetails" xlink:title="00000030 - Disclosure - 6. Options Outstanding (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationNarrative" xlink:title="00000031 - Disclosure - 6. Stock-Based Compensation (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EstimatedForfeitureRates" xlink:label="loc_oclsEstimatedForfeitureRates_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_oclsEstimatedForfeitureRates_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationDetails" xlink:title="00000032 - Disclosure - 8. Segment and Geographic Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_USMember" xlink:label="loc_oclsUSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_oclsUSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_MexicoMember" xlink:label="loc_oclsMexicoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_oclsMexicoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EuropeOtherMember" xlink:label="loc_oclsEuropeOtherMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_oclsEuropeOtherMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaapOtherSalesRevenueNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherSalesRevenueNet_170" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationNarrative" xlink:title="00000033 - Disclosure - 8. Segment and Geographic Information (Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" xlink:title="00000034 - Disclosure - 9. Significant Customer Concentrations (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerOneMember" xlink:label="loc_oclsCustomerOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsCustomerOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_SecondCustomerMember" xlink:label="loc_oclsSecondCustomerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsSecondCustomerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ThirdCustomerMember" xlink:label="loc_oclsThirdCustomerMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsThirdCustomerMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_130" xlink:to="loc_us-gaapConcentrationRiskPercentage1_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AccountsReceivableAbstract" xlink:label="loc_oclsAccountsReceivableAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_130" xlink:to="loc_oclsAccountsReceivableAbstract_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ConcentrationRiskPercentage2" xlink:label="loc_oclsConcentrationRiskPercentage2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oclsAccountsReceivableAbstract_130" xlink:to="loc_oclsConcentrationRiskPercentage2_130" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ocls-20130930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: oculus_10q%2D093013.xfr; Date: 2013%2D11%2D18T18:51:34 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WarrantsWithoutFixedSettlementProvisionsMember" xlink:label="ocls_WarrantsWithoutFixedSettlementProvisionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WarrantsWithoutFixedSettlementProvisionsMember" xlink:to="ocls_WarrantsWithoutFixedSettlementProvisionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WarrantsWithoutFixedSettlementProvisionsMember_lbl" xml:lang="en-US">WarrantsWithoutFixedSettlementProvisionsMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US">Measurement Basis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WarrantsWithNetCashSettlementProvisionsMember" xlink:label="ocls_WarrantsWithNetCashSettlementProvisionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WarrantsWithNetCashSettlementProvisionsMember" xlink:to="ocls_WarrantsWithNetCashSettlementProvisionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WarrantsWithNetCashSettlementProvisionsMember_lbl" xml:lang="en-US">WarrantsWithNetCashSettlementProvisionsMember</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_HojabrAlimiMember" xlink:label="ocls_HojabrAlimiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_HojabrAlimiMember" xlink:to="ocls_HojabrAlimiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_HojabrAlimiMember_lbl" xml:lang="en-US">HojabrAlimiMember</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_StockBasedCompensationExpenseMember" xlink:label="ocls_StockBasedCompensationExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_StockBasedCompensationExpenseMember" xlink:to="ocls_StockBasedCompensationExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_StockBasedCompensationExpenseMember_lbl" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xml:lang="en-US">Nature of Expense [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_USMember" xlink:label="ocls_USMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_USMember" xlink:to="ocls_USMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_USMember_lbl" xml:lang="en-US">U.S.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_MexicoMember" xlink:label="ocls_MexicoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_MexicoMember" xlink:to="ocls_MexicoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_MexicoMember_lbl" xml:lang="en-US">Mexico</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EuropeAndOtherMember" xlink:label="ocls_EuropeAndOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EuropeAndOtherMember" xlink:to="ocls_EuropeAndOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_EuropeAndOtherMember_lbl" xml:lang="en-US">Europe and Other</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ModificationIncrementalFairValueMember" xlink:label="ocls_ModificationIncrementalFairValueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ModificationIncrementalFairValueMember" xlink:to="ocls_ModificationIncrementalFairValueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ModificationIncrementalFairValueMember_lbl" xml:lang="en-US">ModificationIncrementalFairValueMember</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_PreModificationMember" xlink:label="ocls_PreModificationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_PreModificationMember" xlink:to="ocls_PreModificationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_PreModificationMember_lbl" xml:lang="en-US">PreModificationMember</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EuropeOtherMember" xlink:label="ocls_EuropeOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EuropeOtherMember" xlink:to="ocls_EuropeOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_EuropeOtherMember_lbl" xml:lang="en-US">Europe and Other</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerOneMember" xlink:label="ocls_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerOneMember" xlink:to="ocls_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CustomerOneMember_lbl" xml:lang="en-US">One Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US">Major Customers [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VentureLendingLeasingMember" xlink:label="ocls_VentureLendingLeasingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VentureLendingLeasingMember" xlink:to="ocls_VentureLendingLeasingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_VentureLendingLeasingMember_lbl" xml:lang="en-US">VLL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_StockPurchaseAgreementMember" xlink:label="ocls_StockPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_StockPurchaseAgreementMember" xlink:to="ocls_StockPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement with Venture Lending &amp;amp;amp;amp; Leasing V, LLC and Venture Lending &amp;amp;amp;amp; Leasing VI, LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueEstimateNotPracticableDisclosureItemsAxis" xlink:label="us-gaap_FairValueEstimateNotPracticableDisclosureItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueEstimateNotPracticableDisclosureItemsAxis" xlink:to="us-gaap_FairValueEstimateNotPracticableDisclosureItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueEstimateNotPracticableDisclosureItemsAxis_lbl" xml:lang="en-US">Fair Value, Estimate Not Practicable, Disclosure Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ShareBasedCompensationMember" xlink:label="ocls_ShareBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ShareBasedCompensationMember" xlink:to="ocls_ShareBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ShareBasedCompensationMember_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerTwoMember" xlink:label="ocls_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerTwoMember" xlink:to="ocls_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CustomerTwoMember_lbl" xml:lang="en-US">Second Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerThreeMember" xlink:label="ocls_CustomerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerThreeMember" xlink:to="ocls_CustomerThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CustomerThreeMember_lbl" xml:lang="en-US">Third Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income / Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_UsefulLifeMember" xlink:label="ocls_UsefulLifeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_UsefulLifeMember" xlink:to="ocls_UsefulLifeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_UsefulLifeMember_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerAMember" xlink:label="ocls_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerAMember" xlink:to="ocls_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CustomerAMember_lbl" xml:lang="en-US">Customer A</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerBMember" xlink:label="ocls_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerBMember" xlink:to="ocls_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CustomerBMember_lbl" xml:lang="en-US">Customer B</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ManufacturingEquipmentMember" xlink:label="ocls_ManufacturingEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ManufacturingEquipmentMember" xlink:to="ocls_ManufacturingEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ManufacturingEquipmentMember_lbl" xml:lang="en-US">Manufacturing, lab and other equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Plan1999Member" xlink:label="ocls_Plan1999Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan1999Member" xlink:to="ocls_Plan1999Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Plan1999Member_lbl" xml:lang="en-US">1999 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Plan2000Member" xlink:label="ocls_Plan2000Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2000Member" xlink:to="ocls_Plan2000Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Plan2000Member_lbl" xml:lang="en-US">2000 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Plan2003Member" xlink:label="ocls_Plan2003Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2003Member" xlink:to="ocls_Plan2003Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Plan2003Member_lbl" xml:lang="en-US">2003 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Plan2004Member" xlink:label="ocls_Plan2004Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2004Member" xlink:to="ocls_Plan2004Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Plan2004Member_lbl" xml:lang="en-US">2004 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Plan2006Member" xlink:label="ocls_Plan2006Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2006Member" xlink:to="ocls_Plan2006Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Plan2006Member_lbl" xml:lang="en-US">2006 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Plan2011Member" xlink:label="ocls_Plan2011Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2011Member" xlink:to="ocls_Plan2011Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Plan2011Member_lbl" xml:lang="en-US">2011 Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_OneCustomerMember" xlink:label="ocls_OneCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_OneCustomerMember" xlink:to="ocls_OneCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_OneCustomerMember_lbl" xml:lang="en-US">One Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_SecondCustomerMember" xlink:label="ocls_SecondCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_SecondCustomerMember" xlink:to="ocls_SecondCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_SecondCustomerMember_lbl" xml:lang="en-US">Second Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ThirdCustomerMember" xlink:label="ocls_ThirdCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ThirdCustomerMember" xlink:to="ocls_ThirdCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_ThirdCustomerMember_lbl" xml:lang="en-US">Third Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Note100kMember" xlink:label="ocls_Note100kMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note100kMember" xlink:to="ocls_Note100kMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Note100kMember_lbl" xml:lang="en-US">$100,000 Note</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Note57kMember" xlink:label="ocls_Note57kMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note57kMember" xlink:to="ocls_Note57kMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Note57kMember_lbl" xml:lang="en-US">$57,000 Note</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Note40kMember" xlink:label="ocls_Note40kMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note40kMember" xlink:to="ocls_Note40kMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Note40kMember_lbl" xml:lang="en-US">$40,000 Note</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Note27kMember" xlink:label="ocls_Note27kMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note27kMember" xlink:to="ocls_Note27kMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Note27kMember_lbl" xml:lang="en-US">$27,000 Note</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Note141kMember" xlink:label="ocls_Note141kMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note141kMember" xlink:to="ocls_Note141kMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Note141kMember_lbl" xml:lang="en-US">$141,000 Note</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_Note155kMember" xlink:label="ocls_Note155kMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note155kMember" xlink:to="ocls_Note155kMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_Note155kMember_lbl" xml:lang="en-US">$155,000 Note</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL5AgreementsMember" xlink:label="ocls_VLL5AgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VLL5AgreementsMember" xlink:to="ocls_VLL5AgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_VLL5AgreementsMember_lbl" xml:lang="en-US">VLL5 Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL6AgreementsMember" xlink:label="ocls_VLL6AgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VLL6AgreementsMember" xlink:to="ocls_VLL6AgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_VLL6AgreementsMember_lbl" xml:lang="en-US">VLL6 Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_LLC6Member" xlink:label="ocls_LLC6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_LLC6Member" xlink:to="ocls_LLC6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_LLC6Member_lbl" xml:lang="en-US">LLC6</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CommercialAgreementsMember" xlink:label="ocls_CommercialAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CommercialAgreementsMember" xlink:to="ocls_CommercialAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CommercialAgreementsMember_lbl" xml:lang="en-US">Commercial Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CollaborationAgreementMember" xlink:label="ocls_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CollaborationAgreementMember" xlink:to="ocls_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ShanghaiSunvicMember" xlink:label="ocls_ShanghaiSunvicMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ShanghaiSunvicMember" xlink:to="ocls_ShanghaiSunvicMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ShanghaiSunvicMember_lbl" xml:lang="en-US">Shanghai Sunvic Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_MorePharmaMember" xlink:label="ocls_MorePharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_MorePharmaMember" xlink:to="ocls_MorePharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_MorePharmaMember_lbl" xml:lang="en-US">More Pharma</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_InnovacynMember" xlink:label="ocls_InnovacynMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_InnovacynMember" xlink:to="ocls_InnovacynMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_InnovacynMember_lbl" xml:lang="en-US">Innovacyn</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AdvocosMember" xlink:label="ocls_AdvocosMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AdvocosMember" xlink:to="ocls_AdvocosMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_AdvocosMember_lbl" xml:lang="en-US">Advocos</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WindsorMember" xlink:label="ocls_WindsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WindsorMember" xlink:to="ocls_WindsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WindsorMember_lbl" xml:lang="en-US">Windsor Corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_NetgainMember" xlink:label="ocls_NetgainMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_NetgainMember" xlink:to="ocls_NetgainMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_NetgainMember_lbl" xml:lang="en-US">Netgain Financial</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WroldwideFinancialMember" xlink:label="ocls_WroldwideFinancialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WroldwideFinancialMember" xlink:to="ocls_WroldwideFinancialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WroldwideFinancialMember_lbl" xml:lang="en-US">Worldwide Financial Marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xml:lang="en-US">US Treasury and Government [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL5WarrantsMember" xlink:label="ocls_VLL5WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VLL5WarrantsMember" xlink:to="ocls_VLL5WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_VLL5WarrantsMember_lbl" xml:lang="en-US">VLL5 Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL6WarrantsMember" xlink:label="ocls_VLL6WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VLL6WarrantsMember" xlink:to="ocls_VLL6WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_VLL6WarrantsMember_lbl" xml:lang="en-US">VLL6 Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WTIMember" xlink:label="ocls_WTIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WTIMember" xlink:to="ocls_WTIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WTIMember_lbl" xml:lang="en-US">WTI</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:label="us-gaap_PublicUtilitiesInventoryRawMaterialsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:to="us-gaap_PublicUtilitiesInventoryRawMaterialsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryRawMaterialsMember_lbl" xml:lang="en-US">Raw Materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_FinishedGoodsMember" xlink:label="ocls_FinishedGoodsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_FinishedGoodsMember" xlink:to="ocls_FinishedGoodsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_FinishedGoodsMember_lbl" xml:lang="en-US">Finished Goods</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_RevenueMember" xlink:label="ocls_RevenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_RevenueMember" xlink:to="ocls_RevenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_RevenueMember_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DocumentAndEntityInformationAbstract" xlink:label="ocls_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DocumentAndEntityInformationAbstract" xlink:to="ocls_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CashSettlementLiabilityCurrent" xlink:label="ocls_CashSettlementLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CashSettlementLiabilityCurrent" xlink:to="ocls_CashSettlementLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CashSettlementLiabilityCurrent_lbl" xml:lang="en-US">Current portion of cash settlement liability (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current portion of long-term debt, net of debt discount of $430 (unaudited) and $521 at September 30, 2013 and March 31, 2013, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt, net of debt discount of $45 (unaudited) and $248 at September 30, 2013 and March 31, 2013, respectively, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CashSettlementLiabilityNoncurrent" xlink:label="ocls_CashSettlementLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CashSettlementLiabilityNoncurrent" xlink:to="ocls_CashSettlementLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_CashSettlementLiabilityNoncurrent_lbl" xml:lang="en-US">Cash settlement liability, less current portion (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized, none issued and outstanding at September 30, 2013 (unaudited) and March 31, 2013, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 14,285,715 shares authorized, 6,633,694 and 6,583,150 shares issued and outstanding at September 30, 2013 (unaudited) and March 31, 2013, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtDiscountCurrentPortionOfLongtermDebt" xlink:label="ocls_DebtDiscountCurrentPortionOfLongtermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DebtDiscountCurrentPortionOfLongtermDebt" xlink:to="ocls_DebtDiscountCurrentPortionOfLongtermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_DebtDiscountCurrentPortionOfLongtermDebt_lbl" xml:lang="en-US">Debt discount, current portion of long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtDiscountLongtermPortionOfLongtermDebt" xlink:label="ocls_DebtDiscountLongtermPortionOfLongtermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DebtDiscountLongtermPortionOfLongtermDebt" xlink:to="ocls_DebtDiscountLongtermPortionOfLongtermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_DebtDiscountLongtermPortionOfLongtermDebt_lbl" xml:lang="en-US">Debt discount, long-term portion of long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock par value (in Dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Convertible preferred stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US">Product licensing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNet" xlink:to="us-gaap_SalesRevenueServicesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueServicesNet_lbl" xml:lang="en-US">Service</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfServices" xlink:to="us-gaap_CostOfServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfServices_lbl" xml:lang="en-US">Service</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Total cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:label="ocls_GainLossDueToChangeInFairValueOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:to="ocls_GainLossDueToChangeInFairValueOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_GainLossDueToChangeInFairValueOfCommonStock_lbl" xml:lang="en-US">Gain (loss) due to change in fair value of common stock (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">(Loss) gain due to change in fair value of derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Preferred stock deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share: basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted-average number of shares used in per common share calculations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_2_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:to="ocls_GainLossDueToChangeInFairValueOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ocls_GainLossDueToChangeInFairValueOfCommonStock_2_lbl" xml:lang="en-US">Loss due to change in fair value of common stock (See Note 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign currency transaction gains</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl" xml:lang="en-US">Long-term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from the issuance of convertible preferred stock, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from the exercise of common stock options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DeferredOfferingCosts1" xlink:label="ocls_DeferredOfferingCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DeferredOfferingCosts1" xlink:to="ocls_DeferredOfferingCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_DeferredOfferingCosts1_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Principal payments on long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease) increase cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash operating and financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" xlink:label="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" xlink:to="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering_lbl" xml:lang="en-US">Warrants issued as derivative liabilities in connection with registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">1. Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_LiquidityAndFinancialConditionAbstract" xlink:label="ocls_LiquidityAndFinancialConditionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_LiquidityAndFinancialConditionAbstract" xlink:to="ocls_LiquidityAndFinancialConditionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_LiquidityAndFinancialConditionAbstract_lbl" xml:lang="en-US">Liquidity And Financial Condition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US">2. Liquidity and Financial Condition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">3. Condensed Consolidated Balance Sheets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">4. Commitments and Contingencies</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">5. Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">6. Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">7. Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">8. Segment and Geographic Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">9. Significant Customer Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">10. Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_OrganizationTextBlock" xlink:label="ocls_OrganizationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_OrganizationTextBlock" xlink:to="ocls_OrganizationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_OrganizationTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ReverseStockSplitTextBlock" xlink:label="ocls_ReverseStockSplitTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ReverseStockSplitTextBlock" xlink:to="ocls_ReverseStockSplitTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ReverseStockSplitTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_BasisOfPresentationPolicyTextBlock" xlink:label="ocls_BasisOfPresentationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_BasisOfPresentationPolicyTextBlock" xlink:to="ocls_BasisOfPresentationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Common Stock Purchase Warrants and Other Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Potentially dilutive securities excluded from computation of net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Employee stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Weighted-average assumptions of fair value of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Summary of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Segment and Geographic Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total securities excluded from computation of basic net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for uncollectible accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Reserve for excess and obsolete inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_LiquidityAndFinancialConditionAbstract" xlink:to="ocls_LiquidityAndFinancialConditionAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_LiquidityAndFinancialConditionAbstract_2_lbl" xml:lang="en-US">Liquidity And Financial Condition Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WorkingCapital" xlink:label="ocls_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WorkingCapital" xlink:to="ocls_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Less: inventory allowances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest payments made</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments made</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Note payable balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Discount on loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MajorCustomersAxis_2_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Potential severance under certain employment agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:to="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent_lbl" xml:lang="en-US">Aggregated annual salaries under certain employment agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_2_lbl" xml:lang="en-US">Product revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_StockOptionsAbstract" xlink:label="ocls_StockOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_StockOptionsAbstract" xlink:to="ocls_StockOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_StockOptionsAbstract_lbl" xml:lang="en-US">Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeited or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Options available for grant, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AggregateIntrinsicValueAbstract" xlink:label="ocls_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AggregateIntrinsicValueAbstract" xlink:to="ocls_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EstimatedForfeitureRates" xlink:label="ocls_EstimatedForfeitureRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EstimatedForfeitureRates" xlink:to="ocls_EstimatedForfeitureRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_EstimatedForfeitureRates_lbl" xml:lang="en-US">Estimated forfeiture rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average amortization period of unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSalesRevenueNet" xlink:to="us-gaap_OtherSalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSalesRevenueNet_lbl" xml:lang="en-US">Sales revenue from geographical territories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNet" xlink:to="us-gaap_SalesRevenueServicesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueServicesNet_2_lbl" xml:lang="en-US">Service revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicensesRevenue_2_lbl" xml:lang="en-US">Product licensing revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Significant customer concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AccountsReceivableAbstract" xlink:label="ocls_AccountsReceivableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AccountsReceivableAbstract" xlink:to="ocls_AccountsReceivableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_AccountsReceivableAbstract_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ConcentrationRiskPercentage2" xlink:label="ocls_ConcentrationRiskPercentage2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ConcentrationRiskPercentage2" xlink:to="ocls_ConcentrationRiskPercentage2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ocls_ConcentrationRiskPercentage2_lbl" xml:lang="en-US">Significant customer concentration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AdvocosMember" xlink:to="ocls_AdvocosMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_AdvocosMember_doc" xml:lang="en-US">Advocos.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_BasisOfPresentationPolicyTextBlock" xlink:to="ocls_BasisOfPresentationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_BasisOfPresentationPolicyTextBlock_doc" xml:lang="en-US">Basis of presentation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CollaborationAgreementMember" xlink:to="ocls_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CommercialAgreementsMember" xlink:to="ocls_CommercialAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CommercialAgreementsMember_doc" xml:lang="en-US">Commercial agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerAMember" xlink:to="ocls_CustomerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CustomerAMember_doc" xml:lang="en-US">Customer A.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerBMember" xlink:to="ocls_CustomerBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CustomerBMember_doc" xml:lang="en-US">Customer B.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerOneMember" xlink:to="ocls_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CustomerOneMember_doc" xml:lang="en-US">One customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerThreeMember" xlink:to="ocls_CustomerThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CustomerThreeMember_doc" xml:lang="en-US">Another customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CustomerTwoMember" xlink:to="ocls_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CustomerTwoMember_doc" xml:lang="en-US">Another customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DocumentAndEntityInformationAbstract" xlink:to="ocls_DocumentAndEntityInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_DocumentAndEntityInformationAbstract_doc" xml:lang="en-US">Document and Entity Information</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EuropeAndOtherMember" xlink:to="ocls_EuropeAndOtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_EuropeAndOtherMember_doc" xml:lang="en-US">Derivative Liability Related To Warrants Without Fixed Settlement Provisions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EuropeOtherMember" xlink:to="ocls_EuropeOtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_EuropeOtherMember_doc" xml:lang="en-US">Employee options expected life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_HojabrAlimiMember" xlink:to="ocls_HojabrAlimiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_HojabrAlimiMember_doc" xml:lang="en-US">Europe and other member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_InnovacynMember" xlink:to="ocls_InnovacynMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_InnovacynMember_doc" xml:lang="en-US">Fair Value Assumptions Dividend Rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_LLC6Member" xlink:to="ocls_LLC6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_LLC6Member_doc" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ManufacturingEquipmentMember" xlink:to="ocls_ManufacturingEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ManufacturingEquipmentMember_doc" xml:lang="en-US">Fair value of warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_MexicoMember" xlink:to="ocls_MexicoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_MexicoMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ModificationIncrementalFairValueMember" xlink:to="ocls_ModificationIncrementalFairValueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ModificationIncrementalFairValueMember_doc" xml:lang="en-US">Impact of change in foreign rate on deferred and true-ups</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_MorePharmaMember" xlink:to="ocls_MorePharmaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_MorePharmaMember_doc" xml:lang="en-US">Income Tax Disclosure text block</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_NetgainMember" xlink:to="ocls_NetgainMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_NetgainMember_doc" xml:lang="en-US">income tax reconciliation, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note100kMember" xlink:to="ocls_Note100kMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Note100kMember_doc" xml:lang="en-US">Note 100k.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note141kMember" xlink:to="ocls_Note141kMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Note141kMember_doc" xml:lang="en-US">Note 141k.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note155kMember" xlink:to="ocls_Note155kMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Note155kMember_doc" xml:lang="en-US">Note 155k.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note27kMember" xlink:to="ocls_Note27kMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Note27kMember_doc" xml:lang="en-US">Loss due to change in fair value of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note40kMember" xlink:to="ocls_Note40kMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Note40kMember_doc" xml:lang="en-US">Note 40k.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Note57kMember" xlink:to="ocls_Note57kMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Note57kMember_doc" xml:lang="en-US">Mark to market net unrealized loss/gain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_OneCustomerMember" xlink:to="ocls_OneCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_OneCustomerMember_doc" xml:lang="en-US">Mexico Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan1999Member" xlink:to="ocls_Plan1999Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Plan1999Member_doc" xml:lang="en-US">Plan 1999.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2000Member" xlink:to="ocls_Plan2000Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Plan2000Member_doc" xml:lang="en-US">Plan 2000.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2003Member" xlink:to="ocls_Plan2003Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Plan2003Member_doc" xml:lang="en-US">Plan 2003.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2004Member" xlink:to="ocls_Plan2004Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Plan2004Member_doc" xml:lang="en-US">Plan 2004.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2006Member" xlink:to="ocls_Plan2006Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Plan2006Member_doc" xml:lang="en-US">Plan 2006.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_Plan2011Member" xlink:to="ocls_Plan2011Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_Plan2011Member_doc" xml:lang="en-US">One customer member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_PreModificationMember" xlink:to="ocls_PreModificationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_PreModificationMember_doc" xml:lang="en-US">Options and restricted stock units outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_SecondCustomerMember" xlink:to="ocls_SecondCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_SecondCustomerMember_doc" xml:lang="en-US">Second customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ShanghaiSunvicMember" xlink:to="ocls_ShanghaiSunvicMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ShanghaiSunvicMember_doc" xml:lang="en-US">Shanghai Sunvice.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ShareBasedCompensationMember" xlink:to="ocls_ShareBasedCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ShareBasedCompensationMember_doc" xml:lang="en-US">Potential severance of key executives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_StockBasedCompensationExpenseMember" xlink:to="ocls_StockBasedCompensationExpenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_StockBasedCompensationExpenseMember_doc" xml:lang="en-US">Stock-based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_StockPurchaseAgreementMember" xlink:to="ocls_StockPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_StockPurchaseAgreementMember_doc" xml:lang="en-US">Prepaid Expenses and Other Current Assets disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ThirdCustomerMember" xlink:to="ocls_ThirdCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ThirdCustomerMember_doc" xml:lang="en-US">Third Customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_USMember" xlink:to="ocls_USMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_USMember_doc" xml:lang="en-US">Sales Tax and Value Added Taxes disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_UsefulLifeMember" xlink:to="ocls_UsefulLifeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_UsefulLifeMember_doc" xml:lang="en-US">Schedule of assumptions for valuation of derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VLL5AgreementsMember" xlink:to="ocls_VLL5AgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_VLL5AgreementsMember_doc" xml:lang="en-US">Schedule of property and equipment useful lives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VLL6AgreementsMember" xlink:to="ocls_VLL6AgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_VLL6AgreementsMember_doc" xml:lang="en-US">Second customer member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_VentureLendingLeasingMember" xlink:to="ocls_VentureLendingLeasingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_VentureLendingLeasingMember_doc" xml:lang="en-US">Segment Reporting Disclosure.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" xlink:to="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering_doc" xml:lang="en-US">Warrants issued as derivative liabilities in connection with registered direct offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WarrantsWithNetCashSettlementProvisionsMember" xlink:to="ocls_WarrantsWithNetCashSettlementProvisionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_WarrantsWithNetCashSettlementProvisionsMember_doc" xml:lang="en-US">Share based compensation member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WarrantsWithoutFixedSettlementProvisionsMember" xlink:to="ocls_WarrantsWithoutFixedSettlementProvisionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_WarrantsWithoutFixedSettlementProvisionsMember_doc" xml:lang="en-US">Stock-based compensation expense member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WindsorMember" xlink:to="ocls_WindsorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_WindsorMember_doc" xml:lang="en-US">Options abstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WroldwideFinancialMember" xlink:to="ocls_WroldwideFinancialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_WroldwideFinancialMember_doc" xml:lang="en-US">Stock purchase agreement member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_WorkingCapital" xlink:to="ocls_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_StockOptionsAbstract" xlink:to="ocls_StockOptionsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_StockOptionsAbstract_doc" xml:lang="en-US">Options abstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AggregateIntrinsicValueAbstract" xlink:to="ocls_AggregateIntrinsicValueAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_AggregateIntrinsicValueAbstract_doc" xml:lang="en-US">Aggregate intrinsic value abstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EstimatedForfeitureRates" xlink:to="ocls_EstimatedForfeitureRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_EstimatedForfeitureRates_doc" xml:lang="en-US">Estimated forfeiture rates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DebtDiscountLongtermPortionOfLongtermDebt" xlink:to="ocls_DebtDiscountLongtermPortionOfLongtermDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_DebtDiscountLongtermPortionOfLongtermDebt_doc" xml:lang="en-US">Debt discount long term portion of long term debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CashSettlementLiabilityCurrent" xlink:to="ocls_CashSettlementLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CashSettlementLiabilityCurrent_doc" xml:lang="en-US">Cash settlement liability, current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_CashSettlementLiabilityNoncurrent" xlink:to="ocls_CashSettlementLiabilityNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_CashSettlementLiabilityNoncurrent_doc" xml:lang="en-US">Cash settlement liability, noncurrent portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DebtDiscountCurrentPortionOfLongtermDebt" xlink:to="ocls_DebtDiscountCurrentPortionOfLongtermDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_DebtDiscountCurrentPortionOfLongtermDebt_doc" xml:lang="en-US">Debt discount, current portion of long-term debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_OrganizationTextBlock" xlink:to="ocls_OrganizationTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_OrganizationTextBlock_doc" xml:lang="en-US">Organization text block</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ReverseStockSplitTextBlock" xlink:to="ocls_ReverseStockSplitTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ReverseStockSplitTextBlock_doc" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:to="ocls_GainLossDueToChangeInFairValueOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_GainLossDueToChangeInFairValueOfCommonStock_doc" xml:lang="en-US">Gain (loss) due to change in fair value of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ConcentrationRiskPercentage2" xlink:to="ocls_ConcentrationRiskPercentage2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_ConcentrationRiskPercentage2_doc" xml:lang="en-US">Customer concentration percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AccountsReceivableAbstract" xlink:to="ocls_AccountsReceivableAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_AccountsReceivableAbstract_doc" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_IncreaseDecreaseInDeferredOfferingCosts" xlink:label="ocls_IncreaseDecreaseInDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_IncreaseDecreaseInDeferredOfferingCosts" xlink:to="ocls_IncreaseDecreaseInDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_IncreaseDecreaseInDeferredOfferingCosts_doc" xml:lang="en-US">Increase decrease in deferred offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DeferredOfferingCosts1" xlink:to="ocls_DeferredOfferingCosts1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ocls_DeferredOfferingCosts1_doc" xml:lang="en-US">Deferred offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_EuropeOtherMember" xlink:to="ocls_EuropeOtherMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_EuropeOtherMember_3_lbl" xml:lang="en-US">EuropeOtherMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_OneCustomerMember" xlink:to="ocls_OneCustomerMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_OneCustomerMember_3_lbl" xml:lang="en-US">OneCustomerMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_SecondCustomerMember" xlink:to="ocls_SecondCustomerMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_SecondCustomerMember_3_lbl" xml:lang="en-US">SecondCustomerMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ThirdCustomerMember" xlink:to="ocls_ThirdCustomerMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ThirdCustomerMember_3_lbl" xml:lang="en-US">ThirdCustomerMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_2_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_2_lbl" xml:lang="en-US">Revenues [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenueAbstract_2_lbl" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_2_lbl" xml:lang="en-US">Cost of Goods Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfServices" xlink:to="us-gaap_CostOfServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfServices_2_lbl" xml:lang="en-US">Cost of Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_DeferredOfferingCosts1" xlink:to="ocls_DeferredOfferingCosts1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_DeferredOfferingCosts1_3_lbl" xml:lang="en-US">DeferredOfferingCosts1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_2_lbl" xml:lang="en-US">Repayments of Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_AccountsReceivableAbstract" xlink:to="ocls_AccountsReceivableAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_AccountsReceivableAbstract_3_lbl" xml:lang="en-US">AccountsReceivableAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_ConcentrationRiskPercentage2" xlink:to="ocls_ConcentrationRiskPercentage2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_ConcentrationRiskPercentage2_3_lbl" xml:lang="en-US">ConcentrationRiskPercentage2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ocls_IncreaseDecreaseInDeferredOfferingCosts" xlink:to="ocls_IncreaseDecreaseInDeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ocls_IncreaseDecreaseInDeferredOfferingCosts_2_lbl" xml:lang="en-US">IncreaseDecreaseInDeferredOfferingCosts</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ocls-20130930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: oculus_10q%2D093013.xfr; Date: 2013%2D11%2D18T18:51:34 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oculus.com/role/DocumentAndEntityInformation" xlink:href="ocls-20130930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/BalanceSheets" xlink:href="ocls-20130930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/BalanceSheetsParenthetical" xlink:href="ocls-20130930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StatementsOfComprehensiveLoss" xlink:href="ocls-20130930.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StatementsOfCashFlows" xlink:href="ocls-20130930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/LiquidityAndFinancialCondition" xlink:href="ocls-20130930.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ocls-20130930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CommitmentsAndContingencies" xlink:href="ocls-20130930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StockholdersEquity" xlink:href="ocls-20130930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensation" xlink:href="ocls-20130930.xsd#Stock-BasedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/IncomeTaxes" xlink:href="ocls-20130930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformation" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SignificantCustomerConcentrations" xlink:href="ocls-20130930.xsd#SignificantCustomerConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SubsequentEvents" xlink:href="ocls-20130930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" xlink:href="ocls-20130930.xsd#CondensedConsolidatedBalanceSheetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationTables" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationTables" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" xlink:href="ocls-20130930.xsd#PotentiallyDilutiveSecuritesTableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:href="ocls-20130930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" xlink:href="ocls-20130930.xsd#LiquidityAndFinancialConditionNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/InventoriesDetails" xlink:href="ocls-20130930.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/NotesPayableNarrative" xlink:href="ocls-20130930.xsd#NotesPayableNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/CommitmentsAndContingenciesNarrative" xlink:href="ocls-20130930.xsd#CommitmentsAndContingenciesNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/StockholdersEquityDetailsNarrative" xlink:href="ocls-20130930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationDetails" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OptionAssumptionsDetails" xlink:href="ocls-20130930.xsd#OptionAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/OptionsOutstandingDetails" xlink:href="ocls-20130930.xsd#OptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/Stock-BasedCompensationNarrative" xlink:href="ocls-20130930.xsd#Stock-BasedCompensationNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationDetails" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SegmentAndGeographicInformationNarrative" xlink:href="ocls-20130930.xsd#SegmentAndGeographicInformationNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" xlink:href="ocls-20130930.xsd#SignificantCustomerConcentrationsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DocumentAndEntityInformationAbstract" xlink:label="loc_oclsDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CashSettlementLiabilityCurrent" xlink:label="loc_oclsCashSettlementLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_oclsCashSettlementLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CashSettlementLiabilityNoncurrent" xlink:label="loc_oclsCashSettlementLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_oclsCashSettlementLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtDiscountCurrentPortionOfLongtermDebt" xlink:label="loc_oclsDebtDiscountCurrentPortionOfLongtermDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_oclsDebtDiscountCurrentPortionOfLongtermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtDiscountLongtermPortionOfLongtermDebt" xlink:label="loc_oclsDebtDiscountLongtermPortionOfLongtermDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_oclsDebtDiscountLongtermPortionOfLongtermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaapSalesRevenueGoodsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapSalesRevenueGoodsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaapSalesRevenueServicesNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapSalesRevenueServicesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="loc_us-gaapCostOfRevenueAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenueAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostOfRevenueAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfServices" xlink:label="loc_us-gaapCostOfServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostOfRevenueAbstract" xlink:to="loc_us-gaapCostOfServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostOfRevenueAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostOfRevenueAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:label="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_GainLossDueToChangeInFairValueOfCommonStock" xlink:label="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_oclsGainLossDueToChangeInFairValueOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DeferredOfferingCosts1" xlink:label="loc_oclsDeferredOfferingCosts1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_oclsDeferredOfferingCosts1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" xlink:label="loc_oclsWarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_oclsWarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000006 - Disclosure - 1. Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/LiquidityAndFinancialCondition" xlink:title="00000007 - Disclosure - 2. Liquidity and Financial Condition">
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_LiquidityAndFinancialConditionAbstract" xlink:label="loc_oclsLiquidityAndFinancialConditionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaapLiquidityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsLiquidityAndFinancialConditionAbstract" xlink:to="loc_us-gaapLiquidityDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000008 - Disclosure - 3. Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - 4. Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - 5. Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensation" xlink:title="00000011 - Disclosure - 6. Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - 7. Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformation" xlink:title="00000013 - Disclosure - 8. Segment and Geographic Information">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SignificantCustomerConcentrations" xlink:title="00000014 - Disclosure - 9. Significant Customer Concentrations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - 10. Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_OrganizationTextBlock" xlink:label="loc_oclsOrganizationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_oclsOrganizationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ReverseStockSplitTextBlock" xlink:label="loc_oclsReverseStockSplitTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_oclsReverseStockSplitTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_BasisOfPresentationPolicyTextBlock" xlink:label="loc_oclsBasisOfPresentationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_oclsBasisOfPresentationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Reclassifications" xlink:label="loc_us-gaapReclassifications" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapReclassifications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000017 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables" xlink:title="00000018 - Disclosure - 3. Condensed Consolidated Balance Sheets (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetRelatedDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationTables" xlink:title="00000019 - Disclosure - 6. Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationTables" xlink:title="00000020 - Disclosure - 8. Segment and Geographic Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails" xlink:title="00000021 - Disclosure - 1. Potentially Dilutive Securites Table (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative" xlink:title="00000022 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/LiquidityAndFinancialConditionNarrative" xlink:title="00000023 - Disclosure - 2. Liquidity and Financial Condition (Narrative)">
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_LiquidityAndFinancialConditionAbstract" xlink:label="loc_oclsLiquidityAndFinancialConditionAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WorkingCapital" xlink:label="loc_oclsWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsLiquidityAndFinancialConditionAbstract" xlink:to="loc_oclsWorkingCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/InventoriesDetails" xlink:title="00000024 - Disclosure - 3. Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaapPublicUtilitiesInventoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPublicUtilitiesInventoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:label="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_FinishedGoodsMember" xlink:label="loc_oclsFinishedGoodsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_oclsFinishedGoodsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/NotesPayableNarrative" xlink:title="00000025 - Disclosure - 3. Notes Payable (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_DebtInstrumentDomain" xlink:label="loc_oclsDebtInstrumentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_oclsDebtInstrumentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL5AgreementsMember" xlink:label="loc_oclsVLL5AgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL5AgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL5WarrantsMember" xlink:label="loc_oclsVLL5WarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL5WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL6AgreementsMember" xlink:label="loc_oclsVLL6AgreementsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL6AgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_VLL6WarrantsMember" xlink:label="loc_oclsVLL6WarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsDebtInstrumentDomain" xlink:to="loc_oclsVLL6WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/CommitmentsAndContingenciesNarrative" xlink:title="00000026 - Disclosure - 4. Commitments and Contingencies (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_InnovacynMember" xlink:label="loc_oclsInnovacynMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsInnovacynMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_MorePharmaMember" xlink:label="loc_oclsMorePharmaMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsMorePharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent" xlink:label="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOtherThanLongtermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="loc_us-gaapAccountsReceivableGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaapSalesRevenueGoodsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalesRevenueGoodsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000027 - Disclosure - 5. Stockholders' Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_StockbasedCompensationDetailsTextAbstract" xlink:label="loc_oclsStockbasedCompensationDetailsTextAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockbasedCompensationDetailsTextAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AdvocosMember" xlink:label="loc_oclsAdvocosMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_oclsAdvocosMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_WindsorMember" xlink:label="loc_oclsWindsorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_oclsWindsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationDetails" xlink:title="00000028 - Disclosure - 6. Stock-Based Compensation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/OptionAssumptionsDetails" xlink:title="00000029 - Disclosure - 6. Option Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/OptionsOutstandingDetails" xlink:title="00000030 - Disclosure - 6. Options Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_StockOptionsAbstract" xlink:label="loc_oclsStockOptionsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_oclsStockOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsStockOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AggregateIntrinsicValueAbstract" xlink:label="loc_oclsAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_oclsAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/Stock-BasedCompensationNarrative" xlink:title="00000031 - Disclosure - 6. Stock-Based Compensation (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EstimatedForfeitureRates" xlink:label="loc_oclsEstimatedForfeitureRates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_oclsEstimatedForfeitureRates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationDetails" xlink:title="00000032 - Disclosure - 8. Segment and Geographic Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_USMember" xlink:label="loc_oclsUSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_oclsUSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_MexicoMember" xlink:label="loc_oclsMexicoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_oclsMexicoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_EuropeOtherMember" xlink:label="loc_oclsEuropeOtherMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_oclsEuropeOtherMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaapOtherSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherSalesRevenueNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SegmentAndGeographicInformationNarrative" xlink:title="00000033 - Disclosure - 8. Segment and Geographic Information (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaapSalesRevenueServicesNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSalesRevenueServicesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oculus.com/role/SignificantCustomerConcentrationsNarrative" xlink:title="00000034 - Disclosure - 9. Significant Customer Concentrations (Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaapMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaapNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorCustomersAxis" xlink:to="loc_us-gaapNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_CustomerOneMember" xlink:label="loc_oclsCustomerOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_SecondCustomerMember" xlink:label="loc_oclsSecondCustomerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsSecondCustomerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ThirdCustomerMember" xlink:label="loc_oclsThirdCustomerMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNameOfMajorCustomerDomain" xlink:to="loc_oclsThirdCustomerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_AccountsReceivableAbstract" xlink:label="loc_oclsAccountsReceivableAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_oclsAccountsReceivableAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocls-20130930.xsd#ocls_ConcentrationRiskPercentage2" xlink:label="loc_oclsConcentrationRiskPercentage2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oclsAccountsReceivableAbstract" xlink:to="loc_oclsConcentrationRiskPercentage2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>1. Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially dilutive securities excluded from computation of net loss per share</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; padding-left: 9pt; text-indent: -9pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options to purchase common stock</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,229</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">988</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase common stock</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,318</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,529</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,547</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,517</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`:,QE5V@$``#$6```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/&
MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,90'^@Y&JZJ,
MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N
M);GWYIY2E^50"1=K`RK<F6I;"1^^VADU(IN+&5#>[?9HII4'Y3N^GD&&@T>8
MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@
MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A
M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD
M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E
M6,S*L9B58S$KQV)6CL6L'(M9.1:S<BQFY5C,RK&8-<%BU@2+61,L9DVPF#7Y
M+[/Z4,@!;3[__G0T8WYIA)Q?E^#._!:W&?I;<BXLR#=O0W5Y=H#OLX]QA&)O
M;+5QH>*T</HI[#K,>G?'A$%@?0'[%K.M#=PGAGKT],"#.A+J`E:";,FF3>$[
M_`(``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N
M<F5L<R"B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````",DL].PS`,QN](O$/D^^IN
M2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#
MNBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\
M(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FR
MMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<
M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````
M__\#`%!+`P04``8`"````"$`_GO?E-(!```<%0``&@`(`7AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````O)C-;L(P$(3OE?H.D>_%[)K?BL"EJL2UI0]@)88@((EL]X>W
MKX40%*F=7J*]1+*C.*/)>KYX9XNOPS[[<#YLFSI7U.NKS-5%4V[K3:[>5L\/
M$Y6%:.O2[IO:Y>KH@EK,[^]F+VYO8WHH5-LV9&F5.N2JBK%]U#H4E3O8T&M:
M5Z<[Z\8?;$Q#O]&M+79VXS3W^R/M?ZZAYC=K9LLR5WY9DE'9ZMBF5_^_>+->
M;POWU!3O!U?'7]ZA/QN_"Y5S,2UJ_<;%7%VF@C[=(=-+FI7^0T[R0U;.!,GA
MD;`<'D$Y)"V'D!PS$)9C!DC.6%C-&(DA%E9##.5(FT/0'1X*N\-#Y(Z1#D$#
M0U"Z='#E2$<@X0A,!!4%!/=1Y?!46LX4R9'F`\2#=.'`NB%Q:Z`W+(U.AN@T
MTI%C8.:83FD5*NM=^1I]^ND.:;N>?TQOIM&FDF851!5)JR$HAZ7)R9B<TL<'
MAL<'TVD$AGC<I^/AM8!/8U2Y)`U+@K`D:5@2A*611H*!2)`F`@2"])>"'XJD
MK2'H#4O#DB$LN5-87MHUUYRY3)T[.`R/=D8Z<PS,'-,I+V-JO+FK,Z>A/EWA
MUI:F$H92TB_9\+L`6]_T-.??````__\#`%!+`P04``8`"````"$`N=ZN0Y8#
M```Z"P``#P```'AL+W=O<FMB;V]K+GAM;)26;T_;,!#&WT_:=XCR?N1?"Q31
MH@'=AC0!4AF\M$SBMA:.'6R'MOOT.[MK>DUH!:^:2YJGS]W][NKSBV4I@C>F
M#5=R&"9'<1@PF:N"R]DP_//PX]MI&!A+94&%DFP8KI@)+T9?OYPOE'YY5NHE
M``%IAN'<VNHLBDP^9R4U1ZIB$IY,E2ZIA5#/(E-I1@LS9\R6(DKC^#@J*9?A
M6N%,?T1#3:<\9]<JKTLF[5I$,T$MV#=S7IEP=#[E@CVN,PIH5=W2$GPO11@(
M:NRXX)85P[`/H5JPG1NZKBYK+N#I((NS,!HU2=[KH&!36@O[`.EMU*%>:2]-
MC]TW72D>.5N8[4LN#)9/7!9JX;X*I5TU408&%O[1$R_L')['<=S<^\7X;&XW
M-T$^0OJ^@O`[_C.0/KU-10ATBHREY79%;N2Z^EQ!"UW5;R"S)`ST&8<+?5,D
MSCA6N5*R8-*P@L"548(7%(I%+JF@,F=(Q;EO9-+/R8"#QDUVC'1\Q3]@9V+!
M58GM])!*[X-N_JM@-SBI?ELF(7=Z1B7_ZUGS=9[494GUBJ@IP3F=(#>>#9Q3
M2G[SUYH#A2NO\8-+J"VGPI6\P#(P>$V)3]IN,O_U?;W",@,D<]J6Z8%,67+K
MALEX/^#"PNS##N`[%09X&S>#MDR?3*S*7^9*%#!W9`P)VA4RT=NA+FZ_?KQ^
M_9*NR2MA=1A?92R1(@-)A]P3H#U7)2,/=`D;:DM8+\/O=5`])1,V<]G[Y'\R
M-=.TFO-\/3Q8!S.6=%`=D`F?20[+B8+656TLF-&N23F(8QT,6=*!-8G)I'XV
M[+5VGL9OKB_X;3POR2<9Q:CW,*1)A]+#L$,KF@GN84R33W*ZXPB#FG1(W<L(
M=/P9=GMCJ(])33JH'FXX-M3'T,+R;NW*A-PK"^V!T14K<LU%;?D;`YSR6G/<
M\71'IT/NX5(#O=O,\`BD'90/;Y:=S/!,I!V6,X#?@:<T9X9<,TNYP!#V\2BD
M'80S<@N%,>2>KJ`SC-Q2K6&:W_`Z2?$40-"J[>&UA%.!/]_M7EK_$^-M^^YB
MVJ2$EW:*YP&"EJ']]+GRH!ZE>!P@Z.C<5>ZH0KX;4Y?^\KT*IW@6(-BC8LA=
M;?WA##;V)BMD)L.C`$%'QF_M[MKU+<,ZF."L0_#AD<++(L,$0]`R=%@(CT*&
M"8:@)71X&V-^,LPR!"`4>8#@?)53D</!SWVXDY.O7[0Y]H[^`0``__\#`%!+
M`P04``8`"````"$`[HTJI>@&``#-'@``&````'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;)Q9VV[C-A!]+]!_$/1N6Z3N09Q%==FV0`L412_/BBW'PMJ6(2F;
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M!E84S"REKRQMZ@-,`#ZM8Z5"`U:D^-;_?:NVW7YMN\'2#QU7`-UZ+MON<Z5,
MVM;FM>WJX[]($MH4&I':"(S01H1<RL@7?G#;R@IGU`O,BJYX>FSJ-PNB!I[9
MG@L5@^(!+`_*<!X7K1])!8W*R$_*2F\+5+3@GZ]/H?^X^@I+NM&4!"FA;8V4
M@%+2@:(64)G-AA_&,8(.R0>&\AXHNLB"Q>*R7'#[^PX;5*A!5$7@TN<E4XJD
MC'3*"$-*R:849B2?,@PC1*A+A5X7J,@0>Z8/(CJW!"F>06&.3&\RLIN,_!J#
MR(.)F'Z\+D^1US:LW1AB,9.'E*@/4=?S>002.(H=.CHSX4`8+NG#-3?A,`B]
MRV@B"7;9?$F*3"5%;%()4CR4%+-82PEJ3`DWF(E&+K.<FZCGC&M%Y`3WR%%D
M)H?MZ`0I*$>ZXT/[":<$#=BVR4S4\\?U1_<0U%@H(@<2U'SO*#*3PZ:4("7H
MO>,Y$8O'E,"^9'(S$PZ]@*U5;L*1;\0CD:2Z$"/%7]]#BDQ31,1S(%(@V"_;
MC*>(FXSL)B._QB#RXGOD*3+U6,A<DB`%/2:DP]2G!'9BYN_,A*64/`8)[!A[
MF4@24*KFNZQG4U$1BY1$<W!;"0ZG!)8NFW5&8-=EFG,">V)<,2I*U>K9<2BP
MLIO)/&+32C1'N\KE>,KPR>XBN/1Y-<@I[L4?"5/5>KXPK.U$&-L_B4`."I.A
MP_"4X"X<!BZ5!M,ZP;V8C\\)'CC&PE&/J3(]7Q@6=?B\Y(6(Y;-$7"O\F.%O
M4[+;E/PJA8I457N^2*SQQ'NLY"8".;C7(IX^4P+[QF[1OL/10U#S'B37PS7N
M>&-L4%FJ>,^7A:6>R.*=H3KP0.[$![N.L1NTXPCN.VRW9F2\'XM)%C''!ZX_
MIC`J3)7Q^<*PZ!-A/.$+Y&AA<<B"-B6XYPCF[XS@H>M,A)GV0S<>[5-AJIK/
M%X:UWQ3&0R419G^P$#(<EU2[#`D8J8MHJHP8D*[1-/4&<O8$.,]>,A'5IJKY
M?&U8^XDV-O5$#/V!.FPN1,2B-:6X-"JMWF9DO.>R\3D=[P<C3H6I@CY?&)9_
M(FQ<L7YBB4`.^H0E]I2`;$FR:V!.P/&91(QD;8=Z&3#CU*Q&T?:#YX:DM[RV
M453,-F!*4"8Y(^!""H;G!!]!*HRU'C.%35N0F"6U1"+G?6\1<#'9/1G!QZGC
MUB)@Y(\P50:Q-#_^I&(S5XWU`^-/<W1.<">^0A,:GK14='3`4F5.8>^#3"CO
MZCMZ-A,U&M:BL._`%+\0[C0$*<$73'>FGZ(MN$*PW9=3@G",LS;UV%W]AISV
M&SP))YKS00R:S<@81/VR9-=&YAH<ULPQ3MM4D*K;1@J<N;FPVI-4..98[36S
M(WC7:Y3PCM<(X3VO$8(4Q@L'*I)U'3-%3KL/'GF)1$[<OR%8P`MD%E@I)[CC
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M7+R4OQ?-2W5JK4.Y`Y/.,H3JU>!U)'[IZG-_@?5<=W"-V/^[AVOC$B[3G"60
M=W7=#5_4E=GE(OKI/P```/__`P!02P,$%``&``@````A`(B;*G*4`P``O0T`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S`N>&ULE%?1;J,X%'U?:?X!\5[`
MD`02):FFJKH[TJXT&NW./#O@)%8!(^PV[=_OM:\+P6DR\-*4]O@<G^M[#\[Z
M_JTJO5?62B[JC4^"R/=8G8N"UX>-_]^_3W>9[TE%ZX*6HF8;_YU)_W[[Y8_U
M2;3/\LB8\H"AEAO_J%2S"D.9'UE%92`:5L-_]J*MJ(+']A#*IF6T,(NJ,HRC
M:!%6E-<^,JS:,1QBO^<Y>Q3Y2\5JA20M*ZF"_<LC;^0'6Y6/H:MH^_S2W.6B
M:H!BQTNNW@VI[U7YZMNA%BW=E>#[C<QH_L%M'B[H*YZW0HJ]"H`NQ(U>>EZ&
MRQ"8MNN"@P-==J]E^XW_E:P>XM@/MVM3H)^<G>39[YX\BM.?+2_^YC6#:L,Y
MZ1/8"?&LH=\*_2=8'%ZL?C(G\+WU"K:G+Z7Z(4Y_,7XX*CCN.3C2QE;%^R.3
M.504:()XKIER4<(&X*=7<=T:4!'Z9CY/O%#'C9\L@GD:)03@WHY)]<0UI>_E
M+U*)ZA>"B*5"DMB2P*<EB>-@%L_3;`1+B#LR!A^IHMMU*TX>=`UHRH;J'B0K
M8-;.$JC/Y\[`DE[S52\R2P$MX3A>M\DB6X>O4,+<8AXN,:1#A"#>[0!4I^]`
M+QKN8)%T]&:3#Y>0N$,,-I`,-W#;N@9#B7SOS/JRXT5EQ,S.,/,.,5`&R+GU
MV\H:O/'!5:^<1ATO*B-F88YDF<ZCJ`<,A*'KQ@MKL"O<GR4*(P:%D^2Z\&**
ML`:[POT9HC!B9L;Q%;/I%$T-=C7=SD(,FKW+R-4JZ_@_FZW;QZO!KO#,.5[$
MH#")X^55Y>4490UVE?N&Q3(C!I4SLK@J3"`[QGLV:%=ZX9BV(*L]RZYK.UEV
MN]X$`VHPR6GJ:B-HQ"@3)\9^(X[A='N8#>7&7YK>)O,@ZB-V,,Q$Y\WH/C-H
MM^;N.%L02L?!LF^'H?*D`".?)9@[6Q;4F<[Z=AA*3XHP_;*^Z'%WNBS(2I,@
M[;-F*#TIQ,AG*=;7$\?+@CK7R37I25E&,*B&+=XWD95&T)@6GY1G9$R@6="Y
M>)+VK]-AV2>%&AF3:A8TD,^NO$7B2<EFT,X](7.GS(+.Y?O&&'B/)T6;0;LC
M[G:[!66WWIQPIYZ0+`;MRO:&L-TLZ'-9O(#C_;2A!_8/;0^\EE[)]G#IB8(4
MQKC%ZS<^*-&86^!.*+@VFU^/\#6)P24U"@"\%T)]/.@+?O?%:_L_````__\#
M`%!+`P04``8`"````"$`4A1EUG0#``!N"P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6R<5EMOFS`4?I^T_X!X+]<DI%&2J@ETJ[1)T[3+LP,FL0H8
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MA^`#[_VV^(X>OC"2?2,5AF!#FF0"-I0^2>AC)I?`V!U8/S0)^,&L#.=H7XB?
M]/`5D^U.0+;'($CJFF6O,>8I!!1HG&`LF5):@`/PWRJ)K`P("'IIG@>2B=W"
M#B?../)"'^#6!G/Q0"2E;:5[+FCY5X'\(Y4B"8XD\#R2!"-G%(RCZ4=8PB,+
M/%N6\.,LHR,+/%N6__`%M#=A@6?+<KTOKHIQD[(8";2<,WJPH`T@BKQ&LJG\
M&3"WN5*1[;+W5O(@:Y+D7K(L[,BV("\<"NYY&4[&<_<9JB0]8E9#3#31(>L6
M(FM"\L;MPHG7UTV2%B$+$B1UNB#O?5WG:Z]U7X*E^^VY*[4`W)V>0#]W/41$
MD0Z)AQ"#)!DB>B2:'"C`OAR9I@DTYF59T@B:IZ]B;,1OI3!0F9U2(V_K=Q'Q
MNXCD$D+3"8[T=5[6)\$+&X+8^1Y,3'T*T]<73LRR.X<QDWD.8_`DYS`G'DTG
MM-KU.B78U#G2BVVE,-&H:3X?OE%>_\]/;HS:6VL&D1/VX9X'!J%^0JP97'%"
MHAE</D&+S>0CL9%@,S9&!:\4YA@;3Y>UOK097]I,WMC4M,`G\?H\2["IQ:BQ
ME<*T6IRIL;\V]Z>ZW-C<-^P3<_]DK^F2HUKOVKC<IQ)LZCKU1?.E7RG,;5.^
M@6-T\;J_.W+,>R/N;P^,8=21QRMJS5@I4G.,NA1+S+9XC8N"6RG=RQDE!(^Z
MU6Y\N@_D76&LK_P9W&##]1C&K6;=[0Q@W*G1%G]';$LJ;A4XAZ,\)X*686I@
M4B^"ULT5O:$"!IWFYP[F6@QWH^<`.*=4M"_R!NPFY>4_````__\#`%!+`P04
M``8`"````"$`QVN?35<#```3"P``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6R45EUOFS`4?9^T_X!X+X1O$B6IFD"W29LT3?MX=L`$JX"1[33MO]\U
M#@F&+6E?2/`]/OC<<VW?Y?U+71G/F'%"FY7I6#/3P$U&<]+L5^:OGX]WL6EP
M@9H<5;3!*_,5<_-^_?'#\DC9$R\Q%@8P-'QEED*T"]OF68EKQ"W:X@8B!64U
M$O#*]C9O&49Y-ZFN;'<V"^T:D<94#`OV%@Y:%"3#"<T.-6Z$(F&X0@+6STO2
M\IZMSMY"5R/V=&CO,EJW0+$C%1&O':EIU-GBR[ZA#.TJT/WB^"CKN;N7"7U-
M,D8Y+80%=+9:Z%3SW)[;P+1>Y@04R+0;#!<K\\%9I'/37B^[_/PF^,@'_PU>
MTN,G1O*OI,&0;+!)&K"C]$E"O^1R"";;D]F/G0'?F9'C`ATJ\8,>/V.R+P6X
M'8`@J6N1OR:89Y!0H+'<0#)EM((%P-.HB:P,2`AZZ7Z/)!?ERO1"*XAFG@-P
M8X>Y>"22TC2R`Q>T_J-`SHE*D;@G$IAQ(G%<RXT#)PAOL]AJ19W`!`FT7C)Z
M-*!HX)N\1;($G04P]\K4.LY:_R<5-$J2!\G2<8$*#O8\K[W06]K/D-/LA-DH
M3&0:9TP4ZI!M#Y$9E+Q)/W"9X^A3TAXA[0-)9UV0K;$N#WS_MV.]##EI)&.F
M?V\SA;@Z8CM%1)$.2::0$4DZ10Q(-*&>+O2Z0`E>F4!^]L`-8GUQ&X6).Q?=
M^=BB8=2+1LM.AE$_'E5`.HR&\26SFA[_/7HD6-<S_NA&0>!YEASH@K<W$<E-
M1'H-H<F#/3:LR^MV2;`N;VJ7POAJTUURVNV?K1;T==W),!B,?$Z'P?`2U+2$
M[]$BP;J6>+0M-@IRS:J;B.0F(KV&T.3!4?5VJR18ES>U2F&45?ZX"H?!\=F9
M#(/1:,.FPZ#C74I`$R,[D<$Y?[WN)%@7XX6CZMDHS#6S;B*2FXCT&D+3-W^/
M/@G6]4W-4IC3,>B.KIVM%HU&7B;#J.?/]7T'C8K\NF+VXTM>E1[5A*@[NL9L
MC[>XJKB1T8-L,%S8Y^=1U?MLG`5<G'#_C<83Z(FZ<?L<@)ZD17O\#;$]:;A1
MX0(H9U8$FYVIKD:]"-IVU^"."NA&NK\E-)\8KN29!>""4M&_R(OWW,ZN_P(`
M`/__`P!02P,$%``&``@````A``DP"X9\`P``$PP``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&ULE);;CMHP$(;O*_4=HMR7'`D'`:N%9-M*K515/5R;
MQ("U21S99ME]^XYM`K'9)KLW0#*?__B?F9A9W#U7I?.$&2>T7KK!R'<=7.>T
M(/5^Z?[^]?!IZCI<H+I`):WQTGW!W+U;??RP.%'VR`\8"P<4:KYT#T(T<\_C
M^0%7B(]H@VN(["BKD(!+MO=XPS`JU**J]$+?3[P*D=K5"G/V%@VZVY$<IS0_
M5K@66H3A$@G8/S^0AK=J5?X6N0JQQV/S*:=5`Q);4A+QHD1=I\KG7_<U96A;
M@N_G($9YJZTN;N0KDC/*Z4Z,0,[3&[WU//-F'BBM%@4!!S+M#L.[I7L?S+/`
M=[W50B7H#\$GWOGM\`,]?6:D^$9J#-F&.LD*;"E]E.C70MZ"Q=[-Z@=5@1_,
M*?`.'4OQDYZ^8+(_""CW&!Q)8_/B)<4\AXR"S"@<2Z6<EK`!^'0J(EL#,H*>
MU?>)%.*P=*-D-)[X40"XL\5</!`IZ3KYD0M:_=50<);2(N%9!%:<18)P%$['
MP3@95O'TCI3!%`FT6C!Z<J!KX)F\0;('@SDHM\[T/BY>_V<5/$J1>ZFBM,`%
MA_H\K:+Q9.$]04[S,[/6S,1U+LPD,9%-B\@,2MVTO7%=$YA+LI:0Y0-+%U^0
M+=M7!'5_O6*M#;G(M)%$YO/6MTAH$IM;8F*E(KU%+)'LENB(&$8CTVB_00DO
M71"_U"`:3\W]KS43=YBQ26P&B5034]4)26*5.>M&9_&UHH8OV$"W@/V^)&S[
MFIF[7FNFS]<@D0X261]A^(.7[>W^)&SY2WS+GV82E?-I$%GV-]UP-`FMJJ=&
M>!K'5LMFW7@01[-KPQJNDO>XDK#MZMH-Z@18:R96KL+K0U5P8P2M?*3=8!#%
M9K8R(QI<A0TW<%B]O482MMU<=;4;S?3UX""1#A)9'V'XD_-)Y_#O?\<D;/NS
M<K[63)^_02+5A.[C(/1G=B?V*1CN9N]Q)V';G=V+FM&]&%G6-VWP>K1:QV8Z
M2&1]A&$-AIUW5$[1EKF;8_\,]=5N&$G/B#[Y8^L,DC.:S/+KS]`&]0RF1Y0*
MLSW>X++D3DZ/<KX*X1RXW-6SWSJ8P]P`?__6_53.A&JJNP1@)&O0'G]';$]J
M[I1X!Y+^:`)G&]-#G;X0M%%3P)8*&,;4SP,,WQ@F$G\$\(Y2T5[(N>,RSJ_^
M`0``__\#`%!+`P04``8`"````"$``%XV4/(#``":#@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6R<5]FNFS`4?*_4?T"\-V`(2Z(D5=G:2JU455V>
M"3@)NH`1=F[N_?L>XT!BD^WV)0MGSN`9#]A>?'RI2NT9M[0@]5)'$U/7<)V1
MO*BW2_WWK^2#KVN4I76>EJ3&2_T54_WCZOV[Q8&T3W2',=.`H:9+?<=8,S<,
MFNUPE=():7`-E0UIJY3!WW9KT*;%:=XU5:5AF:9K5&E1ZX)AWC["03:;(L,1
MR?85KID@:7&9,A@_W14-[=FJ[!&Z*FV?]LV'C%0-4*R+LF"O':FN5=G\Z[8F
M;;HN0?<+FJ99S]W]&=%71=822C9L`G2&&.A8\\R8&<"T6N0%*."V:RW>+/5/
M:)X@I!NK16?0GP(?Z-EOC>[(X7-;Y-^*&H/;,$]\!M:$/''HUYQ?@F9CU)UT
M,_"CU7*\2?<E^TD.7W"QW3&8;@<4<6'S_#7"-`-'@69B.9PI(R4,`#ZUJN#1
M`$?2E^[[4.1LM]1M=^)XIHT`KJTQ94G!*74MVU-&JK\"U"D:2*PC"70<29`U
ML7P'.>X;6-PC"WR?6!X<BB%D=2Y%*4M7BY8<-(@>#)PV*0\RF@-Q;X\0,QAV
MS2\PBI-\XBP=%UA!89*?5[9C+HQGF)CLB`D$QM.U`>.Y,B3L(7P:.&_47SCU
M(+DE[A%]2R(N=/X;H'$0"G.@"K4A39=ST.OB38HN5=888LE##,<(SY,AT1BB
MD,1CA$J2C"'VR2W)"_M_O.!-2QUN,LR?[9SXN_D*!,;O$H#\J2W+#$5Y>D;A
MR(CH-D%\ER"YA9`\@%&\/0^\2?5`F:E`8%SA@8V4O(2B#)^#C:H'MPGBNP3)
M+83D`;R/SCVX_2QPL*I=F>!`8(1V>^JHS[=4]F>*-=%YV45JON/SLN=Z4SDZ
MB2A?-E92#:^YQU5SL*I:N7,@,)?OW#T7X5U$=!<1WT4DMQ"2`_`2?MP!#E8=
M4"(;",RTR[QO*F^%L*]>CWR/X"O'J#_NJU?[DQ[!^RWW-#^2:KZE.UOJ;J>=
M@U75:MH%YOBD6_Y,#F0HERVE')V7+=-6'H98*MNNXG@BRI<S)ZF>O44U!ZNJ
ME8<X$)C+=Q9IOXN([B+BNXCD%D)R`,$R__C$=VC5`\7]X`@2@?>0LIR'0_EJ
M8J,!PB,[8HB'\E6&9(!P!L<_Y4<6S_=##Z<>=N+C`*BQ/X+$*F][OA)[J8Q\
MI3N2RIZCK)ZQ5!YU\Z,"'^#E]`GAXB@@-KD5;K<XQ&5)M8SL^3;?@G?4<%4<
M00(TAYTG;""5ZQ&:P_82KAM#`4X&3;K%W]-V6]14*_$&*,V)!VM/*\X6X@\C
M3;=M7!,&9X+NYP[.@!CVM.8$P!M"6/^'WV`X5:[^`0``__\#`%!+`P04``8`
M"````"$`FR!^TE\$```>$0``&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6R46-MNXS80?2_0?Q#TOI:HFR^PO5A=TBZP!8JBNWV69=H6(HF&J,3)WW<H
MZC:4(RLOB>US>,PS,QQJO/WZEF?:*RUYRHJ=3A:FKM$B8<>T.._TG_\^?5GI
M&J_BXAAGK*`[_9UR_>O^]]^V-U8^\PNEE08*!=_IEZJZ;@R#)Q>:QWS!KK0`
MY,3*/*[@;7DV^+6D\;%>E&>&99J>D<=IH4N%33E'@YU.:4)#EKSDM*BD2$FS
MN(+]\TMZY:U:GLR1R^/R^>7Z)6'Y%20.:996[[6HKN7)YONY8&5\R,#W&W'B
MI-6NWXSD\S0I&6>G:@%RAMSHV//:6!N@M-\>4W`@PJZ5]+33OY%-1#S=V&_K
M`/U*Z8T/7FO\PFY_E.GQ1UI0B#;D263@P-BSH'X_BH]@L3%:_51GX.]2.])3
M_))5_[#;GS0]7RI(MPN.A+'-\3VD/(&(@LS"<H52PC+8`/S5\E24!D0D?JO_
MW])C==GIMK=PEZ9-@*X=**^>4B&I:\D+KUC^GR211DJ*6(T(K&A$B+6P5BYQ
MO<<JAMQ1;3",JWB_+=E-@ZJ![^376-0@V8!RZTSNH_/ZD57P*$2^"95:"UQP
MR,_KWG;(UGB%F"8-QY><I:YUG*6'*4%+$1$4NF'[0;]&48U:AD@?6.I\0;14
M7S;D_7[&6AMBD6+#Q%OTQQ0+,X(Q8[G$E'!,442B,6,@@HS:V.BT04'>Z2#>
MY8`0):*^Y#@#CHNW'SQDA)*QJBO!6CMX?31$;=/N4.0+-C!,X+0O0<:^;$<)
MJ2\Y4[X>,L*'C&B*@?S!89OO3Y!5?WW<ZK/B2XY3QUPIN&"(N4I)AT/04E9&
M0Y"8Z_NY\C[C19!5+TJ%^)(CO5@*&"!PM>JV)%O&$'5=I<-$"/5Z%*4&>M3\
MU`BR:D<Y,+[D3)7>0T;XD!%-,9`_\5@RZ/G31TN0L;]QRY"<#](U!#VE:,,A
MN%8*,QJ"<%-VB49FUI\Q(\C8C.WT12#/D>1(,\16RBMHT;Z#]ON2!=@RQ"TX
M6A^UZ+WUR!>!VVI^EFJVZDPYRWY#FJK#QY3P,26:I&"7XOZ>78M$WO;#^\MV
ME)+R&Y),H*N@`4*7:NX02HC2>2(,N_W-B3V)RWN^)WG58T_*%_M$DIH39JE%
MB6#B*'"(8,?IFWA=L!&"K8^:(A&W]GQ7\H['KI1]^;7D3I^L1ZDS00D?JT23
M%)P[^*9/N!1L?.K&S9%(4M-03"6U`8+7?4G)9H)02UT<(9@L^P!C4^(2GY\Z
M>>7CU*E-4DP_X-RKGS:([2FM)FCPR;Q-2T23$MB?N-7G^Y//`-B?<B9\F":%
M/_D$ZRQ'26N?(^ZU\29SDPIB7!5?<#]`TIT<1^6TEM/R3`.:95Q+V(L8-2T(
M??>I'(-]LH$1"B8AY?-0C,?U@-L!,)U>XS/]*R[/:<&UC)Y`TEPL(2>EG&_E
MFXI=ZX'HP"J82^N7%_@=@L)P9BZ`?&*L:M^($:S[96/_/P```/__`P!02P,$
M%``&``@````A`!T^/FT)`P``^P@``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C0N>&ULE%9=;YLP%'V?M/]@^;T0(`D0):D:JFZ3-FF:]O'L@`E6`2/;:=I_
MOVL[)>!L4?(28M_CP[GGVKXL[U^;&KU0(1EO5SCP)AC1-N<%:W<K_.OGTUV"
MD52D+4C-6[K";U3B^_7'#\L#%\^RHE0A8&CE"E=*=0O?EWE%&R(]WM$6(B47
M#5$P%#M?=H*2PBQJ:C^<3.9^0UB++<-"7,/!RY+E])'G^X:VRI((6A,%^F7%
M.OG.UN37T#5$/.^[NYPW'5!L6<W4FR'%J,D77W8M%V1;0]ZOP93D[]QF<$;?
ML%QPR4OE`9UOA9[GG/JI#TSK9<$@`VT[$K1<X8=@D:787R^-/[\9/<C!?R0K
M?O@D6/&5M13,AC+I`FPY?];0+X6>@L7^V>HG4X#O`A6T)/M:_>"'SY3M*@75
MGD%".J]%\?9(90Z&`HT7SC13SFL0`+^H87IG@"'DU3P/K%#5"D=S;Q9/H@#@
M:$NE>F*:$J-\+Q5O_EA0<*2R).&1!)Y'DB#TPF06S.8WL$1'%GB>6*Z4XMNT
MC$N/1)'U4O`#@IT'PF5']#X.%D#\;UO`#XU]T&"S!#*64,J7=13%2_\%_,^/
MF(W%Q!CUF'",R,X14=!#?-#5BP._AN)T[2+8`9=%ZD6.R$E/;_+86$AL:J03
MRP83(P'@R%#`Y1=K\`H#59]Y%"7.FRTF,=XEX6P<S8;1()B?C!N)FMXB2H/'
MHH+$%64Q4R/J+IX[HD;1(#YY.1(%A^%ZIS1X+"IRK-A8B-443U-'TS":IO_Q
M:7Z+)`UV)$7.6S<6`W[T!7949Y<0([O@?%QOEP:[VMP:6HSU:Y:>SI/9\-DP
MF@R\'FG2'>_JJT"#'4W3T]:PQ\QB+OEU"3'2EMZB38,=;6<'T6+L00RCJ;._
MAM$H/%UQ5I-M-O8:;:C8T8S6M40YW^M&$L(YZF=MC]L$"[ASH+DX\QGT/C/O
M]P'H/1W9T6]$[%@K44U+H)QX,>QX8;N7'2C>F4MNRQ5T'?.W@H\,"K?9Q`-P
MR;EZ'^C^V'^VK/\"``#__P,`4$L#!!0`!@`(````(0##+Y>QC0(``#0'```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)Q5VV[B,!1\7VG_P?)[X]P@
M@`A5*Y;=2EMIM=K+LW$<8C6.(]M<^O=['`.%L*UH><B%S)F9,\=QIK<[6:,-
MUT:H)L=1$&+$&Z8*T:QR_/O7XF:$D;&T*6BM&I[C9V[P[>SSI^E6Z2=3<6X1
M,#0FQY6U[800PRHNJ0E4RQMX4BHMJ85;O2*FU9P679&L21R&0R*I:+!GF.AK
M.%19"L;GBJTE;ZPGT;RF%OR;2K3FP";9-722ZJ=U>\.4;(%B*6IAGSM2C"2;
M/*P:I>FRAKYW44K9@;N[N:"7@FEE5&D#H"/>Z&7/8S(FP#2;%@(Z<+$CS<L<
MWT63^Q$FLVF7SQ_!M^;D&IE*;;]J47P7#8>P84QN`$NEGASTH7!_03&YJ%YT
M`_BA4<%+NJ[M3[7]QL6JLC#M`33D^IH4SW-N&`0*-$$\<$Q,U6``CD@*MS(@
M$+KKSEM1V"K'R3`89&$2`1PMN;$+X2@Q8FMCE?SK0=&>RI/$>Q(X[TGB)$CC
M03:Z@H5X1UV#<VKI;*K5%L&B`4W34K<$HPDPN\X2R.?_G4%+KN;.%76E@#8P
MC<TL&<53LH$(V1YS?XF)C@@"XD<'H/I^!ZZHYR`\TG<F[R\A+Q;/#"0?,>"*
M<@P:)Q$D/0<>,^H"BM+PY?&9?/H1>5?4ET][\AX#QQ.+@R/FS`.LPM,9O#U]
M!^YK#X^\/GR/.=5^17GX'F4'[BMG/66/R5*?>C",QV>_+S>OK(+L/48<N&]D
MU#/B,5=$X#X2)Z_@V^$[<%^Y'X''["-(@VQXEL#X,@*_\?E]H:4K_DCU2C0&
MU;R$M1,&&8Q3^VW/WUC5=F_?4EG8KKK+"KY.'#:',`!PJ90]W+B-]?B]F_T#
M``#__P,`4$L#!!0`!@`(````(0!B,QWF>0,``'<+```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;)267V^;,!3%WR?M.R#>%PP$"%&2J0ETF[1)T[0_
MSPXXB57`R'::]MOO&@>*H2.=5*7!^?G8YQ[`=_7QJ2RL1\(%9=7:=F?(MDB5
ML9Q6Q[7]Z^?]AX5M"8FK'!>L(FO[F0C[X^;]N]6%\0=Q(D1:H%")M7V2LEXZ
MCLA.I,1BQFI2P2\'QDLLX9(?'5%S@O-F4EDX'D*A4V):V5IAR=^BP0X'FI&$
M9>>25%*+<%)@"?L7)UJ+5JW,WB)78OYPKC]DK*Q!8D\+*I\;4=LJL^678\4X
MWA?@^\F=XZS5;BY&\B7-.!/L(&<@Y^B-CCW'3NR`TF:54W"@RFYQ<EC;=^XR
MC6UGLVKJ\YN2B^A]M\2)73YQFG^E%8%B0TPJ@#UC#PK]DJLAF.R,9M\W`7SG
M5DX.^%S('^SRF=#C24+:`1A2OI;Y<T)$!@4%F9D7**6,%;`!^+1*JNX,*`A^
M:OY?:"Y/:]L/9T&$?!=P:T^$O*=*TK:RLY"L_*,A]RJE1;RK",RXBKC>S%L$
M;A#>5G'TCAJ#"99XL^+L8L%-`VN*&JM;T%V"<NM,[Z/S^B^KX%&)W"F5M1W9
M%K@0$,_CQE_$*^<1:II=F>V8B4(3V;6(JJ#23=J!%UW7G)*VA(H/+'6^H%I]
M7Z\GU6Y?P6K[[;I;/0#:G1_/7'<W)J+(1)(Q,A!)QT1/Q+#CFW943#[<QM.V
MU*2U#8MT+OP8F9O<:F9QS2SP$1H0NSXQ]\+YB$CZ1(00_`TTTCZQ0`L`7@C#
MY]ST.>U/P0-_:%#BK6;@LZM!8%9@=Y-(;A+I%&'X@T>L?UN^+4<U:>!SE*-F
MPB9'=Q&K$@]\WB22/N%[GCO22`TB]@W"\!F:/J=S5/#`'_+-W6\U,Y7C32*Y
M2:13A.$/7G7_GZ.:-/`YRE$SUQS]`,[Y88X&L0C'1-(GO"@*1QIIG_`]]4B_
MK&+X5`U,[WB8SE'!`W]H/LA1,U,YWB22FT0Z11C^8M/?VYY'-6G@<Y2C9O1[
M-42OO%;[0(!>>:OV`1>I1^TEH^9TA(Y'[4.O$:.X#VB3NJ'1YWU)^)'L2%$(
M*V-GU:SX\++H1KL^ZLY3Q^!@?.LNX7`>CR?0=S7C3C<!^IX:'\DWS(^T$E9!
M#K`4FD7PZN"Z<](7DM5-][%G$CJ>YNL)&EP"QSZ:`7Q@3+87ZG#O6N;-7P``
M`/__`P!02P,$%``&``@````A`-S-TS39`@``O`<``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULC%7;;IPP$'VOU'^P_!ZN>T7+1MEETT9*I:KJY=D+
M9K$"&-G>;/+W'>-`,+1)7@![SAS/F1D/F^NGJD2/5$C&ZQC[CH<1K5.>L?H4
MXU\_;Z]6&$E%ZHR4O*8Q?J827V\_?]I<N'B0!:4*`4,M8UPHU42N*]."5D0Z
MO*$U6'(N*J)@*4ZN;`0E6>M4E6[@>0NW(JS&AB$2'^'@><Y2FO#T7-%:&1)!
M2Z(@?EFP1G9L5?H1NHJ(AW-SE?*J`8HC*YEZ;DDQJM+H[E1S08XEZ'[R9R3M
MN-O%A+YBJ>"2Y\H!.M<$.M6\=M<N,&TW&0,%.NU(T#S&-WYTF&-WNVGS\YO1
MBQQ\(UGPRQ?!LGM64T@VE$D7X,CY@X;>97H+G-V)]VU;@.\"930GYU+]X)>O
ME)T*!=6>@R"M*\J>$RI32"C0.$$;1LI+"`">J&*Z,R`AY*E]7UBFBAB'"V>^
M]$(?X.A(I;IEFA*C]"P5K_X8D*^#ZDF"%Q+P>"'Q`R=8S?WYXGT6UT34"DR(
M(MN-X!<$30-GRH;H%O0C8.Z4F3AZK?^3"N%IDAO-TG*!"@GE>=R&:W_C/D).
MTQ?,SF"6&/68Y<*&[#N(EJUYDV[CU6?$>N@0NGP@J=<%V1KK"J'N_ZY8)T,[
MC61X=HB[*22P$?LI8KFT(<D4,B(Y3!$#$DMH:`M]6Z`&0_,-:A"L5W9P.X.9
M#3!S&[%_%Y&\BSB\A;#T02##0KZM3X-C#,GK>RQ<CU*[,YA5VZ5!.&Y!R[H8
M^29#ZVP^L_-RL*SKUZ);>N"2?5R/!H_UA/:I.X,Q>L+!J>T-VEO6Y2CB9&A=
MA:->AXFJ3S?,,^\U4T:/F99FF%14G.B>EJ5$*3_K21A`?OM=,Z1W?@0W'"[J
M:#^!X=WNN[T!AF=#3O0;$2=62U32'"@]9PD1"3-^S4+QIKVO1ZY@;+:?!?PE
M*<P.SP%PSKGJ%GI"]/_=[5\```#__P,`4$L#!!0`!@`(````(0"/5?W.EP4`
M``X7```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE%A;;ZLX$'Y?:?\#
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M??/Z6UMM_JB.`M2&.,D(/#;-DX3^V,A;L-B;K'X8(O!GZVS$MG@^]'\UK[^+
M:K?O(=P1[$AN;+EYOQ=="8J"FP6/I*>R.0`!^'3J2J8&*%*\#=^OU:;?K]P@
M7D2)'S"`.X^BZQ\JZ=)URN>N;^K_$,24*W3"E1/X5DX87_`T8E%\A9=`>8%O
M[64F%0^W-:AT7_3%W6W;O#J0>D"\.Q4RD=D2'$MY`A#Y<WE`%[GFNUPT+`5T
M!S%]N>/9K?<"82@59(V0Q'4TQ$;D4T3`1H@']$:.(-OU'.4BFV/@C^Z';:P1
MD@RADOO*C1L6`1#&)'!9'`D&$8V=!YP\&"&A`8EL1'X)85$#)_.I2?#*A5V.
M00D"^\%KA*1#4`.6$<ERTYQDOC9;I*`RYI.28$(J)*00$F.FA9R8<]/,$C\9
M5UNDXFM(23`A14*T1D@XD$I"DO^Y:<TRG0`6)2@/4Z=YQ2<7$6KQN&-,;(0@
MM6A"S;1F@=Z614W./Z,O7$YY"2:4=!"0$D(PA''&M""#.3?-C$6!#K'%*KN&
ME0035BD1"B$H5)82SKEI3<_E.H-N.5^I`4U(D=19*PRR2B?9;IG#,T(QTM<O
MQV]`VZQ"7=H80(5!5BPBI'/;;$AIQ8_)#CL[K08TH:5'A**%/1L3*TU3FEC*
M!]IA9L=G\IW)CCN?&?9G^!P[:4B>O!X\KESHF"-&/QNS_B+$%DXVWOGTL$V;
MC3ZDC9XA1@GC<YK\RJZRT->58_,BK7Y>"Y,O8*0TC416@44,/C_.)OEFFN%U
M;"QLFQYI^C/I3;M_2$*W9F:#9XQTX-PR!UI;FQWI_U\4Z;3QA^2Q:X88#"H/
M.,G)G-IUD=O$2/>7LL5?OQ5.QT"H=ZZBBAB,:I3HL*F"L.8`-[J,S>^J.<"F
M@R#4Z:QX(0:%"Q,C8HJ8:8^842T6,7[5,!C0I+_1B"J,*M,TI8I9=AXS72<V
M,3(/YD64XSNZU4?T`U`YA5$1-9Z/PEGF.-';L^F1N3"O3CGV?I->I#-:T4,,
MTF/91#[3'.MRL=E=-1LXS@:+%9U:"H-130+Z!R&W[&F8GIGR_*JI,*#M=(OT
MCI5<.!7@4P^MB687,;9R9#Q<[G#ROS",!7.J1GKGBN!'WS<(CKU?I=PEB$WO
MD_&0P.HO:$['0T3'`S?'`\G)_(S1ID9F@ZR([,L6S*<S(M(EIQ1$C*H(JMWG
M1IL:F0Y?J#6="A&="MQJ^V$43E[C""),C8EKDR.C868GF8Z(B(X(;HZ`F\!/
MR"YR&\"S3%>]15&>K\Q_EQO0I&II#U88;"<W+/13&O6<0((D,5YI;'ID5%P.
M;S`=$3')][7"J!D6T1Z=6W8@?TXWV:N-=^!YH87#1?JN&>L'8$DH#)YZ?/(G
MPK)_]B<"CQ_Q8*T6[4[DXG#HG+)YED>+',X(QKMX[+EF2SA^@N-&<C^'X]#A
MOC<:X#3R5.S$SZ+=5<?..8@MN/07LD^U>)Z)%WUS&LZ['IL>SB&'GWLX=Q9P
ML.4O`+QMFO[C0IZ8CB?9=_\#``#__P,`4$L#!!0`!@`(````(0##:3&2;@,`
M`*P+```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG)9=;YLP%(;O)^T_
M(.X;8@CD0TFJ0M>MTB9-TSZN'7`2JX"1[33MO]^QG1+L?#1I+TK`[WEY?(ZQ
MS_3VI2J]9\(%9?7,1[V^[Y$Z9P6M5S/_S^^'FY'O"8GK`I>L)C/_E0C_=O[Y
MTW3+^)-8$R(]<*C%S%]+V4R"0.1K4F'18PVI863)>(4EW/)5(!I.<*&#JC((
M^_TDJ#"M?>,PX9=XL.62YN2>Y9N*U-*8<%)B"?QB31OQYE;EE]A5F#]MFIN<
M50U8+&A)Y:LV];TJGSRN:L;QHH1YOZ`!SM^\]<V!?45SS@1;RA[8!0;T<,[C
M8!R`TWQ:4)B!2KO'R7+FWZ%)AB(_F$]U@OY2LA6=WYY8L^U73HOOM":0;:B3
MJL""L2<E?2S4(P@.#J(?=`5^<J\@2[PIY2^V_4;H:BVAW#',2$UL4KS>$Y%#
M1L&F%\;**6<E`,!_KZ)J:4!&\(N^;FDAUS,_2GKQL!\AD'L+(N0#59:^EV^$
M9-4_(T([*V,2[DS@NC-!82\<Q2A.KG")=BYPW;M<B!*8:>DLW6.)YU/.MAXL
M/0`7#58+&4W`6*4G@B0?3P_D1<7<J2`="FH!-7V>)^$T>(8RY#M):B1#WVLE
MCB([5$2H-0D`KV6$M%W/J((<QJBUU]-(C62H2Z7FE74>6`"0F.L!5!`DLY.!
M9.``&,F@(XEM179.82&"R?6(*FCFPZS;(B4.0&HD(UWD0=1W\+JC<7BB?/"=
M7(^F@ARTQ'YY:B0[-(<[ZPZ&@U$;:B4M^0B9"G+(AJV]65A&,M9)0U]NG+)G
M)X<M./AVKD^;"G+@]G,W<$:2:+BXK_]L_.R<PD)4A^35FX<*<A#'-D!J)`.-
MZ"ZYXV,6UO@C6"K(QAHZKTZ-Y#C6\3$+"\&^>GVZ=)0#MO_03$EWFI,+[O2X
M#>@<!N\<`F8#[^X>0V>/3Y'1F,6&!G#D#9'[I9[7V(!J@^XLN'<`S79N`;I'
M`#(:`Y@D492,W:_5EL2C",7[A6'CJ=WZ<CRSMUMXSKM3Z(S4JCR+9TF.XIGF
MR!S[%>$KDI&R%%[.-JKQ">$S:Y^:IBQ%$S@<H1ERGF?0K.GG03L`O5*#5^0'
MYBM:"Z\D2[#L]X:P_W+3;9D;R1I]&B^8A"Y)_UQ#5TS@V.WW0+QD3+[=J'ZN
M[;/G_P$``/__`P!02P,$%``&``@````A`'%)%-^26P``6"P!`!0```!X;"]S
M:&%R9613=')I;F=S+GAM;-R=VVX<5Y:F[P>8=P@(JK$$D#0/(BFY76[0E%2C
M:ME2F[(]C49?!#.#9):3F:R,3$FLJWJ(N1E@!O`3]$/X4>I)YOO7VGO'CD.2
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M8!UVA@U`%,RRKIGZB^Z<QV5]829JI']4?UY-WI;3:K;LT>IH9':O+A;5J.*A
MTVFU4<RJ97?`%[.WO#Y?3*3Z`W]_O:BNRLFXJ-YC<FMX*?MHFRQ&08=\J=V!
MW\R7*-;-S[Q>8,@76%H-JLU<28T'U_&T.JM06>8^XQ\2^=&\[F_[E<A?W+2B
MX;]%LD\GY>ED.EE"CA[M$TFORFO1L[MC_KY8L<(;2)4-WWT[KL`T&@V:GQ7&
M8\1@.:W,O,6WKXL')U55?#M?5L5>3RP3I185K%WUECDP$7[W?'-9+2Z+<77J
M]-?\^J$88R'E+O6+^X_VMHL'JUFY&D_0DX?&M_O[NSM%N<3N72VKRU/('SV?
M_1EI'UTD<=]`'J48\CG3G@UIRTS<+KSH$NOEG1>\WU_O[J/'OW*]&X7I>!3J
MP*KNXDQ'A]@V_/J-S'2*W$`)V=O)4N+AJHD=DT/`EP^0[;-??O[EY^YRS51?
MS*=C$-IGQ3.T<-EC#*,"X)83I+X`9P55K-W(W]_>DMLOKO"A6*-5]4_%_@:_
MT?\7M7N`<K6\P,C\I1JCW7C'8B+G.'9KTGB'-7SIBMR'R%1P2.O7NO-H8_?Q
M_L;ASO[08@\V#O;V-@Z>/+*E'FSL/][;V-E/^_J[;>-HC,H!1+&ILL>;DQGF
MX6J"C>WR$S.TNEQ-S9$%0XW'7E07V&\AO>F\[NE3_LZX.IN,)CU'X9)H9$S"
M(I/=%Y:>S!KI[O+F'=WQ:T`%X+M:3L!N#^_FGJOW(^R3`Y("+U]^B,<6NG(3
MC!%\/ID!#B8PXO6\-IX4_WYT*K0]6OY'EQE/<Q.ZD=QA9N3;MO>6]YN'[SS"
M#:K;:&SQ`'EZ.I].RT5=X))=$WJNY::Q>HK>W<H=7G9M^A4OSAL3TG_;`*F)
MWZ_8</;R'7;8?WK=EOI/WKB'09B:Q!+8>0:"S;7\)5J.9C2N>@V(W;MS(-O#
MWM\YON@9$U#=>#7J&9#PZV(Z&<D2@>#.JKYG/ZD6;WF@RT6W*0'1]&8\!@J*
M!.O^[F\+,-[TU!\6HMG58G[6MWZO4`H"918=T5UWA=]5-4$D4$=8=@QIIG-#
ML]WG3H@4&6>CP$<SYM2>+\>7DYE%[`)&W5=\^8+*-R_!>'ZVF%\6X5EBFNY8
M+V;@O`I"A'VL_?N$%$T_<_"'$D/Q0"[D83%>5<5R7HPN2O!&P>_/RDE``"(S
MKRL2=,6[";`^T+H?%N<:^I8QP2C$,I:PF,PPN9:RZ>W1@X"PP<%HXMMJ.>@'
M7[>Q#7S$[,/.R=L)<>*X2ZPX3%&^+2=3Q01&D+!Q(9_@*M>^*%L;":7GORA.
MRWHR<B&:3%>@[.Z[/U:3\PM^OUD"R4HH/UL9ZH;DP4*M%-!"S.[@((8IB1_H
MAV#TPINO;YO8R<IJ;P$3S^<+E@@^L?AP=%TH$57[M$4Y_M.J=KS:W=@:[]^Q
M<HI[GT_G[^YDW0R*G]G3N5Z@QCAKF*HXK[N,HV:%XB;Q\QQW#VN)CDUH]%O]
MV\*S!X'8#V4X)"7CXO0ZZE]KGA[!GU80$B`A=K@5N%0VYR_VB^ZJ3H2U-Q$.
M)A`+,*&#SQVOT<9,<V(TT4/Y9C]NT<`HK%K.C9'+M_/9IE%H<HO%&187\0>R
MR"CT..1[K"7BC5'TN-[H&#>X)HA?%Z1GKW6I+T7_0'9WA^B*XH2(JC:/THAB
M3T1>K_`H\-P</`*&1G>S)=UY\M#X2@"U1[ZTF6@GAI;2';:[_#-'P3=+."Y_
M5%7CNC#E$Q2RM%K'.9B%EL>X.;73'@SX;S%D,^`-$:JT]5>,7[VO%B.E\CH+
M1NK,A)JPO2L7RK/WJ/R:)-5H<F7QVK7'Y\AS`^"57.D2.7%FV*H,T;P[Q#/2
M8R/;+1&/VP)0`UM0O(CI%#JQ?]R0.]0R'HRK$065NGJ(FOF_[CZ`"<O03!O%
M*96)V4Q`"J(BSB3VNUNXX6U\\/KW3E975YXI@^A*6P%35@OGGK8N/\!F4DVG
MIVTVL64[>88G'2EUEY<,6V9[6-9=F/-CD)64_:A!&`G19/9'I@VW,U.B#,Z]
MFRPO<$2JZ0#>A$=P'&*RIT*[*]S9*EXMSLM9<"7&\Y/5Y:6*"E#]!.=,8GJD
MZE#(:8H?KTE_#R6-\J$VLCQY]%JO@9.$X^[&&+Z)CS//O3Y"SH?O;N2V,E7Q
M0&;@;W_]W\=X1&H2?_OK_WE8O"OE&4;S!2&R)4%6!$^+0D].2V`#2]2_;7'Z
MX;B<3N#W;%**ZD=7B\FTV'GRY$G0;F70/V2XIQ6S@.0TV%-R[X;-5([<HEI0
M691F*_U?"C6BB8"3!#V(!09B9(OF[=<5V9W5)9F*9HFM0?1\69Q/YZ<(_$55
M3I<7(\TL?,`<;).T[+BJX7>](7Q"6*8TOS038?A)M0T@2#U:3,R@V1_(SFVV
M?NGO\2A+VCUD<)+!*A=L%2^66L$5@E!Y2A[-CO7$])942?2&!]1JY]/Y^?5&
M@5Z>*WG#6L9O9<+'Q3O&]7S@TF)FK,V"DH76BB13A<IW&%;?HL;?_NHD-3$_
M4_U(JT-[<(':/-2&H*C`LAI=S&PAQ16H5/:`R:ARC8MO)B-<UO7LE_\LWJ2G
M-`LC9:_QDR,Q1J^FJ.)"FYE>*Q9:G#/._/WUZ&)*PI-,9ZT*6G$YY[D5Z>/`
M$!X"1K*><XQMB8:/JP(_`IQ')*EGL^?ZDDG%PE&)IY9%DSTN'ER5Y%*)'NN'
M6\4)@::"R,&%%QDE`_LAA23$A2*L`3,/(V?R&[#2T\C5#-^!1$JJ9!S>70@!
M8WM6(_THAL)TK![<Q8Y,3B=SLG%UKW"L',&"11M\+4ZN**UTE=P]EC*3*&Y0
M3DRK54!.5R0*K*R6--/+9ANVA*#V165.C^64+-$G]+"SUH0:5#*00U?4(6:K
MBY2_CGFOK>(9@UP7AS&@8H#\Y>(=5IB91E-`IY7X3$QYY)35*O2"M4IRUPKI
M-'W^]A:%&P"1`UQ89P_5/J9GBT0([:1>36WQHO;`OE!`8F":'C:*JB3QX"^(
M/=W1NTLP&[F0PK':U94D4<M]1[0:%NV:-3`IL\B*(+T2@6[D&=AW',TQ&IEO
MO<AR7(X)'QUL;#_>WMC?V=,B4GK=IU]:";&9I"DB1*)U2&O[HMP_-WU7,*6$
M.7HY#F#&@C-(*V<EHNQ\<6BLTV8:@5#<G%BG/[7V@%\&MJMXP8I/JR@^/=$_
M0NOCBY(#5ZQF[/)2EE0$PGD&N3&J\HM0E.9?35$Z``Q)3$Q'U\4%20`6@;8L
MJN5B;J$$A;409OL:R6G(1B%2.Z:OAT/"A`R9$DD/@P]T3>OM2WD"4]37["DZ
M_JY2OX%J)25H<T02R50TU'[OO#VW"&LJB]&S+"\65$/E*.K)>PRM]>7`-FRS
M"7A#HRL5LP6@<&5:W6)L1L[@E?BLW\$3K3?X9AGLD*@354<J(OC[>O[[F<J@
M#B6,)+2BR!48F0T_3BXC,(1O&?:TY5ZM%HJ(EN8)&,Y36L$*(US/Y9G4&6-/
M'R'.(_3SL027!I^0R"E.-O^'?J/UG.!B%I;4L#>>Q0C@6$5"3!7NZ@%HZ>39
ML2$ED8Q?Z<V:+B%+/2&E\CH)J$`(HQG.5+YC-ENQD5#_%2MOED_7XUMY#WXQ
M1ECW5G`#?::[S5\C/IE.N%%@W7G%RUBB?0U*BPM*?THC(XTCNPY$]/[=YH_Q
M!J%OP#^9;-XZF_GH1#6"II4<]&BZ`B0(3&1)-&I*,('`0$([GR&D;'^FOKAI
M@8<B!:<_M%[`E^,M<A[;$`"T&J<.0JR%DLRS>TH74B9%CZ+66"-+,B!:&UDR
MQEV16SR+-D,.+M#"XSX'GUB0:AS=C3Q>0[(/9!6N=C9?IBU,H,5D-D8=+5\,
M6>*JW&XK/SR2^D8.7:L)#-Z(8-_D70N/`&1.#T#UV6JIH#)JMV_%U[]&-#K2
MO6P/OH<-!T[*A,,!S"\+4@K_`W3LO\_?"?5LH*+%>([%$AER>0GFH6M_>(R'
M%\H$R"B>FH'[=`90UG]:D7N0>*7>JD9P&I5U\K7\Q1I:#KV-KYZOIJQ?**DT
MX\[;?UK-LN`Y:.[-R^A)`D1I"<*>FP&G&T/B<^>1T#9OIE06C@1[B0D%C,C6
M1I/^+QN"U*BAHM4SL#4!D()\#8!YUJ-_7`')=D.?:,\+O_;84?X)[AXG"J.(
M7W9Z5=\P9I>VMQ`B"H^6$YRBS9/MSTRC?()0H\S..T'?>G5:3\:3TOO)COZ\
MPJ^,FUB*L-$;3,T/A3_+%VT4(=9/81>/:F??5.\GHWEQLG6TA7X4QUL_;-G,
MZU,#!>DK6(-'45O>U_&%[^A`F>#*L_GCK[2`K4)X3:%R3(V8A@<$TQ!!/M/J
M&8[?<P1632=4\6+TW@@]+&'T0`HI^XRB6>B="SDDV-?C\/>$31#@&::=P+E?
MIQ!;L<P`FI1Z^1"E`0+Q.+:/]J%K%[[`Z8^'/\&DU&099E2HK'D-3;DL?ZH*
M);UM/\9&`JC59<BF6JQ;>OY2@N9:@_A$I`PUAK/\-E23\3/!87/RB;@7*LZI
MJ4\-1AJ;#A"7+_WP(60S_J]9G,(E`@-W>[%.3$G37'"S(Z,OIGX^)H=R-%H*
M4477!/[$DHTGRNRY'^`]!"%1C9`_D]'TZQXQHP;+=2^H--@#[P"'U>885979
MGYJHPA=P0F@1]<=4#T@]H;[NT1P'XU0TA&%Y[*EY*V>)@S.U?[DT`E/F[PS4
MV43:,S-I,,#H5<R`T6OD79W+\CVFX9>?]4`S"`SW%B-GL-RC._.L^.LFN=6J
MZ+O04)$^)D.IMA;RSB8FJRN\K<E(WI402(+LF2\FE[2D&+Z`7Z^-<9[NZ20A
M?-V!U(ZXZK0"UF0!!X287@=_ET@D!(*[PHXJ!Z,R<C*Z#6^`YX:2&<DB1Q8'
M1>\_L38[B>7]W5UKNPN>A4"GY9L&AO3*"Y9`M-+?4[BV!@JWO>$ZQ6D!'FPP
M,IA:/GWK02K-X:HSB[X+[6!^BE\28H@2>+UFTX>D#6@NM%WO'%JG872HW6W'
MH<SUJ!#T]]UNUQE_E[)&PJ78_>X#QY3XU`E!`(I4.+Q,%K`)99&+)OLD^3'F
MR140P!-8@LJ11`0D&/FH?6=^X$'-\/(>"=<;7S`TS;AA?9YBP&5-$`X5'5Q:
M<BUFG+<3&N%!`<EFB])J$^FY-167K-#,UHH3)4:Z%'C3&`G;%4T0EF^E+2*.
M:JT-GJ(!M5I[ABS,P)\'.S-4O`Z=&4*]DOYWH:N"5HYN5P64M4863^*T4EC0
M72]'+B'"2+/"-(^A/:5B=D;Y^"OP-DX)TZ@UT]PA7M4I9M\JGGK'!^D\RA&S
M<P*DF(D"VU,N<WZIAY9L.7XB&GFMP0<T[N#C_.]S6D&Q+%>!9TT]4^*B>JFE
M!.16P3ZWK([)3)JRIAXE9ST73%)AJ6KABL#1,J]`*FGGYQ"(O[%VGX]P2W^Y
M!*'A_13IE]3LL*;8/+<,$N-54TPBS3[,=HF\MOV!,2(<4CA?/'#[C`UE;<T:
M4@0PE/E<DR![V.;Y;60$[U"A4"=TM$1+:QPZI6'L'3&,)_O9&KU4QE_CD?.3
M"$?)]LTH/#WE:IGMKEZIQQ.Z^X&57F_GJXC"2)Z&K@-I7VKAZHZ6:IE(Q9U>
MP&)H,*\$O(Y3I&%DR[W#Z&GCYY^G7ENENM>T>[U!#!C\2BJ6C&(G\9Q62&G.
MRO7F.[P]^DSI0X)1C_PM"'<SV@2;&=Z0T`90@NA(!!%M:_ZE(VGR$`MHX71Q
M=7&-Z`+MLI,`R"PF:M,-5_-[,B<+WN7E<UD$C1GW4U)2FJLTB)+J54NF-&_J
MQ>PG&*R(3*?0;`Y6]`'+(`9:0TJC;-JEX?1\JT,+0]AD"&4@5,HPFL0X0&8Z
MVTB+B*:/9&Z%0`NS7PX-C-88-O^#$M"T_*IHEC@PGXI(&?$(*MM$M>1NM2!B
M4A/-AU+VUU`T<A;62DKDUV7#EYARFL6DV68$*T)_+'U)5EK'OL35,D4M`2TF
MB>`)_2>)NOMI[5V\ES`/R#+30#NO$BD7(;XH!A(L&(.XB`*M`&2AL]$F-G5&
MC0K3G%;+=\I5K0G$8$S,)[6E*4T":E5-\Z:U1B@7<O#F+R&?LIS:9E+A=99G
M@W0VI4^=O7/Q4-BSH+YO."G`IK"?3)L;"S-\#`5F&IM8/[%S@&G-8JQ2NY;)
M6+?A5Z*]&%(BHU0FT8GG;(R%9Z8J"W%[3N&YVG)_T,$<4:\QJ4=VQ-`,X<LF
M0N[:^>;YS`@"1Y)ZFR;+>ML_I.D$0F@OP'\PY(B`G#:`]/=PHL[6PB^M0R_;
MDN7#Z0<@J\3&,1YT<D<AR5(,N-`)]L%`Q6+^/J09LJ[DT-LHBI(S7"S]S!LI
M&V5TW7@`@;-]N@QG(_!0.';#43!5X^>GT\FY(WE;O?9O?=^@7[I>A2V:I3`Q
MK-!&KLTPA@J@8%!HR%!ITI9BV2<TV7H\EDLT5\)L$31#*.UC365M);LT"!;`
M9WO5C2];H[FIH4'42;UCJ"#.Q^0P01!"!-(%+$?JE-LL:YW2&M7O2V"?&S$0
M%U;]/1EJ&U)=9::;2<=E]"[5H6\=(4O21B"52)6(]I)YC,*A%+_60"F/E%]H
M-?;4'%C*315PBU87U7<IH-&1IZ)K0,2!8.:89`X[Y"R1(9":@_F5N$UOQJD2
M*@;9)C.@*KQ#]M6^WWMT->L__$YU29]6(M`PJ3TUDVE6(9,I(CVU&"+,9]RX
M+(F-JX+G3"S"1K+Q>MUM+S7.+S_O_/+SW_[Z/XL_KPA&QLX,:^T1T0`?3BRO
MP:CG'9*!88+,P*)(>,+IKJ4($^P.32`&UE"(`T9Q,)$M&\T8V5X#[^1;5F3?
M$'3-['L^>_>]%BL>:#75^U+E">IGL5:'^(VQ('`EO)U4@NW'+&4/-S?V,=],
MX(=9JX;'$CNAH5B64W2#_+"O+"JP0&"8>\5>BV)Z44DG^.BA6&N7D02>==-S
M9J9"\.7]3R9*-G^65'0K$X0T'7N36<AWXE!KC0M2G2-_.M,S@`N*QET#%@*I
MZ($&F^BP.[?!^9L7$\)QFJ#Q%EI!0$%>7&FJ]9(EMW#J;9*F2Z7E(I3=%.")
M^8]C!LR=X"OKO*-VE@"*09.&7%>A+=+4'%M.[PO>HG9US<[YV-_C($[IL)LA
MKD@"XZ8SJK;H9)MJCM2@A^GPALF,Z,%*B.YK^J]H=++,[`=3R18N&3!7);L>
M4B)K2+75/4*\T/TI<3,_)#FS2HYN6PF&@L?TG]?\5_T7R>WO[SV^]_E77Y+V
MA!@L^Y*[7W;TF\5S8)0_\69RB2'\MGI7?#?'T^NO9R5FY-K_;(]_;F,NOPHZ
MP_C912UQ78W_R]4T0Y6BV[`TFY]+17,(A<YF)9S@7L11QL!)-!D=U-HJ[4`6
M'WYI0#M)1\;Y``/K5@GJ3ZOQN?DFQ@ZI;"LF'5MCMYGM;(B6\/PZ)3.YHF8S
MO59^PN*%D-M*MG#4S!V6!(-87V8C3:*P<G+*!E1-LO#T\K!=N_VFT6IY,_>U
M7T]+3KN<$/M:@=.[4QN=-$,MC=:OJD:14K8@Y[&"#5H9?0SI%$9894J0FF+,
M9E2K"4FOX:_/P'NQC9AU"=4$:(&><^`+9HF_P#=Q-S=-WGUH2,<:-"P_H#J/
M!`!@3`%L15""45M,ZI\L:#/D)\RL5D#2<?SOV_D449%B]ZAVU)*3V-XF'ZJE
M-"\:9VY\=NVR&6M".MZ$-28<,3?J213FR@=%'4E>`?B&I7&KR`36UB>V&:31
M3VNT3B8I"1$SDD?\Z)."2CX&&N7[Q@P,M:0U#0IR3"-23.V>HCY7;$^M))Q=
M`66^B^U8WRBF(P)DTV!TAUR&9DBVRHYP0AK@EH._L.:,O,DO]A9QTLCV,V51
M>CCMFZ8HJVITY1J`IF9:P;0&D[%IC=BS.R640SF3_M%S;UCP1`*<7$/'QO9F
M%#5:A'[7!]_J*I.=[8>]S7Q'K(&2'C6N_C7E.GI4:*SO[PW3;S>&?5%3JL";
MP"^!]>K>5R]B/\7V#A?O2.H:W)8-?F+7D"W&=?'UO%R,K4OA^=')U^H00!OL
MRHK!Q[^_,B*HN^[HY'M[_-OYEIB_L[E-#X=;/?F_X`(G>++?Q@U*L!LY?6''
M>(L';^97)-)W=[<??E&\%EFR$QM#;_06_)LL5M>[]9D5;/#YBNN8U(1.Y8ET
M67`-4D-:'ASPI.XW[CLAI8=Q-W'E`?L%.M7(GN-`B[MY#M-NQYO<=C.^$F":
MC'?(%M%ZGTI9*)\G?MH60,[AL@(-T8:=G_1(`H;<))DY^9ZN[R`/ZB;LD?>W
MDP>_#PC?P\XD^,]2G^]3Y1J$6VA;]1O4H(:'"UT100];>3,S="^,3J_<>*$6
MZ=H1S^,/B96L+PH2%:-'AM]$RKZBS2+.2>W'F@Z<[ZW$M"?P5$=0[Q$Z)"5!
M#-H[SWLIC7B&DB0:M-#S/%2^.RE.$2RK6KHPF03?0+R0M3C#N$5N-O+=V%:V
M"X!PF<UV:-Y&A$B2N+UO@&]&NZ#WW3CX;STC:65U(9<O`<J&E+B$^&I(.8J0
MV(;IP@NT/GBUA/9Y)7<&UBZ\PM/+=W-@M/0<"57WJX`Z8;.E*`9>JZ6&/]H9
M%:VP'/L)32<2<`[:<+TD!CVL'3O!8Q)0E3;8A*-:^RT*`3S3J\I1?X!+\_Y+
M[DH3/:U2KZP>B$]WQ:ROGFMK`]V1L:W69,)QERE=KV,LCW?6.\`W[%>>S+I-
MHR=K9&%O4V:KIXZ_G55ZX7[IC?I^HG<Z?#3DG<CN?3\3$*0U3U$)KQ1?<W<&
MMW3`<I4BU/%7O")0`:N2O;'N@F,E66$E^7G*Y25=4YY\TMMZP"HSI0UV3/,K
M8^5O%,_>4VSX.P6NPTZ0A*E+_:Q&58+M-@X^HQ.)0[3G?L%DS1X((9[/%Z,J
M5/#HN8SF7+JD>$8J;0:"'Q%N:+K*:4K[%=E$HVD@C'(FQ)J:^,:'F][;*S>8
M<,@FQ;.D<*PQ30IKE`'3!3$:'M4KW2"K`UG+\!2OO%)IEC'(.]M5.XDGSS.^
MQJ2B7M4#8?GZ$0<OOEJZ/;VA;B/N@6(99[1;<8T$8,-=7O5>W1F_Q:R>,&#H
MM_&6D)`0:"")H<<544CH:M!NRG>1[5F#PI^(&VN:VB/UO/H+CX`_S15AP9U`
M!;0KR]Z['?&F-EE`>B:IKH5&/;':6)!,#TS04T;;VU>36L^#D;5W(:D24_"9
MX!Y%%$1CR/#K](K*'?I3>,S6EO4&9E)A(3?E?#4X.9)?)\E97_@'R&9,'3B<
M#.(MBWXJWQ5.^%FO=MZ\Z`N4,+&Y-?JG@+;I(9&$AV8L'3Q`<$4;*_MP:,BS
M+J0"/#]*VP:)I?!<<X2^/,.[]*WV`(A:G)_^_M[SYS3-\7\?D6-[2CQF)YK;
M%QAG@<W`Y'#S(W-[PR9RR]+,'%B^6E&%&[E069^?Y"?CPO^/E'_4<]:_">7!
MSL]*5=82IL*;()UTC5,_ZLE[XP[,9F'3":V:[D^S]V#3=2H;C!5U0A4"EVXJ
M4KPB([E5?*>#CG'(V+MEYG!@96N!(,]*J=,A("S/!T&VH7Q1X_"2!95.WQ6\
M+;_*4@L1L0:*-(V?`;MA/:"LC&#*UPL<<.4RIT>859UW'@&DD3;E*X0;3KE[
M/?J%,7<908=HLA.75]AMDI#QN)/Y)ZG1AQ'M`]"SMRG&^7N)H-VMXB7%!,Z6
MJ'<'JCY/Z.*8[)W=P^@:T5S2WKQP=+<79+QC4)#"?X<A!C[PD/>Y_A.HC!6U
MX$^&Y@XG^XC([GQ!KH8,BXAEKA18XW)T-V>[`WSGT?;&X_V\(WKO<./PD=_!
M*NGK-%_''5YP5NK=?/&31"(V-6B'NQL[A_:RT?G^P<:C[4-OMS8<VD]OVG/?
MY"?F]H::ON.\KG,>@-LE`NC>HM0].QF"B0NR_GM!LX6N/JWG]`TBNB!,J_C+
MGB!C2#5E`!%.YQ*$H3!0\K6`6`OA2%3HJ@=TQ3&6(KMTMP!_(8@P1:6KPJ*^
MO,D7B6?&V*&2]7NX\>OM*EL1,"RD2R4^C"*GKV7ROV07*NLB"`<*M0`5]6^E
M"%L&_I"*M)5B!(2EP=#IQD&H@SH0"Y$RXYX#8#U),>+HO+1O<EL2CL-P$2,,
MX\T,B:(&UL_G)B!<@@8/MHKOR7/8'G2]CO[""!K-$1P4]MGI)W:G'"^I255%
M#[I-M--I,0HA\3"6G\]R9!=I^VZ"SP!_H9.ZBUQ4C,U4=@LX<XK03"XJIBM%
M[.0)OX1B<72;=MT*]7(<UVUG>4X'QGC3.JCC@1Y(*O)GY[8E;2E$"VD+!3?V
MMM7O1*"X&:`O!P<-ZLW]W%5<7':?VB-"N4&3881!57S?[9,@;I>(@.B1L\.%
M]Q_O/C+-Q=LU]DR-8^'836).)*.QLLQ/@JPQX:TS'FXH'KN5T(G&?++Z]@LO
MS0V3X.E9_3<9W8S#LZ6@B+I2:.217EIP8XD:M7$8!_6/K`T-&KOTU"O5^OG,
M!;B"PVA<[6^BWS6!67J+X7-M1D\(EYC4=55=15(`_21U'KK],QDA>GFL7@*H
M4>,8^8K1<J[+TDF[Z##&5M&<XLV,&RW[9+W<M@4!,A%N[A'+;GX9L@6ZEYAV
M"_>9,AW)',PHJFOI!K:TCV`?VJIWHTDZPYJ*!;ZUJ/!")CJH1;2#P[:N!,2-
M&;!&=DXKX"3[12JP(M%</WRJ.YO0'=0IXA?*VNJC8Z57V?D)-&BE+&C*^IAZ
M@@.L.:.+!+*25VH2-,G)%5/%,$1?AY'$=K]=6YP-3B?M$UON-Z$'"_=;;/B?
MBHMXJKN[1D$PZS$P>T?/NVYWL(87LXSB:Z*P@VC4GT.7A,M<#,#&U"4NBZ_K
M*B$LLD%EBS(?]$Q$239IG;&,6L7LM%')M9IO0[[==+:6H4#6E;#)@6`@M7)=
ML6<=OB+]E9^%,(-*.E4][Q4]!-QTT^KL5D*%ZQ'"?:M.BP'P8`G9T"C7)'YA
M[4I'K,C)HM!K%3=SHB9\2QU>S0!*Z+8P60G"F(QHCDVL`&E3J=&L9^'V*(ZG
MZC/_:E+!7[<^0M*5Z-9?B8D<W3Q-M][5-UQ*_J(YW]D=-OL3W+&6:W'6J>\9
M,YF*]E&27K-:PH+=X;\CBQ13XKVZ]/WNTT#\"5>"C(OS.:>%NG]]B:)^@>?W
MLZH(<4QD]9Y\<'C0?;G7QO>`8X3=A[XUY/=Z^&L?/^!'U#;\DKR52/+?:"?\
M)WZBI6]V_LO//X1SYK);MSWZPI_M3O]JQNT#U\%!\#&IW`ZT0`1G!>@U-BD-
MO4=00\C%L(=60/4E78XHXZ:A;GK'\ELW+KN(&U3)^X>7+_>MYLW06/`%!YG\
M5BFMZIR5T"%M4)/HB<C)(,D#V7L==P6WAN:^,%)Q%-=>:U`N,W1"$%3@*3N$
M\.F0$<*6.#2611L\FRSPLRH(TSQMU.$/?'TK)+`.;Q[.8CQ;:1@.TJ*H<3P*
M3K_\_":2$7L4+3+-<TABR`=&S0FN&U\;"VF"R[9_=05AB_%C>$J/3B(&'4T6
MU%05O^.4E/AP)0_\:VVO+1V7)8;=#C3Z=4A@)DLLTK"U:7?$A.YQ`ZWW=_C&
MQ<$V)',WWJ3XG$`6YE`K5ZYQ8)HXL!$8Q]^[])2(,H23[-'7D^:R.RX<`6$(
M.QML$[P]M<4!'"=;7F1[H[.+GUI[>[RQQR=KXM8:=2*=`/,^;E=$V?ND`?J[
M:F3,*,C.)"A1!HPY)%;(7Q#4R&HA8&'1N*/U/)8PW=_9,SD7Q)*_=57.R0C$
M*L=T,8=D^X?,UB:X37?@:056R&QISN$--KGM)!,6=P;]<7F5->K,@_+L[&WM
M_0Z5>DIU`ULJ[85G-+\;B^E1LHN\UF0>=*"S+1VVZ;2(ED"$3`:KN+\?SHT#
M`5*&Q+/P:\0X!%/:POW=QX_-W@A`I+<YP=MLX`YI(=.9#UK^;K;^G6T[^]].
MM=RX@?T\2[3OO&V_WL,G+_H7T8H[LOB9G6Z3/Z0H5<1OCD?-;W:#\B<O7QZS
M?'IIP@VJND]%P+(IR0AL"K#*Z?"T.9UP$`BPYV8_.9P-,KIR?7Z-($<UPKW-
M(&`B1&\=E4H=NB"DRV1M;S^&<Z+N@:2_Z;GVZXD:\0V[TD?UZM3]ZA-ZI<Y<
M<K,A=\X\*S%2'A/I]Z#>U"\NS6/J?$C==J*KFK!YIBXS==`AZ0+%:H;0BM,S
M:-@IE]@R-&>K#*MC.'31JVTE*4K(<!2ZZ\-U4&FT`/X,+C0GO@>4W4]U:_),
M"SY&C1,1[^>:=^`8HJ5XEO-8OZ&.5;6366UK\^N5M5GD$P<V9AYVN+A)<.03
MK%*<7/#54\`P'(QYEXPK1*WYA2`[>V:9%/GU#68\-8=$X*EU4X$24<;LD%\A
MRDZ5_R;+H+@]W=/>NFPEOO[!2:.>J7D5>S2?F-L,?9K1;?[#$2^8/@!U,S]8
MB8,[85Y'PL!3P(+AR;7(]R"SJ&9W@AYKJNQ/,70/!_`Z.-=`0IH+8>1#5TK9
M*M\E`8K@,J0(P"`TQ@`,Z5ZK97T[SMF'"\@:G9$TFBEH0UY90>O<2'G0R#<7
M,\TL.].#O(;N_:JS0;8W^'XG;:H%*`*^MW%Z\MZ1(2R4B?K0WH6E0NRBS;3)
M8*,WJ,>_[-L9/*UTX/48++3M+9`*/T:&KN)(R^P<EH?CGZZ0D<P[V[_35;^*
MQUL7PFN>3A"0Z@L6^F`P(H)J.VC#1UWTW(D,=`X=$W(?;"64VT!H?>/((;N#
MZ`1L^?HMP?U/*I:D,$#&,/F7%A`#BNSR';T^>FZ8Z+.0&FT^?A=#Q2A=EE:R
M>\76(6H38$*<?9H=$9QF]%V7-X9?0]NV"&PTQ9M/1UR%)WN)MD>K\Q41:_@T
M[$=1=VUL\KPZ7:QTOZ<3=__CB7MXN,$'GT7;[MCF_3@OXLH/V,W:7Y)0>(C`
M5<P$`)\*.-R`__<-/1CP#F%IVT?;7^S]1HA;<KN[&]RKHH"=1_^0*&"';U9B
MDGT7._N>JFA!C5NW\>A1?G'81X8"N7=J6YH0"G#!O>-I6=E;\DHX6:"]4HQC
M?7:+_`A!??HN%^^3IG?X+_]K&\U32:U'+8^E0"&\]..;%^:SHYU,U\)@)0BL
M]_9VX\4I_,*J2MD-.#*'97/7#?)!PESVJ[9KWBEVX$Q9W_V=G:W])ZCO*\^H
M-Z'_*;?[<,\RAXS/K8#`P^,%*=&^Q\A1=YNB'@I06%$-D0&,PHW?SNC,O@^\
MP.BW]_%M@6:-!V[6APB1);EM9UV7;@4H(C$<B%_VY(3!CTU(D3M9TD3:&E=8
MCTED<BIM=5EM]F[:\C<LC_CCT6OC3\BI!D>/B[?`2(/P<)/WL*X4S1#=04WQ
MJ+GWHVW`,YSS06!A[2@F>OGL,>YMX$/DQA"9]_F6[,$G$K>=QT\^$J+$S:!H
M]":81$:B!JD-G0]MJ:.YF*[ZN$W$\9,*W;`&WBIH/R!&2AG)[]PF0H[:]*0)
M$VK?5\9!A-"\V'^AK;&96+3)-2P5CQ\_^B12L;UUL!M2CQZ$!RX1^?E!ML@M
MM74I%TI"TOI)UUI3#*_VZFGZ@^+'D"+9B&;XUG3+4([&\)F@H#Q:.U.:0FO-
M>G\G/M3)W^B/%B'%]<C6TSNO),^OR;DT\WQ@UN4?F'.Q1E@1XM.D6W:V,WSQ
MQ+O=X%,_P3*06&G#*6_1U<H^189E-U_7SJ$#L5^[L#<L:FU>):7.@OVP6*R5
M9GET&&@TE&8)@?+:X?O#[6SL'83<[M"`[:8>Y\BOR>%\TFQ-;&'9\WBXDX1O
M)6R:+#GM+W0.<[HC%?D<HUC65>&BZ3*VR?JWS>"H[<MN._+C\\)&\@QYDYZE
MI%J]>:]SH.!M-.$\"])(`U4SO^%-$")SF_>ZJ+A:DV`E)9(UX>$3/E)S&#T=
M1Y;2!9+1BG_0E9'L+V'/'$I]=#*[J8*F;Z/)$)Y`=/\V'FVTX?"L(2WM6G8N
MSP8J[><ME#%1K7;AH`D!%000.'AN/N8H[7,>_1M@7RF]`9:V;XZ`Z=K>TC[?
MTY(=<E+VM=%$L,0ZEQQ`?8K-Y=J\D65>Z/=PKL&P/3A!5[4\?XO7Y]2+::=4
MP=J.VWM75%8NV(MY*#]J=$7QUJ\:(TRYO[]U<&@Q`9W97/1XI<]/V0+,]:5K
MM20S"DN,BLUVD`H:<3B[/`X)>%.*Z->\M",1O<-KF7N.T"X;FR)UH(Y,<RMU
M>[Q.7,@4T!>X$*I2%@9Q:!)BEK#MZ']`&2WBPHZ#G<.-72`.%D&?35-]I\VA
MC'*Y9J3RS(G=PVO""[W8QFT-F6N$Q[%&B\*)4F:#(MW]VH;$&!;,WKNVKY?-
MIF-)\:*.E])Z1?W%+R/KOB>/;8V!X:AL:IVQKD!57?^X0K!"3FB_H4*CT$^1
M5>N4,)ZJW=)QFA/*M,L3BDAJ]CE6<\JA!5C_]L>;1BU=S,M>L0WAI%R:^P]\
MO*P*-Z&+#[W^GP=EK[]&Y)"IT8'-;#9A3UJ>[`R#)'+<U$_S6=Q$9-=?($@:
M)>T(J.AWTL4^,\I<5$Q8?Q!UMF']3&B6-1B:Q4@\E170>&N%7TET1=LZT8NV
MKRXS@Y!,;D\&'IQ^<CIT#OKU"6`-\]J+6E5C&B'PEDJ/SC_2X`C]LH:9!W9!
M3V/%]K9V=YO,QD,[@1W*&,GZX0'7F+Y:"LIW.&/'7Q"DAA$D41J7SDKXN:DY
M:>G\/PT'W*VG8]L6FU%^HO2EPR[!#0$ALI[K=2K>;:EZ,/I_F2%WIVU@QJ/H
MBGK,.-S:?9QS$)YX_Z5)AC[SAYGE1()=+BW%1)!(95FSKMM49$5^H?N)M%])
M]_$GIKNIKY?PVT*]GB0'6X>Y4&\4^]N_B_K1E-Q%GZ14K:'UE_O-\%&\[TA0
MLWZWSYCX%(_/62S[#U.7ZK=C&S5'N2G@P=T-41LI$O_D7;VA"F1Q?XH7'`72
M)T&[KSCEO2!KS7S'+J8O<WD>P>\#\I=U?>P9.B7_U[/[H5LY6%WY.-HSW,_=
MY.#<,[+,67Z15G!UCH'9,U[H5)=F21/-PP$S`G@(CV9@W[!!@C4MJRMRK"4$
MF*KU<&:,:>+G=.9B<LIM'!ACYCS'TX(2=&N5:4//\1A2SNXOC&K7)J5[#'EI
M79$_<%7<JS[L"L5M39N@?Z2"X<2VR*2,4M<%93(H:TBR*5;K=5EY:3OTVO%:
MDB4J9[02WU4/];Z<=FK$(+0%0@HV>C)T-)0&L#FL6AYB[CW?7Y`T)>`D:=>L
M^52W=.?02OL2G?HH*LKIW6;L=)ML'(0$4:3;$V]0[,*#W:W#1[;\^[M;^[EO
M:E.E$V5@@8?*WD2K=GN3TAF#49HVZMM:*P#B:403&4WXI5YN/,+])Z'-SL]4
M#61=6O$3RQTZ&PR4X1`B<:UA+P(;]`M%KW7GKITMC6F$.V7P/';)5MV2>04>
MK3ABK\NS)]N>0GIP?V]K.V?&W<B?WS=X"_G=+'16@PEKZO!M20[I!2Q[['9S
M\@38EVVYSZA=FL.MZ>KOPZD[9#1OX9-A"`1FZ>=7S;!;OL$J>_:OI><X!/M=
M8+D3$.36T">0(<F7;.N`>+D+#'ZBT0Z[_RE:"?W:/XNCN-,>ZD29(3W%65.N
M::(MEYL!N)\7H3&I7L=3F=#U9E/9I_M[L9>5U8>SBSLT;:C(/:!P`ZUJ6NWZ
M.8+TW$516\FKVW:&GXCF+Y/,MC(F$-&(M.H3F7^]FWOYU7OH!D%TO*!EX<@8
M2\$O')L,\K$\CD?VCL_<^##?+*IU$EA'8?[]Z!1@P!6I_]&=\B4G0/A(?:G,
M;V_\%['O;WO[H&>M/:JG?X#K4KDB1J)]N9IQ*;F!CX0Y+&N'T$)Z?3F#2R-)
M\2I>)^)U(2V0V?BY(R4"E]7H8N:W8,>OQ%H2`-MI5\S$022>#K4PX'R:3P?-
M;5S`7W6N!`.>B):HP/3X6I/4(^XUX?369;<(_:?L]J&QH3NMCLMRXHBMA19_
M+*_8DPXZ;&47GL$B?LU7I>+77T_]4PC,S'XT?2"090[)5,\#`5$NHBC.5*]2
MSK$5X?47*G'A"E/V#D>Y&H_+:I*$RW=!):5=H)%@39N?'#T4/"&^NNGH8>2E
M64<];T?O?,)P_RZCQ_RAE0+6DDM;#WM@315WER[GBR'2?=;Z6&6B8W/4N"$E
M^`XI#/R!@&!51I:=FM(`0;+.5Y<NRHT'WLQP&T'0%9W"!,9#R<[ARXEGMB(1
M[*PY$#+?/M\WT;W#^:_"![]$K>XU)AR'1_+I_?`O:V)&/`^>'35L^B')"MA5
M&G(`4-@^QXQDLU_L58Y77(ZCW$D"-#<&UK[=H1-IYJ3\]*-CFT2J'M9])0L`
MX<+7;CN-E2FWQPSA4TB,7[ZK.5Q,`Z2^G8L3#!^*1=N.JYJO#'#D]US/7Q2O
M]?$,OB$KR7W-=0F3V>PM]Z3D7Y0EUF&WJCI8PG#-"$%WP\Q$Z)@6TU@W!4*J
MF9'Q=ECX;;FME4HLB,D9A7:U!6DQ',,O$0ZB*%+[=-/0K8"\<D)76E6W*0SQ
M@M>#3N'*WIBU#+2PRU`9WX[06.?3%#5'23DG0%;8IE2W;#UESI#P',\Y86:H
M%%J*BY'8K=G-:D`A_\#MP@X,$[[;6086EHQ,9(H6B\3H6#"KU5+0&3J0T3Y;
MA2AA)\>YP7O"IP#\VX&ZE0"J2#JC&+968>O[""E[(XC@AI)F3HM6E9E'6_UP
M-*OF-.E\JBOP$2A7+U=NO"37KHEH`6Y9'41ME!!7RH6.:-WI3I&FZSD.X$-K
M"*7:^)+-4J\WQCV:<VZYCY_,#48\$-AT/HZFG$(C#R(*?X&^Y?16`],,<=N.
MTFZDOX[*9$^CTD,O?@\!E+Y'P:!EBWX8$O\R#JA1N6"M\F[&*4X,F](M/XJK
M[FB:ONQ\`/L9HCCW`O)1JCIW'SJZ$<+&/2O"UETR8;CDY24Z!1?)H-FF>6>*
MZX)0_%2AL7:/@VYD<9'.7@S>L&T":!2RZQ%B5!@36@QI7=T2VG?H[?7F&0(8
MC\GQUUK8W"J@,(3+'M01A\FW<2QA9#_K^/Q8EB9\Q:ISTO1'-!9+8`?;3#]Z
M%7-0Q1#:3S<T9.MH=4WL;#Q^U'3@I@K[&+,P4_LD10O[=G@W8-WST*[G.>!+
MN$$@.R#19:W<2\GPZ-LN"'-WFV##0%'DJ@Q_NI)%UVZF01.?G*T_5,MCD&Z\
MHZ8DY)A.H.V,CXL1KU+&".8<_H3P389>-;E\0K.GV<4=;Q(6W?0B!U<07T*-
MBZJ<+B^XP-)RTKKG!Q,#=W5J!UO-:E#YT?7LE__<T@_-TG"/_"G<:NLF=:;.
M4Y:57@H'U-_H>M!LFXQKG1=,@=RDEFY.8`7"N:?.?N20@3>3TP:BW7;*PC1U
MO<9&YA?FI.G:;`B:D&TLK-%4ZG0U_4FVTZX[TCS=G7"9,CT.-:E+/AZ!#>5?
MD?AU\8FIG?F2Z#*A&^;JO5ACQ[%,YRPT\(7)'*0E__*?*3>7?A<V>^2`W:K&
MO(+%Q;](9EM7\6\T8T4BP3F^=T.W]"8?@&09I]=\-(4K9I;%UROB]-DY?%4`
MKU.9+'9:`XG(Y>+Q@2@QVH@J86&#_@L7N55\0XS?#"+3P/>"F"+%7^$U$^Q3
MNSJ?I<>QL:R9).D$O\[QTR/5550=D^G^#N5M+(W?.KE.?6_47+N?X1O.>HPY
M8X'[13I>S$9;R,B'*'$TF,Z8Z`J[^JP#E)LP;M..:**(4[NZSL3Q'"06I!A?
M\,.:98'PXQ=*0%`C^^9*6X]?$$J]+5'^P'X9N56NBAG5G.##VME6P:CZ^)_<
M*E@T(NS2G55XP"XUL$3F8G)^@<CH[FX,7D8K8:,>41HJ]$6^)_#(^SI229K_
M$8+_R\_:?2;YO_Q\5]$O!N7<+*N;4OZ[:Q=DR[KDYRI8XD@1W(X@0%%NQ?9;
M8W-_@\+*(1`!^WT!:6C,D(;-C&./2WADZ8H'@Q*!@("CH?"`07_@\B90?EGL
M;?^N6,RO<5WV02IE_]0;QQ5]G^R`#Y/Z\>HP<&>#&,SD8@R9B5%NE0WEJ9?X
M<7;^A1\Y#6:IXX!Z[%:2UG+OD.TU6O:/\W_L8JFGD"-7*E2\HE*U=S!PN-AQ
M9:0'VINF%3(-;C/\N:')'6YZ2YEE(]VHEPDH2)(.H4&7K,ZMD)G&$`L`,;(F
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MR#1U']NG7KF6*7TZA5/E/L\@?907CJ&ZD@)VB7L#G)M[-)0NE_0&ZQ0N6`^G
M@/.A>QKKZ95RM>03B2:U0$:RC+K?T0[T:,_=)5A-PX2:O)):`K4VW=BB]=D?
MV2!I9V4E^=]<K47&F&T2.%6F3YVBII[6GXBN9JJ8M>5G98;>+M0A'6_'HK?$
MTD7Q!ICEG&_FA0L,M)O`@Z:'OG5I)]TZVADY#)[5N:9>VJ`MLD0G-[B$CLG.
M;5K2)*58[F:JH]FE;-;TT-S=]J:^E+89&%*TQJ-D\MY-2D0A1^[D[7YKX]?6
M1P]!W61U70<*SGJ:/212S[F$+#F"Y$+B/:FXZ<WTJ'$ENK5>RNM#?(LF#+BW
MN031T(HBR2^*(TKXYZLR7`+X=;DX78W+C>)H04F57+O]<W4:_TZ>IAR5B/37
MY<7_9>_<=NLZDC/\*AL#&98`2F,>)%(!8D#6:138DB%2]D60BRT>9,8427!S
M2Z*O\@ZYRIV?Q8^2)\GWUZ%7KUYK'RS/##)!KD3MM59W=75UG:N:``#:M;Z@
M];G^PLG^"V;Z-UP)].&4#[^Y..<.6/UR-?WE%/?N-WC1:8LX>3Z_P57<_?\%
M?GV<ZAN8LS<24]W_=2\2/Q/LY/H*OG@,*!N3)[KR#!G7_74^>7WL35PW)D\/
MYP`$KI^>3?:G9Q_\/\\4O.BF?LY_IUKH<U[F3L=+IN%/$EUPXVU,_C(%4OX!
MTZP8R/Z%U=J,W^DN[G-=#KLQ><DO5U.PMT&DQOZXX:_CJSDQ&A@KJ+D6Y+RI
M__X`DP"G@6D'0/;)OA+'I^\W)@?\R[UQ1_'&P<7;Z3M0?3"7T#`3$@2=TJJS
M0]";*QHOJ`Z%RO3C7^:H!G:8?SC5-3OYVH"'',"'4K*$NJT;BF0)B47=NK\1
M0JA6-O1DP/EL-CT99PKBOZG7B\]0#D.[=%G::O.FM&BFEQH$2Q%JRNFHU23L
M>;P\IM*HS1-DJRB4O<JG%K4/N['<J(-H!+$EE^;ZAAL$8>L8=;@W6*/ZLR&X
MS=7M4@TNHF7D@,M4@VBO:S<ZW=J*?@;!A2Q(%9%>[ZE:J6N?@\%<1>;L8@I"
M?[I,"A^9!LQ]!-.E"=;OP73"E]LDVPMB,-?[I3(B4+)G?VL[:9?*FF(EWM\+
M);TV:$G=)'W!G':50*_,W,]ON1<K%DYO;4=EIB3BK<V]T7Y=B;'P2,2.>+`B
MR&A^":30\\DQ\6^W"1D]V'!%(P7^/V:BQ_5B=`7Q!,:_&_0'%0$6-*J)CKNZ
MS0$C#ZIZ,YV=X5?T@B$_]XUNIC?*I])V_5VP+'%ZB.L33GHU4I/'*;@B9CZ:
MH).]H-W3V!K4%?BFK;LK;N(^Z,YL'G;XE]\.;IXW+)>MW5>JI#3AE\2YCV2$
MEO#-YI[9[-ONRI1J5WUN=!W?L.#21I#O.U]HI!ALTVUTCDQ'/N.'X-3CY>`.
M(>LV3%-\'5=1VC[Y'U.\Z#.$T^,2ZAF(@E=%@:0&#I\"\-5<!:9<AY=F?K%A
M3SMQ3EQ`,K-2;'2JS&H%$*&&#\1KX?(N3DS,N#>O9O.HZW9=@QTOO?W3Z65_
M;$<=#)`*(1I7GK)68^KOQ-49772R^&OT:K593B%W*-V?OF*@F/U*\(T,/,9O
M!Q8^.,62[M\'T5<%+^&<IYX&H!RA.<+)W=W@CK`=@RE8$3Z$<55;YY4C(D>H
M(FY7'VP3.Y/.9%V"J%N-4&2<T_3=A2('2Y[N;5NP'2%)IHWVAI2M&(#I+G57
M9>"AVGM#18:S#6[A%\\]48"WIR2'ER2T\I*MM;X`DX"6H8[`#EQ/L3^AW6XI
M=20V-J3,=<'H$KH@@*UU\S<O[DB#,W&RUK9AI:F2[P9$6^#?;H0>'(A4<;0G
M^^H\?=.%9UO^T08'EVUR_US9TLSO4>P$)LKO6]-F-.M""DRN7W^CSZJK?/YD
M*$&"8A-#+5I-?<^*_L]61`#Z])<>`6!^`PRVB#7?8=->OSFXOW?W001)A<*X
MU]CS;YC\%"]6T-D;E`>^,5:($O8835]Z]M.YRK10[GG.F1,`EA`H!^@)F3]\
MHH/B^WR0Z6[>NBSQ08X&&B/6/BR%4X8'TUB=^[;4B\ZO$F`0W3:D*%_`E(C5
MK*U/TKK/9&VK.U:7,<%'K/G(TH=T%^VF@-:A639#ZG!3?:IU\GZTYBD-#$F,
MD@+<V?]BX>HQ#JYV[VWF:5TV3;^-CF4++&7G_95LK;.2/C_6%R=SG!7(7UN;
MK2PWJUF:VHRG;^/WK\WH1?0A%-HT<BN96U_8['S:8N^ZN^/2MB@]7PLF?W!O
M<WL]S#Z2>]86ZO/Z^8FTG@+&LMV!S-4(%3?2>_+X3JP^F:7PR\F<P>%\&#4:
MUEGB@"\=K"`R%[-'G(CD`+Y90D_A,=%&6#Y[75XQ,XY1>PBL/V!E%O5E9L.M
M0]DM;!H6!QOZ=*E5:-I$![\F400.H9CII?FI0<`18EQTCIOC$FJO?*&=V+11
M+0<:E5I;AIM47;'.=#X&"TAG8-9_I\Q?`3\Y8:@8E=_QXK__XS_-J2BK\^+(
M6;CU?A`4EXJ<E(7-Z4]_<O?RXI"K=6"M7,%K.`@-!PJ5*G`XMSNB@Q,+K)Z3
M7IPUD%JA99DMFF8AP_QT^M88K^F27;?CV`0ODQWF[FG++.1=``D%C@PL5-F>
MYF$BI;Q78;UBU]K[0H"1-&WC:VVL&\U&J7<Q"B@B44,Z`9,-@[_]";T/M%5\
M,$+@$'8*NP^DC>]ODJ%`&S#_5J07V!.S(W6:7HDI(O1@II5ZT*8VF]$F"4,!
M/377?-8Z&-[Z-'&@C'CH+HD5GYR=`V%E@8+JWZ=7V?9(P[ZYMZ^@S`4H8:E/
M<`T1X)"G3%X7DR2WGSUY=*=2A%?.<7GZX>(:#?@0?XUY8/#\\E^-;T#&2AA=
MTNOX_`H=VS@O?"U1:;L8\FY\O'MD!Y0PDJ,BQ`K*ZHRK?@)\#[%IJ17/R6F@
M5?CH6W5&ZEH,6F5M1O2#LPRVQ1/78"0YE$$<P1/E`(0=ZRZBW#8[9X(EE5''
M!2C-M#Y]EB1@+QFUYR2PCND,HA=W+-]D+"XF2<T!_B/7(9EADUP,*-'Q9,D?
ME!V833JVO[#-V2*109MD+\!WO.2P+)1/9++8+=6^.&G<Z,5G1QFO9&#$%)H9
M)^T2H2MF!8JT8/<>BY^%BTT_^C#*]U,+TLI&=5=YB?.E2"Z<<ZF.NDBP%^0_
M-GOBQHY6T]5ANPB(OA1;0O0K+;^675BA)LINVFR/TF??OG@`BA+6T3Y!ZQE_
MSC`_FOUBM27.\OPP^MXLY!K0%,GIIA2/FK6C]I$LN"X#,CRJ<M1"'PQHQ3"%
MHHT3X9>0H8E4<3NV#H[EL\B7@*:XZ<`BTU"!WU6V00(H#0JGN'QQ'>#P4>MH
MYSAA(+\V5_@3SGE\(BJL+!\E,Z-,<*Z*:X2S($7#"%F,BOP'XMXD^9A,N,'Y
MK**%1]!^I&,-?$`I8F(/.Y=083N>[PUZ&\?LO%3P]PE/N_696R*H74^QS'HS
M'6J(ZKQVL(16Y;>^R;R6$8^#*YW%0W\:#J=T"*Q%S>#S;^4B,EA7NH4J>;;B
M!*P\WM8'L?*(%#%CA5SXVKP0R42?S46MD#'&W^E!,KJ3)4'@1XI/,%9L=16E
MBM;V[MW/>'O?;=7-*`#R%DQK4U`Z%+&!"&1"W?-K[T%LZS!1E'-"!^Z!&5VM
M<:CBQ)/W5L%"P04YH0*875K`CC/A4O.M'RQI/BK8D0`1H(5'V"&6KTY4R*$[
MJ!BCQ:)\?,Z1\_@8Q"J#*OUXP7AU%R:7QZ:_9^B:JJ*?X97B*^CSEDQTBK@^
MXLI9E?MT<B*'MS6M))N6V3_K;9F28@R*_NQ8$[$VG';]6$ZHLPE$=AD+G+&M
MM%I'T6&#E%$.JHH**'U)#(X1\FM;PEAV)X4Q76SXDHT]I#,&@_42$L0RC,ET
MP/;L>.WM&`G9QN*=7#0N.HFN\'!YID&Z\7-YJ!<4&]EMG%:>8GJEO>8!MIG;
M8T6AX&6,"W-;P7/-XCJG;@?C5RE&::AUJI2\1(UFDT`<$[(54,1V-!38#++-
M%[SD`G'Q#G<46E&2^FVAJQR6_-EKRJ(,B],$RY!FJ(]\*7=::#4YJ@1D:=S@
M_A>#':W3#P,XYKY%_^ZB]H!`::\(&>^=UK=&3,_^J&QG3(_$CMOG/0I8<[LK
M#3YUWFKOT>/0"DQ+T])2$S+=UXBXH%"[DI2((O"!G3@]D1LPG??T,<,641\S
MMF7'UHM'^Z<TG\2.-46ZBMN3P+=C/GU"*?@5SZ:74I`Z.V.,M)UY5ZN0VUV4
MIL/G_5_P?Y2S#0"")X]C4E(>9LY==<]`7K%+<XN]M?>1X5TQ3[0*H"H#,F$Q
MP+G1L+,'2Q)*>649J-`3>E2<B5Z;=+<4+"Z?ADAO!5)8QD;.:76<&AY8JYWZ
M='PG3";IL:5ZZH_$P;%N:'0MT'U=?NEXR5"TI<.ERCYUW#2=)XBC_NO_$)RW
MTK?=>W[\B?L]E49CYJ=P]/DL<PVV*$]7Q7=[=/#WY$BM4#Y82$1*1`U;1ERD
MJBV\()5)=N_)2:@,BJ]Y-\Q,1R/L_/X20H/$_^RR4BF)^'0[%N!(.SL^?T=>
M'^S`K2B9RIU%8BHE"AS;@S.=X\(=R@@%G&8MXZB)/,]/Z%'OI_].HHS7+NBU
M3'5$I%=:FT:O$QLA_&@XR?;HL]&C9JS1(VCH&RW'T9C2UDO07.KB[?3VPC5R
M%7?,^.@ZJ&T^O/?0A)LF'I-IC2)SB*L$;=E:BHWZR$>!-WT606;;Z\F5)&52
MVWWD;32TZ0*`V&.VEPBV';=TD\GF-F@JW*#T#.F,NYZ4)'0N!:+P[HJ1H8=H
M.((50LJP"U2B8BW=TNC1"2:_4S"T]G&12_#^+4:ZE*G"_RH'C-GJAH'1-VV&
ML@K3]1`?N'.BFI5%O,6DM^H<&C*H0!?ZP84[I?=&ZS1[>TRW1L0USX73!-EU
M4!]%F3RNS?L)B50CT\CY*,6\UK)8AJL('S`6"//U":,<>^.-5O(HXTFI[BA&
M<AF\/S\]P3T;%?Y^,JD:5ZI]4#%T"[!"B#[,DS`E%8,>U++NG+ITVX2_XDT2
M4+O0%$5"=1.=:BBIT&QU:,KB,`6@B)BT,A.:2XP7^N2W^K`7&9!R4KJ"ZSNI
M`WJ'=[8=GRT[I36E5PL+N+;V&Y%M5@B)B-<$9B>CETN7JY>%I15OOHCJP`,(
M8?&A[FT@W45H[Q)YW]5AD,[%=BK^)DZ';E3J.Z%,VS+/G+FB&?%_@>79'+4`
M8X+1R4]^CV9'\D1JEI=3S"\MX!*VRFHE'K`\Z*>A'\O(XO05#"X$<D`'"!N.
MY)WSHRFD$;PWMB5X@Q5\.DU50\5R0LB:&25!`9GA>2X`-/.[.:WWJN4AW@Z5
M!L_JY%LF/\+.?_>#TN6QTJ8?N'3>@H604P6)@<G_Y4Y"JQ2&NO4+&XF:P8F\
M?X\,`:QQ;]HU^W+R%*?]]4TKM$&'V+V]2CKK;,YQ`8277`#JK1&48/<,3K,?
MWL9V@%?D-\&0SR9=%7@%?Y^<I=PFI;M)_>B(=D/DV]*Y''-)"CX2][`$!*XH
M8<S<"3M8'&CZ),B@TDEO=L"0Y6YRMNH0A<P9`T10M9VL"0`_+SCL%]$'G?2R
M+-8N4[?E&0:)A=A&+EL2EI8L*SE&"'<:Q9/V@SL36?CVXGQNT0L%\(Q90LPE
MOD""TBE>2;/8.0:%L_`;.7[\8F@P'T%1V#O8K/WZ2N@.U>V=G4_CUUK]%-U`
M>W"HN&+=1L(TE""4DGHI<O!\(UNM6)Q$R_[Q)9H=->@4A7IFG&%@4':'-#:J
MW-O8W'YHKVQO[-+!>!RLMOAO1#WHUR_WP/S\+-$`DOM5=W9V#4KREK<?;OWU
MP#SH=`]+2ZRZO!:9,VPTQQ:5+<M@EY(K#Z=G5"::@L7_`I<?\3,'NGF7WRT5
M$"_)T:GRE=120@Y594$QI>NRPREU1BV_C@J`(WFN<?Q;MVBX5UL%IIQ6NPM9
M1#(RE#7O;BDM=*G>SOT1`BM`W-JJTGNWO*Z6LQ3SU1*_3T-]HNO!]?D4U4&U
MN5U=N;/)I9N*AW\.7"*A7(RVMTPA$L!1Q09M3$H("<XXK:+;>&_RVV"1"C)9
M;SF))5GWTM-AIWAID'L*R*+B7/./V)1Q);W?]`H;D2=/:-AOC(&D=2OV=]'^
M."*1#%;%0P8BY4>4RAELZW%7^$H[B<G(SY5-"E73WU`FR!&IM(J,%2KN"^3/
ME`0CLZ/#2U'B9D!TU"O.ER5M;_CE5,!?G]Q19EL@#!7M2,NLN40>6(GT[/4W
M/&.]>?ZQ#OT:AZM/.L&E=80>[B;7D_RLN"18?.+VDWC2[YZBG*E;<8NFA+&Q
M,2;II&4>I;1RC<HP1HI^U"8EA4TGF-;B=?V%<U2M^1[-5%ON(1UI0$KA0A$Y
M8-73.B="(.-"5Y2<"9Z1Y3ZYO8]*\U(WSV]^=<<5D5SS_U;6\R!4YKO?D#>B
MQJ?=?K5<:E_9!-&0J7Z/LCX,FW>NF&&]U>]]'S7(CSYBCE``6$JC)\\CHD^-
M5_1+G2UIF%H?\8CSNPELFY-=HC0)JM:GP^@/HVWV[F3L2]EO=$M1%-XKFDJ)
M7UNU:'7%D=^C``WKM:D&;93**)?"$<P+?>[236?T?W'I28C&]I0QI3JUNU6=
MFJPD&\:<+S2;+("&<S#U?8-CQD'][=<>\I/`BD4OF,BDED7!$M!8<J%F&8"2
M$[H>8TP[_F3"^E$-4(-L"W*Z#^PR;NQZT4EU,M?@%GP)?43P=?/>`_*)./L[
M]W9WOQC8<&F!.52QLZ-L1)Q#BY!S![^@"6CRCS`I9L,K>`Y4GO?;K]]95&=`
MV:>?)N-/GDIM;U]_3"*FV1NN]*%2$*Z;'[>O'5B2FR%W9!GMVZ,]0XRAH9^:
MDCH_%Y^-LJP>1CPSE-VFD<O.5]Y/KF*RO?VM',4B'8OTLAD86M7H1I6DK1R+
M7(^/[A+&,EN>,(T*!3WOS^/=0@0=['<\L6"PG0=0H^A5/H(D1(GF-<]-1DV.
M)]_03/#GN_N'V/:0KA.KO**'4L3(?CX^<\I=ZSA".I[X&0N"-C__A)J6IQ5Q
MIH10U1+$:3759"V()!\Z_'3+[GR7P\W`1B1*H"3GP8U33W-K:<<W(,S[]_8>
M^G:U1,B3R!!IG[P^G?U\]T3UD$I<D.O?V$'[VA-=48T)-+DYY=;`]ND/%V>0
MCG*DVB?/J.GNKI!*KAEE_.W+HJF.=K'/[##V^&UI8.L\.NDW2%:;U3\4BIMT
M0ZJ;LN75U[$#N2I$-R8GH18-TGTB*"K[LMM`RQ]4;=4E2(MDB'!Q4HHA5ZBB
M&AK\:<@MG9?W:&UL+%V8*7DA4"1C<J[2^7?TG:/1-G^A:%`J0L:ZI!QWT)+.
MP(^XTG$R3\E"B3,R"X:>!.'K]K2&#V4_BM<HSJJ[E7HH%856VC5K4`P09SDP
M"1=5174U;DC19`%:YZ*7(QE(CVLH,&WF2$[E[>$.]=7D<.8CDK<I+PR@+NCL
M)EK/+%BI0.COFSI.QT&21#$'`)8<[0O!;`O.8:4VV[9%U0-^7:L6)4GP+6R:
MYI+%O^DPDZDQ=H*8,6<?D)?E7A\HS7;.^G&Q7E]%=V**2A6:$=5I7V1^XBK%
M2G07HX#NK[&_#\/M;:C$KIK7.5X"7;U)OOGN5/:)748P;1D*[Z#.4W\'D^>9
M-E(TDW+(*J+2L%&FKRW$QS(G*"HS9FAA2$6,FQD'$ND1[FCNTP&A`"?U)V2)
MDF8^6&#"&/H"5YVKEIR$47,)O*-OF:L/5J$3+\-=L2YTE`&3?CF7Q?_;KQ<G
M#8>;?'I_]D\S5+CC?_Z3#8(#^$]?FUX]FS3O?OUC"NGVP2,7VNW/3R-SX;=?
MOU=N4_-X?.K'X:,F\0][N_GDZP/(L/WMT3N<WK0[;L?_^@7>;BCY]+#]X@<:
M9@S>?E7W0Z./D^H.?_LU;G_<;H=X%=KV`KF1C_/$#N03E3F+A@PU6(H"-L6G
M2UJ0##Z_O;<Y^+P/?R$JUA`.X/:+V!YS.&*IK/%%+JOP&^-;;M3`&Z#R-08Y
M@&.4]L.2\;Y)(9,AYDJX,:@8S$A^CO,=JP)3G$NI<\%X&G$;8F`N9^G9C41(
M7TO20#5_X907E^[D-E<F[>[<L67VQS67CWMTSZWA*!]1+-Y@H3C?![Q!6(AI
M69Y?'M5UYH#=*ZZ%Z@-7O,!UIJ-M\4F#8D3)'TSPDJI6:O35>GCZ";9@(7!S
M;5N)=:6"M_K[R.C&XG$_FACBYH1JR)FGGL6@5.JK$87EOA;B[VM``TAK5)@+
M284='Q?XC[Q4((?6GO?V93#XKHIS#`T'TT_#&U:Z9^M=IU+#RJBJ<&*YY$1>
MSX_PX7>LVC)FG3\;*\E[9+<ML\(N@%0:"M1'ODRTF67#)%^OJ4("J9S_0[0V
MI63`"/)=?8`&A)K)GB("WBO[#C!B"#N$.0:)FAP+ODA*,V$,?\$9@<JWV*&Y
MT=<]$2YY'84&L[5ND"0U`G8!60H->5JJV#"88,8T.<`%_-I-6$`B,$N(W@J[
MMO?HMO;;KR]PV8;?IN]@@RN<DZ$H6\?.N1T/<[U8!;4Z7EQ9PX5J!];Q%O@I
MMGH#7Z2V8&P[C'U`2:L6T?<1$W2U<DQ3FN`_XC[2`SK^244A1HP%4U&VU3Q.
MSB.15%Q\IYB?DC>\PIR3#$-0(I#O+5F8H,;4R+P!19$CX<J69N'PDOYB.JR>
MF0D>1Y4%GY!G#U[=9&FT)DC(:5#7BK"5VE>Z:O]4W0^`!21;76N#V?)!,IVR
M__K(*`?O!WQ2V:Y^-(JXZ!CEXFB61(,KX&8(J'B[0IE!M@!;?45PH,K'I1X8
MG`N0C=>BV"/E)#8TV&OD#Z"ZFP%["@*WI:-:PQJ+J@HV,$,#\;%!<"KU@M..
MEMF$SWPM]L=WUE".+IY2[[%[/NR$%WJI]B+)!@AF)QX[KT'*/(Z9GSOY)1U6
MR/7BHR639)3<U6$6MTSSQ<X4+<,V!.`AB4(R&>L9>TG:O%/9G1BBEE0R$Y.P
M-BG&)`XN:(,UV54GFI:GE15+,,5218QD,%E!APR^HPL[%^#$4DX2IM%/*VVH
M4*;C?7HE<\BS1)198)>9,.F1C`3SD+#*,Y/74(U*.4E`DJ0HD7SPH)Q^+ND1
M9NHGE4S6B>ENX.A.6!XI\\YZSDE)7V!E,N!@'EC,33'A_6WWU5D+$50)60_&
M'$:7#S.06)'/VGB2LPKF;%7(/7SZQ^\L3T+H?GZL?*/+G]BF%^<LP>5,^U%^
M0<N[X!N+KR\[Z(17A$Z5D19N4+B1WR6C%`;41O&P[*':):E:Q35JIF?^1"-9
M@,5]T=ST@*E&];N[2"H*@V63E^6!V^'L5;D?#XT-%O]_!T0&$27]5;"#C@O)
M6#EY5R,Z<#IX]B8++D47L\!VZ5DC0HE%1PVK3VHB1U7\$)E'M-Z5S6'NF7J+
MRZK'*T3.K:8H#NZ!];A_^FFA/SO33,S,:'=:7H7V-^]LV_[J[55,@+P"]5?M
M\V<A0=8*SMDPPTP7CI??:><5]1(BA9#`TJWMAU47M^W=D6[74+NN_RI?B>*"
MGQBCKHC&&'%:,NKRP`RY3]WW(D/&H(6,TOTYN3`'#:*66"C;JA^IJCE@J.GU
M[3:3C]]I?(XT(]F9'EF?62K4Y]%4QAL?:Y9U-"0=Z]^/RKT(A.KK6SM<+DA.
M19O&\7\!E2V9'G3LRAU?_;@-I\PJLMAH^,"MK6V_9].PM/7`,T]TH(T$K,OC
M"FVIHO2..*P=`XC7*+5:$&RI(M\:F)W[51K,3AR%!&8UI6PE*)O-/K<H>L@A
MX@H3$^LX$1_C<55C/"!%#59^H@G1]BL%!9PQO^$UTR;,F[U8<OPNCJ%L$21(
MPE)\^FS4-B%$SFYUEX*M=/'[6^W[W8%;AWL1X5\X]M;N8.P64;GLU3NVO62B
M[<%$RQ<]`IBEM:['998N>6^PY*$:LB"BN1"/[.FRQ7_%4YW)A=]O;AI06IWH
M0IHP(1/+^$+"&.^.RVS),PE?8G$`+)MY9QE<6P]6PN6%ENO`U=(-MP(AW/+F
MF\E3XLS7@_MB!R\LR:.`\\B/MF^1G1?2T(SIU:G/JS*?FZ27GMJ/E61#;G*=
M]NY7"YQ%I%GJ/K5I%^^+#!V&NAC-64/^IK'N]H\X8-'GBA97N1G6.=/;?0/4
M:Q@1U\ZCM1*SL-S)("/T$A4AFC+Z-9LB1S/$SZ_1R+M&0;3-/%-5>U4467("
M%6B&';R?[-_=GMQ^IAX3"N1M;V_?W=S=W-G<O&-4+FI)DX4%FHHQQ\&@YH&>
M:>.YA@+!@6'<9FL&6EYISC;SX*'-I-FWA'E-^2TNV_0HMHT*?=NR%F2\^>FK
M#HC/[GJW&@9!6LO0-5NL#NY=0]/NVKTMF[;J@X$?H*Z3LEY`JYLT625>B$B5
MX&*3B(_)ZZ:(6-F8W!>,-VQ7VY)H<M1\I!0U.5<X2)P.(LEFC%=-_98MYZ_4
MU&_9%'UB$7G]%9OZ+9U8)X+I_G9-_9;-/DR5+336WV.D:YZDXBH8T-64A:A1
MENR@_^\*9FT$";+_P:Y@!>WF0.@*1$K]<AY3>7T7]CGM_`.R6.51\N:0[OOH
M^),Y0!NWSW8IPN^R>\32Y'9:T)P-3XESA$7%B9-'BF0S"G:*<3633=V=#I#0
M2O[^!YM);L)6ZN(E0;#?A=IK^Z)R*WZO<C&Y.F[G7W<&6M`?'/A`NM]L,.SW
M67>$[*;8@UN+L.OAMH2+S(K!'RB?9,3-M#ES$OO#:R`-T^[TQO_K>DX+->H%
MUA-Q!,^KK>H#OJ$,5C&@_9^XPH6%+X!O26KNPF_6SIYLH2U9!)DJA;^V),5`
M//WP[#&$>G%#,E@OS->.66U^DV/1OKF6QW+AHM-U*8);S]D)J=:[_R1W'SFJ
MW8<:;4\FMY]P+?7IV9!V(K=S36)1E<.A&27+2<;5\HCGMSCZ<:HTZZ'Z_T>/
MW4N-*]J_,[G]9O_)Y-;@H,!:(MH@O9M>Y*3<2N$P;]C0RFH!?^W1,^.$X6/7
M3EV\Q0>L=J`T8$8+HOZD_9#HX[=V4:AEY?#)LU*RHI/E-=ZW5\/_X\75S^+2
M$<EOI^&@O@@0C`_EGB]"1[Y,`?<[-/.!/?9Z^E$W!Q!81,*TD[$$[ZK_G)::
M@Z>`\A*N-./FEQLS6-=8W0_??GN_ZR8^&-*BHZB;I*?9E=\$)BF^;<$B%8A:
MH$MTC:6OV5R+"%&0Z_/:TF[G88`'2X"UQXO&5Z6`=T[B,OJ+Z7D[]HX8+IF3
MUJ_;W5*0B7S_Q')M9U>32N$*"`*E3XE-NP&86H&S/@^N9%WO`.DE^TD!C?Y%
MWI\QVO?]VRK;=9<+'ML'(65K#TC[RG?=K8GMHP7%U(4G3E9CT_F9)&>)LRF+
M#XG83A8UT>W/D?(67H7:ZJ<J7^4H`\PO^\+J.MHI1JK4VE>6"N)5W&+?:PR7
ME!B.3.<B@-Z1G0PNHF@16_HR>_NIB;6'\[>^HJKE9H"CD3<?C+[(PC.YK$[$
M6PG*`@E6CT%JVUO\(^>6/HQ^X6'T%A7/)?&&B7:1(S=\@&-%.:3H;`BJ!5EZ
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M=H17N.@R%-8^J\W9$J(ZK,-E[1=%'+^VD+?4I/85[`\4VX5STKJ'IBY#B/X\
MFUU__3\"````__\#`%!+`P04``8`"````"$`HQ8:72\,``!L<@``#0```'AL
M+W-T>6QE<RYX;6SL77N/XL@1_S]2OH/E3:([*3.`,0/,#7-:V'&RTF9RNITH
MD7)1Y`$SXUL_B#&[,W?*=T]5^U4-V&Z_:'+)CE:`H:M^]:YNM^V;;U]<1_EL
M!5O;]V;JX+*O*I:W]%>V]S13__)@7$Q491N:WLIT?,^:J:_65OWV]M>_NMF&
MKX[U\=FR0@5(>-N9^AR&F^M>;[M\MEQS>^EO+`^^6?N!:X;P,7CJ;3>!9:ZV
M.,AU>EJ_?]5S3=M3(PK7[E*$B&L&GW:;BZ7O;LS0?K0=.WQEM%3%75Z_?_+\
MP'QT`.K+0#>7"6WVX8"\:R\#?^NOPTL@U_/7:WMI':*<]J8]H'1[X^U<PPVW
MRM+?>>%,U=)#2O3-^]5,O5*52.2%OP(0O_O7S@^_^4WT\N;W;][T__GU-W__
MWEK]XX>O#K_[X6NUE[`A-,$&Q30O^X5DX>N(<B^6X/9F[7M$D!&H";5U_<GS
MOW@&?@?.`.+ASVYOMC\IGTT'C@P0WM)W_$`)P<H@'SOBF:X5_6)A.O9C8.//
MUJ9K.Z_180T/,,>(?^?:8"8\V(LXG);/(Z))9)H@#$ZF(1ZA,KD@DHD'BV4R
M?SPB$\=K5,ZKB?XX7DR*8KE:XW7H%P<Z;,(KM17A$SP]SE3#@!PRZ/=1K=1@
M'3&;+OK`[V3,KD8GDVQH#(UQJY)QOGAH-V0X--I490E#X^WXW<G4V3ZS/.GB
M-'RJ","`:U>+-H1N07R/#?P[A9^<N*!U8K'#6L8B+TN-#[9K;95[ZXORO>^:
M'NJ5UC3V:ZXD4[_KACIU@/8Y)*Y52KE9Y[(C7ES*JK(13JZBM+@>1GL%\,R1
MMN!AMN.D3?-PA&TE'+F]@?X]M`+/@`]*_/[A=0--I0=3#73-7O2[DE\_!>;K
M0&.ME=B`K>_8*T3QM&"M;"SMXNK.6-PQO@29*(H<HH:Q&'=`]&X^7;2/=#&=
MMDU4,^"O9:)O1_C7,E$#_BU:TVE<3/2V0*;TE-#&J6?_<CR=3B>#J\ED,M6'
M`UUG2GZ,/=KV5M:+A;/1UM1TB&`$"*;#R?1*`R!]?<)8G13!$`",1Z/):##5
M=/C/RE?W"-K6*<R^)5N5()!D58)`DE79[*?70N:/(P46@B1;E2"09%6"0))5
MQRUGX+%TJQ($DJQ*$$BR*FNQ6XQ56&"5'*L$@22K$@22K-I:\QEGX*ETJQ($
MDJQ*$)S:JO&TZH[]PS1\V)FUUA_'O+")-]AJ415>;-8(\]1'/UC!F;#D],Y`
MASEB=.SVQK'6(8@0V$_/^!KZ&Q3(#T,X;W1[L[+-)]\S'7C;2T8DKP4CX<P:
MG$2;J>&SO?P$S+C5^D@W$8NN.*193\?9A#[6^V-]I%U%$[:66+O6RMZYA]*E
MO(_Z):@1=5LN.-&AES*)W2%;/.RA%6+S"8Y@IF:6%AP`/I&XA."(-F3,%M)%
M920CQ&0D`P1E)"-$9830.19<B297_@Y.ZNX;V#`F_7ZT:"G*IY@@`7[$8XZ#
M(&,.]5DZY(A&2\=4E17RRT%LS#7\8]WQ$4E+1AS*63+@B)0E(T1EY/TFL2Y'
M/%VZP/1\!,F>OKF?UX,!C**!"9Z])!CG)UQ=C<ZF"*<[7MP#/GNBM,5'6(PC
MVNU(]#J00%W'*G5<LJ$#6%J.\Q%K\M_6:1L`*VNW-R]KLAT#]LC@?@7<[8%O
M8?DZ?AN5_.@#\,H;I.4.4LS-QGF]W[F/5F"PC3.,!3N*R^39ISGK5;+/;QW[
MR7,MMC:H1F2^"_S06H9L8P\[VY2'9YB#9Q`3$L'3A+^>PQ_T)*R/)OQA[>FH
M$4$O4OF#<PGS;],?<`M3[-1@`NK417C:1``K#`D",((,!+CE*M8!N*<,!#!S
M2Q"`@V8(`$Z!5S2)@P')9N`#&4O@WQ5+R#&)E!S+#J7,2[_`OT!*@TN_C=1,
M\BTX>J9F^%``H!'+O!0K*\40LT.D92J`#P4J,*#JME/R!GDY7YI"2-(%#)E&
M(`T4::0]KR0Y%WAF`(HU,F^Q#R%.@:E(-@2`(P4",<1`4OT=4`R2*C#U!DDE
MF$+@:O`)8X):@JN0DC``'BE1D?4)`ZYBG%`-!(*L#$F\09.5(BD&63DR,X4F
M*T42"+(R)+6$K!1),<C*D<04LE(D@0`:D9(AJ25DI4B*05:.S$PQE)4B"019
M&9)88MAQBNS19=-H$96LGXYQPV_>TB,8*)G^[]OJ95VZD#K(FS0!K61X-'N*
M9HY@"S:7(E-IO,C-3-9.E6<_L'^"229>[+:$Q50K4/'BR-!>TB-?`G/S8+W`
M5#0Z]?2R;B1@"::,/RRNJTH5YJWKIP$6`4N7**)4<C:I+UV8W_,,?G&[U$-*
M0>#BCFP,J.L80^LNT%*(8.3*5A,42>D8B*FPH2]+AI6R6:FO$N8XJ?KE,*=.
M^N-N&]KKUVJ9LW5;-$<$J>DL##3<G^T455J#K4^69E6J'=R-P!M+P<L9<.6W
MO-QJ1$M=`"T-*9+^:4B58#E>A`Q(D"AT'/355<FV:?"ZA-/2O:)^I0)HZ?#V
MI[QGZX@=`"UU1)+;N:#@L.`RN[C6YO%:?^*1N6UT*;B\*"D!5SU,A"'3#%0C
M;#@5<PD2[IEQ5BHN`7>^*A[`>D*K!9":/)GLE7HN":M<0&515<LIZR#$M='.
M5%:KKT+U01T[LE]J+TCJYQ9BH>;<&DQX6V\A*_GF_]MYE3A";JC";XKJ7ZX7
MTMQ1*Q!:]X[&B&CG!VKAEK`;ZZB@J8^NIBWJ2<\OC5%=E;3VM;KDNJ$^Y!JH
M$N<6G)NU@Z6L)O)@:E7(&FU;OAUEM6TT:9$<SCM91^!H"JFA3`V[>J'BSL=$
MATF6K`:TDM(:M`/4U7YQ6*CGI.6P@;+^!UR)JJR@.I8O>5''ZB+_4Z!UL@*)
MP;TL5JD^"9>$VO6*GQEW`ZZA,O-MW5%)J*U,KA'I"%Q39>8M*."NRZ*.5]@5
M*<`Z\W?.W)Q[5O+.W`)+K7M&B^P-"@>G,<X'ST=C'<"JJC'LQM?)&6+:9A9C
MJ[XXF.MZ-#3BJM*:$,61<EY"8`[Z;S=$GC,5VX&?!/#SOURWJ>HC)X36@D<3
MM/2$`AP^V6I,>;_9.C):A>J?GAR`MQ45;=[!:I7P5KM?,*HXW-QX..)T5=1)
M;7GN<P>N-)WG<E*^.COJ@$MM#4%Q=N6E-FBNGAQZ0/7"WFD6$%+]H5^<F12T
M)*%$;:[OE3H";5,1B!#SXPK,S:#'0+`-S;"%F=P0@K\=1+KA6<%;:\.30/J_
M52Z4MTN<Y*7G^_&DT^/.=N#.<GB^$S>C+V$OFN_.HX/Q?J8B6NE$%!?$*"U(
MAE5I`86HX&AX@0+!!?U_55K`/J(U!&D)+;A71F5:<-%(3`LO'\EPZ;!%M"HN
M&!+3XG4_$M2]?LR.>*J.X$*117!16ID=L8IE,L+-L"O3RNP(AJ.T0.2JN#([
M`D)"2P<F56EE=@0K4%K@;E5II7;4>=V/!'5_==2.O*_B51$BN"BMS(Z\KPX%
M?972RNS(^RJ*7!579D>@2G4/7U2EE=F1SQ.Z8)Z@,F9VY'4_$M3]?D;E/5X3
M]/B(2F8[>$=TA(O2(CJ*J&16X[U\*.CE$97,7KQ_ZX+^'5')+`7TB$0Z?"$N
M46JC(:]=75"[<W.59%W>8;#.B,"`)R\L=PX\R\O')X&QJWZP+2("X08`(4K/
MUO*3LH";.*6$^'C`,BI"Z.YEXYB>&?K!JX)7^J3D>*./!,G]P?=3'?$4-/@H
M`NB/\-PT>"2;`GJ)-,3[,%[E485,&@N\>O"R_RID8'2$AO<_7(2M0@9&1V3X
MI(K]DPB9]]YFEUJ(SZ58ND5(?+"]3]:*]QQ>PQJ`%*%T;^W"P$S]CP\I35`Q
M]WCKKY0&GR+8G;SV>\9[N--7HD2\"HK$#O;0(L#_O`N)&G$4(8(36Q$B#W8(
M-VE,@I@C@;"$2/AP]5U*8B^C"-+XJQEX&"U<Z.[Y:(Y$V;6,T/VO7K+;P#&]
MA_AD07:#N'0^`(I:66MSYX0/Z9<S-7O_)W;[4W"F^%??V9_]D)&8J=G[#WA?
M68AB6/^"=/-A"_<JA5=E%]@S]>>[^7CZ[L[0+B;]^>1"'UJCB^EH_NYBI"_F
M[]X9T[[67_P;5(:/8;R&Y_@U>,PA>QPC7,TXT*^W#CP,,8B%C<%_S([-5/(A
M@L]N)@FPX1*#1(C>-GU,Y.U_````__\#`%!+`P04``8`"````"$`^V*E;90&
M``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTG
MMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?
M)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(
MQ#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HE
MFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!
M0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6
M"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)UZ8+Q=,WP%,$H9UKKUUM7=G+Z!L#4
M,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZG
MT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]<YVM]MT\`9D\<TE?/]*JUEW\084
M,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7*(B&/+HTBPF/U:I8B_!]+OH`T$"&
M%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^7!K2O)#T!4U4V_LPP9`1"WJOGG__
MZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[VY]<?HS^>?O/R\1?E
M>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0(
M'?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW
M9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9
M`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTR
MI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<<NDA(",Q*A!\2YICQ.IXI')61
M'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R;,UM`?H6G'X#0[TJ=?L>FT<N
M4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]
MEQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E
M\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E
M12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C<AT&]SAPZ27X02T)XU)D,
M#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB
M*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*
MHL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21
M#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQXBM4*W%J:[!MP.XN3BNSJ*]AEWGL3
M+V41O/`24#N9CBPN)B>+T5';:S76&A[R<=+V)G!4AL<H`:]+W4QB%L!]DZ^$
M#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'$B'5#I:A#0TSE88`BS4G*_]:`\QZ
M40J45*.S2;&^`<'PKTD!=G1=2R83XJNBLPLCVG;V-2VE?*:(&(3C(S1B,W&`
MP?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+0IR66YVB629;N"E(
MN0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"
M#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0
M$+(/9<E$WRG$:NG>94FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN
M9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>
M[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$
M]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3
MUDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#
MD^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:<J@:&''I@\@.2W',W2K;\```#_
M_P,`4$L#!!0`!@`(````(0#6*]VC.00``.42```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;)2876^C.!2&[T?:_X"X'PC0)$V49-0`WAUI1AJM]N.:
M@).@`HZPT[3_?HXQ'[%I;=J+)C$/+SZOC\VQ-]]>R\)ZP37-2;6U/6=F6[A*
M2997IZW][S_HZZ-M499465*0"F_M-TSM;[L_OFQNI'ZF9XR9!0H5W=IGQBYK
MUZ7I&9<)=<@%5W#E2.HR8?"S/KGT4N,D:VXJ"]>?S19NF>25+136]10-<CSF
M*8Y(>BUQQ81(C8N$0?_I.;_03JU,I\B52?U\O7Q-27D!B4->Y.RM$;6M,EU_
M/U6D3@X%Q/WJ/21II]W\&,F7>5H32H[,`3E7='0<\\I=N:"TVV0Y1,!MMVI\
MW-I/WAIY<]O=;1J#_LOQC=Y]M^B9W/ZL\^Q'7F%P&\:)C\"!D&>.?L]X$]SL
MCNY&S0C\JJT,'Y-KP?XFM[]P?CHS&.XY1,0#6V=O$:8I.`HRCM]T(R4%=`#^
M6V7.4P,<25Z;SUN>L?/6#A;.?#D+/,"M`Z8,Y5S2MM(K9:3\7T`>[U0OXK<B
M<$<KXOF._SCWYHM/J"Q:%?@<5"9VQ15A-2Y%"4MVFYK<+$@]Z#B])#R1O34(
M=_:(8'K#/O(+8N0B3UQE:R]M"ZR@,,@ONV#UL'%?8&#2EMF/F>5"1L(.X=YQ
MW:AK&'0]^9:X([I;D&AH_'<AQCY0&(/[0-\?_RX>#O-X.M6]:`#M/D!?[D@X
M)I9+&8G&B"(2CPE5!(V18/!$BCCX3,0<WMH@W@<8K.9R__>">;AC%"(T$I&1
MB(T$TA&2`]#5Z6/.89C==]$M'Q4#!*(SP$A$1B(V$DA'2`;`@C/=``ZK*:#,
MT+U@E@_-')\Y02`[%"K7?74**-<#Y7JL7/<?9]*?\C@D<+"CS]HA(R4C8&F;
M;@2'Y4P(5DI']X)Y_\G-VA4:B<A(Q$8"Z0C)`5B<ISO`85,J".;C5!#7-0Y%
M!H78J(!4A>&=(\7.B[F[EYQ^[>>P&KNZ$`A&$UMH)"(C$1L)I",D!U:?<8##
M<OZ/5D*!Z`PP$I&1B(T$TA&2`1Y4CM-SH*'5)%#7PA8:9H#R-@];0.-2I&JH
M"V9LUD!:1#:!%T>3)X(G2JG[-^)X'6PA38RA&8G,2&Q&D!:1C>!5U'0C1,TE
M%T>C;!#0D`W*F]$3US5&12WRD41LED"JA#]T4S:`UU#3#1`5EVS`2@YP[PE(
M$V!H1B(S$IL1I$5D(Z"_GS""T_+2^,Z4$)#6"",2>48D-B-(B\A&\%IJ>D:(
MRDO.B"'7F@IHS_?9X%:?S]ZP41$E4@MHG(I,&K%9@Y\OR/U0BT1Q>B#VQ26N
M3SC$14&ME%SYR4``Q6[?VI]://E\=ZBT[[TU;&+'[9&WAITJM+O]#7#(<$E.
M^&=2G_**6@4^PJ-FSA+Z6HMC"O&#D4NS2S\0!L<+S=<S'"=AV![/'("/A+#N
M!W]`?T"U^PT``/__`P!02P,$%``&``@````A`(8WJC:[`P``F`T``!@```!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6R4E]%NHS@4AN]7VG=`OI^`24+:**0J
M5-VMM".-9G=FKAUP$E3`K.TT[=O/,2;$-LD,N4D"_/SG\SD^MK-Z>*]*[XUR
M4;`Z1G@2((_6&<N+>A>C;_\]?[I#GI"DSDG):AJC#RK0P_K//U9'QE_%GE+I
M@4,M8K27LEGZOLCVM")BPAI:PY,MXQ61<,EWOF@X)7G[4E7Z81!$?D6*&FF'
M)1_CP;;;(J-/+#M4M);:A-.22.`7^Z(1)[<J&V-7$?YZ:#YEK&K`8E.4A?QH
M39%79<N77<TXV90P[G<\(]G)N[T8V%=%QIE@6SD!.U^##L=\[]_[X+1>Y06,
M0*7=XW0;HT>\3'&$_/6J3=#W@AZ%\=L3>W;\BQ?Y/T5-(=M0)TDV_]*29I+F
M4#GDJ8IL&'M5K[[`K0""B%:@@HC_3V$>0Q7%[\.8OT\AG]NR?>%>3K?D4,JO
M[/@W+79["9'FD`:5C67^\41%!F6`6)-PKEPS5H(%?'I5H>83I)&\:[HBE_L8
M3:/)?!%,,<B]#17RN5"6R,L.0K+JAQ;ASDJ;A)T)?!\[DV""9T%T@\>T\X#O
MS@.'8T%\/:@V7T]$DO6*LZ,'LQ6P14/4W,=+,+Z<%,B&TCXJ<8P64+88":C,
MVSI8^6^0^ZQ3)%H!G[T"VXKTI%#E`X8>!#(S'D2)%8BJEB)+]`TS;NC$'2JF
MO<("@2R,!U%BF!#&>&>]JR;3BIFAF-N*]%<*BPQ,QI,I<8Q@U'TE(CMNHA4F
MV<)6I$/%F=TB@T883Z;$-MF='3?1"I/LWE:D0\45LN@6,B6VR;`[P;7$1,/N
M#!]*KK!!(XW/FA([;,X43[1DWC;F#,]G;CGU<Y/]"IC:+T<O"DKL@)T[2_>`
MEIB!L=,FZ5!RA>W^%C8E=MC.MII-2RPVIU'2H>1L8K4!AAW-3)S::J9P[S>K
MJGK+H71*E[3.,;(PG:Y)+VBN<:I%>'2!L5ZRS:4$._V8=)I?\VD?4W.-3RW6
MX_GTTF[RA6[;8JTQ8X=NWU[07.-32_9X/KW`6WQNZ^+A)A`Z791>T%SC@W&:
M?"/GH7K+GH>ATZ8)UAHSCV>&MJ'23A*URU`4S6:+Z.QBM\M-VX8ZL[EX3NRD
MTYAXH=O-%S1G&YOOILT##KX#OD$;#_>&<-#&0XW+I\^]^AQ74;ZC*2U+X67L
MH,ZQ&#+?W^T/YMV)N7\`1]R&[.AGPG=%+;R2;N'58+*`+'-]2-87DC7M*7'#
M)!QNVY][^`=$X=053$"\94R>+M29KO]/M?X)``#__P,`4$L#!!0`!@`(````
M(0".V&ET@@(``!@&```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)24
M76_;(!2&[R?M/R#N:_R1Q*D5IVI2=:NT2M.TCVN"L8UBC`6D:?_]#I!Z:3)5
MZ4UL\,N3][P'6-P\RPX]<6V$ZDN<1#%&O&>J$GU3XE\_[Z_F&!E+^XIVJN<E
M?N$&WRP_?UKLE=Z:EG.+@-";$K?6#@4AAK5<4A.I@??PI59:4@M#W1`S:$XK
MOTAV)(WC&9%4]#@0"GT)0]6U8/Q.L9WDO0T0S3MJP;]IQ6!>:9)=@I-4;W?#
M%5-R`,1&=,*^>"A&DA4/3:\TW710]W,RH>R5[0=G>"F85D;5-@(<"4;/:[XF
MUP1(RT4EH`(7.]*\+O%M4JPGF"P7/I_?@N_-T3LRK=I_T:+Z)GH.84.;7`,V
M2FV=]*%R4["8G*V^]PWXKE'%:[KK[`^U_\I%TUKH]A0*<G45U<L=-PP"!4R4
M3AV)J0X,P"^2PNT,"(0^^^=>5+8M<3:+IGF<)2!'&V[LO7!(C-C.6"7_!%%R
M0`5(>H#`\P!)TBB=3Y/I[`.4[$"!YS_*A59(*,NG=$<M72ZTVB/8>6#<#-3M
MXZ0`L(LG@Y#_'P_DXM;<ND5^*:@-M/1IF673!7F"/K"#9A4T.4:C)GVK6)\K
MLF24$/`WFH3</F[2+3HQ&8]X7\<J2'+?*U?8^FCBC0%(YMC`^^DX,:1X5'F2
MST[^.6@F1YJ3_-;O*=YX`\CEWIRXQ%#FV)4L._46-'/?US3)3XT=?YY-XGRL
M++@*)S'L,<EUP]>\ZPQB:N=.60K4<39<`*ND@$;`R3N97\/%X.?)^`$.YD`;
M_DAU(WJ#.EX#,HYR.(DZ'.TPL&KPG=\H"T?2O[9P`W-H<1R!N%;*O@[<Y3'>
MZ<N_````__\#`%!+`P04``8`"````"$`\/P!-]4"``#,!P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6R4E5UOFS`4AN\G[3]8OB^?)2112)6DZE9I
MDZ9I']>.,6`58V0[3?OO=XP3%&#+VAL2P^O7SWEM#JN[%U&C9Z8TETV&0R_`
MB#54YKPI,_SSQ\/-'"-M2).36C8LPZ],X[OUQP^KHU1/NF+,('!H=(8K8]JE
M[VM:,4&T)UO6P)-"*D$,#%7IZU8QDG>31.U'03#S!>$-=@Y+]18/612<LGM)
M#X(UQIDH5A,#_+KBK3Z["?H6.T'4TZ&]H5*T8+'G-3>OG2E&@BX?RT8JLJ^A
M[I?PEM"S=S>8V`M.E=2R,![8^0YT6O/"7_C@M%[E'"JPL2/%B@QOPN4NQ?YZ
MU>7SB[.COOB/="6/GQ3/O_"&0=BP378#]E(^6>EC;F_!9'\R^Z';@&\*Y:P@
MA]I\E\?/C)>5@=U.H"!;US)_O6>:0J!@XT6)=:*R!@"X(L'MR8!`R$OW>^2Y
MJ3(<S[PD#>(0Y&C/M'G@UA(C>M!&BM].%)ZLG$ET,HF!_O0\\J)Y$B:S_[OX
MCJ@K\)X8LEXI>41P:&!-W1)[!,,E.)\K<QQ]K?\J%6JT)AOKDN$4(ZA"P_8\
MK^-HOO*?(5-ZTFRGFG"HV)T5=BL`KV>$RB\9_Y[Z&<6*+8K=!<NV=3?`NV>+
M1NM.%6G:2P8DD-`EB4TKAM-TG<A.RC`LT@/$T:+W=Y!.,^NBBY+;-`B"H6(W
M5(0#Q8#Q=LAXG<V*1VSQ:.6MT\"UYT]&;-<4`S8X[>_/STX:,4[R<QJ77QA%
MBVE^EXK%?'XI&"#.AHC7X[/B$5H\.M5;I[D6WS7%@`U>L/?'9R>-&"?Q.<TI
MOC@<I-,=4.BNUN6D2(8!.T;7/5US$4R5;,?J6B,J#[8S1G"T^[M]T]Y$]CT=
MW=]",^]:G]\_@&;:DI)]):KDC48U*\`R\%+85.7:L1L8V78M;2\-M-'N;P5?
M309](/!`7$AIS@/;9?KO\/H/````__\#`%!+`P04``8`"````"$`XMP]&LX3
M``#(;0``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLG5MSVSBRQ]^W
M:K^#R^]C6U?+JB1;L7B_D[7GG&?'5F+7V);+4B8SWWX;!%H`^L]HI.S9A_7D
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M^L?6^>^S[>/F1_S^]%`\O:ZIM2E.*@)?-IO?E6GZH!`Y7X)WU$>@>3][6'^]
M^_Z\ZS8_DO73M\<=A7M&9Z1.;/GP5[#>WE.+DLS%N*_&_>:9*D#_?_;RI"X-
M:I&[/S^>C^G`3P^[QX_GD_G%[/IJ,B+SLR_K[2YZ4I+G9_??M[O-R_]IHY&J
MU%YD8D3HKQ$9WUQ,Q[/K1:]RP'-J/.FO\9Q=+&:SZ7QQ38<_X$BE?;WIKW$<
MS8_SG!M/^FL\I\<Y7AM'^GOB65)GZRM+?T\[RQOC2']//,L174G],4<4NA.K
M.Z*+0?O:J^+(L(SX4E#_<6J5^6)0U^^I5>:HCFQ8CZTRQW5D`WOLM33BR*K_
M.*[*E[H#]OTYN-O=??KPOOEQ1H,DQ6G[=J>&W-%2R7%/UIU@W[=_UK6I.RJ5
MSTKFXSF="O7:+8U'?WP:SZX^7/Y!8\B]L;E%FY%OL6(+U<N5;"!!*$$D02Q!
M(D$J029!+D$A02E!)4$M02-!*T'G@$L*SSY&U!_^/V*D9%2,N'5O&3A!$P%A
M"W8))`@EB"2()4@D2"7(),@E*"0H):@DJ"5H)&@EZ!S@!81&&0C(G(:^X>F/
M^XCRHHG.ZR.B!]QJFS%UQ'U'FHF8[$WV00$2`HF`Q$`2("F0#$@.I`!2`JF`
MU$`:("V0SB5>C&A8AQBI(?[$@4W)T#J%IL)]0'!D,T:'HK8WV4<-2`@D`A(#
M28"D0#(@.9`"2`FD`E(#:8"T0#J7>%&C`'E1.]RCE'4?'&[46TTFU'&=<(U%
M#]H;L5L`)`02`8F!)$!2(!F0'$@!I`12`:F!-$!:()U+O%C0FN:$6"AK/Q::
M3/2B74WG*R`!D!!(!"0&D@!)@61`<B`%D!)(!:0&T@!I@70N\1J>EE$G-+RR
M]AM>$VIXMQ-,1"?8&^T[`9`02`0D!I(`28%D0'(@!9`22`6D!M(`:8%T+O%B
M06/Z";%0UGXL-'$[`9``2`@D`A(#28"D0#(@.9`"2`FD`E(#:8"T0#J7>`U/
M,^X)#:^L_8;79&J7NRM-1M/]`C@P7C0".K/%U.\HX=Z(.TH$)`:2`$F!9)HX
M%<J!%'LOMXIB25CNC;B*%9`:2`.D!=)IHJOHA4?=Z9\0G][<#Y!!;H0,<EHD
M8$<_1G,1(VO%+1`ABA$EB%)$F4%.O7)$A75T8R6J6EHKKFJ%J$;4(&H1=08-
M14S=7N*M_H5*>>T>G^Y_O]U0+R"C@377A&[IS8V^ODFE!3%7_U;E>JCS>8'4
MR&FPP%B-:=;;=[;13-S_A-:*Y2-$,:($48HH,\BI5XZHL(X'JEI:*ZYJA:A&
MU"!J$74&#052W9;^]X'4-[=>(#7R`JF1TV"!RM-1N&?JFJ`TS]5(K"Q":\`-
M$QGDR,2($NMHE,7"/;4&K)RA3(ZHL([#=2ZM`2M7*%,C:JSC<)U;:\#*G2?C
MCZKJ=M8-[4!?I`SYOC.:NU^W,VJD[G3WW8Q2XOYXN5)Y4HHAI2VY4H%!$UH)
M[1U'"S%ZA>RXZ(,_$2F^B(NM;HPH.>I0*3N:0XEI.>-B>Z@<47'4H4IVU(>:
MB9.NN-@>JD;4''6HEAWUH>;B4!T7]X?R+PUUSWS"I6%NL=U+0Z,1S>G[""_@
MRC!^_?,?DX0%%%)'[H=\?193L1Z)3/'8BL2($D2IKSL7(TN&'CFB`E'IZUXO
M_.Y0H4>-J$'4^KHCV1\ZS\4/)W50+YPZ\7[J;*Q4Q+)*(V\`6(@37JE2V?\U
MFMH+)C16LRL]TH_%9!VA2HPH,<@13H7PM;A^,E3)$14H7/K"D^F-##2<=XW"
M#0JWOO!T(4:CSE/Q`ZUN\]U^^VN!ULD";[;6R.O.XQE$VCC:KABHAU5J`J<U
MVGX<&!CIC=58!_]&C%214?'Z.!PK.>I8*5OI8TVNQ;R?X;%R1`6K'#RODJWT
ML:8+,<94*%PC:ECEX+%:MM+'FB_$=-EYPOY5HQ(2AZZ:?V_>?K98=Q<(.J_A
M739NJJ,?X%?J$21=$$Z2(D`4(HH0Q8@21"FB#%&.J$!4(JH0U8@:1"VBSD-^
MC%3NPHW1WRS6=*K#BX7)?M"*>M\3QS,Q:*W48UD5GK&S6`,4HE6$*$:4($H1
M98AR1`6B$E&%J$;4(&H1=1[RPZ-R%R>$QR0_[/QWJX96OU^L$`6(0D01HAA1
M@BA%E"'*$16(2D05HAI1@ZA%U'G(BP7-$J?$HC?WES4&^4]VYF)`75FK_7T-
MHA!1A"A&E"!*$66(<D0%HA)1A:A&U"!J$74>\L.CTC7'=Y6Q,A?AT<@9HU;&
MRD$!HA!1A"A&E"!*$66(<D0%HA)1A:A&U"!J$74>\F.ATBLGQ$)G8]Q99:S1
M?+*?+U:,G-RW0;18<.<>L:X-K15WJ`A1C"A!E"+*#)K;>N6("NOH5E7<-)36
MBJM:(:H1-8A:1)U!NJI^Q$Y+VHPQ:6.0%S%MY;1,P(Y^Q,2Z/+16W`P1HAA1
M@BA%E!GDU"M'5%A'-V*BJJ6UXJI6B&I$#:(646?04,14^L+M8[]T3S8V>1%G
MQ6"0%TAMY318P(YTN[1?]F$JW%IQZT2(8D0)HA119I!3KQQ181T/5+6T5ES5
M"E&-J$'4(NH,&@JDNI__[P.ILP+>&*J1FPI7(R7->I32X9,,#/IY*MP:L$^$
M,C&BQ#H.IY53:\#*&<KDB`KK^)-4N#5@Y0IE:D2-=1RN<VL-6+GS9/Q15243
MW-`>OKM2SY7DFD2C&77`?3<;ST42:V4<]6YYG?`T:$X!=QQ%4B*T5GPV$6K%
MB!+KZ,J+/$1JK5@^0ZT<46$=77E1^]):L7R%6C6BQCJZ\J+VK;5B^<[3\D,M
MDQU_$VI,:HPUFKDCZG@N%C,KMK)[`@)$(2.=VQ[1&P57[O]&X6^B+2/VL+HQ
MH@11RD@?ZOIBXA[HZHH.)=HU8P][J!Q1@:AD=/195>QA#U4C:A"UC(X^JXX]
M^D/YEX9*=)PP"NB\B#>2:R1&`;%X7*D=MS1\>*,`H)"M;OJ<J+CYC+A4O_"B
M-KS%B!)$*:-!V8Q+K6R.J$!4,AJ4K;C4RM:(&D0MHT'9CDM[63^4I^5C*(8P
MH&LD>KE85:Z,X\Q>MP&BT"#:M:TFJZL+^:0S0I\848(H!661DL_0)T=4("I!
M69QZA3XUH@91"\JBSIWGXX5U<EIJIS?W<P<&B1XJ'TRRE;U>`X/F!Y/P(5N9
M!QD78@$0H7",*&&5@\=*V<H\7+BX%A'*4#E'5+#,P8.5;/63$ZM0N$;4L,K!
M8[5L];,3ZSQE_P(AY1.&<+5M52SD#'(R22M$`:(0480H1I0@2A%EB')$!:(2
M486H1M0@:A%U'O)C<5IR265;92PT\F(!*#".CE6(*$(4(TH0I8@R1#FB`E&)
MJ$)4(VH0M8@Z#_FQD&DCE8283/H=`">^I#+!E))!ZO#./8P8UE?6BI?I`:(0
M480H1I0@2A%EB')$!:(2486H1M0@:A%U'O)#)_-'AV]8)I@H,HAZ*C?\"E&`
M*$04(8H1)8A21!FB'%&!J$14(:H1-8A:1)V'_%BHM,SQ=P@3G<6A]0PW_*U!
MHJO(I[#6BAT#1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH\Y(?GM#3.!-,X
M!GE=15LY*$"K$%&$*$:4($H198AR1`6B$E&%J$;4(&H1=1[R8W%:GD5M!96S
MOT9N?MM8.7GD@!V]_-FUN%T.K15WJ`BU8D2)=72F-KEG*+56+)^A5HZHL(X'
MY$MKQ?(5:M6(&NOHRHN[G=9:L7SG:?EQ59F*$X9`G=CPAD"-O+@:Y*2[)\;1
MCZNXGPJM%5<],LBY1F)$B75T6T9DP%)KQ?(9:N6("NMX0+ZT5BQ?H5:-J+&.
MKKQ8<+76BN4[3\N/ZVD9DPEF3`SRXJJMG%@$[.C&=3036<[06G'5(Y:WUTB,
M*+&.;LN(Y&QJK5@^0ZT<46$=77F1X"NM%<M7J%4C:JRC*R]6!ZVU8OG.T_+B
M.I4IDU]Z_-BK^)D4@]QP,[(A"MC1;F</$47H&"-*T#%%E*%CCJBPCFY+BPQ*
M::VXI2O4JA$UZ-@BZCQ'/VJGY3&FF,<P2.T5MO=D<E/HBJUL>`)$(2.=9+^1
M6Z@C+K<J,:+$(#6U[&L$6X%3=C3/#F875V)8R]C"'BU'5"`J#9I;QPJM:D0-
MHA:U.L_*CZ9*6AP_9TYUCL.=,PU2F][V;3=>B-EPQ8[._FM$H4%3W<*3B1B]
M(G2)$26(4E]X?'$CE#/TR1$5B$J#YC;-7J%5C:A!U*)6YUGYD9-YD\,WWU/,
MC1@D^J&8[U9L92_-`%'(B)9&SE4@%BT16UFM&%&"*&5T4#YC*RN?(RH0E09Y
MW4^W%VU-Y_&U1L<&48M:G6?E!U%F4'YM"L3$RE0CT2O%8F-EK&A'))]DP,AF
M9$*#U$3NQ%;TH(BMW!"-;L3=3LSR]H@)(WO$E+7TL[41?4M,3'\9.UF='%'!
MR$J7!LT7^U.NV,IJU8@:1E:K1:V.K7HM/]0TW7DC[:^%6JF(U8Y&HAN+!EM-
MC96]G@.#:'\81S]D-.T?!X[&8['`BU`F1I08I!81^RMF8#[55:+)23U['(TN
MY,UKAM(YHL(@YSQ*KH"6OJ;-"^(-*)2I$34L<_`\6K:BE<[^;,?RA9K.D_>O
M#)D;ZJ\,^A`DZ:D7TOD=E^/?3I]B^L@@,2"(^^T5.]JN$!@TMYG"T*"9?@JV
M&(EK+4*5&%'"*FZS#5PD^E3,L6@HF(A09BB=(RH,<DZCY`KHTYA?R.5&A3(U
MHH9E#IY'RU;>@PB\2$S@!H8/F;12%\EX:E^4_(6K!!-;M-%/#2]B+!'+W!5;
MN6.)T7+'$HU,]UY,A4J$*C&B!%%JD#-;9VB5(RH0E:A5H56-J$'4HE;G6?F=
M7B61W(6WG`XXGG^SK%,R8C[0B/+X/*RO:$&MK!P4(`H118AB1`FB%%&&*$=4
M("H158AJ1`VB%E'G(3]&*D?DQNAO8J%32M[-D4;^,Y6%F%17]$XPA`=0B%81
MHAA1@BA%E"'*$16(2D05HAI1@ZA%U'G("P^]D'U*>'ISOZL8Y#Q`62$*$(6(
M(D0QH@11BBA#E",J$)6(*D0UH@91BZCSD!\+E>8YOJNHEZ[%L&40Q<)91<G[
MAY6UXL$M0!0BBA#%B!)$*:(,48ZH0%0BJA#5B!I$+:+.0WYX3DOST&H+PJ.1
M,X6LC)6#`D0AH@A1C"A!E"+*$.6("D0EH@I1C:A!U"+J/.3'XK3$#;U5`;'0
MR)]5;F3*S3AZX=D[<N\)T2I"%"-*$*6(,D0YH@)1B:A"5"-J$+6(.@_YX9$I
MF<.3OMJN*4<RC9R&7QDK!P6(0D01HAA1@BA%E"'*$16(2D05HAI1@ZA%U'G(
MCX7*$)PPJ^B$@KL`HYWL*CQB5A&WD"MKQ?TB0!0BBA#%B!)$*:(,48ZH0%0B
MJA#5B!I$+2+U`QJF":EQ='CT#V+H#^B_K-^_K5?KY^?MV?WFN_JQBX7Z)-H>
MZU_BN)U-Z:<X^J=O4#+C'^F0)=/%4JW.Z;!0<D,E?49"ELRN2*V_?882]6,@
M??8.2L94TM\N0<F$2OI[6EDR(36];H024M,='4I(C7;3#9S/A%J']G8-E5#K
MT+:BH9(YE?2WX/(XU&R#K3:Z7JKO>`QHC<B%/B$Q5$(M34FC@9(QM;3.',OC
MCZEMZ,UN]*'-&Q2WH>C0+[5\'HP`20TIW5(C#]JK)AXX\N?I\C-=R%BE6VKY
MP8975^60/;7Z8*/3F0TU+6V'6:HGLWADVA6S5`]HL80VQRS5UI>AD@65#`6*
M'M!3R5"@Z(GO4CWB137:";14#Z6QA#8$+=6S:2RA?4%+M>MGJ&1!)4-UH[T)
M5#)4-WK8O52/LE&--D$MU<-W+*&]4$OU#!Y+:$O44FUX&BI94,E0W6A;!I4,
MU8T>ZB_54WQ4"\;SI7KO$4OHI<:E>F412^A]Q*5ZVQ!+Z%7"I7I1$$MNZ7QN
M!VNPHI+58`GM.ENJ/66H%DP65#+4!K3SA4J&VH`V22S5K@A4HP\4+-6;TEA"
MWRF@\QGJG/0^/)4,=4]ZP9I*AM3H@P/4TX=*Z+5CBL)0'Z77ABD*0R7TVB]%
M8:B$7MNE&@R5T)<^E^ICGGBF]*7.93I80E_:7*J/::(/?2ESJ3Z&B26W=*:W
M@V=*WZU8K@9+`BI)!]N:/I-`)4-M3>_=4\E0B])W*);JA7BL6T"=9.CZ*&C0
M&>+TO6)JF:'KACX/3.<_5$*?QB6?H<&>OD1+/GW)Y7ZNH=_1>KO[MB[OWK\]
MO6[/GM=?:>EQU>?#W_4O<>E_[,P7PKYL=O0+6OW'PA[I%]/6]%[BE7K$\G6S
MV?$_Z,0O][_!]ND_`@```/__`P!02P,$%``&``@````A`-IU5;FY`@``9`<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&ULE%7;CILP$'VOU'^P_+XX
M$')#(:ML5]NNU$I5U<NS8PQ8BS&RG<WNWW=L9Q&YJ$M?"`S'Y\R9&2;KVQ?9
MH&>NC5!MCN-H@A%OF2I$6^7XU\^'FR5&QM*VH(UJ>8Y?N<&WFX\?U@>EGTS-
MN47`T)H<U]9V&2&&U5Q2$ZF.M_"F5%I2"X^Z(J;3G!;^D&Q(,IG,B:2BQ8$A
MTV,X5%D*QN\5VTO>VD"B>4,MY&]JT9DW-LG&T$FJG_;=#5.R`XJ=:(1]]:08
M298]5JW2=->`[Y<XI>R-VS]<T$O!M#*JM!'0D9#HI><561%@VJP+`0Y<V9'F
M98ZW<7:WPF2S]O7Y+?C!#.Z1J=7ALQ;%5]%R*#:TR35@I]23@SX6+@2'R<7I
M!]^`[QH5O*3[QOY0AR]<5+6%;L_`D/.5%:_WW#`H*-!$R<PQ,=5``G!%4KC)
M@(+0%_][$(6M<YS$49K,%LL8\&C'C7T0CA,CMC=6R3\!%1^Y`DMR9('?(\MT
M'LT6D^D($A(R\@;OJ:6;M58'!$,#DJ:C;@3C#(BO.P(K#KMUX!PO,()<#73A
M>9.D\S5YAM*Q(^8N8.#:8^(>04"T5P:U\<H.[)1=;5TJ=R$PE$FNRTS_1\:!
M<PS7/OE9VM,&X0!)AY`><>(/(./].3!,Q6I`>UG:`!HA#3,UE';CFDS=:+[3
M7W?.9]&7.43B8462=''=\/Q4]=^CY,"G4B$2^YD_*23,V[F;Z7*,'7?P5"-$
M8AB>OL%)NKQNQ^WNT5^&`Y]*A0A(N<4RG'OH\9#7-V<QB1;O=L<=/-4(D3,[
MJS,[8:N%CUYR7?%/O&D,8FKO-E8"GW$?[9?IUJ=]'D^SK5^RI'\!2ZZC%?]&
M=25:@QI>`F7PHL.:#`]6=7[5[)2%[>9O:_@WX_`E3R(P7BIEWQY<O?K_Q\U?
M````__\#`%!+`P04``8`"````"$`%@YX$L`%``#'&P``&````'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;)2976^K.!"&[U?:_X"X/R$VT#91DJ-VJ^X>:5=:
MK?;CFA(G00TX`OKU[W<\IL2>V`%NJL89S_".Q\^8>/7]HSP&;Z)N"EFM0S:;
MAX&H<KDMJOTZ_.?OIV]W8="T6;7-CK(2Z_!3-.'WS<\_K=YE_=(<A&@#\%`U
MZ_#0MJ=E%#7Y0919,Y,G4<$W.UF760L?ZWW4G&J1;7%2>8SX?'X3E5E1A=K#
MLA[C0^YV12X>9?Y:BJK53FIQS%IX_N90G)HO;V4^QEV9U2^OIV^Y+$_@XKDX
M%NTG.@V#,E_^V%>RSIZ/H/N#)5G^Y1L_7+@OB[R6C=RU,W`7Z0>]U+R(%A%X
MVJRV!2A0:0]JL5N']VSYD"[":+/"!/U;B/?&^#]H#O+]U[K8_EY4`K(-ZZ16
MX%G*%V7Z8ZN&8')T,?L)5^#/.MB*7?9Z;/^2[[^)8G]H8;E34*2$+;>?CZ+)
M(:/@9L93Y2F71W@`^!N4A2H-R$CVL0XY!"ZV[6$=QC>S]'8>,S`/GD73/A7*
M91CDKTTKR_^T$<.'TK[PT1ZS-MNL:OD>P'J#=7/*5/6P)3AV/PL\A+*]5\;K
M\#8,($P#"7S;<):LHC<0G7<V#]H&_O8VK+>((&@?&:*-CZR,5625%?4H#WK`
M#,/=86([C$IZ#$MW7:B:!':&",[2WK]^`FV3&#9G"TLHF(P7JHQAB1>&V\L<
M:Z,1H:$NQH=6QABZ3[(>878>;OH\6"IOIH12QG8H/<(X%JM9)E!MI@2U?CR&
MP>L+J&;9`?0(!#@7)F>W;BV*N*,WA3*V0^D1AQ985=,O`B`9U*)FV0'T"-%R
MY];"H-C-H-?SAM9VL&[((8>IO6[D"?6P6-%K8'EP)@G3@<->H(5'E-K^1N0!
M41H6L*GZRE:Y@Z2Z1*E]/=ZUIH#E6@_9NX;//4(FP8'U=#@+T4,N(63SX^K,
M0?=`LBXQH)J43I:Q=[@'ZVP2"-":%$*'`MVW3!0PM8?'+\TE`]`!K#ILB;X[
M<>YI'&P2!=":".DXX!#B``'GZ>QV>.-<PH"Y:,!C=[WQ231`:UM4-Z3VCY'"
M\R'`Z@G<!8B;Q6Q0)DXD@5U\X)Z6R]7V'ETI:$VB]7P8(Y,@`WL42T;(O*0'
M[^AAY]?3<_DD>J`UD>FEAV*XF4&E*4[&+)V&A4E$](6P-9/IZ;U\$C_0FFCR
M'B4XX0>N4W(WHE_A3!)&XX5L!$\3YI-8@M8DFO=,H8Z*=*'X8DP3QIDDC),E
MGB:LCM%FY.M]!:WM:-V0HW?%!!P#KC4:S))#!U!RL)O.F(H]33B>1`NT)D)Z
M6D!?M@@8$S0,"+GD`3I8AXG%@]C3>^-)/$!K(L3+@]C!@Q2VP("@2QB@(PJ#
MV-.#XTDP0&LBR`L#]0YA5B\>C^[F(WHPSB1A7#"(/3TXG@0#M";1O#"("0P&
M5D?O=FO?=$.@Q]@WGO:>$``@3V_'I!!GVJ*Z(9NGL:>_)Y/X@-8D6G^:H#M6
M[31:%WP^AJ<XDX3IP6"FT]/-DTFL0&L23>/#P=.$@`%7:O@M&J>1&#TA3$6>
M7IX0:%PO1[0FT30_7(HFD2'1&#`K_6O(KG1/_U8OZ;0H6#KFY(`SB2@G+#Q-
M-ID$"[0FT;RP2";!`JV):Q<L$D^331VP8*-XBS/MR-V0#8O$TQ732;!`:Q+-
M"XO4`8MDOIA!N5VO=9Q(HKA8D7@:8SJ)%6A-HGE9D3I8P4;]JH,S21@7+A)/
M8TPGX0*M230O+E*""^SV?,0K&DXD431,2/%Y>J0Z(YGD&"@+C0:34^@`STNT
M4Z4$#0CU49T*9Q)1/28,KB>>]@NW)%-$=9@P?GY#![8H?6VB[R9*4>_%+^)X
M;()<OJHK$0ZW#?UH?UUSCS\7T_%D>:^O<:+^&[A&.65[\4=6[XNJ"8YB!S[U
M0:76%S'Z0RM/\%1PF2);N$#!?P]P82;@QF&N7N=W4K9?']1R]%=PF_\!``#_
M_P,`4$L#!!0`!@`(````(0!K:<:#8@L``.`Z```8````>&PO=V]R:W-H965T
M<R]S:&5E=#@N>&ULK)M=;]LZ$H;O%]C_8/C^Q)9D.[:1Y*"11)'"+K`X.&?W
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MN-]MUH?Z6#^?;LC=R`P48UZ,%B/R]'#WM*$(M.R#0_5\/_P4+<MI-!P]W#4"
M_7M3O1^]_P^.K_5[<=@\_6.SKTAM.D_Z#'RNZR_:5#UI1)U'T%LT9^!?A\%3
M];SZNCW]4;_+:O/R>J+3/:6(=&#+IQ]9=5R3HN3F)IYJ3^MZ2P.@?P>[C4X-
M4F3UO?E]WSR=7N^'R>QF>CM.(C(??*Z.)['1+H>#]=?CJ=[]QQ@U$;5.8NN$
M?GN<G.F8V([T:SM&-,[Y-)K.].'/])S8GO3;<\@/CIL.T01/O^[P\<U\.IW,
MYK?G#S^S/>G7]IQVJIT9]JWM1[]NV,E--!E?"I>F:S-2^K7]O+-TYG@+VX]^
M782W'QIH1)EH$D.GI#GI9T,<F<1J\C1;G58/=X?Z?4"3GU+G^+;22TFTU%Y=
MAII1MSG[LY2E7-5>/FDW]T/2C;+Q2//LVT,T']^-OM'<6%N;QQX;;I$Z"ST1
MM-LL!'D(1`B*$,@0J!"4'AB1+*TV-&'^']IH-UH;%]6C`YU8<2"$LW!=LA#D
M(1`A*$(@0Z!"4'J`"4$+``B14++T+V,N)W0O6K!83D0\T$=C$]/$:1-GRDW2
MUJ05`T@.1``I@$@@"DCI$Z8)+6V@B5[:KYPXVLW],*85H!4`9XXU.J=2:]*J
M!"0'(H`40"00!:3T"5.)!&$JG<\8;=V(X8)X-$3GFB=/.%M:(]<M`Y(#$4`*
M(!*(`E+ZA,5.N\\5L6MK'KLAB=G,]7*8`LF`Y$`$D`*(!**`E#YA@=*R?T6@
MVIH':DA"JX]WDI-@&6B-VI,,)`<B@!1`)!`%I/0)BYWFY!6Q:VL>NR$4NPLK
M!9(!R8$((`40"40!*7W"`J45ZHI`M34/U)!HT@4*)+.]:$9UB3`-MHR\-7**
M"7!4`)%M+\_U?,)S3+5&SG7I.V)RZ%J)Z6$*IQM=F9Y>-^LOCS7%0)5%SXJ7
M4(%DRR;MA>O4.*:>GE"(,HOB65-KQ>,HF"YY9^!B$>BF0"2[CKJ*0\^J,W">
M2^:&RZ1K*[^^[)&#KB5:/4PI1MNA\_T8&930#.R28AX6"=8JFK4=L_Z.,W[*
M<]=QW@@Y7039)EQ[Y[A`)#]T+.4ZFF/-DR"(TK4WQ^(RZLK,E_'7LLW4=TQ=
M@Q*:]IZZMURD-+(=FXM=6YE;U.U.N;5*%B8GDV!V"?12()(.=8X5=YS$P?!*
MU\5<B_L5?*3+-U^W"^EGJST__0SR$BMMG-(,[5(B0Y0[9$]V')QLX=H[+P4B
MB4@Y=-O('$6SH!PJG4%/&NDZS9?CU]+(5GN^2@8%:30/T\AV]-/(HNYLY[3R
MZ361TLA/R07W)9P52]Q%<,E96*NX.Z)TJ#NB<K[8$<.5H'16/SLBG["Z*OS?
ME3:U)9NP!GG)E^JK#A+,0YE%$UXWP]IG.DZB)I-N)Z`Q."[P6/)#QU+.RAQK
ML8"D]8_%I=1UYSDI_ZS??K;3^EN+*5^9EGY%VRQK*8G8)%^7'1FB')%`5""2
MB!2BDB&NA:Y#?2TNK&>F;&4QVTJ6949X-M*HM7+[<(8H1R00%8@D(H6H9(C+
MH*O4*V30YD&59="D6WW3"%"&*$<D$!6()"*%J&2(QZQ+T2MB-I4K._4&4<S>
MPKH("L<T:JVZ4P\H1RN!J$`D$2E$)4-,!EK*KY&A,>>GWB+_D@M1ABA')!`5
MB"0BA:ADB,<<%M%ZVUZ0$%?>:XJQNK:(7WLO@LHM[:S:G$"4(Q*("D02D4)4
M,L3UT;7HQZ=&;$M7KWZQB.6$L?)0AE8Y(H&H0"01*40E0SSFL++5.3&=Z<=(
M5Z<%5KVQ04%:!"5LVEEU:=%V="A'*X&H0"01*40E0UPB74A>D1:V%/73PI:B
MWMV9&%"&*$<D$!6()"*%J&2(QZS+*#_FIL(?1[^4%Z8D\[<0G5VZ-J>YT5TN
M+H*Z,NVL7!)DB')$`E&!2")2B$J&N$:ZQO,U.E]$T3V6L'JPR%L;4D09HAR1
M0%0@DH@4HI(A'O-UA6.,A:-%+&9;)7;3(T.K')%`5""2B!2BDB$><U@E-G,A
M3II[=-=NG5A"ZH=6.!>">Q-I9]7-A;:C0SE:"40%(HE((2H9XAKITNZ*N6`J
M0;8D&,3R`E!&/:Q87<R`!%H5B"0BA:ADB,6LGR:QF'5>)+^4%HTK7EY:%"R1
MX:V0SLKID2'*$0E$!2*)2"$J&>(2A17G^262GE&%2Z1%?EH@RA#EB`2B`I%$
MI!"5#/&8PRI2I\7D^G)*G_G@:M.B(">"VRUI9]7E!!2A.5H)1`4BB4@A*AGB
M^H05YX6<P*HR@>(P190ARA$)1`4BB4@A*AGB,5]70B980EJD96TK)GH)C]_-
M3#NK[M1#H9FCE4!4()*(%**2(2Y#6%5>./58."9MX>@"3!%EB')$`E&!2")2
MB$J&>,QAE:B7`WN!=2%\+!@3@R9)^W@J=8A.LY<8P>.GS%F1?)Y5=_.4#_FZ
M(D\_4@L7*H/8.`%EMJ.QXB/H*[GTG8H+BF%UI1\ET.#82"SBB@7WKS+7D2O6
MW='@X]4UR,?+'_U,(E3,(#9.0)GMV*.8OD7/1J#3[';>U*CG16MZ\MK#(G\P
M#G'1@BOYS%EQT;KK.B8:/2_@0[XP3BP.&@_\Y"+*&.(CZ-NJ(WN5>V$TN#M/
M#&*J6<15"VK[S'7DJG6E'A_S==LGC29,-8O8.(V5AS)FQ4=`T4"JS>B%TTO3
M<Z([!IEFD'?@U%KI'V^I"HJ<S%DQS:)N/^0C)BLVX@OG5IL'XS2(MM]VW]$E
M'5EY*$.4(Q*("D02D4)4,L1C[MMWXEB?I2NO6?6-_E`.@W@U$@6;3FH[,H7:
MCD[''*T$H@*11*00E0QQA:[;YB:XS5GD!9@BRA#EB`2B`I%$I!"5#/&8PXWU
MPDS`#75B4'#JNTK"//_LK-QYSA#EB`2B`I%$I!"5#'$9KMNO)[A?6\1.O;'R
M4(96.2*!J$`D$2E$)4,LYFE8(9P_]8TY7P0M\@),$66(<D0"48%((E*(2H9X
MS&&)X55%5ZZ"]'E/N`I:%$R%H)!,.ZMV*B#*$0E$!2*)2"'2'R=UFY61R'QL
M9#[BV%6'ERJMMMOC8%U_U1\24='T<-=B\Y73X[3]S"ELF4R7>B^B"*%E1BW-
MXW%HN:66YG,&:)E3R[S7VX):FB<K89_IF#[!:M[/"5L2:J%;5#UC2R@>NI'3
MUQ)32[/9@[>$6IKK+VB94$OSNB6TD#ITA=ASG)CZT%.8OA;J0\\>^EI(4;I#
MW]="BM)][+X64I3NWO:UD*)TC[.G):(^]!Y!7POUH4?K/2TQ:4T/H/M:2&MZ
M]-K70EK3`\J^%M*:GLOUM)`XO=J0-+W*D#"]NE"(_1&2(WI]IN?($;FB-TJP
M)5LLZ9UBY'*QI!>"D=.[MTO]>BVVT+NS2_UZ++;0=X:?>I4B<?NU)0%[_#SJ
M).[AGR;+3[14X($?*4^;-!VUN4W?%[ZM7JI_K@XOF_UQL*V>:=D8-Q><!_.%
MHOGC9%^K^ER?Z,O"Y@VK5_J2M*(/$<:Z&GVNZY/[@PX\:K]-??@O````__\#
M`%!+`P04``8`"````"$`SD?Q.K,"``!B!P``&````'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;)1576^;,!1]G[3_8/F].)`F-"BD2E=UJ[1)T[2/9\<8L((Q
MLIVF_?>[Q@F%),K8"Q^7XW/NN=>^+.]?985>N#9"U2D.@PE&O&8J$W61XE\_
MGV[N,#*6UAFM5,U3_,8-OE]]_+#<*[TU)><6`4-M4EQ:VR2$&%9R24V@&E[#
MEUQI22V\ZH*81G.:M8MD1:+)9$XD%37V#(D>PZ'R7##^J-A.\MIZ$LTK:B%_
M4XK&'-DD&T,GJ=[NFANF9`,4&U$)^]:28B19\ES42M--!;Y?PUO*CMSMRQF]
M%$PKHW(;`!WQB9Y[7I`%`:;5,A/@P)4=:9ZG>!TF#PM,5LNV/K\%WYO>,S*E
MVG_6(OLJ:@[%AC:Y!FR4VCKH<^9"L)B<K7YJ&_!=HXSG=%?9'VK_A8NBM-#M
M&1AROI+L[9$;!@4%FB":.2:F*D@`KD@*MS.@(/2UO>]%9LL43Z-@%D^F(<#1
MAAO[)!PE1FQGK))_/"@\4'F2Z$`"]R/)?"P)\0FU_AZII:NE5GL$>P8D34/=
M#@P3(+YL")PX[-J!4QQC!+D::,++*HQG2_("E6,'S(/'P/4=TR$(B';*H#9>
MV8&=LBNM2^7!!_HRT669Z?_(.##TII]\/.]XO;+'W/8P[R48&`3(>(,.G.)H
MT:,]KZT'C9"&3=67=MMU&D'?KK?7K6ISZ*KL(R$4^[V;<=P59&!W/M2\+N7`
M0RD?"=LM/^"%M$^]A--9$$-NUS7<PJ&&CYS8N;MLQTWNT0?#@8=2/G+!#G2X
MS^LGR9T;&_^PXQ8.-7SDQ,[BQ(Z?:?[,2ZX+_HE7E4%,[=R\BN`4=]%NE*XC
M=]!.X[?)NAVQI/L`(ZZA!?]&=2%J@RJ>`^6D;8WV0]*_6-6TDV:C+`RW]K&$
M?QF'@SP)P'BNE#V^@##I_HZKOP```/__`P!02P,$%``&``@````A`$\QI*>>
M#P``%UX``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6RLG-MNW$B61=\'
MF'\0]-Z6\BX+MAM6,JZ8`0:#[I[GM)2V$B4I!66Z7/7W?8(,)GEBL613F)=2
M><6)2)X=%VX&+Q_^_L?CP]GOVY?#;O_T\7SR[O+\;/MTN[_;/7W[>/[/?]B_
M79V?'8Z;I[O-P_YI^_'\S^WA_.^?_O,_/OS8O_QVN-]NCV?2PM/AX_G]\?A\
M?7%QN+W?/FX.[_;/VR<I^;I_>=P<Y9\OWRX.SR_;S5U=Z?'A8GIYN;QXW.R>
MSIL6KE]^I8W]UZ^[VVVUO_W^N'TZ-HV\;!\V1SG^P_WN^="V]GC[*\T];EY^
M^_[\M]O]X[,T\67WL#O^63=Z?O9X>QV^/>U?-E\>).\_)O/-;=MV_0\T_[B[
M?=D?]E^/[Z2YB^9`F?/[B_<7TM*G#W<[R2#)?O:R_?KQ_//D.EY=GE]\^E`+
M]*_=]L>A]_]GA_O]#_>RN_NOW=-6U)9^2CWP9;__+86&NX2D\@5JV[H'_N?E
M[&[[=?/]X?B_^Q]^N_MV?Y3N7DA&*;'KNS^K[>%6%)5FWDT7J:7;_8,<@/SW
M['&7AH8HLOFC_OMC=W>\_W@^6[Y;K"YG$PD_^[(]'.TN-7E^=OO]<-P__E\3
M-,E--8U,<R/R=Z"15RK.<L7YJ>)TUOWZ*Q7EV.K#EK_Y%R?3=_/I8G55'_<K
M-9>YIDR`7/,7?_)]KBA_1_[D1'JU$3EU;R/@ZS]ZT?12W>G5YKCY].%E_^-,
M9I+TP^%YD^;EY#HUVW9WD_!I`/Q5_TO'IU8^IV8^GJ_.SZ1K#S)H?_\TF<T_
M7/PN`^TVQ]P,Q.B(=1N11E5JMBJ!*8$M@2N!+T$H0>R!"Y'EI(V,OO\/;5(S
M29LVJYL6=&)-"R':B+9*50)3`EL"5P)?@E""V`-*")E5$&+^EVM".R92+9G]
M:DPL=*(W3<Q4YLYIX!0AZU/(20P0`V)!'(@'"2"Q3Y0FLL)`D[1.CIPXJ9F/
MYU-9`TX"<.;DH-=4.H6<5`(Q(!;$@7B0`!+[1*DD@BB5AL\B[8A)T;48;1(W
M#9G)PM239ZD'T?H4U%:K0`R(!7$@'B2`Q#Y1N<N)843N*5KGWI!9<V9,R^$:
MI`(Q(!;$@7B0`!+[1"4JR[Y*-)U#TO(P<BJD9K0"#9G)LM3K_571^Z>@4^^#
M&!`+XD`\2`")?:)$27ZX?V)]?>2G:)U[0V:STVEC#5*!&!`+XD`\2`")?:(2
ME:5K1*(I6B?:D)DL(;U.OBHZ^11TZF00`V)!'(@'"2"Q3U3NR3&-2+X.U]EG
M)&.\S6Q-5!$9(DODB#Q1((H*Z9R37>J/[#3=9[-WJ_$S?M(X+SG[M<G?9%3,
M^??%<.BBVHH5D2&R1([($P6BJ)"6*!FIOD2O3_Y)X[N4#`U2PP*HRA5[48;(
M$CDB3Q2(HD(ZY^241N2<C56_ZQNDNWY^67;]*:KK>B`S`;)$CL@3!:*HD)8A
M6:$1,F3GU)>A0;U.74^`*B)#9(D<D2<*1%$AG7.R0"-R;AR3&NX-TCYO/BF[
M_A35=3V0229<3C'25AMEB1R1)PI$42$M0S)((V1H_)22H6^QZBO@]02H(C)$
MEL@1>:)`%!72.2?_T\\YG0Q65V\Z&3162NEQ<E<];S`O+Y8GIZBVPRLB0V2)
M')$G"D11(2U1<DY]B7YR,FB,EI(A>Z_>E<`$J"(R1);($7FB0!05TCDGQS0B
MY\9@J9Q/GJO?];-R13A%=5T/9"9`EL@1>:)`%!52,DS'V<,Z7-O#C/HG`Z**
MR!!9(D?DB0)15$CG/&0/I]-WLBJ/O!Z<TAUF5%B$8J-QW46=1@61(;)$CL@3
M!:*HD%9HG#N<TAUFU#O%K8DJ(D-DB1R1)PI$42&=<_)CO[X@3!O[UE\0,BHL
M0KE9V$5U79^M8.<'#*,LD2/R1($H*J1E&.<.IW2'&<GE<IO@FJ@B,D26R!%Y
MHD`4%=(Y)S_6[_ID$1;+=/=H](K06#LU+!I4K`CE#F'ZK>0)NZOLBL@062)'
MY(D"451(2S3..4[I'#/J);@FJH@,D25R1)XH$$6%=,ZE<WS=%DWI#C,J5H1R
M>["+:B=,162(+)$C\D2!*"JD91CG#M.=DF+_+"/5]=D=]H<[D&%%2^2(/%$@
MB@KIG),?ZZ\(/^GZQKZI69\=G9P:NTW#>;EI*#4PZX$,HRR1(_)$@2@JI&1(
M`W>$#'6X=H<9R9]V;*^)*B)#9(D<D2<*1%$AG7/I#E_O>KGY40[WC-)/]+J^
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M%?UD6*3P8N5LD)CH-L%U>KY.HGJH(C)$EL@1>:)`%!72.9=V]B<YT[?.&Y0N
M''I=7ZS/ZRZJ5:8B,D26R!%YHD`4%=(RC+.K<]K5C-2*T$3U4,4H0V2)')$G
M"D11(9USZ4W3BI!&RLC;?W.:UHR*Y:`P3>LNJAL335N]:V##*$ODB#Q1((H*
M:7U*9_J3J4$+.F]0;P"LB2HB0V2)')$G"D11(97SHO24K^=<A^LE,*.BZXL+
MC747=>IZ(D-DB1R1)PI$42$M0^D9?R(#O>&B0;*/T":X)JJ(#)$E<D2>*!!%
MA73.X[SA@MXP(]WURW)KKXMJE:F(#)$E<D2>*!!%A;0,X[SA@MXP(]7UV1MV
MHZ%BE"&R1([($P6BJ)#.N?2&/QGN]'^+DXWKF8!EL6FW[J*ZKC]5;)%AE"5R
M1)XH$$6%M`S)JOVZ_ULTSJZ_YY!1?\$GJH@,D25R1)XH$$6%=,[C_-^"_B\C
MR;G?]<4.W+J+:ONY(C)$EL@1>:)`%!72,HSS?POZOXQZSF5-5!$9(DODB#Q1
M((H*Z9R'_-_;W@]8T`)F5)P,RGW++JH;%K2`C+)$CL@3!:*HD)9HG`5<T`)F
MI(9%=H6]>UN,,D26R!%YHD`4%5(Y+\=9P#I<6\",TLV![HIP6>Z\=E&GKB<R
M1);($7FB0!05TC*,LX!+6L",^EU/5!$9(DODB#Q1((H*Z9Q+"YBN"-_T2.B2
M[C"C8D$H=PZ[J&Y4-&WU=#2,LD2.R!,%HJB05FB<.US2'6;4RV9-5!$9(DOD
MB#Q1((H*Z9S'N<,EW6%&1=>7NX-=5-?U=(>,LD2.R!,%HJB0EF&<.US2'6:D
MNKZ)ZJ&*48;($CDB3Q2(HD(ZY](=OGU!H'%<-J@8%>7&81?5C8I3Q1891EDB
M1^2)`E%42"LTSC@N:1PSZ@V!-5%%9(@LD2/R1($H*J1S+HWCZY>+2YK#C(JN
M+_<'NZBVGRLB0V2)')$G"D11(2W#.'.XI#G,2&ZFM0FNB2HB0V2)')$G"D11
M(97S:IPYK,.U.<Q(WT!<EON#752K3$5DB"R1(_)$@2@JI&489PY7-(<9]7<*
MB"HB0V2)')$G"D11(9US:0Y?G_4K.L",]*Q?E?N#7537]72`C+)$CL@3!:*H
MD)9AG`-<T0%FU%_PB2HB0V2)')$G"D11(9WS.`>XH@/,2-\D7)7[@UU4U_79
M`79W5`VC+)$C\D2!*"JD91CG`--W%HK[PQFIKJ<#9)0ALD2.R!,%HJB0SGG(
M`;[ML8$5+6!&Q8I0[AUV4=VPH`5DE"5R1)XH$$6%M$3C+."*%C`C-2R:J!ZJ
M&&6(+)$C\D2!*"JD<RXM8+HP6*[>\/+HBNXPHV)4E%N'750W*IJV>J(91EDB
M1^2)`E%42"LTSAVNZ`XSZF6S)JJ(#)$E<D2>*!!%A53.\KG+,3=0ZG#M#C,J
MNK[<.NRB3EU/9(@LD2/R1($H?=NS?K"GWL9M9&B^U=E\MO%Q^_)MN]X^/!S.
M;O??TW<XI<*G#R?<?"3T9K6Z3M-,\D#)E91<#9:\EY+Z2=>RSM5E^\W1LF0E
M7R,5;S?T.U,IJ9-`G9F4U`]AHF0N)?4I&24+*:EO<Z)D*27U(Z5ER5+JR![$
MP+$MI8Y<>P^5B&YRA3I4(KK)1=M0B>@FES8#)2O13=S^0,E"ZLA>^4#)4NK(
M]O%0B6@MFZQ#):*U;"X.E8C6L@4W5"):RZ[40,E"ZLA-W:$2J2/W.8=*1&NY
M&SA4(EK+#;*A$M%:;B,-E8C6<O=DH&0N=>31HZ$2J2,/W0R5B-;R:,I`R4*T
MEJ<UADI$:WFF8:A$M);;_`,E<ZDCS\@.E4@=>6QTJ$2TEH<KATI$:WFF<*A$
MM);GJ89*1&MY&&V@9"H:-'>4RUDR$PV:G0*42#[-A21*))_F_($2R4?>;QHX
M@IGDTSRM6-:92AUY97Z@SE3JR(OE0R6B@3Q%/50B&LA;QT,E,G;D1=RA$AD[
M\KKJ0,E$ZLBG789*I(Y\`&6H1+26UP,&2J:B=?-*`#00K>6+$4-U1&OYKL)`
MR43JR#?(ADJDCGRI:ZA$M):/5PV5B-;-FR;EL4U$:WE/9*B.:-T\SE_62<O!
M4`VI,-@W(O.@RB+RH,8B\:#"$U%8/EW'8Y7WOZ[3&UE#)<OK]'H32^3=):DS
M5"+O!TG)T!'+Y[D_#RLO!S;P&S>I>X=XFD@#_//\^K.<\7FP-VF]2/SBU!?R
M6>[GS;?M?V]>ONV>#F</VZ]B%R[K5\I>F@][-_\XYC<5ONR/\D'N^J6%>_D`
M^U8^.7J9K/?7_?[8_B/]P.F3[I_^#0``__\#`%!+`P04``8`"````"$`\<+J
M]Q4&``"R&@``&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)Q9VVZC2!!]
M7VG_`?'N2W=C8Z(XHX'1[(ZT(ZU6>WDF&,=HC+&`3&;^?JNI-MU5X%M>DCAU
MNGRZJOH<+H\??I1[[WM>-T5U6/MB.O>]_)!5F^+PLO;_^?OS9.5[39L>-NF^
M.N1K_V?>^!^>?OWE\:VJOS6[/&\]R'!HUOZN;8\/LUF3[?(R;:;5,3]`9%O5
M9=K"Q_IEUASK/-UTB\K]3,[GRUF9%@<?,SS4M^2HMMLBRS]5V6N9'UI,4N?[
MM`7^S:XX-J=L979+NC*MO[T>)UE5'B'%<[$OVI]=4M\KLX<O+X>J3I_WL.\?
M(DBS4^[NPR!]661UU53;=@KI9DATN.=H%LT@T]/CIH`=Z+)[=;Y=^Q_%0Z)6
M_NSIL2O0OT7^UCA_>\VN>ONM+C9_%(<<J@U]TAUXKJIO&OIEH_\%BV>#U9^[
M#OQ9>YM\F[[NV[^JM]_SXF770KL7L".]L8?-ST]YDT%%(<U4+G2FK-H#`?CI
ME84>#:A(^J/[_59LVMW:5\OI(IPK`7#O.6_:SX5.Z7O9:]-6Y7\($B85)I$F
MB0+V)BZG<K40B^7U+#-DU&WP4]JF3X]U]>;!U,!W-L=4SZ!X@,RGG2&/?J_G
MM@I[U$D^ZBQ=+MA%`_WY_B3FP>/L.]0T,Y@8,:'O60Q%)">$;@70ZSG"SCE'
M!3T<K_Z)DEY$*:DY_;YX")$4D0P18=A#"$>HG<OQ,C<-AAEP2S%?]'F[DL:(
M"1P,0R27$(0;)+F=FP:O?=AXWZ9HR:@A9-7U>:*$$#2>D+B8AW82""T8?9>6
M'KW@[*$ZM54OXJ7C_!`#+/HM\-)=0A".2\KQ<ELUF)8.-D]K$R,FP#.B&//D
M7)1P@B/DUNTR)PWFG%:,$V*0TW+).;G1*+"])IRTTS$9N7Y$]2+.+6+<$(/<
MV/E-W-ADM;!A0BUZ#S6]B%$3-C^>4,0@-<FCB1NU*PDS`2+F5NUR)SLTYV3;
M@9P,R)"*[,GKP@D)J[GJBTUY,5.XP@MEVU4,(9B0Q@)!R&O"CR.)VA-#26DM
MOGO$!"HXD5IAMVV*AJ!+@F'RC$,H3RW+#L\KQ4,1=XNG6--B<1)Z[:N34+'C
MF["XXR24F);EVXEI-)TVQ=H6"\2<3@`+)R0<GCL#6HH=5MH%KBN'OOCB[)AN
MQ0:#[-22"4M"PBM;<UJSN_1?#`T@&,R:*_%2#FKFAB?2MIK2NLL"Q(@'"+MA
M<P9<F0]9+1.3PAS?T*H.I<5<X,KH#^4_8-\;"R+Q862_V.@9QI>=G09!:)M,
MB;W+`\28";"&Q0:$#"8R6+#")@2@9&25D5"4=WE!AV:708(7SX#&-0OK=Q%"
M^=WE"7+,$ZRPX\@9D!DJ-=`U&E^>*QSSA<M#)U'J7;T5PIXR0PQ!1M=861.3
MPM`6S@FG!;O+!^30!X2PTVQX$2.`F\?>ODTW25R>,P)YEQ%T:#9JTHJY879R
M@O.7W";/^#32RKW+$O0],+,$(9E>Q`:$O6.;2$P0C[*('&VF])@GW';?(H?>
M("1K8&Q`9^BYUA`Y-Q:4';.&V_Q4CEB$Y-9E0&?8N?[A2!$E=Y=!R*%!J,&1
MH`:Q&O34C=L@9<7<X8J"C+B"9*(?2P095Q!BJ&T(,"(2G;M%UE="]U\==:OH
MM1L\:*)B$1O0B6+$53`A`+$Z2Y$9PVT#IT8,0C*EC0W(%(F'$Q;N]T>:JY@]
MW$AOQ"8D]Z\N]=HW%0S"P2T@`031P@XOI<B<XD:*(X[A7"^B+BL$(<4PFML3
M@(Y!XDHMK%Y2ALPQ;F2(ID"\5MH:&(8(0H9*1`.&;GREG!I3AN_R#(6>`47J
MGQ2)P5-"`P(>/8B=I>0BA/)DYG%9:]2(:2C;(U-!UQ?<RQ'38C<LEY8ZY?4N
MVU`H^K1^W-0,Z&+]3N8Q5F+*DSF(GL3K#PWAW<#@VD!Q>S,@?*PY&$/,@$&I
M`JL%2`]?'>"3]3*O7_(DW^\;+ZM>]6L!`?<G_7_QE44,KRRZY_NS/@!O#([I
M2_XUK5^*0^/M\RTLG4]#&-(:WSG@A[8Z=@^VGZL6WA5T?^[@W5`.#^+G4P!O
MJZH]?="/TONW34__`P``__\#`%!+`P04``8`"````"$`OBQ%8:8"``"^!@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R45<MNVS`0O!?H/Q"\1]3#
MCT2P',0.T@9H@:+HXTQ3E$1$%`62CI._[Y*T%5MNF^1BBN3L>'9VM5I</\D6
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M7X!O&I6\HMO6?E>[SUS4C85J3R$AEU=>/M]RP\!0H(E2+X.I%@3`+Y+"=088
M0I_\NA.E;0J<S:+I/,X2@*,--_9..$J,V-98)7\'4.)$#23IG@36/4F21NGE
M-)G.WL&2[5E@?6%YHQ02TO(NW5)+EPNM=@@Z#X2;GKH^3G(@=O9,_FD/I.1B
M;ER0#P6T@9(^+K,L79!'J`/;8U8!,\=HP(P0ZW-$E@PD!/0-(L&WL<@,.N'O
M-3R(=$$CD?%`[_-8!<C<U\HEMCXZ.!$`SHP%O.Z2"X)V.7(@R:8C!0$S.<*,
M$.O_(4XT`LE8X^LFN:`"0]I#E;(L&VD,F$M?YZO3N_7Q7?I2X!-AT$[O%^:"
MQL(FIW^^"I@@;#X[O829X@C"93)_J7R0%N9%>!,DUS5?\[8UB*FMFP4IY#J<
MAC&U2G)H%WBI1^=K&%_^G`P7,#YZ6O.O5->B,ZCE%5#&T1P4Z3"`PL:JWO?G
M1ED8'/ZQ@>\$AT:,(P!72MG#QHVXX<NS_`,``/__`P!02P,$%``&``@````A
M`'2XZKZ7`@``E@8``!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULE%7+
M;MLP$+P7Z#\0O$>4Y%<L6`Z<!FD+M$!1]'&F*4HB(HH"2<?)WW=7C`793EKW
M(IFKX<S.[I)>W3SIACQ*ZY1I<YI$,26R%:90;973GS_NKZXI<9ZW!6],*W/Z
M+!V]6;]_M]H;^^!J*3T!AM;EM/:^RQASHI::N\ATLH4OI;&:>UC:BKG.2E[T
MFW3#TCB>,\U52P-#9B_A,&6IA+PS8J=EZP.)E0WWD+^K5><.;%I<0J>Y?=AU
M5\+H#BBVJE'^N2>E1(OL<]4:R[<-^'Y*IEP<N/O%&;U6PAIG2A\!'0N)GGM>
MLB4#IO6J4.``RTZL+'.Z2;+;!67K55^?7TKNW>@W<;79?[2J^*):"<6&-F$#
MML8\(/1S@2'8S,YVW_<-^&9)(4N^:_QWL_\D555[Z/8,#*&OK'B^DTY`08$F
M2F?()$P#"<"3:(63`07A3_U[KPI?YW021]-TMKA.`$^VTOE[A9R4B)WS1O\.
MJ.2%*["D+RSP/K#,H]DBGEQ`PD)&O<$[[OEZ9<V>P-"`I.LXCF"2`?'KCL`*
M8C<(SNF"$LC501<>U^ERLF*/4#KQ@KD-&'@.F&1`,!`=E$'M<F4$HS+6%E.Y
M#8&Q3/JZS.1_9!`,S1DEGRZG`V]0#ICI"#,;$$<&`7*Y003G-%V.:,]K&T`7
M2,-0C:5Q7B?Q-'IS9`\-QGU]%D.=0R2!<@_]3)=O&)X?J_Y]EA!\+!4B((5'
M<3PI,'"G;I)D@D?M'_.*&X\U0N3$SORD?^$>",=$2UO)#[)I'!%FAV<\A<$?
MHL/UL^G3/HU/LTT_LVSX`-="QROYE=M*M8XTL@3*.%J`%QLNEK#PINL/Y]9X
MN`_ZGS7<_Q)F/\8^EL;XPP+K-?RCK/\```#__P,`4$L#!!0`!@`(````(0`T
M3Z@3KP(``%,'```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)15[V_:
M,!#]/FG_@^7OC1,HI42$BJ[J5FF3IFD_/AO'22SB.+)-:?_[W<4T"@6Q[`N0
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MS!:A3SF&()F=9#]V`_AN22X+OJO]#[/_(E59>9CV#`RAKS1_?9!.0$.!)IK,
MD$F8&@J`3Z(5G@QH"'_IOO<J]U5&IS>4;*3SCPJI*!$[YXW^$UXF!XJ0/#DD
MPW>?',WF\30!K7^0L%!(Y^N!>[Y:6K,G<%9`TK4<3UZ2`O%Y(^``L6L$9W1.
M"=3JH/G/JVD\7[)GZ)@X8.X#!CY[3-(C&(CVRJ`V7AG!J(PMQ5+N0V`H,SDO
M,_T?&03#3`;%3^/;GC<H!\SU`#/K$4<&`3+>(((S.ED,:$][&T`CI.$\#*7Q
MF,Y@;)>GBTE="7V30R2!7O?#G,:+\V[A'`\E+TLA^%@J1$`*K]_PF$#90]YQ
M5C#IF#]$CJTD\7DKN*Q'WPD$'TN%R!DK,-PA+UJ9+R)H\N5F8=JQ0HB\,_/^
MFH4E%BZ[EK:4GV1=.R+,#A?4!*YO'^UWY[KK__OX=;KN=BKK7\!.:WDIOW%;
MJL:16A9`&4=S\&+#5@P/WK3=BMD8#UNM^UG!GY>$&QRC\<(8__:`@^__#E=_
M`0``__\#`%!+`P04``8`"````"$`>\]_+8D&``""'```&0```'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6RLF6MOXC@4AK^OM/\!Y?M"+D`@*HP*X1ZNVLOG
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M/7<;W08I]1_V$=T!:_9:$AYZVJ/A[`Q3:_0?\@;Z.PK?T\KG6GJ,WR=)M/>B
M2TBM33XQ!Y[B^(6%SO8,4>$&E![G#FR2VCX\^*^G;!>_3\/H^9B1W2VZ(W9C
MSOZ;&Z8!M2C)U,T64PKB$R5`_VOGB'4-:A'_:WY]C_;9L:=9[7K+UBV#PFM/
M89J-(R:IU8+7-(O/__`@HY#B(F8A0M="Q##KMJ%W+?M^D68A0M=2I-YIM9KM
MSB=$J+K\=NA:B-B?%Z&QD8O0]<<SZ18B=/WQ3*CG%/94FO;S-V18I0Q]^(EL
MVJ4,??CQEC'L4H8^?#J;!N_`^7AP_<SO/R3Q>XTF&>JBZ=5G4Y;A&&1=.1)X
MOQ5CX[^&!HT)IO+(9'H:94:]/J7Q_-:WS/9#XXW&8%#$###&D".&900;<$S6
M5<%(!6,53%0P5<%,!7,5+%3@J6"I@I4*UBK8J&"K@ET%-,@>X1'UXE_A$9-A
M'I6M.RC!AVFF8D@9419Q53!2P5@%$Q5,53!3P5P%"Q5X*EBJ8*6"M0HV*MBJ
M8%<!DB$T'_P*0Y@,/3DJ@\;L=F0'!CS&I)$I1E9+#AF*$.$2D!&0,9`)D"F0
M&9`YD`40#\@2R`K(&L@&R!;(KDHDT^@)^2M,8S(]S:0'E##$,FW9DD$1]#W7
M1(AP#<@(R!C(!,@4R`S(',@"B`=D"60%9`UD`V0+9%<EDFNT))%<N[U"*Q]#
M+#HWIVS4`2=&4\QZ0R!N48HNPE*SU90M'8F@4GH,9`)D"F0&9,Y))<4%$$^4
M^DC1TG4YQ:4(*E-<`5D#V0#9`MEQPE.4[*$ES2?L8=&R/9Q4[GT(Q"U*40X5
M>Y3%Q4@$E?<^!C(!,@4R`S+GI)+B`H@G2GTGQ:4(*E-<`5D#V0#9`MEQ<L,>
M6I!)]O#579V]&F3'*'@9Q-2DM.RX,:HL6L7QM1T3D5WCI-(D0R!N48I2$ZY9
MNK+@&XF@LDG&0"9`ID!F0.:<5%)<`/%$J>^DN!1!98HK(&L@&R!;(#M.;KA&
MCXV?=XV)R*YQ4FF2(1"7DQ8S_ZUOZH8E3S$C\7O9&F/0F`"9BE*%JK+,G(G?
M2]4Y:"R`>*+4[5R7XO=2=04::R`;4>IVKEOQ>ZFZJVI(DR.M$20?;XPRVBXH
MAQF+E@WCQ*)^4AE"2ML->9#1%@\X]T8QHZ/.ET4Q.S?:Z'0[NOHX&8/R!,CT
MGKIF_U_7')070+Q[ZEI*=5FF:<!]K4!Y#61S3UU;N:ZNA77MJLI2WS!HS^H3
MG2,/EWM'@2SJ?I7NH0S885DPWP\K7JI9U:3U@49%E*WS[F"U:#]265V,46F"
M:(IHIHAWVB@^QV(+1!ZBI2QNVG8;,E]AL36B#:*M+&Z93=)6FF4G%9,M9N_S
MN+?RR:>OP7<%Z(6CG'`&!5(F!F7!.BRBJC-#@9H?6J,"V4;N?%NG5:5RAV,4
MFB":HO9,UF[IK/GDY\D<A1:(/-1>RMJ&SL:>(KY"I36B#8IO9?&NW@7MG20D
MV\YV#7[>=K[W(-E>H(]Q.V0[G?)0=@O4HFXCI@6<_HLHV\QMMSJM6[Z#^`3K
MF]Y5WTRNKVFV;_4%J&^!]7EWU;>4Z[-UG?Z@>T!]:ZQO<U=]6[F^CLX>ITI]
M[$#CPRS>9?@!!=^0/8?)<S@,3Z>T%L2O[/"!AF[_06!^,N)V'%J$T52@\&G'
MH644<J_CT$((^:;CT%(&.9V\/.8'+XK^@)W(W(@?F`YMDZ'.P')H*P;Y8]-Y
MI(;`'P9-AW8!D+LMA]Z9D7LMAUY4D;MMAU[BD'MMA]Z<D+NV0Z\/R#W;H34[
M\89H"3H!NOK/X=)/GJ-+6CN%!S))S^?SA)\A\2]9?,W?JI[BC,Y^\H]'.NL+
M:4=;K].KUR&.L_(+JT"<'O;_!0``__\#`%!+`P04``8`"````"$`ST`%EM0.
M``",20``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RLG-MR&S<2AN^W
M:M]!I?M0FN%!%,MVRCS,B3.<0V5WKVF)MEB11!5)V\G;;X-`#X#^QXSD)!>1
M_*'[!P8-8(`FQ'>__O'T>/%MLS]L=\_O+X/>]>7%YOEN=[]]_O+^\C^_1;^,
M+R\.Q_7S_?IQ][QY?_GGYG#YZX=__^O=]]W^]\/#9G.\((7GP_O+A^/Q97)U
M=;A[V#RM#[W=R^:92C[O]D_K(_US_^7J\++?K.]/3D^/5^'U]>CJ:;U]OM0*
MD_UK-':?/V_O-O/=W=>GS?-1B^PWC^LCM?_PL'TYL-K3W6ODGM;[W[^^_'*W
M>WHAB4_;Q^WQSY/HY<73W23]\KS;KS\]TG/_$0S6=ZQ]^@?(/VWO]KO#[O.Q
M1W)7NJ'XS+=7MU>D].'=_9:>0'7[Q7[S^?WEQV#2]`>75Q_>G3KHO]O-]X/S
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M[@W72;^8.D=G'*_T.#H-R_GZN/[P;K_[?D%SG4;*X66M5HY@$E`?\X#47=4.
MT1^-4!J:2N6CDGE_26VAP7>@:?7M0S\,WUU]HZEP9VRF:!/X%C.V4.->R<XE
M6$@021!+D$B02I!)L)0@EZ"08"5!*4$E02U!XX`K"D\;(QJ1_T2,E(R*$??N
ME($-F@C9C"W892[!0H)(@EB"1()4@DR"I02Y!(4$*PE*"2H):@D:!W@!H7D.
M`1G1NZ![%><YHKQHO7;F2#@4,V"J;4*:B.U$&HI)TIJT00&R`!(!B8$D0%(@
M&9`ED!Q(`60%I`12`:F!-"[Q8D0O-XB1>M.^<6%3,O2ZI;=)&Y!^V/=#,C5&
MYZ+6FK11`[(`$@&)@21`4B`9D"60'$@!9`6D!%(!J8$T+O&B1@'RHG9^1BGK
M4W"X4Z>:#.PB-],D..WI]$O%>-&/-J3A<."'=-$:L70$)`:2`$F!9)HX#5H"
MR5LOMXEB(2A:(V[B"D@)I`)2`VDTT4WTPD.[E#>$1UG[X='$#8\F3F_,C1>U
MP0G/2(2G->)GCX#$0!(@*9!,$Z=!2R!YZW6FB45KQ$U<`2F!5$!J((TF'>&A
M_9<7'KV9ZZG]Z_%A>_?[=$==2KN,CEG5ITV;WLHI$3]JFKA1T\3II+GQHJ:U
M40ODVVW1&G&71$!B(`F0%$BFB=.@)9"\]3K3Q*(UXB:N@)1`*B`UD$:3CJC1
M:^/O1TV)^%'3Q(V:)DXGS349JN!_^Q!>!^+%MFC+N3<BT(B!)*V7416[RK0M
M9]4,-)9`\M:KNZU%6\ZJ*]`H@52M5W=;Z[:<51M7PUL<:8_@Q;%CEM$AE*>9
MLO8#IHG:H[13B`[9_L(W,T:C=A<_UZ1/PZMU"\9RO31N8WTTN_9%(Q"-@22O
MJ2;UJQ'OU`Q$ET#RUU13>-4,Q;.N0+0$4KVFFMJK9B2J:5Q1;QP$=!)XPT`X
MF?LCP:"`JFAC.I8C@?U."2=S7%8UDY1%"V,UT)$?B#U$A"(QH@11ZNN.Q,*1
MH<<248ZH\'5OQOY(7:%'B:A"5/NZ05],@<9S\<.ICN68(GGC6S70AWLZ2/!"
M,C7(F_!C\<`S-G(FO$$#*[4P:'BM%_)0'"LC5(D1)2B<"N$;,7XR5%DBRE&X
M\(7[@UL9:-U?E!?C_BI1N$+AVA<>C,4BU'@J?J#5<?_O!UHG#;Q`:^1-YW`(
MD3:.=O+.52Z2YO.0^J)=!W!M9ZM0!_]6+%21*7=6A1A1PBIGZTK92M?5OQ&O
M]@R%EXAR5CE;5\%6NJ[!6*PQ*Q0N$56L<K:NFJUT7:,Q+`]N</Q1HS(0YT;-
M;[N7'VVZG>U`8!(9[I+?#\7@G;(5[4':`2&FY,S:\,R9(UH@BA#%B!)$*:(,
MT1)1CJA`M$)4(JH0U8@:#_EQ5#D)-X[GMV^TBY;[-X-&_7;)FC%RL@_LZ&_S
M1*`7UHJ#&"&*$26(4D2902/;KB6BW#K:T18.Q7@KK!4W=86H1%0AJA$U!NFF
M^A&C+GQ+Q)2YV&=IY$7,(-LS<_6"5H[THYUTH=QU+JP5=T.$*$:4($H1909Y
M$8.FYM;Q3%,+:\5-72$J$56(:D2-05T14YD+=X[]5()"?58F`ZF1%TB#W$`:
M1_K1!A*3%"QO=QX1HAA1@BA%E!GD!1*:FEO',TTMK)4-9/N,C$JTJA#5B!J#
MN@*IDAE_/Y`F26(WLM-`(S=K81"M`_Q$<X-^G+>P!NP3H4R,*+&.W?F`U!JP
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M9I@91W>6(UH81+<EU,OJNB<SU1'ZQ(@21"DHBP1+ACY+1#FB`I3%HZ_0IT14
M(:I!6;2Y\7S\L*J,Q.L7[]`D,)R]ED%BALHT,UO9\3HW:'0VI;)@*Y.6ZHD-
M0(3",:*$5<[6E;*5217U;D2$,E1>(LI9YFQE!5O]X,%6*%PBJECE;%TU6_WH
MP1I/V1\@W8FI-]^`"3LS4V(AG[(5;>':39^PF5D;WIS,$2T018AB1`FB%%&&
M:(DH1U0@6B$J$56(:D2-A_Q`OBTS%6)FRB#W>,S(.56QH[?]OA%OVX6UXB!&
MJ!4C2JRC'2&A3""GUHKE,]1:(LJMXQGYPEJQ_`JU2D25=73EQ6)96RN6;SPM
M/ZXJ?_.&%5RG>]SMMTI)T;O:BZM!;ER-(_UHIV9X(Y;CA=&B']STB.6M5HPH
ML8ZNO-A`I]:*Y3/46B+*K>,9^<):L?P*M4I$E75TY<5KN+96+-]X6GY<50KF
M#7$U&1OWS:R1%U>#;"SFH7%TXQH,Q2%I8:VXZ9%!3@HJ1I181[=GQ-DNM58L
MGZ'6$E%N'5UY\<HHK!7+KU"K1%191U=>?,I86RN6;SPM/Z[_2-(KQ*2705ZX
MM943HCD[VKSD`E'$6G:<Q(@2=$P19>BX1)1;1[>GQ0:LL%;<TRO4*A%5Z%@C
M:CQ'/VHJJ?2&V:AS4-XJJY%*:]OU4WY".%-WMFDMIIPI/^`<T8*1/J/?RL_3
M(RZW*C&BQ*#S=WY2=C2IAV'O6BQK&5O8VI:(<D2%02/KN$*K$E&%J$:MQK/R
MH_FVE!6%$0ZS&JG4AQ--\3:<L:/S83RBA4'F<DV_+U:O"%UB1`FBU!<.>[="
M.4.?):(<46'0R&:75FA5(JH0U:C5>%9>Y/IORRB=S/TTA$%B'HKWW8RM[-"<
M(UHPHDGKC`*Q:8G8RFK%B!)$*:.S\AE;6?DEHAQ189`[_="J1%0AJE&K\:S\
M(-)IU5M,?^H#O+Y2$;'52,Q*L=F8L:,S*QGIOW!4'R,L#.K[,US,H(BMW!`%
MM^*T$[.\K3%A9&M,64NGYH(A9+4R=K(Z2T0Y(RM=&#0:MZ^5%5M9K1)1Q<AJ
MU:C5L-5)RP^US"_]7*@Q[=372$QCL5^8L96=&W.#Z*#,;]@%H\$IFQB$H=C@
M12@3(TH,&M`2U:X&<,\J9:M`5Q;TY.$U0^DEHMP@YSD*7_J&/OL0U^%0ID14
ML<S9YZC9RLT\A?)V5>/)^R.C,[%$?X9,O:?^RH`O/+W^3P[Z;8J)(SLU2"P(
MXKP]8T<[%>8&C>QQ:F'04"?1QH$8:Q&JQ(@25G&[K6.0Z$<Q==%2T!>AS%!Z
MB2@WR'F,@AN@'V/4D]N-%<J4B"J6.?L<-5O19&VG1,<@,8'K6#YDTDHM'^'`
MWIK]B5&"B2WZ4_W3IMO?FHMM[HRMW+7$:+EKB48#/;W'`Z$2H4J,*$&4&N2\
MK3.T6B+*$16HM4*K$E&%J$8M]=4']A"C)[W^*@/]-^-/F_V7S6SS^'BXN-M]
M55]30`?4#^]:K+]#@7+!$Y7.I+DL2B@91B6GK:<HH>]=^!AV>$SI^QA.;S!A
M/PU)J,N>JNZJ^>-@\I'N>&*3IM2BTUE95/`QZ%.+.CVH1-TC1*V/].`?J0NQ
MA)*,$W7>Q1+*-4[4L1=+*.4X40G%KI(AE9P2=:+5E/:@DM,XAY(;*NFJA_*K
M$W74QWHHS3I1)WXLH6SK1.52NTJ&5-+5-LKX4$E7VRB%0"5=]5!J>:)2&E@/
M99@G*K.!)91HGJ@T<E?)D$JZVD;)+BKI:ANE2JBDJYYY,)ZHRR@=]5")ND>"
M)71)9**N@&`)W>^8J-L;6#*EYYEVMF!&);/.DCF5J$P]JLW#(95T]0'E$ZFD
MJP\H]40E77U`MT8G2YWR$..-+H_2\W2U@"XI4DE7"^C6&Y5TM8!N@=*<ZRJA
MNV`4A:ZVT5TNBD)7"=W%HBATE=!=*FI!5\F<@MT5G81"W<5S"G07KRC,77Q*
M3SCM?$*Z1#R9=9;,J43=[NV(,O6QND7:54(CO5.-+@5/U.W$#A\2Z]+**9!=
M?$Y5=.GD%-XN/J=`=?5Y3L$X\:MV<-%WX;RLOVR*]?[+]OEP\;CY3"^AZ].N
M8J^_34?_XV@NW7_:'>E;<$[W[Q_H6X\V=#Z\5AO5S[O=D?]!#WS5?H_2A_\#
M``#__P,`4$L#!!0`!@`(````(0`2+:$3D@@``#,I```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;*R:VW*C2!*&[S=BWT&A^[$X6"?"]H1UX"!`'&)V
M]UJ6L:UH23B$W.Y^^\FB**#J9SS23D=T-/)'9E91?V45)-S]_N.P[WW/3L4N
M/][W]1NMW\N.V_QY=WR][__G#_NW2;]7G#?'Y\T^/V;W_9]9T?_]X=__NOO,
M3]^*MRP[]RC"L;COOYW/[]9@4&S?LL.FN,G?LR.=><E/A\V9_CR]#HKW4[9Y
M+IT.^X&A::/!8;,[]GD$ZW1)C/SE9;?-%OGVXY`=SSS(*=MOSM3_XFWW7HAH
MA^TEX0Z;T[>/]]^V^>&=0CSM]KOSSS)HOW?86M[K,3]MGO9TW3_TV\U6Q"[_
M@/"'W?:4%_G+^8;"#7A'\9JG@^F`(CW</>_H"MBP]T[9RWW_4;=2?=H?/-R5
M`_3?7?99M'[WBK?\TSGMGH/=,:/1)IV8`D]Y_HV9>L\,D?,`O.U2@?C4>\Y>
M-A_[<YI_NMGN]>U,<@_IBMB%6<\_%UFQI1&E,#?&D$7:YGOJ`/W?.^S8U*`1
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MZ/N#,1W?#;[3TK&M;&9HH\L6<V'!U@D6=J&"I0IL%3@J<%7@J6"E`E\%@0I"
M%:Q5$*D@5D&B@K0%!B1/K1'EPJ_0B(5A&HG1G0G0$DT11%@(EX4*EBJP5>"H
MP%6!IX*5"GP5!"H(5;!60:2"6`6)"M(6D`2A%>97",+"T(8G)<U$5F#&;0S*
MS#JSAK+)O#:I50*R!&(#<8"X0#P@*R`^D`!("&0-)`(2`TF`I&TBB4:+_*\0
MC86Y[QNT*]:"X%)7&7VE6FU2JP9D"<0&X@!Q@7A`5D!\(`&0$,@:2`0D!I(`
M2=M$4HUV9$FU[AM+L0TQZU(<,:@S3DS*Y)9<4R6#:B/AM@"R!&(#<8"X0#P@
M*R`^D`!("&0-)`(2`TF`I&TB:4&W.%=HP:QE+3@Q^<T[V]_G0!9`ED!L(`X0
M%X@'9`7$!Q(`"8&L@41`8B`)D+1-I(&G^ZHK!IY9RP//"=WFBOD]![*HO$C\
M)E&&MW*B+&LC$<@&X@!Q@7A`5IRTNN@#"6JOIHNFILE=#&LCT<4UD`A(#"0!
MDG+"NRC)0\O\%?(P:UD>3EK7/@>RJ+QD>4;RM2]K(W'M-A`'B`O$`[+BI-5%
M'TA0>S7R&$.EBV%M)+JX!A(!B8$D0%)..N2AK5J2AS_BW+`'[O/;;OMMEM.,
MIWOOCJW%I$<9_H##@LBJ<=(:DCF01>5%B5TGE:DI3SW+VD@,B0W$`>("\8"L
M.&EUT0<2U%Y?=#&LC407UT`B(#&0!$C*28=JK(KPSV4KH\BZ5:@U*G-$BPH-
MV0R@AUE--Y5<:PS$F-@8QD'D-HY59$..[#4&(O(*P_B(@L:QN\]A8R`BKS%,
MA"AN'+O[G#0&(G(JA9'62YT]Z+:+#AV91W4TD7JEN:(A?U0V:4EN)98RD//*
MD4HSHE.+"DF.^D19I);"<5R*KT^F$TW=9VQATP1W$+D7M><)QR_:6PF;ICT?
M47!1>Z%PY.V9AJ'#]:V%3=->A"B^J+U$.%;M34UL+Q4V97OR=&&/X5=,%_[4
M3D]H0O49JR;2ZFW2%M&:+DI&SRLKHZQX5_6G*E:#EI756.-SPQS2&P?E'L3&
M2`XB%Y&G!)^,,/@*W7Q$`:)0#FZ,QR/H^1K=(D0QHD0.;AJW%%L9EE1RDR5F
M3^UMB?^O/9I5?I5-ND)2OIN:<EL[KZRDA8+'NFUFT;*R&NNE\B.-[CV5*[0Q
MD(/(K5`KMB?''FIL^.1M886!?$0!Q@[EV+K&DD\)OL9($:(8@R=R\*DVA=BI
M%$B6G3WV_W/9J^)!(]6,-O=R)C1Y.T>TJ-"0-I-Z6>C8#'BLL5'*;DZ&7;I#
M>PZVYU[4GE=95>W=&J.NN0#M^=A><%%[H=S>6-/H'TP/:"_"]N*+VDOD]B8:
MVUN5]E(IN#QE6'7BJRGS1_[^5W?S[7L*%D:YI^"(2D5BWYBS]T%LWVC0`M$2
MD8W(0>0B\A"M$/F(`D0AHC6B"%&,*$&42DC6B!4RVAK]S?T=KWM(&W95"FD&
M?LY>L*E:`%JBE8W(0>0B\A"M$/F(`D0AHC6B"%&,*$&42DC6@E4MVEJPG=4P
M;FAF7_N*KZJ(M)=9CJ3JJJFI[R?TVDHDU@+1$I&-R$'D(O(0K1#YB`)$(:(U
MH@A1C"A!E$I(5HX5--K*_4T65161MCP<M9:O.7O%JV81H"5:V8@<1"XB#]$*
MD8\H0!0B6B.*$,6($D2IA&0M6)GB"BVJ.D=;"XZ45%$>/.?TJ0[(`VB)5C8B
M!Y&+R$.T0N0C"A"%B-:((D0QH@01^XZI&1PN#_\NB7_0<,A.K]D\V^^+WC;_
M8-\<&:QX4V/^0=1,GXHOHM0S0XM>?=`2I?*1197Y#JZ3`VV"76?(A9;DKC-C
M.E.^@E=;T2=T9M+A0Z4H:TG%%(Q&I22+58OP#)6"+%;MP3-4RK%8M0;/T*=B
MC^5^"SVCCG78SPR+7I!CG)EIT4M8Y(^WUB-)B"=FMQ:]_T.^&%OTH@!Y,+:2
M+KZ86%2Y[K"?6$D77TPMJIEVV$^MI.2#>B3HD[7WS6L6;DZONV/1VV<O-+VT
MLH1\XA^]\3_.U<WG4WZFC]7*^]`W^C@QHW==&MMR7_+\+/Z@A@?UYXX/?P(`
M`/__`P!02P,$%``&``@````A`')6<M("!0``31(``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3@N>&ULK%C+CN(X%-V/-/\09=^$O"!$0*L@Y*49:32:QSH$
M`U$E,4I21=7?][4=A]BF$=WJ3:5R<N^Q?7Q\;;/\^E&5VCMJV@+7*]V<3'4-
MU3D^%/5II?_[3_C%T[6VR^I#5N(:K?1/U.I?U[__MKSBYK4](]1IP%"W*_W<
M=1??,-K\C*JLG>`+JN'+$3=5UL%K<S+:2X.R`TVJ2L.:3F=&E16USAC\YAD.
M?#P6.0IP_E:ANF,D#2JS#OK?GHM+R]FJ_!FZ*FM>WRY?<EQ=@&)?E$7W24EU
MK<K]Y%3C)MN7,.X/T\ERSDU?%/JJR!O<XF,W`3J#=50=\\)8&,"T7AX*&`&1
M76O0<:6_F'YJFKJQ7E*!_BO0M1W]K[5G?(V:XO!'42-0&^:)S,`>XU<2FAP(
M!,F&DAW2&?BKT0[HF+V5W=_X&J/B=.Y@NET8$1F8?_@,4)N#HD`SL5S"E.,2
M.@!_M:H@U@!%L@_ZO!:'[KS2[=G$G4]M$\*U/6J[L""4NI:_M1VN_F=!=$0#
MB=63P+,G,1=/)SM],CQY#R:>ZSHS;PX]>-`J?*5=AV>?.)\XECOW:-<?),[Z
M1'CR[O[PD&']T,;AV7-8$].9SHAJ#YH&66@://LT][G!FN`,-E'$(OTD/-MK
M@TTZ]5"0==EZV>"K!@L3IK6]9&29FSYI@;N'C6#PT_?L!#XB+"^$9J7/=0V<
MTL(:>%_;EKDTWL&W>1^S46.DB"V/("8EM($,[&0@E(%(!F(92&0@'0$&R#)H
M`V;^%=H0&J(-']6&`S>Q+%&J+8_@*8$,[&0@E(%(!F(92&0@'0&"$/8=(6PP
MR_T2PSU!LJ"8C#QA>M*,;UB,!6MH,(XK:3&$#&(HR$Y!0@6)%"16D$1!TC$B
M:`+%ZE>8@]"L=`NJP2"`Z4EVV/1!CU0:0@:5%&2G(*&"1`H2*TBB(.D8$52"
M6BBH]-@Q))J*P0>Q88CI#(MGJR!!GP6/FX2N9+3=$,2I0X4H4I!XR!I1>XYH
MT&0(XM3IF$B0`_8;00Y6;2=DF^O.1?ZZP3`$*$=W9+*AJK):2TA$E1@R5DE!
M@CYK1HNS-35M<12[X3L?1:AP1`H2#UFDY*NLR?"=LZ9C#D$;V#P$;>YH`%LK
M%X%$BR(PQ![O0:8G%Q,69,X&/P5WTV:2.'V:1\5S%Y*Y0H4U4I#XF782H1W/
MEGJ?CED%[:`R"-K]E*\(B2@I0^QQW3&]N:C-MD^CAU2V:_<(.R&2?7S7$RV8
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M6SYL.A(>NS[LURH>S'S8`54\GOFPAZDX7.I?K#OXAESV[^&6#Z=KE6=C^W#$
M5/$7QW\!(=0/&\>'TQ;@QC`RN,Q?LA/Z,VM.1=UJ)3J"*%-JL(;]',!>.GRA
MAXL][N`:3_\]P\\V"`KT=`(GD"/&'7\A#0P_!*V_`0``__\#`%!+`P04``8`
M"````"$`KC6S#MH0``!-9```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
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MOON_@/NG[=U^=]A]/KXC=Q?^1#'F]Q?O+\C3QP_W6XK`I?ULO_E\<W[;7-NK
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M[OL9K20:A\/+VJW+YMJYC</M`QXFP(_&GP;>>;EU;F[.E^=G-+0'FK2_?YPV
M5Q\N?J>)=A=L5FC3<(LV6KA9Y=QV)1`ED"50)=`E,"6P&;B@M`RYH=GW5^3&
MN7&YB5&M(DC)FA2)B!:Q2U<"40)9`E4"70)3`IL!E@A:59"(V0]K0IP3KA>M
M_FQ.--,Y#W3E;2:T=H:)4YBT@\F0#"`"B`2B@&@@!HC-"<L)51C(B:N3(Q>.
M<W-S/J$:,"2@F2Z*+`6C4UD:3(8L`1%`)!`%1`,Q0&Q.6)8H(2Q+]:M(G#'.
MND]&#&+ER90*TX_3TPY&L5L'1`"10!00#<0`L3EAL=.%843LSIK'[LG47QE=
M.6R!=$`$$`E$`=%`#!";$Q8HE7T6J+N&N/(P<BDX-SP#GDRI+&6CO^2+HQV,
MAM$'(H!((`J(!F*`V)RPI#@]_!=<6)T;J`_EE348G:H/@\F0)2`"B`2B@&@@
M!HC-"<L2U3V6I=/UP5GS&>+)E.I/-D.*]+2#T1`[$`%$`E%`-!`#Q.:$Q>[D
MUHC@>W,>?4"T0&)D+:(.D4`D$2E$&I%!9!GB,3NM52Z+Z?3=<GRY:+QLHTMG
M#'X54%$PWA<%(UG%CATB@4@B4H@T(H/(,L13Y%18GJ+3:Z+QHHVEP2,V+0!U
MH6-F)1!)1`J11F00689XS$YFC8@YJ+)\Z#WB0S^[+(=^L$I##T@T@"0BA4@C
M,H@L0SP-3D?E:7CKW5C08U1Z4EF<%7=;JV90;<FJ%-_))B5LZ!:10"N)2"'2
MB`PBRQ!/F!-?><)>62M>J[&UXA%7F&6J6B?LZ<I#5C'F#I%`)!$I1!J10609
MXFEPTFQ$&KR28VG(Q5U_[]TV@#I$`I%$I!!I1`:198C'[)17'K-;*\NK-UU)
MO(AC^1AT75H;S:R\36\&JS0M``FTDH@4(HW((+(,\10YV56FR,VBD<*\"?*-
MEY,IKZVK:$7&0]&!<I(+P;#%`T@D3S&M$I%"I!$91)8AGC"GU?*$O5).O+1C
M\\8C+DAG1:K:9K"*`7:(!"*)2"'2B`PBRQ!+PV2<,.W-N3`-*-,6+:(.D4`D
M$2E$&I%!9!GB,=>$Z63R;OQJF:`N#:@0)S.^@-ID-<P*1`*11*00:40&D66(
M9ZC4I6\4)Y-!L*8ZT<R*2K&*5J>J2;))"0O.KX8+M4`KB4@ATH@,(LL03YB3
MD3]?329>=>;5)*!"G!2I:I-52D-0L$FO"+22B!0BC<@@L@SQ-)2B]G11G0S:
M-4:S"HB*:D0MH@Z10"01*40:D4%D&>(Q.[V8#[U;*_.%>V(V]N+KNA2;'@$5
MY:38-&Z35<Q:AT@@DH@4(HW((+(,\125FO6MY600LWDY*38)5Y-@=;*<##8I
M88!$\A2M)"*%2",RB"Q#/&%.6>9SZI5UY(4H*R=!F[+=]%F1JG8R6,4`.T0"
MD42D$&E$!I%EB*?!Z<41:0CR,MLJ<$^;W,U<MFN&J$,D$$E$"I%&9!!9AGC,
MXW0IC3F4C*`XZ?(XB/-F5FZ4AHY99CI$`I%$I!!I1`:198BEP5T'V="_L63T
M?LI-]5FQ3;B*5J=*1K(9U@HB@4@B4H@T(H/(,L035HK:TR6#'C65\R8@=XAL
MWA2I:I-52H/W11TC$F@E$2E$&I%!9!GB:2B5ZRMI&`1J//65N]2ZDI$]BT/4
M(1*()"*%2",RB"Q#/.92?+JU\K:-]BD*TX#<X=.TF)>[K<DJ)K)#)!!)1`J1
M1F00689XBL8)4W=/7PBQ@"@-,<`648=(()*(%"*-R""R#/&82V'ZRE)`\3GU
MB/9D4\R`NF#EY%\V08H=:)&LHB^)2"'2B`PB&Y`_59X&I^MR$>&O)/WFX?%A
M>_=UM:/3IA)62<^47F_R+SU-@SK,M$5`+#O>*D-=[+CHWY2:7#;%!I%(!BDQ
MX$;AP73JZ-[!(L_%EJ5)!M&S96YXFL9)SBE*SH"RX%M$7>S(9TMQZB)9Q5.7
MB!0BC<@@L@'59LLXR3E%R1F0VWO-ED,QZFVT6@Q+JT,D(EKVDZ>93(JKL8P&
MR8U"I!&9B*YZS^^O"GEH8WOOF$^44J"^;3VA;IUZY/8JL\25.V?!BG;WXLSH
M(DI7;!'1Q"<.7E"4T2"Y48AT1,FSB2AXGI=#8J-![YEE;E;7M",K4>^%;\$&
M1`]08DY:1%WL.!VL1$0S7YSFY0VB1#<*D8YNDF<34?3<%+>>EKGA:2J5;#G!
M?MN]_*A@TT4H5NP9*MR`<FF'J$,D$$E$"I%&9!!9AG@N2CGK<S%Z9VDVZ-Q\
M;16[BZMH=>HV*-G$N=8A$H@D(H5((S*(+$,\8:46KES5\TF">G?F$;\-FA>I
M:I-52L/0,2*!5A*10J01&426(9Z&<7IWAGHW(+96O%6&.K02B"0BA4@C,H@L
M0SQF)TU+H?>VC5CW1F.A_P,J;H/*C=AD%>=`AT@@DH@4(HW((+(,\135M?#X
M<C*HX;R<%"5^-0M6)\O)8),2!D@D3]%*(E*(-"*#R#+$$S9.%<]0%0?D;M,R
M55.DJDU6,<`.D4`D$2E$&I%!9!GB:1BGBF>HB@/*:D>+J$,D$$E$"I%&9!!9
MAGC,-9WKEM;(-RIFJ'0#*FI)(<';9)7FA/>5;4((M)*(%"*-R""R#+'\S$LU
M>_I*VYMSV1I0/B<0=8@$(HE((=*(#"++$(^YE*:OQ(P2=.Y1,?3%;5V;K(:A
M1R00240*D49D$%F&>!I*5?I*&@;Q&:-9S3VB79N(6D0=(H%((E*(-"*#R#+$
M8QXG+.<H+`/B0[\H-U*35<Q,AT@@DH@4(HW((+(,\32,$Y9S%)8!L:$/PC+-
MA@ZM!"*)2"'2B`PBRQ"/N126KTQW%(]SCXJA+[9(VV25AG[H&)%`*XE((=*(
M#"++$$^#TV6YOGXE#4'&93NF<X]8P0?4H95`)!$I1!J10609XC&/TW]SU'\!
M4<R9_EL4^YUMLHKCW"$2B"0BA4@C,H@L0SP-X_3?'/5?0)ER:1%UB`0BB4@A
MTH@,(LL0C[FF_][V5&V.$C"@HB*4N\3)*DT+E(!H)1$I1!J106098BE:C).`
MO3F7@`'ETP)1AT@@DH@4(HW((+(,\9C'2<`%2L"`^H=JW/4X6;5`6150Q?4X
M];)`]1(0&REOE:$.K00BB4@ATH@,(LL03^<XJ;)`J1*0>VB6[MT7Y1.)9#4L
M4D0"D42D$&E$!I%EB*=AG'I9H'H)*!OG%E&'2""2B!0BC<@@L@SQF)VJR*6*
MVS9_TQO>"Z]/Z$6E.+BK@"@=^:PH-XB35>S8(1*()"*%2",RB"Q#/$/CA,T"
MA4U`;%9XJPQU:"40240*D49D$%F&>,SC5,P"54Q`Q="7F\#)*@V]]Y5E1J"5
M1*00:40&D66(IZ$4-J=U_`+%2T!9-"VB#I%`)!$I1!J106098C$O2Z7RYH+0
M>^(B)J!B5I1;O,EJF!6(!"*)2"'2B`PBRQ#/T#A=LT1=$U`^*Q!UB`0BB4@A
MTH@,(LL0CWF<X%JBX`JH&/IR)S=9I:'WOK)D";22B!0BC<@@L@SQ-)3B\(T/
MF9>#:LPOC,7>YBI:444<1%5Y\4PV*6'!>?9K'[22B!0BC<@@L@SQA(U3EDM4
ME@'QA\R+(E5MLDII\+[R=VW12B)2B#0B@\@RQ-,P3EFZ[SX4#U4#RC>$$'6(
M!"*)2"'2B`PBRQ"/N526IR^>2Y2/`?&2L2RW@9-5&GKOBY4,0!([*D0:D4%D
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M6@E$$I%"I!$91)8A'O,X:4E?!RXU54#%T)>;ELDJ)JM#)!!)1`J11F00N6\;
MN[/W8^'3X+]5[#];^[39?]FTF\?'P]G=[IO[#O%[]];U@,-'DI?+ZUOR1'$4
M+:0;KMTEN=9R12W]K03T>4\M_6Y?V7)U25]C[M_JAA;WG>;^'7%HF5!+_Y,A
M:)E22__"-+3,J*4>#YT!W<'7XJ$SH/O<6@N=`=WZ8<OM<GI]2PH/6^@6C?I4
MSVU)YT8W!+4^<VKI'^"7\2P7U%(]SH*\T<9UQ=N"O-'V;JV%O-&V9JV%1ILV
M_VHM--JT'U9KH=&F7:-*RYR.0\^%:RUT''I46FNAX]`#Q5H+'8>>HU5:%C2F
M]+2IUD*C0$\W*BUSZD,O*=5::![0>SNU%IH']'9+K86.0R]\U%IH?.BUB%H+
MC0^]*8`MM[/)]2V])8<M]';YM7MQN]9"9T#O,M=:Z`SHC=]:"YU!]3BWLP7-
MZ_IQ:$SI7<^:-QI3>OVQUD)C2B\)UEIH3.GU.&RYG5Y2#JJC0"WN-[S89S6E
MD?/WP>7ZF5+>?(F$%LH;_>:QYHWR1G<*E989':=Z;K<3&CEZ-;[2AUK<MT]J
M+70&]#F06@N=`7TTH]9"(U<]SNV$1L[?\I214HO[7$+-&XT<?4&@UD(C1[^S
MK[70R%6/<]O,KF_I(UN5/M3B/DY7:Z%XZ-=>M18Z:_^CG#*>ALZZ>IS;YHIR
M4)T[U.*^9U4[#L5#/YNJM$QHOOF?2I5G,*%Y4#^.6]HU7Q1,=00HE%K&;BD0
M^OQAY:0HCFH8%$4UB(:"H,^,5CPU%`1]7;/60E.6OD%9:Z$I6STO^B'KM?MI
M*?:A'W%>N]]I8@O]")/ZU%KHAX[44DU,0R-<\;5RP=2X6WTU[E9_A=_2'*X=
M=^5JJ;._&.8"_6,.+^LOFW^N]U^VSX>SQ\UG$EF7_0_2]OZ?@_!_.89?7'W:
M'>F?<>A_?/5`_VS'ACY4?>EN6#[O=L?X%W>`X1\"^?A_`0```/__`P!02P,$
M%``&``@````A`%8W?#;6`@``-P@``!D```!X;"]W;W)K<VAE971S+W-H965T
M,34N>&ULE%7+;MLP$+P7Z#\0O$=//QK!<N`T2!N@!8JBCS--41(1411(.D[^
MODO25B7;3=2++*V&,SN[Z]7JYEDTZ(DIS66;XSB(,&(ME05OJQS__'%_]0$C
M;4A;D$:V+,<O3..;]?MWJ[U4C[IFS"!@:'6.:V.Z+`PUK9D@.I`=:^%-*94@
M!AY5%>I.,5*X0Z()DRA:A(+P%GN&3$WAD&7)*;N3="=8:SR)8@TQD+^N>:>/
M;().H1-$/>ZZ*RI%!Q1;WG#SXD@Q$C1[J%JIR+8!W\_QC-`CMWLXHQ><*JEE
M:0*@"WVBYYZOP^L0F-:K@H,#6W:D6)GC39S=QC$.URM7H%^<[?7@'NE:[C\I
M7GSA+8-J0Y]L![92/EKH0V%#<#@\.WWO.O!-H8*59->8[W+_F?&J-M#N.3BR
MQK+BY8YI"A4%FB"96R8J&T@`KDAP.QI0$?+L?O>\,'6.DV4P7T9I#'"T9=K<
M<TN)$=UI(\5O#W*.>I+D0`*_!Y)T,94D]`DY?W?$D/5*R3V"H0%)W1$[@G$&
MQ)<-@1.+W5APCI<80:X:NO"T!@.K\`DJ1P^86X^!:X^)>T0(HKTRJ$U7MF"K
M;$MK4[GU@:',WT1&,NG_R%APCN':)Y_&:9^^5_:8V0`S[Q$C98!,-VC!,!77
M`]KSVGK0!&D8JJ&T'=<DM:/Y1H/M.9=%7V<?F4&Y!R6973:\&*N^/DL6/);R
MD3AQ_\3AI,#`G;J)(\CH=0%[:BS@(R`P]/*/YMG-/?E_8<%C*1^YX`4:/.2=
MW!E[;BSA(\OQL"XN=R:&C3>4?;UR#CT6.X3\CAU-.81&U-91NHB"Y9O#YDZ>
MR!RVQ[A%RQ-3?DW[-2:8JMA'UC0:4;FS*SB!Q=1'^\_#QHW5:7R6;0Z6^C>P
MMCM2L:]$5;S5J&$E<'H[RB]^_V!DY[;G5AI8V.ZVA@\T@^44!>"]E-(<'^RG
MI?_DK_\```#__P,`4$L#!!0`!@`(````(0`_9MM+>P0``*@/```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;*R7VV[C-A"&[POT'03=KV7JX(-@>Q%;
MUL%H@:+8;:\5F;:%2*(A*7'R]CL4147DN(ND[4T4?Q[^YOP<CLC5U]>R,%YH
MW>2L6IMD,C4-6F7LF%?GM?G]6_AE81I-FU;'M&`579MOM#&_;G[]975C]5-S
MH;0U0*%JUN:E;:^^9379A99I,V%76L$W)U:7:0L?Z[/57&N:'KM!96'9T^G,
M*M.\,H6"7W]$@YU.>48#ECV7M&J%2$V+M(7Y-Y?\VDBU,ON(7)G63\_7+QDK
MKR#QF!=Y^]:)FD:9^<FY8G7Z6$#>K\1-,ZG=?4#R99[5K&&G=@)REI@HSGEI
M+2U0VJR..63`;3=J>EJ;#\0_D*EI;5:=07_E]-:,_C>:"[M%=7[\+:\HN`WK
MQ%?@D;$G'IH<.8+!%AH==BOP1VT<Z2E]+MH_V2VF^?G2PG)[D!%/S#^^!;3)
MP%&0F=@>5\I8`1.`OT:9\](`1]+7[GG+C^UE;3JSB3>?.@3"C4?:M&'.)4TC
M>VY:5OXM@D@O)43L7@2>O8@]G]@+CWBS3ZC`[W53@6>OXDX6GN?.%O./3V79
MB\#STR*6\*:S.DC;=+.JV<V`^H7LFVO*=P/Q83$-:;*P9+#]GUP'N[G*`Y=9
MFW/3`$,;*)67C4.6*^L%EC?K8[8XAJ@1.QG!UY++!CK8ZR#40:2#6`>)#@XC
M8($M@S>PYO^'-UR&>R.SVDKP;I:M&2$CY)!`!WL=A#J(=!#K(-'!8004(YP[
M1KA0N/=WHJP)/@KVW*@FB..IB6Y%C`TM>R@<+60WA`QF(+)')$0D0B1&)$'D
M,":*)^X=3WAW^N3&X3)KTX8]/1C@V%/-I3[H9RX-(8-+B.P1"1&)$(D121`Y
MC(GB$ABB;*&?5PR/[LR026P%(>ZP>7:(!/TH>`P6$D]K+?LA2$J'B$2(Q(@D
MB!P$$5-4<I]IN8O6.N$=O[WDV=.6P7RA]]SQQ($6*AHK%U$M$61L"2)!/VK6
M=6)[2ARUH/;#]X,;2"-")!Y&\?X.JEK72H;OI>IAK*%X`V^*3]0%CU9-$&1L
M`B)!/XK;+5]*Q-/FO!^"Y)Q#1")$8D021`Z"W*D+?CX=OW+OK#\<+60!\&@U
M=T%XKQGEI:WPK@^:#1LG0&3?DWE7)<2VM1=VB$9$B,2()#U9=*K+Q4(MO<-X
M@%(2T`(56_[5=N$BJEN"D'&#)9ZK3FK7#^O.H^+DT1-Q&.1GD7U/;.&60[3$
M0J01(1(CU415]?0U.(PU%+OX8>V_^]6IJ(;UB+R7S@ZC0`YTA@+;2^1V#MF>
M.U==#K%,A%$L9=Z5$XFD,M&4^36$K[N8L[!)7"O$6;>D]9GN:%$T1L:>^94!
M!FQ6`Q;WF<#SH;U#']#YS(>&B7D\\Z'E81[,?6@'F,-]Z<&^P[?\'G6/VSZ<
MR+#.UO'A6(+Y@^L_0%[XBZWKPQL:N#5D!O>D:WJFOZ?U.:\:HZ`G,&7:O9MJ
M<=,2'UIV[=Y1CZR%&U+W[P5NQ!0VQ'0"'>C$6"L_\!\8[MB;'P```/__`P!0
M2P,$%``&``@````A`,CMN4\Q`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM
M;""B!`$HH``!````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````)R104_#
M(!B&[R;^AX9[2]ET4=*R1,U.+C%Q1N,-X5M++)0`VNW?2[NNSNC)(WE?'I[O
MHUCN=)-\@O.J-24B68X2,**5RE0E>MJLTBN4^,"-Y$UKH$1[\&C)SL\*8:EH
M'3RXUH(+"GP22<9384M4AV`IQE[4H+G/8L/$<-LZS4,\N@I;+MYY!7B6YPNL
M(7#)`\<],+43$8U(*2:D_7#-`)`"0P,:3/"89`1_=P,X[?^\,"0G3:W"WL:9
M1MU3MA2'<&KOO)J*7==EW7S0B/X$OZSO'X=14V7Z70E`K-]/PWU8QU5N%<B;
M/=N]N2;QOB[P[ZR08K"CP@$/()/X'CW8'9/G^>W=9H78+"?SE)"47&]FA)(+
M>KEX+?"Q-=YG$U"/`O\F'@%L\/[YY^P+``#__P,`4$L#!!0`!@`(````(0`9
MAYIW%0,``'X)```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````)Q66T_;,!1^G[3_4.4=TML8J](@
M:,N8Q&BE%/9H&>>TM7#L8#M1RZ_?<;+>AAL)WFR?V^?OG./CZ&J=B58)VG`E
MAT'GO!VT0#*5<KD<!H_SV[/+H&4LE2D52L(PV(`)KN*O7Z*95CEHR\&TT(4T
MPV!E;3X(0\-6D%%SCF*)DH72&;6XU<M0+1:<P5BQ(@-IPVZ[?1'"VH),(3W+
M=PZ#VN.@M)]UFBKF\)FG^29'P'%TG>>",VKQEO%OSK0R:F%;DS4#$86'P@C1
M)<`*S>TF;D?AX39*&!4P0L?Q@@H#4;@_B.Z`.M)FE&L31Z4=E,"LTBW#WY"V
M;M!ZI@8<G&%04LVIM`C+J=6;:BUR8W7\1^D7LP*P)@I1H3ZLEH>ZAVO>CWO]
M2@-7QYK.0XT$!<<8Y]P*,-/%C&KK@=SK'V*N4-2(:T#;+!*L#3*1%ODBOV2=
M;:X.D>_N,%*8:&D@);@R2O"46MS<4$$E0S9WBHZ7.DJS2><C-HG%:-F'POPS
M\8?ID*E>4LG?JJJJ:$B*+*-Z0]2">)%UR3U_+7CJN'*TW7*)-^=4.$)2KTFO
M$IUBS6O21Y,LX];UF*GBH'>+M8F-S?WW_T82J]C+2HD4GP(R09!VXW5^46O>
M8#&[-&;8Y*8BP*O]'4N"J0S(G*[AJ)QW&;XD"2P=U`KI3U!+3?,59W4Q>;W^
M(`E?2HYO"781&17&8@CMB&+HQVO2:9.D>#;P6KA(D])1XU=LS.IG*J'KC=.<
M5W^<D]PCO<_XCNTXW?=/,[O^,!TR4_@F6ZQ+L2%C+@K+2\`T5:^B-TQS+_2\
M-LW-X(?6PZIPN5,:YPX9@Z5<^//8(P]X"4-F=(/<`'F@6F.=EO[Z;VX9/Q9O
MSVPQ^?O_=`+=5;PL79!I[J86N3:FR*IE\\6W!H9,"UM-;NS\+:P3(:KF?]_2
M%6E>D^:R\E=\LXV_1IH[_2@O1X/NO]%VS^6+><SG:HPC8#N[CP^C9$4UI#C5
MMO+]072'8UL+YV2THOB.IEN=]P+WTWBJOU-QIW_>[K7Q$W%P%H7[CU/\%P``
M__\#`%!+`0(M`!0`!@`(````(0`:,QE5V@$``#$6```3````````````````
M``````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U
M````3`(```L`````````````````$P0``%]R96QS+RYR96QS4$L!`BT`%``&
M``@````A`/Y[WY32`0``'!4``!H`````````````````.0<``'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A`+G>KD.6`P``.@L`
M``\`````````````````2PH``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(
M````(0#NC2JEZ`8``,T>```8``````````````````X.``!X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`B)LJ<I0#``"]#0``&0``
M```````````````L%0``>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+`0(M
M`!0`!@`(````(0!2%&76=`,``&X+```9`````````````````/<8``!X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`,=KGTU7`P``
M$PL``!D`````````````````HAP``'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"+0`4``8`"````"$`"3`+AGP#```3#```&0`````````````````P
M(```>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0``
M7C90\@,``)H.```9`````````````````.,C``!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L!`BT`%``&``@````A`)L@?M)?!```'A$``!D`````````
M````````#"@``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`
M"````"$`'3X^;0D#``#["```&0````````````````"B+```>&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0##+Y>QC0(``#0'```9
M`````````````````.(O``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!
M`BT`%``&``@````A`&(S'>9Y`P``=PL``!D`````````````````IC(``'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`W,W3--D"
M``"\!P``&0````````````````!6-@``>&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;%!+`0(M`!0`!@`(````(0"/5?W.EP4```X7```8````````````````
M`&8Y``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`
MPVDQDFX#``"L"P``&``````````````````S/P``>&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L!`BT`%``&``@````A`'%)%-^26P``6"P!`!0`````````
M````````UT(``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`%``&``@````A
M`*,6&ETO#```;'(```T`````````````````FYX``'AL+W-T>6QE<RYX;6Q0
M2P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P````````````````#UJ@``
M>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#6*]VC.00``.42
M```9`````````````````+JQ``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L!`BT`%``&``@````A`(8WJC:[`P``F`T``!@`````````````````*K8`
M`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0".V&ET
M@@(``!@&```9`````````````````!NZ``!X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L!`BT`%``&``@````A`/#\`3?5`@``S`<``!D`````````````
M````U+P``'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"```
M`"$`XMP]&LX3``#(;0``&0````````````````#@OP``>&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(````(0#:=56YN0(``&0'```9````
M`````````````.73``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`
M%``&``@````A`!8.>!+`!0``QQL``!@`````````````````U=8``'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0!K:<:#8@L``.`Z
M```8`````````````````,O<``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"+0`4``8`"````"$`SD?Q.K,"``!B!P``&`````````````````!CZ```
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`$\QI*>>
M#P``%UX``!@`````````````````3.L``'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+`0(M`!0`!@`(````(0#QPNKW%08``+(:```8````````````````
M`"#[``!X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`
MOBQ%8:8"``"^!@``&0````````````````!K`0$`>&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0!TN.J^EP(``)8&```9````````
M`````````$@$`0!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&
M``@````A`#1/J!.O`@``4P<``!D`````````````````%@<!`'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`>\]_+8D&``""'```
M&0````````````````#\"0$`>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M`0(M`!0`!@`(````(0#/0`66U`X``(Q)```9`````````````````+P0`0!X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`!(MH1.2
M"```,RD``!D`````````````````QQ\!`'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"+0`4``8`"````"$`<E9RT@(%``!-$@``&0``````````````
M``"0*`$`>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````
M(0"N-;,.VA```$UD```9`````````````````,DM`0!X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L!`BT`%``&``@````A`%8W?#;6`@``-P@``!D`````
M````````````VCX!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4
M``8`"````"$`/V;;2WL$``"H#P``&0````````````````#G00$`>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0#([;E/,0$``$`"
M```1`````````````````)E&`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`
M!@`(````(0`9AYIW%0,``'X)```0``````````````````%)`0!D;V-0<F]P
?<R]A<'`N>&UL4$L%!@`````K`"L`GPL``$Q-`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUMBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product</a></td>
        <td class="nump">$ 3,456<span></span></td>
        <td class="nump">$ 3,890<span></span></td>
        <td class="nump">$ 6,177<span></span></td>
        <td class="nump">$ 7,674<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Product licensing fees</a></td>
        <td class="nump">397<span></span></td>
        <td class="nump">374<span></span></td>
        <td class="nump">830<span></span></td>
        <td class="nump">406<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service</a></td>
        <td class="nump">236<span></span></td>
        <td class="nump">262<span></span></td>
        <td class="nump">454<span></span></td>
        <td class="nump">497<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">4,089<span></span></td>
        <td class="nump">4,526<span></span></td>
        <td class="nump">7,461<span></span></td>
        <td class="nump">8,577<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Product</a></td>
        <td class="nump">1,203<span></span></td>
        <td class="nump">1,092<span></span></td>
        <td class="nump">2,224<span></span></td>
        <td class="nump">2,080<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Service</a></td>
        <td class="nump">181<span></span></td>
        <td class="nump">234<span></span></td>
        <td class="nump">332<span></span></td>
        <td class="nump">413<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenues</a></td>
        <td class="nump">1,384<span></span></td>
        <td class="nump">1,326<span></span></td>
        <td class="nump">2,556<span></span></td>
        <td class="nump">2,493<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">2,705<span></span></td>
        <td class="nump">3,200<span></span></td>
        <td class="nump">4,905<span></span></td>
        <td class="nump">6,084<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">883<span></span></td>
        <td class="nump">513<span></span></td>
        <td class="nump">1,390<span></span></td>
        <td class="nump">1,045<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">3,093<span></span></td>
        <td class="nump">3,504<span></span></td>
        <td class="nump">5,912<span></span></td>
        <td class="nump">6,351<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">3,976<span></span></td>
        <td class="nump">4,017<span></span></td>
        <td class="nump">7,302<span></span></td>
        <td class="nump">7,396<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(1,271)<span></span></td>
        <td class="num">(817)<span></span></td>
        <td class="num">(2,397)<span></span></td>
        <td class="num">(1,312)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(188)<span></span></td>
        <td class="num">(280)<span></span></td>
        <td class="num">(438)<span></span></td>
        <td class="num">(568)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_GainLossDueToChangeInFairValueOfCommonStock', window );">Gain (loss) due to change in fair value of common stock (See Note 3)</a></td>
        <td class="nump">99<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(210)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Loss) gain due to change in fair value of derivative instruments</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(397)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
        <td class="num">(39)<span></span></td>
        <td class="num">(26)<span></span></td>
        <td class="num">(67)<span></span></td>
        <td class="num">(46)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(1,399)<span></span></td>
        <td class="num">(1,519)<span></span></td>
        <td class="num">(3,111)<span></span></td>
        <td class="num">(1,074)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock deemed dividend</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,062)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
        <td class="num">(1,399)<span></span></td>
        <td class="num">(1,519)<span></span></td>
        <td class="num">(3,111)<span></span></td>
        <td class="num">(2,136)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share: basic and diluted</a></td>
        <td class="num">$ (0.21)<span></span></td>
        <td class="num">$ (0.33)<span></span></td>
        <td class="num">$ (0.47)<span></span></td>
        <td class="num">$ (0.47)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average number of shares used in per common share calculations:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="nump">6,631<span></span></td>
        <td class="nump">4,659<span></span></td>
        <td class="nump">6,625<span></span></td>
        <td class="nump">4,587<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(1,399)<span></span></td>
        <td class="num">(1,519)<span></span></td>
        <td class="num">(3,111)<span></span></td>
        <td class="num">(1,074)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
        <td class="nump">13<span></span></td>
        <td class="nump">119<span></span></td>
        <td class="num">(86)<span></span></td>
        <td class="num">(1)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Other comprehensive loss</a></td>
        <td class="num">$ (1,386)<span></span></td>
        <td class="num">$ (1,400)<span></span></td>
        <td class="num">$ (3,197)<span></span></td>
        <td class="num">$ (1,075)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_GainLossDueToChangeInFairValueOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) due to change in fair value of common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_GainLossDueToChangeInFairValueOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsAndServicesSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to services rendered by an entity during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 405<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DividendsPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossTaxAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueServicesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>5. Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">5. Stockholders' Equity</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock Issued to Non-Employees
For Services</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2009, the Company entered
into an agreement with Advocos LLC, a contract sales organization that serves as part of the Company&#146;s sales force, for the
sale of the Company&#146;s wound care products in the United States. Pursuant to the agreement, the Company agreed to pay the
contract sales organization a monthly fee and potential bonuses that will be based on achievement of certain levels of sales. The
Company agreed to issue the contract sales organization cash or shares of common stock as compensation for its services. During
the three months ended September 30, 2013 and 2012, the Company issued 8,139 and 3,728 shares of common stock, respectively, in
connection with this agreement. During the six months ended September 30, 2013 and 2012, the Company issued 38,447 and 14,392 shares
of common stock, respectively, in connection with this agreement. The Company has determined that the fair value of the common
stock, which was calculated as shares were issued, was more readily determinable than the fair value of the services rendered.
Accordingly, the Company recorded the fair  value of the stock as compensation expense. During the three months ended September
30, 2013 and 2012, the Company recorded $22,000 and $20,000 of expense related to this agreement, respectively. During the six
months ended September 30, 2013 and 2012, the Company recorded $134,000 and $112,000 of expense related to this agreement, respectively.
The expense was recorded as selling, general and administrative expense in the accompanying condensed consolidated statements of
comprehensive loss.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 17, 2009, the Company entered
into an agreement with Windsor Corporation.&#160; Windsor Corporation provides financial advisory services to the Company. Pursuant
to the agreement, the Company agreed to pay Windsor Corporation, on a quarterly basis, cash or common stock as compensation for
services provided.&#160; The Company determined that the fair value of the common stock was more readily determinable than the
fair value of the services rendered. Accordingly, the Company recorded the fair  value of the stock as compensation expense.
During the six months ended September 30, 2013, the Company issued 12,097 shares of common stock.&#160;During the six months ended
September 30, 2013, the Company recorded $49,000 of stock compensation expense related to this agreement. Additionally, during
the three months ended September 30, 2013, the Company accrued $30,000 of expense for services provided which was settled with
shares of common stock on October 2, 2013 (See Note 10). The expense was recorded as selling, general and administrative expense
in the accompanying condensed consolidated statements of comprehensive loss.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>3. Inventories (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
        <td class="nump">$ 825<span></span></td>
        <td class="nump">$ 1,162<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: inventory allowances</a></td>
        <td class="num">(76)<span></span></td>
        <td class="num">(170)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
        <td class="nump">749<span></span></td>
        <td class="nump">992<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Raw Materials</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
        <td class="nump">591<span></span></td>
        <td class="nump">835<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Finished Goods</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
        <td class="nump">$ 234<span></span></td>
        <td class="nump">$ 327<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of valuation reserve for inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SX 210.12-09)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryValuationReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. Condensed Consolidated Balance Sheets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>March 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Raw materials</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">591</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">835</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Finished goods</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">234</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">327</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">825</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,162</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Less: inventory allowances</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(76</font></td>
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(170</font></td>
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">749</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">992</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BalanceSheetRelatedDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>5. Stockholders' Equity (Details Narrative) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 666<span></span></td>
        <td class="nump">$ 941<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Advocos</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
        <td class="nump">8,139<span></span></td>
        <td class="nump">3,728<span></span></td>
        <td class="nump">38,447<span></span></td>
        <td class="nump">14,392<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services, value</a></td>
        <td class="nump">22<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="nump">134<span></span></td>
        <td class="nump">112<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Windsor Corporation</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,097<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services, value</a></td>
        <td class="nump">30<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 49<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>4. Commitments and Contingencies (Narrative) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Potential severance under certain employment agreements</a></td>
        <td class="nump">$ 1,843<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,843<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent', window );">Aggregated annual salaries under certain employment agreements</a></td>
        <td class="nump">1,310<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,310<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
        <td class="nump">3,456<span></span></td>
        <td class="nump">3,890<span></span></td>
        <td class="nump">6,177<span></span></td>
        <td class="nump">7,674<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Innovacyn</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
        <td class="nump">801<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">801<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">264<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
        <td class="nump">1,289<span></span></td>
        <td class="nump">1,229<span></span></td>
        <td class="nump">2,030<span></span></td>
        <td class="nump">2,365<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">More Pharma</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
        <td class="nump">717<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">717<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">580<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
        <td class="nump">$ 378<span></span></td>
        <td class="nump">$ 183<span></span></td>
        <td class="nump">$ 752<span></span></td>
        <td class="nump">$ 183<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueGoodsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>9. Significant Customer Concentrations (Narrative)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">One Customer</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
        <td class="nump">33.00%<span></span></td>
        <td class="nump">27.00%<span></span></td>
        <td class="nump">37.00%<span></span></td>
        <td class="nump">28.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_AccountsReceivableAbstract', window );"><strong>Accounts Receivable</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_ConcentrationRiskPercentage2', window );">Significant customer concentration</a></td>
        <td class="nump">33.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Second Customer</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
        <td class="nump">32.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_AccountsReceivableAbstract', window );"><strong>Accounts Receivable</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_ConcentrationRiskPercentage2', window );">Significant customer concentration</a></td>
        <td class="nump">30.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Third Customer</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_AccountsReceivableAbstract', window );"><strong>Accounts Receivable</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_ConcentrationRiskPercentage2', window );">Significant customer concentration</a></td>
        <td class="nump">11.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_AccountsReceivableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_AccountsReceivableAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_ConcentrationRiskPercentage2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Customer concentration percentage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_ConcentrationRiskPercentage2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. Stock-Based Compensation (Narrative) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to stock options</a></td>
        <td class="nump">$ 1,403<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period of unrecognized compensation costs</a></td>
        <td class="text">2 years 6 months 14 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_EstimatedForfeitureRates', window );">Estimated forfeiture rates</a></td>
        <td class="nump">1.63%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_EstimatedForfeitureRates', window );">Estimated forfeiture rates</a></td>
        <td class="nump">4.77%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_EstimatedForfeitureRates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Estimated forfeiture rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_EstimatedForfeitureRates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. Notes Payable (Narrative) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 294<span></span></td>
        <td class="nump">$ 303<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">VLL5 Agreements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest payments made</a></td>
        <td class="nump">7<span></span></td>
        <td class="nump">50<span></span></td>
        <td class="nump">27<span></span></td>
        <td class="nump">109<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments made</a></td>
        <td class="nump">24<span></span></td>
        <td class="nump">288<span></span></td>
        <td class="nump">556<span></span></td>
        <td class="nump">566<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">VLL5 Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
        <td class="nump">24<span></span></td>
        <td class="nump">63<span></span></td>
        <td class="nump">90<span></span></td>
        <td class="nump">125<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable balance</a></td>
        <td class="nump">138<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">138<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">VLL6 Agreements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest payments made</a></td>
        <td class="nump">53<span></span></td>
        <td class="nump">75<span></span></td>
        <td class="nump">114<span></span></td>
        <td class="nump">151<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments made</a></td>
        <td class="nump">228<span></span></td>
        <td class="nump">148<span></span></td>
        <td class="nump">449<span></span></td>
        <td class="nump">266<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">VLL6 Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
        <td class="nump">104<span></span></td>
        <td class="nump">91<span></span></td>
        <td class="nump">204<span></span></td>
        <td class="nump">178<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable balance</a></td>
        <td class="nump">1,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,367<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on loan</a></td>
        <td class="nump">$ 474<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 474<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestAndDebtExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001019687-13-004492-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019687-13-004492-xbrl.zip
M4$L#!!0````(`)>!<T-NBL.4;Y<``/O3!0`1`!P`;V-L<RTR,#$S,#DS,"YX
M;6Q55`D``T[4BU).U(M2=7@+``$$)0X```0Y`0``[%U;<^,VEG[?JOT/6$]F
M*E.E^]WNRY1C=V>]2;<]5G<R\Y2"24A"0A$*0-K6_/H]!R`I4J(DZM*V9",/
M'5D$<#X<?#@7`(3>_N-Q[)%[)A47_KN3>J5V0ICO")?[PW<G7_OE\_[%U=4)
M^<?[__XO`O^]_9]RF7SDS'//R*5PRE?^0+PAG^F8G9$?F<\D#81\0WZA7HC?
MB(_<8Y)<B/'$8P&#!T;2&6E6.G>D7"[0["_,=X7\>GN5-#L*@LE9M?KP\%#Q
MQ3U]$/(/57%$L>;Z(I0.2]H23NB%ZK=Z[<^_-BYKI\U:O5EY'$`7+FD`CQOP
M-SRHU_&?WI=Z[ZQ=/VNV"HH*:!"J1%3ML1;]9ZJ_?;R3'C_#?PF,@J_.'A5_
M=Y+JW4.S(N2PVJC5ZM5_??JY[XS8F):YKP+J.^PDKN5Q_X^\>O73T].J?AH7
M72B)PF,9S2H^OJ-JUC("7%%^`0D\=8.D0KIPNVH>9HKRW*(=4Y3'15TV5TXQ
MIS(4]U5X4,4!*M?JY68]+B[98"GD3A6>Q@6Y$JU&O;NJ?Z9$7"%4Y2&EDZ3"
M@*H[73AZD`,&GDCA,95;1S_)J>0+WP_'^;C<0%:#Z815H5`92C')G:3>^DK9
M"H`!O\Y'IY_DH!..-ZM@I@],OK$NB1/H))X9R*8SI3E[RP9$$_%LI(<'VRC'
M%2J/RCV)'J/0=R>*H[TX(=6X*3-3'.$'[#$@W'UW\E&*L<'6`GB!,)]/RS/Y
M237F!SR8)M\FWW,7GPPX&"B-DF64%Y/LXNJGD_<P9^O-3K?6:[ZMSE>>B:OF
MRHND34#QPEU$`3-(!FALWL^Z$[<T>[90#8QBJA+V>R;>S52)O\\`B+^,5+I<
MS^?J>G"TNC7V*<A14OQDKTIJE&M-G"A'JZ2H`]]&2<MG[&_]0#A_7$\"B`P^
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M&7=5I;S&0O>MUUBRFGR$%BR[FOSMEMQ7A.P1`7^[$"JX'O2IQ]3+F%%7O@/S
M)@G*?A8.Q:7D[!KS0J]M_%[4/%O"/#]A#L\<K[`TMTPQ*IW1.0@$U^V)":KC
MP^,$!N*%>/%"%"J@!VN%BEHA2ZKC(-516:H^\SSN#\T1/0]4>NZ.N<]5($'S
M]RS2ZFMR>QMIQ%JOHM;+$NUXB7:P%BV7:/;,D*7(:J?W*Y62^L&+ID>FC]9-
M%;4>EAJOVVIDCS7_=N7CBR3.](6XDJ5+[W/]?&I2//%Y[.0<F)#L9D3EF+[P
MX9WOZ,L?7]S&6]Q/>[$#_.Q;9X>SB?K+SS^WSX>2Z<SKA>23E^PNN`(]RA`;
M28U[7F>M1R^:!UC&'`!C#C8]6,V8SFMBS$)G+6,V]TJ6,=8K;7),Y1-]Y.-P
M_#*X<DO]X=PR1*9_UJ!L3`_NOVQZI/MGZ;%%3!NM\[T";S/75<N6+7)FRQ8;
MF>2LD5J&//=BVK.<E4ZE+:]GV#L'9!B.U(U8ME@WLMJ-6(:\-#<RM^L6#;7=
M.G]1&V_Y@VQWT%_8,,]"PF[Y15V?N/F;Z4]S?6*]7JZWCTRW&3+J#CPU&6/[
M8^_X>MJ4Y,!FT?)[-"Q!GB<+.<P+0%98$'O3E[4DA2R))8JU*(4LBKWMR]J6
M#6V+I8RU,D6MC+W%YG`N)3DJ6V.)<SC$.4J+8R\@.8X+2([2*EER'0>YCM)R
MV<M'CO?RD:.T9I9PQTNX0[9PR\[IV3>=[2F]HESI,RCOQGHTVGI=%TWG:<#2
M:-7QO=BOW81WH)RO`?=XP)FZ\H$N@9#36_KP"81+3KT7XM26]33KU8KKXZGY
M]4R'_RQ1CILH3W&`,.V,/F(,.&+NCT*XKX(0V@'E]/J5V`<[[(<T[,]QCM3>
MNG((2>Y1K:I8QAP`8PYY6625C7D]KQL=TGO-QVI?+%NL;2EL6^R-3M:^;&9?
M+&.LC=G0QKP>CW1(+]0?JWVQ;+&VI9AML>_G6ZM2Q*I8GEA[4N3R'\L3>^U/
MD>,GEB?V?$FA%[/MU3(V0BGV9K9EBHU1"L4HEBDV2BD6I5BFV#BE6)QR[MX+
M1[R0!3?\L<CKP3DNK`W9W)I;IJ//39.C"U(L36R$4B!"R6BO=]KHM7J]9M?R
MQ<8I!;R/Y8N-5M9$*[]RWU5"OB*^9'K\W'PYS+!EA7W):,_2Q)H5^_[Q@;U_
M?+`F91E7\MZ^?;%T.<17C0^3,2MRYX4Y][I>5S\LDW-X677^FZ76)3T9/Y[^
M75+K3Y[1GSSOJ\-VN)]UN)_Z@H`O(RY?RVCG]/5US6T[V"]F9H<^-R/]M7^Y
M,(9C1E4HV7NN1*M1[YY!F;BQ^%%6!+:VI/W^B$JFEHJ(]*4+;2T#\-TLD>/R
M>R#/HFZQ[N<0AI8&0BYR9P,=S&/,:S4E])+Y8LS]=6+7ZV5>;E[#\?.,%@HH
M](9)![BZ9M0F\+'XF+F,GWW0_+]E0WVQH!]\IF-&(G[>LL&J%<^3]]=.Z(6*
MF(.;>"DAZ3N<^0Y3)?C2J;RM+A.Q".$">B>I=^6[[/$G-BV,(6V:EK:6%G<I
M'/UR#*YM%I92KY7_:=I/5\]K]D9/^`\F7RO<?MI[+&TM+>X<GKI8XJ-'AX7%
M#*BGF)&0:2#=\D4H)7[-E4.]?S,J-^U+.;:,JUI;),"OS/-^\L6#WP?B"I^Y
M5TJ%X"**BOTLT@18TMJBV%^$%_J0DD\_<@_\S9;BYEK)H;?1PRV;"!EP?XB7
M?X;%I?T;;<ZZUA:E:C07H.ZAD,6G5'],/:A'DN;)A1A/J#]-0\@TG3<1S)`;
M`G^$[XIW]I^-["18:&FY.&389L+@<RM/7-)2+"R.3\Z58D&V_6P@?D+0R.H'
MZ,J)RQP.&E7O3LK-D_>]7J\!-NMM-=O>1E)P>JV64F^T.^T"8O0/BIA'GX7O
M&%IMW;=Z^S0C,[?U72`4Z'BONSF$2S9@\,"]'L#_@>_XTP<[C'"CE8&0V_HN
M$-9KH;4%@AO\@1D93&\\\-'GOOOASY#KJ]0_L^T9<3HW'*N$[`'0>LWT:K6M
M`1D:7>PX23JG]3P#<)%/S2(R"\R*>KO9*B[T1K()Y6YTQ31H)36+=NU^NW4Z
M-P!K9>T/WGI-G3;;N\)++K+;9>)TY]24;G0+@04Z?MHH+/#<<02$.^J6.8S?
MTSN/0:%=B=%HS=G-55+V@*C`K.G6NELC^IG3N^AFP^U)T&QF!R75Z.;R"AC'
M5J]56)[PAU^8'..-`WL('=KU+-_SF]\)Q/K^=[J=+4#$WC7:6]U''-7K-7,=
M^(*(7;&LUTFC,S<RA;&DR+.K;6AUF]UEQ%P__W:U`^UZ8V/I*>;L[#&[S:6L
MW%E\H51B^=1<(G^.(SN[AF:CL8J#^T!18"9H8[PQBMAIW-`I>HPDA'`<&3)W
M'VZB<WJ:ZZ;62MPWU/4Z[-::WP3JK@RKUQKYKC[;_DXHBB0GO2U`I+0$^NL'
MPOEC)#R7287)3##=WU+%.DE[0K;-\L:FT/:HIGJ[G;4+>Y1>(-6O]>H;2K]E
M`>4^<S]0Z7-_J(!FX3CT:,!<,&FXC;:U+LIUP-/.1E'KQ>T-X'IUE>O-;K?5
MWA%@JH2V5[@^*MD(MS+OF?EUIY^%4I`=7`^^T,?MU=FL=1?LTB:2OPWP`FIN
MG)[6]PK<=3G^1A;U;B`=O_(OZ(0'U(-6QL+7E-]^_K;:K?DUV;72]H:O@+%K
MM7KUSH[X4H]^H5[(=O"4:2#SS6XIMH`2-A)[(Z/0;`\=SBX&S3>[O>3U?=Y%
M\@V5UU+_PIRK2]\PJ??C"ZLAWKY/8;KZ_!%`57#'=1FR96+W"G91<T\)UH@Z
M#X.1D/P_S"VFT24`=>106SK0\[+V@FQ.?4^'3&_![J:O-7B,A)VQ%-/0WK!<
MAP$>'G)QI_4;*B<E9C^H]J*F%:A25O[)S%D!F?N#N;TAVPWF7DU8O=7HM;OU
M=BZX=69B<U#%2+=?4'LP7)U.L]DY;:W`DV\O-L-23#F==J]9;^>'4QMAV9?A
M6J^<8E9BOX9KO9I6H$JVSWZ4D-7L<)8@FZIFF]U*:)'=XLZ2O<#MI6[[HYBK
M5\;G<LP]:6?O.'O-O8_BNI\$7+.2W?HF>ML63W-N\;4@'G1W^H>S;YEB\GZ7
MC=9.OOP%"3MC*;3KO"$8?3H>=V,NN=(+QKA#`_0<W^#Q/>%?#^(OL-#VFW"&
MQ)M)VRO&`GLTK=X.(-.&G@?Z=SC.??<"L("%9[ZSV2;-H^)G/O?>G00R9">D
MNKN4O/XODV)>=*1JU&=!X)G?F8_6R*?[V*(^;<X4O5;,7D`5V+]O[!G3SMM*
MT;I=`1F[PUFOGV@3?5,TZ7D4/=^S96G6\F?M*FG[A%C@#$"COCW$>,;_$"KN
M,Z4NF7(DGV`%F/D_4,4!"23'"AK2%OX+0/S!FU\T7G6,^6]>\&9"5##UV+N3
M`50Z([U)4/6%A#Z0+WP,1N4S>R"W8DS]DOFB1/H0PPS>D#&50^Z?D=K)WX;!
M&VSJ+O[`\<.U'%*?_T=#PR^K/'Y<30I6)_K37^K-Z)^]`'I#L/=E[N/K9O!W
MI<U]`Y*.)V_^`M/KVPNG'A_"G[]#<,,'4RU]W8LOY/M@Q`P2@[/5?1.=H8^_
MZ+WY.WF@BG#?$7(B).;OP$"720)UB4<?%!$#_5DG]_C'!4`9".ES"M7(^41R
MC]1/3T\)Y""Z,<GRF]-0<IN\9/`UKE!`@Y?,,6_E@1GM5,@7*#<'NO-&$9`*
M/FH">A2#`7>@IB)`52T0&KEA`<0I8UI*H<VVA5B@#B5#3]Q!,R-&O6#DF&42
M700@T@`FH`+%@T8G4KBAUBWV$X;G#SP:/Y&S6:0?^,(O9[XT]0+4,6ETB9ZN
M$KQK14.X"A#Y!`HR?2@:2B6CF=0$_%I?H,<Q#80GAM,242$0Q*$>X''O*8PZ
M*!_:=C6*@&/N3+`[!B_,G'&VEU$/#(SE6H9B4P"`+S,`4.@/U[T6\(CAJR;`
M3F?D:TQDXM$`L(Y!KN<!GD_<D<*9^E&3W=8;\B4IC<,!+::J<Z6QW%$%=4$2
M\Y@#JL+&IL2!7'>(WS].G9$G0%>,*'Q%A(P%E`L]F$QFK*!0($B`Q0,8WP?N
M,J*OCD*F"6U$U%B9T75HJ$"O7#$02KZ?T&`D(/I1?S=JZ;-[)D%M*SN25O9L
MS/"/#![)0![W!]`G&&VE1X7Y(QPY/2PX^`\C[@%8!DW@GSCFP`M78T$24(C.
M[K@(N`/C]K069[D-3`QUUA@^C4W.,8N+G@./1DF%]@:=67\"(<:S.)"B&GU6
MK_)AH"D*]H<FAEI,F(^?[Z+000,1B?$O$0P"2KIH9$4(T\T`]RGPV:A?:?4K
M5#\VQO6K);B899Z`B:62W.O-RN_,4C.9X&OAN,I5(1^@D2GIFC\1F0:1;H`\
M,(FSQ_&H4OA6N+&%4.0.#U;`Y(-Y*-!NZ-5P@)"N72&?!1E(ZI@M[5B.;I.;
MY4ZJ=&]4Z`619C2&G/Y5"/[^&:-NB3#JC*)*.*?G)<S#,!X4#3FZS@F)(#^,
MP,K%JD!KG1&J81C%:N.!)@=M1Z@=*4A(E)8>H[2EST`0J;7+`81[I-4IU7JU
M4KO>1#R=4KO7+-7;-8,D$.!K(UF&&`-"9POH,]$+W82X5FA?8L)6;><AX)5,
M>X"[*6H;PSVL7#_K&L\&$F<\2?@1=\W(,/I(SCMP/S1&^"YAUN&8SV>=[.?@
M/^-A,>.$.IYIE8[UT;]HJOGFA!)&,D;7V!ME]@&4\+BKPZ\!]\&I<20XQG=Z
M:8&,*!B4.P9F1+)`"JHM#`PW=1&.&1W)!NCQ8=3K.N3I+B-Y*;(N:*0R)NA5
MC>H29Z<3.9P.Z53N4/(E:!Y;34LH*S`36DR>YK#$!F#KM4FP'YC?2-B2>&6-
M4M#,4B?*2\`J:T2A3T.7!V;Z%9Z(QJGWV20P65:S9J:.GOAQHA&,)&/Z&\4?
M(<#V@Q$&S#![F?9+.)M-K(XS>H)OITEC%Q"E='50^\"#D6Z-F@/$Z$VBM`V#
M=0BS,;9&&^`X"">Q*U]]W2N='6JTYV.&:8"&!TX<_AC/.F<R.1_S#IID89-0
MJA"B91UYCS"OQ%\CC2)O^.XC9BEXG8(N?0[NQP'WVD-AMVR(!P2QI7[Y7TFJ
M"BF&-*?.L<:'1\A',*70RZ<*[X[1.+Z?9=K]#Q?I+!MK"=,_A;=;W.EI2E4F
M:(HTJ71L1'T_A+%+#?+JH37>.&%%;+/SF`$)KQXB-6*8(RVA1&F5E4]1RKCV
MV3E*2,253EHUA*5\,E1:PD2\?+"4./QB&*@:D8$G'F8),TC3&(I*U%E;HL$2
MQ+N8LCE>""DDIIK&6VF))0V%*TUKX0.-`4)D)R6216?SZ0H:"61XSB@SYKH9
M/"8-J9X#L;7)MR'7(P/*I5Y@B*UX3,;9Z$^$TD<P2QBB8ZP$,DVL:7B:U4DR
M'N8^(!4WSMPXIC0U5YJ!Y4H$W?DB2+K!02=@6V'B:D<-V*/V#0P=C;''B<D2
M8I%3!K$=,Z'G)RI!5TWCVUN0NAN]@,X&81#JU2)C"TQW3!^*,3[0&#("FF#5
ME`E18#0`L6MBWPWFW_^*!PQ82C!]B2M@&J,ZTOR)QB]EK30.LVZ$QDZR/T,N
MH^!WGV83)ZC'S/TI.=V(`N:L*4E[G(U\C!J)T'-Q?"&4U_B@SN^AK^WOS"\4
M@K+`#%Q7RHQ;B<STAV>Z&5`K4GJBFYR,)S*O4E\O@J8Y]@D_E8B>I6:^`B<&
M'!>S$MA@V+'X_X60EC7:Z<!SPV#EY:Q$+T:A-S/&XI)Q,M+/%8L>4-R^7(UY
MDZ[`#(DM3"K6FD_U]13!H`+7$=!7/6`>I\([<#V<XG)TB9S_&4)@XLY6-OEL
M(V$6UD2E4J&-<6S19D2Z,F+XQ!ZY(TB_<EX!LTHN*K]4-);E>Q>@09S%8*Y=
M$/]#7.$V#$8<C-\BHOA)"I)9O<7D%A=@^0"LH!\8=Q$O[B>*TC&&I+ZB47@X
M2U69Q_7-:2RV83,25Q)UH=?P!8EWC2,_#&6_?3*Z:C$VGHASC'ZR>;<$SE>E
M(X$/0/HQ^JF#-@8'H\S5)L-D#4F$F.^IS1Y"GK<VU,:(!-\`U&YN;Z%'%,\H
MZ(I/S8]WQ-'?F/X!\5_,`[-)I50XGD1)&F[/4+W,HT48/XV+L./$P%%S/156
M]5*O!>/?+E<.I"%ALO08G6L)TB5-\&7:=V/HFZYLQ3E*'D!IWLF.-GO,[2V*
MN*&,=W=D?+F9AA*%Y6!;G,#$)B8>=W0XY7*\.,D$I5!7I;17(?V4G5NNU-A3
MR/AXF-ZRA;R6E5UP"2I:SM;OQYD5N?B*$5.41Z?`M&<P^!V!6V3FV`9VV1/^
ML.SI\-D,CREX'Q\;PSA8/.A87`O2FA!+@C2-QXV.ZY.`/H+<V1S,M@NRF7F)
M58\_AO#&L9C</TK:S+.[0!,DY0!&,VWJ$81!,2<-XEPI7MD.)S``FD8.9KNX
M0LYTX(Z:BG,&)[XXMD+,A7%F$W-NA\1@CX=)9XHJ/7AZ*04D>-,H'H\UE^P'
M0D@-[AQ70F&(9BYM-FQQWJ,B5IIA_>ZT5*O5M-CO&@W\'(6\Q.S!SV+GG"9+
MD."A+TV2R4S$LB2YGLNTBB1I,%A`TPF+5HJ3#!6)JY,"]NC$6U%Z<>4.&L(,
M)R;I=$GGNYU9[^O=VJKN9_ANNDV6=UE#V7>W#\89/M^*]FVRH^>8R.H`G.^!
M9A`73.(>#7IMF"'&="4.*0EL(S.?VB>-EPAT&(%'3T(Y$>BK8,)$P4%LI0?Z
M8DJS))->G-(35*7W7Z/1,G(A1.;0OA-$JZ`:0^Z1$W;/1:@@RD@\*LX\7%.T
M$74.'+QN#=]9U[MV^HV00]GL>?9<>K;$.IZ$Z%)QT=U)Z(0:,[FTWNN\FQ)]
M'S;:]'21>"OTGG)/^U0])V9;V=$M%U@?Y\<#X\.1CB(P,!JF=^&S.ZVI7?;$
MH<\69Z.04?LBLTE@]CQ-X(M[!2(`A7.S:<Z]4,];E6Q35,@E?@DX6'2AQ*PO
M)<('L[7?$IX;\]QH'V6VE&`:U;,58F1=A@@'VH<8*-K)8(^04'-,Z?0-R;A9
M&X5BN-JY!J$YCY'6I-G64G%P/$OQ\?`4Q/+3J%B2Z*.2JB![5I(/(B!!>HV"
MC%DPP@5O/'3P_^V]:7/;R)(`^'TC]C\@//:N'4&Q>9-JSWL1:A]O/.MK+;M[
MY],$2!1%O`8!-@[)ZE^_>505"B!`$11(D1+F:%,D4)65F969E97'"HOT(R&5
MPQB90]N061919KGD@1T=X^IVX:6^[08P4SCTL$6!,OJFFUT:YFWWJRQ_W(5N
M.`;`OJ&8#&G&Q&PB"C`KX;\<"P??NR$;043+&^7*Q=BS,S7N"9DEO,B9\+P(
MU`_PUC^>=9[1WRO;<=3?>:@I;G0:NBWKOX1W+6*@%(!J^]&9A/?&=>(%W@%W
M7KRVIF"HB_`,C7%[%8E?+?7I60H/@A*J>9!!\4R@ECD-8C@PI$]CP#:]X:@W
M/-<79PN2+3!K=_BB:/FQLY\18#F`//\?ST8:4R:1L">`"%];)3,4W&\SCC>R
M1%;=9;953JUEW.ZUH8`^AH^,?CU-/\FR##@LP+-!Y'2!*'0NR6["`]`7Y=E!
MR/HT<=MKMLS)B;R7I*7A*(0W(:^.E8"@_("[KRAB%15@$/YJ_<<[^I]-M)7J
M<S0![2GU\)DGY@#B^2K.:?LS^JI^3']9Z7@@.._.%I@"D#%'JR%:600O2F&M
MP+E[&:S_(BM[0AQS'YCMMGJ]\T>'OM.DQ?ED<AA*U"0\;A9N+#:)CH<2%W_8
MV($^KDU>W)^7[K(S]C_#@:1)OUN5AQ_4=GAJY!E6%O;':90<+=/TVKWA"F,*
MDZDG]L8XN5D.PCR]UG`P?BQ[^U&3J;M/,A7L\5_(<9?YZL0O*THN<+B@ETQ.
M_:H,"VUM4+0<1L19;W5,`P'U7D>C?$@C'`CZYN['N/M1EYRY'$=EP<DH7P/9
M`2%[CAY^G05IA).D04!&8`E>+,CH$U>'$,68ZAE9+]U7*@[*6BUN(U175J2+
MGE@R+M\7\1G?,J2_M?!BY:4+`USAU)F`3FNV"+#P`:8=P*L4Z9\9U?S+Y;S]
MX$;?/KTL`(5C7$*K")17F?())EIE$H-<+5T6F4LN`NXEWS-1AH1ZD'Z(`X4+
MRW@G@U"Z._$MC*R*^3Y*QB;->6[^P>7[-=<Q7@Z\7%3LJU8.N13L(L*5'<9<
M(:(REC=@URK#K*(R0")S+"G.)<;4V&LWHH@'`@9XS"7FA/53<)5%>2(JHNTV
M2R)\`O_/RM['J]1K9/`"_@9DQBIG637>Q#`511I'8%T9EU*2!0-CR5PH#"3,
M3C45\0T&TI8$ZKEIPD,6=#V)PS3-PRLAT3"K^!U=%<2[5>DYN-R;NTYN+2N"
M@2(*A2`^P)"XT)6I$]DUZ9TN+TP-&1`7)E&Q/(%U`'ID>$8*$!6A*"$Z9_`4
MOB+1I@5'GB_IH;AHOU(6NR'.#'H<SZ7>FHX\OL#;=1C?8[H6UUH'GDNU\P4Q
MOXY3,WJ$-,H:T5:D3UM6JB&0MS7VB-&1^:]M3T9T%H4HZAA`X_<5]Z_A:$MN
M[9,-&PZIADM(>P1W910KN9*+7IX*SQ4D*E>P6W_*>$U*U^.R!$XB5+A4M``A
M>H;BS/)MREIC'11E`E-9_!DC4#XCM5.P/*I-$TP!=3+\32%#J#:AEA?8?@X<
MOLC'!5&4H@H"HQH67/L'BRO03)08`<(5!;(=QR#\9<T:&@*CRV]QEO4"2K*[
M.\<?9*%/S:02X:_+_'`@B=0A(,%GPHPXH20R%5L;9%0?!V?8KJRO`QB8BXP^
MM%ZBH?#3C7G85RKNP2@>%5I+H#.74(J!QD$2*>RHJ`RM:=-Q,3(6%"D>SCS&
MA)%!HK6>'`>M"1>GHZ!PAD`BCFB'VC6K_I8V$-']6^(UX92)8(JAK\3!KK]*
M)$9!2?*C.AQ7/I[XZR_<8`8W3TV!RYI@V>D3"ORC$!</V-R+F$=H"*+,TKY%
MNB01LXE<#(U'8-"8OSY22<;_BU.6R[2/B+84F*X!%W\:=E];?R6!RLL@]HPX
MX)JTLBHO1AGON$JR)>5.,EA1*9'#K/1D$-[;$N&(W@CVCV>'I3;J&DVH"$&Z
M&:CXC-YJ#376J=$OI`;C4(HMB<>,T'K)0?XV)BZWTDQV$-B.\+A4'E%!*Q([
MS71Y]4B%3\YB,AE52F&R74Q5[-,16Q8D8/.%2T_@(30-":0HP/W+[).(HB?^
MM?IKUB%AU+$H0I5C50N4K+3[TL0DCCV5I0(5IYMYJ?(-TR90A1XR)I4L`5EX
M<B.'(%9(2-\PQHLLK(QY)2MR88H?B#6URO6Y%JX(,7,EF["429Y/$P2I;@QQ
MI)#'<C1XV'MULPA4@KW*\8*QS</1%ZK>&;;2(S\=]E/LK0+/G:FL/C!O9\)!
MBY,M%@>7$+`)S)E=/$A:6D$NKHA0*%X4#LK01HM+?P,E/)/%89@C.&HW6J&O
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M%+V.UGP"#G9W]2279ZM^F7I5WDWAZ:2E;SPP%1QW`V!KB2XDT#(M*W2C/_F2
MBB9LX:`W`FM4@?8,4$?1C4##.CC3149,J!*CRAV4HDM=@-D;G[^+;GC9%@5L
M)LCD*E4U%D^3YMC>K05FMRBSV]BN,\27LBS34@4E<MCF2K@L3N#%-$/J)28+
MOK*N\%)!^BG3^YNLP9F.G;_K,%*KRI&R8^6XAF>99S=5Y0L%%2;F^Y_4^4D\
M`OP;)'2$T*(.:Q+P-91TZ$FB%>FT)LFV`)S+5`6\NV[B+"2+?M+7(E0%216T
M<$R-*1A=4K!F"BW1Y;TLA1(&R=5"%V*I7(3%K-+]\G,`(W0[KQI!4AKWE2^Z
MN\;PW\1,W79=I$?6KV'@P^>9V!QK=("BO15NDH^NX/!N-/J@2@YVNMV6ONTQ
MKIE3,EUBF(0=.I'U6P#_F,72WE]<_F:6I95[IO#E'RO:BV;QM\L?YLN?@S:!
M<]89MC2"5$R;H=4_@&6\A(&^!RMW9O5ZG5>_9JI3<XG`]3=2!I.&]E7B<FUA
M=TG.D4C5?,?"%>Q_T759A3^[U3>E)'>PM"Y\F;V=3*-<N,`1FWHRHQKTINMC
M53H.FA'+*"U*@9J65&K6@G$)<L,K`VLA,(R^-D!`&A^)H2EP^2/%)]:^U;A\
M2_6/;!V\E#9H>(ODP</T!>Q'AR6A]+/ET;M>0T6>Y3_0JKZPP0!LD"P3+O_$
M,8>%A,2V/P"N)+U))?UUMV=1W:9(NLB,$"\.>4%K$0U5689`'NKSL39I^5PN
M^8.G:WPW\*67='N(IT`M6<.'ODKC*C-O$"#RK4!923/M?RTN_(J5!ID9C)5&
M"D_&-M%%<FW5'F-ZNT9Z:6RK^(<U!&J?:A'GJ1`Q>=+PKSRA>B#@W78!_'RA
M9<4W@15Q(3E9VSNAT"1TT>0"'XVE&WS^!S6OH1MSAP_BC#0WXCA*E$2ZOJT9
MFY2>0`C#5!I71JD1(!4,`2Z]ZU(Y6*X[@\$.W"0U6W^FY,!2-+PJLJREB:K+
MAK?RN7*/1ZL^CD;-U3T;/'K_XOJD%A$:M&/7)7+_#$6VELA2/'S'>G1*JXT'
M15K-]JT?/I[#X<2/[D%XQ?I-^&(.;/H'1F/86.[4^J*+=W]414?>8.`.[(4;
MV#8M>.Q27E/C"/A0BV,_\<\WL*%<K%B1OF&]^PDJT+#0K)<V;V8_2K3O@/3/
MNZ5`3%Y9U&X[@A&C/[$6\DR\2GN#V:F"H:,C[&E$#VT\>:GE6XFYTA@`F_)*
M):BRRXM$2_G#:?5H7:)&2L12":PZ\SA<XA\EBFV9=0-E$`_754<ED)9+IS(_
MLQRV55``OHH/M%+/$'XU8XQGW\)Z="NJIC\/L%(?>@<#&=T4T\W.3C-;:E:6
MA>LSLX\]-@H4V6;)3!W`F[;UH['M&\4&1B6:?R>A&SFNQJ*,OZ9P8L=QN4N/
MTD^X!Z@FHQFO)1U=JDHEUEE,*SXBZ6EV)5*MH!)$JJBZ>07`&`8%%Y,F22*1
M]@V07QNUV($0CGZ,_6>%7$)^6ED%K26O$+,,*R,!>2\7\*QU)[^F\61428B'
M0#"G(FU:1?58UX'D"U#62,5[$RV-M$T.KDE6;L-"ZK(29K:`?J1N/N(%K%H]
M-Q4@'7PRD.?PM)67J#*]CG*3GK&].DO+(79E@?2,TFFC?,%.B2MJ;<YDTC5%
MC?74M`9)JAW78<DU#')K>&>'U,!(VCHN%=A:NK%NIV`L).4/8FT=A12DE1Y)
M:($=6288Y2X3*-C5#D]QPT&$W["WDAI2[:(RZ!SCMF3-4),R1?=G`.!V,:<V
MVVU:"L"D<DL?CV'U%'P*QK%?4=Z(R$H+H4N+"$M*8K>V*(U*0!.B12T19"DV
M/@;IT<Y0@^#XT\!QE:9P`F(N)<#U%D)0/,LF"&2+#])<ZM"T/3=6\1U2-3L%
M0QFS_><ON[=/SC=@OL3XZL037^9O%)C:C7.IX?J.ZN_(6C!_2.OA-@[P+#ZT
MV\G1K@*R`E6H6+::SPE%G33U\_92(^S1U\][A$C4Y;P/@D"O>MV+4]H`QU<D
MKRE`>.JXW6'+U%"_KG[,?;-OM&4;5<37@4N?W6.5SW=<V<%*IPW/N\>-_(:2
M6P(XZ0\/0\F:)-"=1?#J1Q$<0=T($W^O`FQW<V@%^$2*I?7Z@X.CMB'.EL3I
M]PY<X^H1U[&[_PB'40R]JHKA&%!S(LCMMKJCWO'OJ`=0MA]%%/UJ="K35Z2-
MXMT3+[X<C^I![3U@>-40=T_$[8X[1TS=IZ7Y[U$:]8!'T*,IK3H>[+-X<D/D
MHR#R^?F![:`G4ST7DWTBZRO7=J/9C[4QJ'=7:ML#Y`71Y+\#I!AK\5%P,5`&
ML#]Y#=_85.M$0_Q[2\7'MRGXJLJK'UH8C=]^L$4?:0S!%]_Z9-_*GGZ=7(MH
M*LQ',6Y<?=6F2G\<+\BE$^#L<!4*D98.L:)DM?)TJ@`.M^D=BB^\DXS6[TP\
M,QGH]X\?AT8V$,<-!7B7'P8W5K*B@#:8]PKFNI*5!I_WJ=TR]E]^J5I78_!;
M*]?P$<>V+A201KKQJ[8E$=8O0AA/+L/KGO?T9"J3PPVCF)*!9@NATOL_!]<R
MSF^\:4CK>3<_'*`SD,E%,)Y9B45_4D&:1`(,L$,*</B4[:45W>99LO]4N1\8
MW$A8PAH`&'L%QN*MC.15E6%G;CA+EAAQ-<.*!-_2]NUZR4P;!C.[NJ7M8,H(
M:!EN8^G=ZFJ09X$/?\G:CP3C\^ZH-1IU=+IF&B')B*/`PE!0?.7Z-#)L6)::
MY'(^J@YC9I;QD)",;3<))CT?Y;_)YI=K"\T2(SL]%8F4Z\N"L;[&2:O?3Y>8
M;LW>YM59VZRL/VX->64$179U*1^J%7[/SV%3!)N''<.]`(LC\>!66$!SS>9$
MN'Z/<4I]H?DQ`L%$J>4(VT&[@P-KJ\R813Y-.1JIK4)A@W+>M47J%(,TEE5C
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MR*Y1OTQF8,.$T@7FM`=5KRZ6W[N+/04PFX+G'4/2]89%XOH^$'^G=*LEF&,4
MZVY[*MU)/RQ3=:C!!`T#.GG",!6W#>`J:FXD*Z&G"46JF)J13^<%_A77&'?$
M-&YQGMF<_C"8T-?"!:L0$I:HOGIQK+Q:1+00(FZ$N#JK<0V&\Y:1QI\[K:D-
MB3F(#W-:RQRZTP-[]NPV,BLYW'5NXV_A0#7<\O0V*CF]&?13AE_N:6Z`X:AR
M[T7&K(8"L-3B_(TE,"DQLSP4I9D>2]>#C1SX5",M9SPJ294>[7)[NN#8%JN2
M\&O'MC1EO_#81B?7<O8A6,S#YG##V97&6I,:.7X$79#+0$QQ85`\M=_-8R+-
MD%KKA1-H:+<_#%M9\0H43MDFBN%TM4SY%QB&(#*/`8H@W<Z+ME5B4V4PU=)U
M_/EK'TO,LD8I,),+S\`$A+9Z,4,41#9H$3K+I0=%C`TWCXIZ9!^+5MM_4K$+
M943KS,4UFQP,ZMZPX/1+4*0DYYD&;>M"Y^5ZV7J]@!#/HXE+3W'$^G"H'W:&
MB.!T=,FA@QR.V194>,Z?N.^-:&L-R7@8[VL<7R17B71F]&O`='H:S_D9WHMI
MF-BA.OD/"Y!,0%1#]'C<&HUI.^?';\FL:18=U-VJ[#`\QZ#)MC3JM#Z_CV&W
MX7@X[*=&T[C`9M+G9AJC[*C;FQBFUZ#HK&O58?"E@!0OIMLU[-;NL%N\'&O3
M4@:#<^/8WAQV3P.B.X[?HVV.W[8Z?&]Y]OY`AV_L<^>X8,PDU)$LU%G\`9XG
M,T=NPQKCME^&><5*T'B9P,=S>G:8/[Y_,&TZ)8YUQS-@X7X/!&I/=:F3G>`R
M?1&QE$?Z"K?C00E)KQ`DXB\J2(LGF&Y[>-Y#2V&6;4XX%3,;2Q$!'5S,'H2'
MG="^*=`:YADII[WLR"@7%#`E9'*P',.@":*0\3+#T[-]):P4SA&KZB*$I%4M
M#*24YK,;O;[I.(>X`JO%_5-A2L^)0W0[9XY]B^5EDZ4XNR$O._*2A(_?,(WR
M/RZ^F@24["4M'T`8M^J#(=?<N+IHHL)>MI]=#N>I&5C)CBP=13L)BQQ7Z8N*
M7$5T&+:&D]'.?,EX5S=0R)?=R?D]+5A51`0V7A`6LK=LR;7.GO'"#??'G<6H
M,=DPNTT-5D0.VY*M)&IT]1BY+7)6?I$)KE_4PG33U8S!)EFT%7/)9#*HR"5L
MO6<YA:57ISWJR5L6-J"T@U4!)2F'[R$C@&E'I4-,X9R7Z@4G8>6D;.7.-<A@
M=_I/BYRN?&+ML9\R:P%K-QV^DCZ4<\@JU4=@I)V&[^4V3><J=YQ:A4Y3Y0@X
MB+O4RKM*L19-+89TZB'M=@Q3\[S+I_@B[V+6JZ@OBO/F\7NY%>[O#`6SU82M
M.Y[D@<NZDPO<GGG@-KH^\X1GWY;I!1V,!VM>4#[A==0-X?9>UNS0W59_--[D
M8L76L.1E?3[I,96R[E;-%G>Z7/4F;1RKNSI6O\SBP"!/[P[?:LJ$E@?2"AL_
MIBY$=I/B!1$%*:$01NF\%-)&T2TMN:^"4B78,3KMB`Q4-9INMJVO4CMJKA`_
MJ32FJG.)_4Q2&%K20,>.KZA#%L)SUMRJX_/6L#M.]<Y++G@J?9\,*0@W;)1"
MZBU:@23.7?U<@);SU'7ZJPTMCN]YAY<&T^1N\=XHJ7&9:@W5Y/;6M&=ML@&S
M%QJXC5ANF]T+*M>4RNRIIH.`WE14;BE"8Q7LN^R.LKTH*+JRD*TL%`_E[A[@
MC*EY$ZTDPCJ\A]\#EVPPS1;V-5=9-K;`%5EZ9%_JYJ&R1U#*>'WE">=2B&F/
M6S"^G@_;HS&=`U9!%)_Q_B`@B-%U6UGJ]65<;%,/,[TR+'1($EX62"0X,O?+
M+;V1MQO!RAI^NB!A^M#T5N%L36_@AK+2S430?$Q[O&/1KA!E%%U:^OF0FEZA
M?9V7/*/NN-4#6QJU/%C)5+0_0SL#GTQ&/G@3*7,"X))>S%TGP>):R$7((OIJ
M2TM;PD4)H[%)D;W>5_A;-UJI\K]&*_=;RJN21AZP#VQ.YR.LN`ROZC;%>6Q)
M_<:N<%E-6E>^H5L!W(?_G<#VDU\,US@BU01OJ1V2P1O(]1%6DR*",N\0RZK>
MS,%,"">B"J+I"=+VM*''K[#3/2VH:-1=S4/SKQ`+>'^E^I`&)$T-KGIK<,7!
M:HN**3V82@)]%G)V0Z<-P-98XZ+R%/?)/+.K)O5)(,]'I5`6\D[]H*,X0(M,
M[3RYKZ@[:>`Y2D,YZ=V,N9%8RZPW*-7[5W=M5QLUQ!9HOM`#V[)FGB,+?<JZ
MNU*2JSESRC"U+%LJ5(';I2?+(ENUH)SC+CEY=[#VOOCY>,=]=-B[CPB85A4!
M)[WML[7`"_:[+OU=H+39)A=1E#]2YLSZ?KO72]W[KRSL12%CD/II#%+964"^
ME+<04KEC8YENXVX^4YR>_8"`G35W@&[HN;TMV\B?1O[L6_[,&OFSF_S97I1(
MV3,H?6'<[DW,%^`?%CX$2`"`P($Z@HE57UF=S`6`T%D9`W_H9$\N%1VAT(B9
M1LP<AYAQGI"8H;,(GR>R(J-<`HS:8]-D:5G#S@OMWM/7I)DC4F9HNK!-AU?&
MRY;R@[Z[>T8ME@RO26,,-5+JN%9Y'RDEGJ:4\E"*Q`O;KW"JRE\49,+M9#@S
M70+JRU*^Y^$V';3MZ<ZPU$63.^1A;S5J)\+A)9F^I#S&`@3/'"14)F.D@M#8
M9]634W'QY]@(^Z80*Z4\1)"L^?+\5-:O>_58I+N<-H)-LU#@DS,/6Q+Q'8&R
MM'.^?WUW8RJ9-,ZVW+V7U4J&_FEA6$D<NE-]^8[-[*--AC]='8(4G&&K4'XI
M!X)B/5:\Z)A,EKAOFKNC\@`-RKPR;X+-_%SC9F<]#"EO<QA2@@.3M!V$J8PV
MT3?>[`]6?,8P&-:*3Q6"9+396M*GO"-W&E(?)40T^T51^!;1F]+I=$"7WM)2
M_F%@"\J_6Q%+Q6/H5"66UH6=DI[;S9J/.1MQP)^.\$1>/N\5ZN->>SR0R23M
MX22CF;,Q=IDK?[<XE4&UKL;?:4T<2$%P%"RO=&/B7DL['[O&,2A[KGA^+NM%
ME"8JFT$-!$9)\([1BPO&S38UIAZ9*N!DJ^A,#A\HHZJ*V\]<:*_1\+S#X8`O
MP63JF(39CA2.*"2%AB?/IZ2X<A`!($4ABR5$(S1M0[1>ET-I.)-O&\J5A5QM
M3;7RJ-5LG.=&NFFUC(VLA31#"*W26B4$$P40-<S$(0.B\2179W2^GDN^7`.>
M;5QIV918YOCU`CZC[1,6VCYR<V`,'Z)9V"$<ND-@(L)9,1Z8QJCVRE4=1M$]
M[ZN"+6D8*^9RKH>Q6B4AK`7J-!MKI#BJ>E1K?H4Y#D[%Y#K!.910"7!Y8LB&
MDQNVPW:F0?5U<+13+D(W;0*X2PN_?!M`V,9+EYO;7_C.&V+M*P%#B.BM&\V`
M#9/PP1H`;BX;F"W!^%%<P<B?;(S"?9B^@"=AQ7Q0V?^=SFA-D//5!:</W838
MIM6GN+O$5QU<]>F&@B:#D%UUGCNC'`BNV2`%C(4QPW*34^-8,5OX@1=<8;ZU
M0P/221!C0['/L1H$Q0H?[&S5=-M)U-AP-A)7N$%`M<$[*NI>OIJ&0DK!*-?&
M4GW]*6J)[=!Y$B%,(BWO,\`2#/]MPTA4J:UM_;%PO6PREF[N/!6P]FO9CMQ`
ME!FQ&8KK(.V("V+'=<R^V*87<PUF;='Y@>41R\\\VUVF0@K-$T"<SRK)H=AJ
M$]*9[2.<LKX%7V3!P2GD&-H<U*SP\/D8/3$\H9UFX7,(/,5N;L2@N18'5PC,
M%81%F/R_(^!BW[YB`FFT`C0NYD+'!HQPO,+NW^EQS\5W*0H?/GGNG[*?L6P&
MCE=;::=6[FJ.BA6K0?BHR/T@CPEWGD$&!9("0"8:6L2\G#1C?"W[D"/H^1ZQ
MML/!]!Q`CUJ!HY0W-R>&Z8V^Q.NV0IK`I`B-'$&HF\W")+7/L#=L*/M8&RAK
MCIUI;1U@F]ZP*%%3B4@"!7#KJF[RGGT3)6X,A//8V/DD?KJS`,70&Q'9&+KJ
M7^'S"^LKR"VP(^C$]34,P(CWKP'"]D4;+';K3?OW-OJH=/_V\A%2BJO9X6"'
MG<9E#V^0D\A5AA2VJ6`,+(FLKR3B%+`Y;`'D>`3($7-[:3-?@[V."9ID>Y*,
MB;))?L`ZTIR3R>$"#2@EU354+00"DQ/Q>S*-P9!`L06G@4AP90S,R8R\]%4G
MF"6REWQ,?*P0GX'`%*F`,*PKY]LAPV+3-17)$#=*18;"E$MI`2M/T!$8H0)A
M8BV!36)=JD,JAFOW*@@!6?`<8`=S=V1@.NW++$IR6XXA:;;=W=O.0&)+VA@8
M'(X!^_!OBX\2UX%WK;-$I!!F+.*)R(UDX1)2#7@XQMHFP&4AZR2DVE1VS3:*
M)*D!>'C\!N\T0U?$^'JJQ)2J2I43`2+5?638,2E((MT@Q!9*!=RI=[9>%<.@
M5H6\Q6>PW)4*NIU)'TT%:DR-2\I]`CZ^DEM>:_OM=)::F,_QJ=+"0\VV6NL!
MF*WHJBS7DCZW&S(7/W=#V^W<=>VV-9R/>;:[:+!VQ'L'$CNXU7O/J.U6=MQ[
M.,*="H/=`>?=/J)4]SF6T`0R\V!!R*P\6X63S7'O2WG\I[A5^:O70IH7]EH-
MOHPI(KV6(!6CM-:7<8=#!;]0;]S`%[=G<Y"4RN^'F8'H!",YB[((!%$:\Z^.
MG)AFN[&V.6=^X5*D>USFE>42;TNRO5<!6!8Q2LD4EIS?=S)(*U[I=#E,GO.Q
M:$1D>Z`61%$ISU:_6Y9OD.>IVN5L<:N)O>Z"^MIWH!-,A*2[MA`J^U17QV:8
MX7G(]JE,7&^$/-PYO[/<Z"S%YEK-T/A-@EFQ6`D4"V%B;AAL/M^EDAZK()2&
M2.I,YQ*DGF=.:AK^G]Q9&,QN??G=>"!+>FK#[8Q#Q&S?18PLA.W%BQG:9B!=
MG&2&9@SL0NG5_1U#"MS,<.TLU!:6H@#10!F]?!;P;395]<NRQ0@?SUPS0Q=]
M6U0`@(/6=`F^WD#AED^?QI^Z,GZ'$WASB;:=MO4UE]^JIULO)"8E:I2'5=;,
M2;P_%5ID8Y7L4]C"R$,&6MFS/\$,ECG%G$BY3@DK3P7IO-J9$M_7S^(153O\
MB2_Q_1+*<O(-,K`H]0O&HNL3MIYOUY9YP8=%.H+HH@I(#SZHLH<'UKZ&1(#[
M9A%XWNU9<"-SS+YAM$)L_9:$'N@L&P\S\`@S@A>I?BJ."\N1[E237G1LQ?\`
M*&WK4]@V!D+U`_O5C#4OV!_3P`X=*L,LIXBRM1\[DHN.^K;_H46@4?!T>)<0
MW"C_=)&^3\`Q3H*>4P1F!W&H;)/20G$$3,&>Q#I%9_#*&97$@25Y[E^)Z]#(
M5\+3F[&]$5HXZDXC\5?"A]LB:?C!]X-K.RL-5>EA+=#RE61+9%RN9H04H'%6
MMI*7%D_+N9GI76IF$ZEJ)11E2>42<JBD^BMY!*4861<,:V*AM1EM>1&A1-`=
M8L*J0T2DVZB$8_3O)#247_T.P6$UDN,N9W)7^9+S"D-5KLUS[!1,?I_X<R'U
MX]Q5!86R_NA,8:PB/8?;:1LI@-&*TI&3*0.\[OZF^BE3])?:<*YY887!+6AR
M"K/%>`&L%>0GHGV/E@]K9HN^>)>#YQ:>.7EEPTTB515N<F[&]?5Z!6UF3)#Y
MYOW^E<YV!+C7ZO0[V0"N7JL_*JA^K$J?\31N-LY$V7+RYVBWR!HE"`H"5$@D
MEF`E&TJT[BPPHR,1(%H\LQ@5FD`\3#JY,+;>:%#4-<-`;U[O'.3T>Q).=A!'
M7+O<.B^HT0.:%\M@\=T_"AJ4.'2-!:((M;WKN"CXN3RUG\Q!W\&I*+2^S!)0
MK:FM[W+Y'GD#9EYLM3*M!-.X@5:JGC-!U9KLU)YBK0/%)ZR(^A4DY!(L)]-<
MNJ09O[4_IE=J1I"_\9I9$297KN6CO'C7_H!,-@`"]IX:0P2^."-[P(PCUJ6B
M3)XG^P36;H)M^\;2-3:TG$_ME&2J(@$RKBD=T.BRWXK2.'):(E>X#.\56_**
M<$.98?,6A,"(S$V6,YE6M)J92"C)AX#29SH\CRV2)<9N8+:7C'L@DP4>]]R_
M11D(&P^4M$Q]T<K5*7&.-"=748;!,:BCNS\6E"(C%N,JJJM5`&R:)5>4-293
M;F6[+(\6A0-)*+DE=""I42C4J#M5WDIA6P[*46C#^0!^\L^H*"!6X!5XR%`)
M@6G),CO;J:%34/!U(3&C0MU0S:D0GNSZ,*9"P<8>3::/RM.#=[",2IHVLA2R
M%E<ANNAV5[IZ$0.W=`&N#\1IP555/EA*0#['J<X-.+29-;"V^?EFS`8ZX^WX
M3!92]T$8<RU>(F<.#`:8R\G,,+\2?\`.:OI'*G9+M0?A7R0JP2`)BRA5]V\>
M]TBC7$D=74KNX70/&U4BC6"BM96TC+M/K&>!*%8=V>*@I5K8:!-,TB--I)3I
M66F'#%@A"QPL3=S<9_.U268/!X6*EP`IZK&;W=.9+*/ME&%.E;TU1]A)GW5;
M6VNT%'!#%FQP7CR0^LB*+Q;]+/"SZY'!)`1FH=@OTM9\I84%`:=G6?*E1G_N
MAFEK%:XT/JMQJ00IX)[*SK%!#Z8T^AQ^M2[\V+U*;*,YQ&]V.$T<NV5=A%=X
M$>73QV1J/O,F">V9#<+@-WMA+^VH16_93H"?!.(<_H6#PK5K\UGM-^!T%SWD
MOX7VWZZ'_\)JHH7UK^36QAG4WQ\B#]8'P[P![@*:IG]C<`7\`\193F%8@&$*
M_WT;H/R9&9]\ZYM8D374LM[-$@`J9!C>>=:E[5W3%]9[#&E*I_\7_&GCHO\%
M+]A>LA+T$4XMM@??_I<-T,$_0`18.4#SW[!JFA7.,(`B]R^L@/X9O@EMP&;+
M^LH?8&M_%6$"@B'F+01HBG$%@KZR?@=1BULHQ2P#0K($CYKV$F0+_`M'+L=X
MZGLPM:\`_=\35,<&70"H($J1]B-,&(K?017]G8!YQEY[%^43.Q;XT48JYZ.,
MU$GYRG?_5EZ*Y\.6-&ZD&R3C7%FW"53N5K%\M2ALC8_EN/6Q-X)-$@(3N+%P
M@2M+ST6QEN(;]OP"G@M"%)!4<A[VMZ[0@D'YL&.5AR@"=>XI$\/(C(IO5])T
MD;7JT2D#JS,,)VE+J`%SQNB:7V9FK]S81H&`1W/9VDB%>Z<^41@ORIX?=D&H
M7(D\H,H"$DL,9?P[[8FG)7J4%N:O@GP%8^JW(1XA2%:($E>'`.S7\S'NFIV=
M)T6MG75H/&=NI4K+<&3=KY$`[@XD;7]L=L^:E+9;S5%84D?E.M-WR0J@Q6LZ
M(8QJ2:YN`Z)X1J^ADA.NT'.H5C$>]NY:19Y'[[6"M8AL#8P^&K+;5;(H6$9G
MJN(M<Z@\%BC;BN]9M6FDGI79"S.0=*!ZPD;:EZ4(?8FYBG"3(G0GX@@QWQ*P
M+L%*-#RI;H.F`FO"/';P[9[%`0"IWY1%4Q:C+=6(0#HO4S%"V7LH<#X+L&CQ
M5*;#<+H3I590CN&9VWB=-(%\!\2"[KENMM4D0&1^0[]M*9#(X2`BK%T"ECK&
MI\SGJ.P0I$LXY]F`J`@-<WU'W<B9G%N]5Z3PBYH;B)4MJPWG3O&:&'3`13.,
M:HI@G"2%[D1T1"0E1?H]*#O\!OY5@$_PH_#2PEW1%#DV)&\^JAA4@NY<VH=7
M:"#Z?.I=&R$%,CURLM%("1524ZJ'3*`XJX*XW,402.GYP\,<<AN56\X>S%=@
MA[F<?(%I:PF8O!QE`!@+;W/7",7>$=G@&B]2T?L07A-39_/I,LMJ6^_2U,+L
M39U.LLNX:U1T/H9SRO1P8)6T5YDF=KFW7472ZQL/BJ2`$<'*=0,CE<[(8*`@
MUT"-+[#/`6+2NSTC7ZYC\1V?JP)K<[Y0\NQ27!W:B.DBF5'9G8OIOV;OM6V(
M:N4(VD*/+S4#7%`*0C";)4W:2ZII$TI>-CCXDCDX==0A8,D#Z%T",1]<N&FO
MK9O?Z76*=I[!"VJ,]>N2@L0;?#D5B]@LALY(1:R(.59X]-*[R(%3G!>LM!Q(
M([-R-KTO;C"_"_N$7=/&_O;C^W!R-I+Q2.0P6*($EH*`3&[=Q>B'3^YS4MKD
MVR)G$WNE$JR0:/OXC/3?4B)QJZACWW>5%\N1[0H]KG]MD]N1"B@ZB2PARUY1
M[%8>*W^#(^94#BN;<%MZC4J]*55!I?,-RHNES07&7=%4GX.VU=V*(Z3W089L
M:?Z0O1AU\TX+C]NQ<9V`1H<L:#)N=]>RH<L6HP/'1ENIXNR*>MNL**^G`VN>
MA'2N2!M[*<+EEF=<ET@0JJZ1/21F#[%,LGAZ+8]"&^]IF/75W4V403#!H``8
MM>$8O166+_#*B18LK[!H7VGW]3:KX.YY5N(O`\?%]K"IV@.C(H$)`$:9D<I:
MJ]$7^LBQ$;,JOCMCY:7>K?0&@[NK8>`%RL.(1*IYF>"&46PZ!K.FWOJU:C;N
MG`7^2H6WF0QA7DW'LJQ-:*_H[D?7A:`[S%6V<WUJYM'(E-,\%T+>2>->\U3Y
MH\PBP$8B('98AX57">8%;R#)/^S0<%B223<AH?YF"-`*HV'T&I/X+)B?K8*9
MJH+%OE!3+"UMM&3!*D+VERI+)J*F=V#XH(3/P-*F:`'E(X5A%N[45<=#`B)M
M2:J+,I1K7[JR,[Q.=#)9KD0LLL(P%S["CQOT,-2;X@S-HK(J!4U%]33$-277
MZ^C;S+SKH9"%<W/[5BJ4!`-)S')Z@41EMHFAR00;A6`35*9%DB%D5(.=?/E6
ME@%4I)6"HW21Q8R*E%L]RAUJ=;0,[V;%#5B'I65TV_J5Y47F#)KA,)-!>"@9
MZ9"RTH_V)<81!1P+_S9,KF!WX:TC7A[0F"_?O[UXE;EIO>O(2U/Q.=>])A3,
M/+K'A(,79U;#5`2Z7!],1)5I_!!FX0@7OW!D:4(5#TLML54L%.*)0%"62K;A
M41HL8@CPN\FJPG[+Z*8J<Y=20>8S8LRP](+K,N%$8AW$H[8E8\C(KJ`*JW):
M1Y>&266*()M']DHU;7]A3J1L5!#F>%N+;='5VO!<S1BX1K&H>M7U7\@;AQ?R
MMAX>T(4/=45R>(6*;/A2\/,B\;@=8;VV*'T7C"`X"X"`6F6[HO-%/M7/2=/Z
M>1ATZBWAE&_X[W+Q:\KHX\5+=:1.2%;1Z:C,?,RG%[$^RA5UU@HXHV$5YBLZ
MAO(^A,;\R[H++MF;=:F\64?B*U@+J<F%^[(3CC?#FB.NR`'*192H])2L/*&+
M_=[-5&C0!-$&QQ0?PM:=4]F.H?+Z7(8`JK)96=L:/J#O3[L7S2`[]9N\Z"6/
M&!_=83,&L$E5VH5G3]&+#_81BJ((*WJR>I"^RV\Z$.1M^BJ"9WA#,-'>)U&L
M/?D838:,C+*%=K,]2RL51[=1++"PSP7F4?+5!0="YJXO<K[+`@7!Y3_6;^+3
M.NU9DDD)O"N)R"U#ICD57:$#M@F56>X$KWA1Y>$A!V4797G=^"I"H+DPS8N7
MU&5]A)(E+U0TL.Q%N.^%"C%'V>W)W7<?*HQX)S5'?OK"VR&4@=&Z$)3^^>+Y
ME)]KXYSL4E*QVKI\KZKA""-/VL-")X`Q.5U_:'\_52'B2OXR]CZD?NK+)$[H
M>HF6E8T1=^,-BR==HFF')`]EDHDJ/LBNI[)^[<P81F@Z!FG,I=&K*2H[3X.D
M!]FP7NO,Z%'-!I$<1")12\B2\62PCDZ)8V.6O`BY<%VJLYJLI'/!3%%QP8(%
M:4P65TJ+QJ#:6:R\SS`TACX3020%F'F5BT>2.\KKM\UD!Z:/L"@HN4@3XAY]
MWI11O&7V2UD2;FCZ5+!0X"QTIQ2R9@3FR[2#A0%WQKD>E^PU8OO('%<&=AEC
MRZ+.EJZJE\ZA5DNYA^XU[FPJ_<,R+%,\@:!7207P\$SP_0O6<$"/&+J#L"^5
MA$"=8-)36K1^8%*`"%GS-"TY+JFB-RU?DMC6E7N-DDH)A)>(-BU=]+KT,4;6
M8P,1A+77,^%>KW)0$P!75(N5Q.CP11FAS7!`"2>`\;P+<E<=JJ2W'L_*NHM6
M]KQ-SI`;<I]%.0]K2<;&1BXPW`=R(AF6K]D-=AP8MMH]H[9#'"A6-]C"T6^!
MC7N-]?SF+4."V3K+!#`TH'5SP%_!67*CQBM5<E3/COJ(FY5VBY6-O%G)U734
M<??<D,4Q5G>'!,BD4\..\80-F^1YOSTQR&MM)"W\X:_=K2ZH"KG.U]`\S&%!
M5ZG72N<E;*/W"$A?[1S@''0II0S`K@H*/5;>D,Q*%/;RHYL;+R=`5[D;YF*J
M1&;'`EZP:1-Z8L8N*'FA(:0=)Y%#*`#9IFF6BF/E"G?SCZ^+[C169%OQ;=4O
MNHT[U'4\&0=/OD,6/VVT3%NIL-Y.YEH%\C;-6MHH5W,#56+T,AFVKH2VDV.-
MF:-.3^6&=>;.T(P[F`6!Q[)V+HW12&]ZE=$5QV*YBLF7^4N:Z3A/O)1[615[
MPK^*%VF7"'1@IDX).M'`H4'3&N7((KA!+7.[+DQ,?:.F88-]:?\["&73-[X2
MEQ5,,R<%'-W,EY1G"QTY(5U4!1@C'<(134;#/.WTDI%;VF^"AL1+=<]IIX[\
M5^1_2-OE=<_;Y[IKIF$/,"#2)BB6,^C7!A"I-UK#[UOP.];`-J(PB$N`\0*'
M+SR500,G556D7]%E):],Y+6-MBY4TH#R)_%M;DB7JBX.%\BBTFM]>G8^M:>E
M?O7FR+5.#(6[G%*98(-#VSF_'2&D\$DM#?2B2">!8%8%*&E-4^$+JDUC.]?L
M_L,K6]NE&Y!"M2@6MC<G)P&.7OP(C=F2S0)9'O!&EXDXJN]DB3NB.1'7OW5T
MY4`T)`@4*K*'OIU;=0/FB*4/`[54H706XA[\QPZ74M@)>2CA%Y7`M.=SUW/)
M`24+I(/MQ(]PZ7FJ71]2&53NM:/WKC$<JH"TZ5"D/-\(E$H<SMF>9FRAD?IC
MZ@9M.)EV-YTA,N=2+[!E>K:`O4_^]31N...RS($@"V/Z6$S%^BC/LVG.YT<X
M+>`WOZ<EH_)/,V.LO_%!OK*=^J>%MBSX1E4D,*'DELT8ML65&U*K-MUD.JJ#
M,P<R/P')9(%SF.\JM)<615JJS;O"(Q$WE!;2J.8A^*(RM:!SMQ#R$H$&U%VE
M27DJWXE;YA1$UL#:;+=K)SX>2)JPY.F0EYY+O*0M*<-&/D%R%:8K!?-I=BL/
MCA@<?D66`\G1](N([G$M^]IV/0K#*@_JQV,@P`0G.PK*UEB1RH@0=M1R+&U=
M5:WM5+YIU24:.]ST+'H'*B^^_1S$XK3Z5;UANXV68GV(HH1%S^?`/^,ZYT*:
MY%B70=WT-C6)9<(-&%:>428WXPM82[A92[.Y<*X#S*3_^/%-BPH6<[JSBD,)
MKVQ?!8AS7P=LW4'IF*AG-N1Q\``4O:JKD^O@CPWOW<!Y&L[<F6*X1<'EFXK]
M9D\B:1R(?6M$8I0OU&:G&UXM"`Y[2TN53P,_B523"W7AJP-=P`[`'A@J4%-K
M1`POX:KK.!OI(8)B'4;LW"N44Z440NH"'H16>AXRSS[D,\@7=:?#F-P[*J,X
M]2+=(SO:Y0T[:77[Y_1(OS7N34I`RR<9IW6[<DT[S7JFF0**NU<BE(#V)ZW!
M8$S/=`>M_GE/@JKN%S:#6]!?-`OJ]YQ]9+3FUO;3>E--GI3W!T_,1QK,BE1M
MLCE<4^+U!KNF\(HX=Y)2UT)A.RZUYY'WB:1%\5A=/*V./0D1ER`J9#Z_V5/5
M1*&NJ*B'*VI+GF<_>6[:N@XFP;!M6<GG/2.5O==1=1=4R8-,%KM)J?*"E\AB
M!,(]"UX^[_8'1I9]M[<K;`0,\I5Z\<8VBELB3PC/(S^GCK#!(X<1L'F=OKMK
M1]GTXN=!V]8<KR)^*V:R4O-X1UW\!ZPJ`E%M5'`TBI$7_9P>6=*60[9S[488
M.J4W=]:,3A6GC$;>7GD60-#BB@U_)6`-B-"[Y7(-+:VA[M)+V1`XN1S'7+8I
M4*L(4SGG=K*1?3Q;R$=K3[*1`*BFY@JU&TJ9\W&)]C70NF$JF0VU9:_KYX-S
M)==XA47+*Q=U^;0-9P?#),>RLLGC\_Z:,ICSG7:6UPQ-&U&O8B?-#B^QKX(T
M5U`FNELO+P%./'I9W<XKF65\?VEMGMOKZ`%>W#MYVR-D_NR9/H)MEU.J?V-B
MO\'T'HK/_0WMXZ\R.O[X3J3?L]S#18CFRKPV^W7<V*$3Z9*@#M\KRB.JD5'/
M@DG`#'Q!3M4!9:[YFHRA07-%^&0MIR@GX)2)FD[)[+C245]I>:<SH[R3+'(E
M4Q<B-];`*@>R"4MD=L#0G]X4;&O)GM+'B`.XL(`9)ZGY&@&$)OC_N7!C2ME5
M"?<9\.6FT4A+7Z#D`^JHZUA.D=QB)VR9F19*6J%;JML>]5^@%!JTQ^,7^S=>
M'L9.H8G>99A$]OXI%,Y<7DFF#UDO]<5ZD$18,N_5KT>)II@4^`P+00'/`5/\
MXUGG&?V]PG@=^7<>0"K:,@VQQJ'PKD5,M0TO;3\ZDZ#=N$Z\P+YRG1>OX;0/
M0CL\FP%J\+;S5TM]>I;"@Z"$:A[8:%2Y4XD9[+P3+-.G47[2&XYZ0P)[YHFY
M;&>7P\D9?X?;^6PA<&O#8]WABR(TQ<Z&F>XQ`BP;D.S_X]E(8]04IC,R;DMA
M]-:[GS$M-G))UEGX'0V!%-9/O.^SGK],T[1]H>(Q(/,2).<!,4@?PV;'');(
M[\B6;W;(D2.OV1PTFM2TO$!8J&>#9=@%HM'A)FN['T)"FF;DH]E$3Q[)3WJS
M]8Z5#_"4=N)[[)AQVVMPV_#M">+V,'R[@TIX;4T!.5<A1BJ@;R`(?[7^XQW]
MSR9M(3T+_=&+U]8]-<<],(Q>6>[_S@Y`6=Z](H:5E^1%'<KM[L'NL=[G.ZZL
M_R++\Y0(LP\`^YWCQGU#R&T).6@(^2@(.1PUA'P4A!P=B)`UV1`W"S<6FRR(
MA[,:OI54RSHEH[?`D[@WSAL,3Q`S)X+;4;_![;YP.YXTN-T7;KN5+?WC/,<^
MG!:ZO#MRZN#L>Y??9/\S'(1Y>[WN"4J&IT*<\2F:&T^$./W!>4.<8R7.8%+5
M:=.<"TW\?:>*VV41AL>AC'OMWA`6XP3)U!/'X`?9!LK#Z(WSJ@Z2HQ5-#9%+
M]<^XUQ#YL1-Y,#E%ITA#Y&J.K\F!'0B_4(Q]YJL3SXPH3P(J[&%.F66AH&QK
M@B+QC3;:F60*;F9$+9A:@PYUU#:SWK*9.FGA-TK"F,F'IKK+.@Y/63O<,N:&
M2"B<,UO62LETXTYS>'KMX8`K5#_6U)8M"Z/K+*)*"51I+ZC?<).?7<X6`=5>
M6,ED6Q?S3*QEX`B/TY6RZ5PEP[JJ_Y+*ZY*U@79.U]+5?](T<96ZM354S%?<
MZ%CB*EU^6D]LG?.B*%GR$/O/"ZHM]_N1)0N%+-$[[0D>ZPX7AEH\_R&#E+/8
M42/=G^&L(:X%_NT4A;IE8].VR45:'0&<14D,QP#7IKCOU7:&3>V,V#"X2:"R
M_+!CX)Z&J^OU.#Y-?;-]X',.AB[#<$JAYJ<G+$^/.KL'JS?4:?;.TZ;.0^Z=
MC0ISI_"8LGN]A[ND>Z=<3)X[KQH@DU]-'*S6&&<OS'L7&LN9=G]QX>W).7O7
MCA*)#<6**#9L*'9B%&OVV*E1[*CV6$6-?F=P31G*CR.=\YL;_7DVQR*)+A48
MC6*JEE8'*8QDF(/NHX>>MU\Z\6'"Q-N#WHN&?J<W[P/S3:<][C=\<X+S-O+F
MM.GW1/GF..7-4_#GO'6Q<+7O6+>N\)SCL+I/:[(#;9!.IY8-<@0(>[R3-:S0
M3-:P0C/9TV:%0SG-'LYH^CWP[-CUW/CV.#!^6I,=9#],1D>R&YK)'I@1)@TC
M'/MDC41H)GN"$N$I^)?>9]*'5!83-;$2C]S==`^L54TK/;8MUFMWJZ:7GAAQ
M&TXZ4#)Z>URUKL2)$;?AI$8FG>!D3YB3CD<F%5B0^ZRS4$\*]9&"M3^(:';5
MQ9?K,XAPF78Y5E9Q*%:AB+"O+4%$351EIKPLRY#V?E;O8-T'L^Q#*):VZUM!
M$D>Q[3M4*<!WJ&P`E=0*N`%P%A)@S%GB9?/V"01[M0H#>[:P$+!9Z$[AB>DM
MC7`I9DGHQB[VJ(4)WLD^ME@V8>E&$0#W?T?696S/Y]3F.O%C'/BWQ/,$?+(^
M!VU@[@ZU;Y6$&8Q?KSP$_MKV7<^SU=<3)E"VM:N"G[&!U12$=:W=LC2LT<A9
M#35Z'>7PAU4+C$[@L#CQT\8BH+)ZP<*%YT/<NL;P#,\\VRK:=TI?<(6NLE``
M$'`J\$EX"T06893MWGL#B*#>QJX/)RCJ]&Y[MW\+3:&2]2,T61K;::T%2[4Q
M=^S8WH2J;,-U&E*$,S<"?K1C&-7'8A3PD&26:]OU4/CP$L+B:%(#D#6N_-&^
MA'=#84<)H,/U`2L)=Z"^600P*RWDAMJ>^Q'@67>[5]A8VV#;\$".HQP5$;$!
MT((AF>Z$>0,4+JH"@.A15_8M;LXLF57=C"C3VEA/:?`4#ANZP@=R(T%"X238
M)KJH%R\3)6TQ__3*N%Q80$%X[I::2,-.DL57;"QS0ML$]R6!4M#K&?'+0BTJ
M;A6-?_JRD[P;65)XHQ017G#3=#IN.AT?>V>LSPFR?+H8V`RXG*DV+DT+=QI:
MOV0(>._I+Q<VRKF#SOG211&NVI%OF/J(2]X=/V/]H4H]'92V%VPM'W3.=](D
M2@GW%8VQAK$:QKK?G&_@I1`LE<3V4MH=5E9^!RNZ8>3],/+%U54HKE1ZW:$H
M^@%X"LY5[NR@L_Y.]1(/P4@%#K%'W8'SB^GGB:U/V%<KQ4R_RT>9B@@__A9T
M!^OZ=EZY&\;Q(^]I]N_K#MN=J@VI3IF6>]]5#PWM\0YV;'BL22D><>N0+_>*
M*WI02U6.<)CV#?U3[.UT(LCMM<\;[-8FZA['"`^.FL.=AQY>^*O+R4;\EYW'
M&:!AYZ1<.0V.'R6.3VQACP`U3^<8((,H,'@BQ&@(-WP`I?!$NEZ^G-34S/<>
M,+QJB+LWI]GDT;1U/%+RG)@::U#[-`Y5V8LE'1YG7"YU=KI<VA-_;-?IL>99
M#B.#6[W>H^GZW33D+"5SM_W4FNN>XFX<MP=/C$I/<3,>Q(OS^,_C,C:20LX;
M(^(A&7K2?33'N$9J;3BM]Y^8<CK%O3AJG^0U?+,9'ZT)<=R>")6TJM)+*6.5
M(GTX?Z^Q*Q[0KAA4C:D\!E'V""[SCG>$!C7'BYH"?7'\]4+V!Q'-CGGXMDK&
MP5H%G"`CB]:YD5$=@^"Q*>_;<MSY7(24B#\5\8T0JK"&JI!`)1ED"8)<S0Y9
M*@(TL`B]6W2QSS-E\K8HQT"@O'S>:X\'KT@A9J>(%W#>O@'X8$%G,-P9O"AN
M\_I2Y[H_UM(`FL"JT(+C.I8?Q$#3E1L#,_R-911N`;,1&A-1,'.I"@H5E2",
MGE$1!@+)K+&P?X2=Q-[Y'`!_80$0*[9_PC[PQ=R-K86-=4%@0X1B%ESY@&1&
M8"BXQDP<F+@MK%U!>\0/S&$C&/=:J(&)=HXU#X-E&OB7W01/BD9KG.Y&40)O
M^O!FQ&GVL/,S!5V2%>%;IB\C*/F*1`8&__.7)#J[LNW5KV_=:.8%41**+_,W
M!NF^,77?P%:**+'_-Z3N5_N6*KA\!]3\YL'8__P__P_48?^IAOM`_//=_IF.
MJY^ERC?PQS<Q_\>S]T!JE%5GG<%9IQL'_/G\K-]Y]L]#Z`B%6&173R`?VS!C
MXMS*XB"$093<V+]25@6A?#Q+I>%1_9XH$A'6LQ'P:`A#R+))KD^+#0,/V-RQ
M@MDL"4,.8%+/XG^$L0F6B1>[*ZSF(8N4R%(F:IS(1>54HDOFB!J69&ER<492
MZJ)(K6SM&V`EF#A*51N@H(5[=6TES%-J):BD5DFX"B+FQ0^88NL#>;Z):X'5
MC=X$#@PG9B0'^I->VTI!^^!;>`#%GUJ9LDN@GU&>VS=8"`NKO""%)#ZP#M:-
M+\)HX:X(EN(J+DRJ@@(PK$2#Q'/DHG'$(HJ1(M]B088@0'`,=+<L>PYO<V$C
M&(RNW3W/./0*JA\T$RUKGGC>+4(DPFODPBL;*R59*"$=`38)(AOE)K(:?,=L
M`&+9E56?//=/X6$1+]LG,!!_M-0H`6;5TI9*3^%O4Y'*6UCT/,'J1+(B6:Z.
M$4S%Q(:-''$U(W0[+*RYZ]L^*%</BYP%8:SKDOFZ?!2"K/E#%:7:@DQMJB\F
M:QRM,8>LG45D#[*HHTE,K&DP&'-W5.(2:*Z1R5B">'A&;Z)TPV?Y<^:&LV2)
MD19<Q0EXC8U,,"YGL=QOB'M=2`J^`E-1$D$2JVU]F$L*&[7,UFC%5";THXU8
M;FAF$&(H>,51`$PTOUV#C@)&[-")F`J,'ZJWY'G!#2Z1L4@,A76K@'D/69[J
MB-3UAII5<#Y0X@8UM@ACK(EGXCD4?R5N*):Z4F"0J;%WJ<B``LB=NS-^ZWNP
M@E/-N#MIW45VD]:X23W7GJHR=DY`,@&8PDL<H<!CZ5KT>EPJ6.T02[HYL)!9
M#)N2+#E\TT'64`41M<&(2XYOL[:BB^;+#-4IFS;Z%VEM*N.3-GJ1!%+BQA3,
M^M,[GE%Q+*P8"]-QC4"JB_B32K8!Z,^'_7ZKT^E8[ISP=8-EP4B8ED@6JMJ(
MVEL.H,1KNXCU4LMKDZF4-ZLNQ17RQS>UUE.QKJY`HH54"2]D+1I)SB![ENT;
MQ![@']D$+2D7$(U?18&'0@^8A>HP)@`,D</V781S`4B.%_0RP/2G8NY,#4<O
M"DHA`#4<P/=!R.4?8ZS9!SR$JL1%X9T"`K"ALB:^70J'ZO8Y`I^"F?UDCD5=
MPK52C\%*3FNCRK[RT'0@&EI3+,J);$XF%"^<8(AL3T\L2R)*L8YE%Z]$<!7:
MJP7-SX^";@A=+"4HJ`CD/$#!'#65ZO98J>XXRN",GA7Y(`]0YN8[LF(*ZR>R
MY0CBJ?9(GLCEP<,C\]+]^2"HW.&:L=D2Y17C\"#3;(%C1]XC9_HC*X=6?(?_
M:'9)@^U'O:V.MLJ@CH$YW4UTS+CM-;AM^/8$<7L8OMU!U-=0C+-^S&%;BHIH
M:@HWUIC_.#F?H'OUN$G0T+.AYY.D9[_5ZW4;>CXB>I[W#TC/FHR$.[,@ZT?4
M)_'3G06G9)M6#D.^EYCO#WL[L-$Q(.AD4#P9-2C>;U'7UG@\:E"\9_MAT-DS
MB@]W$MU#$GT2!BL.B/Z"(60'Y\13JOAT#SR/.OT3W>A/A$##SJ`AT#$3"$X-
MW7U+\H9$]R+1>>?\-%3MKN>YAV>:IB1"N:4W&3XJ'=N0N@SP0:LW>E3:NB%U
M:44\(/.X(?53(/6DU9D\P%']^$L4'"E8^X.(9G\OD_0XW:`X38\`T8D_Z,3`
M\(-LFEXH9L+%5$;/G0D?DQ_2U(M@;CWOGY-\H;>?]\>D5UJ8([7"W,IKX=VV
MK4M,M]%OV53X@%*4,"6$$S9*BBK(Z@XRO4ZF5QA#809)B!EK<P^FX[PZ6C67
M-9P&U[*2@\J.E5`9^1?P[95*2[JA+%[*#BI8+I5L$';H"Z=MO=\^"7)KS!(,
M&>Q.^IT4NX/.J#)V2\M5;,8L05(C=JWM,7O@S7*DV_=[,=ED0E..3DO,+N24
MIN>]_BCEF!Y?0>B,W4W"H(A=349KY3.R#+@(C#QL5@:NP7!@<+(4&MMG$O<4
M5-T<^Z?$27/QMLBORZ?DO0E\C.X*N5J"&_UYS#EYE65[RPI\8<U@B&`).`W%
M"M.LB3;]_@L4`+[0FY\P7?Y\+_]\*@O7X2$HUHFY`9[>>&W\1B*81-^\5PB4
MNTB^AN+-)"\@R1;JSV3`C02?K!/\H1!]I*2_*$K4+D<I8[[_8A,+=%ZT-A.]
MVWVABA`@:6Q.88^DU4(&P-3VL&Y`V[J(<\54F`W+9Q]L@JTWNA.VX=:P%:F'
M;63]6LIV,HW$7PF\]NXZ4S+G:)0"CN_BAS=<1^B2B@5]P,QLTL"?`__LW7+E
M!;>"4[5Q"U_*!&E"DZO/>$]^QWWQK2^S.,#]UE/;+5N\!-%*H(!%TAEW2NHX
MM;A:F9V6CWO.%GT+2?('+#L"*KP)PE40ZKH)JLX,?T'UXU0>N\Y>3ZOER//3
M%H9=-J4=#?,H%E038B%H150%A`UZK)L"&^[:#9(("T"X'A8$@4U)-61\+`HA
MJ`P*FOO10GAS>7C!04-=<B2F0AA8G0BX;6E=GO6ME^]A+.#&-I@>_;/NN#OH
M=E]IVU)5E8"%DI&7@,V;K%8>C^/0;_@L`Q2LD>E)&0O9?7\!*'*H[@AAMTMX
MPD\]2Y9=^$@G+];VEXC56^OB"A@'7^+S+S+KMR1>N%<"IOW@S]H'E`Q'+`3.
M"X0`P4`9(4*6MM`4D`38`NTL'TH.Z3>+`$LB89TL![;!%*2":X=P$M,D(AB0
M3-;7),0-'*M)L=*0+B.T"8)T-"Q1),O7<'D,^T^0*;#10)2!*E[):G%R!II:
M"1,J5Z?*X:2O"-*5[37$V$N6461!"I!W3OXE^#I&T0?(@1$O99VN<;NK"JG=
MM:RV!>3['%RS"!P5"?$-M"O:,GR6*:2?QB"5L0JYF!0.2&.4X673&K>;G*1F
M8$R5H7I:SP15!1)V16^M$K#5;*SD50C`J-WM;PO!!K[+(=1@L[3.5([7;/@4
MP]9%-3DD+4F%>]@W5\J(FI[*FS!WPRC6+JW`)]]%6E!%,BM7"I3^+P5;I@H?
M#;,4(E:N.;U7,>D(-%K`NNAMF%Q9%\[2]5/=]_+]VXM7<DK$_K;3K=QK0L',
M@]&P-DP<8EDDA7\"73X)$R%VA1_"+(1H(&+1R'*'%0_=3NE"%79L)"V11+%)
MIHX4VN!DZN/"'>!C+UAI5BQC."X2E*-4KDQ3'[>'QP:/0AIM'HTX/E,4(P^V
M,$L46%J,"%LE4\^=`:[G5*\/1!#P7,"E&HE#R98!M+B9>FMW:LA0+'$K)_Z2
MRG=):X2JN<$$L*X9O\S&4;%WJNPHH<X<P<R+?OT27MF^+"KV4(>-;&JB-C1,
MT'+FP?1I&@JSQ`-#]8/O!]<V6<27,Q?K049L0UDOE;Y4/#M^G5/WD]>OK!L[
MHIJ+?!@`UDI]ZYY]HWGT$LUJ_`.K*0''^:Z-#'BQ"EW/ZIZ?GW.=,QN5>?%P
M!$KAD&_!_+[A*P3X/&/EV>MT1IFS@[GS8%9_YJY(:L_1_0M&!+"J+:\+O@H0
M.<G2;AG09L="6%PLK'7E!=-L*;"9%!=4DLX1$2`>,,J"'7'+,H?+A:%W8!:Z
M*ZYI2`6*_;/,E[HJ&8#5&UOD,\!B6VTVHJA"XPH>%%SATTVIJ=]4&@;P"'(K
M\((K4"U1`@P"\A3@<:[Q".5@75*?)0.71K-P.:W-!<\8C'(LPV,H.&?`:``H
MGA1IU0'\!#B&WV(Q6_@$D[6"0Q06D<5K'CPG?7)G83"[52)S/'AM?==/(SG<
MR'S=98>^KBPK\/HGQ#5Z5"`SO,+O?][.%EX08@'-:(GU4)<!/)=@*3.F%:N1
M&!\'_8#%O4#G4WE6X+2`A$BTE(4O9W9"!0<C+.-GO03EM@A`QD>OVM*%?`WG
M86_S0DQDIS3#/S+PA,)&53D7L[3BN_`7=/A%LB#Q;Q9X2*5"F$H1`5^P#B;E
MY<?NU`UB=Y:MPUPNNC/"'8O0AI$@%\WERG/CXW0G9<6^!%HZE@CL!Y'^1W0`
M+T??.^T<L;64#5:"K#]5,E`Z297D+CRBT#!4SCJ4Z.<BX!&B'P=#*9#U.*UL
MU:W@>:<-!G072\RR?ZIM@<D!HF*<NJL(B$SI<;J,#<7,LZ,H-7'@D:FL7`N;
M",UP&B+O\&J#M0_VGDU["TL;\CS<[8!]D7:VB*K21P7K:X/VC&)A.RU+V'3)
MC2]12X;<#&OUTTG]H11&O;>R),AXH!8*%=\7(HM4OL4DQ*H2N+3Q$]*"6']=
M^_BV:`)A!4:79K*`!R,*T1ERL?%1:SCIM[K##D/")Q^>2UFZ-EBZ(&"Q2FI)
MF7A<)IGMJ`BX=C`):4>8!5$M.I3@R]U?Q]K5EO*)Y@^U-)Z#\1$KJ82UE4F"
M3C5G/2EOVX;[&:H^S61A.B&.4ZSR17@DMYJ/AZDTF`(/(7CFH.,(A9N3[926
MQ-5NU&R3A3@,;'D)#H8'@L/4D=$:0/4NV2OC,B9O&1[<C`A:UVCE^JK@'EVN
M`5CQ*WR:W9Z";OO*5JS'6RRSB$;';6S.,Y-&.CLYBAA8BA'-Q*H\=2Q?IZN[
MK$SE0W5<Y@%U$<Z+OQ)["=]J^\]-CUOI,4L^91RSV&<JCVSFRP@#IXU;E^V+
M-LA0ZTW[]S8G]Y6>\`"#Z%7PX"F8_C?U0M:);D*4=U\`2&SCHA1!,Y6J@I,W
M)Q:A.@)I1)'T!BLZLJ7YFLH$X;E+0+H\><U,)FYK=&'_%^P'P=<XLK!Q:3^1
M3=LYO_5_1.++_!VPQY(J)1^%JP)@0K)JJ(YZ,Z]!G]O>#PNWWO)PJ`;308<.
M%NLO/BD5Z3!F33R=<@5WO!Y-Z^.O4D',M;YQ^\/O>)FI5>8/W\6_R&NA?,UX
M/%4>Y0@]D?95ZK53#F:AN9..XF"/+LV>7)G&#FA.H;6ZU`+*+JZZ3YY0'4$@
M;31:#6XPXTD.UN/Q'05Z51,@O2A=!S`3%RN;-47&57%:79]`T5U"+F9Q0K7W
MN7D,=;J0/=2T[S8RL->V+@TY58Y4)>EE3P]^X"8$XITY(-(C:??K/@)I_$8D
MW:KH(`U8WC/\LP`=`8316URR%V#?4PJC9?*4M[>@B62OD0UAC&:G!)@WW8/9
M<6%NV?:`/>&A*Q4#]GL)$R)62_XVC8E!#`&^2+%)%`2BR/X1DBCJ")"L@`#$
M1BIH=BZ$BG11/;94D`P0YBN]SJZ:W%%2MD219"*+,3*)9W3[H!.)QISV>B0^
MEF!'DY'B?\O#;G*QG^=&1&J/HQ_2@OQFL'+!D"T*\3'"Q#,61TGT:JZU4\G^
MDL!B^`(Q3C:LFH^':3,:[F:A`Z.#*0PDJ"DA,^EMR>+'1CQN=]S9M/P,O_.R
MK?(EKT?OU[#L(B,@J]CS:O^;]A1P+Y,CT?QK8!V!"CU2._Z-O)\&W8L]+$B"
M:+6BS4LIK`VW$.X*8LQ0NLE5@RA@>ZGBE:R=@_@#6('Z`TO&\4F[]#NIEG"-
MB6A>,%1=&)]N<?,Q!UGWN(Y4TGH1]P]VNBIDZ37NR'/U.SOT8;=%($^I7][#
M'F5+>!R.'M9'6"*Y&@C,YCKN:KTA8(+J;6ICWUC%%(@Q/I>2@V:*S4>O77+5
MF8\H_XUN]$:<G?K?X'0*FC_"]Y'+;RB+#C4Z&BE7INLPZQXR7(-:N9)+3NX]
M,M](+W`_6W;41*J'WBJ(`>$N>_I<+^$@/`%G.K(SV]9;_!+@$)*+T[6TL`^2
MCJ1M<0<]OH,SCN4\*.TYW66/>@5R[$1L]M(E(>"C?TB:17@5=`>$[$1>:YF;
M1,I038_+>%T#=O6M?$P?FA%)O\#<Z9/N7`(2F^=]:PGG<^ROAI[2U0IV,1*2
MU3LSA[;GLBRB3&3)`]D4&J10E<POZZ5VT6$?*@V''K;(NZ_=<^P>,%UTK[+\
M<1>ZP22'?:.:!*8I7%,!)A[\EV_?N'L=\0'1DND^%73;=:;&/2&?;].EZ/XC
M/'Q7D6Q^2U:M'4V9E..GWS&7/&_*R3_!<O+'OV4>3.2])"T-!QJ\57AUK`2\
M7S^`T02TI]3#9YZ8`XCGJSBG[<_HJ_HQ_46Y?<TP5],<K8;HXR^7?<`*\KW>
M^:-#WVG2XGPR.0PE:A(>=]:5>RAQ\8<=AK;,.*A#7C0E$;<O5-ZMRL-'6[OJ
M,9)G6%G8'Z=1<K1,LUW!LYIG.5#Y]N%@_%CV]J,F4W>?9"K8X_NL*;>='S&]
M*;KC(BA_;_16!P)$NOS0EWGZ[04Z=#%JX"@ND#*E(KXJPT9;.[JLO94N@"CR
M7D>F?$BC'0A[S=V3<?>DKDIS@>'*@B2`;DQD<X+B'&\8=.BX$5J2!@09029X
ML2$C45P=3A1C?'QDO71?J9@H:[6XC2CM,Q)Q+.LI!'P)YHOXC&\YTM]:>+'S
MTH4!KG#J3'"F-5L$F.K%97O.9G:TR(YJ_N5RIE)PHV^_7A:`PO$NH54$RJML
MX0H#K7S#IU9+EU7FDHN`>\GW7(A9'2]&/\2!PH5EO)-!*-W=^#)!G>[#9)S2
MG.?F'UR^WW,=X^7`RT6XOFKED$N!+R)<V6',.7&5L;P!NU899A65`1(9F$XQ
M+S$7&HDH;H*``1YS.:W=YT`K?-'6T6VW61+A$_A_5O:67>6K((,7\#<@,U:)
M'E)T4IR<(HTC,'77I3P.P<!@-AHFE&%087:JJ8AO,"BV)&C/*'60!5U/XC!-
M\_!*2#3,*I9'YT%ZMUS`):+LEIN[3HXM*X*!(@JH(#[`\+C0M3FZ(KLFO=/E
MA:TA`THJ1''",^!(%R%(`:*TNQ*B<\I/X2L2;5IPY/F2'HJ+]BNE_ACBS*!'
M89#&MKHTKX/?VV[X.R:V?**K8P*+U?;I)"3@&JS?5=&@5-]>$#OK*+2/1G1I
MHWYCPS#)A&&F,A^Y56./6!?9^=KV9+QF40"BCO`S?E_9MUP$%6,I9[,P$;F@
MX)#R4$/B>MQG4:PD12XV>2H\5Y#P2PLB@,A!^G-VEI,(%485+6`7G*&`LGP[
M3G3"5I0).V6!9HR`\2?VRL4$,X_R:X,IH$Z&Q2EDI.4:O,#V<^!P:``NB&(0
M57`8I?)Q_C+FF-%,E+8`XA)%K!W'(,YEWBT-@;'CMUPY))\$ON3=RA$-6>A3
MPZ=$G.M490Y-D5H!9/),F#$L5'1$1<X&&67&X1ZV*W.$`0-SD=%PUDM4_3_=
MF(=]I2(IC`3XT%H"G3D-/`8:!TFDL*/B/+3N3,?%N%=0C7C<\Q@31GZ'UF-R
M'+0/7)R.0KX9@F4JYDA?9A7:T@8BNG]+O":<$!%,,;"5.-CU5XG$*%8PH4=U
ML*U\//'77P`=[,NI*2Q9$RP[?4(!@10TXV&YD(AYA(8@RBSM6Z1+$LE",+P8
M&H_`H#%_?:22C/\7IRR7:1\1;2DP70,N_C3LOK;^2@*5=4'L&7$X->E952(!
M>=#%59)U*'>2P8I*B1QFI2>#\-Z6"*="?;!_/#LLM3K7:((D,38#Y>#JK=90
M8YT:_4)J,`ZEV))XS`BMEQS";V,QH18K_CG&OBT#1WA<[H.HH!6)G>:QO'JD
MPB=G,9F,*J4PV2ZF*O;IT(S)@^HHA$&3;.X808845[A_F7T2T?7$OU9_S3HD
MC#I6H@O_%RE9:?>E:4<<S2K+G2A.-[-&Y1NF32`]#UF32I:Q*3R+D8L/]HOQ
MAC$>-@^(Q94L3(`)?"#6U"K7YUJX(L2\E&PZDAF];Z3_<6E/7V<=.9AJ&+,_
MZF812,>`SN""L<W#T1>J0!2VTD,\'=]3[*WP_*=R]L"\G0D'+4ZV6/+5S-0@
MMEE\C(RB`D*A>%$X*$,;+2[]S6C!P!P1RR8*Z#U(,]PVI*H5(\Y*D:8;9)`Q
M?\WE(#9@[B0K;U>*\C5B=_,!NEN$1>BWMK^M+!CU:.Y"3D)^XOB)*4A_U]N9
MLO?=OQ)IM])3C=;):)UYH7J7#DI3J!7K`I)K[+:(%US#QZP>D#W<1KF<`WI)
MY3N;PI2.]%H0$A0Z<]O49?].G"OEOI:)JI0S]H:.]V1.UZNB6*JBO/1M[_9O
MRJ!!WRZGY6C;<);.G^;/!F$F]QDE+Z8KAXXL>;3B6FUX/F]8-']5)KT$POH-
M[[G/+F=8J`EPNM*ZUS"!T&1'$X")MYG3J=0;5@]090'1[ZX+<!JF@<.)[50*
MCV<P:B=&:VX9X&?;]227VU&9:2,O_/"`V-+72)AK3T5(6X`F+)8:@VT4NM&?
M?/-'$U+%VAO08?CO=8!F`EVS-*R#,UUDQ(0J=J4\<BFZU*VBO?'YN^B&-YA1
MP)::S)A3]<OP0&^.[=U:</(19:8SF]:&^%+&?5H+HD0.<Q\N*4[@Q33M[25F
M@+ZRKO"F1KJ*TTNQK,V?CIV_0#+RY3;T#"O.)S>*4W"BXRH4"RQ6@$O()N`^
M:9XE]!3=TK%FQ1)Y?*F6^I^)1X!_@X1.<5K48=$'OMN3/E5)M"*=5GBUMO45
MV5U]4([A7JWD"BT%U6)8FQLRF.F3OGVB4E"J*HAC:D4N3Z^$9Z;:%$4]R'HR
M89!<+70UF\J5;,R:D"\_!S!"M_-JJXK9VW$J7CPEGO@ROX`CLLI>O=0&ZCM.
MH'60/]^DB<!?YOF(K]W8NLD]?0R)6$WNZ://CVQR3YO<TR,D:Y-[VN2>;H7H
M)M^QR3T]0EHTN:=-[NFI)S<VN:='39XF][1):FQR3Q\YF1XN]]3P/];N2BQW
M5GY0R09O^([].X+3N"`?_#S>>SHNR$>(1%T9^UC]&:>T`8[/S]CX<$\=MP_C
M`JP?<]_L&PSJP0Q>+SIN5]0]5OE\QY4=S/LT/.\>-_(;2FX)X*0_/`PE:Y)`
M=_H1ZT?1>VP\CUFV5P%VCCFT`GPB_J9>?W!*ML73(DZ_=V`WP2-V!=Y_A,,H
MAEY5Q7`,J#D1Y'9;W5'O^'?4`RC;CR**?C6:?NDN:8WBW1,OOAR/ZD'M/6!X
MU1!W3\3MCCM'3-VGI?GO<;MTP"/HT=Q.C0?[O']NB'P41#X_/[`=M/D"<O/U
M8/FUXJ6@3%I=1^\#M6>D:\K?;N6/S2WC@U\$/%C4[W>LT)7"^BG`OG8$\>G>
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M<XI1[W;/NL-G5N*[_`._]@S;O[A+VXO^\>S#Y_?/_CD:#0;CT>`_?]ENKGR(
M_1L[6ESX#O[S+NTD?A&_D;VRN8=[(8`<1)\"^./RK0G=6?_9/_O=<R!C)\7G
M5M/5!F/OK-,_ZW?O@+$_[#X@C/UM8!P3&A\2CW?3>M+OU@&CV7_G@S\+EN*S
MB+_,O]L_MTWKV`@EH/I\G`6S?,9[`@=H&RO@MD+A67>0I_,^@1M4!*XS'AX(
MN+Z!N>W(VNU/1KL"1_[.@N??!R$H$Y]3E6:WW]-&,L#6]!<WU;IPL$,-*@`U
MPU?4$?!#'(?N-"&]\CWX:E/3P5JX.+?8@Z[@Z-!7>9]U22TUZ-M=$C38VUE4
M=?O'@SUXA6?#)GQUZ==NECTR<U0&8`<=.LSM[GL#4%U/#FH$8!==>%X!`W_0
M@4DX%]<BM*_$YP03-N"\@R<'X^#PFQVY,V"]MU@^F!ND56.6TO-+;YA"NALP
M^UO29O8K6=)@-#P_ZB5M8.BR)0TGX^-=TN8M4LIX_6[=2\H7S+[WIH'M_;4$
M_K-.>V#0Y(ZI:X#T3E&\`=)^_\"0;I;91X/3.X7[!DA[W9TAS2B$BVO;]=A*
M,#Q'B\!S1!C10(>P#.Z&8@^+J-NZ>*A%5+10>MW^Z,@64;>54WT19(A_#OQ@
M!1H`/;SO?JZP%VPMS#\:KQO]!7/=!Z;*O-PK\"'4#U,UUASL'Z;*G-8O<!9L
M`1.6NN&#&7/E!\RX@V]JX:>L("V;ZCX@57>J'`*D:MS4VSM(E9EI)WCX^SKE
MT:`_R>$F,\<.(%07/Y-._2!4XX_AJ&XL5/<&32J!\$4)G;K=-KU^[EJD8*8=
M@:EN9$VZ>X2EJC>GW^WM"9@=;)[>N+LS,)*EZF&8<;]3@A8US4YP5.:50:>,
M5^X+1S4^&??/1WN`8P=C95P1CDOA>?#SOX0/#WIP9KQPEEB1/\;7KD6=6F=X
MGMM+V\U='\25V:L_[`P>&N)JC#C*AS,<&N+J+-LY[]<`\3<1"6R3A5X/<2V\
M8(6F59WLV^WGHEDV3GEO^"HSZS!WM;1W\*IQ9K<S&!X0OLI\.)G<`WW_"D'U
M?@V#N5O/`6]PWLDBRYB@XMS5A5XO%X5RK[DKBJ_.9%#3W)49H#?>'N=O@BC^
M,O\7=JP!_K@4X;4[$]%EX.WFY%\#93C,A[.4S7<_R*H?\_N]@T%6\;0_R.F1
M?4&VPY5_CJFK0J:>J(6W^OU>`3!JBNH`5#_Y]XNP<2\`*GH9NT6,LCL`.YSZ
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M@2<_!:'XNK##I;T-E/WQY"%XLAJ0W9SK\D`\>3Q`;N#):D".A^5&:1[(8.9%
MO_YAAZ'MQ]&'*$J$<Q&]%:%[3?<4'UU[ZGIN[(KH@_\F\'U!Z1M_N/'BF[AR
M([SH=]ZZ(7S]93Z'UW*9P+MJ98"^?L@.N^;JQ_C^@"V1_:T\'Z'QU7;K<<5T
M!]E]84Y0=?+JB,LIBDV3%R?T?@4L!<X'?Q8*.Q)O!?];3U3*8+Q53G$Q"'6#
MO\-I<GA>&_3O@!V1*=_]G"UL_TI\LV/QQ2\>L::0H*S%6`6`NH'?(<2Y-MA!
MX.,37\/@VG6$\]OMCT@`M=Z[ONUCO\`+D"#7)%'J07OWO)NU.+8'H%[0JU_P
M3M83WW:$_)M8V;=XW1I]F7\,_*OO(ER^%=.:@F>[N>C'LMGN`U5E[)WGD+<M
M4(#=F1!.A/.BPL-FWE_FH-NH"MK4$U]#`9H,]!J%P-=E8NPX_1Z@KX[I3M9K
ML:<EZ*R#0Z%<3U@+A-6W_WEON!5>2^$LD1<<*+T'49L/[=Q^_GHAWT6]#6N"
M/&]W?/#?BE40N359$3DCHGRV^\&U0USOFM6]+61?I5C^'ES,P&R`TR563@[C
MVZ\>'#K`H$!C@F*%:KJNSRJK[:>O%_#JH3R]FN`N86X=V5JW6.CE+\NV!Z!>
MT"NCO-\[WTJB;0%YT7Y@)5CGE=+9^#R?-W3'M+7`6?TH-QB?UPWGQ6P6)'C^
MLV\Q41'C7&>S,!&.X:2HYXK_+AF\#23[6T]UV3V^BV?VLJ":XF[R_I8[9JT%
MS!T,C'Q:TKW!!"-Z9;M.G0'9_=%=FS([:1U`5@\Z&=0,(QIU?AR$]>F[[ET\
M:4QY;_AVV.[Y1,%[@:<8]YN8"?>ZMHT]7LNHO'OBNH"M?CG=V58*E0-;7J#J
M7[;K8R;:#Q\&\]R_=RQ\LI;>D`&YRO1U@[X;"]<#NTH_GZ'7LD99VCO/RJF"
M>78$I;H5VRDHD58+*!NN"7__^'&H[HVVN2C,Q9KL%5V[PMC-&1N'0N2H"I"]
MS@$9;U<@N[DH@%HQ61:H4)7<O3TBLBQ.H2J,HSUN[0UXK$;L?7+D!D16`O*\
MH`CG9AA3G:*TS!<_O1FOQY8T(+ICNAJ@JUY8(!\X>1`8J\:H=PX,XGUJF%2$
M3M4F$PY6/`4FI1*F]<2BCG(!CH53[0Y0]5NF07>O`&U0P7^XOA,%X39B9'"^
M`Y!OQ2J$4>@W^.P)69;V8HFE9_^NCZCY.F7;3%P7L-7OOVH`MAC_%Z@6K@3Z
MQG^[31^1'O6+&SMTOJSP0;/3`Y>PS*RLM'5#29'!]5C7NL%[J/7G6BZ4K/\\
M5_#^Z)?_+PY[\SFDB-*7J^_#$F3T^_4BHP#6-73@)3$'\;U-,!:/GV4`Z4<Y
MUKN?(IRY48UEB<V%5H:B;K*^#\*Y<.,$YL-[LI\K-Z01-/9J6_9D&YU5(^!U
M8TJ2`/U5-<B_27<;F^(>T-6V_$R]XK3X)>"?MMG]L#"8U(.%.X#<HR[(57=6
M&_5KZ,ZV;VY45HJWVVV/>WM1$IO`/BYLK;<P*L76L-V9'#^VHDK::VN,;6L(
MEV&OUSX?5D!>?:LXN$H[&$J!(2>C`ZJ\0V+94#C[%8'#=K]&$;@EV(78FMX]
M[;2R+/DFEK:+!=;?`*)">Q8GMH?QN+UM.?&?7\?_,_S4?9O#T6&!K1M?Y60J
M`Z&[/;Y&_S/X-*H17SL`NT<5^P%F<OW(G=VOO^)^SJ99X/;(-=F)NK6A82_0
MY?%PX7G!S`8V*L9\K=6:<YF3VTU='\`[E&GH/33`%6-5<U6`#@UPD3-7COJ_
MLC@4)J)NX]'-)?H?`>JKKF#TL"LHHL7&6I!;Y15/CHXJ]UY3MW]\FV:[VK%;
ML6$_=S=R##2K<7F#7&#B`U"O8B6D\P>7"VL1!CO*Z`?>.$5A"+NNY.B82*_D
MWO(M5Z[XF*AT[[6-'M:BW$2W&F5<K]<]6A+6N<QQ+9SJQZZ#_>)@]DLQ2T)*
MDWCW<^8ECG!P13A($M,87^;YEG,72PP8KNTFJC<<9&-U:@'O(=?\O\9=X1I5
MM[V!/RTL;#Z'E5*^>\J4+S3;JE/^/-<8Z+204,3^,KIQ:];O=T\9`T5L4!4#
MPWUN?JJ4]"Z*84;0%.FU!=9&V39J1"NS3_9/=YDLUU8&4\_`,%E;6KLS&(]E
MM:8R&/8#**C8:H!V1_TM`55D>K=<><&M4.59BY7PYX!R\X5#WL?H>Q#;GOD[
MVN&?@_A_!,`W"Z[\M5R4*@[2[B"74K$W$`^&"[Y,`TK(K_"Y"M<+O?\9?>H.
MWAX`(X6`UG:U\-YV0_)/7T11LF0?]C<W^O-]*'1#0632ZG;9AATQJ..N;UO(
MCP)5FSW@Y:CJC/M/$%4;;+X&55N[P,I0U7E4.Q`/H[,8BRYBA0K?J5=8U7%!
MNBW41X&FW0354T33#D+JR:%I1P'U@&C:]-[O@0?3>VY\6[-%9,:/;0]`O:#O
M:*%,)D<!^BX6PS&`OJL&KX=C=MY=6&HKOOW@1W&8<(E)3!_]OK#];0)#Z<>W
M`(^&O.88UVX=$J3N-9X4\N^,V"E#_J`]KB,8]JDC?W/T48/\O8J=S6$%)RIV
MN+!]$/Z)@:KVRHUM;V=W8*\K+PP+!JT^WWKNQ]IE\Z`SWFH^E43^-A'?@S=4
MJON#KU%1?U'=LYZL+U]U]CJAKAQ=^?#P5@NN?&!X*P<:G9_?BR=T_K<\ID3[
M+<!=,LT]H-F%(?<*3=4^X[G*L_7#=)^2&5M"4UP\FW77#]\1X0<?SQ;N-5:W
M+-966%@7%`W>#H*\-3.5#U.1O"9@'QPSU3DP&ZAX4.Q@[,\-SO`^"-\&R32>
M)]X=502KF`[K(;%W3U8KB'=;&[WUW(/J,"K_-P783>/-,5Z;ZK5=7(6"<S&W
M*SV5KVA:!,;NP-Y1`*\:L+WQ`\(ZJHC8;KX,:[W`WE%KKB*PPWR!X]HQNZGF
M7#5@]\L$=Y2>JP9JKK368=%:D0>&Q4W!#H/7BK".BWN(;8;5[&_S.8A%Q?K5
M]^""4;[U>#$@]P&X5CD['#XTP!7Y83#(-SRO'^!:!6[O,"Q1G]#ME?>*JA'!
M]4G>WJ2\X]9A$%R5(WK[![A6&=P=[`9P:1^S[*E@YQ+$N;+HFSJ950>E6EG7
M_FB\-2SX7>K$_>';7+0/+Y^CV5K,;ST`#G(=X.Z$H;`*+7JDW!C?V#U<=#(H
M*-.;#KQ&N+2KAO9V(W)CB5RL2TNUSN\!4C_7"73[.=>.GVN'O_5">3F"5NIK
M/>GDDHZ*YZL!K(JMC?-I%?N`"X_GBO^K=0,?#0X+737D#?,%`K8#;V/M0/[^
M?1#*F.-MJ_.J%5PXU\$L6!<M)1=<DV[_?,NJAFN0U;^N#<JOXKKZX][DJ-95
M9I=FUC4Y[TT&DTE_O$4>R*!_WCN>%6XX*NRZPOYD,!B?Q`K+2BN7YN]USO>]
M,+J)VI<LN=N_6@FJVI>T@Q@I[$%Q7$O:68(4>CZ/B5[W$1Z%9N'@N!97MK\R
M<F/+Q?7KY$H4,;O4Q=H4G5BQI-OP?[J=3[U.'47=[H3J8==?=(,NUU]+3;OC
M7_[:A>D36GY1=,##<O^;@&Z8N1(IIOC(R&3[2FQ+0"7(WM`_(OSBRSHCZ@?9
M]W3[S%K3:M\$X'T7LT'EK"UF&[C[XP>'^U+`\XZ"_KYT.-QZRK3C;G3H/SC<
M1738"O3>84#?8!W7N(]WY)_/XD9Z4="6"0,?/L[8X?TU\-S9+?_W.ZSI-Z]"
MX-P__R\O?KVRHOC6$_]X-H>7?K6ZG55L?7>78+?!M-:W8&G[+?ZB98'-Y,Y?
M6TL[O'+]7ZW.:PNG.;,]]PK^_#>@Q9W?/ON_KN+7./(O*_KT']V^_,]>9\,!
MS<'/(O=O\:LU6<7ZD:GZX.('=$CY,4&68M?*HI>6X>H%Z0%^P1D.ND[Y)1C'
M`@?LM(>NO_7:[>7J]7]T1YT'@GU;.#_XUG\GOK"`1;LM`B=>".N]Z]O^S+4]
MRR#3)5;@Q<H"UF\!_&.]E&L<C%^_O[C\3?TU>?W*<LGB+W[YQ\K!?"7C[8O+
M'^;+GX,V@7/6&;8T@H@AT!()Q0*,$?=:6!_\&<@(Z^7W8.7.+#CXO_H56$E$
MN*-QAUO!W"IZ(V6PMO5]X4;65>(Z&(-EN?!P@(W($`?PZ,H.V8]_V\+]';E1
MC"U1"2A8CA5C;U1X"+_$V>8:;:%8X74(+!R?<V4'6QX8YEBZOL`)X1TW%LM(
M/B_P42O`&P.:/H7<)<C;*5?!6@B,M["CJ)4($9#&1V)H"ES^2/'9[;4LC4ON
M"`^@`@SXUKOY'$PTG`LC_*UY$%H7L!\=VI-6'-!#>?3"?O;L*'+G[HR^BP@F
M^.$#K>I+$N-3P`;),O&P.(E%UR&%9,&E([B2]":5]-?='@AX@)L1&8J_$C<D
MJ0%_VS&3S,?6SBL&E,`)<T!:MH.;A!>&ZQ3V;$'O!CX.50GB*5#+\D4L*43D
M+GB#`)%O`00(_=QF!J#/FG$B0"[+05BVYTEF,%8:*3P9V\0"%K3\(+9L(B(`
M/;U=(SV!X*HHS74$!I()"SG/$BX!`G/;5@3ORTMCUT^")"J"WPKHZ?@FL"*!
M&REF)$P3NF>+Q(PJ!14OW>#S/Q8NS(70VDZP4HP7X[Z-I$Q1ZW#HL3?$!+>X
MH!F%Q#.&@W!IQ[SAF$O1.,+0'RI<$X$V=XC<1?"TX"7+<1W"\<(&J&T+:^V$
M^!@(#7L6*ZK*V94\&[V.RH9?!1&56]'2!%@V\8"^`&.P$K(Q0_NXU<?1J+FZ
M9X-'[X>9[U(2$S0+.RJ0R/TS%-E:(DOQ\-W^"1!*K38>%&DUV[>PMZ6NO`2O
M6+\)7\R!3?^`C0OL^1E$TA?F(MCLF"1"@+RQP_`6]@(>U%OPV*6[=#T[I!'P
MH19N6YO^?`,;"L8SW[#>_005:%AHUDN;-[,?)9$29J1_WH'U?H53D_,O@A&C
M/ZWW`=C;K]H$">+'3A4,B@K<TX@>VG@LT6&EB;G2&`";\DHEJ*1G-5K*'XX6
M0>*!8!1*-PA'2L12"6P!U6S8EDY"[<]1HMBL?T(Y.J@5P/.<`$$E$&B,>W3/
MF\-V)+&-K^(#+)/I;?QJQAC/OB5^S@0PHXVJ"H/%02]\9V4,O(ER=K>9+34K
MR\+UF8%?6:6H3EB6'4NEH4P;LN,2S!&@'VAL^T:Q@;U:P0F)WOQW$KJ1XVHL
M`M)B'!"DM.TX)`5M3^DGW`,Q[0'B@!LB&\M&:PZF$PWNN)&M0N>)]#2[$JFX
MN`H0.8&@M4IK@70)8Q@47$R:)(E$BW2[\;5Z#7@7".'HQPB^8BZ)$K`T5DD(
M@,H'\PS+.E+NY0*>M>[D5T_&GMP2O'((!'-*-NT43$_'N@%U7@`D,M>"]73)
MWD1+0VA3$=<T=Z,9@'$K[#!J27,75>/26M$50$23T1BP:O7<5(!T\,E`GL/3
M5EZBS@(O"'^UIIX]^_,9VZMLZ!)PW6&+!&A&Z;11OL!*_54R!3HSF5P4[G%6
MUM2T!DFJ'==AR34,<FMX9X?>;6KK`-H!A*4;`^V)..9"4OX@UI82#<X7T8H7
MYQ'SPDXI%8QREPD4[&J'I[C!'=X&*S].AU2[J`PZ";@Z"&0--2E3A'0'(W"[
MF%.;[38M!6!2N:6/Q[!Z"CX%X]BO*!])UX(M[>>I$+ZRB&#_`<NB2*1SBS(A
M`*AW;Y"&O\`#?`S2HYVA!L'QIX'C*DWA!,1<2H#K+82@>)9-$,P3+(S)FDL=
MFK;GQ@I'!BM9T4F382ACMM0W6=7?N![E"*L&57J+X9>@X6&5#^:;+&;NHV+1
M[\9!4?E>6.V1-44V%(B+Y_U6%VST3J=#:@)Y(')_6DL8<!&!@G&`^I=@GK%$
M[W=8*\')/2[XFO3*)RR,;_6[_%6K1,@Q*(83`E2U.P.+P*8JN<RKS[N#3FLR
M'!%X./;S;G_<&@^&^$4+32:M!5@VJP4O;#``N,X!F'Q</0$7VVMUQT,U&H'P
M?-0:=,;\%2%DRU65S\V;C?TWON"%A+8;"<,25$#QCD63#TW=$'^)@B3$^`9T
MDX5D>`;*#\$FFQ?`B1^^!JV$>@P(*X,AEBO&)-NKJ/BF202V$!`:?B%E@9Q@
MW])O0=IPC*#P,4C=6LEP^0#LBRNI1HI79T#E4JBOLLQ%I#D)_@6C3M"(4BXA
M$$L`H0PS;*Q+DL'O8$I&.$6,'J\`SRG`*;KC`DP-[U'!?M@_*U#X>/<A<`O]
M*>(4$#"EI2M2#Q,1*'H-9%A>!0H;,[Q("?VV]6.E)".L#9<H+6VVB,E:10A`
M)[-)%H!E0:B0<KY`O4?)-`)!9H>W+>M;`N;#E0`9`&?C=G:S(!PW+E@V4SJ2
MV*Y#ZP&X8ANX8Q9$9+E2F+5#J[&=:SPN()F9%0"!:@83@C*8"2-R>-9'-B9!
M.&<HZ@D>(=LBM)@P-KO5Z"0"_*@/R-(?1B:*2J/(N*X$Y:B1$1JPJ:[@M%Y>
M"F%ARH0U>)65,P2!VI6$*TJN0S1DI,8Y"[060G.S<&'?/I_T!K3'7<,1#237
MYP.-`H55MJAG[&^]Y5^D:E0,DJK'J>W1,2U:"!&SH)JP3+FQLQ-&W'6B95UQ
MWPE)-K/SA"5Q?##S[5%;:J;LD@D)GKK>B$'AK*B*.5E7*!QF=K3@;8`?T,ZZ
M!M&!UH[:B5$R1T4E'<I+)#B^F-<V&7]V1ECBJ0;;^VBO*`LKM?]"V5J&_C!%
MG9+U\2(,DJL%'F4\8<.9YLLL#NBXQ:>MMO5?P0V\%[8R.D3\1'^TV*2.4;.<
MD5[YY,["8':KA,9X\+I0^A++BBL^AZ.PU@+8!ZKBEW3JPJ5)B9R1<.N*@'&2
MJLDYZ+)TQ4I<H34-=(%I!%5[TKL7AG<P>4F:J_3%+`AA^W']0,^SIX$\'5G:
MYEX*VV=ML`K0WP224;((.<:$X7FBK>EP>^$3WY_6:7FK[R4$/MF^S2%=L(,]
M%SC8.*W%&;LQ0J&/)A/N6;V7E5&F.1'L'!>MFONQI-0D&]CRM;50FSD/)Q[L
M\(Z)E?\M>KY4XAF:";@#]:3L]P#E%P-V6_`JF!%@$;JQ<J=@31SV5L*)-21E
MII&C-7.9V:!$(RI+3\1\X*77>2494%))JOVN[$GQ:078_A7W'Y%A%9/I2*8%
M2+,Y"0OTPWR89]`!"TM\?C20."DPMNF."T7.5!CW:0&J!;!XI'<VCLHEL&%L
MLL2S_\S,`Q3#4VG$-XTD.K0Y8=KRD0BOA58W=Y^<-YU\UT(M9PN8V1-?YEMU
M5)"MJESL5Y+OF8#=%*+=CMA,MQD8.]'*1JK_XUGG&?V]0GS)OS/2`/:J]0:V
M]S1T6]9_">\:5.+,!D$`N^!,2H,;UXD7*#@Z+UY;4T+I&6V?502[77UZEDH>
M!"54\\`NPB$])42F01P'R_1IQ".]X:@W)+!GGIA+>943R6?\'9ATXFQ!I03A
ML>[P19$(CIT-,]UC!%@V(-G_Q[.1QJ@I*F=D:I?"6"`\F18;!7,V^.G[`DS\
M%-9/Y#O8%-JT+U0\!F1>NC^M`V*0/H;-CCDLD=^AZZ#9(<>.O&9ST&A2T_("
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M@*:*_#L.9=QK]X8K3&Q,IIXX!C_(-E`>1F^<5W60'*UH:HA<JG_&O8;(CYW(
M@\DI.D4:(E=S?$T.[$#XA6+L\2NCHO&^@O_+LPPNTA+(/V#X[PA4DS,`]E[(
MA.VT)VC='2X:K7C^0\8J9K&C1EJMD>X7'RO6>5NG@%E#7`O\VRF*>,F&J&R3
MDK`Z`CB+8IF/`:Y-X9^K[>1;[8S8,+A)H+(TD6/@GH:KZW4\/$U]LWW\8PZ&
M+L-P2A&GIR<L3X\ZN\>L-M1I]L[3ILY#[IV-"G.G6_(R]_[#^>I5^R`8>E[U
MGCR_FCA8K3'.7ICW+C26,^W^PD/;DW,N7GJ42&PH5D2Q84.Q$Z-8L\=.C6)'
MM<<J:O0[[]C+4'X<65W8A^ML'@HN&AF**+:H^%,-I#!BX@^ZCQYZWG[IQ(>)
M%FT/>B\:^IW>O`_,-YWVN-_PS0G.V\B;TZ;?$^6;XY0W3\&?\];%BIJ^8]VZ
MPG..P^H^K<D.M$$ZG5HVR!$@[/%.UK!",UG#"LUD3YL5#N4T>SBCZ??`LV-J
M['<<&#^MR0ZR'R:C(]D-S60/S`B3AA&.?;)&(C23/4&)\!3\2^]M-[2N;2\1
MW/.5>\=<A39U_3X*,NQKLGM@K6IVV;%ML5Z[6S7+[,2(VW#2@7)2V^.JZ>4G
M1MR&DQJ9=(*3/6%..AZ95&!!;DZWWI@%79X\_07;XY7D9F-O:3>^;1*JFT8>
M]]E4^"ZE;7Q.J(6R7DPPI^44IW1,0^N7#`'O/3UQ>60==,Z7U,8Y2"+;=Z)7
M&Z8^XFH<Q\]8?]"HPCD[*&TO0)#85^*@<[[[B=U)(Z.NP-?0G6V"H6&LAK&V
MF/,-O!3:LSBQO91VAY65WT6X;!AY/XQ\<745BBL5\G\HBGX`GG+]R)T==-;?
MT2=Y$$8J,-(?=7.@+TD<Q6#)R';>G[#D?XJ9?K=EZ2SJ[1%^_-TQ#M:0XKQR
MH=[C1][3;"W2';8[56OEGS(M][ZK'AK:XQWLV/!8DU(\XJK&7^YUU_F@EJH<
MX3"59?NG6';^1)#;:Y\WV*U-U#V.$1X<-8<[#SV\\!?2$]>(_[+S.`,T[)R4
M*Z?!\:/$\8DM[!&@YND<`^9!.!<N5DX+0E`+*S=\`*7P1!KRO)S4U&?L'C"\
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M?"+!_LQ*?)<?E4,\LQPQ<Y>V%_WCV8?/[Y_]L]T?_.<O=\YZ7_`PD?I_9P3>
MCE#V#PSEI8!G'`5K!4`[!P"4J'U/0'NC`V/T^\(-=X"SVSTP0G>%<U@53A`-
M+D#P-101_HR/?PT\=W:[6XF"7/M?M"LW6R)&X]^LV?-O6+P[O\U9JIWVT/6U
MY6/T(-8R\3X0E)I49Y'[MR"[2C\R51]<_$!H1'O61"2!Z&I@]1M9BZOF-6Q$
MV%WKRBJ>`X"9)?:V<'Y?",N>S4"AV?XMG&P(HL2W$X<"AU`6@:;C3W3Q;./7
M<]>W_9EK>S`R?+$$_$3Y4XBE#A^6[3MT6`$E"O^/S9[PF\C]:2T#[-*-/_B6
MP,;8UL*^%@3#5,!WJU"L0.DZENL3E*$#TPKKQHT7-!I^E_@QWLZN0A<@6GF`
MLBOAB]#VO%O\'<&A]_'Y'SZMZA*!)F@O0";`X9#`HPY4[C)=','A^G-LNHU,
M2&"ODC!*\-`5!S2DZT=QF,SX<`;?O8>G@7YG_R\]?8%G3SBK37"R;^(J\7BD
MR[/_#[_!`4#@)Z$;NP`0OO'NYVQA^U?"`B-CZ481,C_"\5)RU&#\^O+=&_7'
MY/4K>BO@]47V4L#!%C>036C%49"R"I.1Y2*E?#\!VAE$WDS:MH5LHKF"X"GA
MC*GM$8FBA1!K!U/-$BV"K60(@Z7@963-4`"#1.ZUL+P@HK@V`J&4GYB52C@1
M.[:VZ-/V,-C1PII[P4VD^1AF(QBVG=$"Y*<8;%G3)`;6F7F)`]![0`L'-R[-
MV")0W(C8.O"!C0$$V?D]1&8)*1K!>($@N5FXLT6&YC0,')`CRQ<S$45V>$OP
M`[MCB<25(5\5,Z;47P61B[^TK&`E4/G!G/!"XL7,IUF<:'K`LV[@1&IPX3#O
MJ#<WBH%R)`+N_"#6RW`!)R"58>/&R!0`NQR?P0BLJ<!X1^X:JZ;$'G\X!2Z$
M$H0MF1<\P/!(P@O@;)[$22BT+.#E\!JVX_B88,A,T`>I%EDDT(`:`#$`!<J_
MRO[[K^!&7(NP!=O7<@+8QH@.DW\D_0QI17`@AN%1>"$4?R48`&I-;^L5F[A!
M/1&+DF40&'E18FJ<2CHF6@2)YR!]0V$3?/#.OQ.?Y&^J%[8"98TSX-DLW5A,
M,/[P!"B`M232-6[D9E,">?1:BU>0N$$8HVA6.N'_:5FT2WF_`D_,70]&TF"#
M8,?'_SOQA=4;,@SM$OM!6J=W&YWY$EM\EK6!XM^`I?Q$?`:VW=(P3>WF'Y=O
M39L9;-9QIP/_UTF/ST43U0C,__ZX7+/FUZ'J]WK=O4'5,Z#J58+JO+\_J(IP
M]4G\=&?!%I#UQN/10?&U-63]WJ!S4)R]2T)0?33"%N!U.]W]@5>$N&K@G7?.
M]PG=.`?=1E@&O='@D*C:",RD,]DK6XVKR-#^9-@_)##*1[*5T.I.SB>'Y*'C
M`6X#YK867]W^L/<0V-L>P,EH?P!NP&`U.3;J[&^#;,!B-2"'G>WE&UEQ;\5<
MA&"<?YG#OV`3OPFB..K>VRH[ZS_[Y]E8RK<-$^T(2R51B[#<"<5__O)S&GKN
MK_A?^//_!U!+`P04````"`"7@7-#\B*Z1M(.``!1M```%0`<`&]C;',M,C`Q
M,S`Y,S!?8V%L+GAM;%54"0`#3M2+4D[4BU)U>`L``00E#@``!#D!``#57=U3
MXS@2?[^J^Q]T;%W=[$,((3.S`SMS6PR!*:HXH`BS=6];PE82W3I61K*![%]_
M+7^$^$.RG,21F(<!$G6[NW^M[E9;EC__]C(/T!/A@K+PR\'@\.@`D=!C/@VG
M7PZ^CWMGX_.KJP,D(ASZ.&`A^7(0LH/?_OWWOR'X]_D?O1ZZI"3P3]&(>;VK
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MZ1#R@C^9T$;+!4P60:6O'Z#^1C)^Q8&TYGA&2"2:A*H=O',I[C`'Q6<DHAX.
M6HE42[D+^>3$(A(.<3N1L863&0D%?2+73#1:S8AXYU)B,;L,V',[Z<I$NY#J
MED]Q2/]*/!>\>1S/YY@O;R=C.@WI!)`")_<\%H.7A],[%E"/DD:IMV*Z"ZVN
MZ8^8^C`OX>J7-`0?I#@X9R%\9#"[S:AW(:=D"MY&?/A%@!U\0-MO->G-.>Q&
MWOF<1HD_@FW@DA)`J!<,?,*`=#>SC'E_SEC@0V5Q`3!&R^8IIJ+8F3R]KSA!
M:+X`J(P23`/9+B2[@C)O3A[P2S-V-4-W8ALRS9+H-\*F'"]FU&N1A`W)=R+I
M:^`ZCT4$QN#@P1Y<G2?7:H[CI@QV(FW\*,B/&)A?/,GYUBB<8KRU_-)IGNDB
MWVPDR`-^##K2L<AZ/YG*3)VV?#J,P68"&Q'O(1H:2MN&R2ZDOF,17`_JHV`Y
MHD$<0>$\)E[,:91YX8A$F`:-@K?E8VW6WF`N0_83Z63B5KAW7PT;*]22S6YJ
M%)F0&`?+&/J1FF(7\MR`E\(Z=BD=TMAN6J*.JW)C(=OPZ*9.S^`REMB<0X<Y
MQ-`KS:AW$M,62;P1(IXGOYG.FR:ZW<DF;N,H:2>#@[423D/8(<+M_-&`?@^U
M@JE7MN*R![G-;=V2SU[6@.;2M^:DD]_#`4B:$%[#WP4*\@)5E4_\G(]49*N&
M.'PL.60W+@:HAW*J]5]ACJ*4!2KPZ$CP^G970=)C$&_52X7?5\L0M+X.01DG
ME+'*Q,T%#IA7$#*0-S88+\*=R9C<O9A@\9C<PHA%;XKQHB_=H$^"2.2?)([1
M.QID=S)^RC[^`P(Q"'`><]DRSR\0X$<2))?](QM7&M:W)[!L3LO"`7[(9/R$
M@Z24B,[!E9<0L).;7FI%#,G+"JZYT!GW$.-0#'PY&!P=Y5?"W"NX3O7&4C:B
M+V1]+AGU8,DQS^DGG,UU%L^LRS919AT9D.(`/1,ZG44@OU4DLT6)N"<>`=EE
MT4JB9D_44IGA=FP9-Q/-G8,K7_`L058U/,519G`,+<-1IYESYK_C9(&I?_$B
M"SX"L_XVFA%N&+Z-B,W`>F\9K!9V<`[#5,JF+.M.]E&%KS=A[#O.%H1'R[L`
MIZ4F9,B%K,JT\4M/Y4IZ4<Z-9I6=PVEM_M[`XJ0IE"F&NY)I%,AHE70.DA&9
M$)#0OYW`3Z@CSYG0A2W%<%?RB0(2K9+.07)-\2,-:$1)<[:O&^M`G9]UIHTK
M_/)X^UE1#8*BP*]7V3GG*HF[*JH\C\?$7]/:&#0="_M)=%,<FPWC'+1YE+LG
ML,:)FR>?:KS]_&H,FEYEYQ"Z9N'T@?#YB#PV=S]J!]M/M,;8:)3=(3#53KC\
M)&D=CDD4!4ES-I=YJ3:ZI&HB,C/^!ZO&-]'#U=EADGPV2"][*A-4TT`-F6L`
ME**IR1)-0^)4[C?+'V]@O;8>54T`4HUW*LD;9)!.H6F71+1FU\3?]N;?4QYO
MD4/>P`Q1[[VOSHZZL78;_VD\2N1JN+U9.]A^1M0\^E#I[JN4=<ZGY$XV%IJ@
M4AUI/P\:0Z)2TSD\SOQT@R@.[C#UK\)SO*"1W#BZDE_3OC"@M9\=C3$S-X5[
M*'I>/)=F)6FOI?"H9/I\D'Q@\H9$MY,'_*+M2+5C9#_]FN.[F9&<`_M>[OP+
MB7^!>4C#J5C3"ZIPZE%-$6M":W]Q;@RIN2F<0W&M:I3/'[0HM9HI[=<NIMJI
ME_CM@+.Z)&ZC8=/SK"I%/_?+>E[#WWO8L5E_+D!A^^9PD^V;Z%V!\\^=[3\U
M.T*@H-![,X5>.2,V007>2#)'[[Z'.(:B@O@_6]RMFK5D-*W`UQ$V5YLX("*3
MY!MCOM!N.:D?;3_PE8U=GOX:)9U+4>O"C@E_HAXQ!Z5`8#]<M\"E1E7GH+D&
M`2$@Y2+KBH720/L+L@8H%*HY!X'<^G([22:Q+``RIQE#:M?U--0T;JAB+'^]
MT/L/N,TP5%HSM<HZZE^Y0DV8O(ZS'VLWA*2LJG.(?.-0U-UQ-M&ML`N#[$^/
M&IDK:^A2.'9TP=6LB8'?577K6=[(NY#',-)PFNW-UTSTFJ%6NU""@"'EHU0C
M\*"`)7NF,]%T2PTMF?T)HP2D,FT,]'<NA(U)`#RGZ>F?`<A^YL]I2$64/M':
M")\IO?UP88IC.XLX!^A*S=<&MD$$61_LT)2KZE`"JRX'.)JNS)52>ZISV0J6
MQ"9^5AIFW\-JY5;!4#/2M5E_%4:$$]&<;BL#[4\,$RP4^KDW(>13L"(YF"?5
M*1=<AXB*PGYGQ@P:O<;.S97D7N\-"UDIS&K2I)+"_MUNHTC6H/$NIY%BP]\W
M3$,IX2@F#^Q\AL,I.,HEICS9#9/<B-'L+Y$L6G&P?\M:BTMK?1R=2M]#3G!`
M_R)^KLUM."*</B6ELJ8@:"0T`_"CY8EEJ+]SN!5T.WO"-)`/9H$;OOI<=DOZ
M*Q;4,RSL3!@Y5OJ9ZUY"OMX[7,-Y1)^H3T)?%'>$JO%4$CA6)FZ,6X-%W"LH
M:S:E->_:TQ+9GX(&.KW)Z:;:17C).,@7I@\I><L'CD.!O>RDV>2OS/S^_^*T
ME,[-<<=X\D44<?H81ZG'I_MD&LK5_8EA/S2T]R<K2+FSH4O_GI+"UJ</&VU]
M`IXH8>K(EB=Y,AC(=,>9#/_^U^5WT.`J7+5XS@#CIX;G(]OPL/JH(3BU1W%Z
M)JA\<U?JO6=SZ:%_%<Z'K'OJT(3:?@II#VCE^41S,SF7:,8S""S*UXW4W*51
MC+<?NK?&46\*YY"SO6+NN%NX'9:;+Z=MW[3/&FR>/$/4M)M8&.Q$(W$[]#1&
M<&X:JNN\W/->?5&-9#LN3O0DMX-X$[.Y-UNAU`<A!1F1].=56#U*5G>_QH3:
MB?[E=F"W,=-;`'GM72-MT"V0F<'ZR]N"M<8P;P'/TK%BF\S8%:D9KI_>%JX*
M`SF7C!LEE\NR%J?H;<K/S`E.WK03:$WIG&=TO+W(82#?1L.[ZFZE8Y_:3-(*
MJ2&.3K>9C"WT!K`M'AK?!MHRI2&R3C>>3.W3_6%:3NZM&;C9:=K=SAO[.V_K
M3)#NQMONCD8M#YMG=^%E<F?I@9UY/V+*B?*$?K6J;7@X>W=#`V[Y!+#6)G//
MP^M2YX()JCM$7T?C[,T.<UB;3>)<&:'0.7LC[59QJI:'W7>E>(3XXA)POQ(B
MEH>;-&7??+XVDSH;E3105M^L8F8@Y[Q8)3G,7!Y16%>;;K!KS<C9J+4][`W&
M<\X)[J&\7V:[9M8/T%6CK:9P]FZM.:Q-YG"OHJAWQ&0'@?@>@L6ODM>ZTB?9
M)JO?6"#K)P'#@EB^USCQU^QUQVWG_,XNZ^RMXVTCQ(Z!Z7XAKF[V-+T#2I(;
M4SM[(]D`\%:*.IH'ZE\8>P>2,[^LFSHJM.-BO_K;1.MJ4[MMV\;1A[F[,X9N
M,;B%,;JL)+HSABZ@N!85+B!V>='MY.+%2UJ*]S@BMV&];=11H1T7^ZE_!]AO
M8CAWMM+?\BD.L_W"LCB19N-+*%[H-*03ZLEV6WH+%MSXC@746W?BPE;[CZB'
M1E1X`1,Q)_#'X!"MLT<X]%%V`;G+?NT2Z/4:Z/4B'1V@>DT!$)]&2]`WFZ'R
M5/0P/2V]7K=?RKH='Z(5GT2Q%2>TQJHC#58/,:P_PU`XY;9>BT]E+8:'9H?;
M=JC)?$Z3!U'D$5<@@70!$JJ=[*2LPGNIPHI)`D6)36?G\"I//EZ7>'!4EOC#
M(5JG_1<J'W/=A:`]]1[S@K2#LK0?,VE3!JA^`_Z.)4ZW#CS@%X47#([+4OYR
MB%(BE%%U94LRE7X&OOJ-L"G'BQGUKL()XW.-38=E:3^!35-&B;^^LD(%7EWI
M\!IWSV,1@=$XS!BY0.6XN.(L:/&^K,7)82&$Y[Q0F5E7:L2/@OR(Y2%E3X7<
M6I#Z0R4I'8'8*U*4TW8DY$;I59MF!SM.L^A=_EMW1Y9O9(4'N=]+88-*.M[6
M!NG%NK-`<\;6J;MQWNY>,45RT6E32>&:%+,'!?017:/(<26S&\7U[E6Z8Y'L
M-N(@6(YH$,N^XYAX,8>54.IF(_F:D4"A5:4"@+FUQA'E+-&*)TJ8HG<96\?B
MR`WFZ=&']>I62HEM0\GJ>MW90;^":5"X4HV8+&7VHM;:1GZMAU8JD:&L_E:T
M:XYH]R`U*<]2^X*!XBC+Y[XE@B0G4AH(G(VSW]>M,W3-$6]5Y9SKP*W$E/OX
M$LWEF;Q<^UBMCL9^F[D--DJE&^[#[K-9=@-I,'\2H2'*5M8=$*,2<I31[R6B
M:MHK#?)75AE-?9:]Z%/MN62AOD&;RGI!T8-9I0ZT+V6JI;,V]556`MK:N?N"
M++E%?28@'J0WJ[7"UQ7^*0>TQF)O8HO;.!(1.#+XL$[N8:7.7\DMT!J//0BN
M<!F]]P_;]/3V,XWU:RXM&)5ZW7#1U3TV>J4:,-JL1[@?M)KZA0VJ;=@XK.J6
MI7KYWR,X+GSR?U!+`P04````"`"7@7-#3';6F^X.``">R0``%0`<`&]C;',M
M,C`Q,S`Y,S!?9&5F+GAM;%54"0`#3M2+4D[4BU)U>`L``00E#@``!#D!``#M
M7=ERVS@6?9^J^0>,NJ8F_:#-BI/8'4^7VDO*5=[*=M(S3RJ(A"1.2,(!2%ON
MKQ\`(B52)$#0YH(DZH>T+%U<G+M@.P#!C[\O/1<\(D(=[!]UAKU!!R#?PK;C
MSX\ZG^^ZX[OC\_,.H`'T;>AB'QUU?-SY_=]__QM@_WW\1[<+SASDVH?@!%O=
M<W^&?P-7T$.'X!/R$8$!)K^!+]`-^3?XS'$1`<?8>W!1@-@/JXH/P:CW;@JZ
M70VU7Y!O8_+Y]GRM=A$$#X?]_M/34\_'C_`)DZ^T9V$]=7<X)!9:Z\)6Z(9T
M,AQ\^^?>R>!@-!B.>LL9,^$$!NSG/?8W^V$XY/]\N!]^.-P?'H[>:E85P""D
MZZH&RT'TWZKX1]?QOQ[R?Z:0(L#BXM/#)76..@D#GT8]3.;]O<%@V/_/Y<6=
MM4`>[#H^CX^%.G$IKB6OW/#@X*`O?HU%,Y++*7'C.D;]&,Y:,_O5#M8%DL+[
M_=6/25%'H3H!FCJ'5%AR@2T8B$PL1`2D$ORO;BS6Y5]UAWO=T;"WI'8GCI-P
M-L$NND4SP/_/,FI=ZRH+6`YY??Y3GT4R])`?C'W[U`^<X)F'E7@"*H,O="T(
MFAUUL.72+L\2GCN\PE]TR@;/#ZQ=48<WBP[HOPCC']#EWKQ;(!30(E"YPI6C
MN(&$&;Y`@6-!MQ2DW))5X.-M$/%PT.L9[X8(6B"?.H_H`M-"KVD5KAPEI(LS
M%S^50[==J`I4UV0.?><OD;DLF^]"SX/D^7IVY\Q]9\8BQ9+<LG#(LMR?WV#7
ML1Q4B/I52JNPZL+Y%CHV:Y>L]C/'9SGH0/<8^^PKC=:M5[H*G%PIRS9DLP^4
M^<%FT;9+-7I]#=7@]3PG$/G(?,.JY`%D4PN-G-`H6DTKP];7!79M-@DY96$,
MGHN;F*Q$97BZ?T`1(>^!A4IK@"DH5@6R<S8C]-`]7!;'+D>T$M^@>32(?D)X
M3N##PK%*#,*:Q2M!NNFXCD,:,&<0EL$6JYV(NHK[<5T%E:`-IQ1]"YGRTT?>
MW@K!2>1;&U]J'6?J&&]>!.0>3MV:;$RK;F:DTC.GK)X:^V`]P%J%&^@--=&6
M45(%ZAL<L/K8_,A]/G'<,&`3YSMDA<0)HBP\00%TW$+@9?6TUFJO(.%=]B.J
MI>%FM-<_&]8VJ*2::N8H?$#"A'E&,X_D):K`<\6RE*UCGWE":OM-6:CF6;DV
MR#(ZZIFG1^'21JROH<8Q1#,K]4I7TJ<]B/Z&TM`3GW3;35&YZK#1ZS`0S#-+
ML%+@%`5KC'"Y?-0HW\!<03<K2VEI`+>^KTOJ:60-J(^^M"85?DBLV(0\X204
M";L>D_R<5M\7"!=,!;'"*>K:CL?I4+Z<CBI*^FBMQ?&#/A/M1S+]7`7UXUY7
MUK6Q!YV2H+.E&T`L:NIZR)LB4A)NNFC]6-GDO!Q"4:!^7#X.QF6AQ64:S4DT
M@Z$;O#@IX^)IS.QKQQ=3\`OV9PHW6K)%E8WL&#E7^*K],/8UUQ!M<0Y!%\2E
MDA_9$`U6*D!*1SVX\\GN%-`]AFZ]D\(^KTD(D&0A0*0)Q*H:P)N_)Y8"/WH)
M>/`FI?G7NHS1VSU+V?-6SYZ-9H!G(*4;<.7@S6<?AFSMB>QFK,OLOJ6LVG^1
M54PG$$J;L.9UNW(I:]_QYNY0R\4T)(C],>R!I'K1!405<$,358!-'6!323T6
M:V[DI4Q[OVW:7@^L]0B[UII`0E4]!I38W4L9\6';B%&OW4Y/9_<O9<'!M@5O
MN05K)2(06VKJZ@.DVX-)P,/!-N#]'DB6_1>(2]>(4[%CF`([W`;[+@*[4@#2
M&NH!G+>IF`*YMPWR?0^L"H&H5$V>U-Q73($=;8/]P#RZ4B1R=:.JB3F1_G9C
MRHBWVT8<]%)==ZP+;"NKR0K9OF0*]'YF+!HPU.NB("YKT*"J'%R'%0^N;"H8
M?3)K9K&U%Y5R0680?JT+5I75YH#2NYHI:U\\6M=NE][F9\J8S,"M&%KJQU]J
M.S1IQUYF/-?JT&NWJ/0^:<JHS+C/VE5"(XA5@K5.()2"-Y':7^.SMK%=+K92
MQKC\L"\FN5R)X#AFD$X%T1'2[AS"ASZG1OO(#6C\C2!+NX-A=+KWE^CKR7KM
MQ#R(SMG'M9$NG")7U#V)A/-D^P9`%][4@!W);4/>9-&8Q.`CHDB3C5NQ4X<6
MFSJSO#MU16U'';K*[!C9C&"OT)^1[[#2@J2#&9`.P(3-AH\ZP\$&"\M&9!]U
M`A+FF-Q@E,9/D-CWK);QTE'DUI98I3'*Y<V+8I)V-5:!E8:CW>:Q@`1E1IDQ
M(9"M[L1Z[X_GC<P-?!:=.K=L8YYOW["AD3^4<1*1]])&5DMME:9!=B="D@/Y
MX<4-V"O+I+W!+I5>5=MDF./!JK(IWD)XX3#05KH)G\@R;M1RQO')[>J$PF6T
M%2<?WK=$)WFMY76Q3F\*RH:..KN$[0E!GLW2WJ/=@>A/OO'N!T5Q3(E-WO[P
M,<S:*XO?VW;C-V8+&3N]+&++_].EY89L@77&7,A]%0;"5=>S4TA\QY_3&T2$
MI\8>9PX4,[\JU$_>MY0ONE/XZJR494G"`1_[.<MC<TBJ[$F<U'HZ0U&_EJ=:
MUU<;@5#V%&_*W@S+K;,YUH15BF._*0,R#/>([RFLR^YXCAW/\>/S'#?AE/4W
MGP/'%3U[G/_/:MI#7<IL%D3'8M-($1EF/G$K6I?JE&V'L-"*A%[PLHXPCHVH
M-X8F,P6UQ-ED&D"&_A8^7;(>BK`I$2U:5^KK:(LX*-$6]8(K,:UR?B!["I]_
M,V'358<ND/T)8UL>'BZ:(]G6RK]\$%0&&+J47UOUB22.DF;;3%K.^,5U#EQI
MKIOA?WZSE5C,WB**R"/2B46FS/<3EWSHTD''C!A=(05KE93Z?N(0@Y5V3VUP
M2.I'>5-,0^98VJ@'1'$0E4_1(@8LV7=LPXYMJ"-*)V@:G/N4X1`;$$J.(4_6
M;&9!;EUU?()D[IJN6KJ<Y++YHNTP``J/X2+$E2_SZW&MR0OSE[N_GM6W)`)?
M+B[VQW."5CN9RI59GNBDX6E.8<KB8KP-=1N\^FA#M]BO:<'&%[QEW9H#M_+E
MK=RM[_03-B,Z.3#;M?F`9<X]J,&YNCF[)3@9YG5-)GDV#Z^T+QBUS<H$B"#*
M3]1S$T^7_.")8NJ=+S\9-IWMY9>A<MQF;A?=HH?5$1]Z/4LN4^6QD94P/SIJ
MY&;R:=?!`I$K[%N0+@J;38ZP^5&1@C:3/+O`_OP>$8^W;WDDDE+FAR"+5H,^
M:YT3^.Q##Y/`^0O9G#%3G\$K+&I^E#1-D(5NOPWFL]3]@"DB-/,X:]&3_#MB
M=$>,_@S$Z"7\'R;Q(_5438SFR9I-C,JM,VWFS(^_7\]2>(O.YBB*M$.J*KR-
M=9%73JZ:%QZ3B=G7A[!1@O;<Y^_ELI[E#SUQL2VI&ORO-34KSGJLQBSMN2HF
MNBXQ03<+2#RH=.NV6%O;^J7\F@M:YMCW[8X)8BV[F:46K-0W@I-A6T^#E5JE
M;P,V<V"^<.`T.N,F4-\OH,]7N$&TPN5<0TB(,C[Z.LP/75E;S"3"HN>>Z"VR
MD//(9Y`%)_PD!<R/EQ*XF:38'701P_N(_!")@Z+*DV5YTN:'18Y:@RQKCG$I
M\7Z#%-^2N3M+<A'A^EDWL*-;=G3+CT^W\-/QU[/$\_%JQD4B;C;IHK31M.E=
M\JJ"L6^SV0O<?'///E%HB?LEBQZ;*:VH'8Y&'1S\.I,,)6_:BK')1$^->=`H
M`S2V'[&%U>=Q4C)-'\I[95O""C.J[E$E+O[3\6V*B=+%*9FV'DFKP,=9.Z33
M\99OJ^.3Z7-*0V2?A(1?%H*(@VUQ^0E=?7^&R1TBCXZE>EJJG)[&#PB6GQN6
M-D<68`,N],H:PA\,0Z\/;[Z:[S6Z"FO,G'3FWYJEB&*NO/GADL/68`4;)CF*
M7XR8(C@RUV4K;YC>7>BSHS9^=&IC]5:,C:F\)NYJ)<&A+&0VS:%AKVGCC@1R
MT4F&@F+M$!DZ[M<*F.$G3^J(F<G$1,5Q-?FVGF-,@^N9V`DJ8IXRHFVML?4:
M$=8`;^C"FM^XP>`LQ$,WC\C%#]S.Z%&"HC!I%)Y\^'X"IVN.+)0?6EYF(9?I
MG']"/B+094:,;8_?/Q2L-AHC.PK;7BDUK+_Y?N+[`LOD,]*6]W%<H1S9^8O.
MPH>=],I/AJ9?75/&#@WFJ\&;D<7M[&-*0T]\4E^AF_>"IY4&D%"16'C7]=*Q
M547784`#Z-NL,:E@CS+O<UK#IB"AHW[<$LI#?:IC5.:-C;L':':TQ\]`>]SR
M#28UR9$0,9O2R-AB&H$A`!9.PI-"[9`364?F.-KP4Q-E?6TRJ5`B'B83!I?,
MEU[H%04E)=;2>8>\#,=JE&9V.9=PJ>7SI%A;3QAI.#T#4^KUBD^1G-+`\?C"
MY`R3&7("-H&\97_F#9M<7B8^V3=U`5:(6F.YU4)^GWH/+GY&*-HVSU\V7F'_
M$5%FEWAK$[W'`7]=R^9WSO!=X>"_*+A%%I[[_!X!>5NIK4ISDZ,1R\WL0&NS
M>77X@[6TZ"LN-VPAZW)Q_+RI*'>'=*+;RJ$/]5NYE31.YHU;FJ_EWAT#V?$A
M/SH?LL:^:0305?,CBB)F\R6%MIHV%D>=5!)NX=N%Y47:X5:*G;Z]R55@LW',
M2Y51,IF5J2R2C3YQ\OE.^21$_'-+O$MQMN-\K%5W6+*[1=#2L;#Z7I&$2&OO
MIB[CQ@Q@:;]2-:<2$OR`Q#4,2H]FY%I[7709M^:CEOFVY6-#`F;RH7[EG05Y
MTN:?+9"CUN@\C%G9%>QQ9]XNK+FVJ__UPHGW-L?W'!UCWV+`B,!0<"?#*//:
MX8->ZEW0L5*0UKK;R-\M7'^&A>ON)DPSUJB[FS"-7ISN;L(T\B;,N.IK7WYF
M@PMFY%I:IY:ZM#$7=$,+UCO$,L>.$2A]FR?Z75PV*@4N]7'%3KY?.$3/QSF2
M;3U14<K%,MPR#[?\Z$2TP*/C*7\8P%(L9;<EFW_54=E):CYBC<W)5AX12RS%
M;AWZ]89-"]D7<(X46]VJ4JW%1^GV[0?&BO!+A]6*;Q?*7)ZI:!#BCAYI`:/]
MK@-=2KQ5/)&1QWY/-J=1%&GGS6N:OL1E;)#Y7^--+-'W_)\II(A]\W]02P,$
M%`````@`EX%S0U3W%\8Z1```H<X#`!4`'`!O8VQS+3(P,3,P.3,P7VQA8BYX
M;6Q55`D``T[4BU).U(M2=7@+``$$)0X```0Y`0``[7W[<QRYD>;O%W'_`V[6
M=YZ)("51E&2/;.]&\R&9MQ3)(ZF9VW!L.(I5Z":LZJJ>JFJ*[;_^`-2[\*QF
M%Y#DWD9X+;,S41^0'Q+OS#__V^,R1@\XRTF:_.6'@U=O?D`X"=.()(N__/#U
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M\O$NB^MO'+ZNX30ETU^)1KZ#)"<?<P[O/`V#@M/+^!FDE&#_:[\6VV=_VC]X
MNW]X\.HQCWZH&Y^W8);&^!K/$:_FQV*SHI3-"6/<#]7?[C,\EX.)L^PUTW^=
MX`4U>,0^]#/[T,$']J%_J?Y\'MSA^`?$)"D1E?7ZN5=6I?3:-=@KG)$T.DVV
M0SW4]@2?]IVL>$(%NOK.JW";%D&\%?BNIG/8%WB[%F_UW+<T'4_P=BW=T>S#
MCMD?S^F_>L#Q8T$'(AS5T%E9&@?'/\7];E5V4WH:]LJ-F;-,,VF+\"+G07['
MRUWG^XL@6+UF8])K'!=Y_9=]]I?]-P>5=_R7ZL]__Q20C(\]9\EJ7>3G^`''
M!U_P\@XWG^-U_<L/5AJOAS5ANK.LKDZ0A88VJ21>ARD=,%;%?ERV?JD^S]*E
M)9"J^5(K\;_'=\TWRA:G,!25Z8EE..=3A5$&[];(OFTKC,N8ZK!I&$[VO][\
M\*]<!!W\^75;'``R'6V:?_Z5T`E?%MYO.-+9(\E-=3<H>Z&8586D;--JPB.>
M#=PA!YE&.8'=0XT2^AO3^$]@Q.STJ[>CO=Q;*%[N[3@O]_89>+FW%E[N+5PR
M'8XFTR$4,AV.(]/A,R#3H069#I]*IC2,<TX1MB/`"<+^\O=?@RP+DB+_E13W
MZ;KX1!YQ=(.+(L9+G!176?I`V.Y&+B7,5B6X(-`3JL8(M86Z=X)MCWE(N'&%
M`'-R1YLO.,C7&<=Z%.0DMYO#R;4\3=YT55#,VF0JWCDY#N>0AQU1Q&5W-$>S
M\(1T^7\<Y/?;.T*+`KSX0>N*2=V@4=L[X[:&K'."QC(F8N1?TW\$=]DL)DNB
M9IU$R!FSE``;]@@2,!BB@C5D@2`'8[2[)92(E_.S)"(/)%H'NGT*A:S+D4T+
MMSN>206],\8&W9`X7!:E<]1*3SMZW11I^(V.DCAB)Y,XR?EQU>DC^R=6>P\K
M-6?^9$0E&@]CH>.=02.!#LG$-?>Y*NKJHDH9AE.Z"`HZ6[N<5Z`T+DDJZ=(A
M::!VW9%$S#N5S-B&["DEF2^J9$%M=7)N7ZX8G;5[4A(YEXQ1PNSR11`"PQ85
M,JFG0:5@#H,@L^]!%MW2KV@<RD#&)3&D\+JDZ`F`(80,U9`,7`8QH6FG+E]O
MU/.3]C=GDY`AG&:F4?_@W8@R-$/C?7UU\PI&!V97QOBJ^3-.%UFPNB>A=L&B
MD7?K\0VP^YY?(>R=*[8(A_SIBDW;_;_@1Q*F:A?0_]V9&Y#!:EQ!]T?O)E8A
M$O=3F<A$5CQ=9RD=39+HLKC'F=J:<CEG5M7!;*PK$X)A90VRH;5+410D$>+"
M4_7>-")S4EZ./4O"<KL^B)L=?TV_MM1TU^-'5:7U!59J,/@S"JO@/ZR4)^+9
M58:[WU?32B'HC$5:H`UII%(P.**#-J2$5';2$<9J>/$YMI@'%E^CR@/.[M+F
M@K!%V_D=68[7>9$N<7:9:`81B9`S>RL!-O86)&#T<!6LH:'I[ZB6A;&6_!+\
M(\UJ2+J;'3)!EZM'-=#NLE&4\DX0(S1A5L`$&YI,?$?C%SKC6&?X'"?L<=\Y
M#G+Z7VKOH!5WYB<L0#<>0R/KG1J6`(<$^>7\'(;S.,%WQ5F2%]F:35PUSD,F
MZ-)YJ(%VG8<HY9TA1FA#;C!!U$HZ."*_HO6\#W(\6V28+V`,9^-*>;>'X@;8
M_=-PA;!W>M@BE)]*U3JH44+?27&/*H^$*I>$_E>P7/VI^Q]4>2GTRQXZ/S_F
M$]<12F=<"X8+:];:IWE!ED&!+]+B*@O"@B[`[F)\0O(P3MFER;,"+ZUNOHXH
MR,MEV-$5E=Z/M2[%>Q]Y,G3=:Z>Z+$0+0YW2]E!;'N(%3NR)[X,,"U=A-)Y8
M*^_.$UO`;CVQ1M@[RVP1"IZ8J4AN(L'PCF=)2-<@S4E7';-!XP:U&B[]G07T
MKF/3B'OGECW&(;M*#=2HH%IG6F]4KUUOOVM.(25"SC>:!(#"1E,CX9T%6EB"
M6\&T":*=[369[$RE++84>V+N;2V"%*W=R@"SMP!,N!]]3[+=&7PWP\=QFCS@
MK"!T0G1%B\59AB.^]-!>3#1JN1Q&+*O0'4H,*MZ)-0[GD&<=+=2H(:X'@W3-
M8'?ZVYH4&S:I2A/Z/W6+-X..EUM2.OC2FU(R!3!DLT$I'(MQ4=3*@KIG36$M
MT\3&G0ER;AV8`F;?90V$P/!&A4QT2TP.DA^:11%A4^T@O@I(=)8<!RM2!+&6
M*P8=I]>P;>#WKF7K%,#PR0:E<&V[T4%,:?\L094:$*:%X7JYCEG`,GY]@#G,
M#-_C)"</N%P"ZEEGK^^4@6.KU6.CK3(<9HY$++"TU2]OD:!>":C:"WB-SM,<
MR$N4:UP$),'1:9`E)%G((P&8A%U24@^XRS^Y)!BR:>'IF'6"YR0DQ50/5W(\
M7\?G9*[931!EW#UD4<!K'[0,!+S;6X=*>.#"Q1"3@^$>KMBMN*S87%&8Q2R)
MV'I@Q>.<;`S/UZPT73J.$57I>A$+->\4&X]5O/-::NXAKLN/DQOM/0?OY>I=
MLYEY#W/FW.DHP`E[ES-(+D<.2EBT55)H!L/A'#-3)$7&CTBN2?[M:'.$D_!^
M&63?--[&K.9XQ]*J$H,M2ZV.=U*-!"K9M&S5W/B2([,O.?+F2XX,ON0(HB\Y
MLO,E1U.]RPJ2]3P(BW5&)\S-\*1YC:65=_<&RP)V^_)*(PR##!8(Q?O4'94]
M1$OC,XR4KY%Q702,$>AR3I=76,\N@ZS+L48+MSO`2`6],\H&G?"$@\M"X\VG
M-5W'L_N7=.+]B3RR?^EW4W0*3J\E&H'WKA\JI<%PR0A1N$Y8*W"O-*]48-"*
M7=G%]VD<G2U76?K`#_#TO-)JN"26!?0NLS3B8*AEQBA&NJXT$.FH3/6@F'Z:
MI9+2O"0>2+A[0BR%UKX=[OWLW=YJ3$/[,@&^:0+#7<COO_*_YK-U<9]FY)\X
M^II$..O$SV+X\Z/-Z2/.0I+CJXR.K]>TEKH-ODF^Y/2:QW1-U;L<LOO/>.\>
MT]=-N(A2"2,NC;CXM+L(#"5MA3=Z7]J5<.I+16@]7]K^[)TL:DQ#(S.!G?A2
MO4GEB4*D$JY-*DD$(OD9E$GUB3Z8@`.3OC.:])TOD[[3F_0=0).^,YGTG0.3
M?C":](,ODW[0F_0#0)-^,)GTP_0F/9`G-91*.#;I$-K`I`=0DA2J,8DF/3@`
MM"XY3O/B<GX3Q(9-,8F<VY,[!<S^4=U`R#LM3,C$P[B\8,&S,_R`DS64K:YK
MG&/:</>S)#IA^<%2OKNK"_<_2M/M+37KJO2OK!G5P'#-'NN0?;4FWVV-6ET8
M++S!,2US\1DG.`MB6KM9M"0)R?G1]0.N*JCW8B/+<+KKL4WU>OL98PH`P]9M
M4(LO.GD9:%$6PND;](J!P>`JS9.6H0,9EPR4PNLRK"<`AD$R5*H$6Q--HR\3
M7-^Q4,^D)4+.)M-*@,U\6I``%2U2A0Y^$,%9&*9KRKQK'&+RP.*?F-Z;*,0=
M/R_1@AZ\)I'*@O$/!H"2&_U<'+7R,)AT%%"<(;ZYQ]@FVHA:W"633*"[3%+)
M@F&2`>"0294XXO*.PHN4P2W,@Y%<SEUP(PW,-JB11`C4J*0!Z"?H"`]T83:^
M5,R9[34@&]-+9$!97HWO.<0>X?M0U^46TP76KT<4LDY7QCJXO16P3!#,Z*%#
M)[@+)HLJX3U$Q='?2H6I!HZ+M,`';][(XS5()9PY##FTQE?T?_9N;C6FH9%_
M1R7VV,DZDY[0K.__8+!J1\"I405@/9LVO\(QZ1"28-'W?W!AT'>F;OK.4R\5
M@/4,^@Y>'QU"$@SZSDD/?6OJH6\]]5`!6,^@;^'UT"$DP:!OG?30@W<'II&T
M(^%V)!6@]4?2YF<X1A4PB2/INP,G9GW_WF36CH1;LPK0^F9M?@9DUB$FT:SO
MWT]MUE_.S]\W,=[EAX<:.7=I/30PVWP>$B$8YM8@DV3P>-]&W9_JQ(9^Y8.E
MV25R+LVNA-DUNR`$QNPJ9!*S?YC>[.?GQYKKB]U?G9E8A-08MOT)ACD%/,*;
M*BHP5>R`=+ED+PV"V*;;ZJ3=110P0FZ#"RA%85C>B$\6<[)4V&&GWM$[\BJ"
MW)(42T/L6[FHTU?D&K"]1^02.>_4L0`G'.#7T?EJV8DCDJ0Q+3(M@Y]89&G2
MRSOT+&;8'=^B%O9.$5N$HG_IJ+0N9KH4,LGB/B`WZ^2!A)I35:F<RY0Q2IC=
M5#&"$`P::)!)4L-P453*3DZ`+VF&K^Z#;!FHC2_*.$PF+H?721O>%X!A<`4J
M,15XAE$I-Y%YSY(D?0C"C28KE"#BS+@*<(UM![_#,*T<E)B#IY*:R*ZSZ"$-
M4\TZ82#@S*928(U%>[_"L*<,DA@+G,M,9,M?21+EJ>96RT#`F2VEP!I;]GZ%
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MX(3`IJ7HT'N!(M"7X)$LUTLM<P8R+BDCA=?E2D\`#$EDJ,2HW%P&&!],<2<]
M18O4QGB$%YG1%$]QEP$4=^0'2&+V`WT9IWY`!J_G![H"8'@@0R7X@5)FZJ<_
M[,9='2!!?P%R*.7T^J,<8N_R8U_$NZWUN*07'R<.5,%NV5F96I!R>N71;.H/
M0$TMQR6][#BQJ7^]/=-LN;8_NMMC'0)J-U7K7V"8<0A'V#:]/8,Q,C>)PV]"
MG`0926W2N/=EO:1OE\&5IFWO"GKGA@TZ8;^@$@$UH;M:W\4D_%J0F!0$YV?)
M`ZU,FFVN@^]?:-4R$L3Z*&IC"G":27)TQ7H)):VUP5!Q-&1QM?$=-9*PV:E+
M::I5@<!`91)3C3QXEFDWYRN9::_O?F(A_NYQ]#E-(\U\5BKF;-ZC`=G,@"0R
MWLUO`"9L:5:2B(O"\"6W]`.7\QF;9R_XD*UQ(@I9E]Y#"[?K-J2"W@EC@TX(
MCT-E6<#CCC0_7KE(D_V@\[=;^L\\X.<L$S\)J(*NJ+W)0,"9'Y$":SQ([U?O
M5%!"$D,.[R;0M<*8)VFXY@Q,HM.D(,7F+)FGV;)\:'#'HL.&A0RZG9XSTX^I
M1L,(&R481!F!=,B?6A7-6&)TKHPZVKL<AG(<OEJD#Z\C3,H1B/YC./#0/_V]
M1'&-%SSZ<%)<!$L\J+5:S`6E3"`9@U0RW@EC`":DIRHIT<HB)NR/%L<\U79\
MED3X\=_Q1EDY0<XM,10P^\P8"`&BAAR9@AN5,.+2B(K[8$?MQ]A\2%*M_L^N
MN"`#55.@^QL(RTL`*0<+)N/3RE<X(RD=ZZ*3H-"9>R#GVNY2F$,"](1`,4&&
M3$F)4IA.(2+$Q'VP8T:!1`S,ISA82.HU^-T5&Z2P:A;T?@1A?1DBX:52+8.8
MD`];'Z^SC&$D>1C$_X&#3.T,U**N&&`"6Y-!)0>"%P9PP@/S4AR5\H@I>'4.
MY63E5QS'_YZDWY,;'.1I@J.S/%\+VQ06\FZGDP;8_6FE0A@$B6P0"GOA>;TP
M#1#3W/_&5%&MBTKE?_-'JE_2>)T40;;Y1&*<#?='-7)N2:2`V2?/0`@0:>3(
M=&1I-!!7\<B0RAE>XU6:L;=A[`A\K2:*2MSQ&E8+>K"4E<H"8H\6H))$OV<Q
MQ"L-5*J@JB2/;.)L/J;CZ"+-U#L@`RFWW)%"[%.F)P*(*3)<BIT/+HIJ68_N
M)5TNTX0GHB]3U%^NB[P(DHC25MTCM$J.78U%!08.1Z,!B$P6,%6[:EP3<=4]
M5"JCCK;/[9=R3E^N^#_1O\E&,HVLZVT8)=SA5HP@"()))G3*+9EJZ57MS'`5
M_ZQA"T$[SG0D_3!&@"KG2R,&D"U#;":N\&7ZSIFR@QNZE_,FQ,)5FA/-^?,X
M52_W=RTJ([W.J]'SSKTMP$H?!W,VIO-.1(U:&_VMU@=R#WB6Y[C(#30<"CE-
M0RD%V$L^V9,`0R(I+&$3^N;F]/8&$A6JI:$5(P19]\10P!7Y,1`$1A,Y.M5^
M=,!U/L*@S7&0LS3S[+].?UN3AR#&++QO<1QDV89.\G\)XO7P2&.DKDM:C:I.
MEV96BF!H-P:M0$.JQ"]HANP?N%6'04@QU^\%+JJNH^J$6A6_69=%\/K,RZT\
M&+)9@%1F8,X:G3V4X"?']MU5>*CJ:0.MAZ+.?1&WH:!$</T`4.WO8"@B`:5Z
M3T)P#H@*5QE>!20Z?5SA)&?!A'CT^MZHKJBRE:;3ATOV5>F]7S*K@:&9/=8A
M^RI-A$O5G`^`*<]4$/:F93!H:4-`CU0SDLH??8JT".)SVQF[ZDD+*P0D,:ZR
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M-#M^;ZKDJT%^?X.+(N:79FK0&[D_L])PEX#5"GJ;@E4K[IU5]AA5@R1_8Y`F
M[.(3/QC.FX(:'FW0CS<8HXNTP.CP)QC.L-X(J:+0Z$=2E;"/S2HY8-EN55_2
M.]6LX"GWJ[)2&@9YSM-D<8NSY0F^,UPQD$HZG<VKH?:F\:(8&,*HL5GXI)@J
M[Q=4&T54G>^5LS^S_X$BDO.QE/WA=^\.WZ`?UTFPCDB!HY_XL/B[]V\/4%"@
M&]K(/)05.GRSAQ@I^,]?:(/<H\.#\D][E*/Y"H<%><#Q3I_4['(1:KU&\KWH
MM%MLPMI-4^+3'Q3N<+XUR>!HW(S7R'L<(O6;\DIAIY1ZP-E=FF,=J4Q`G]^0
M:>232MC7P*EGDEP2Y/!I),^Y]7#Y7APMW[[[XY:CY1Z*<9XW#K$:O]TN/I6L
MM%7RO025L]1.PSM;1\&47DV6+3SEO`*X'#7OOGG;7S/LH/G:(QLS&=/.PL#-
MOMC[:5(L^<W\)#I.$Q;#`2>AFAM:#:?/*,S0>X\GU.+>'9(]1L$;M1I\X.OI
MP*#8Z)-S*&?EXT['G\%Y^.@3\*["[U&I`H-45UFU\N`0=0_`I)*.[[RKH`[N
MN`_%P!!'C4WT1PE=9A;D+L9H56NAO`S/\;LWK]Z\>7.`5D&&'E@A?T+O]^A?
MV']07L;N",HTM?_$$5T0I`E&A,4MB\J3HS:NAV+N/UPFP-\UZX0^T3YC%,1<
M#[4RD,/QM2L#AKP*8+*1E$[7U50]>+?W]H_O]_YP\%[&U0]['PX/]S[\_([S
M[L/>^S\>[AV\;VC]PED\BR(>?""(KP(2G27'P8K0^6ZGZ54GS!:*3@_XK2O2
M.]DW:H'I#=90A;/\1A&Q5TK[)$%AJ0N$@F&X7J[C@/8:?DF!UH@.0/<XR6D_
M.4O"=(G/TSR_P,7E_#9X5-]X&%>*X]LGVU1Q<`=E3!%P:+L5;LE]E+J4^AI*
MMQP4TR)@L/D:%P%)<'0:9`D=*/(.\A,\)R%1+9YL%)WF3;>N2"^ANE$+##.M
MH>K(&)62,+@G+A.MUY.^%^AV"W-8>X=*?/(MQ+RW)L>`UN2FZ_;FO5.%&J0'
M$H9M::D.++Y9HC5N8/.ER11L5"59PW?%274L6-UXN"K/6"[G["BQJ,X=98<]
M]KKNDJV-K$Z;<,U2T?L(N0U:\8)!YS!X3SA<$RY=.>!>C7HK\AF4O;#/JD)2
M^FDUX?'/!JZ!@"W;)J/@%!OD5T%VF?'`D1'?`[O"&8^5;+7?JU;VMXUNJI!Z
M9UVEZ9VN6\$=L?_>[F6B'TF"3M(X#K(<K>@JF&]2`KF=T*]^&=%[UFRT6K69
MJ.2/J*H*J`DZU`!*3`7,,804MM'A,I!GSQG#OEK!-_/ZP$VL*Z5!,ZX'<0NV
ME2<Q<)FF3DIAK>6;<XJT%)8JH-EG3DQA0<%TFOP4.SF$'CE3M-+T=%0]9HYH
MH0:&E_98=6?<SV0Z**2&,<X%M1J>J&@S"]2(0Z2>]?RO0SF@$SZA5MK9GE+:
M*[?4\SR%*%Q.&69X(I\@3>E&)!FS4_'**L-,#G1ZL1$@;4@&;M)6WGIHLL$8
M+E4KI=W&#=="[H<0EXJ"894>GQA8G$FC-G4/M"0]U8-/4YH>4<SM71(YR/[-
MD;X,M!>V"GQ#PM1B,-AQ$\0XKR!]3M,H5T=REHLZO16B`=N[%R*1`^->-.`D
MD9JC=0CDV.F<A#S24P5=>05A(.7VAH<48O]"1T\$#"ODN!2$0#&79M?,YQBB
M)[G!V0.%:.E,>M*^_(D$LLJE=$3!\$>/3WC]54K`($X](!J&53\3$MU$!-;E
MKP$J^26O#-3D@X68OYQ7P`WS4X6LVS6T!FY_\2P1A#9=U8$45\TYC]<!D3Y\
M#G63QNI-O8&4>\H($$6R-"(P:3*$!WJF6D*N1T%MO5HA]ZP8`A1)44O`Y,0`
M'>@Y1H?%[&9TA=S.:P@*GAR(`KC"EPRD8<U5C#@5D>Y`#D.?LS3/J0.<*U]N
M]21<LD<"K4N7SL^P^"$"&Q*"2Z`5%X%!@\L5S@(6H:7*#VC:<-7(.TT_9(+=
M2T&D$@:S#C8A%%(1U?)-)',8;+K&.6:Q`:A[/*'>+DYYDK:J4LH5H%;'[?+9
M`GY_3:U1@#;_L0$K;ON7.OQM5=1JP:#;#8YIF8O/.*'=(:;UFD5+DA#6=5@P
M"CWO;)6=;NV-JE!OI\]*$XS#&P57G*-SY3VT*-4Y.8->`3#X*;AU6_?O>3"U
M&D1AS;U4\.13\A3H^-G4HHT@8:IO5](+:42H4MJT8D")(P`4PP/3N3MKA)H^
M:0*$-F=)@6GC&"9:@I3;FS92B/T;-CT1-S3YN:1)@A?LSK*.*')XXL6:4JIV
M+%`(\D`QL8E;R?(:I;*J*G&WE-&#[G-'+@MFPF,`J*01X=(3O2+_')"$>;63
M-;Y-C^\I`(KK4T`R?G?_<JX.ES9>W=E+\BTJU;PE'Z'KG5E;`A:VI&@)Z$<6
M:.HG%*TQ*E(4\G(H]="<EE2]R6`IKKJW4.&%$?^:9#B(V2W^NE4NDQ.<D0>^
M(E!-I(Q:+EV>916ZGL^@XIVFXW`.V?GC.2?F@I'4P,ZH*8S^1M>!:QZ$&@8U
M>8BXBS1)!ZL4U9Q4*>X\Q;L&M)#E72(+;1)GP"E/^5Y-Y7A"$!A\NL"%<84X
MD'')'"F\+EUZ`K#6@S)H0UI0&4"A&4_(`XEP$N7]]\&*^BFEG2:KTD/NI:J2
MBT)S+'J8XL63_COL".,EB[I8%0*#5[V>,'L(2,QR[M)I9CNGK`*M'04Y"6WZ
MDTTIWAR5?165KLQ<!&!G9PU>Y0Y14)?`YVG5:H&]5JL*@<'K.C!J_3:=5XT=
MBI%X72A?V1JU7/+6L@I=GAI4P*P3['`J*;@J8R@WS/N([E@!Y?EE600,%OZ*
MR>*>HID]T)GH`E^L6<C]R[GP(K2LO_Y2QI9EN63LDZK;Y?%6!8%A]U/0#SE?
ME[4?E(6AA)?&UL+5$^%U3B<5=*$\[!0H#.*017IF1Q@?X?<'H6%,SGK;PJ#T
M"'.%;;N$NJ1GT2>,\(>=X@BFM]?E"+@-'DV7[FRUG6\/V5=)V"TRJX)AZ#B\
M\DVD<8D=X&S.O`5C!3DNV'LS*N9\2C/J]9(R`'6XN<V")*<,HN,Q]7#\?Y6C
M\RSZQ[H\-JPSB52Q@F=%D9&[=5&NUZX"34)IQQ@@^*!)F]?&DTT"`$Q/]%'K
M83^OOE5%8`\WJ&C+1T'S`2!^0-)8AL1/6@W',9A,T`<AF%3BL/:^S$!W,9"[
MS))3Q?*YG+.4X)_B]+OI,8=>Q6WF'#/X?@X=M3P8-VD!4DQP6P=DHJMXGMF=
M:X$+ST1["D-WE:7LQ"(ZVGS-<726-)<I9RP;9)G214_!;0IR?$*P944'4^J1
MI8`A\=;0A=?XC,USSN;N)5J6=+0I`@:YV^E)?IM>8\82$N/>\N,VW0W]I_F4
MVP2ETS56/Z7I[K\#II--6#DQ;6KS*79*E]4?8Y=;RB,4^E?V[Y#UUQ^K+>2?
MV*-5_F5TMY%V72#;R">83LY"PI<!]-\QKE8?LR5;8?R3_UUUA&^EZO2:Q(C*
M].Y,6.B!X?X(L&(NI%:U?`36T8'!Q_H,$T=LO4$7#3H&JH2=SL2U@'MS<*DD
M&%YIX8GS[C3\MG_'I/D"KQ;WM$<[P3U@1_NX]C>F;`$+\TCS_=\Z*:0V\^,$
MYG/Z_@",0;=&+GU@][S?(-3WB]GDR>Z.=T_2Q_5N"539S>Z.&!@7K\8FG`JE
MR3Z?T!*0[_/4&^=UOVJ]I:(MQA7ADFC;5*[+P#'Z4'SB$[#;'724A?"',4!V
M3>A2E=8DQR>X_._.XO0X6)$BB,T9`:P+<)PD8&3%!GD#++7!N-71D.53M)R-
MWIVM@CS'19FDNY.T&\BV@5CE6<@S[.;7.,1T7GD7JY_5VZCZ):RZ,GJJBGK0
M'.P(S,).6"7(]L`J24!/O,2*L2?D"?T:4;YE->CXY:`$OIY\'07XK!/!BD_Z
M&PG0-+O*\"H@D2F6B$G-+]GDE=#SK:\#+7J;)5[)2S,FU,0YXN-O6EYDX!/*
MHAJ8H=*Q]M)7P6:K0;C1@S$"#ZIA-_Q62O`I*0>L''A7I=@SH1X[DPC#;$V'
MAG;^NFW3*`H#15)MA4<Q5UH2X/7."/@2<C-!F</M+'N@4OZD>I>L3Y=DH>>7
MR(IJZ#D[4(+O;>6`Q4/2ZJEY%7\<!O7LKQ4]^5X2U`MC3[LH!NLR[6C<LF<;
M(V^<@"9R&>]M!S<AM04!(+9%12T(KBD%S#1A:^BFFY"D+@'>=2HZ`:INI<W"
MW]8DP[3VM"L6FRM:HX+.BT[I7WE$<$6CC2G`)9O'5ZS+8GMM:#M7HY$+&PH4
MU'W`)K;IG+EHKLPGN;C6A$%=V7QIE>:DL%^SM0J^I[-]X*9Y;"D-QG$:(8H7
M09+%?H&S)8HJ01B4LA\!GCR$0!W;GS:F/XM)JQJW<M):!]J0C>2@J?N))$$2
M[F":JBT(`)4M*FI!:4TI8+SMUM!-T]1Y70+`:6J6AAA'^2>*\RS/UQ2G-GSU
M"#VGDU+;:O3FHB8E,,RT12I)T\GUJM52I3F\#<H/5=D?T_D<9XRF+/$>$/>K
MJCH=+[*"W,78*G;GZ%(@D-=011LJ*XH`3VP];CW-BWL\H'I3&EUV]<*'/D/F
MEP'/OB81SNCJ@*X9R0,[99&_V6!+TYR*Q6L6!XHWX>6*QRX;98^=?=-_K]IQ
M\YG[X(X^"+S'[K:6YOZ-'W$6DEQ\V)"6!?%ME>]!E@4["&2BR`%2'P]=5KZ#
M);G-#P;-II5TEME##[5Y1",7@W*<9X:H/,"#Z-ZO\:K:4;R<LVV;6YPM3_"=
M:O6H%G>;YU,/NI_B4RX+;6/7@%-T1H2NY59!C&HU1+U/W-EXNP.RCVN_GGWR
M@ACJ3L73=BB>Q::;&O?(DV+9+@4,(I]2]QT6E_/3Q_)QXS7MTI<):PPZQV#_
MQ8Y>'H*8=49%XXTKPFE$\BTJUPM//D(?S"QR"]!#-I=%L`D@K@I!&2V%.6-.
M<C8#Y/_`;5$PZ"ROYA6=H:31\,1'T7[CBG`:]&Z+RO6BX(W0A^6?MT`N\]`_
M1I7,3RR%(?_7=H1V;N09'9^R;$-'$/YTW=ZZ`T7'D7-7W$(W19`5X\VK@BX]
M$I!9<`_=X05)6.8&?B^`@WF99CWT8-;31#OW'P=\A%$QN[ML8TZ'`776JU7,
M0R0&<1U5\2R9I]FR#"UKB'AIJ^TTY,ZX*O5B\-BI@IDQC<,K1.GI:*.(Y&&<
MYNNLW#ZK#ROI<-,4!^1TLD[F>Q405?2&OHB/Q-Q=<+*LW.QW,#22@))Z-?[T
MC=*A"?L!@Q`U\ZO0)>V%DR22K(-/&J(;G-O3BW4]Q=Y%(PQ'\*>4"8;@.ZJ(
M,@Q.YSX]'>*GV#-1'#?\6IUFL$,7',WR-N)7YVG567*<)@GF(4Y^)<7]-9U;
MYJP#1R<DXRON<B-<MK6^XP\X.]R8I&&:,Y&=ENZ]ETQ6)2'%5O4-?A*/(Q3D
MLC!SI`QU$C9?0M_IIU#6?(O.5;)REZ?\&HQ1Z#);!$D5+).V4I[&)`JJX)M7
MU%1LFL7^Y^6\<CE!W(0G-]T2W%'93N.A[;(Y>A'4=E&P]SXW16V$!`N=LO=0
MKW0^3G7+9Y/^Y@NH_02X4/E'ZYPD.*?^*0\SLJJ:BN4IRR_GW1K=XL?B*%;?
M_MJF()<=:/N*=GO+^%+`=(VMH0_[P<$KU.T*G/LWZ^4RR#:,]C=DD9`Y">G(
MA*J7ZFSN=D4[2SC=S.V<_+8F$2DV[1R4KN'3A/Y)O>\R2M/97&M<59I)E)V:
M=SJ.QRJ\OZF5$=7N>-E&'X9G;6"VZQ^3#]6KN/26-N"[?E$G[YUR(T`.N?;V
M%6KI%D"FVU$0LVN"-_<8%]<X9A=RVFJ:)L2VRDX'[%$5Z@W25II@:#D*KIA1
MEBLCKHTJ==31!S?CO`GO<;2.RROH$8M"$TGFXK<\R9[!7VY7E-/#DR=4MG>2
MLD4Y8`C^!/!#NA^^0DT9G248_1^]C@#E$DJZ7)(RFPT[`$WY3!@GX:AM\W%E
M.,Z].+YZ@VR,]@6`H?,VJ(7SG[8,/JWHE=)QW^"\MU7E37Y[;"'@2*WUU>-*
M>%ZT-OGG=\P_:ZCMZ=(-?_]RG\81SG)V!X4N/+7I.U72CF]-6<1=L\`JS294
MJ?P>E4JHF]N893@ILQN#<S]B=5F"%7O/,T+?;8+9D=72TU6A#,;5C$4\9/#[
M5TA&8B`4E;['F[&CN@6?Z1YM6I$JX-'L>Y!%LZC<3PCBSSC!61#;K]\G_J;_
M#&\[;CYSHK@=?1!.EW-02V&@8056:>NZ7T6=S[)',5VYZM.(?WL/M5]'U>=!
M[VVTV'CDB*;&U;X,?T@I-'-N&K2>7*K3K*"[:8)>PM"G%0FF#^ZF'L->]J$:
M#/>/A(X&HU.468)O@T?K/0^MAN-@=R;H@VAW*G$P)#1C%%.#,`U$52!O3$CJ
M9?*K>A7//--Z1)T\9*:9?-D?7J&6;5!>QM[@!7/$UWC%TC<G"]-<7"GN=!IM
M`-V;`2MDP3#)`%"8=Y;BJ)$'YZR&%1JQ@6&CZ9-HMIL69C6P]+/W9W^D<[.*
MC&PK]#-.%UFPNB<AZCPK@D'):Y)_8QN_7ZG%LR(@B46T38..TZ`I-O![D5-T
M"F"H9X-R2#JNP_G6TP+G!(]3'L4J*]=`%/28`R0;5;?'1O:5Z1\6F?7`L'$$
MV"$I?W[5NQAZO,X+.LW+4*](*!.^]5V.?UM36*</%J\)U.)NG^GJ0???Y<IE
MP1#-`%!\>5N+HU(>G*\;5L@XS5/+^R25?DJG$@9+*^--]S?4:PVY-=$%]NZ5
M>A4[=(+.KJ=K@3:WT:52WHE@A*9[\S.1X5E^M"S'?`_W9A630FM]G;0S"I@A
M-SQ0B\(@@Q&?,+LN%<H]=\15)B*&Y&D.?T2ST1+$1LL94>RKT!#&K`*#.-8X
MQ1O;5)$]E.JJPIBE]-XTZKEFI^)X!68$/UAY*>6]4VP$2$7LU+C,@=4K``;+
MON;X<GZ:%V09%,JPJ$,AETR2`^QRIR\!ABU26$-^?"TC>C=B,$AQC<,XR'.^
M/Z`+GB^1<QN;60&S'Y1Y(`2&("IDXB1G(`>#)*=!QF+XL7B/_)Z$W1!EU'(:
MB=:N"KW@LWH5,.2RPRD+QWF>YCD+XU?>!(/!M39@2]X<_%S.V[]6\8TVJKL^
MUNI.+V>-K%3O%I:E+A@^C@0L>Z*3)M4ZK\XKBIJ8.^Q\Y;*XIZ1M2^R\#CY+
M\B);+^$$1/X4D(Q'VOR"`[9ASZ"5/=3.BX[0=\GHT=7J4MI:&0RGQR(>DIKI
M(UY`/T+-+,]Q1>I.?"H8S!WNVHYAK:6NSSUU:[9:*8)AZABTQO,<&$2\P-_;
M@#9769K0?X;EX^4QG!Q?C-N\']M5LI_]8UP98$B[)7#)\@D/HA_URH)!Y_99
M_HR"C$B\9G.8&QRN,^[]3Q]9]C`<L2QD[%;YN@Z=-ISHVX=IV-V'_`1QV'5#
MR4,\[.HK8+K59%43]C[3@O8O.J&)-ZC^#,J;[[`L)OQ#99*[L/T4FPVQ-)5Q
MO1+-X:Q$V]9C@783^I7-\3ICSW-'!DDQJ?OI4W:5DO<4O2Y`_EL!%A]@E$IP
M9N1-?4Z7JSC=8-J7LP?"8AA)7QG&'`OOT71H3!<)^2>.RJ0M_-&3/85W_CT_
MG)^HV>2=9,<?`]BKIJFAD`RK^DJ9!;5ZKQIVW[7B1_9O<,,&7=ROEV7.5I;.
M;N2H8=#V-!&SJ9)B=J53!4AN&[Q"9'!,%O<%CO:#!YP%"XR"MA`VU9FS;:"'
M>AL(]XA=I_>%QF*^V:KHVM5.[DAF;U&B'[9O775Y#QA=',!>L6T=Q*VF)G!Q
MR?LZR024:")-C8>OD#HOB(XVU8_VW!]9FA_>;U5E.>='%060[]O@5[V+A/X4
MK8D)R7NPJFD&0F[#-<D`]F,R=27@\$D&2XP/5@FAOW$Q*$\H:ECG),%G])^J
M*T(R02_L$(!*&=)(P6/)$)J&*4P4<5D@='GB3N-LR;;N%0VTH[)=DG*GS='E
M\4X*!D/]7=9FV%MN67)CZ]WHNR"G8S/4/6FVF?*=Q5O^E&8GZ?JNF*_CZK@K
M9Z=?Y$$S=-LJ.^T?HRK4ZP!6FG`8/@;ND,*-,D];N4["-(Y94C$6-#2H"D%9
M4PH,KC9[[NS>2Q5P*\?9@_+NN4[!;50@$_!^3""5-!CN&2&*!^G\9\XVZBUQ
M7EY12N]R^JD"(U(7Z#BNL(,\/6`B#6\#>G3*'G3![E6R47>JS)YI]HV.U,?!
MBM!16%;%H82[W)I2:&URS-[/WONR&I.P"5T*H;"4`C88?,[HM,KDIRHA+TZ_
M!U#JZ+F$=T)H8:F.LC=[:,'$/,6#W]G(ZLA+_UPV?X(7+%"HS$N/P"HX9SJL
M?FR'4A34DSSOUKG`BC";[>^.Q\F"K>&LVK^+37.A8X\M\:"XQC(+/1VB3_!=
M<5H>9BOK*1=VZRIU@/N,D4D"<IT:>")Y2F&TJ@($HV40`5EJ7>,:U.6<A?3/
MKX*-9B-`+>[V3:<>=/]IIUP6#)4,`!6/Q>E4'"";SM-D<8NS)>L3BNKV19QF
MR)2`ZV7$[/P.AAT24,)[3$H:1@:>".:N3*H&@PX,=/NL[FL2+-E1Z#_+;(F:
MW7H+/;=O,"VKT7]\:5`"0S%;I$/>U3^C-$%Q&FB/HB>TSI?@'VE61R?,9X]$
MNB(0I>#LUUA@%)ZZUM$8_\;$@!S@\1L^;3(Q12T%*9==60&QRY2!")AN*L>E
M?$^!<A;VBN_\KY.(,J4*+%O='2ROE2PR#.E]4^<A*Z_M[7V0L`&PJ`;`"VK@
M\A:^:K0<48#;Y-QC*]9/U6VK#8:LHR$+YU8+RDV^=X*")%DS/M.9#5M_/Q\Z
MBX=TNBU,I;330U4]Y-XIJEP4#`7U^`2^C3L+G?(R4A"S\!</.%GCSVD:Y8H]
M-9D<O#F-%J6XMDVC=5A0&W!Y&+V8AQ,YR_,UG1"O,_;*F#]`X;='\O+OG]*L
M>LBBON$VKA#GJ2Q'5U#(9VE=`A@/L15L:<J\'!$NSH^]\TIAK[S^`V0P4E26
M1Q9Y(HM590`@L;YZ%AR6%P"=PEK48QC,7QSY&@BE;T6DMI-*`AP,]3BE:9\!
MOU>LWF?B2%XO_7&4K;+K*X7V%1I>*31K@G$;H^`J;L4JGM3"H":OUYTY>>[=
M,'EN$ZZK\XB3-4=(&XOMPQ_HNO9$'W2>S'G2AA,<]R1?`]/5)J^B\.B]DD$Q
MF0,9*+9.92UK`Y;%Z%.&<7VJ?DW]V*CQ=J???1:)UL<VXTZ2K=M^%%9/=5!3
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MGJG^SK,8!TS-M!-_KOJ(TZZQ*D^(BR`KQA_T/+V20B]KY5!0H#N\(`D+;\$<
M;PGU973`_L"DNT4UR9>>4R?4--4NNZ'D,]['J.GK-NQ_GW<SJ7%P4:D[=)\^
MXBPDM.[;W(M1%`3@KH=%1:TO+4E+@4/P;:&+9T75[T`8_,2.^RG-YI@4:]H*
MLR0Z?5R1K$R&6/?EB1R&Q7>?TQ!BW8R['%",'X7V;M]5A87E=:F'(\1#[%`U
M??<%3#1/"P:W]\+*>?AI,BF9U)4T+!G8X<4+6RQ4@QJ[PC_I:EWRG>?DY97-
MM,O.)WSDY74]5145<RW^2ON%=;RRWI?S<@(Z>PA(S*I)1RJ^0-IUPQL_]RRZ
MH66C[:0W&K[U@CJE74T5N]4HJ.7Y-7A^9+''>BH=+)]Y%[6==`X.?>H%XE5&
M0JPX6`&&[5ET_BG,X70U9@,,SGX)H-90)?Y!E2ZJE1'7?AENI[/HT#75](LC
M_=>?D^L8V:03K:AUGW[A!W,657^QQW7YJ!.4*;K\+A&`ZO:[;]I177]WGW\>
MCR^GK#KLT\*G-D==8Z_=?"2(9]73MVK@G7;V40A>7'_?IO;_U0]8/<SNGX@)
ME$MPT?Q@M@G^__:`QG&\S%->J"O5EWTB;%7U_]+GQ!Z&+>NO/Z<!:F233G32
M#&;0<7W^O/T$]26>2M</5:(R8540LX#5<9KS<7K:HRS#-Y]3E[9JOEUV9.T'
M7\R<T::6QJ.BXS3A\BP\+@L)`ZC#WIF;YF[TS.4:+P/"-LP[%6?U?JLSDFLD
MSR):T].;>B=AG+:'`<L1>*G[,YVQ/Z&MU%,=55OM/%S;4Y`\)\_PA*;>I6?8
M`L:+\0S;U]WE)%_Q(+^)WW]&$9(D)V$9R43S-M^HXNR9OB7XYL6^0=X[(T>`
M5.9A0(T:^L44%/CY+`X[8V:_6:;?E1M^[SDM"HW--M$F;O]C+V\OQU35_])3
MOGZ+.)C9"1]\IA,X1<---$\;?`UH)YVRK@"F7Z=Y09;L!6M[-LGBQ`VC9AAD
MG4VX3'";F99*$,84RX!.X$4MSEZ;5/(\]"N0L$FG/+46QE7^"/G@=I$F#SAG
M:Q/617(>'+[[^W&:%Q=I\1^XN,9ANDA88DE%QYSP>RX]]^3-UG7<DWW,>X]R
M5<-AK_R:9(U(/_E&2`MA"<)BWF>+M,R!4$>X>^%]MKS)0AU;]2<FIYJ#N0;Q
M(GJWMH&=='DI@I?O!W355AW![0?5$5R5++ET$.64CDWNUGHG`L-7\/"?W01]
MG4R#@\:7BSK/W*L`*Z3O'<B!X;`&G)#\B4G5F1`1:PNTP.DB"U;W)`QB5.`L
M(Y081#];G'*%VJE'G6+,(E=E1Q1@ABX#4,%*I4QM)U^F.*<8DKQ!+C/!0`1>
MTZL`JI*$QER>[7S9-+X[KWK,S,6.99B[9[D]Z/C"_D!'"]5\2:_BTLO:@.^R
M2B</QNM:@!3Z-:%C]YPZVJ1`X9K.\Y<LY72WG*G.S82LQ=HC,XVTN],R(^3V
MH$PI"L4;V<%49H^^MLH>_01^:+@\O`5E(>^,(S:P&Y;HA$'QQ`+H;AW+9%TX
M>DCIPN0+'L8!$W_]>Y2&S@Q`O\4S%?"&D?94"32A<Y8RKWPT+%V@DOQR?D4K
M7U?C*J4SE\TM?BR.:,?_)K2V6066":SQ#NW"%?E)2$?5BY6.TYC^E);];[;(
M,#\&4O0&G3`LRU@@'=JDIX*"6L>3599+=G`6Q`UVE8=2BT*SB`&G:(]:H36&
M'T]V7`U6,Y4)^K\#:W<I.*&QZ_%XYK6%CPPM?`2YA8_L6OC(:PM?)MC0QHT$
MS%8>PA/N!26XF5WZ;.A;NI8Q-75'!F9CBP"%&6:2LHU=&$W^/34U>"T!M+D'
M\"`V]DE5&?;</REX4K5YFBW+B99J\\-&"99)1B`6,J-6JBA((E0JHXZV#Z.=
MKK-TA6E=^"F,HI/(A&`918-0,`+.R`,MZ`&C<Q+<\4R@Z+JZOW";HE^#C,>T
M0K^2XCY=%^@3>:2_W."BB/E4$UUEZ0/)V?4&+P-V65>SO8`;RVRI^G"[29>(
MJSRO*"9S[5[B5$W_U_0?P5TVB\F2*)I>D(#5]"IX0M-S$W$_50XL2R[MH\W/
MDB1]",)-HFCQP>^PVEL.3IH<E-^619VLQJA)I,WN2WIQ->?GQQ\4S=[^!*O%
M!5R6C<UVJM$G.JEE;WHPA5;P9C_PTNY?@F0]9T_86!XKEJ%VI=E[TPG#LHT%
M4GW>W._UV$QXGB\OIL&/)%2M)KH_`FMZ$9E\'P*=QOYV-[^D$3\'8K4X2\*,
M(PGB)KFRJMFMU(`99`SFH:G.EBO:C5B/"._9`PU$$G9='I-%PN_*HS1!$9[C
M+*.3)3:(%]D:[Z]7KJ_B5#7-\-5]0!<Y2O/U!:`92HI.,$D2TH4WN@T>41N\
M!!7XL4!W[+S'1\M?X&(1$-7$J?<KK#:701LV."D;O*`-SJZ5)B%=R?$"]]""
M92?UTN`IG3&\>?--U>*]GX$UN0S;L,V9$&)27D8'#O'=@;9UFY\!MNX0F[QU
MJ92_UGW_7MNZS<\`6W>(3=ZZ5,I;Z[[]@ZYQFU_AM>T0VK!ISZF[11&=HA=I
M=T+2F[I39[VDLQ+^.LB7`=YI/?,[N(YY"$W*[7<>W?)[+;7?PZ7V$-JP9;\$
MV3=&ZR7];UR@A/Z'/6,)8OZ(A<[R\M=LIN*CW2\37!\/*=I>D(#5_BIX@@WX
MVA5]\;8%>47A'/S\\\^*9N[_#*N-I=B$UP/T?R$FY<5_L*]3A3>:UFU_AM>Z
M`C9IZS(IGZU[J&_=0\"M>VC5NH<^6_>=OG7?`6[==U:M^\YGZZJ.(/H_@VQ=
M_5%$W;H?/+;NP8&V=>N?(;;N`)ONOI?'\\NK#'?W>E6M+9,"UN@:B,K<P4F$
MV%E:1OBY?1D;8IV0(D=I&Z;+AUENV)YA9)A`RX1@&46#4'R6RT2;+N'%Y]RP
MW8'[@-RLDP<2JEI=(@2LU=4(A5:O1%$IZ^<<7QX70MW\2F%P9C`A%89<NN9/
M"O9T(,<L6@5M-[8[]0UO$'[$X9K="_-R='##7*-0E]-']D_5N:>%#C"#60,6
MNA'3W.?1Y_JA0W"I[*=;,5!7M)7N*2[3$RF=,$`KZ9&*\0?P*B`1JDQ9#OS\
MAA\Z7F<9NS4YRW-,A_VH.1SU8;';>Y*9!GV)#"S[J`$.S<(ET;'/$?_KC:*9
MZQ]@M>T`E3P`#3OD9P2O;I%%$;LY'#QBW^S^FN/Y.CXG<]6`,10`UO9R=((-
MPGL<K6,^;@>=&WSSM#QN*L<%^F/4W/3V,J+_<G[^WOA(4R8$RRH:A#K+K-@%
MXJS8\(Z"Z[M^:,UMC&*/1OE@8Q1!")Q15`@-RSZ/.R&_4*S4,YYCON@_QP$+
M5*0R@5H6F"6,0$6#+'A7N,8K%B8O670NC'D9HNL7+V?\4NTL;U_(U`]D",OW
M?)PF"0Y9.["7,==X07)V43HZ(1G]\^5\CMFU7L&2.RT=ENVGJ)H07+%_Y9F.
M>)UQC?K1YCOLRD78?`E]IY]"6?,M.C-A'Z.>N?R:5Z*Q9KC`Q7&0W[?/JMI7
M50J7,$H;)E'&0)=L)&4825;`_AQZMUKINN`/Y;8TJ%D=KD6ML8_=U/!I6I)$
M>:I:(O=^!688"33EZ43U7-=+`U.IZ#N)\">2!`D+9J)J:X4@L&;7HY0R'ZVJ
M/:8VC(M/QJ?9-Y8]+%B1(HA%,_1^!M;X,FS"1*(40F$IY6_#M$[VJ@H)(!."
MU=X:A!!=S:XSMX&RA1U8=08WTF1P*Z\J^S34TS.^@#*-`:5]YA<OONH$WQ5L
M8<YBF)ZGR8(NHY97;,&>)I?S^@],2+".M28L<XV%+0;6N"OX!C@K`,54@<5C
M7Z)560;;%&S_&%%A/^&N>FNO)@)(=4HEV%(O#LN`5EB%5[]4">5M<)-Z1V&S
MA\+JY*XR("!K75"U<09K-9Z%S02X(\R6-+H^+=?U)A4#QWM/G2(L.XY$K?6=
M0L^K7>=^XSJ]O#?)%D%297511^J52L&RE0ZB,'_OR'I^S<UR0&0YYHN/FQ7M
MZVHCJ$5A6<*(<VB.2@&5^P=<Q8<I/@<D88\>3];X-CWF+Q[/DB9TP^7\F#]V
MY"`%VXS0A66L\<"'UF,EH!_9H[F?H#\7W5UL?E`VM$"J#$_;"\C/TGI5BEZV
M-':27@.4:8PXE?DULJGS:_#X-$&.3W#YWV?)215<ICZ\9"GDI'ETK56=9=T8
M69E.G#DK/5BD&@=:$M.&:]$I9_4/THDK5!\EF[/W3;?&D-3E0+"<7`R6H;08
MQ=4"&!-L$XSTT'L2+`,P>33,CN1S>>X/I*75P"1O]OJ2S^MI&)#VUF*3WP_T
MW^K;7LT'TN8Z:-)K^5Y;O,X"6#[*D&Q^2P4<Y\>4M;4>ES!%YE)[]1L4KXVL
M;EUPS6IH3V_Y7)N[CAK"BE*`FE<#3HBIU8KZYF\]W:S3,TL/7XS"@,Q@QJB<
M<5<J>ZA5\M\=#/T`4,O+4&F8[RN)-]MUO$_C"&<Y"U-=;&0M+$H!:F@-..E=
MO$KT]Z@41K.BR,C=NF"[2FR?]BJ`0?59$ME9QZ0#R%;64#4]I4PIP\4]&:GR
MC-)[?2H90$900I,=03%!]+=:]#\]M[BNI0&VL$7+TN$V6,<%.F<E^&I>M@5W
M.:]`Z5@M%034\'I\8G;-G$>6K^3]T[R$_SE-H_R&ND6U!1H1<&TO(E.U.I=$
M3-1K:]_@C`6KD;J6O@2XMA:`J9JZ%O1/:S;J5V`L&#Z0!F<`+4@][]DDIE;S
MV0D^LP0"5UDZ)U*'W_D94.O+4`DW,)@,*H6\S5IR3,7O*4-.Z!`3ISPP0!4X
M1CZ5T2@`:G\[G.*DI]3BW._HU:%T/%GI<H7918]D44?TD5E&$`)D#34V\8E.
M)=E$+_+=YF4N&7;72MOJK1C$=I>@4[=\E3WG1R;^DZ?FK_.^:5S10`10LZN0
MB5<ZJN1VGMT+.TN_2)-TT$NE?%?(`FI](T2!^3PT6E?#LT'J7)-T`E%M=0NW
M5PVB@,QA0BCL[M?R>ZC1**\8>[+&!2Y:]SE["$C,]F%OT\X5VVJ'\"C(22BS
MTL@B`%EO6^1"4A1<],<5U!3&=K3+XE"WO#W$2_2V(%RN,GQ/G0!YP"5P6H7+
M^6WP*%\1*L4!&=,&I;@F[.CT3;B'F%7I>I'J[\$ZI/A4YE\LCVK#S6T6)'G`
M8_'4%^>_-HEC9/8<HP_(P%O!%K*\5KDKZU)0IQA4OAJHS-\6YFV6.+Q1*U[<
MED\=S7J`S#H*KO+>\(^U^D_LYG!S8?W:ZL*Z4R.>)0_4=:29XC1=JP#:;#*<
MEO;JJ(*Q4Q5H6+M&T^N`MI8"JJ7!!E&8P1BM[OA7P6:\>ZR40)M-A76L8ZST
MP1AN<%'*SG`#)="&4V&U--SP6IB_Y2*+!\"CSD4X.MI\S7%TEC3;:S,ZD7I0
MWA2SUP9DRBU`R]:'/(Q"70BZVZ`?63G4M#^A=G.R+<N3?:E;X'%^;]-9^-N:
M9/BJ"J[,\B`5LR0ZK>,KR^QKKPW(OEN`%G(25$6PE6%5"*I+V4.\G+WFVA0O
M"E;W9=.O?.ON*]$&9-XM0(_LODU1_KKO#MXH`GG<8D"GNBW=%_=VWKRJ'$$9
MB>56$GC&)`NHYQ@AB@?,M0+;-SMOPLB<N`\C8^C]5>C0+1V>1!N0V;8`/=+A
M-47YGZ\PE'2(9O_%QM:'(&;TNZ*^((V&<W#IUO8(?4`VW@JV-+`7FY7P?W3*
MH5,67A*2K$5\O9.0YE^;L<C8"QZ6[&C3BE33L=GW((NJJ*B7;0K(B_7PP>=D
M'P$PJ$Y?-VGT^"K4>/=;J/,QYD^Z<M4'$?_B'JJ^2?_1?G4/E=]]I@1L`Y.R
M"XNGCRM21K?)SY*RLTU!2.-'`;DT=W6=DK`=%.6"K\7!MTTYDF=*X=-'G(4D
M9]N&T_E0X2,OB*+JNDU)R<Y7GZL/+5%?SOFO[44-VMD^L]08.^6AX5LO@8ZV
M59R`E>6G^9L(_O'.11F65(]__[FQ4YPA_8K)XK[`T8SE_5W@J@?BJXR$TE6(
MHT^_S.FH58V=35)K-*B"4[M?MB%,`4'E=FYH[\]E]K%J*K5S?N_N\\_)/T]0
MZVUXGML2_7.5'JZ>Q[Y8MM>U\$?X40A>$N>WJ_BDM&\@O0#FVZ]07,]A+#_]
MG+B^XQH[6R2^3&YWIFG]!$X3S\C['WM!_#77T=FLN_D^X@!\,O3.W*!W9H?0
M;]`#)44G^1HTCDY;26=NU2])=QC,WO\V@BU"52![4>5Y9WX`8A$KC.(;++62
M#ZM,';7?OW/="J[JGK)!7V+![I_.Z;_HG^L_T?_''"K]R_\#4$L#!!0````(
M`)>!<T/1:YJO)2,``.<]`@`5`!P`;V-L<RTR,#$S,#DS,%]P<F4N>&UL550)
M``-.U(M23M2+4G5X"P`!!"4.```$.0$``.U=ZW/;.)+_?E7W/_"R=;5S'^S$
M=C(SR<[<EN)'RK6.Y;*=F=M/4S0)29BA"`T?BC5__0%\2!1)``V*$$#%^V'C
ML=%@=_^Z\6B@&S_]\WD>.$L4Q9B$/[\Z.7[SRD&A1WP<3G]^]>7A:/1P?GW]
MRHD3-_3=@(3HYU<A>?7/__W/_W#H_W[ZKZ,CYPJCP/_@7!#OZ#J<D'\XM^X<
M?7`^H1!%;D*B?SB_N$'*?D.N<(`BYYS,%P%*$/U#_N$/SMGQ]T_.T1&@VU]0
MZ)/HR_WUNMM9DBP^O'[]]>O7XY`LW:\D^B,^]@BLNP>21AY:]T6\-$CCWT[>
M_/G?IQ=OWI^].3D[?IY0$2[<A/[YE/XW_</)"?N_'Q]/?OSP[N3#V5O@IQ(W
M2>/UI]X\ORG^EY/_%.#PCP_L_Y[<&#D4ES#^\!SCGU]5!/QZ=DRBZ>O3-V].
M7O_?YYL';X;F[A$.&3X>>E52L5[:Z$[>OW__.OMKV;31\ODI"LIOG+TNV5GW
M3/^*!>TKG,3X0YRQ=T,\-\G,2_H9A]N"_==1V>R(_>KHY/3H[.3X.?9?E<K/
M-!B1`-VCB</^I6:R_FH.+36,^6OVI]<4GG2.PF04^I=A@I,5PRJ:9ZQ2]K.^
M9A&:_/R*>$%\Q*!G!L$^^#<(;;):4&>),;/U5\[K3CQ^=`.FS8<90DDL8ZJU
M<>]<W+D1%7R&$NRY@1)+K91]\,<<"S$XXO&$C2T1FJ$PQDMT0V*IUD#$O7/I
MQK.K@'Q5XZY.U`=7XVCJAOBOS'*I-3^D\[D;K<:3!SP-\80B18W<\TA*K3R<
MWI$`>QA)N=ZITSZDNL%_IMBG?DF_?H5#:H/8#<Y)2'\%\&X8=1]\LDZIM2&?
M_A!3/?@4;5_)Z>$]],/O?(Z3S!ZI;N@G&8!TO0"P"0!I/UY&O#]F)/#IRN*2
MPIBLY"[&H^B-GZ./;H;0?$&A`DTP$K(^.+NFR[PY>G2?Y=BU-.U%-VA:3**?
M$)E&[F*&/85)&$C>"Z>;@>L\C1.JC(A:L$>_'F7?DH_CT`YZX39]BM&?*>W\
M<LG\3<H<I[VQ^47K/*-CONG$R*/[%&B2<;OK_<Q4,'%4^]$X!L,8!A'O830$
M<JO221]<WY&$?H^NCX+5!0[2A"Z<'Y"71C@IK/`")2X.I(RK]F/,:V_=B`W9
M2Z3%<1N]ZU\-@P52[*:?-0J;D$A$-0.T(SY%'_S<4BNE^]@5,TBPWH1$FE?E
M8"95^M"S3B_@`G,,[T'C'`*T2AAU+V/:(AMOXCB=9S]!_49&UQ]O\3A-LG`R
M-3`EY@2$&A%6LT<`_1[6"E"K5.IE#WS#=:W8SU[V@'#NE7L2\;^(4$Q),\H;
M^HLM$O1,EU4^\LN.F"0[1<3IKUD/Q<G%B7/DE%35'ZF3.GD73K6/@N^2\X!X
M6\P&[*"`1#+UL=_\)N)U]!1337I)V5'@/J$@Z_XW1@LC?=V%V4*QV=%%C+SC
M*5F^]A%^S?AG/V2"'+TY*0XN_D9_]5O.PSV:8O;I,&&'12V<TZ;M+>N,5NUA
M%'D.B>@,21$K^W0C;\L*FF<M18O7BRQ@?^3-<+`VH$E$YJJJ+-1&)()4M4M9
MV#L$YYD#!M?47Y[_A58B#!I-@2"<V(<"1VH3,)1R/-)NV[6_W0*H]%.;E-XF
MHTE=WZ$($RJ!SPZXQ4JO-05J_\Q&[;=*;0*&$>7&9QQ=!>ZT7?VU)D"UO[5)
M[:U2FE#W>1HQ$:]P[+G!OY$;"0V?WQH(PCN;0)#);F[B_14%P;]"\C5\0&Y,
M0N1?TVTHBD03,)<$B,SW-B$#TH(Y>'XA04HU&*VRVUNQ")9&4R`</]@'!T=J
M@\O3W'_OT8)$+#B77R<3KE(Y%$!0?K0/%+$.S&&3V<@Y'4RG)!)N'&H-@4B\
MMP^)5HD-.@>9STF8A>`>9E3R:JQ0Z")".O"NSCY\(`HQN>_(ER'Y.OR*_HXS
MD`F:0\&Q:L\M%=\\)FQI"$:DTAB*AY7;<8[H+6C\]+HUZJHI)-M^DV\K!GOJ
M'#GK:Z+TY_4-"Z=ZQ<(I>G**KG:UK8D;/V4XI?'1U'47N8&A((G+W]0MK?CU
M;VM>QY/U*?(=B;$D<EN0PZAW=IWNXHWBF.I7+DB]G:DPKI)>M_V'(TG_`]FN
M:!3+1B@HC>;&HKM]@<-1@!T8L7OM[,X!_8>=XR_=(+N%D)R[4;2BRY4L7X:/
M&9#<6+`8!`3I(I)-(!97F>)[Y"'*,+OJ@I)"6H&_":F,19@[0`:1WPZDRAM2
M*\H@'YGM5L:"SAV0:)//#LW?16CA8O_RF5T.0=3!Q\D,15NR\0$!$1N+2W?`
M24$;=L`'!*H;)/T'I+L,8A+E4]XGB/[1O\FEYG*8L9>0Q`VREH:]CBQ0E*SN
M`C??'M(9=<$64\+Q3TQE+*S=R<_D\MOA8!>%=8TG]%^ZS#DG<=(6A2C:<YH;
MBVYWP$8HL1V@5$;E6Q)ZLM&/T]Q8H+L#*$*)[0`EYTXV!YD,8'>>?0YEVKG!
M[A,.Z!8=L0OUS<OJ\F`$O`=SH?#=`Q2J>K+#`2M<@X-+(AISP?->$;0ZSE1N
MT8M4''!PHMX>BI6VN`1`X>W!B7;)K41GO1_TO"BE(_]&9#!@HBZ@&&J+:.R*
MH5P_N\+*N7C/@I(/*$F";+0HO[OB>Q.CDA%!X=`6N(##`1'')K\JMQCW:(G"
M5#[J\=I#(=(6R%#V&+'D=J!S0\+I(XKF%^A)'BUO;0S%15LL0AD7@<R6@-*0
M2&51!X=$6PA"'1*NQ$/?AM4&`4@(0T`"159;'&/705`8T%`#>(FB)Q(C\Q!7
MQQ,(OKSVX!-B:\`52[[?!:!0\X)%4Q<$M,4Q>ED&VAHT!.VANNR23K5%)7:9
MR`YE!@,4SFNY%",B@L)J3P`#7#S0M(]UB?/V$-D]U1:GV"$N.)18[ETY*F0,
M2VZ;M3:&HJ0M?`%0=>/R!4]F.T"IY"_([O\U6D+AT!:J4(:#)ZT=6(S\O,07
M]7P7^]?AN;O`"2O]M69:$),%T$+QTA;"4,8+KA%+$/2\=)X&+!$@BQIO%;K.
MJ[NR<M>WB`[SC^ZS,,2NUA$46VVQ$'5LN^G*#J#O6<VF$/F7;A32)5)<$>8"
M3;"'!>L0""T43FT!$&4XX1JQ`T%^.6K(RE'ATK0U",D*<`]WZR:[V]#][@<<
M9XUW/A1QAFJC5]0-INNUOW>QE;MWUB5WS_ENJ^?_><GE@U>-0T_)!8ZSD_0B
M\G#'*@F0<#QAP=2D"*9R0IAP\@%F\ZD)J#7$7&6C_&Q7G"3T0TSM4Q31IM7-
M=MR!CF/C*-.`GVU[[U"4%2N`AE_X]*83878(FZFIR$98\X(3HS29D0C_M9DZ
M97`VZ4PGS_0&(T\E]L*759]2A*ZD,9T>TS-LVZJP%S)QS1N!@%V*WF@,V/0*
MGN:Z-[U$N-7G01"Q\>R/':!4T(YU<,+G/R'1D+,Z`-JP%#;9O,<E&'(*AT0+
MED(%FN_ZJ?"F[2I$GZ#!IKK]1L1@SZMN!<7>PH)BFYX=,G&V^G98Y\YW7T(W
M]3%M:S)$EI\8K9F51\6X!$:/E;+;HX"R5LV6AD-A$OTW3HO:!1W^+=D'-T!Q
M(=XG0OQ86/Z@O;7I8!D7'0)@WJ:I[`9[;$0KF12=`]4:FBYC!82`(Z`=VJ_:
MQP.*EI17N#=L$9BN4-7!(5H$M@.54A;YW&*^'A50[W61AGZ>S<J3C">%5/*U
M`*>YZ=B\VHI`*//PEP6Y>-DL^4`"X;ZWUM!T;%X,3!N(#2D/!;YR3)>AMVEG
M.D*O#EY=QD/!+C-*=A^FD`_LA0T:TX'[C@[)D7WH<^6GB,3Q740FHBN76XU,
MU\A2P:]%NJ$#-EX@]NAF."TJ4@*"'0(2XV<O:JL<J?"V[!%B1'E@Q9$OJ)T&
M)"MD6/`LVC@(R8P?M,BU7]]7`-0P_`GR`06TS^DG%%+U!%38D3_'8?9F*'L<
M5PH[E-[XR8TJ_FJ*L<-U&S(J#*L6G-.H0L05]V"FR4TJ#`#):F/CM;<Z8]D4
M>>AH7H<)HNJ73Z&-AL9+=JFBR!%5'<'W.8(AFK)S2!LP7%*QV`H@M\]24!&8
M/`KC5;[4414+K^F&^B<7AVP<N$C1(SF?N>&4?OG*Q5%V0RD[ZA;DQK(NE'HP
M7N0+#(NR:#:M4;Z$$7(#=DFI%&$<7J`(+[-EE6">DQ(:+PFFZE=`5=B!6Y:G
M>TM"4A-2L##A4A@O\:6\.I$(/_P)[A8ED,5FK9GQ<EZJ0+:*.?0%Y@5>8A^%
M?KQ]-YN/(I?`>'$P53PEHA^87XZ6+@Y896(ZY6_F]R+!]Z,;8P_HN9".C!<F
MV\FWX:H:NO>711?**_N9<"QJB8,T$=VREA(:KV&F:@%`5=BQH/H5X>F,<C5:
M4B&GZ#:=/Z%H/&E<,\Z%D)Z3=.S.>/$SM3.4G91F/^X-"0!NW+4_XP75=L,2
M;A=RI=IA&*)*2(_N,^"H%-J!\>)MB@>G:HJQ`\TN&ZK?3BTHU*:J;<$BC,EC
M$R8\T:Y(1,>/,*_&X:T>(S>,J8A,XZ&?_5>0Z]__/<T#H65ELJ(<Q"A)(OR4
M)OF",R\=H^ZGFM@P7AYN-XLR`IH=]MHBM;Q\H)#(>&VYW6P!H)`!5[;:RN-S
MX]E50+YR\O?>=<K?HWTZ6:>6Y.U5$C/7\BJ5M&JA,COE,X;N(L*"4O['U1<*
MR'6XWL6.Z.BTS&NS287LTI<]!;&X:#97"QTU9L<`K35JKBW(NH/6U:+I1NLI
ME[-^_$CND4="#P=HB^%'TINWZOF:Z3S$#@ZM4^UV&-8%HC!X.`.!_AR@8L4Y
MFK-5Y5_9[P4G+R!JTRF/6E&LOYT$5Z<=!E!&EI'/5J-TT26!G-?>='[E'D$6
MJ\P.6(W?2]$69]TCT.HW6O9^+#NHRV;:`K#[L(G=KZD-],R^O"WD4?V!;TEM
M-3:=.KK'(4.@+#LF!GZ<L33NS:C'AUFM%]-IIGO$OXMZAS]$4#U2H6)T@?)_
M*YHKWKD!%;$"]V$Z[[7#5E)=17:,%TV^RV?EJ2,ANA1Z"H0Y(!!J&S)?5<&1
MH<O7TB&Z.\NI".G7A"],2LB,Y]1JL((6O1PB_'<16KC8!Z2$R2B-)]9J,()V
M[0P_V9H_Z-VYJZ[SPIK4>/ZNQDFAII]OP!18#-3SHI0*!GE3NFM_QA.%]1N-
M4).VKADO"JN65J\$D!I/(]:`,4<_PQ\8X(>S?5P>L"`;>6?C4-?8T%,^.!+G
M>=K]7#01]F4\5;J_JR8`G=DQ1=#)K(C'C;P_4QPA*@FU\&1U%[AA0N<X]L!C
M5J.(C[5*'\:SJ7<`C'26^G!WG!=HP9X\4%I";FB,9VSW9@URS=CA[W"!^QC;
M+4CE[@UA=<T=Z'J@>.RDE_6`L"_C:>/]K0<`.K-C?*",>PCY\175!7M)B#U>
M++NF4$Z(<E+CR=\[P%-_KPZH)[MAI8-7E."G`$%K/"AW9#S;6SOD$AW:;`!Y
M4NR7D$)`%S!4EWC)XEKM%^O8NC:FS8*4Y;QF,HX7[`^"I8+FSQI/,]=L7#WC
MHZFB6ADT&T_HORR^0N(D/N'<9^,U-IXWOCN4(O$.)8YXCQ;%OC=_J_R1_YQ[
M0<*G,)XOWIOWRK0R_)T_7%5][`$LR%?OS3;4-3?T?>,E'?L\NF>Z?/:RJ[GW
MU(3'(5,"G;O8/RPRMG0#YB]\:U'KQ7@V>F_VTD5[=JPQVWF\H_,@\>OQ,3[N
M:KT8SSSO#?<NVAOZ2-$N\XAJ-(I65'G9=7Y54VF0@_/>!FHC''UU-HY%9G,/
MB1LEWX:)*!3(.=MW^K0F(VFMH=/%3"Y#"U:G#^EB$6216C<H([77X81$<[?M
M->Z6;$IH!U`SV<>KX]"8M*)V[%A,E-7@[UPLR'_9;@4%1ULX2%73[<\<5$6V
M`XQ2EB*A:G/F%?HMX],%CKV`Q&D$>6ATYYZAH&L+'.T&>E^JU13;^Y5.&BZ=
M/EA,$OFC>)-V6[GU>!V>DS!$67K5KSB9W:,ICIDM^Q<XRC8S>3",$Q+L^1M0
M@]#WO&E?D!)M.N+:S'Y+4XVCJ1L6Y1A87#N=S]UH-9X\X&F()]AC%VGR6[>4
MZSL28*\:)MDJ7?6]<^1L5$G_X^38J7;ON*'O%!]@5:LJGW`VWW#6'S&8YUOA
M>E-V*]?0747UXTEA36ZP*<@%*.?93_<&9Z./:8Q#%%,?B+T(+PK>61'6>#RI
MBO!(C?%C(#S/[-*7X8)8O=I';3;JKEKC8\D-IIL='R>KS3!+YV,2TE]5JX)L
M#1H_U`>-TV-GW4\V8JQ[<C9=]3B]BID6.#.CAA(;=-4UBQLM`YQ23&7*_514
MWNI<$&48=Z-UR<=JQ<>/;L`.I!]F""6<^??'NBN='?/*1Q:].45W!B>2BECW
M*&#,;40`3*50>I.1$6^&_#3(+ZKD8+3,"H]9L5JY8W;KS?!\J89R/7:R@_XL
M\.7Y'.?U-EA`D&1+7!3R%]'OZT[\ECGQNI-L1MSNQF@58YYP2@$(M6[,EFV6
M<PIP8M5^#+MO)YR;!9X[J,ZX_U8?%V*A_&35ZK8G;^IN^^[8J=+^W2FH3=9D
MKHL"J<C,IS$YI3;8NB4)4G)!A2Z,5U^6X5:?,%6U8X>7'?'K2&ZYVDG=U;XO
M7"WOP-GJP;9JHB,60YQF2Y:/JTV3(I-M]-6-_)&?;V7<H'BB7FE!K/FS1A]#
M+/G);OFO92L6E-DUSX9H,6`HV+ECTP/$/BRM\3QC+V`8'WGRLG>/[C-G/7YR
M6A]M?CAV<B(GIS*:"IKSKK+8%A*9S6NM\P5P73&58;\$X--,894JP;C+/*!I
M-H*$_B=$II&[F&&O<MC:[D9G=3?ZD4[:>4?9EG;3E5/MR^#TG3-WCQ:L7'DX
M!<R\7`J3*^4:4VIK9`BQZ<E/@E-];0S7AWE'VYR/GJ=Q0D>&B.Z;60Y2Y&XG
M%6VYVMNZJ[T_WCIJ+?MR:IT9S&C!\1\L*O"%\A,E+@YA"<T2,J-QHHIF&9N*
MT2$(M6&_`V'6B`'!U6+>^]*G&/V9TLXNEUL7_;><[5WCSL,;ZFUK4J>@-7DO
M<UL,R$5,'H71ZZ7;3$%F+SZ)Z3E+@DGC\JA$=N.^TND2D?`RT4G/EXF<[\J?
M3#Z+=\#WBCBW*ZHLB7R6->:T/<2[/@)QN2[=!QRLJ&(4HRQ<^K`(<"+#1$1@
M^K4[;<C(M:0)GI9;7MFPM9+!!"$T_>B<-KC@6K/D*G]5>#F^F\6S@,KTPW(Z
M;T1"]&4'LE]B-)Y<Q@F>4]%$+XO5VIE^,4XG>NTZL0.O>^0%;AQGZ\:MB$I;
M#8U&4]//O^E$C:L9.X"[=*.0+N]9;G9VR@0>1:6$IM]OTPDJ4&MV0%QY77`=
MK1U/-K\MTG=6?*SA/9A^E4TGZ*IZM`/]]4N"GY'+`@!,TMQ<P:ZNT(7I5]ET
MXJ^L23L,H![T4@0?2&[Z]32=P"MIT`[0;]'72IPP(B']T<N%5<1?O2?C+Z_I
MM(6NBAUF9#G+!>#$E1OY9KO&E?./O425+<Y6W620C"AZ/@Y2MO!Y0%X:94G;
ME\^L8B?R6>5/=IDM+06J+YB5\G/Z^]8A1L`UJLN2H4N>QB<:ISHG\]DP(GU3
M67WEPY:K_*7C1#V33];#863OP?1DW&TYN0@B7VWD[`DR$FQPSY?4!&V#P>5\
M$9`5HC-8M,3,9UI%#C)>LGF,O<%.5YA_48FS8F[9S7FET:/W3YJ^'6,@G4$[
M@';LKRNKK3A.YWEI>E;D4'W.DG1@^FZ`62,":=<VDQ@GLV(MW=1;$2-6-Y,.
MG9J^IV#6=#JC8'[A),X+$2R@3AO9TZ#L$"N64@>2)K*VOSI[%7U3N\__J#0"
M*'9H?.)0S"?937'&G?:.T,8)=H-@=;$=?"G"J!<H<7'`\=M&*O;)L5/IT2F[
M=-9].EFGSG=%MR]A4YO#IB4[&68"7Z^UD[EPP_2'%[6L25P]&[(!,#HFH&OZ
MH^`^4UM;.X!K-SL>`A7VJP^9&D0A6PL^TJ^,GK$`@%JS`>F^QGEE1C9I^[)5
M>\Q=MJ_%H0-#X(:W[AQ=D+F+0X'W:/F:'3;0:K]U]],B_R:P9+JV4/YJWV<T
M?T*1:`QM-#5]#UNG&[25&6I3E!V!C:)<MPS#6C/3=WKWB%^K@NS`;L>SX-&<
M7=,03+W]=&\Z3LY=[=7GZSZU:7S'VNE&T"VS=29_^SZV4>1GUTM!Z^^];'`M
MWN"R8YRO[&C[BD07)'U*)FE0P!G?(P_AI7CC"Z4_X/L[:BJT8W997T1@UZ(S
MR>^I$J*E*&-+1&,Z9*D37[FNC$\(XH+PDI&_49<*\OS`SN/[X)XBX#U-1*(_
MV`O;[@(G;L!AK-YH>(\'M$EAB?&7_LG**(LB]8VB4&>LC.&:UHJ`_'JL4:MG
M*""R(18[R.`Y`(J7D+AE85F+0^)WZ1/=&7U)UH^D%=8ECI"+J0:$C%@0.^+G
M/!Y91$D6#8?0V@$7Q!"!X%6%LR)PS6/TWOWZF1II1%<ZL2P:JM*'Z5`WW&*!
MB/(5I:G<#UV!XGB&_$^$^'QH6-/6EJ9CU>H`<$6Q,CSP*2(Q)"10M#-^;Q$:
M#VX7T#+E[S<VH_^M<#`HD$`+\)7X]_D>,413EK-C_HWXM8RW"+*CRUJ9+HVD
M#F!%.'7(SG+($I*X00VP_086V),Q\9V[8LM:20RM40/W[-C)R)V"WI+SD`OT
ME*B$%GCM;=C.#C*J(`;@):!@V;;5XH`"LZ3KD-I/FMU_$(81VMH."(4V]G<-
M&7#V(]N?XN[Z6=OVIG:HE6\<U7U(NP0[[N0YBOWEYN;=:!JA_,A-N--K;VKL
MB)&OJ:9&15)JVD&S3Q;WF.1JK3<TMG]656J[A/I4^CW<5EN:FBNDI*A7KI@:
M-0LUUD9#J%;[WPBI:E6/M?:U`TT051Q+4F0B73ZS*Y:"=32OO>DK'PJ[4I'`
M=H!RCQ;%^X#C277;R8>%3S&8()Q,:#N@R;*1;TGHN?%,ZBRMC0<3@!.(:@<6
M-R2</J)HSOR8#\)VJ\%$S]J$LT/MVU/?E]"=L_S>O_(:2.)[Y@!2TV<X8(#`
M:C!^)4KPTKPDD-EX<^@MJ[FV[BV[#KC5GR6!38'$*O%.Q6YL",(-,@S:":Z7
MZ*AE<3F+HZ.?W=])5#[S&8NCHVUM!X1"&_MV7*AB^7?CR19_LGM4`A([(.$;
M5KW>-%\2/1'6ZS`D2]=;\7-V6;-&*]/;1:F15(,K'!DU1:L^DPC=S=QH[@I5
MVFQF^C$%)9WRI+1C[Y'M23?+!<G6N]IP,`$JCHAVZ/\&NT_%[;:,S\>9&[*=
M:E+L5%FX("]F*]B0*_1A>CB";]>5%6,'H,W41,DE/R[!8.):$I'MP.7!#5#V
M[&:8HNQBJ/"&6'OKP<2Z1,)VOC&V1-$3B9'1.V-919`9":B>X\L_4YRLBJPR
M2=RE\2;'NZ)^=M'7WYV\MW66FJ,G_S+[YE.]^$;Q35:[3Y*"J4!OPQY]6,$3
M106_1$VLW*];'#5A:0OC2:74CCAPPFD^("PX$M@1/JF6/!J%/EU0NIO?/-*?
M8NKFK,"V+*5)N2,[$!1:8WV)IRJBGAC,R%\2CXBOMM3:F-ZF=K2R:@2A56I-
M,9E?<>C')!)JN-;&]`%C#QINE=J2?0M;D%S'<8K\BS1B!:>R-R"RNEEQ_OLK
M$A5O20AG=;5^AE)ZK)M^K,8V>TMU=VAYW9@>$7>%5JP>2Y!M+;(H@)#3?C#A
M.K'`PX\Y-)_K$A;#:;RM)WRORX+*."\/=KW$0/:'RTOHQ,KMNL6AD^N0CL=H
MPV#Q.)HX@"(D&A`N0CGL"*9P6)3=1Y&0V8$1P/9@@%E5S(>](CB>9"=%L@!7
M2U/3FWZ0O=50X4ILQYZ!5>.@/,RR1)HE"LB"258D"L@@`A$#07MO$V@*6K$#
MQ@<4T#ZGQ?*'LCWRYZP@49(?)Q:<2WU.L1OHIE[;KKX+MIU490?*Q?NLR&]?
M*4LSF:#T0PG#J>G#>`9'_JA(Y1%5X6Z^[?7MO`>GTL7+/OX@]_&,[<:%@*9D
M3W7)KEP<9:'*BHDP-_"HD[`\M!.)-C5]T_2`8B*PH!U".^:DSKIMD_,>QW]<
M10B5Z=WW='#7X/_P3QL_MC!EN?M`]``-N'34"[S$/ET9[-&`VS]M_"QGZ`8L
M0M0.`Q9Q_0L)W*R0[4ILB2I]&+\B;L"DU'5LAVUTUE5^,WF3&;_)A\CW(/&G
MK!C.=9@?C_^*\'1&=3%:4KU.4?;'"ZJ-M=XT#(+]LVC\JOV0!DM=%F+)-CT>
MITF<N*&/PZEHGW[VAKM/CYU*'R\;=;LVZJ)<B0(^2%I$H^FWM-7E:^$@YL#F
M0'";2N+G_7_*:(E,(;@]S2,R+7>^QK7([V0F;I28KQ&_JWJV)U-)=J>6CQG;
M2>[9$`6:MF0\$UT^KBKJ\AE%'HXWRQ[%"]J<OHSM_U0-H;.>+,%Y1T.^(M$$
MX22;P$.?[E9QE/6PMFU]`PC@T\;V6GL>3L`H#/\=E"$OM'X[-5PXV^12BPG?
MRV+K,CP`,RRF@^R%&,UFV/(IH!%^/W0CY&KYFS;!7!7C2;Y(&2U='#`-T4DD
M6Y9JL$3I%X$&^<-@#1*H\V_:+J&+F5J4MUQ9WT78`U1JM80]TY7>!G4,H,,R
M#F/_55EFB83?RR)7S(#I*]IV&9^VQ3;$"KZ1:&>L%(33Y#Y],F'N=:!#\*'^
MS:'GY.\A^E"I%]-NI,B'\:22@_:D3D;Q#3B33DPMW?#`7<V^VZ$VN-H^3.9E
M)[3/1;C"(<")?==;!^`3"CB\!-U:(N5FO`?,@+G'/+\!WU$T@Q?/">--/'0_
MUU5AGX5Z2?]'?`..+X.@M&BU]"07]4EYDKQ'K*X!_3U[7(T)GKH!2PD]E=CR
MOIF!6GC_9X9[M;:>$GYWA_TP[)X_P?$4H".;?1=FH'9OW\FA0;O?`79-Y:A'
MTVF4W:F[II_%88R]//5/G`XBI0)?H+;..KKFA@`5:='PU<_>=EO<O80UZI^$
M&IN>O!$H\-JB"^T(',R>J)_A=EM)^YE,&]^$&JJ>O)(=#%4K!KU;JA75J\7O
M99V=*-6OMN*)\KU,J<-(J'VI8/U2P?JE@K5E%:SOF>&)ZU57F@Q(YQ6N[:A%
MG3$D+9A;;62'MAL6TJ;HGA[8ZD?3GW&(Y^E<INM:,].5W%KLHZ;I5KGLV!M_
M=I]!*M]N9KKV&$#E;7)IBBI=Q@F>LT3-S2$CJQ?5-C*S]OSFIBN,2*OSBMFW
MR:XOYXN`K!`JWG-J7[[=DG")8A:69"NU^)$D;E#].ZOP?DN2?Z/D'GED&N*_
M1!GW&C]I>H@#UVW6KO8#MZ[\+@+UK.)7K)T@?+-O/DR/^^;M4`B0\0)G#VB:
M;3Q#_Q,BT\A=S+!W'4Y(-,\Z%U8[.ZW':'X\=HK^'#?TG4V/3J5+.XJ?Y6S>
MHP6)$AQ.`6$6+H4-&^MA1D@D(+P$-RS;:%L<W%BSMAETW$`<[!"0#!&3IA1V
M!$,*+Z^R)WN42T!B&3(\:VN\,\,52,\[Y5\>A`]H;_YL?)\@LX[J1K(NE:;=
M^6?TC#TB5.!V$^-5L%64V":=KC!'&I$%RFH!"[79TL[T\VY**N7*.?QDN4RH
M[,6Z>[1$88IND6"1W-[:^!@#W0.*A+5]IR8Y3S_KN%>SXV3]0'9K%<LJ7XT7
MNA.7P'385W'C)I9[^(/D#96(O1-8R,@'M-'0^-"HAB1'T)X1W/.XBJ<AGM`)
M/DS.TS@A<Q2=DY#*F13Y7I*1]6U]9'U/1]9-GT[9J;/=JR5#*WN3B>6W?:&\
M10E=WR08<NE(0F9#(&"0(3$0'"]Q,5MC,/;%Q3Z[OY.H'()B<4"LK>V`4&AC
MWXX0V*T[1^/)%G^R$)B`Q`Y(^(95@T4@B9[85_F5<<B_@\4:MK0SO1R3&DHU
MZL"54U,TYP%Y)/3+KPI5V][4]%FPDG9%TIK<L7#`>9SA"(9-:TO351^5H!'(
M.OR]9+&U@JS!&RU-.Q@XT,83<OCP;6WRV&K^#D7L%^Y4E%0EIC)]O,!%BR@(
MH75J&GD>2<,DOD<>PDNV1I0EZ`H(3+_\*%.WC'_SKL1;F/$-I*UJ1;;&$9(8
M?:0#``&!"K+G,%KQ%_9_+"V1_N;_`5!+`P04````"`"7@7-#4M!O<1@,````
M>@``$0`<`&]C;',M,C`Q,S`Y,S`N>'-D550)``-.U(M23M2+4G5X"P`!!"4.
M```$.0$``.U=ZU/CNA7_W,[T?U`ST^EV.GD#"URX=X#`-M,`N81=[NR7.XJM
M)"J.E)5D"/WK>^17_(IP`GOCJ7<_++;.T='O/'3TL.6<_+*<.^B)"$DY.ZVU
M&ZT:(LSB-F73T]KG4?UL=-'OU]`O/__ESPC^G?RU7D=7E#CV,>IQJ]YG$_X3
MNL%S<HP^$48$5ES\A+Y@Q]4E_(HZ1*`+/E\X1!$@^"T=HV[C8(SJ]0)BOQ!F
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M\-LJJA!GWF_ZQ`0KS64]\%EIR.K*^A3C1<0[P7+L\0:$I@Z#>JM=[[9C501W
MB,RMXU%R*C'.F#O/5]=6HJE>%J0)3'7@(H):4;W7*R4K``9=G(_.H^2@XY:S
MJN#W"^A5<X]3]PS(#`Z9$Z:NN)CWR`2[#GCBFXL=.J'$KB&%Q90H';QR@2UB
ME!7&/V:,0S>!G!"4Z++%@D(_@((_G>B`.=;VO`?42%]`)LB3K$E-Z$*N1GC&
M[$NFJ'K1_4G,/?DU1.W3FI%#MPCM>VW:9$(9]8`%O;:-ZBBL'K_$S$:^+!03
M=M),BXD)=R6Q;]G/WO5"$`EBO$H#*`@J!BQK*EG8`=4WJ[."DELE*`AMO87U
MS[&C^^IH1HB2OKF316;[=L"H.F62P,`7G-F$`3Y]);E#;:#9*!")?)E5-_,0
M"]!J1A0%K#DV3]+-#NANXP#T(='$/RKHD,AF\G:BISJ"S,!L](D,N`SZ@9G%
M[):]8FY9-8'X!"4:0;H5].$SPZY-@;?R3L)R=N7PYSSG1"2S4_:W<@H(1Y[T
MBCOC5DPQH__U4,%(/'+G<RQ>;B<C.F4PF;`P#-"6Q5T85=ET"-:T*`F<M5U5
MLS,/]'`.LVV'2U<0N&DW4+P=;X@/6M)^C+6%5HVAL+4*.G1`O[D4POD%7')%
M&8P/%#NZ3]#5U.L5'K.+/J9=U&F@2*#GGT@DBF16T!%1'HJGH9R)60$^LT,.
MTP[I-G[,V-8Z93ZGRAL&(/;!-CI=$+9*:B8&LQN.TF[8TVZ(I'D](R&O@N8?
M*6X]SKAC$R$O(66HEW#<SY0;C=UNI8V]WT!Q(7]'OIBJVKA^CKV,,E]`%H@M
MNM<1S=9NIZU]$%C;EX3BHBIH\3Z#2W*/EV$2B1>8+=M)6_9C`_FUD5>]@M8<
MD6FP+?2)\*G`BQFU,IM'KS&9K=Y-6_T0XMF7Z*7IE<R*[R/%IM<7KE00E@*&
M,`N4$Q[2<-GV*IO9'WMI?QPU$C/[4"A*2JVB0]RQ)-]<4.;R2<\J`ONG2\WF
MWL\LLEI@[T@&\H54T+I;K6C?85%<;''<?N?%,?H07OW8^"CHJ'L\=M[DZ4"`
MV<^9%?9;_>RW6D4OO[ZXCKNT,+?9?ULOR*OLJ34KD[A[S"QFGV16YX8E3*7=
M8)Y8)]Q1B-7HEDYF'5]H)EYE!PVY`D4H=IR7'G5<19_(B%BNH"H877I$8>H$
M/BK,;7939@,`1J28:!3*1I%PY$E''P+Y5?345A.$&RSTZN:)O&&2L9)A]FIF
M\^&M\XRHX2JZV_Q0)>77HLQF!V;V,8H\BJFXF_I,KVZY@(!-9,J<<K/Q,YL6
M7;UU%PFI=.J[@;%!#O&+'@-2D9]/,ILZLV$!IO;DH$!0Q6/:\-`J9?U"G&9G
M9'8A7GO.57'G9)]M!8DAY9H"?&;'9+8-UCP3BS(3^N&7[&HR,2B\PF/V1V8;
MP+CDK/!H<;OPIK=2NG/O*CDPKZ6:K9^WX/=%H9BL'W9G\M95^M5^?=`DQ_!Y
M9*/ENYDU?61YB6+"*FWZ-8DE;T@P<9D=L<EC^ZH/TN:]K.2@4(S7[)O,VKO@
MQE>5^XS9[NF^4Y3;[*?M7A6H>F]Z[7V`M*^*\YN]M>6+!/^?[M+_Z1-^=V2"
MO).!Q_J\V6E-4GT&M!:4S029G-;TB;-Z>"3L=U"ML9P[(8L6;3@9Z+D\;8V@
MX5`$%E9&2N;D(@CA"R(4K!F;(?A0@*)*5Q_&FD&Z'<C)S?=0V<'C356&*L3Y
MCKH.M/QW51*B;U,E4P'[G52]6+7RK@I#U]E4X61O^T[Z]J)&XNH&ARZ;JU.7
MP7WZ9.8)*,Z%0BQSP--T;M<_<3S@EB?*4$7?U<-Z=5U4;W?JW79C*>T5TDU`
MK,RP&8BPWA8@/&F26(TI?P*GTL0QVS4H<NOHB_JJ<M'VC2>73>WG5FP21\FP
MY(UHLJ>.MX?CR=H"3X$#UT4B)5[SQJ^H0^5(ATK[X(U@M@/R&HK@Y+8W[]')
MZO<'/?5@2CY0->.NNJ)+8H^(4C[?4/`GJC_4(*_)?$Q$S<-_6MNT%AY+F.U8
MZK2FA`O]D%''T3OGX;UW_/\8TA;E]KV776U7!"_<^MG6/S)_;/,YIJROR%RS
M@75<D$R5JUD_">XN3FN^+`HL1?6^(4J?R-M,[0*5RJ?UO_A_\%B<.71.DYKE
M$,J'WML]R.Q'7"[U)4GJ4XBU?!I^'B75B-WO'-LU65*+)_&ERG:.\=+5DQ]8
M==^J&1%)K&MH.\=\S6UO@:@K]IDE/#)VKC`5WC=?4A8OR%V^V(;%4QQ\4JTU
MQ/)IX4?1VO`J66R%.PZW+!5&>82=H_T"=ZX@`^+MT`\(EO`GB=O(4KYH\8:A
MH2NL&0Q%9U-!/'K.4+66IX0ZS;`@F:$UI9.1IWPZA=WA_IGG]Y,XH3QH9Q`L
M:_`F2#M'_%F2B>L,Z"0%-UM>WM@XR[?T6?F1G^<C/R\O\FO,W`D@<@6D=_W>
MR"*;-\T\Y=-IZ&"FM^E2$Y]4:3EQ=UJM5A9WO+2TN+NYN+NEQ[V7BWNO]+@/
M<G$?E!UWNYV'>U5:/MPP=0\S>1)Z'F'G:$?$XLS.![R&MG/,]S,JUD#.)^T<
ML7XMN=UJ/2;!IDO+%\L:X?[''-BQPG*BWLLS]E[9;=W)LW6G[+9N[[7S(CM6
M6E+<^_MYN&.EY</]93#8CS8C4H]!UM#*@/G`@#F/MG/,@\%%:L84+RE?7.BS
M%D3H,UWK+&WB**,^&@'W&UFS0V?F*9].HQEFTQFF(Y<]42NS,Y=#*Y\.UUR0
MX0R+.4X__\B4[QQKG^F?'[!>4IN@V>*=(SVSG[C%4QTV7;ASE`^4V9*G9MSI
MPIVCO"%J"I)2`WNJ<.<H'P1W[&=JD^@L;LJL:^GERPEZWA&^@I&=D60H9<![
ML!9OEK)SO`_W_51PQ`IVC@X"E,H9L3]Q;J?,F4_:.>([\D18^@%^NG#G*$V_
MA'$6Y(`0?#'>MV<.GP.D4#9]CTE>XD6M`<5CZ@#X"U?H7RR(IGFO<;VJAO_6
MJ@I)8__S2J<U2Q";JJ1R<\Z(PN+E^ZEWPYE52,,$8UF5[)&QTH<K]'<_`I<,
MN=!B;B<#SJ:*Z!^C&:]"M3C_UBK;9/P':1PB+JSR:Q7*ZN9/D-3TKU3T7'+/
M+_1BA?19]':3]Z,9T)KWSD2H]F95-LA%?W2`3PB$J7T[@;^0]RZX5+*]\NT:
MZO;Z?-_H#:<W?2E=8I_)'D!Z\@XYA7F'$MEG%S":$4M+UR_5WI$IE1"EQ.Y1
M`<6AMND7<-]+:%F-9_Y`3WI4+LI=NG$Y_KFG>[)4YTZL6Z\C;CMA4J&,=YK9
M"4F\G#):0-AET!LYRJ#".994WD[B1]J\3VF]9%0IQ%D&E1ZX>-2I$2^HTC^"
M%>2,=&F)A_L^M"R\&7;/F]['1_8LK7PK="_<QVL^6*+#)9VZ-JA0NNSE80\^
M+9&K5X96.A7.IE-!IEC!A$F+E-3RYDQI;5YE*YUBEU!MKK]Q>\7%A%#]SO`=
MW,KH;>WU],T[$?0@H.L3W>_A$O_3AO*.6`3F-H`DXPT#1^D<D3CJ?D?EX]"W
M%)Z2SNKYBI&G>+[^'O[P#EE`@NH1_V^?Y4[%5YO^1=EW/_<\:?J'"^'R?U!+
M`0(>`Q0````(`)>!<T-NBL.4;Y<``/O3!0`1`!@```````$```"D@0````!O
M8VQS+3(P,3,P.3,P+GAM;%54!0`#3M2+4G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`)>!<T/R(KI&T@X``%&T```5`!@```````$```"D@;J7``!O8VQS
M+3(P,3,P.3,P7V-A;"YX;6Q55`4``T[4BU)U>`L``00E#@``!#D!``!02P$"
M'@,4````"`"7@7-#3';6F^X.``">R0``%0`8```````!````I(';I@``;V-L
M<RTR,#$S,#DS,%]D968N>&UL550%``-.U(M2=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`EX%S0U3W%\8Z1```H<X#`!4`&````````0```*2!&+8``&]C
M;',M,C`Q,S`Y,S!?;&%B+GAM;%54!0`#3M2+4G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`)>!<T/1:YJO)2,``.<]`@`5`!@```````$```"D@:'Z``!O
M8VQS+3(P,3,P.3,P7W!R92YX;6Q55`4``T[4BU)U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`"7@7-#4M!O<1@,````>@``$0`8```````!````I($5'@$`
M;V-L<RTR,#$S,#DS,"YX<V155`4``T[4BU)U>`L``00E#@``!#D!``!02P4&
2``````8`!@`:`@``>"H!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>1. Organization and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">1. Organization and Summary of Significant Accounting Policies</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Organization</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Oculus Innovative Sciences, Inc. (the
&#147;Company&#148;) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the
laws of the State of Delaware in December 2006. The Company&#146;s principal office is located in Petaluma, California. The Company
is a global healthcare company that designs, produces, and markets prescription and non-prescription products in 27 countries.
It is pioneering innovative products for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets.
The Company&#146;s primary focus is on its proprietary technology platform called Microcyn&#174; Technology. This technology is
based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens).
Several Microcyn&#174; Technology tissue care products are designed to treat infections and enhance healing while reducing the need
for antibiotics.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective as of the open of business
on April 1, 2013, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every 7 shares of
common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the
reverse stock split. Instead, each resulting fractional share of common stock was rounded up to one whole share. The reverse stock
split reduced the number of shares of the Company&#146;s common stock outstanding from 46,080,513 to 6,583,150. The total number
of authorized shares of common stock was also proportionally decreased by a ratio of 1:7 and the par value per share of the common
stock continued to be $0.0001.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All common shares and per share amounts
contained in the condensed consolidated financial statements have been retroactively adjusted to reflect a 1 for 7 reverse stock
split, effective April 1, 2013.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Basis of Presentation</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">The accompanying
unaudited condensed consolidated financial statements as of September 30, 2013 and for the three and six months then ended have
been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial
information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission
(&#147;SEC&#148;) and on the same basis as the Company prepares its annual audited consolidated financial statements. The unaudited
condensed consolidated balance sheet as of September 30, 2013, the condensed consolidated statements of comprehensive loss for
the three and six months ended September 30, 2013 and 2012, and the condensed consolidated statements of cash flows for the six
months ended September 30, 2013 and 2012 are unaudited, but include all adjustments, consisting only of normal recurring adjustments,
which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for
the periods presented. The results for the three and six months ended September 30, 2013 are not necessarily indicative of results
to be expected for the year ending March 31, 2014 or for any future interim period. The condensed consolidated balance sheet at
March 31, 2013 has been derived from audited consolidated financial statements. However, it does not include all of the information
and notes required by accounting principles generally accepted in the United States of America for complete consolidated financial
statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements for the year ended March 31, 2013, and notes thereto included in the Company&#146;s annual report on Form 10-K, which
was filed with the SEC on June 25, 2013.</font></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries, Aquamed Technologies, Inc. (&#147;Aquamed&#148;),
Oculus Technologies of Mexico S.A. de C.V. and Oculus Innovative Sciences Netherlands, B.V. and Ruthigen, Inc. (&#147;Ruthigen&#148;).
All significant intercompany accounts and transactions have been eliminated in consolidation. Aquamed has no current operations.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Use of Estimates</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities
at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs
related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company&#146;s
deferred taxes,&#160;the valuation of equity and derivative instruments, and debt discounts and the estimated amortization periods
of upfront licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. The allowance
for uncollectible accounts receivable balances amounted to $9,000 and $22,000, which are included in accounts receivable, net in
the accompanying September 30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively. The reserve for excess
and obsolete inventory balances amounted to $76,000 and $170,000, which are included in inventories, net in the accompanying September
30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Reclassifications</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been
reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the
Company&#146;s previously reported net loss.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss per Share</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per
share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding
for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would
include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock
using the &#147;treasury stock&#148; and/or &#147;if converted&#148; methods as applicable. The computation of basic net loss
per share for the three and six months ended September 30, 2013 and 2012 (adjusted if applicable for the reverse stock split effective
April 1, 2013) excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; padding-left: 9pt; text-indent: -9pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options to purchase common stock</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,229</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">988</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase common stock</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,318</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,529</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,547</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,517</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Common Stock Purchase Warrants and Other Derivative
Financial Instruments</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies common stock purchase
warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or
net-share settlement, or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement
or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to
net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty
a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions
as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to
determine whether a change in classification between assets and liabilities is required. The Company determined that its freestanding
derivatives, which principally consist of warrants to purchase common stock, satisfied the criteria for classification as equity
instruments at September 30, 2013, other than certain warrants that contain reset provisions and certain warrants that require
net-cash settlement that the Company classified as derivative liabilities.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Assets
and Liabilities</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including cash
and cash equivalents, accounts receivable, inventory, accounts payable and accrued liabilities are carried at cost, which management
believes approximates fair value due to the short-term nature of these instruments. The fair value of capital lease obligations
and equipment loans approximates their carrying amounts as a market rate of interest is attached to their repayment. The Company
measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or
paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes
the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair
value:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&#160;1&#160;&#151; quoted
prices in active markets for identical assets or liabilities</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&#160;2&#160;&#151; quoted
prices for similar assets and liabilities in active markets or inputs that are observable</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&#160;3&#160;&#151; inputs
that are unobservable (for example, cash flow modeling inputs based on assumptions)</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Financial liabilities measured at fair value on a recurring
basis are summarized below:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 liabilities are valued using
unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities.
For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company&#146;s accounting and finance
department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination
of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company&#146;s
accounting and finance department and are approved by the Chief Financial Officer.&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Level 3 Valuation Techniques</u>:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 financial liabilities consist
of the derivative liabilities for which there is no current market for these securities such that the determination of fair value
requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy
are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option
valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates
transaction details such as the Company&#146;s stock price, contractual terms, maturity, risk free rates, as well as volatility.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A significant decrease in the volatility
or a significant decrease in the Company&#146;s stock price, in isolation, would result in a significantly lower fair value measurement.
Changes in the values of the derivative liabilities are recorded in &#147;(Loss) gain due to change in fair value of derivative
instruments&#148; in the Company&#146;s condensed consolidated statements of comprehensive loss.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2013, there were
no transfers in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Subsequent Events</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events
or transactions occurring through the date the condensed consolidated financial statements were issued (Note 10).</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b><i>Recent
Accounting Pronouncements</i></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">In June 2011,
the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. 2011-05,
<i>Comprehensive Income (Topic 220): Presentation of Comprehensive Income</i>. This guidance improves the comparability, consistency
and transparency of financial reporting and increases the prominence of items reported in other comprehensive income.&#160; In
December 2011, the FASB issued ASU No. 2011-12, <i>Deferral of the Effective Date for Amendments to the Presentation of Reclassifications
of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05</i>. ASU 2011-12 defers the requirement that companies present
reclassification adjustments for each component of Accumulated Other Comprehensive Income in both net income and Other Comprehensive
Income on the face of the financial statements. All other requirements in ASU No. 2011-05 are not affected by ASU No. 2011-12,
including the requirement to report comprehensive income either in a single continuous financial statement or in two separate
but consecutive financial statements.&#160; While the adoption of this standard required the Company to change the format of its
condensed consolidated financial statements, it did not have a material impact on the Company&#146;s consolidated financial position
and results of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The FASB
has issued ASU No. 2013-11, <i>Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss
Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</i> (a consensus of the FASB Emerging Issues Task Force).
The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented
in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss,
or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax
credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional
income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not
require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax
benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The
amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after <font style="color: black">December
15, 2013</font>. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years,
beginning after <font style="color: black">December 15, 2014</font>. Early adoption is permitted. The amendments should be applied
prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption
of this standard is not expected to have a material impact on the Company&#146;s condensed consolidated financial position and
results of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">Accounting standards
that have been issued or proposed by the FASB, SEC and/or other standards-setting bodies that do not require adoption until a
future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>3. Condensed Consolidated Balance Sheets<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">3. Condensed Consolidated Balance Sheets</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Inventories</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories consisted of the following
(in thousands):</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>March 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Raw materials</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">591</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">835</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Finished goods</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">234</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">327</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">825</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,162</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Less: inventory allowances</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(76</font></td>
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(170</font></td>
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">749</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">992</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Notes Payable</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Venture Lending &#38; Leasing&#160;V,
Inc. and Venture Lending &#38; Leasing&#160;VI, Inc.</i></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2010, the Company entered into
a loan and security agreement and a supplement to the loan and security agreement with Venture Lending &#38; Leasing V, Inc. (&#147;VLL5&#148;)
to borrow up to an aggregate of $3,000,000 (collectively, the &#147;VLL5 Agreements&#148;). On May 3, 2010, the Company borrowed
$2,000,000 on the first tranche and on November 17, 2010, the Company borrowed $1,000,000 on the second tranche.&#160;&#160;The
loan is secured by all assets of the Company excluding intellectual property under certain circumstances. Related to the first
tranche, the Company made eight monthly interest-only payments of $16,660 through December 1, 2010. Thereafter, the Company made
interest and principal payments of $75,000 per month through June 1, 2013. Related to the second tranche, the Company paid monthly
interest only payments of $8,330 through May 1, 2012. Thereafter, the Company made interest and principal payments of $37,500 per
month through November 1, 2013. The Company made a final balloon payment related to the first tranche of $132,000 prior to the
June 1, 2013 deadline, and made a final balloon payment related to the second tranche of $66,000 on or prior to November 1, 2013.
The effective interest rate on the first and second tranche is 13.3%.&#160;During the three months ended September 30, 2013 and
2012, the Company made interest payments of $7,000 and $50,000, respectively, and principal payments of $24,000 and $288,000, respectively.
During the six months ended September 30, 2013 and 2012, the Company made interest payments of $27,000 and $109,000, respectively,
and principal payments of $556,000 and $566,000, respectively.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the VLL5 Agreements,
the Company issued two warrants to Venture Lending &#38; Leasing V, LLC, a Delaware limited liability company (&#147;LLC5&#148;),
which, in the aggregate, had a total put option cash value of $750,000 (the &#147;VLL5 Warrants&#148;). The $750,000 cash value
of the VLL5 Warrants was recorded as a cash settlement liability and a corresponding amount of $750,000 was recorded as a discount
on the note payable.&#160; The discount is being accreted to non-cash interest expense over the term of the loan using the effective
interest method.&#160; During the three months ended September 30, 2013 and 2012, the Company recorded $24,000 and $63,000, respectively,
of non-cash interest expense related to the loans.&#160;During the six months ended September 30, 2013 and 2012, the Company recorded
$90,000 and $125,000, respectively, of non-cash interest expense related to the loans.&#160;The remaining balance of the loans
amounted to $138,000 at September 30, 2013, which is included in the current portion of long-term debt, net of debt discount in
the accompanying condensed consolidated balance sheet.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2011, the Company entered
into a loan and security agreement and a supplement to the loan and security agreement with Venture Lending &#38; Leasing&#160;VI,
Inc. (&#147;VLL6&#148;) to borrow up to an aggregate of up to $2,500,000 (collectively, the &#147;VLL6 Agreements&#148;).&#160;
The VLL6 Agreements provided for a first tranche of $1,500,000 and, upon meeting certain financial milestones, a second tranche
of $1,000,000.&#160;The loan is secured by the assets of the Company including intellectual property. On June 29, 2011, the Company
borrowed $1,500,000 on the first tranche. On September 30, 2011, the Company met the financial milestones to borrow the second
tranche. On November 10, 2011, the Company borrowed the second tranche.&#160;&#160;The cash interest or &#147;streaming&#148;
rate on the loan is 10%. In connection with the first tranche, for the first nine months, the Company made monthly interest-only
payments set at $12,500 through March 1, 2012. The Company now makes principal and interest payments of $56,250 per month through
September 1, 2014. Additionally, the Company will make a final balloon payment of $116,505 on September 29, 2014. In connection
with the second tranche, for the first nine months, the Company made monthly interest-only payments set at $8,333 through August
31, 2012. The Company now makes principal and interest payments of $37,500 per month through February 1, 2015. Additionally, the
Company will make a final balloon payment of $77,670 on February 1, 2015, resulting in an effective interest rate of 13%. During
the three months ended September 30, 2013 and 2012, the Company made interest payments of $53,000 and $75,000, respectively and
made principal payments of $228,000 and $148,000, respectively. During the six months ended September 30, 2013 and 2012, the Company
made interest payments of $114,000 and $151,000, respectively and made principal payments of $449,000 and $266,000, respectively.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the VLL6 Agreements,
the Company issued a warrant to Venture Lending &#38; Leasing VI, LLC (individually referred to as &#147;LLC6&#148; and collectively
referred to with LLC5 as &#147;WTI&#148;) for the purchase of 32,332 shares of its common stock at a purchase price per share
equal to $11.592. Once the Company became eligible to draw the second tranche of the loan, the Company was required to issue a
second warrant to LLC6 with coverage equal to $62,500 for the purchase of additional shares of the Company&#146;s common stock
at a strike price equal to the 10-day volume-weighted average price (&#147;VWAP&#148;) ending on the trading day prior to the
date the Company satisfied the second tranche milestones. On September 30, 2011, the Company met the second tranche milestones
and the Company issued the second warrant for the purchase of 5,586 shares of its common stock at a purchase price per share equal
to $11.189. On November 10, 2011, the Company borrowed the second tranche and therefore the Company became obligated to issue a
third warrant to LLC6 with coverage equal to $62,500 for the purchase of additional shares of its common stock at a strike price
equal to the 10-day VWAP ending on the trading day prior to the borrowing date of the second tranche. In connection with borrowing
the second tranche, the Company issued the third warrant for the purchase of 5,884 shares of its common stock at a purchase price
per share equal to $10.623. The three warrants issued to LLC6 are hereinafter collectively referred to as the &#147;VLL6 Warrants,&#148;
and had a total put option cash value, in the aggregate, of $1,250,000. The Company recorded the $1,250,000 cash value of the VLL6
Warrants as a cash settlement liability and a corresponding amount of $1,250,000 was recorded as a discount on the note payable.
The discount is being accreted to non-cash interest expense over the term of the loan using the effective interest method. For
the three months ended September 30, 2013 and 2012, the Company recorded $104,000 and $91,000 of non-cash interest related to the
loan, respectively. For the six months ended September 30, 2013 and 2012, the Company recorded $204,000 and $178,000 of non-cash
interest related to the loan, respectively. The remaining balance of the discount on the loan amounted to $474,000 at September
30, 2013.&#160;The remaining balance of the loan amounted to $1,367,000 at September 30, 2013, of which $821,000 is included in
the current portion of long-term debt in the accompanying condensed consolidated balance sheet.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2012, the Company entered
into respective letter agreements with VLL5 and VLL6 to amend the repayment terms of its outstanding debt obligations. Prior to
the execution of these agreements, LLC5 and LLC6 held an aggregate of 79,517 warrants (adjusted for the reverse stock split effective
April 1, 2013) to purchase common stock, which, in the aggregate, had a total put option cash value of $2,000,000 (the &#147;Cash
Settlement Liability&#148;) and was included in long term liabilities on the Company&#146;s condensed consolidated balance sheets.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On that same day, the Company also entered
into a stock purchase agreement with WTI for the issuance to WTI of shares of its common stock having an aggregate grant date fair
market value of $3,500,000, or approximately $5.67 per post-split share, in exchange for LLC5&#146;s agreement to surrender the
VLL5 Warrants, and LLC6&#146;s agreement to surrender the VLL6 Warrants, and the surrender by WTI of the accompanying Cash Settlement
Liability. Accordingly, on November 1, 2012, the Company issued an aggregate of 617,284 restricted shares of its post-split common
stock (the &#147;Shares&#148;) to WTI, pursuant to the terms of the stock purchase agreement. The VLL5 Warrants and the VLL6
Warrants were surrendered on October 30, 2012.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If at any time between October 30, 2012
through either March 31, 2014 or July 31, 2015 (the &#147;Settlement Dates&#148;) WTI sells the Shares, then the proceeds from
the sale of the Shares will be applied as follows (the &#147;Grace Period&#148;):</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 2%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="width: 2%; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(a)</font></td>
    <td style="width: 96%; padding-right: 0.8pt; text-align: justify; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period, the fair value of the proceeds received will be retained by WTI as consideration for surrendering the Cash Settlement Liability, up to a maximum value of $2,000,000.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(b)</font></td>
    <td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period, any additional proceeds received from the sale of the Shares in excess of $2,000,000 (approximately $3.22 per share) but up to $3,500,000 (approximately $5.67 per share) will be applied by WTI as a prepayment of a portion of the then outstanding debt based on the terms of the stock purchase agreement.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(c)</font></td>
    <td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period, any additional proceeds received from the sale of the Shares in excess of $3,500,000 (approximately $5.67 per share) up to $4,500,000 (approximately $7.28 per share) shall be the sole possession and property of WTI, in accordance with the terms of the stock purchase agreement.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(d)</font></td>
    <td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period for value in excess of $4,500,000 (approximately $6.72 per share), 50% of the amount of the proceeds in excess of the $4,500,000 will be the sole possession and property of WTI and 50% of the amount of the proceeds shall be applied as a prepayment of a portion of the then outstanding debt based on the terms of the stock purchase agreement.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(e)</font></td>
    <td style="padding-right: 0.8pt; text-align: justify; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">If and when the Shares are sold by WTI during the Grace Period for value less than $2,000,000 (approximately $3.22 per share), the Company is required to make a cash payment to WTI until the total Cash Settlement Liability of $2,000,000 has been settled (&#147;Cash Shortfall&#148;).</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Shares are not sold during the
Grace Period, then the then fair value of the stock is to be determined at either of the Settlement Dates and the repayment of
the Cash Settlement Liability, prepayment of outstanding, distribution of gains from the sale of the Shares, or calculation of
the Cash Shortfall will consummate.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2012, upon the issuance
of the Shares, the Company recorded a prepayment of $2,000,000 and $1,500,000 net against the Cash Settlement Liability and the
outstanding notes payable, respectively, on that date.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2013 and June 30, 2013,
the Shares had not yet been sold by WTI and the fair value of the Shares at September 30, 2013 and June 30, 2013 amounted to $1,691,000
and $1,592,000 (approximately $2.74 and $2.58 per share), respectively. Accordingly, in connection with the increase in fair market
value of the Shares, the Company recorded a gain on the fair value in the amount of $99,000, which is included in the accompanying
condensed consolidated statements of comprehensive loss for the three months ended September 30, 2013. The fair value of the Shares
at March 31, 2013 amounted to $1,901,000 ($3.08 per share). Accordingly, in connection with the decrease in fair market value of
the Shares from March 31, 2013 to September 30, 2013, the Company recorded a loss on the fair value in the amount of $210,000,
which is included in the accompanying condensed consolidated statements of comprehensive loss for the six months ended September
30, 2013. The fair value of the Shares will continue to be marked to market with any gain or loss recorded in the statement of
comprehensive loss until either the Shares are sold by the holder or the Settlement Dates, whichever is earlier. As of September
30, 2013, the net Cash Settlement Liability was $309,000, of which $116,000 is included in the current portion of the Cash Settlement
Liability on the accompanying condensed consolidated balance sheet. As of September 30, 2013, the $1,691,000 fair value of the
Shares has been recorded as a prepayment against the Cash Settlement Liability on the accompanying condensed consolidated balance
sheet.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BalanceSheetRelatedDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">6. Stock-Based Compensation</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based
awards exchanged for employee services at the estimated grant date fair value of the award. The Company amortizes the fair value
of employee stock options on a straight-line basis over the requisite service period of the awards.&#160;&#160;Compensation expense
includes the impact of an estimate for forfeitures for all stock options. The estimated forfeiture rates used during the six months
ended September 30, 2013 ranged from 1.63% to 4.77%.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Employee stock-based compensation expense is as follows (in
thousands):</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three&#160;Months</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Cost of service revenue</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">30</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">34</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">56</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">66</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">45</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">63</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">78</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">130</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Selling, general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">221</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">275</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">349</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">484</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Total stock-based compensation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">296</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">372</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">483</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">680</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2013, there were
unrecognized compensation costs of $1,403,000 related to stock options which are  expected to be recognized over a
weighted-average amortization period of 2.54 years.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimated the fair value
of employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options
was estimated using the following weighted-average assumptions:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Three&#160;Months</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Ended</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>September 30,</b></p></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Six Months</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Ended</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>September 30,</b></p></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Expected life</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.89 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.85 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.89 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.85 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: bottom; width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1.42%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.73%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1.42%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.73%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Volatility</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">86%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">88%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">86%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">88%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Fair value of options granted</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2.10</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2.10</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected term of stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the
approach prescribed by the Securities and Exchange Commission's Staff Accounting Bulletin No. 110 for &#147;plain vanilla&#148;
options. The expected stock price volatility for the Company&#146;s stock options was determined by examining the historical volatility
of the Company and the historical volatilities of the Company&#146;s industry peers. The Company will continue to analyze the
stock price volatility and expected term assumptions as more data for the Company&#146;s common stock and exercise patterns become
available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the
expected term of the Company&#146;s stock options. The expected dividend assumption is based on the Company&#146;s history and
expectation of dividend payouts. The Company estimates forfeitures based on historical experience and reduces compensation expense
accordingly.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of all option activity as of
September 30, 2013 and changes during the six months then ended is presented below:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number&#160;of</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Shares </b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Average</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Exercise&#160;Price</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Average</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Contractual&#160; </b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Term</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Aggregate</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Intrinsic</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Value</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at March&#160;31, 2013</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">975</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">15.08</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">335</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2.95</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options forfeited or expired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(81</font></td>
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">15.86</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at September&#160;30, 2013</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,229</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">11.72</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7.42</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable at September&#160;30, 2013</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">816</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">15.32</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">6.35</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options available for grant as of September&#160;30, 2013</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">848</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated
as the difference between the exercise price of the stock options and the underlying fair value of the Company&#146;s common stock
($2.74) for stock options that were in-the-money as of September 30, 2013.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The Company did not capitalize any cost associated with stock-based
compensation.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">No income tax benefit has been recognized
related to stock-based compensation expense and no tax benefits have been realized from exercised stock options.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The Company issues new shares of common stock upon exercise
of stock options.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>4. Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">4. Commitments and Contingencies</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2006, the Company received a
written communication from the grantor of a license to an earlier version of its technology indicating that such license was terminated
due to an alleged breach of the license agreement by the Company. The license agreement extends to its use of the technology in
Japan only. While the Company does not believe that the grantor&#146;s revocation is valid under the terms of the license agreement
and no legal claim has been threatened to date, the Company cannot provide any assurance that the grantor will not take legal action
to restrict its use of the technology in the licensed territory. While the Company's management does not anticipate that the outcome
of this matter is likely to result in a material loss, there can be no assurance that if the grantor pursues legal action, such
legal action would not have a material adverse effect on its consolidated financial position or results of comprehensive loss.
The Company has not accrued a loss reserve for this matter.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2011, the Company received
notice of a lawsuit filed in Mexico by Cesar Mangotich Pacheco and Prodinnv, S.A. de C.V. represented by Cesar Mangotich Pacheco.
The lawsuit appears to allege conversion of assets, tortious interference and defamation, among other claims. The Company is currently
evaluating the lawsuit, conferring with local counsel and translating the documents it has received. The Company&#146;s preliminary
assessment is that the lawsuit is completely without merit and intends to vigorously defend its position. The Company has not accrued
a loss reserve for this matter.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, from time to time, is involved
in legal matters arising in the ordinary course of its business including matters involving proprietary technology. While management
believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of
business for which the Company is or could become involved in litigation, will not have a material adverse effect on its business,
financial condition or results of comprehensive loss.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b><i>Employment
Agreements</i></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">As of September
30, 2013, the Company had employment agreements in place with five of its key executives. The agreements provide, among other
things, for the payment of nine to twenty-four months of severance compensation for terminations under certain circumstances.
With respect to these agreements, at September 30, 2013, potential severance amounted to $1,843,000 and aggregated annual salaries
amounted to $1,310,000.</font></p>


<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Commercial Agreements</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 26, 2009, the Company entered
into a commercial agreement with VetCure, Inc., a California corporation, to market and sell the Company&#146;s Microcyn&#174;
Technology-based animal healthcare products branded as Vetericyn&#174;. VetCure, Inc. later changed its name to Vetericyn, Inc.
This agreement was amended on February 24, 2009, July 24, 2009, June 1, 2010, and November 1, 2010. Pursuant to the agreement,
the Company provides Vetericyn, Inc. with bulk product and Vetericyn, Inc. bottles, packages, and sells Microcyn&#174; Technology-based
animal healthcare products branded as Vetericyn&#174;. The Company receives a fixed amount for each bottle of Vetericyn&#174; sold
by Vetericyn, Inc. At the time of these 2009 transactions, Vetericyn, Inc. was wholly-owned by Robert Burlingame, who was also
a director of the Company at that time. Mr. Burlingame resigned from the Company&#146;s board of directors on February 10, 2010.&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 15, 2009, the Company entered
a commercial agreement with V&#38;M Industries, Inc., a California corporation, to market and sell certain of the Company&#146;s
Microcyn&#174; over-the-counter liquid and gel products. V&#38;M Industries, Inc. subsequently changed its name to Innovacyn, Inc.
On June 1, 2010, September 1, 2010, and November 1, 2010, the Company amended this agreement granting Innovacyn, Inc. the exclusive
right to sell certain of its over-the-counter products. At the time of the 2009 transaction, V&#38;M Industries, Inc. was wholly-owned
by Robert Burlingame, who was also a director of the Company at that time. Mr. Burlingame resigned from&#160;the Company&#146;s&#160;board
of directors on February 10, 2010. &#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2011, Vetericyn, Inc. and
Innovacyn, Inc. began to share profits with the Company related to the Vetericyn&#174; and Microcyn&#174; over-the-counter sales,
resulting in the Company receiving about a 30% royalty of net revenue. During the three months ended September 30, 2013 and 2012,
the Company recorded revenue related to these agreements in the amounts of $1,289,000 and $1,229,000, respectively. During the
six months ended September 30, 2013 and 2012, the Company recorded revenue related to these agreements in the amounts of $2,030,000
and $2,365,000, respectively. The revenue is recorded in product revenues in the accompanying condensed consolidated statements
of comprehensive loss . At September 30, 2013 and March 31, 2013, the Company had outstanding accounts receivable of $801,000
and $264,000, respectively, related to Innovacyn, Inc.</p>


<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2012, the Company, along
with its Mexican subsidiary and manufacturer Oculus Technologies of Mexico S.A. de C.V., entered into a license, exclusive distribution
and supply agreement with More Pharma Corporation, S. de R.L. de C.V. (&#147;More Pharma&#148;) (the &#147;License Agreement&#148;).
For a one-time payment of $500,000, the Company granted More Pharma an exclusive license, with the right to sublicense under certain
conditions and with the Company&#146;s consent, to all of the Company&#146;s proprietary rights related to certain of its pharmaceutical
products for human application that utilize the Company&#146;s Microcyn&#174; Technology within Mexico. For an additional one-time
payment of $3,000,000, the Company also agreed to appoint More Pharma as the exclusive distributor of certain of its products in
Mexico for the term of the agreement. Additionally, the Company granted More Pharma an exclusive license to certain of the Company&#146;s
then-held trademarks in exchange for a payment of $100,000. The Company has the ability to terminate the agreement if certain annual
purchase minimums are not met. The term of the agreement is twenty-five years from the effective date of August 15, 2012. The term
of the License Agreement will automatically renew after the twenty-five year term for successive two year terms as long as More
Pharma has materially complied with any and all of the obligations under the License Agreement, including but not limited to, meeting
the minimum purchase requirements set forth therein.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, on August 9, 2012, the
Company entered into an exclusive distribution and supply agreement with More Pharma (the &#147;Distribution Agreement&#148;).
For a one-time payment of $1,500,000, the Company granted More Pharma exclusive ability to market and sell certain of its pharmaceutical
products for human application that utilize the Company&#146;s Microcyn&#174; Technology. The Company also appointed More Pharma
as its exclusive distributor, with the right to execute sub-distribution agreements under certain conditions and with the Company&#146;s
consent, within the following countries: Antigua &#38; Barbuda, Argentina, Aruba &#38; Curacao, Bahamas, Barbados, Belize, Bolivia,
Bonaire, Brazil, British Guyana, British Islands, Cayman Islands, Chile, Colombia, Cuba, Dominica, Dominican Republic, Ecuador,
El Salvador, French Guyana, Grenada, Guadalupe, Guatemala, Haiti, Honduras, Jamaica, Martinique, Nicaragua, Paraguay, Peru, St.
Bartolome, St. Vincent &#38; Grenades, Surinam, Trinidad &#38; Tobago, Turks &#38; Caicos Islands, Uruguay, Venezuela and Virgin
Islands.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is recognizing the $5,100,000
related to the License Agreement and the Distribution Agreement as revenue on a straight line basis consistent with the Company&#146;s
historical experience with contracts with similar terms, which is typically over three to five years of the contract. Additionally,
the Company capitalized $214,000 of its transaction costs related to the License Agreement and the Distribution Agreement, which
will be amortized by the Company as expense on a straight line basis consistent with the related revenue recognition practices.
At September 30, 2013 and March 31, 2013, the Company had outstanding accounts receivable of $717,000 and $580,000, respectively,
due from More Pharma. During three months ended September 30, 2013 and 2012, the Company recognized $378,000 and $183,000, respectively,
related to the amortization of the upfront fees received in the transaction. During six months ended September 30, 2013 and 2012,
the Company recognized $752,000 and $183,000, respectively, related to the amortization of the upfront fees received in the transaction.
The Company recognizes product sales on a sell-through basis as More Pharma sells products through to its customers.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Matters</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Ruthigen, Inc.</i></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s wholly owned subsidiary,
Ruthigen, Inc., was incorporated in the State of Nevada on January 18, 2013, and reincorporated from Nevada to Delaware on September
25, 2013. Ruthigen has established offices in Santa Rosa, California.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 2, 2013, the Company entered
into a separation agreement with Ruthigen that contains key provisions relating to the Company&#146;s ongoing relationship with
Ruthigen, and more specifically governs its relationship with Ruthigen following the completion of Ruthigen&#146;s intended initial
public offering. The Company previously announced its entry into a license and supply agreement and a shared services agreement
with Ruthigen. Each of these agreements has been entered into in the overall context of the separation of the Company&#146;s business
and its novel biotechnology business into two separate, publicly-traded companies. The effective date for all three agreements
is the closing date of Ruthigen&#146;s intended initial public offering, if any should occur.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>License and Supply Agreement</u></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the license and supply agreement,
the Company agreed to exclusively license certain of its proprietary technology to Ruthigen to enable Ruthigen&#146;s research
and development and commercialization of the newly discovered RUT58-60, and any improvements to it, in the United States, Canada,
European Union and Japan, referred to as the Territory, for certain invasive procedures in human treatment as defined in the license
and supply agreement. On October 9, 2013, the Company entered into Amendment No. 1 to the license and supply agreement, which amended
the second milestone event set forth in Section 7.1 of the license and supply agreement. On November 6, 2013, the Company entered
into Amendment No. 2 to the license and supply agreement with Ruthigen to further amend the certain milestone events set forth
in Section 7.1 of the license and supply agreement and to amend the terms of the manufacturing equipment purchases set forth in
Section 6.13 of the license and supply agreement. All other terms and conditions of the license and supply agreement remain unmodified
and in full force and effect.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The license and supply agreement provides
Ruthigen with the exclusive option, exercisable within the first five years following the effective date of the agreement, to expand
the license to certain other therapeutic indications upon payment of a license expansion fee of $10 million within the first two
years following the effective date of the agreement or, after the two&#150;year period, the same fee plus certain out-of-pocket
costs the Company may incur in developing products for any of the indications. Additionally, the Company will be prohibited from
using the licensed proprietary technology to sell products that compete with Ruthigen&#146;s products within the Territory, and
Ruthigen cannot sell any device or product that competes with the Company&#146;s products being sold or developed as of the effective
date of the license and supply agreement.</p>


<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Ruthigen will be required to make a
total of $5,000,000 in milestone payments to the Company for the first product only, as follows: upon completion of
Ruthigen&#146;s first meeting with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen&#146;s first
pivotal clinical trial and upon first patient enrollment in Ruthigen&#146;s second pivotal clinical trial. In addition, as
further consideration under the agreement, Ruthigen will be required to make royalty payments to the Company based on
Ruthigen&#146;s annual net sales of the product from the date of first commercial sale to the date that Ruthigen ceases to
commercialize the product, which percentage royalty rate will vary between 3% and 20% and will increase based on various net
sales thresholds and will differ depending on the country in which the sales are made. Ruthigen also agreed to purchase
certain research and development and manufacturing equipment from the Company for approximately $3 million following the
completion of Ruthigen&#146;s intended initial public offering.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Shared Services Agreement</u></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also entered into a shared
services agreement with Ruthigen that would take effect upon the completion of Ruthigen&#146;s proposed initial public offering,
if any should occur, pursuant to which it will provide Ruthigen with general services, including general accounting, human resources,
laboratory personnel and shared R&#38;D resources while Ruthigen plans to establish an independent facility and systems. As a wholly
owned subsidiary of the Company, Ruthigen will be financed by the Company until the completion of the proposed initial public offering,
if any should occur, and after such event, Ruthigen would become responsible for its own expenses.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Separation Agreement</u></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a separation
agreement with Ruthigen that contains key provisions relating to its ongoing relationship with Ruthigen following the completion
of Ruthigen&#146;s intended initial public offering. The separation agreement takes effect upon the closing of Ruthigen&#146;s
intended initial public offering and terminates on the earlier of 8.5 years following the closing of the offering, or when the
parties mutually agree to terminate it. The separation agreement also contains a series of restrictions on the Company&#146;s
ability to transfer the Ruthigen shares it owns. The Company is restricted from transferring any of the Ruthigen shares it owns
during the first year (the &#147;lock up period&#148;) immediately following Ruthigen&#146;s intended initial public offering.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the one-year lock up
period, transfers by the Company of the Ruthigen shares it owns must be conducted with the consent of Ruthigen&#146;s board
of directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed
requirements include that the transfers must be in private placement transactions, the purchase price discount may not exceed
certain percentages depending on the transferee, the amount of shares transferred in a given transfer (or series of transfers
comprising a single transaction) may not exceed the greater of 5% of Ruthigen&#146;s outstanding shares or $1.5 million in
net proceeds to the Company, as well as certain other requirements set forth in the separation agreement. In addition to the
prescribed manner for the Company to conduct transfers described above, if, following a minimum of 41.5 months following the
closing of Ruthigen&#146;s initial public offering have lapsed under the separation agreement and the Company has not
consummated transfers of the Ruthigen shares it owns resulting in at least $3.8 million in net proceeds to the Company, then
the Company has a one-time transfer and registration right to transfer the Ruthigen shares it owns in an amount equal to the
difference between $3.8 million and the Ruthigen shares transferred by the Company pursuant to the separation agreement as of
the time the Company elects to exercise its one-time right. Transfers conducted using this one-time right must be conducted
with the consent of Ruthigen&#146;s board of directors or within the prescribed requirements for such transfers set forth in
the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the
amount of shares transferred may not exceed $3.8 million in net proceeds to the Company, as well as certain other
requirements set forth in the separation agreement.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The separation agreement also provides
for certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether
and how many Ruthigen shares the Company transfers. The majority of the material restrictions and obligations contained in the
separation agreement lapse if and when the Company and its subsidiaries (other than Ruthigen) own less than 19.9% of the outstanding
shares of Ruthigen&#146;s common stock.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The separation agreement also sets forth
the methodology for the allocation of the operational and offering related expenses incurred prior to and in connection with Ruthigen&#146;s
intended initial public offering for which Ruthigen is required to reimburse the Company. Ruthigen will also reimburse the Company
for expenses such as salaries and benefits advanced or paid on Ruthigen&#146;s behalf, or for Ruthigen&#146;s benefit, during
a transition period following the closing of Ruthigen&#146;s intended initial public offering.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The separation agreement provides that
each party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against
the other party. This includes an indemnification by the Company to Ruthigen related to obligations that the Company has under
certain loan and security agreements entered into by the Company with Venture Lending &#38; Leasing V, Inc. and Venture Lending
&#38; Leasing VI, Inc. The separation agreement also provides that, so long as the Company shall maintain a directors&#146; and
officers&#146; insurance program covering the past and present officers and directors of the Company, the program shall be standard
in the Company&#146;s industry and the Company shall not exclude any former director of the Company from any insurance policy
coverage if such coverage is made available to the Company&#146;s then existing directors and officers.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. Stock-Based Compensation (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
        <td class="nump">$ 296<span></span></td>
        <td class="nump">$ 372<span></span></td>
        <td class="nump">$ 483<span></span></td>
        <td class="nump">$ 680<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cost of revenues</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
        <td class="nump">30<span></span></td>
        <td class="nump">34<span></span></td>
        <td class="nump">56<span></span></td>
        <td class="nump">66<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
        <td class="nump">45<span></span></td>
        <td class="nump">63<span></span></td>
        <td class="nump">78<span></span></td>
        <td class="nump">130<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Selling general and administrative</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
        <td class="nump">$ 221<span></span></td>
        <td class="nump">$ 275<span></span></td>
        <td class="nump">$ 349<span></span></td>
        <td class="nump">$ 484<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>8. Segment and Geographic Information (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Sales revenue from geographical territories</a></td>
        <td class="nump">$ 3,853,000<span></span></td>
        <td class="nump">$ 4,264,000<span></span></td>
        <td class="nump">$ 7,007,000<span></span></td>
        <td class="nump">$ 8,080,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">U.S.</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Sales revenue from geographical territories</a></td>
        <td class="nump">1,898,000<span></span></td>
        <td class="nump">1,898,000<span></span></td>
        <td class="nump">3,221,000<span></span></td>
        <td class="nump">3,931,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Mexico</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Sales revenue from geographical territories</a></td>
        <td class="nump">1,352,000<span></span></td>
        <td class="nump">1,862,000<span></span></td>
        <td class="nump">2,776,000<span></span></td>
        <td class="nump">3,240,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Europe and Other</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Sales revenue from geographical territories</a></td>
        <td class="nump">$ 603,000<span></span></td>
        <td class="nump">$ 504,000<span></span></td>
        <td class="nump">$ 1,010,000<span></span></td>
        <td class="nump">$ 909,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherSalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>33
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ7T]R
M9V%N:7IA=&EO;E]A;F1?4W5M;6%R>5]O9E\\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93XR7TQI<75I9&ET>5]A;F1?1FEN86YC:6%L
M7T-O;F0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XS
M7T-O;F1E;G-E9%]#;VYS;VQI9&%T961?0F%L86X\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93XT7T-O;6UI=&UE;G1S7V%N9%]#;VYT
M:6YG96YC:64\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93XU7U-T;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93XV7U-T;V-K0F%S961?0V]M<&5N<V%T:6]N/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^-U]);F-O;65?
M5&%X97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XX
M7U-E9VUE;G1?86YD7T=E;V=R87!H:6-?26YF;W(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93XY7U-I9VYI9FEC86YT7T-U<W1O;65R
M7T-O;F-E;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93XQ,%]3=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/C%?3W)G86YI>F%T:6]N7V%N9%]3=6UM87)Y7V]F
M7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ7T]R
M9V%N:7IA=&EO;E]A;F1?4W5M;6%R>5]O9E\R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^,U]#;VYD96YS961?0V]N<V]L:61A=&5D
M7T)A;&%N,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/C9?4W1O8VM"87-E9%]#;VUP96YS871I;VY?5&%B;#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/CA?4V5G;65N=%]A;F1?1V5O9W)A
M<&AI8U]);F9O<C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93XQ7U!O=&5N=&EA;&QY7T1I;'5T:79E7U-E8W5R:70\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XQ7T]R9V%N:7IA=&EO;E]A
M;F1?4W5M;6%R>5]O9E\S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^,E],:7%U:61I='E?86YD7T9I;F%N8VEA;%]#;VYD,3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C-?26YV96YT;W)I
M97-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/C-?3F]T97-?4&%Y86)L95].87)R871I=F4\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C4N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93XT7T-O;6UI=&UE;G1S7V%N9%]#;VYT
M:6YG96YC:64Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^-5]3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I;'-?/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^-E]3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;E]$971A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(X+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^-E]/<'1I;VY?07-S=6UP=&EO;G-?1&5T86EL<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C9?3W!T:6]N<U]/=71S=&%N
M9&EN9U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^-E]3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E].87)R/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^.%]396=M96YT7V%N9%]'
M96]G<F%P:&EC7TEN9F]R,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/CA?4V5G;65N=%]A;F1?1V5O9W)A<&AI8U]);F9O<C,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93XY7U-I9VYI9FEC
M86YT7T-U<W1O;65R7T-O;F-E;G0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T
M<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T
M+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*
M("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U
M<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD
M;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^
M#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B
M92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D
M8S)F,V-?-3=D-U\T,3@Y7V(V-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T
M.38T9#<Q83$U-B]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.
M1T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I
M='D@26YF;W)M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y.;W8N(#$U+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I
M;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG3V-U;'5S($EN;F]V871I=F4@4V-I96YC97,L($EN8RX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<P,#`Q,S8W,#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P+5$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!0
M97)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/E-E<"`S,"P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!9
M96%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M+2TP,RTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES($5N=&ET>2!A(%=E;&PM:VYO=VX@4V5A<V]N960@27-S
M=65R/SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TYO/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27,@
M16YT:71Y(&$@5F]L=6YT87)Y($9I;&5R/SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27,@16YT:71Y)W,@4F5P;W)T:6YG(%-T871U
M<R!#=7)R96YT/SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)UEE
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8T-"PW-C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I
M<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B=1,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@V9&,R9C-C7S4W9#=?-#$X.5]B
M-C4X7S,T.38T9#<Q83$U-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\X-F1C,F8S8U\U-V0W7S0Q.#E?8C8U.%\S-#DV-&0W,6$Q-38O5V]R:W-H
M965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44E!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE
M971S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L,3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`W+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L92P@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0R-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S`W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E
M;G1O<FEE<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPY,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,2PU,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX+#@X,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#4V-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R
M96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#(W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S
M(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@<&]R=&EO;B!O9B!C
M87-H('-E='1L96UE;G0@;&EA8FEL:71Y("A3964@3F]T92`S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S(R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B="P@;F5T(&]F(&1E
M8G0@9&ES8V]U;G0@;V8@)#0S,"`H=6YA=61I=&5D*2!A;F0@)#4R,2!A="!3
M97!T96UB97(@,S`L(#(P,3,@86YD($UA<F-H(#,Q+"`R,#$S+"!R97-P96-T
M:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C4Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PW,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#$R-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX.#,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8Q.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N
M9RUT97)M(&1E8G0L(&YE="!O9B!D96)T(&1I<V-O=6YT(&]F("0T-2`H=6YA
M=61I=&5D*2!A;F0@)#(T."!A="!397!T96UB97(@,S`L(#(P,3,@86YD($UA
M<F-H(#,Q+"`R,#$S+"!R97-P96-T:79E;'DL(&QE<W,@8W5R<F5N="!P;W)T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@<V5T=&QE;65N="!L:6%B:6QI='DL(&QE<W,@8W5R<F5N="!P;W)T:6]N
M("A3964@3F]T92`S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPS,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX+#0X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@
M17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"`D,"XP,#`Q('!A
M<B!V86QU93L@-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D+"!N;VYE(&ES
M<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P+"`R,#$S("AU
M;F%U9&ET960I(&%N9"!-87)C:"`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"`D,"XP,#`Q('!A<B!V86QU93L@,30L,C@U+#<Q-2!S:&%R97,@875T:&]R
M:7IE9"P@-BPV,S,L-CDT(&%N9"`V+#4X,RPQ-3`@<VAA<F5S(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R(#,P+"`R,#$S("AU;F%U9&ET
M960I(&%N9"!-87)C:"`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN
M(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-2PT
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#0L.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&QO
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,#<W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.3DQ
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,30P+#@U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,S<L-S0U*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R
M<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4U
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,#@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@
M97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L.#@R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,BPU-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F1C,F8S8U\U-V0W7S0Q.#E?
M8C8U.%\S-#DV-&0W,6$Q-38O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%2T-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L*2`H
M55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N="!O
M9B!&:6YA;F-I86P@4&]S:71I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@9&ES8V]U;G0L
M(&-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,S`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4R,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!D:7-C;W5N
M="P@;&]N9RUT97)M('!O<G1I;VX@;V8@;&]N9RUT97)M(&1E8G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K('!A<B!V86QU92`H:6X@1&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@<VAA<F5S
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@<VAA<F5S(&]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K('!A<B!V86QU92`H:6X@1&]L;&%R<R!P97(@<VAA<F4I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T+#(X-2PW,34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR.#4L-S$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VL@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPV,S,L-CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPU.#,L,34P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA
M<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#8S,RPV.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#4X,RPQ-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T
M9#<Q83$U-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F1C,F8S
M8U\U-V0W7S0Q.#E?8C8U.%\S-#DV-&0W,6$Q-38O5V]R:W-H965T<R]3:&5E
M=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%54U"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@0V]M<')E
M:&5N<VEV92!,;W-S("A5;F%U9&ET960I("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU97,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V1U8W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPT-38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L.#DP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#$W
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-RPV-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V1U8W0@;&EC96YS:6YG(&9E97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R=FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M,#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PU,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L-3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O<W0@;V8@<F5V96YU97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V1U8W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C`S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#(R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y397)V:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C;W-T(&]F(')E=F5N
M=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S(V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPU-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#0Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=R;W-S('!R;V9I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPW,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.3`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP.#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E
M<F%T:6YG(&5X<&5N<V5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,SDP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`Y,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3`T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,U,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&]P97)A=&EN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPY-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#`Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S`R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS.38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@
M;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR
M-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH.#$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L,SDW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L,S$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(X,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,S@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-38X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT
M97)E<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'86EN("AL;W-S*2!D=64@=&\@8VAA;F=E(&EN(&9A:7(@=F%L=64@
M;V8@8V]M;6]N('-T;V-K("A3964@3F]T92`S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA,;W-S*2!G86EN(&1U92!T;R!C
M:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&EN<W1R=6UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,SDW*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T
M:&5R(&5X<&5N<V4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L,SDY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L-3$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L,3$Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#<T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K(&1E96UE9"!D:79I9&5N9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PP-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@879A:6QA8FQE('1O
M(&-O;6UO;B!S:&%R96AO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,SDY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-3$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,L,3$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,3,V*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R
M(&-O;6UO;B!S:&%R93H@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XT
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^5V5I9VAT960M879E<F%G92!N=6UB97(@;V8@<VAA<F5S
M('5S960@:6X@<&5R(&-O;6UO;B!S:&%R92!C86QC=6QA=&EO;G,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I
M8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPV,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#8U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L-C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PU.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@8V]M<')E:&5N
M<VEV92!L;W-S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PS.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PU,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPQ,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PP-S0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N(&-U<G)E
M;F-Y('1R86YS;&%T:6]N(&%D:G5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8V]M<')E:&5N<VEV
M92!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L,S@V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,2PT,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@S+#$Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#$L,#<U*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y7V(V-3A?
M,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@V
M9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K<VAE971S
M+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5,4T%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#
M87-H($9L;W=S("A5;F%U9&ET960I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@
M;W!E<F%T:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@S+#$Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L,#<T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU
M<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@*'5S
M960@:6XI('!R;W9I9&5D(&)Y(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E
M8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@
M:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@U,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9'5E('1O(&-H
M86YG92!I;B!F86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C:R`H4V5E($YO=&4@
M,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC
M87-H(&EN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F]R96EG;B!C=7)R96YC>2!T<F%N<V%C=&EO;B!G
M86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@<F5C96EV86)L92P@;F5T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-S`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,L(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X
M<&5N<V5S(&%N9"!O=&AE<B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@W,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Y,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0W.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H
M("AU<V5D(&EN*2!P<F]V:61E9"!B>2!O<&5R871I;F<@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPT-30I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR.3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U
M<F-H87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5P;W-I
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30S*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,Q,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@
M9FQO=W,@9G)O;2!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG(&-O
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!E
M>&5R8VES92!O9B!C;VUM;VX@<W1O8VL@;W!T:6]N<R!A;F0@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@
M;V9F97)I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<FEN8VEP86P@<&%Y;65N=',@;VX@;&]N9RUT97)M(&1E8G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,3,X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DW-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@8V%S:"`H=7-E9"!I;BD@<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.3$X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M.#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%9F9E8W0@;V8@97AC:&%N9V4@<F%T92!O;B!C87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="`H9&5C<F5A<V4I(&EN8W)E87-E(&-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L
M-S$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L.34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!B96=I;FYI
M;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,S4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!E;F0@;V8@
M<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$Y,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M,S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&-A<V@@
M9FQO=R!I;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R(&EN=&5R97-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N
M+6-A<V@@;W!E<F%T:6YG(&%N9"!F:6YA;F-I;F<@86-T:79I=&EE<SPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G1S(&ES<W5E9"!A<R!D97)I=F%T:79E(&QI86)I;&ET:65S(&EN(&-O;FYE
M8W1I;VX@=VET:"!R96=I<W1E<F5D(&1I<F5C="!O9F9E<FEN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#,T-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T
M,3@Y7V(V-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7
M;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SXQ+B!/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO
M;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA
M;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C$N($]R9V%N:7IA=&EO;B!A;F0@4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\8CX\:3Y/<F=A;FEZ871I;VX\+VD^/"]B/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY/8W5L=7,@26YN;W9A=&EV92!38VEE;F-E<RP@26YC
M+B`H=&AE#0HF(S$T-SM#;VUP86YY)B,Q-#@[*2!W87,@:6YC;W)P;W)A=&5D
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M9R!W:&EL92!R961U8VEN9R!T:&4@;F5E9`T*9F]R(&%N=&EB:6]T:6-S+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQB/B8C,38P.SPO8CX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&(^/&D^4F5V97)S92!3=&]C:R!3<&QI=#PO:3X\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D5F9F5C
M=&EV92!A<R!O9B!T:&4@;W!E;B!O9B!B=7-I;F5S<PT*;VX@07!R:6P@,2P@
M,C`Q,RP@=&AE($-O;7!A;GD@969F96-T960@82!R979E<G-E('-T;V-K('-P
M;&ET(&]F(&ET<R!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D,"XP,#`Q('!E
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M=71S=&%N9&EN9R!F<F]M(#0V+#`X,"PU,3,@=&\@-BPU.#,L,34P+B!4:&4@
M=&]T86P@;G5M8F5R#0IO9B!A=71H;W)I>F5D('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@=V%S(&%L<V\@<')O<&]R=&EO;F%L;'D@9&5C<F5A<V5D(&)Y(&$@
M<F%T:6\@;V8@,3HW(&%N9"!T:&4@<&%R('9A;'5E('!E<B!S:&%R92!O9B!T
M:&4@8V]M;6]N#0IS=&]C:R!C;VYT:6YU960@=&\@8F4@)#`N,#`P,2X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^06QL
M(&-O;6UO;B!S:&%R97,@86YD('!E<B!S:&%R92!A;6]U;G1S#0IC;VYT86EN
M960@:6X@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
M871E;65N=',@:&%V92!B965N(')E=')O86-T:79E;'D@861J=7-T960@=&\@
M<F5F;&5C="!A(#$@9F]R(#<@<F5V97)S92!S=&]C:PT*<W!L:70L(&5F9F5C
M=&EV92!!<')I;"`Q+"`R,#$S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M8CX\:3Y"87-I<R!O9B!0<F5S96YT871I;VX\+VD^/"]B/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SY4:&4@86-C;VUP
M86YY:6YG#0IU;F%U9&ET960@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA
M;F-I86P@<W1A=&5M96YT<R!A<R!O9B!397!T96UB97(@,S`L(#(P,3,@86YD
M(&9O<B!T:&4@=&AR964@86YD('-I>"!M;VYT:',@=&AE;B!E;F1E9"!H879E
M#0IB965N('!R97!A<F5D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@86-C;W5N
M=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI
M=&5D(%-T871E<R!O9B!!;65R:6-A(&9O<B!I;G1E<FEM(&9I;F%N8VEA;`T*
M:6YF;W)M871I;VX@86YD('!U<G-U86YT('1O('1H92!I;G-T<G5C=&EO;G,@
M=&\@1F]R;2`Q,"U1(&%N9"!!<G1I8VQE(#@@;V8@4F5G=6QA=&EO;B!3+5@@
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M8F5R(#,P+"`R,#$S+"!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T
M96UE;G1S(&]F(&-O;7!R96AE;G-I=F4@;&]S<R!F;W(-"G1H92!T:')E92!A
M;F0@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P
M,3(L(&%N9"!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G1S
M(&]F(&-A<V@@9FQO=W,@9F]R('1H92!S:7@-"FUO;G1H<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,3,@86YD(#(P,3(@87)E('5N875D:71E9"P@8G5T(&EN
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M4V5P=&5M8F5R(#,P+"`R,#$S(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A
M=&EV92!O9B!R97-U;'1S#0IT;R!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@
M96YD:6YG($UA<F-H(#,Q+"`R,#$T(&]R(&9O<B!A;GD@9G5T=7)E(&EN=&5R
M:6T@<&5R:6]D+B!4:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E
M('-H965T(&%T#0I-87)C:"`S,2P@,C`Q,R!H87,@8F5E;B!D97)I=F5D(&9R
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M8VEA;`T*<W1A=&5M96YT<RX@5&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S('-H;W5L9"!B92!R
M96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&-O;G-O;&ED871E9"!F:6YA
M;F-I86P-"G-T871E;65N=',@9F]R('1H92!Y96%R(&5N9&5D($UA<F-H(#,Q
M+"`R,#$S+"!A;F0@;F]T97,@=&AE<F5T;R!I;F-L=61E9"!I;B!T:&4@0V]M
M<&%N>28C,30V.W,@86YN=6%L(')E<&]R="!O;B!&;W)M(#$P+4LL('=H:6-H
M#0IW87,@9FEL960@=VET:"!T:&4@4T5#(&]N($IU;F4@,C4L(#(P,3,N/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CX\:3Y0<FEN8VEP;&5S
M(&]F($-O;G-O;&ED871I;VX\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@86-C;VUP86YY:6YG(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P-"G-T871E;65N=',@:6YC;'5D92!T:&4@
M86-C;W5N=',@;V8@=&AE($-O;7!A;GD@86YD(&ET<R!W:&]L;'D@;W=N960@
M<W5B<VED:6%R:65S+"!!<75A;65D(%1E8VAN;VQO9VEE<RP@26YC+B`H)B,Q
M-#<[07%U86UE9"8C,30X.RDL#0I/8W5L=7,@5&5C:&YO;&]G:65S(&]F($UE
M>&EC;R!3+D$N(&1E($,N5BX@86YD($]C=6QU<R!);FYO=F%T:79E(%-C:65N
M8V5S($YE=&AE<FQA;F1S+"!"+E8N(&%N9"!2=71H:6=E;BP@26YC+B`H)B,Q
M-#<[4G5T:&EG96XF(S$T.#LI+@T*06QL('-I9VYI9FEC86YT(&EN=&5R8V]M
M<&%N>2!A8V-O=6YT<R!A;F0@=')A;G-A8W1I;VYS(&AA=F4@8F5E;B!E;&EM
M:6YA=&5D(&EN(&-O;G-O;&ED871I;VXN($%Q=6%M960@:&%S(&YO(&-U<G)E
M;G0@;W!E<F%T:6]N<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CX\:3Y5<V4@;V8@
M17-T:6UA=&5S/"]I/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@<')E<&%R871I
M;VX@;V8@8V]N9&5N<V5D(&-O;G-O;&ED871E9`T*9FEN86YC:6%L('-T871E
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M,#`P(&%N9"`D,C(L,#`P+"!W:&EC:"!A<F4@:6YC;'5D960@:6X@86-C;W5N
M=',@<F5C96EV86)L92P@;F5T(&EN#0IT:&4@86-C;VUP86YY:6YG(%-E<'1E
M;6)E<B`S,"P@,C`Q,R!A;F0@36%R8V@@,S$L(#(P,3,@8V]N9&5N<V5D(&-O
M;G-O;&ED871E9"!B86QA;F-E('-H965T<RP@<F5S<&5C=&EV96QY+B!4:&4@
M<F5S97)V92!F;W(@97AC97-S#0IA;F0@;V)S;VQE=&4@:6YV96YT;W)Y(&)A
M;&%N8V5S(&%M;W5N=&5D('1O("0W-BPP,#`@86YD("0Q-S`L,#`P+"!W:&EC
M:"!A<F4@:6YC;'5D960@:6X@:6YV96YT;W)I97,L(&YE="!I;B!T:&4@86-C
M;VUP86YY:6YG(%-E<'1E;6)E<@T*,S`L(#(P,3,@86YD($UA<F-H(#,Q+"`R
M,#$S(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E=',L(')E
M<W!E8W1I=F5L>2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^/&D^4F5C
M;&%S<VEF:6-A=&EO;G,\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#97)T86EN('!R:6]R('!E<FEO9"!A
M;6]U;G1S(&AA=F4@8F5E;@T*<F5C;&%S<VEF:65D(&9O<B!C;VUP87)A=&EV
M92!P=7)P;W-E<R!T;R!C;VYF;W)M('1O('1H92!F:7-C86P@,C`Q-"!P<F5S
M96YT871I;VXN(%1H97-E(')E8VQA<W-I9FEC871I;VYS(&AA=F4@;F\@:6UP
M86-T(&]N('1H90T*0V]M<&%N>28C,30V.W,@<')E=FEO=7-L>2!R97!O<G1E
M9"!N970@;&]S<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CX\:3Y.970@3&]S<R!P
M97(@4VAA<F4\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@
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M:&%R92P@:68@<')E<V5N=&5D+"!W;W5L9`T*:6YC;'5D92!T:&4@9&EL=71I
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M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R("AA9&IU
M<W1E9"!I9B!A<'!L:6-A8FQE(&9O<B!T:&4@<F5V97)S92!S=&]C:R!S<&QI
M="!E9F9E8W1I=F4-"D%P<FEL(#$L(#(P,3,I(&5X8VQU9&5S('1H92!P;W1E
M;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S('-U;6UA<FEZ960@:6X@=&AE
M('1A8FQE(&)E;&]W(&)E8V%U<V4@=&AE:7(@:6YC;'5S:6]N('=O=6QD(&)E
M(&%N=&DM9&EL=71I=F4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R:2P@2&5L=F5T:6-A
M+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX\8CY397!T96UB97(@,S`L/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$S/"]B/CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$R/"]B/CPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&(^*&EN('1H;W5S86YD<RD\+V(^/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`V."4[('!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N
M=#H@+3EP=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3W!T:6]N
M<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$L,C(Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXY.#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY787)R86YT<R!T;R!P=7)C:&%S
M92!C;VUM;VX@<W1O8VL\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L,S$X/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,2PU,CD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L-30W/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXR+#4Q-SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&(^/&D^0V]M;6]N(%-T;V-K(%!U<F-H87-E(%=A<G)A;G1S
M(&%N9"!/=&AE<B!$97)I=F%T:79E#0I&:6YA;F-I86P@26YS=')U;65N=',\
M+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!C
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M870@*&DI(')E<75I<F4@;F5T+6-A<V@@<V5T=&QE;65N="`H:6YC;'5D:6YG
M(&$@<F5Q=6ER96UE;G0@=&\-"FYE="!C87-H('-E='1L92!T:&4@8V]N=')A
M8W0@:68@86X@979E;G0@;V-C=7)S(&%N9"!I9B!T:&%T(&5V96YT(&ES(&]U
M='-I9&4@=&AE(&-O;G1R;VP@;V8@=&AE($-O;7!A;GDI+"`H:6DI(&=I=F4@
M=&AE(&-O=6YT97)P87)T>0T*82!C:&]I8V4@;V8@;F5T+6-A<V@@<V5T=&QE
M;65N="!O<B!S971T;&5M96YT(&EN('-H87)E<R`H<&AY<VEC86P@<V5T=&QE
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M87,@97%U:71Y#0II;G-T<G5M96YT<R!A="!397!T96UB97(@,S`L(#(P,3,L
M(&]T:&5R('1H86X@8V5R=&%I;B!W87)R86YT<R!T:&%T(&-O;G1A:6X@<F5S
M970@<')O=FES:6]N<R!A;F0@8V5R=&%I;B!W87)R86YT<R!T:&%T(')E<75I
M<F4-"FYE="UC87-H('-E='1L96UE;G0@=&AA="!T:&4@0V]M<&%N>2!C;&%S
M<VEF:65D(&%S(&1E<FEV871I=F4@;&EA8FEL:71I97,N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&(^/&D^1F%I<B!686QU92!O9B!&:6YA;F-I86P@07-S971S#0IA;F0@
M3&EA8FEL:71I97,\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&
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M<F4@9F%I<@T*=F%L=64Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY,979E;"8C,38P.S$F(S$V,#LF(S$U,3L@<75O=&5D#0IP<FEC97,@
M:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@;W(@;&EA
M8FEL:71I97,\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@
M,"XU:6X[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N-6EN.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY,979E;"8C,38P.S(F(S$V,#LF(S$U,3L@<75O=&5D#0IP<FEC
M97,@9F]R('-I;6EL87(@87-S971S(&%N9"!L:6%B:6QI=&EE<R!I;B!A8W1I
M=F4@;6%R:V5T<R!O<B!I;G!U=',@=&AA="!A<F4@;V)S97)V86)L93PO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"`P(#`@,"XU:6X[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DQE=F5L
M)B,Q-C`[,R8C,38P.R8C,34Q.R!I;G!U=',-"G1H870@87)E('5N;V)S97)V
M86)L92`H9F]R(&5X86UP;&4L(&-A<V@@9FQO=R!M;V1E;&EN9R!I;G!U=',@
M8F%S960@;VX@87-S=6UP=&EO;G,I/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/D9I;F%N8VEA;"!L:6%B:6QI=&EE
M<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG#0IB87-I
M<R!A<F4@<W5M;6%R:7IE9"!B96QO=SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
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M;G1S(&-A=&5G;W)I>F5D('=I=&AI;B!,979E;"`S(&]F('1H92!F86ER('9A
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M86P@3V9F:6-E<BXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/'4^3&5V96P@,R!686QU871I;VX@5&5C:&YI
M<75E<SPO=3XZ/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
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M<F]P<FEA=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
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M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D$@<VEG
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M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!<R!O
M9B!397!T96UB97(@,S`L(#(P,3,L('1H97)E('=E<F4-"FYO('1R86YS9F5R
M<R!I;B!O<B!O=70@;V8@3&5V96P@,R!F<F]M(&]T:&5R(&QE=F5L<R!I;B!T
M:&4@9F%I<B!V86QU92!H:65R87)C:'DN/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^/&(^/&D^)B,Q-C`[
M/"]I/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^
M/&D^4W5B<V5Q=65N="!%=F5N=',\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY-86YA9V5M96YT(&AA<R!E=F%L=6%T960@<W5B<V5Q=65N="!E
M=F5N=',-"F]R('1R86YS86-T:6]N<R!O8V-U<G)I;F<@=&AR;W5G:"!T:&4@
M9&%T92!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<R!W97)E(&ES<W5E9"`H3F]T92`Q,"DN/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)SX\8CX\:3Y296-E;G0-"D%C8V]U;G1I;F<@4')O
M;F]U;F-E;65N=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^26X@2G5N
M92`R,#$Q+`T*=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!"
M;V%R9"`H)B,Q-#<[1D%30B8C,30X.RD@:7-S=65D($%C8V]U;G1I;F<@4W1A
M;F1A<F1S(%5P9&%T92`H)B,Q-#<[05-5)B,Q-#@[*2!.;RX@,C`Q,2TP-2P-
M"CQI/D-O;7!R96AE;G-I=F4@26YC;VUE("A4;W!I8R`R,C`I.B!0<F5S96YT
M871I;VX@;V8@0V]M<')E:&5N<VEV92!);F-O;64\+VD^+B!4:&ES(&=U:61A
M;F-E(&EM<')O=F5S('1H92!C;VUP87)A8FEL:71Y+"!C;VYS:7-T96YC>0T*
M86YD('1R86YS<&%R96YC>2!O9B!F:6YA;F-I86P@<F5P;W)T:6YG(&%N9"!I
M;F-R96%S97,@=&AE('!R;VUI;F5N8V4@;V8@:71E;7,@<F5P;W)T960@:6X@
M;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64N)B,Q-C`[($EN#0I$96-E;6)E
M<B`R,#$Q+"!T:&4@1D%30B!I<W-U960@05-5($YO+B`R,#$Q+3$R+"`\:3Y$
M969E<G)A;"!O9B!T:&4@169F96-T:79E($1A=&4@9F]R($%M96YD;65N=',@
M=&\@=&AE(%!R97-E;G1A=&EO;B!O9B!296-L87-S:69I8V%T:6]N<PT*;V8@
M271E;7,@3W5T(&]F($%C8W5M=6QA=&5D($]T:&5R($-O;7!R96AE;G-I=F4@
M26YC;VUE(&EN($%352`R,#$Q+3`U/"]I/BX@05-5(#(P,3$M,3(@9&5F97)S
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M;"!O=&AE<B!R97%U:7)E;65N=',@:6X@05-5($YO+B`R,#$Q+3`U(&%R92!N
M;W0@869F96-T960@8GD@05-5($YO+B`R,#$Q+3$R+`T*:6YC;'5D:6YG('1H
M92!R97%U:7)E;65N="!T;R!R97!O<G0@8V]M<')E:&5N<VEV92!I;F-O;64@
M96ET:&5R(&EN(&$@<VEN9VQE(&-O;G1I;G5O=7,@9FEN86YC:6%L('-T871E
M;65N="!O<B!I;B!T=V\@<V5P87)A=&4-"F)U="!C;VYS96-U=&EV92!F:6YA
M;F-I86P@<W1A=&5M96YT<RXF(S$V,#L@5VAI;&4@=&AE(&%D;W!T:6]N(&]F
M('1H:7,@<W1A;F1A<F0@<F5Q=6ER960@=&AE($-O;7!A;GD@=&\@8VAA;F=E
M('1H92!F;W)M870@;V8@:71S#0IC;VYD96YS960@8V]N<V]L:61A=&5D(&9I
M;F%N8VEA;"!S=&%T96UE;G1S+"!I="!D:60@;F]T(&AA=F4@82!M871E<FEA
M;"!I;7!A8W0@;VX@=&AE($-O;7!A;GDF(S$T-CMS(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<&]S:71I;VX-"F%N9"!R97-U;'1S(&]F(&]P97)A=&EO;G,N
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,'!T(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T)SY4:&4@1D%30@T*:&%S(&ES<W5E9"!!4U4@3F\N(#(P,3,M,3$L
M(#QI/DEN8V]M92!487AE<R`H5&]P:6,@-S0P*3H@4')E<V5N=&%T:6]N(&]F
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M9`T*:6X@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%S(&$@<F5D=6-T:6]N
M('1O(&$@9&5F97)R960@=&%X(&%S<V5T(&9O<B!A(&YE="!O<&5R871I;F<@
M;&]S<R!C87)R>69O<G=A<F0L(&$@<VEM:6QA<B!T87@@;&]S<RP-"F]R(&$@
M=&%X(&-R961I="!C87)R>69O<G=A<F0L(&5X8V5P="!A<R!F;VQL;W=S+B!4
M;R!T:&4@97AT96YT(&$@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R
M9"P@82!S:6UI;&%R('1A>"!L;W-S+"!O<B!A('1A>`T*8W)E9&ET(&-A<G)Y
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M(&IU<FES9&EC=&EO;B!D;V5S(&YO=`T*<F5Q=6ER92!T:&4@96YT:71Y('1O
M('5S92P@86YD('1H92!E;G1I='D@9&]E<R!N;W0@:6YT96YD('1O('5S92P@
M=&AE(&1E9F5R<F5D('1A>"!A<W-E="!F;W(@<W5C:"!P=7)P;W-E+"!T:&4@
M=6YR96-O9VYI>F5D('1A>`T*8F5N969I="!S:&]U;&0@8F4@<')E<V5N=&5D
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M=VET:&EN('1H;W-E('EE87)S+`T*8F5G:6YN:6YG(&%F=&5R(#QF;VYT('-T
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M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`X<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0G/D%C8V]U;G1I;F<@<W1A;F1A<F1S#0IT:&%T(&AA=F4@8F5E
M;B!I<W-U960@;W(@<')O<&]S960@8GD@=&AE($9!4T(L(%-%0R!A;F0O;W(@
M;W1H97(@<W1A;F1A<F1S+7-E='1I;F<@8F]D:65S('1H870@9&\@;F]T(')E
M<75I<F4@861O<'1I;VX@=6YT:6P@80T*9G5T=7)E(&1A=&4@87)E(&YO="!E
M>'!E8W1E9"!T;R!H879E(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!C;VYD
M96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S('5P;VX@
M861O<'1I;VXN/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T
M9#<Q83$U-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F1C,F8S
M8U\U-V0W7S0Q.#E?8C8U.%\S-#DV-&0W,6$Q-38O5V]R:W-H965T<R]3:&5E
M=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M,BX@3&EQ=6ED:71Y(&%N9"!&:6YA;F-I86P@0V]N9&ET:6]N/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EQ=6ED
M:71Y($%N9"!&:6YA;F-I86P@0V]N9&ET:6]N/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR+B!,:7%U:61I='D@86YD($9I
M;F%N8VEA;"!#;VYD:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SY4:&4@0V]M<&%N
M>2!R97!O<G1E9`T*82!N970@;&]S<R!O9B`D,RPQ,3$L,#`P(&9O<B!T:&4@
M<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,N($%T(%-E<'1E
M;6)E<B`S,"P@,C`Q,R!A;F0@36%R8V@@,S$L(#(P,3,L('1H92!#;VUP86YY
M)B,Q-#8[<PT*86-C=6UU;&%T960@9&5F:6-I="!A;6]U;G1E9"!T;R`D,30P
M+#@U-BPP,#`@86YD("0Q,S<L-S0U+#`P,"P@<F5S<&5C=&EV96QY+B!4:&4@
M0V]M<&%N>2!H860@=V]R:VEN9R!C87!I=&%L(&]F("0R+#$W-2PP,#`@86YD
M#0HD-BPT,#<L,#`P(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@36%R
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M0V]M<&%N>2!E;G1E<F5D(&EN=&\@=VET:"!2=71H:6=E;B`H4V5E($YO=&4@
M-"DN($%T(%-E<'1E;6)E<@T*,S`L(#(P,3,L('1H97-E(&-O<W1S(&%M;W5N
M=&5D('1O("0Y,3$L,#`P+"!O9B!W:&EC:"`D.#(T+#`P,"!I<R!R97!O<G1E
M9"!A<R!D969E<G)E9"!O9F9E<FEN9R!C;W-T<R!I;B!T:&4@86-C;VUP86YY
M:6YG(&-O;F1E;G-E9`T*8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970@86YD
M("0X-RPP,#`@=V%S(')E<&]R=&5D(&%S('-E;&QI;F<L(&=E;F5R86P@86YD
M(&%D;6EN:7-T<F%T:79E(&5X<&5N<V4N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T
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M<R!T:')O=6=H(&%T(&QE87-T($]C=&]B97(@,2P@,C`Q-"X@2&]W979E<BP@
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M=&EN9R!E>'!E;F1I='5R97,N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P/B`\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS
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M9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C,N($-O;F1E;G-E
M9"!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"86QA;F-E(%-H965T
M(%)E;&%T960@1&ES8VQO<W5R97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,RX@0V]N9&5N<V5D($-O
M;G-O;&ED871E9"!"86QA;F-E(%-H965T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^/&D^
M26YV96YT;W)I97,\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY)
M;G9E;G1O<FEE<R!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9PT**&EN('1H
M;W5S86YD<RDZ/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS
M+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY3
M97!T96UB97(@,S`L/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^36%R8V@@,S$L/"]B/CPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C@E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY287<@;6%T97)I86QS
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-3DQ/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^.#,U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9I;FES:&5D(&=O;V1S
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXR,S0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,C<\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@R-3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PQ-C(\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQE<W,Z
M(&EN=F5N=&]R>2!A;&QO=V%N8V5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-S8\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$W,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW-#D\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXY.3(\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/CQB/CQI/DYO=&5S(%!A>6%B;&4\+VD^/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQI/B8C,38P.SPO:3X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&D^5F5N='5R92!,96YD:6YG("8C,S@[($QE87-I;F<F(S$V,#M6
M+`T*26YC+B!A;F0@5F5N='5R92!,96YD:6YG("8C,S@[($QE87-I;F<F(S$V
M,#M622P@26YC+CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^3VX@36%Y(#$L(#(P,3`L('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;PT*82!L;V%N(&%N9"!S96-U<FET>2!A9W)E96UE;G0@86YD
M(&$@<W5P<&QE;65N="!T;R!T:&4@;&]A;B!A;F0@<V5C=7)I='D@86=R965M
M96YT('=I=&@@5F5N='5R92!,96YD:6YG("8C,S@[($QE87-I;F<@5BP@26YC
M+B`H)B,Q-#<[5DQ,-28C,30X.RD-"G1O(&)O<G)O=R!U<"!T;R!A;B!A9V=R
M96=A=&4@;V8@)#,L,#`P+#`P,"`H8V]L;&5C=&EV96QY+"!T:&4@)B,Q-#<[
M5DQ,-2!!9W)E96UE;G1S)B,Q-#@[*2X@3VX@36%Y(#,L(#(P,3`L('1H92!#
M;VUP86YY(&)O<G)O=V5D#0HD,BPP,#`L,#`P(&]N('1H92!F:7)S="!T<F%N
M8VAE(&%N9"!O;B!.;W9E;6)E<B`Q-RP@,C`Q,"P@=&AE($-O;7!A;GD@8F]R
M<F]W960@)#$L,#`P+#`P,"!O;B!T:&4@<V5C;VYD('1R86YC:&4N)B,Q-C`[
M)B,Q-C`[5&AE#0IL;V%N(&ES('-E8W5R960@8GD@86QL(&%S<V5T<R!O9B!T
M:&4@0V]M<&%N>2!E>&-L=61I;F<@:6YT96QL96-T=6%L('!R;W!E<G1Y('5N
M9&5R(&-E<G1A:6X@8VER8W5M<W1A;F-E<RX@4F5L871E9"!T;R!T:&4@9FER
M<W0-"G1R86YC:&4L('1H92!#;VUP86YY(&UA9&4@96EG:'0@;6]N=&AL>2!I
M;G1E<F5S="UO;FQY('!A>6UE;G1S(&]F("0Q-BPV-C`@=&AR;W5G:"!$96-E
M;6)E<B`Q+"`R,#$P+B!4:&5R96%F=&5R+"!T:&4@0V]M<&%N>2!M861E#0II
M;G1E<F5S="!A;F0@<')I;F-I<&%L('!A>6UE;G1S(&]F("0W-2PP,#`@<&5R
M(&UO;G1H('1H<F]U9V@@2G5N92`Q+"`R,#$S+B!296QA=&5D('1O('1H92!S
M96-O;F0@=')A;F-H92P@=&AE($-O;7!A;GD@<&%I9"!M;VYT:&QY#0II;G1E
M<F5S="!O;FQY('!A>6UE;G1S(&]F("0X+#,S,"!T:')O=6=H($UA>2`Q+"`R
M,#$R+B!4:&5R96%F=&5R+"!T:&4@0V]M<&%N>2!M861E(&EN=&5R97-T(&%N
M9"!P<FEN8VEP86P@<&%Y;65N=',@;V8@)#,W+#4P,"!P97(-"FUO;G1H('1H
M<F]U9V@@3F]V96UB97(@,2P@,C`Q,RX@5&AE($-O;7!A;GD@;6%D92!A(&9I
M;F%L(&)A;&QO;VX@<&%Y;65N="!R96QA=&5D('1O('1H92!F:7)S="!T<F%N
M8VAE(&]F("0Q,S(L,#`P('!R:6]R('1O('1H90T*2G5N92`Q+"`R,#$S(&1E
M861L:6YE+"!A;F0@;6%D92!A(&9I;F%L(&)A;&QO;VX@<&%Y;65N="!R96QA
M=&5D('1O('1H92!S96-O;F0@=')A;F-H92!O9B`D-C8L,#`P(&]N(&]R('!R
M:6]R('1O($YO=F5M8F5R(#$L(#(P,3,N#0I4:&4@969F96-T:79E(&EN=&5R
M97-T(')A=&4@;VX@=&AE(&9I<G-T(&%N9"!S96-O;F0@=')A;F-H92!I<R`Q
M,RXS)2XF(S$V,#M$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,3,@86YD#0HR,#$R+"!T:&4@0V]M<&%N>2!M861E(&EN
M=&5R97-T('!A>6UE;G1S(&]F("0W+#`P,"!A;F0@)#4P+#`P,"P@<F5S<&5C
M=&EV96QY+"!A;F0@<')I;F-I<&%L('!A>6UE;G1S(&]F("0R-"PP,#`@86YD
M("0R.#@L,#`P+"!R97-P96-T:79E;'DN#0I$=7)I;F<@=&AE('-I>"!M;VYT
M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M
M<&%N>2!M861E(&EN=&5R97-T('!A>6UE;G1S(&]F("0R-RPP,#`@86YD("0Q
M,#DL,#`P+"!R97-P96-T:79E;'DL#0IA;F0@<')I;F-I<&%L('!A>6UE;G1S
M(&]F("0U-38L,#`P(&%N9"`D-38V+#`P,"P@<F5S<&5C=&EV96QY+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!C
M;VYN96-T:6]N('=I=&@@=&AE(%9,3#4@06=R965M96YT<RP-"G1H92!#;VUP
M86YY(&ES<W5E9"!T=V\@=V%R<F%N=',@=&\@5F5N='5R92!,96YD:6YG("8C
M,S@[($QE87-I;F<@5BP@3$Q#+"!A($1E;&%W87)E(&QI;6ET960@;&EA8FEL
M:71Y(&-O;7!A;GD@*"8C,30W.TQ,0S4F(S$T.#LI+`T*=VAI8V@L(&EN('1H
M92!A9V=R96=A=&4L(&AA9"!A('1O=&%L('!U="!O<'1I;VX@8V%S:"!V86QU
M92!O9B`D-S4P+#`P,"`H=&AE("8C,30W.U9,3#4@5V%R<F%N=',F(S$T.#LI
M+B!4:&4@)#<U,"PP,#`@8V%S:"!V86QU90T*;V8@=&AE(%9,3#4@5V%R<F%N
M=',@=V%S(')E8V]R9&5D(&%S(&$@8V%S:"!S971T;&5M96YT(&QI86)I;&ET
M>2!A;F0@82!C;W)R97-P;VYD:6YG(&%M;W5N="!O9B`D-S4P+#`P,"!W87,@
M<F5C;W)D960@87,@82!D:7-C;W5N=`T*;VX@=&AE(&YO=&4@<&%Y86)L92XF
M(S$V,#L@5&AE(&1I<V-O=6YT(&ES(&)E:6YG(&%C8W)E=&5D('1O(&YO;BUC
M87-H(&EN=&5R97-T(&5X<&5N<V4@;W9E<B!T:&4@=&5R;2!O9B!T:&4@;&]A
M;B!U<VEN9R!T:&4@969F96-T:79E#0II;G1E<F5S="!M971H;V0N)B,Q-C`[
M($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@
M,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@<F5C;W)D960@)#(T+#`P,"!A
M;F0@)#8S+#`P,"P@<F5S<&5C=&EV96QY+`T*;V8@;F]N+6-A<V@@:6YT97)E
M<W0@97AP96YS92!R96QA=&5D('1O('1H92!L;V%N<RXF(S$V,#M$=7)I;F<@
M=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R
M,#$R+"!T:&4@0V]M<&%N>2!R96-O<F1E9`T*)#DP+#`P,"!A;F0@)#$R-2PP
M,#`L(')E<W!E8W1I=F5L>2P@;V8@;F]N+6-A<V@@:6YT97)E<W0@97AP96YS
M92!R96QA=&5D('1O('1H92!L;V%N<RXF(S$V,#M4:&4@<F5M86EN:6YG(&)A
M;&%N8V4@;V8@=&AE(&QO86YS#0IA;6]U;G1E9"!T;R`D,3,X+#`P,"!A="!3
M97!T96UB97(@,S`L(#(P,3,L('=H:6-H(&ES(&EN8VQU9&5D(&EN('1H92!C
M=7)R96YT('!O<G1I;VX@;V8@;&]N9RUT97)M(&1E8G0L(&YE="!O9B!D96)T
M(&1I<V-O=6YT(&EN#0IT:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@8F%L86YC92!S:&5E="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@2G5N92`R.2P@,C`Q,2P@=&AE
M($-O;7!A;GD@96YT97)E9`T*:6YT;R!A(&QO86X@86YD('-E8W5R:71Y(&%G
M<F5E;65N="!A;F0@82!S=7!P;&5M96YT('1O('1H92!L;V%N(&%N9"!S96-U
M<FET>2!A9W)E96UE;G0@=VET:"!696YT=7)E($QE;F1I;F<@)B,S.#L@3&5A
M<VEN9R8C,38P.U9)+`T*26YC+B`H)B,Q-#<[5DQ,-B8C,30X.RD@=&\@8F]R
M<F]W('5P('1O(&%N(&%G9W)E9V%T92!O9B!U<"!T;R`D,BPU,#`L,#`P("AC
M;VQL96-T:79E;'DL('1H92`F(S$T-SM63$PV($%G<F5E;65N=',F(S$T.#LI
M+B8C,38P.PT*5&AE(%9,3#8@06=R965M96YT<R!P<F]V:61E9"!F;W(@82!F
M:7)S="!T<F%N8VAE(&]F("0Q+#4P,"PP,#`@86YD+"!U<&]N(&UE971I;F<@
M8V5R=&%I;B!F:6YA;F-I86P@;6EL97-T;VYE<RP@82!S96-O;F0@=')A;F-H
M90T*;V8@)#$L,#`P+#`P,"XF(S$V,#M4:&4@;&]A;B!I<R!S96-U<F5D(&)Y
M('1H92!A<W-E=',@;V8@=&AE($-O;7!A;GD@:6YC;'5D:6YG(&EN=&5L;&5C
M='5A;"!P<F]P97)T>2X@3VX@2G5N92`R.2P@,C`Q,2P@=&AE($-O;7!A;GD-
M"F)O<G)O=V5D("0Q+#4P,"PP,#`@;VX@=&AE(&9I<G-T('1R86YC:&4N($]N
M(%-E<'1E;6)E<B`S,"P@,C`Q,2P@=&AE($-O;7!A;GD@;65T('1H92!F:6YA
M;F-I86P@;6EL97-T;VYE<R!T;R!B;W)R;W<@=&AE('-E8V]N9`T*=')A;F-H
M92X@3VX@3F]V96UB97(@,3`L(#(P,3$L('1H92!#;VUP86YY(&)O<G)O=V5D
M('1H92!S96-O;F0@=')A;F-H92XF(S$V,#LF(S$V,#M4:&4@8V%S:"!I;G1E
M<F5S="!O<B`F(S$T-SMS=')E86UI;F<F(S$T.#L-"G)A=&4@;VX@=&AE(&QO
M86X@:7,@,3`E+B!);B!C;VYN96-T:6]N('=I=&@@=&AE(&9I<G-T('1R86YC
M:&4L(&9O<B!T:&4@9FER<W0@;FEN92!M;VYT:',L('1H92!#;VUP86YY(&UA
M9&4@;6]N=&AL>2!I;G1E<F5S="UO;FQY#0IP87EM96YT<R!S970@870@)#$R
M+#4P,"!T:')O=6=H($UA<F-H(#$L(#(P,3(N(%1H92!#;VUP86YY(&YO=R!M
M86ME<R!P<FEN8VEP86P@86YD(&EN=&5R97-T('!A>6UE;G1S(&]F("0U-BPR
M-3`@<&5R(&UO;G1H('1H<F]U9V@-"E-E<'1E;6)E<B`Q+"`R,#$T+B!!9&1I
M=&EO;F%L;'DL('1H92!#;VUP86YY('=I;&P@;6%K92!A(&9I;F%L(&)A;&QO
M;VX@<&%Y;65N="!O9B`D,3$V+#4P-2!O;B!397!T96UB97(@,CDL(#(P,30N
M($EN(&-O;FYE8W1I;VX-"G=I=&@@=&AE('-E8V]N9"!T<F%N8VAE+"!F;W(@
M=&AE(&9I<G-T(&YI;F4@;6]N=&AS+"!T:&4@0V]M<&%N>2!M861E(&UO;G1H
M;'D@:6YT97)E<W0M;VYL>2!P87EM96YT<R!S970@870@)#@L,S,S('1H<F]U
M9V@@075G=7-T#0HS,2P@,C`Q,BX@5&AE($-O;7!A;GD@;F]W(&UA:V5S('!R
M:6YC:7!A;"!A;F0@:6YT97)E<W0@<&%Y;65N=',@;V8@)#,W+#4P,"!P97(@
M;6]N=&@@=&AR;W5G:"!&96)R=6%R>2`Q+"`R,#$U+B!!9&1I=&EO;F%L;'DL
M('1H90T*0V]M<&%N>2!W:6QL(&UA:V4@82!F:6YA;"!B86QL;V]N('!A>6UE
M;G0@;V8@)#<W+#8W,"!O;B!&96)R=6%R>2`Q+"`R,#$U+"!R97-U;'1I;F<@
M:6X@86X@969F96-T:79E(&EN=&5R97-T(')A=&4@;V8@,3,E+B!$=7)I;F<-
M"G1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N
M9"`R,#$R+"!T:&4@0V]M<&%N>2!M861E(&EN=&5R97-T('!A>6UE;G1S(&]F
M("0U,RPP,#`@86YD("0W-2PP,#`L(')E<W!E8W1I=F5L>2!A;F0-"FUA9&4@
M<')I;F-I<&%L('!A>6UE;G1S(&]F("0R,C@L,#`P(&%N9"`D,30X+#`P,"P@
M<F5S<&5C=&EV96QY+B!$=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@4V5P
M=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>0T*;6%D92!I
M;G1E<F5S="!P87EM96YT<R!O9B`D,3$T+#`P,"!A;F0@)#$U,2PP,#`L(')E
M<W!E8W1I=F5L>2!A;F0@;6%D92!P<FEN8VEP86P@<&%Y;65N=',@;V8@)#0T
M.2PP,#`@86YD("0R-C8L,#`P+"!R97-P96-T:79E;'DN/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&-O;FYE8W1I;VX@=VET:"!T
M:&4@5DQ,-B!!9W)E96UE;G1S+`T*=&AE($-O;7!A;GD@:7-S=65D(&$@=V%R
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M(&$@<W1R:6ME('!R:6-E(&5Q=6%L('1O('1H92`Q,"UD87D@=F]L=6UE+7=E
M:6=H=&5D(&%V97)A9V4@<')I8V4@*"8C,30W.U9705`F(S$T.#LI(&5N9&EN
M9R!O;B!T:&4@=')A9&EN9R!D87D@<')I;W(@=&\@=&AE#0ID871E('1H92!#
M;VUP86YY('-A=&ES9FEE9"!T:&4@<V5C;VYD('1R86YC:&4@;6EL97-T;VYE
M<RX@3VX@4V5P=&5M8F5R(#,P+"`R,#$Q+"!T:&4@0V]M<&%N>2!M970@=&AE
M('-E8V]N9"!T<F%N8VAE(&UI;&5S=&]N97,-"F%N9"!T:&4@0V]M<&%N>2!I
M<W-U960@=&AE('-E8V]N9"!W87)R86YT(&9O<B!T:&4@<'5R8VAA<V4@;V8@
M-2PU.#8@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@870@82!P=7)C:&%S
M92!P<FEC92!P97(@<VAA<F4@97%U86P-"G1O("0Q,2XQ.#DN($]N($YO=F5M
M8F5R(#$P+"`R,#$Q+"!T:&4@0V]M<&%N>2!B;W)R;W=E9"!T:&4@<V5C;VYD
M('1R86YC:&4@86YD('1H97)E9F]R92!T:&4@0V]M<&%N>2!B96-A;64@;V)L
M:6=A=&5D('1O(&ES<W5E(&$-"G1H:7)D('=A<G)A;G0@=&\@3$Q#-B!W:71H
M(&-O=F5R86=E(&5Q=6%L('1O("0V,BPU,#`@9F]R('1H92!P=7)C:&%S92!O
M9B!A9&1I=&EO;F%L('-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K(&%T(&$@
M<W1R:6ME('!R:6-E#0IE<75A;"!T;R!T:&4@,3`M9&%Y(%9705`@96YD:6YG
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M<')I8V4-"G!E<B!S:&%R92!E<75A;"!T;R`D,3`N-C(S+B!4:&4@=&AR964@
M=V%R<F%N=',@:7-S=65D('1O($Q,0S8@87)E(&AE<F5I;F%F=&5R(&-O;&QE
M8W1I=F5L>2!R969E<G)E9"!T;R!A<R!T:&4@)B,Q-#<[5DQ,-B!787)R86YT
M<RPF(S$T.#L-"F%N9"!H860@82!T;W1A;"!P=70@;W!T:6]N(&-A<V@@=F%L
M=64L(&EN('1H92!A9V=R96=A=&4L(&]F("0Q+#(U,"PP,#`N(%1H92!#;VUP
M86YY(')E8V]R9&5D('1H92`D,2PR-3`L,#`P(&-A<V@@=F%L=64@;V8@=&AE
M(%9,3#8-"E=A<G)A;G1S(&%S(&$@8V%S:"!S971T;&5M96YT(&QI86)I;&ET
M>2!A;F0@82!C;W)R97-P;VYD:6YG(&%M;W5N="!O9B`D,2PR-3`L,#`P('=A
M<R!R96-O<F1E9"!A<R!A(&1I<V-O=6YT(&]N('1H92!N;W1E('!A>6%B;&4N
M#0I4:&4@9&ES8V]U;G0@:7,@8F5I;F<@86-C<F5T960@=&\@;F]N+6-A<V@@
M:6YT97)E<W0@97AP96YS92!O=F5R('1H92!T97)M(&]F('1H92!L;V%N('5S
M:6YG('1H92!E9F9E8W1I=F4@:6YT97)E<W0@;65T:&]D+B!&;W(-"G1H92!T
M:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R
M+"!T:&4@0V]M<&%N>2!R96-O<F1E9"`D,3`T+#`P,"!A;F0@)#DQ+#`P,"!O
M9B!N;VXM8V%S:"!I;G1E<F5S="!R96QA=&5D('1O('1H90T*;&]A;BP@<F5S
M<&5C=&EV96QY+B!&;W(@=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R
M(#,P+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!R96-O<F1E9"`D,C`T
M+#`P,"!A;F0@)#$W."PP,#`@;V8@;F]N+6-A<V@-"FEN=&5R97-T(')E;&%T
M960@=&\@=&AE(&QO86XL(')E<W!E8W1I=F5L>2X@5&AE(')E;6%I;FEN9R!B
M86QA;F-E(&]F('1H92!D:7-C;W5N="!O;B!T:&4@;&]A;B!A;6]U;G1E9"!T
M;R`D-#<T+#`P,"!A="!397!T96UB97(-"C,P+"`R,#$S+B8C,38P.U1H92!R
M96UA:6YI;F<@8F%L86YC92!O9B!T:&4@;&]A;B!A;6]U;G1E9"!T;R`D,2PS
M-C<L,#`P(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,RP@;V8@=VAI8V@@)#@R,2PP
M,#`@:7,@:6YC;'5D960@:6X-"G1H92!C=7)R96YT('!O<G1I;VX@;V8@;&]N
M9RUT97)M(&1E8G0@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8V]N
M<V]L:61A=&5D(&)A;&%N8V4@<VAE970N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($]C=&]B97(@,S`L(#(P,3(L
M('1H92!#;VUP86YY(&5N=&5R960-"FEN=&\@<F5S<&5C=&EV92!L971T97(@
M86=R965M96YT<R!W:71H(%9,3#4@86YD(%9,3#8@=&\@86UE;F0@=&AE(')E
M<&%Y;65N="!T97)M<R!O9B!I=',@;W5T<W1A;F1I;F<@9&5B="!O8FQI9V%T
M:6]N<RX@4')I;W(@=&\-"G1H92!E>&5C=71I;VX@;V8@=&AE<V4@86=R965M
M96YT<RP@3$Q#-2!A;F0@3$Q#-B!H96QD(&%N(&%G9W)E9V%T92!O9B`W.2PU
M,3<@=V%R<F%N=',@*&%D:G5S=&5D(&9O<B!T:&4@<F5V97)S92!S=&]C:R!S
M<&QI="!E9F9E8W1I=F4-"D%P<FEL(#$L(#(P,3,I('1O('!U<F-H87-E(&-O
M;6UO;B!S=&]C:RP@=VAI8V@L(&EN('1H92!A9V=R96=A=&4L(&AA9"!A('1O
M=&%L('!U="!O<'1I;VX@8V%S:"!V86QU92!O9B`D,BPP,#`L,#`P("AT:&4@
M)B,Q-#<[0V%S:`T*4V5T=&QE;65N="!,:6%B:6QI='DF(S$T.#LI(&%N9"!W
M87,@:6YC;'5D960@:6X@;&]N9R!T97)M(&QI86)I;&ET:65S(&]N('1H92!#
M;VUP86YY)B,Q-#8[<R!C;VYD96YS960@8V]N<V]L:61A=&5D(&)A;&%N8V4@
M<VAE971S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY/;B!T:&%T('-A;64@9&%Y+"!T:&4@0V]M<&%N>2!A;'-O(&5N
M=&5R960-"FEN=&\@82!S=&]C:R!P=7)C:&%S92!A9W)E96UE;G0@=VET:"!7
M5$D@9F]R('1H92!I<W-U86YC92!T;R!75$D@;V8@<VAA<F5S(&]F(&ET<R!C
M;VUM;VX@<W1O8VL@:&%V:6YG(&%N(&%G9W)E9V%T92!G<F%N="!D871E(&9A
M:7(-"FUA<FME="!V86QU92!O9B`D,RPU,#`L,#`P+"!O<B!A<'!R;WAI;6%T
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M<W5R<F5N9&5R960@;VX@3V-T;V)E<B`S,"P@,C`Q,BX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^268@870@86YY('1I
M;64@8F5T=V5E;B!/8W1O8F5R(#,P+"`R,#$R#0IT:')O=6=H(&5I=&AE<B!-
M87)C:"`S,2P@,C`Q-"!O<B!*=6QY(#,Q+"`R,#$U("AT:&4@)B,Q-#<[4V5T
M=&QE;65N="!$871E<R8C,30X.RD@5U1)('-E;&QS('1H92!3:&%R97,L('1H
M96X@=&AE('!R;V-E961S(&9R;VT-"G1H92!S86QE(&]F('1H92!3:&%R97,@
M=VEL;"!B92!A<'!L:65D(&%S(&9O;&QO=W,@*'1H92`F(S$T-SM'<F%C92!0
M97)I;V0F(S$T.#LI.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T($-A;&EB<FDL($AE;'9E=&EC82P@
M4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4[('!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#(E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*&$I/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y-B4[('!A9&1I;F<M<FEG:'0Z(#`N
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M:"!3971T;&5M96YT($QI86)I;&ET>2P@=7`@=&\@82!M87AI;75M('9A;'5E
M(&]F("0R+#`P,"PP,#`N/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXH8BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DEF(&%N9"!W:&5N('1H
M92!3:&%R97,@87)E('-O;&0@8GD@5U1)(&1U<FEN9R!T:&4@1W)A8V4@4&5R
M:6]D+"!A;GD@861D:71I;VYA;"!P<F]C965D<R!R96-E:79E9"!F<F]M('1H
M92!S86QE(&]F('1H92!3:&%R97,@:6X@97AC97-S(&]F("0R+#`P,"PP,#`@
M*&%P<')O>&EM871E;'D@)#,N,C(@<&5R('-H87)E*2!B=70@=7`@=&\@)#,L
M-3`P+#`P,"`H87!P<F]X:6UA=&5L>2`D-2XV-R!P97(@<VAA<F4I('=I;&P@
M8F4@87!P;&EE9"!B>2!75$D@87,@82!P<F5P87EM96YT(&]F(&$@<&]R=&EO
M;B!O9B!T:&4@=&AE;B!O=71S=&%N9&EN9R!D96)T(&)A<V5D(&]N('1H92!T
M97)M<R!O9B!T:&4@<W1O8VL@<'5R8VAA<V4@86=R965M96YT+CPO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*&,I/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T
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M(&5X8V5S<R!O9B`D,RPU,#`L,#`P("AA<'!R;WAI;6%T96QY("0U+C8W('!E
M<B!S:&%R92D@=7`@=&\@)#0L-3`P+#`P,"`H87!P<F]X:6UA=&5L>2`D-RXR
M."!P97(@<VAA<F4I('-H86QL(&)E('1H92!S;VQE('!O<W-E<W-I;VX@86YD
M('!R;W!E<G1Y(&]F(%=422P@:6X@86-C;W)D86YC92!W:71H('1H92!T97)M
M<R!O9B!T:&4@<W1O8VL@<'5R8VAA<V4@86=R965M96YT+CPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*&0I/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY)9B!A;F0@=VAE;B!T:&4@4VAA<F5S(&%R92!S;VQD(&)Y(%=422!D
M=7)I;F<@=&AE($=R86-E(%!E<FEO9"!F;W(@=F%L=64@:6X@97AC97-S(&]F
M("0T+#4P,"PP,#`@*&%P<')O>&EM871E;'D@)#8N-S(@<&5R('-H87)E*2P@
M-3`E(&]F('1H92!A;6]U;G0@;V8@=&AE('!R;V-E961S(&EN(&5X8V5S<R!O
M9B!T:&4@)#0L-3`P+#`P,"!W:6QL(&)E('1H92!S;VQE('!O<W-E<W-I;VX@
M86YD('!R;W!E<G1Y(&]F(%=422!A;F0@-3`E(&]F('1H92!A;6]U;G0@;V8@
M=&AE('!R;V-E961S('-H86QL(&)E(&%P<&QI960@87,@82!P<F5P87EM96YT
M(&]F(&$@<&]R=&EO;B!O9B!T:&4@=&AE;B!O=71S=&%N9&EN9R!D96)T(&)A
M<V5D(&]N('1H92!T97)M<R!O9B!T:&4@<W1O8VL@<'5R8VAA<V4@86=R965M
M96YT+CPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<"<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*&4I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY)9B!A;F0@=VAE;B!T:&4@4VAA<F5S(&%R
M92!S;VQD(&)Y(%=422!D=7)I;F<@=&AE($=R86-E(%!E<FEO9"!F;W(@=F%L
M=64@;&5S<R!T:&%N("0R+#`P,"PP,#`@*&%P<')O>&EM871E;'D@)#,N,C(@
M<&5R('-H87)E*2P@=&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%K92!A
M(&-A<V@@<&%Y;65N="!T;R!75$D@=6YT:6P@=&AE('1O=&%L($-A<V@@4V5T
M=&QE;65N="!,:6%B:6QI='D@;V8@)#(L,#`P+#`P,"!H87,@8F5E;B!S971T
M;&5D("@F(S$T-SM#87-H(%-H;W)T9F%L;"8C,30X.RDN/"]F;VYT/CPO=&0^
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
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M:&]R=&9A;&P@=VEL;"!C;VYS=6UM871E+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!/8W1O8F5R(#,P+"`R,#$R
M+"!U<&]N('1H92!I<W-U86YC90T*;V8@=&AE(%-H87)E<RP@=&AE($-O;7!A
M;GD@<F5C;W)D960@82!P<F5P87EM96YT(&]F("0R+#`P,"PP,#`@86YD("0Q
M+#4P,"PP,#`@;F5T(&%G86EN<W0@=&AE($-A<V@@4V5T=&QE;65N="!,:6%B
M:6QI='D@86YD('1H90T*;W5T<W1A;F1I;F<@;F]T97,@<&%Y86)L92P@<F5S
M<&5C=&EV96QY+"!O;B!T:&%T(&1A=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@2G5N
M92`S,"P@,C`Q,RP-"G1H92!3:&%R97,@:&%D(&YO="!Y970@8F5E;B!S;VQD
M(&)Y(%=422!A;F0@=&AE(&9A:7(@=F%L=64@;V8@=&AE(%-H87)E<R!A="!3
M97!T96UB97(@,S`L(#(P,3,@86YD($IU;F4@,S`L(#(P,3,@86UO=6YT960@
M=&\@)#$L-CDQ+#`P,`T*86YD("0Q+#4Y,BPP,#`@*&%P<')O>&EM871E;'D@
M)#(N-S0@86YD("0R+C4X('!E<B!S:&%R92DL(')E<W!E8W1I=F5L>2X@06-C
M;W)D:6YG;'DL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:6YC<F5A<V4@:6X@
M9F%I<B!M87)K970-"G9A;'5E(&]F('1H92!3:&%R97,L('1H92!#;VUP86YY
M(')E8V]R9&5D(&$@9V%I;B!O;B!T:&4@9F%I<B!V86QU92!I;B!T:&4@86UO
M=6YT(&]F("0Y.2PP,#`L('=H:6-H(&ES(&EN8VQU9&5D(&EN('1H92!A8V-O
M;7!A;GEI;F<-"F-O;F1E;G-E9"!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O
M9B!C;VUP<F5H96YS:79E(&QO<W,@9F]R('1H92!T:')E92!M;VYT:',@96YD
M960@4V5P=&5M8F5R(#,P+"`R,#$S+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@
M4VAA<F5S#0IA="!-87)C:"`S,2P@,C`Q,R!A;6]U;G1E9"!T;R`D,2PY,#$L
M,#`P("@D,RXP."!P97(@<VAA<F4I+B!!8V-O<F1I;F=L>2P@:6X@8V]N;F5C
M=&EO;B!W:71H('1H92!D96-R96%S92!I;B!F86ER(&UA<FME="!V86QU92!O
M9@T*=&AE(%-H87)E<R!F<F]M($UA<F-H(#,Q+"`R,#$S('1O(%-E<'1E;6)E
M<B`S,"P@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;W)D960@82!L;W-S(&]N('1H
M92!F86ER('9A;'5E(&EN('1H92!A;6]U;G0@;V8@)#(Q,"PP,#`L#0IW:&EC
M:"!I<R!I;F-L=61E9"!I;B!T:&4@86-C;VUP86YY:6YG(&-O;F1E;G-E9"!C
M;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!C;VUP<F5H96YS:79E(&QO<W,@
M9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<@T*,S`L(#(P,3,N
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M<FQI97(N($%S(&]F(%-E<'1E;6)E<@T*,S`L(#(P,3,L('1H92!N970@0V%S
M:"!3971T;&5M96YT($QI86)I;&ET>2!W87,@)#,P.2PP,#`L(&]F('=H:6-H
M("0Q,38L,#`P(&ES(&EN8VQU9&5D(&EN('1H92!C=7)R96YT('!O<G1I;VX@
M;V8@=&AE($-A<V@@4V5T=&QE;65N=`T*3&EA8FEL:71Y(&]N('1H92!A8V-O
M;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T
M+B!!<R!O9B!397!T96UB97(@,S`L(#(P,3,L('1H92`D,2PV.3$L,#`P(&9A
M:7(@=F%L=64@;V8@=&AE#0I3:&%R97,@:&%S(&)E96X@<F5C;W)D960@87,@
M82!P<F5P87EM96YT(&%G86EN<W0@=&AE($-A<V@@4V5T=&QE;65N="!,:6%B
M:6QI='D@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8V]N<V]L:61A
M=&5D(&)A;&%N8V4-"G-H965T+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T
M.38T9#<Q83$U-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X-F1C
M,F8S8U\U-V0W7S0Q.#E?8C8U.%\S-#DV-&0W,6$Q-38O5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^-"X@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M
M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C0N
M($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\8CX\:3Y,96=A;"!-871T97)S/"]I/CPO
M8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^26X@2G5N92`R,#`V+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A#0IW<FET
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M=7)S=65S(&QE9V%L(&%C=&EO;BP@<W5C:`T*;&5G86P@86-T:6]N('=O=6QD
M(&YO="!H879E(&$@;6%T97)I86P@861V97)S92!E9F9E8W0@;VX@:71S(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<&]S:71I;VX@;W(@<F5S=6QT<R!O9B!C
M;VUP<F5H96YS:79E(&QO<W,N#0I4:&4@0V]M<&%N>2!H87,@;F]T(&%C8W)U
M960@82!L;W-S(')E<V5R=F4@9F]R('1H:7,@;6%T=&5R+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*=6QY(#(U
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!R96-E:79E9`T*;F]T:6-E(&]F(&$@;&%W
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M:&ES(&UA='1E<BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^5&AE($-O;7!A;GDL(&9R;VT@=&EM92!T;R!T:6UE+"!I
M<R!I;G9O;'9E9`T*:6X@;&5G86P@;6%T=&5R<R!A<FES:6YG(&EN('1H92!O
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M<VEV92!L;W-S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)SX\8CX\:3Y%;7!L;WEM96YT#0I!9W)E96UE;G1S
M/"]I/CPO8CX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@
M.'!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@.'!T)SY!<R!O9B!397!T96UB97(-"C,P+"`R,#$S+"!T:&4@0V]M<&%N
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M(%-E<'1E;6)E<B`S,"P@,C`Q,RP@<&]T96YT:6%L('-E=F5R86YC92!A;6]U
M;G1E9"!T;R`D,2PX-#,L,#`P(&%N9"!A9V=R96=A=&5D(&%N;G5A;"!S86QA
M<FEE<PT*86UO=6YT960@=&\@)#$L,S$P+#`P,"X\+V9O;G0^/"]P/@T*#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CX\:3Y#;VUM
M97)C:6%L($%G<F5E;65N=',\+VD^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY/;B!*86YU87)Y(#(V+"`R,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D
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M96YT('=A<R!A;65N9&5D(&]N($9E8G)U87)Y(#(T+"`R,#`Y+"!*=6QY(#(T
M+"`R,#`Y+"!*=6YE(#$L(#(P,3`L(&%N9"!.;W9E;6)E<B`Q+"`R,#$P+B!0
M=7)S=6%N="!T;R!T:&4@86=R965M96YT+`T*=&AE($-O;7!A;GD@<')O=FED
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M070@=&AE('1I;64@;V8@=&AE<V4@,C`P.2!T<F%N<V%C=&EO;G,L(%9E=&5R
M:6-Y;BP@26YC+B!W87,@=VAO;&QY+6]W;F5D(&)Y(%)O8F5R="!"=7)L:6YG
M86UE+"!W:&\@=V%S(&%L<V\-"F$@9&ER96-T;W(@;V8@=&AE($-O;7!A;GD@
M870@=&AA="!T:6UE+B!-<BX@0G5R;&EN9V%M92!R97-I9VYE9"!F<F]M('1H
M92!#;VUP86YY)B,Q-#8[<R!B;V%R9"!O9B!D:7)E8W1O<G,@;VX@1F5B<G5A
M<GD@,3`L(#(P,3`N)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N(%-E<'1E;6)E<B`Q-2P@,C`P
M.2P@=&AE($-O;7!A;GD@96YT97)E9`T*82!C;VUM97)C:6%L(&%G<F5E;65N
M="!W:71H(%8F(S,X.TT@26YD=7-T<FEE<RP@26YC+BP@82!#86QI9F]R;FEA
M(&-O<G!O<F%T:6]N+"!T;R!M87)K970@86YD('-E;&P@8V5R=&%I;B!O9B!T
M:&4@0V]M<&%N>28C,30V.W,-"DUI8W)O8WEN)B,Q-S0[(&]V97(M=&AE+6-O
M=6YT97(@;&EQ=6ED(&%N9"!G96P@<')O9'5C=',N(%8F(S,X.TT@26YD=7-T
M<FEE<RP@26YC+B!S=6)S97%U96YT;'D@8VAA;F=E9"!I=',@;F%M92!T;R!)
M;FYO=F%C>6XL($EN8RX-"D]N($IU;F4@,2P@,C`Q,"P@4V5P=&5M8F5R(#$L
M(#(P,3`L(&%N9"!.;W9E;6)E<B`Q+"`R,#$P+"!T:&4@0V]M<&%N>2!A;65N
M9&5D('1H:7,@86=R965M96YT(&=R86YT:6YG($EN;F]V86-Y;BP@26YC+B!T
M:&4@97AC;'5S:79E#0IR:6=H="!T;R!S96QL(&-E<G1A:6X@;V8@:71S(&]V
M97(M=&AE+6-O=6YT97(@<')O9'5C=',N($%T('1H92!T:6UE(&]F('1H92`R
M,#`Y('1R86YS86-T:6]N+"!6)B,S.#M-($EN9'5S=')I97,L($EN8RX@=V%S
M('=H;VQL>2UO=VYE9`T*8GD@4F]B97)T($)U<FQI;F=A;64L('=H;R!W87,@
M86QS;R!A(&1I<F5C=&]R(&]F('1H92!#;VUP86YY(&%T('1H870@=&EM92X@
M37(N($)U<FQI;F=A;64@<F5S:6=N960@9G)O;28C,38P.W1H92!#;VUP86YY
M)B,Q-#8[<R8C,38P.V)O87)D#0IO9B!D:7)E8W1O<G,@;VX@1F5B<G5A<GD@
M,3`L(#(P,3`N("8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*=6QY(#$L(#(P,3$L(%9E=&5R
M:6-Y;BP@26YC+B!A;F0-"DEN;F]V86-Y;BP@26YC+B!B96=A;B!T;R!S:&%R
M92!P<F]F:71S('=I=&@@=&AE($-O;7!A;GD@<F5L871E9"!T;R!T:&4@5F5T
M97)I8WEN)B,Q-S0[(&%N9"!-:6-R;V-Y;B8C,3<T.R!O=F5R+71H92UC;W5N
M=&5R('-A;&5S+`T*<F5S=6QT:6YG(&EN('1H92!#;VUP86YY(')E8V5I=FEN
M9R!A8F]U="!A(#,P)2!R;WEA;'1Y(&]F(&YE="!R979E;G5E+B!$=7)I;F<@
M=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD
M(#(P,3(L#0IT:&4@0V]M<&%N>2!R96-O<F1E9"!R979E;G5E(')E;&%T960@
M=&\@=&AE<V4@86=R965M96YT<R!I;B!T:&4@86UO=6YT<R!O9B`D,2PR.#DL
M,#`P(&%N9"`D,2PR,CDL,#`P+"!R97-P96-T:79E;'DN($1U<FEN9R!T:&4-
M"G-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R
M+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!R979E;G5E(')E;&%T960@=&\@=&AE
M<V4@86=R965M96YT<R!I;B!T:&4@86UO=6YT<R!O9B`D,BPP,S`L,#`P#0IA
M;F0@)#(L,S8U+#`P,"P@<F5S<&5C=&EV96QY+B!4:&4@<F5V96YU92!I<R!R
M96-O<F1E9"!I;B!P<F]D=6-T(')E=F5N=65S(&EN('1H92!A8V-O;7!A;GEI
M;F<@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G1S#0IO9B!C;VUP
M<F5H96YS:79E(&QO<W,@+B!!="!397!T96UB97(@,S`L(#(P,3,@86YD($UA
M<F-H(#,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!H860@;W5T<W1A;F1I;F<@86-C
M;W5N=',@<F5C96EV86)L92!O9B`D.#`Q+#`P,`T*86YD("0R-C0L,#`P+"!R
M97-P96-T:79E;'DL(')E;&%T960@=&\@26YN;W9A8WEN+"!);F,N/"]P/@T*
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
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M+B!D92!2+DPN(&1E($,N5BX@*"8C,30W.TUO<F4@4&AA<FUA)B,Q-#@[*2`H
M=&AE("8C,30W.TQI8V5N<V4@06=R965M96YT)B,Q-#@[*2X-"D9O<B!A(&]N
M92UT:6UE('!A>6UE;G0@;V8@)#4P,"PP,#`L('1H92!#;VUP86YY(&=R86YT
M960@36]R92!0:&%R;6$@86X@97AC;'5S:79E(&QI8V5N<V4L('=I=&@@=&AE
M(')I9VAT('1O('-U8FQI8V5N<V4@=6YD97(@8V5R=&%I;@T*8V]N9&ET:6]N
M<R!A;F0@=VET:"!T:&4@0V]M<&%N>28C,30V.W,@8V]N<V5N="P@=&\@86QL
M(&]F('1H92!#;VUP86YY)B,Q-#8[<R!P<F]P<FEE=&%R>2!R:6=H=',@<F5L
M871E9"!T;R!C97)T86EN(&]F(&ET<R!P:&%R;6%C975T:6-A;`T*<')O9'5C
M=',@9F]R(&AU;6%N(&%P<&QI8V%T:6]N('1H870@=71I;&EZ92!T:&4@0V]M
M<&%N>28C,30V.W,@36EC<F]C>6XF(S$W-#L@5&5C:&YO;&]G>2!W:71H:6X@
M365X:6-O+B!&;W(@86X@861D:71I;VYA;"!O;F4M=&EM90T*<&%Y;65N="!O
M9B`D,RPP,#`L,#`P+"!T:&4@0V]M<&%N>2!A;'-O(&%G<F5E9"!T;R!A<'!O
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M=')A9&5M87)K<R!I;B!E>&-H86YG92!F;W(@82!P87EM96YT(&]F("0Q,#`L
M,#`P+B!4:&4@0V]M<&%N>2!H87,@=&AE(&%B:6QI='D@=&\@=&5R;6EN871E
M('1H92!A9W)E96UE;G0@:68@8V5R=&%I;B!A;FYU86P-"G!U<F-H87-E(&UI
M;FEM=6US(&%R92!N;W0@;65T+B!4:&4@=&5R;2!O9B!T:&4@86=R965M96YT
M(&ES('1W96YT>2UF:79E('EE87)S(&9R;VT@=&AE(&5F9F5C=&EV92!D871E
M(&]F($%U9W5S="`Q-2P@,C`Q,BX@5&AE('1E<FT-"F]F('1H92!,:6-E;G-E
M($%G<F5E;65N="!W:6QL(&%U=&]M871I8V%L;'D@<F5N97<@869T97(@=&AE
M('1W96YT>2UF:79E('EE87(@=&5R;2!F;W(@<W5C8V5S<VEV92!T=V\@>65A
M<B!T97)M<R!A<R!L;VYG(&%S($UO<F4-"E!H87)M82!H87,@;6%T97)I86QL
M>2!C;VUP;&EE9"!W:71H(&%N>2!A;F0@86QL(&]F('1H92!O8FQI9V%T:6]N
M<R!U;F1E<B!T:&4@3&EC96YS92!!9W)E96UE;G0L(&EN8VQU9&EN9R!B=70@
M;F]T(&QI;6ET960@=&\L(&UE971I;F<-"G1H92!M:6YI;75M('!U<F-H87-E
M(')E<75I<F5M96YT<R!S970@9F]R=&@@=&AE<F5I;BX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^061D:71I;VYA;&QY
M+"!O;B!!=6=U<W0@.2P@,C`Q,BP@=&AE#0I#;VUP86YY(&5N=&5R960@:6YT
M;R!A;B!E>&-L=7-I=F4@9&ES=')I8G5T:6]N(&%N9"!S=7!P;'D@86=R965M
M96YT('=I=&@@36]R92!0:&%R;6$@*'1H92`F(S$T-SM$:7-T<FEB=71I;VX@
M06=R965M96YT)B,Q-#@[*2X-"D9O<B!A(&]N92UT:6UE('!A>6UE;G0@;V8@
M)#$L-3`P+#`P,"P@=&AE($-O;7!A;GD@9W)A;G1E9"!-;W)E(%!H87)M82!E
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M:6YA+"!!<G5B82`F(S,X.R!#=7)A8V%O+"!"86AA;6%S+"!"87)B861O<RP@
M0F5L:7IE+"!";VQI=FEA+`T*0F]N86ER92P@0G)A>FEL+"!"<FET:7-H($=U
M>6%N82P@0G)I=&ES:"!)<VQA;F1S+"!#87EM86X@27-L86YD<RP@0VAI;&4L
M($-O;&]M8FEA+"!#=6)A+"!$;VUI;FEC82P@1&]M:6YI8V%N(%)E<'5B;&EC
M+"!%8W5A9&]R+`T*16P@4V%L=F%D;W(L($9R96YC:"!'=7EA;F$L($=R96YA
M9&$L($=U861A;'5P92P@1W5A=&5M86QA+"!(86ET:2P@2&]N9'5R87,L($IA
M;6%I8V$L($UA<G1I;FEQ=64L($YI8V%R86=U82P@4&%R86=U87DL(%!E<G4L
M(%-T+@T*0F%R=&]L;VUE+"!3="X@5FEN8V5N="`F(S,X.R!'<F5N861E<RP@
M4W5R:6YA;2P@5')I;FED860@)B,S.#L@5&]B86=O+"!4=7)K<R`F(S,X.R!#
M86EC;W,@27-L86YD<RP@57)U9W5A>2P@5F5N97IU96QA(&%N9"!6:7)G:6X-
M"DES;&%N9',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/E1H92!#;VUP86YY(&ES(')E8V]G;FEZ:6YG('1H92`D-2PQ
M,#`L,#`P#0IR96QA=&5D('1O('1H92!,:6-E;G-E($%G<F5E;65N="!A;F0@
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M86QL>2P-"G1H92!#;VUP86YY(&-A<&ET86QI>F5D("0R,30L,#`P(&]F(&ET
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M97!T96UB97(@,S`L(#(P,3,@86YD($UA<F-H(#,Q+"`R,#$S+"!T:&4@0V]M
M<&%N>2!H860@;W5T<W1A;F1I;F<@86-C;W5N=',@<F5C96EV86)L92!O9B`D
M-S$W+#`P,"!A;F0@)#4X,"PP,#`L(')E<W!E8W1I=F5L>2P-"F1U92!F<F]M
M($UO<F4@4&AA<FUA+B!$=7)I;F<@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E
M;6)E<B`S,"P@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@<F5C;V=N:7IE
M9"`D,S<X+#`P,"!A;F0@)#$X,RPP,#`L(')E<W!E8W1I=F5L>2P-"G)E;&%T
M960@=&\@=&AE(&%M;W)T:7IA=&EO;B!O9B!T:&4@=7!F<F]N="!F965S(')E
M8V5I=F5D(&EN('1H92!T<F%N<V%C=&EO;BX@1'5R:6YG('-I>"!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+`T*=&AE($-O;7!A
M;GD@<F5C;V=N:7IE9"`D-S4R+#`P,"!A;F0@)#$X,RPP,#`L(')E<W!E8W1I
M=F5L>2P@<F5L871E9"!T;R!T:&4@86UO<G1I>F%T:6]N(&]F('1H92!U<&9R
M;VYT(&9E97,@<F5C96EV960@:6X@=&AE('1R86YS86-T:6]N+@T*5&AE($-O
M;7!A;GD@<F5C;V=N:7IE<R!P<F]D=6-T('-A;&5S(&]N(&$@<V5L;"UT:')O
M=6=H(&)A<VES(&%S($UO<F4@4&AA<FUA('-E;&QS('!R;V1U8W1S('1H<F]U
M9V@@=&\@:71S(&-U<W1O;65R<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^/&D^3W1H97(@36%T=&5R<SPO:3X\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQI/E)U=&AI9V5N+"!);F,N/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>28C,30V.W,@
M=VAO;&QY(&]W;F5D('-U8G-I9&EA<GDL#0I2=71H:6=E;BP@26YC+BP@=V%S
M(&EN8V]R<&]R871E9"!I;B!T:&4@4W1A=&4@;V8@3F5V861A(&]N($IA;G5A
M<GD@,3@L(#(P,3,L(&%N9"!R96EN8V]R<&]R871E9"!F<F]M($YE=F%D82!T
M;R!$96QA=V%R92!O;B!397!T96UB97(-"C(U+"`R,#$S+B!2=71H:6=E;B!H
M87,@97-T86)L:7-H960@;V9F:6-E<R!I;B!386YT82!2;W-A+"!#86QI9F]R
M;FEA+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY/;B!!=6=U<W0@,BP@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9`T*
M:6YT;R!A('-E<&%R871I;VX@86=R965M96YT('=I=&@@4G5T:&EG96X@=&AA
M="!C;VYT86EN<R!K97D@<')O=FES:6]N<R!R96QA=&EN9R!T;R!T:&4@0V]M
M<&%N>28C,30V.W,@;VYG;VEN9R!R96QA=&EO;G-H:7`@=VET:`T*4G5T:&EG
M96XL(&%N9"!M;W)E('-P96-I9FEC86QL>2!G;W9E<FYS(&ET<R!R96QA=&EO
M;G-H:7`@=VET:"!2=71H:6=E;B!F;VQL;W=I;F<@=&AE(&-O;7!L971I;VX@
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M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/DQI8V5N<V4@86YD(%-U
M<'!L>2!!9W)E96UE;G0\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E!U<G-U86YT('1O('1H92!L
M:6-E;G-E(&%N9"!S=7!P;'D@86=R965M96YT+`T*=&AE($-O;7!A;GD@86=R
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M=&]B97(@.2P@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O($%M96YD
M;65N="!.;RX@,2!T;R!T:&4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N
M="P@=VAI8V@@86UE;F1E9`T*=&AE('-E8V]N9"!M:6QE<W1O;F4@979E;G0@
M<V5T(&9O<G1H(&EN(%-E8W1I;VX@-RXQ(&]F('1H92!L:6-E;G-E(&%N9"!S
M=7!P;'D@86=R965M96YT+B!/;B!.;W9E;6)E<B`V+"`R,#$S+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D#0II;G1O($%M96YD;65N="!.;RX@,B!T;R!T:&4@;&EC
M96YS92!A;F0@<W5P<&QY(&%G<F5E;65N="!W:71H(%)U=&AI9V5N('1O(&9U
M<G1H97(@86UE;F0@=&AE(&-E<G1A:6X@;6EL97-T;VYE(&5V96YT<R!S970@
M9F]R=&@-"FEN(%-E8W1I;VX@-RXQ(&]F('1H92!L:6-E;G-E(&%N9"!S=7!P
M;'D@86=R965M96YT(&%N9"!T;R!A;65N9"!T:&4@=&5R;7,@;V8@=&AE(&UA
M;G5F86-T=7)I;F<@97%U:7!M96YT('!U<F-H87-E<R!S970@9F]R=&@@:6X-
M"E-E8W1I;VX@-BXQ,R!O9B!T:&4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E
M;65N="X@06QL(&]T:&5R('1E<FUS(&%N9"!C;VYD:71I;VYS(&]F('1H92!L
M:6-E;G-E(&%N9"!S=7!P;'D@86=R965M96YT(')E;6%I;B!U;FUO9&EF:65D
M#0IA;F0@:6X@9G5L;"!F;W)C92!A;F0@969F96-T+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@;&EC96YS92!A
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M;65N="!O9B!A(&QI8V5N<V4@97AP86YS:6]N(&9E92!O9B`D,3`@;6EL;&EO
M;B!W:71H:6X@=&AE(&9I<G-T('1W;PT*>65A<G,@9F]L;&]W:6YG('1H92!E
M9F9E8W1I=F4@9&%T92!O9B!T:&4@86=R965M96YT(&]R+"!A9G1E<B!T:&4@
M='=O)B,Q-3`[>65A<B!P97)I;V0L('1H92!S86UE(&9E92!P;'5S(&-E<G1A
M:6X@;W5T+6]F+7!O8VME=`T*8V]S=',@=&AE($-O;7!A;GD@;6%Y(&EN8W5R
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M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^4G5T:&EG96X@=VEL;"!B92!R97%U:7)E9"!T;R!M86ME(&$-"G1O
M=&%L(&]F("0U+#`P,"PP,#`@:6X@;6EL97-T;VYE('!A>6UE;G1S('1O('1H
M92!#;VUP86YY(&9O<B!T:&4@9FER<W0@<')O9'5C="!O;FQY+"!A<R!F;VQL
M;W=S.B!U<&]N(&-O;7!L971I;VX@;V8-"E)U=&AI9V5N)B,Q-#8[<R!F:7)S
M="!M965T:6YG('=I=&@@=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES
M=')A=&EO;B`H1D1!*2!F;VQL;W=I;F<@8V]M<&QE=&EO;B!O9B!2=71H:6=E
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M8F5T=V5E;B`S)2!A;F0@,C`E(&%N9"!W:6QL(&EN8W)E87-E(&)A<V5D(&]N
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M<FEN9RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/'4^4VAA<F5D(%-E<G9I8V5S($%G<F5E;65N=#PO=3X\+W`^#0H-
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M=&AE('!R;W!O<V5D(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG+`T*:68@86YY
M('-H;W5L9"!O8V-U<BP@86YD(&%F=&5R('-U8V@@979E;G0L(%)U=&AI9V5N
M('=O=6QD(&)E8V]M92!R97-P;VYS:6)L92!F;W(@:71S(&]W;B!E>'!E;G-E
M<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/'4^4V5P87)A=&EO;B!!9W)E96UE;G0\+W4^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#
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M"F1U<FEN9R!T:&4@9FER<W0@>65A<B`H=&AE("8C,30W.VQO8VL@=7`@<&5R
M:6]D)B,Q-#@[*2!I;6UE9&EA=&5L>2!F;VQL;W=I;F<@4G5T:&EG96XF(S$T
M-CMS(&EN=&5N9&5D(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&;VQL;W=I
M;F<@=&AE(&]N92UY96%R(&QO8VL@=7`-"G!E<FEO9"P@=')A;G-F97)S(&)Y
M('1H92!#;VUP86YY(&]F('1H92!2=71H:6=E;B!S:&%R97,@:70@;W=N<R!M
M=7-T(&)E(&-O;F1U8W1E9"!W:71H('1H92!C;VYS96YT(&]F(%)U=&AI9V5N
M)B,Q-#8[<R!B;V%R9`T*;V8@9&ER96-T;W)S(&]R('=I=&AI;B!T:&4@<')E
M<V-R:6)E9"!R97%U:7)E;65N=',@9F]R('-U8V@@=')A;G-F97)S('-E="!F
M;W)T:"!I;B!T:&4@<V5P87)A=&EO;B!A9W)E96UE;G0N(%1H97-E('!R97-C
M<FEB960-"G)E<75I<F5M96YT<R!I;F-L=61E('1H870@=&AE('1R86YS9F5R
M<R!M=7-T(&)E(&EN('!R:79A=&4@<&QA8V5M96YT('1R86YS86-T:6]N<RP@
M=&AE('!U<F-H87-E('!R:6-E(&1I<V-O=6YT(&UA>2!N;W0@97AC965D#0IC
M97)T86EN('!E<F-E;G1A9V5S(&1E<&5N9&EN9R!O;B!T:&4@=')A;G-F97)E
M92P@=&AE(&%M;W5N="!O9B!S:&%R97,@=')A;G-F97)R960@:6X@82!G:79E
M;B!T<F%N<V9E<B`H;W(@<V5R:65S(&]F('1R86YS9F5R<PT*8V]M<')I<VEN
M9R!A('-I;F=L92!T<F%N<V%C=&EO;BD@;6%Y(&YO="!E>&-E960@=&AE(&=R
M96%T97(@;V8@-24@;V8@4G5T:&EG96XF(S$T-CMS(&]U='-T86YD:6YG('-H
M87)E<R!O<B`D,2XU(&UI;&QI;VX@:6X-"FYE="!P<F]C965D<R!T;R!T:&4@
M0V]M<&%N>2P@87,@=V5L;"!A<R!C97)T86EN(&]T:&5R(')E<75I<F5M96YT
M<R!S970@9F]R=&@@:6X@=&AE('-E<&%R871I;VX@86=R965M96YT+B!);B!A
M9&1I=&EO;B!T;R!T:&4-"G!R97-C<FEB960@;6%N;F5R(&9O<B!T:&4@0V]M
M<&%N>2!T;R!C;VYD=6-T('1R86YS9F5R<R!D97-C<FEB960@86)O=F4L(&EF
M+"!F;VQL;W=I;F<@82!M:6YI;75M(&]F(#0Q+C4@;6]N=&AS(&9O;&QO=VEN
M9R!T:&4-"F-L;W-I;F<@;V8@4G5T:&EG96XF(S$T-CMS(&EN:71I86P@<'5B
M;&EC(&]F9F5R:6YG(&AA=F4@;&%P<V5D('5N9&5R('1H92!S97!A<F%T:6]N
M(&%G<F5E;65N="!A;F0@=&AE($-O;7!A;GD@:&%S(&YO=`T*8V]N<W5M;6%T
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M=7-I;F<@=&AI<R!O;F4M=&EM92!R:6=H="!M=7-T(&)E(&-O;F1U8W1E9`T*
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M(&%G<F5E;65N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
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M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!S97!A
M<F%T:6]N(&%G<F5E;65N="!A;'-O('-E=',@9F]R=&@-"G1H92!M971H;V1O
M;&]G>2!F;W(@=&AE(&%L;&]C871I;VX@;V8@=&AE(&]P97)A=&EO;F%L(&%N
M9"!O9F9E<FEN9R!R96QA=&5D(&5X<&5N<V5S(&EN8W5R<F5D('!R:6]R('1O
M(&%N9"!I;B!C;VYN96-T:6]N('=I=&@@4G5T:&EG96XF(S$T-CMS#0II;G1E
M;F1E9"!I;FET:6%L('!U8FQI8R!O9F9E<FEN9R!F;W(@=VAI8V@@4G5T:&EG
M96X@:7,@<F5Q=6ER960@=&\@<F5I;6)U<G-E('1H92!#;VUP86YY+B!2=71H
M:6=E;B!W:6QL(&%L<V\@<F5I;6)U<G-E('1H92!#;VUP86YY#0IF;W(@97AP
M96YS97,@<W5C:"!A<R!S86QA<FEE<R!A;F0@8F5N969I=',@861V86YC960@
M;W(@<&%I9"!O;B!2=71H:6=E;B8C,30V.W,@8F5H86QF+"!O<B!F;W(@4G5T
M:&EG96XF(S$T-CMS(&)E;F5F:70L(&1U<FEN9PT*82!T<F%N<VET:6]N('!E
M<FEO9"!F;VQL;W=I;F<@=&AE(&-L;W-I;F<@;V8@4G5T:&EG96XF(S$T-CMS
M(&EN=&5N9&5D(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@<V5P87)A
M=&EO;B!A9W)E96UE;G0@<')O=FED97,@=&AA=`T*96%C:"!P87)T>2!W:6QL
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M9FEC97)S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@V
M9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X-F1C,F8S8U\U-V0W7S0Q.#E?8C8U.%\S
M-#DV-&0W,6$Q-38O5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^-2X@4W1O8VMH;VQD97)S)R!%
M<75I='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^-2X@4W1O8VMH;VQD97)S)R!%
M<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/CQI
M/D-O;6UO;B!3=&]C:R!)<W-U960@=&\@3F]N+45M<&QO>65E<PT*1F]R(%-E
M<G9I8V5S/"]I/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
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M<RX@1'5R:6YG#0IT:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S
M,"P@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#@L,3,Y(&%N
M9"`S+#<R."!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!R97-P96-T:79E;'DL
M(&EN#0IC;VYN96-T:6]N('=I=&@@=&AI<R!A9W)E96UE;G0N($1U<FEN9R!T
M:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P
M,3(L('1H92!#;VUP86YY(&ES<W5E9"`S."PT-#<@86YD(#$T+#,Y,B!S:&%R
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M:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R#0HS,"P@,C`Q,R!A;F0@,C`Q
M,BP@=&AE($-O;7!A;GD@<F5C;W)D960@)#(R+#`P,"!A;F0@)#(P+#`P,"!O
M9B!E>'!E;G-E(')E;&%T960@=&\@=&AI<R!A9W)E96UE;G0L(')E<W!E8W1I
M=F5L>2X@1'5R:6YG('1H92!S:7@-"FUO;G1H<R!E;F1E9"!397!T96UB97(@
M,S`L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(')E8V]R9&5D("0Q,S0L
M,#`P(&%N9"`D,3$R+#`P,"!O9B!E>'!E;G-E(')E;&%T960@=&\@=&AI<R!A
M9W)E96UE;G0L(')E<W!E8W1I=F5L>2X-"E1H92!E>'!E;G-E('=A<R!R96-O
M<F1E9"!A<R!S96QL:6YG+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E
M>'!E;G-E(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED
M871E9"!S=&%T96UE;G1S(&]F#0IC;VUP<F5H96YS:79E(&QO<W,N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($1E
M8V5M8F5R(#$W+"`R,#`Y+"!T:&4@0V]M<&%N>2!E;G1E<F5D#0II;G1O(&%N
M(&%G<F5E;65N="!W:71H(%=I;F1S;W(@0V]R<&]R871I;VXN)B,Q-C`[(%=I
M;F1S;W(@0V]R<&]R871I;VX@<')O=FED97,@9FEN86YC:6%L(&%D=FES;W)Y
M('-E<G9I8V5S('1O('1H92!#;VUP86YY+B!0=7)S=6%N=`T*=&\@=&AE(&%G
M<F5E;65N="P@=&AE($-O;7!A;GD@86=R965D('1O('!A>2!7:6YD<V]R($-O
M<G!O<F%T:6]N+"!O;B!A('%U87)T97)L>2!B87-I<RP@8V%S:"!O<B!C;VUM
M;VX@<W1O8VL@87,@8V]M<&5N<V%T:6]N(&9O<@T*<V5R=FEC97,@<')O=FED
M960N)B,Q-C`[(%1H92!#;VUP86YY(&1E=&5R;6EN960@=&AA="!T:&4@9F%I
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M=&5M8F5R(#,P+"`R,#$S+"!T:&4@0V]M<&%N>2!I<W-U960@,3(L,#DW('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VLN)B,Q-C`[1'5R:6YG('1H92!S:7@@;6]N
M=&AS(&5N9&5D#0I397!T96UB97(@,S`L(#(P,3,L('1H92!#;VUP86YY(')E
M8V]R9&5D("0T.2PP,#`@;V8@<W1O8VL@8V]M<&5N<V%T:6]N(&5X<&5N<V4@
M<F5L871E9"!T;R!T:&ES(&%G<F5E;65N="X@061D:71I;VYA;&QY+"!D=7)I
M;F<-"G1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S
M+"!T:&4@0V]M<&%N>2!A8V-R=65D("0S,"PP,#`@;V8@97AP96YS92!F;W(@
M<V5R=FEC97,@<')O=FED960@=VAI8V@@=V%S('-E='1L960@=VET:`T*<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!O;B!/8W1O8F5R(#(L(#(P,3,@*%-E92!.
M;W1E(#$P*2X@5&AE(&5X<&5N<V4@=V%S(')E8V]R9&5D(&%S('-E;&QI;F<L
M(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V4-"FEN('1H92!A
M8V-O;7!A;GEI;F<@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G1S
M(&]F(&-O;7!R96AE;G-I=F4@;&]S<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/C8N(%-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D+"!!9&1I=&EO;F%L($=E;F5R86P@1&ES8VQO<W5R97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^-BX@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!A8V-O=6YT
M<R!F;W(@<VAA<F4M8F%S960-"F%W87)D<R!E>&-H86YG960@9F]R(&5M<&QO
M>65E('-E<G9I8V5S(&%T('1H92!E<W1I;6%T960@9W)A;G0@9&%T92!F86ER
M('9A;'5E(&]F('1H92!A=V%R9"X@5&AE($-O;7!A;GD@86UO<G1I>F5S('1H
M92!F86ER('9A;'5E#0IO9B!E;7!L;WEE92!S=&]C:R!O<'1I;VYS(&]N(&$@
M<W1R86EG:'0M;&EN92!B87-I<R!O=F5R('1H92!R97%U:7-I=&4@<V5R=FEC
M92!P97)I;V0@;V8@=&AE(&%W87)D<RXF(S$V,#LF(S$V,#M#;VUP96YS871I
M;VX@97AP96YS90T*:6YC;'5D97,@=&AE(&EM<&%C="!O9B!A;B!E<W1I;6%T
M92!F;W(@9F]R9F5I='5R97,@9F]R(&%L;"!S=&]C:R!O<'1I;VYS+B!4:&4@
M97-T:6UA=&5D(&9O<F9E:71U<F4@<F%T97,@=7-E9"!D=7)I;F<@=&AE('-I
M>"!M;VYT:',-"F5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,R!R86YG960@9G)O
M;2`Q+C8S)2!T;R`T+C<W)2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^16UP;&]Y964@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@:7,@87,@9F]L;&]W<R`H:6X-"G1H;W5S86YD
M<RDZ/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`X<'0@0V%L:6)R
M:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&(^5&AR964F(S$V,#M-;VYT:',\+V(^/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M8CY3:7@@36]N=&AS/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$-B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D5N9&5D/"]B/CPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&(^16YD960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CY397!T96UB97(@,S`L/"]B/CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY397!T96UB97(@,S`L
M/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,CPO8CX\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#,V)3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D-O<W0@;V8@<V5R=FEC92!R979E;G5E/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,S`\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS-#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C4V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C8\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXT-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-C,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C<X/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,S`\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-E;&QI;F<L(&=E;F5R86P@86YD
M(&%D;6EN:7-T<F%T:79E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,C$\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXR-S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS-#D\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXT.#0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY4;W1A;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(Y-CPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,W,CPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0X,SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8X,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^070@
M4V5P=&5M8F5R(#,P+"`R,#$S+"!T:&5R92!W97)E#0IU;G)E8V]G;FEZ960@
M8V]M<&5N<V%T:6]N(&-O<W1S(&]F("0Q+#0P,RPP,#`@<F5L871E9"!T;R!S
M=&]C:R!O<'1I;VYS('=H:6-H(&%R92`@97AP96-T960@=&\@8F4@<F5C;V=N
M:7IE9"!O=F5R(&$-"G=E:6=H=&5D+6%V97)A9V4@86UO<G1I>F%T:6]N('!E
M<FEO9"!O9B`R+C4T('EE87)S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4
M:&4@0V]M<&%N>2!E<W1I;6%T960@=&AE(&9A:7(@=F%L=64-"F]F(&5M<&QO
M>65E('-T;V-K(&]P=&EO;G,@=7-I;F<@=&AE($)L86-K+5-C:&]L97,@;W!T
M:6]N('!R:6-I;F<@;6]D96PN(%1H92!F86ER('9A;'5E(&]F(&5M<&QO>65E
M('-T;V-K(&]P=&EO;G,@:7,@8F5I;F<@86UO<G1I>F5D#0IO;B!A('-T<F%I
M9VAT+6QI;F4@8F%S:7,@;W9E<B!T:&4@<F5Q=6ES:71E('-E<G9I8V4@<&5R
M:6]D<R!O9B!T:&4@<F5S<&5C=&EV92!A=V%R9',N(%1H92!F86ER('9A;'5E
M(&]F(&5M<&QO>65E('-T;V-K(&]P=&EO;G,-"G=A<R!E<W1I;6%T960@=7-I
M;F<@=&AE(&9O;&QO=VEN9R!W96EG:'1E9"UA=F5R86=E(&%S<W5M<'1I;VYS
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G9F]N=#H@.'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@<&%D9&EN9RUL969T.B`Q
M,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9"<^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`U
M+CAP="`P(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^5&AR964F(S$V,#M-
M;VYT:',\+V(^/"]P/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`@-2XX<'0@,"`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/D5N9&5D/"]B
M/CPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#4N.'!T
M(#`@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\8CY397!T96UB97(@,S`L/"]B
M/CPO<#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED)SX-"B`@("`@("`@
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#4N.'!T(#`@,#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SX\8CY3:7@@36]N=&AS/"]B/CPO<#X-"B`@("`@("`@/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#4N.'!T(#`@,#L@=&5X="UA;&EG;CH@
M8V5N=&5R)SX\8CY%;F1E9#PO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$
M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"`U+CAP="`P(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^
M/&(^4V5P=&5M8F5R(#,P+#PO8CX\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`Q
M+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`Q+CAP=#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR
M,#$R/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P
M861D:6YG+7)I9VAT.B`Q+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$S/"]B/CPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!P861D:6YG+7)I9VAT.B`Q
M+CAP=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N
M=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5X<&5C
M=&5D(&QI9F4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT
M.B`Q+CAP=#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C4N.#D@>65A<G,\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT
M.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('!A9&1I;F<M<FEG:'0Z(#$N.'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2XX-2!Y96%R<SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D9&EN9RUR:6=H=#H@,2XX<'0[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXU+C@Y('EE87)S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG
M+7)I9VAT.B`Q+CAP=#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C4N.#4@>65A<G,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T
M:#H@,S8E.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4FES:RUF<F5E(&EN
M=&5R97-T(')A=&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#$E.R!P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W
M:61T:#H@,3,E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$N-#(E/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[('=I9'1H.B`Q)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,24[('!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#$E.R!P861D
M:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I
M9'1H.B`Q,R4[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XW,R4\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#L@=VED=&@Z(#$E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,24[('!A9&1I
M;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED
M=&@Z(#$S)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+C0R)3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R!W:61T:#H@,24[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@=VED=&@Z(#$E.R!P861D:6YG+7)I9VAT.B`P+CAP
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T
M:#H@,3,E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N-S,E/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M('=I9'1H.B`Q)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$
M:79I9&5N9"!Y:65L9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXP+C`P)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C`N,#`E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,"XP,"4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXP+C`P)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY6
M;VQA=&EL:71Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C@V)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@X
M)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@V)3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@X)3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9A:7(@=F%L=64@
M;V8@;W!T:6]N<R!G<F%N=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+C$P/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG
M+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0N-S8\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@
M<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,BXQ,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXT+C<V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@97AP96-T960@
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M9&EN9VQY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!('-U;6UA<GD@;V8@
M86QL(&]P=&EO;B!A8W1I=FET>2!A<R!O9@T*4V5P=&5M8F5R(#,P+"`R,#$S
M(&%N9"!C:&%N9V5S(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!T:&5N(&5N9&5D
M(&ES('!R97-E;G1E9"!B96QO=SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)V9O;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I
M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CQB/DYU;6)E<B8C,38P.V]F/"]B/CPO9F]N=#X\8G(@
M+SX-"CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&(^4VAA<F5S(#PO8CX\+V9O;G0^/&)R("\^#0H\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQB/BAI;B!T:&]U<V%N9',I/"]B/CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY796EG:'1E9"T\+V(^
M/"]F;VYT/CQB<B`O/@T*/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY!=F5R86=E/"]B/CPO9F]N
M=#X\8G(@+SX-"CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&(^17AE<F-I<V4F(S$V,#M0<FEC93PO
M8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M/&(^5V5I9VAT960M/"]B/CPO9F]N=#X\8G(@+SX-"CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^
M079E<F%G93PO8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D-O;G1R
M86-T=6%L)B,Q-C`[(#PO8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB
M/E1E<FT\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQB/D%G9W)E9V%T93PO8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/CQB/DEN=')I;G-I8SPO8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQB/E9A;'5E/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S8E.R!P861D
M:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3W5T<W1A;F1I;F<@870@36%R8V@F(S$V
M,#LS,2P@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.3<U
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,34N,#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@
M=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY/<'1I;VYS(&=R86YT960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,S,U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+CDU/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%
M144G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3W!T:6]N<R!E>&5R8VES960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-3`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$U,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[
M('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3W!T:6]N<R!F;W)F96ET960@;W(@97AP:7)E9#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*#@Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$U
M+C@V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY/=71S=&%N9&EN9R!A="!397!T96UB97(F(S$V
M,#LS,"P@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#(R.3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$Q+C<R/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW+C0R/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V%B;&4@870@4V5P
M=&5M8F5R)B,Q-C`[,S`L(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M.#$V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,34N,S(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8N,S4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$U,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]P=&EO;G,@
M879A:6QA8FQE(&9O<B!G<F%N="!A<R!O9B!397!T96UB97(F(S$V,#LS,"P@
M,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX-#@\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!A9V=R96=A=&4@:6YT
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M,S`L(#(P,3,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/E1H92!#;VUP86YY(&1I9"!N;W0@8V%P:71A;&EZ92!A
M;GD@8V]S="!A<W-O8VEA=&5D('=I=&@@<W1O8VLM8F%S960-"F-O;7!E;G-A
M=&EO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
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M;2!E>&5R8VES960@<W1O8VL@;W!T:6]N<RX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^5&AE($-O;7!A;GD@:7-S=65S(&YE=R!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K('5P;VX@97AE<F-I<V4-"F]F('-T;V-K(&]P=&EO;G,N/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F
M,V-?-3=D-U\T,3@Y7V(V-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T
M9#<Q83$U-B]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXW+B!);F-O;64@5&%X97,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O
M;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^-RX@26YC;VUE(%1A>&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N
M=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!C
M;VUP;&5T960@82!S='5D>2!D=7)I;F<-"G1H92!Y96%R(&5N9&5D($UA<F-H
M(#,Q+"`R,#$S('1O(&%S<V5S<R!W:&5T:&5R(&$@8VAA;F=E(&EN(&-O;G1R
M;VP@:&%D(&]C8W5R<F5D(&]R('=H971H97(@=&AE<F4@:&%V92!B965N(&UU
M;'1I<&QE(&-H86YG97,@;V8-"F-O;G1R;VP@<VEN8V4@=&AE($-O;7!A;GDF
M(S$T-CMS(&9O<FUA=&EO;BXF(S$V,#L@5&AE($-O;7!A;GD@9&5T97)M:6YE
M9"P@8F%S960@;VX@=&AE(')E<W5L=',@;V8@=&AE('-T=61Y+"!N;R!C:&%N
M9V4@:6X@8V]N=')O;`T*;V-C=7)R960@9F]R('!U<G!O<V5S(&]F($EN=&5R
M;F%L(%)E=F5N=64@0V]D92!S96-T:6]N(#,X,BX@)B,Q-C`[26X@861D:71I
M;VXL('1H92!#;VUP86YY(&ES(&YO="!A=V%R92!O9B!A;GD@8VAA;F=E<R!I
M;B!O=VYE<G-H:7`-"F1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T
M96UB97(@,S`L(#(P,3,@=&AA="!W;W5L9"!R97-U;'0@:6X@82!C:&%N9V4@
M:6X@8V]N=')O;"!U;F1E<B!);G1E<FYA;"!2979E;G5E($-O9&4@<V5C=&EO
M;B`S.#(N)B,Q-C`[#0I4:&4@0V]M<&%N>2P@869T97(@8V]N<VED97)I;F<@
M86QL(&%V86EL86)L92!E=FED96YC92P@9G5L;'D@<F5S97)V960@86=A:6YS
M="!I=',@9&5F97)R960@=&%X(&%S<V5T<R!S:6YC92!I="!I<R!M;W)E(&QI
M:V5L>2!T:&%N#0IN;W0@=&AA="!S=6-H(&)E;F5F:71S('=I;&P@;F]T(&)E
M(')E86QI>F5D(&EN(&9U='5R92!P97)I;V1S+B!4:&4@0V]M<&%N>2!I;F-U
M<G)E9"!L;W-S97,@9F]R(&)O=&@@9FEN86YC:6%L(')E<&]R=&EN9R!A;F0@
M:6YC;VUE#0IT87@@<'5R<&]S97,@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D
M(%-E<'1E;6)E<B`S,"P@,C`Q,RX@06-C;W)D:6YG;'DL('1H92!#;VUP86YY
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M(&%C8V]R9&EN9VQY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
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M+"`R,#$S('1H870@87)O<V4@9&ER96-T;'D@9G)O;2!T87@@9&5D=6-T:6]N
M<R!R96QA=&5D('1O(&5Q=6ET>2!C;VUP96YS871I;VX@:6X@97AC97-S(&]F
M(&-O;7!E;G-A=&EO;@T*<F5C;V=N:7IE9"!F;W(@9FEN86YC:6%L(')E<&]R
M=&EN9R!P=7)P;W-E<RXF(S$V,#LF(S$V,#M%<75I='D@=VEL;"!B92!I;F-R
M96%S960@8GD@87!P<F]X:6UA=&5L>2`D-3,S+#`P,"!I9B!A;F0@=VAE;B!S
M=6-H(&1E9F5R<F5D#0IT87@@87-S971S(&%R92!U;'1I;6%T96QY(')E86QI
M>F5D+B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^."X@4V5G
M;65N="!A;F0@1V5O9W)A<&AI8R!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-E9VUE;G0@4F5P
M;W)T:6YG(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C@N(%-E9VUE;G0@86YD($=E;V=R87!H:6,@26YF
M;W)M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H
M92!#;VUP86YY(&=E;F5R871E<R!R979E;G5E<R!F<F]M('1I<W-U90T*8V%R
M92!P<F]D=6-T<R!W:&EC:"!A<F4@<V]L9"!I;G1O('1H92!H=6UA;B!A;F0@
M86YI;6%L(&AE86QT:&-A<F4@;6%R:V5T<R!A;F0@=&AE($-O;7!A;GD@86QS
M;R!G96YE<F%T97,@<F5V96YU97,@9G)O;2!L86)O<F%T;W)Y#0IT97-T:6YG
M('-E<G9I8V5S('=H:6-H(&%R92!P<F]V:61E9"!T;R!M961I8V%L(&1E=FEC
M92!M86YU9F%C='5R97)S+B!4:&4@0V]M<&%N>2!O<&5R871E<R!A('-I;F=L
M92!S96=M96YT(&)U<VEN97-S(&9O<B!P<F]D=6-T#0IS86QE<R!W:&EC:"!C
M;VYS:7-T<R!O9B!T:')E92!G96]G<F%P:&EC86P@<V%L97,@=&5R<FET;W)I
M97,@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z
M(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q
M,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$-B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/E1H<F5E)B,Q-C`[36]N=&AS
M/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&(^4VEX)B,Q-C`[36]N=&AS/"]B/CPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&(^16YD960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY%;F1E9#PO8CX\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^
M4V5P=&5M8F5R)B,Q-C`[,S`L/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY397!T96UB97(F(S$V,#LS,"P\+V(^
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/C(P,3(\+V(^/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`S-B4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/E4N4RX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXQ+#@Y."PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#@Y."PP,#`\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXS+#(R,2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+#DS,2PP
M,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^365X:6-O/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C$L,S4R+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PX-C(L,#`P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#<W-BPP
M,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C,L,C0P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-%145%144G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY%=7)O<&4@86YD($]T:&5R/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXV,#,L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-3`T+#`P,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$L,#$P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDP
M.2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,RPX-3,L,#`P/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-"PR-C0L,#`P
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-RPP
M,#<L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^."PP.#`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9O<B!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D(%-E<'1E;6)E<@T*,S`L(#(P,3,@86YD(#(P,3(L('1H
M92!#;VUP86YY(')E8V5I=F5D(&QI8V5N<VEN9R!R979E;G5E<R!O9B`D,SDW
M+#`P,"!A;F0@)#,W-"PP,#`L(')E<W!E8W1I=F5L>2X@4W5C:"!R979E;G5E
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M,S`L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(')E8V5I=F5D(&QI8V5N
M<VEN9PT*<F5V96YU97,@;V8@)#@S,"PP,#`@86YD("0T,#8L,#`P+"!R97-P
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M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY)B,Q
M-#8[<R!S97)V:6-E(')E=F5N=65S#0IA;6]U;G1E9"!T;R`D,C,V+#`P,"!A
M;F0@)#(V,BPP,#`@9F]R('1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M
M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DL(&%N9"!T:&4@
M0V]M<&%N>28C,30V.W,-"G-E<G9I8V4@<F5V96YU97,@86UO=6YT960@=&\@
M)#0U-"PP,#`@86YD("0T.3<L,#`P(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/CDN(%-I9VYI9FEC86YT($-U
M<W1O;65R($-O;F-E;G1R871I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4FES:W,@86YD(%5N8V5R=&%I;G1I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^.2X@4VEG;FEF:6-A;G0@0W5S=&]M97(@0V]N8V5N=')A
M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9O<B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<@T*,S`L(#(P,3,L(&]N
M92!C=7-T;VUE<B!R97!R97-E;G1E9"`S,R4@;V8@;F5T(')E=F5N=64@86YD
M(&]N92!C=7-T;VUE<B!R97!R97-E;G1E9"`S,B4@;V8@;F5T(')E=F5N=64N
M($9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D#0I397!T96UB97(@,S`L(#(P
M,3(L(&]N92!C=7-T;VUE<B!R97!R97-E;G1E9"`R-R4@;V8@;F5T(')E=F5N
M=64N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L#0HR
M,#$S+"!O;F4@8W5S=&]M97(@<F5P<F5S96YT960@,S<E(&]F(&YE="!R979E
M;G5E(&%N9"!O;F4@8W5S=&]M97(@<F5P<F5S96YT960@,C<E(&]F(&YE="!R
M979E;G5E+B!&;W(@=&AE('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R#0HS
M,"P@,C`Q,BP@;VYE(&-U<W1O;65R(')E<')E<V5N=&5D(#(X)2!O9B!N970@
M<F5V96YU92XF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^070@4V5P=&5M8F5R(#,P+"`R,#$S+"!O;F4@8W5S
M=&]M97(@<F5P<F5S96YT960-"C,S)2P@;VYE(&-U<W1O;65R(')E<')E<V5N
M=&5D(#,P)2P@86YD(&]N92!C=7-T;VUE<B!R97!R97-E;G1E9"`Q,24@;V8@
M=&AE(&YE="!A8V-O=6YT<R!R96-E:79A8FQE(&)A;&%N8V4N($%T($UA<F-H
M(#,Q+"`R,#$S+`T*;VYE(&-U<W1O;65R(')E<')E<V5N=&5D(#,T)2P@;VYE
M(&-U<W1O;65R(')E<')E<V5N=&5D(#(V)2P@86YD(&]N92!C=7-T;VUE<B!R
M97!R97-E;G1E9"`Q-24@;V8@=&AE(&YE="!A8V-O=6YT<R!R96-E:79A8FQE
M(&)A;&%N8V4N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y7V(V-3A?,S0Y-C1D-S%A,34V
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@V9&,R9C-C7S4W9#=?
M-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K<VAE971S+U-H965T,34N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXQ,"X@4W5B
M<V5Q=65N="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XQ
M,"X@4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQI/D-O;6UO;B!3=&]C:R!)<W-U960@=&\@3F]N+45M<&QO
M>65E#0I&;W(@4V5R=FEC97,\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($]C=&]B97(@,BP@,C`Q,RP@=&AE
M($-O;7!A;GD@:7-S=65D#0HQ,2PP-S`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:RP@=VET:"!A('9A;'5E(&]F("0S,"PP,#`L('1O(%=I;F1S;W(@0V]R<&]R
M871I;VX@:6X@8V]N<VED97)A=&EO;B!F;W(@<V5R=FEC97,@<')O=FED960@
M9'5R:6YG('1H90T*=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@
M,C`Q,RX@5&AE($-O;7!A;GD@<F5G:7-T97)E9"!T:&4@:7-S=6%N8V4@=6YD
M97(@:71S('!R979I;W5S;'D@9FEL960@86YD(&-U<G)E;G1L>2!E9F9E8W1I
M=F4@<VAE;&8-"G)E9VES=')A=&EO;B!S=&%T96UE;G0@;VX@1F]R;2!3+3,@
M*$9I;&4@3F\N(#,S,RTQ-S$T,3$I(&%N9"!T:&4@<F5L871E9"!P<F]S<&5C
M='5S('-U<'!L96UE;G0@9&%T960@86YD(&9I;&5D(&]N($]C=&]B97(@,BP@
M,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&D^06UE;F1M96YT<R!.
M;RX@,2!A;F0@3F\N(#(@=&\@=&AE($QI8V5N<V4@86YD(%-U<'!L>2!!9W)E
M96UE;G0-"G=I=&@@4G5T:&EG96XL($EN8RX\+VD^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/D]N($]C=&]B97(@.2P@,C`Q,RP@=&AE($-O;7!A;GD-"F5N
M=&5R960@:6YT;R!!;65N9&UE;G0@3F\N(#$@=&\@=&AE($QI8V5N<V4@86YD
M(%-U<'!L>2!!9W)E96UE;G0@=VET:"!T:&4@0V]M<&%N>28C,30V.W,@=VAO
M;&QY(&]W;F5D('-U8G-I9&EA<GDL(%)U=&AI9V5N+`T*26YC+B!0=7)S=6%N
M="!T;R!T:&4@=&5R;7,@;V8@=&AE($QI8V5N<V4@86YD(%-U<'!L>2!!9W)E
M96UE;G0L(%)U=&AI9V5N(&ES(')E<75I<F5D('1O(&UA:V4@;6EL97-T;VYE
M('!A>6UE;G1S('1O('1H90T*0V]M<&%N>2!U<&]N(&-E<G1A:6X@;6EL97-T
M;VYE(&5V96YT<RX@06UE;F1M96YT($YO+B`Q(&%M96YD960@=&AE('-E8V]N
M9"!M:6QE<W1O;F4@979E;G0@<V5T(&9O<G1H(&EN(%-E8W1I;VX@-RXQ(&]F
M#0IT:&4@3&EC96YS92!A;F0@4W5P<&QY($%G<F5E;65N="X@3VX@3F]V96UB
M97(@-BP@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O($%M96YD;65N
M="!.;RX@,B!T;R!T:&4@3&EC96YS92!A;F0-"E-U<'!L>2!!9W)E96UE;G0@
M=VET:"!2=71H:6=E;B!T;R!F=7)T:&5R(&%M96YD('1H92!C97)T86EN(&UI
M;&5S=&]N92!E=F5N=',@<V5T(&9O<G1H(&EN(%-E8W1I;VX@-RXQ(&]F('1H
M92!,:6-E;G-E(&%N9`T*4W5P<&QY($%G<F5E;65N="!A;F0@=&\@86UE;F0@
M=&AE('1E<FUS(&]F('1H92!M86YU9F%C='5R:6YG(&5Q=6EP;65N="!P=7)C
M:&%S97,@<V5T(&9O<G1H(&EN(%-E8W1I;VX@-BXQ,R!O9B!T:&4@3&EC96YS
M92!A;F0-"E-U<'!L>2!!9W)E96UE;G0N(%!U<G-U86YT('1O('1H92!T97)M
M<R!O9B!!;65N9&UE;G0@3F\N(#(L(%)U=&AI9V5N('=I;&P@8F4@<F5Q=6ER
M960@=&\@;6%K92!A('1O=&%L(&]F("0U+#`P,"PP,#`@:6X-"FUI;&5S=&]N
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M<75I<&UE;G0@9G)O;2!T:&4@0V]M<&%N>2!F;W(@87!P<F]X:6UA=&5L>2`D
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M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y7V(V
M-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K<VAE
M971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$592T%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/C$N($]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A
M;FEZ871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&
M:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CQB/CQI/D]R9V%N:7IA=&EO;CPO:3X\+V(^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
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M,C`P-BX@5&AE($-O;7!A;GDF(S$T-CMS('!R:6YC:7!A;"!O9F9I8V4@:7,@
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M870@8V%U<V4@9&ES96%S92`H<&%T:&]G96YS*2X-"E-E=F5R86P@36EC<F]C
M>6XF(S$W-#L@5&5C:&YO;&]G>2!T:7-S=64@8V%R92!P<F]D=6-T<R!A<F4@
M9&5S:6=N960@=&\@=')E870@:6YF96-T:6]N<R!A;F0@96YH86YC92!H96%L
M:6YG('=H:6QE(')E9'5C:6YG('1H92!N965D#0IF;W(@86YT:6)I;W1I8W,N
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5V97)S92!3=&]C:R!3<&QI=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&(^/&D^4F5V97)S92!3=&]C:R!3<&QI=#PO:3X\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D5F9F5C=&EV92!A<R!O9B!T:&4@;W!E;B!O9B!B=7-I;F5S<PT*;VX@
M07!R:6P@,2P@,C`Q,RP@=&AE($-O;7!A;GD@969F96-T960@82!R979E<G-E
M('-T;V-K('-P;&ET(&]F(&ET<R!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D
M,"XP,#`Q('!E<B!S:&%R92X@179E<GD@-R!S:&%R97,@;V8-"F-O;6UO;B!S
M=&]C:R!W97)E(')E8VQA<W-I9FEE9"!A;F0@8V]M8FEN960@:6YT;R!O;F4@
M<VAA<F4@;V8@8V]M;6]N('-T;V-K+B!.;R!F<F%C=&EO;F%L('-H87)E<R!W
M97)E(&ES<W5E9"!A<R!A(')E<W5L="!O9B!T:&4-"G)E=F5R<V4@<W1O8VL@
M<W!L:70N($EN<W1E860L(&5A8V@@<F5S=6QT:6YG(&9R86-T:6]N86P@<VAA
M<F4@;V8@8V]M;6]N('-T;V-K('=A<R!R;W5N9&5D('5P('1O(&]N92!W:&]L
M92!S:&%R92X@5&AE(')E=F5R<V4@<W1O8VL-"G-P;&ET(')E9'5C960@=&AE
M(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO
M;B!S=&]C:R!O=71S=&%N9&EN9R!F<F]M(#0V+#`X,"PU,3,@=&\@-BPU.#,L
M,34P+B!4:&4@=&]T86P@;G5M8F5R#0IO9B!A=71H;W)I>F5D('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@=V%S(&%L<V\@<')O<&]R=&EO;F%L;'D@9&5C<F5A
M<V5D(&)Y(&$@<F%T:6\@;V8@,3HW(&%N9"!T:&4@<&%R('9A;'5E('!E<B!S
M:&%R92!O9B!T:&4@8V]M;6]N#0IS=&]C:R!C;VYT:6YU960@=&\@8F4@)#`N
M,#`P,2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
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M:70L(&5F9F5C=&EV92!!<')I;"`Q+"`R,#$S+CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R
M97-E;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/CQB/CQI/D)A<VES(&]F(%!R
M97-E;G1A=&EO;CPO:3X\+V(^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<VEZ93H@.'!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@.'!T)SY4:&4@86-C;VUP86YY:6YG#0IU;F%U9&ET960@
M8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A
M<R!O9B!397!T96UB97(@,S`L(#(P,3,@86YD(&9O<B!T:&4@=&AR964@86YD
M('-I>"!M;VYT:',@=&AE;B!E;F1E9"!H879E#0IB965N('!R97!A<F5D(&EN
M(&%C8V]R9&%N8V4@=VET:"!T:&4@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E
M;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O9B!!;65R
M:6-A(&9O<B!I;G1E<FEM(&9I;F%N8VEA;`T*:6YF;W)M871I;VX@86YD('!U
M<G-U86YT('1O('1H92!I;G-T<G5C=&EO;G,@=&\@1F]R;2`Q,"U1(&%N9"!!
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M(&)A;&%N8V4@<VAE970@87,@;V8@4V5P=&5M8F5R(#,P+"`R,#$S+"!T:&4@
M8V]N9&5N<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&-O;7!R96AE
M;G-I=F4@;&]S<R!F;W(-"G1H92!T:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E
M9"!397!T96UB97(@,S`L(#(P,3,@86YD(#(P,3(L(&%N9"!T:&4@8V]N9&5N
M<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&-A<V@@9FQO=W,@9F]R
M('1H92!S:7@-"FUO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@86YD
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M=&AR964@86YD('-I>"!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S
M(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!R97-U;'1S#0IT
M;R!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@96YD:6YG($UA<F-H(#,Q+"`R
M,#$T(&]R(&9O<B!A;GD@9G5T=7)E(&EN=&5R:6T@<&5R:6]D+B!4:&4@8V]N
M9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%T#0I-87)C:"`S
M,2P@,C`Q,R!H87,@8F5E;B!D97)I=F5D(&9R;VT@875D:71E9"!C;VYS;VQI
M9&%T960@9FEN86YC:6%L('-T871E;65N=',N($AO=V5V97(L(&ET(&1O97,@
M;F]T(&EN8VQU9&4@86QL(&]F('1H92!I;F9O<FUA=&EO;@T*86YD(&YO=&5S
M(')E<75I<F5D(&)Y(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@
M86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC82!F;W(@
M8V]M<&QE=&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;`T*<W1A=&5M96YT<RX@
M5&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N
M8VEA;"!S=&%T96UE;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N
M('=I=&@@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"G-T871E;65N=',@
M9F]R('1H92!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$S+"!A;F0@;F]T97,@
M=&AE<F5T;R!I;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C,30V.W,@86YN=6%L
M(')E<&]R="!O;B!&;W)M(#$P+4LL('=H:6-H#0IW87,@9FEL960@=VET:"!T
M:&4@4T5#(&]N($IU;F4@,C4L(#(P,3,N/"]F;VYT/CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!L
M97,@;V8@0V]N<V]L:61A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&(^/&D^4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T:6]N/"]I
M/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
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M9"!496-H;F]L;V=I97,L($EN8RX@*"8C,30W.T%Q=6%M960F(S$T.#LI+`T*
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M57-E(&]F($5S=&EM871E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^/&D^57-E(&]F($5S
M=&EM871E<SPO:3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
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M97)I8V$@<F5Q=6ER97,@;6%N86=E;65N=`T*=&\@;6%K92!E<W1I;6%T97,@
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M-C`[=&AE('9A;'5A=&EO;B!O9B!E<75I='D@86YD(&1E<FEV871I=F4@:6YS
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M8V-O=6YT<R!R96-E:79A8FQE(&)A;&%N8V5S(&%M;W5N=&5D('1O("0Y+#`P
M,"!A;F0@)#(R+#`P,"P@=VAI8V@@87)E(&EN8VQU9&5D(&EN(&%C8V]U;G1S
M(')E8V5I=F%B;&4L(&YE="!I;@T*=&AE(&%C8V]M<&%N>6EN9R!397!T96UB
M97(@,S`L(#(P,3,@86YD($UA<F-H(#,Q+"`R,#$S(&-O;F1E;G-E9"!C;VYS
M;VQI9&%T960@8F%L86YC92!S:&5E=',L(')E<W!E8W1I=F5L>2X@5&AE(')E
M<V5R=F4@9F]R(&5X8V5S<PT*86YD(&]B<V]L971E(&EN=F5N=&]R>2!B86QA
M;F-E<R!A;6]U;G1E9"!T;R`D-S8L,#`P(&%N9"`D,3<P+#`P,"P@=VAI8V@@
M87)E(&EN8VQU9&5D(&EN(&EN=F5N=&]R:65S+"!N970@:6X@=&AE(&%C8V]M
M<&%N>6EN9R!397!T96UB97(-"C,P+"`R,#$S(&%N9"!-87)C:"`S,2P@,C`Q
M,R!C;VYD96YS960@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE971S+"!R97-P
M96-T:79E;'DN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5C;&%S<VEF:6-A=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G
M/CQB/CQI/E)E8VQA<W-I9FEC871I;VYS/"]I/CPO8CX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
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M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@<&5R(%-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\8CX\:3Y.970@3&]S<R!P97(@4VAA<F4\+VD^/"]B
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!C;VUP=71E
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M=&5D+"!W;W5L9`T*:6YC;'5D92!T:&4@9&EL=71I;VX@=&AA="!W;W5L9"!O
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M=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R("AA9&IU<W1E9"!I9B!A<'!L:6-A
M8FQE(&9O<B!T:&4@<F5V97)S92!S=&]C:R!S<&QI="!E9F9E8W1I=F4-"D%P
M<FEL(#$L(#(P,3,I(&5X8VQU9&5S('1H92!P;W1E;G1I86QL>2!D:6QU=&EV
M92!S96-U<FET:65S('-U;6UA<FEZ960@:6X@=&AE('1A8FQE(&)E;&]W(&)E
M8V%U<V4@=&AE:7(@:6YC;'5S:6]N('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS
M1"=F;VYT.B`X<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W
M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY397!T96UB97(@
M,S`L/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CXR,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$R/"]B/CPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^
M*&EN('1H;W5S86YD<RD\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V."4[
M('!A9&1I;F<M;&5F=#H@.7!T.R!T97AT+6EN9&5N=#H@+3EP=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^3W!T:6]N<R!T;R!P=7)C:&%S92!C
M;VUM;VX@<W1O8VL\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L
M,C(Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXY.#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY787)R86YT<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C$L,S$X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PU
M,CD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%)SX-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(L-30W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR+#4Q-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@86YD
M($]T:&5R($1E<FEV871I=F4@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\8CX\:3Y#;VUM;VX@4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@
M86YD($]T:&5R($1E<FEV871I=F4-"D9I;F%N8VEA;"!);G-T<G5M96YT<SPO
M:3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY(&-L
M87-S:69I97,@8V]M;6]N('-T;V-K('!U<F-H87-E#0IW87)R86YT<R!A;F0@
M;W1H97(@9G)E92!S=&%N9&EN9R!D97)I=F%T:79E(&9I;F%N8VEA;"!I;G-T
M<G5M96YT<R!A<R!E<75I='D@:68@=&AE(&-O;G1R86-T<R`H:2D@<F5Q=6ER
M92!P:'ES:6-A;"!S971T;&5M96YT(&]R#0IN970M<VAA<F4@<V5T=&QE;65N
M="P@;W(@*&EI*2!G:79E('1H92!#;VUP86YY(&$@8VAO:6-E(&]F(&YE="UC
M87-H('-E='1L96UE;G0@;W(@<V5T=&QE;65N="!I;B!I=',@;W=N('-H87)E
M<R`H<&AY<VEC86P@<V5T=&QE;65N=`T*;W(@;F5T+7-H87)E('-E='1L96UE
M;G0I+B!4:&4@0V]M<&%N>2!C;&%S<VEF:65S(&%N>2!C;VYT<F%C=',@=&AA
M="`H:2D@<F5Q=6ER92!N970M8V%S:"!S971T;&5M96YT("AI;F-L=61I;F<@
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M<R!E<75I='D-"FEN<W1R=6UE;G1S(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,RP@
M;W1H97(@=&AA;B!C97)T86EN('=A<G)A;G1S('1H870@8V]N=&%I;B!R97-E
M="!P<F]V:7-I;VYS(&%N9"!C97)T86EN('=A<G)A;G1S('1H870@<F5Q=6ER
M90T*;F5T+6-A<V@@<V5T=&QE;65N="!T:&%T('1H92!#;VUP86YY(&-L87-S
M:69I960@87,@9&5R:79A=&EV92!L:6%B:6QI=&EE<RX\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A
M;'5E(&]F($9I;F%N8VEA;"!!<W-E=',@86YD($QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@
M.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CX\:3Y&86ER(%9A;'5E
M(&]F($9I;F%N8VEA;"!!<W-E=',-"F%N9"!,:6%B:6QI=&EE<SPO:3X\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9I;F%N8VEA;"!I;G-T<G5M96YT
M<RP@:6YC;'5D:6YG(&-A<V@-"F%N9"!C87-H(&5Q=6EV86QE;G1S+"!A8V-O
M=6YT<R!R96-E:79A8FQE+"!I;G9E;G1O<GDL(&%C8V]U;G1S('!A>6%B;&4@
M86YD(&%C8W)U960@;&EA8FEL:71I97,@87)E(&-A<G)I960@870@8V]S="P@
M=VAI8V@@;6%N86=E;65N=`T*8F5L:65V97,@87!P<F]X:6UA=&5S(&9A:7(@
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M<&%I9"!T;R!T<F%N<V9E<B!A(&QI86)I;&ET>2`H86X@97AI="!P<FEC92D@
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M('1H870@;6%Y(&)E('5S960@=&\@;65A<W5R92!F86ER#0IV86QU93H\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P
M(#`@,"XU:6X[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DQE=F5L)B,Q-C`[,28C
M,38P.R8C,34Q.R!Q=6]T960-"G!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<R!F
M;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI=&EE<SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XU:6X[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DQE=F5L)B,Q-C`[
M,B8C,38P.R8C,34Q.R!Q=6]T960-"G!R:6-E<R!F;W(@<VEM:6QA<B!A<W-E
M=',@86YD(&QI86)I;&ET:65S(&EN(&%C=&EV92!M87)K971S(&]R(&EN<'5T
M<R!T:&%T(&%R92!O8G-E<G9A8FQE/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@,"`P(#`N-6EN.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P(#`@,"`P+C5I;CL@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^3&5V96PF(S$V,#LS)B,Q-C`[)B,Q-3$[
M(&EN<'5T<PT*=&AA="!A<F4@=6YO8G-E<G9A8FQE("AF;W(@97AA;7!L92P@
M8V%S:"!F;&]W(&UO9&5L:6YG(&EN<'5T<R!B87-E9"!O;B!A<W-U;7!T:6]N
M<RD\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^1FEN86YC:6%L(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@
M=F%L=64@;VX@82!R96-U<G)I;F<-"F)A<VES(&%R92!S=6UM87)I>F5D(&)E
M;&]W.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY,979E;"`S(&QI86)I;&ET:65S(&%R92!V86QU960@=7-I;F<-"G5N
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M('1H92!U;F]B<V5R=F%B;&4@:6YP=71S(&9O<B!,979E;"`S(&9A:7(@=F%L
M=64@;65A<W5R96UE;G1S(&%N9"!F86ER('9A;'5E(&-A;&-U;&%T:6]N<R!A
M<F4@=&AE(')E<W!O;G-I8FEL:71Y(&]F('1H92!#;VUP86YY)B,Q-#8[<PT*
M86-C;W5N=&EN9R!A;F0@9FEN86YC92!D97!A<G1M96YT(&%N9"!A<F4@87!P
M<F]V960@8GD@=&AE($-H:65F($9I;F%N8VEA;"!/9F9I8V5R+B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A
M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G
M=VED=&@Z(#$P,"4G/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,3`P)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\=3Y,979E;"`S(%9A;'5A=&EO;B!496-H;FEQ=65S
M/"]U/CH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^3&5V96P@,R!F:6YA;F-I86P@;&EA8FEL:71I97,@8V]N<VES=`T*
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M=&AI;B!,979E;"`S(&]F('1H92!F86ER('9A;'5E(&AI97)A<F-H>0T*87)E
M(&%N86QY>F5D(&5A8V@@<&5R:6]D(&)A<V5D(&]N(&-H86YG97,@:6X@97-T
M:6UA=&5S(&]R(&%S<W5M<'1I;VYS(&%N9"!R96-O<F1E9"!A<R!A<'!R;W!R
M:6%T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^5&AE($-O;7!A;GD@=7-E<R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I
M;VX-"G9A;'5A=&EO;B!M;V1E;"!T;R!V86QU92!,979E;"`S(&9I;F%N8VEA
M;"!L:6%B:6QI=&EE<R!A="!I;F-E<'1I;VX@86YD(&]N('-U8G-E<75E;G0@
M=F%L=6%T:6]N(&1A=&5S+B!4:&ES(&UO9&5L(&EN8V]R<&]R871E<PT*=')A
M;G-A8W1I;VX@9&5T86EL<R!S=6-H(&%S('1H92!#;VUP86YY)B,Q-#8[<R!S
M=&]C:R!P<FEC92P@8V]N=')A8W1U86P@=&5R;7,L(&UA='5R:71Y+"!R:7-K
M(&9R964@<F%T97,L(&%S('=E;&P@87,@=F]L871I;&ET>2X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
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M92!R96-O<F1E9"!I;B`F(S$T-SLH3&]S<RD@9V%I;B!D=64@=&\@8VAA;F=E
M(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV90T*:6YS=')U;65N=',F(S$T
M.#L@:6X@=&AE($-O;7!A;GDF(S$T-CMS(&-O;F1E;G-E9"!C;VYS;VQI9&%T
M960@<W1A=&5M96YT<R!O9B!C;VUP<F5H96YS:79E(&QO<W,N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%S(&]F(%-E
M<'1E;6)E<B`S,"P@,C`Q,RP@=&AE<F4@=V5R90T*;F\@=')A;G-F97)S(&EN
M(&]R(&]U="!O9B!,979E;"`S(&9R;VT@;W1H97(@;&5V96QS(&EN('1H92!F
M86ER('9A;'5E(&AI97)A<F-H>2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O
M;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/&(^/&D^4W5B<V5Q=65N="!%=F5N=',\+VD^/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@.'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-86YA9V5M96YT(&AA<R!E=F%L=6%T
M960@<W5B<V5Q=65N="!E=F5N=',-"F]R('1R86YS86-T:6]N<R!O8V-U<G)I
M;F<@=&AR;W5G:"!T:&4@9&%T92!T:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E
M9"!F:6YA;F-I86P@<W1A=&5M96YT<R!W97)E(&ES<W5E9"`H3F]T92`Q,"DN
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#AP="<^/&(^/&D^4F5C96YT#0I!8V-O=6YT:6YG(%!R;VYO=6YC
M96UE;G1S/"]I/CPO8CX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/DEN($IU;F4@,C`Q
M,2P-"G1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@
M*"8C,30W.T9!4T(F(S$T.#LI(&ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D
M<R!5<&1A=&4@*"8C,30W.T%3528C,30X.RD@3F\N(#(P,3$M,#4L#0H\:3Y#
M;VUP<F5H96YS:79E($EN8V]M92`H5&]P:6,@,C(P*3H@4')E<V5N=&%T:6]N
M(&]F($-O;7!R96AE;G-I=F4@26YC;VUE/"]I/BX@5&AI<R!G=6ED86YC92!I
M;7!R;W9E<R!T:&4@8V]M<&%R86)I;&ET>2P@8V]N<VES=&5N8WD-"F%N9"!T
M<F%N<W!A<F5N8WD@;V8@9FEN86YC:6%L(')E<&]R=&EN9R!A;F0@:6YC<F5A
M<V5S('1H92!P<F]M:6YE;F-E(&]F(&ET96US(')E<&]R=&5D(&EN(&]T:&5R
M(&-O;7!R96AE;G-I=F4@:6YC;VUE+B8C,38P.R!);@T*1&5C96UB97(@,C`Q
M,2P@=&AE($9!4T(@:7-S=65D($%352!.;RX@,C`Q,2TQ,BP@/&D^1&5F97)R
M86P@;V8@=&AE($5F9F5C=&EV92!$871E(&9O<B!!;65N9&UE;G1S('1O('1H
M92!0<F5S96YT871I;VX@;V8@4F5C;&%S<VEF:6-A=&EO;G,-"F]F($ET96US
M($]U="!O9B!!8V-U;75L871E9"!/=&AE<B!#;VUP<F5H96YS:79E($EN8V]M
M92!I;B!!4U4@,C`Q,2TP-3PO:3XN($%352`R,#$Q+3$R(&1E9F5R<R!T:&4@
M<F5Q=6ER96UE;G0@=&AA="!C;VUP86YI97,@<')E<V5N=`T*<F5C;&%S<VEF
M:6-A=&EO;B!A9&IU<W1M96YT<R!F;W(@96%C:"!C;VUP;VYE;G0@;V8@06-C
M=6UU;&%T960@3W1H97(@0V]M<')E:&5N<VEV92!);F-O;64@:6X@8F]T:"!N
M970@:6YC;VUE(&%N9"!/=&AE<B!#;VUP<F5H96YS:79E#0I);F-O;64@;VX@
M=&AE(&9A8V4@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S+B!!;&P@;W1H
M97(@<F5Q=6ER96UE;G1S(&EN($%352!.;RX@,C`Q,2TP-2!A<F4@;F]T(&%F
M9F5C=&5D(&)Y($%352!.;RX@,C`Q,2TQ,BP-"FEN8VQU9&EN9R!T:&4@<F5Q
M=6ER96UE;G0@=&\@<F5P;W)T(&-O;7!R96AE;G-I=F4@:6YC;VUE(&5I=&AE
M<B!I;B!A('-I;F=L92!C;VYT:6YU;W5S(&9I;F%N8VEA;"!S=&%T96UE;G0@
M;W(@:6X@='=O('-E<&%R871E#0IB=70@8V]N<V5C=71I=F4@9FEN86YC:6%L
M('-T871E;65N=',N)B,Q-C`[(%=H:6QE('1H92!A9&]P=&EO;B!O9B!T:&ES
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M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P.SPO
M9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#!P="`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M="<^5&AE($9!4T(-"FAA<R!I<W-U960@05-5($YO+B`R,#$S+3$Q+"`\:3Y)
M;F-O;64@5&%X97,@*%1O<&EC(#<T,"DZ(%!R97-E;G1A=&EO;B!O9B!A;B!5
M;G)E8V]G;FEZ960@5&%X($)E;F5F:70@5VAE;B!A($YE="!/<&5R871I;F<@
M3&]S<PT*0V%R<GEF;W)W87)D+"!A(%-I;6EL87(@5&%X($QO<W,L(&]R(&$@
M5&%X($-R961I="!#87)R>69O<G=A<F0@17AI<W1S/"]I/B`H82!C;VYS96YS
M=7,@;V8@=&AE($9!4T(@16UE<F=I;F<@27-S=65S(%1A<VL@1F]R8V4I+@T*
M5&AE(&%M96YD;65N=',@:6X@=&AI<R!!4U4@<W1A=&4@=&AA="!A;B!U;G)E
M8V]G;FEZ960@=&%X(&)E;F5F:70L(&]R(&$@<&]R=&EO;B!O9B!A;B!U;G)E
M8V]G;FEZ960@=&%X(&)E;F5F:70L('-H;W5L9"!B92!P<F5S96YT960-"FEN
M('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!A<R!A(')E9'5C=&EO;B!T;R!A
M(&1E9F5R<F5D('1A>"!A<W-E="!F;W(@82!N970@;W!E<F%T:6YG(&QO<W,@
M8V%R<GEF;W)W87)D+"!A('-I;6EL87(@=&%X(&QO<W,L#0IO<B!A('1A>"!C
M<F5D:70@8V%R<GEF;W)W87)D+"!E>&-E<'0@87,@9F]L;&]W<RX@5&\@=&AE
M(&5X=&5N="!A(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F0L(&$@
M<VEM:6QA<B!T87@@;&]S<RP@;W(@82!T87@-"F-R961I="!C87)R>69O<G=A
M<F0@:7,@;F]T(&%V86EL86)L92!A="!T:&4@<F5P;W)T:6YG(&1A=&4@=6YD
M97(@=&AE('1A>"!L87<@;V8@=&AE(&%P<&QI8V%B;&4@:G5R:7-D:6-T:6]N
M('1O('-E='1L92!A;GD@861D:71I;VYA;`T*:6YC;VUE('1A>&5S('1H870@
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M;&]R.B!B;&%C:R<^1&5C96UB97(-"C$U+"`R,#$S/"]F;VYT/BX@1F]R(&YO
M;G!U8FQI8R!E;G1I=&EE<RP@=&AE(&%M96YD;65N=',@87)E(&5F9F5C=&EV
M92!F;W(@9FES8V%L('EE87)S+"!A;F0@:6YT97)I;2!P97)I;V1S('=I=&AI
M;B!T:&]S92!Y96%R<RP-"F)E9VEN;FEN9R!A9G1E<B`\9F]N="!S='EL93TS
M1"=C;VQO<CH@8FQA8VLG/D1E8V5M8F5R(#$U+"`R,#$T/"]F;VYT/BX@16%R
M;'D@861O<'1I;VX@:7,@<&5R;6ET=&5D+B!4:&4@86UE;F1M96YT<R!S:&]U
M;&0@8F4@87!P;&EE9`T*<')O<W!E8W1I=F5L>2!T;R!A;&P@=6YR96-O9VYI
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
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M:6]N+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C$N($]R
M9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI
M9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N
M=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R!E
M>&-L=61E9"!F<F]M(&-O;7!U=&%T:6]N(&]F(&YE="!L;W-S('!E<B!S:&%R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP
M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$-B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/E-E<'1E;6)E<B`S,"P\+V(^/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB
M/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXH:6X@=&AO=7-A
M;F1S*3PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%
M145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#8X)3L@<&%D9&EN9RUL
M969T.B`Y<'0[('1E>'0M:6YD96YT.B`M.7!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY/<'1I;VYS('1O('!U<F-H87-E(&-O;6UO;B!S=&]C
M:SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PR,CD\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDX.#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#L@=&5X
M="UI;F1E;G0Z("TY<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E=A<G)A;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,2PS,3@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#4R.3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,BPU-#<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L-3$W
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y
M7V(V-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K
M<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SXS+B!#;VYD96YS960@0V]N<V]L:61A=&5D($)A;&%N8V4@
M4VAE971S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0F%L86YC92!3:&5E="!296QA=&5D($1I<V-L
M;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@.'!T($-A;&EB<FDL($AE;'9E=&EC
M82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&(^4V5P=&5M8F5R(#,P+#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/DUA<F-H(#,Q
M+#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#8X)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4F%W(&UA
M=&5R:6%L<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S
M)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C4Y,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@S-3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&:6YI<VAE
M9"!G;V]D<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,C,T/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,S(W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%
M12<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX,C4\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L
M,38R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY,97-S.B!I;G9E;G1O<GD@86QL;W=A;F-E<SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#<V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q-S`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%
M145%12<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-S0Y/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.3DR/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y7V(V-3A?
M,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@V
M9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K<VAE971S
M+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5(2#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SXV+B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*%1A8FQE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"P@061D:71I;VYA;"!'96YE<F%L($1I<V-L
M;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G9F]N=#H@.'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$-B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/E1H<F5E)B,Q-C`[36]N
M=&AS/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0V('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&(^4VEX($UO;G1H<SPO8CX\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\
M8CY%;F1E9#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$-B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D5N9&5D/"]B/CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^4V5P=&5M8F5R(#,P
M+#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&(^4V5P=&5M8F5R(#,P+#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/C(P,3(\+V(^/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/C(P,3,\
M+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S-B4[('!A9&1I
M;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY#;W-T(&]F('-E<G9I8V4@<F5V96YU93PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,P
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,S0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU-CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C8V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#4\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW.#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,3,P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3
M96QL:6YG+"!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C(Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C<U/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,S0Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#@T/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@<W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXR.38\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXS-S(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXT.#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXV.#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"UA=F5R86=E(&%S<W5M<'1I;VYS(&]F(&9A:7(@=F%L=64@;V8@
M96UP;&]Y964@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)V9O;G0Z(#AP="!#86QI8G)I+"!(96QV971I8V$L(%-A
M;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[('!A9&1I
M;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60G/@T*("`@("`@("`\<"!S='EL93TS1"=F;VYT
M.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`@-2XX<'0@,"`P.R!T97AT+6%L:6=N.B!C96YT97(G/CQB/E1H
M<F5E)B,Q-C`[36]N=&AS/"]B/CPO<#X-"B`@("`@("`@/'`@<W1Y;&4],T0G
M9F]N=#H@.'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P(#4N.'!T(#`@,#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\
M8CY%;F1E9#PO8CX\+W`^#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"`U+CAP="`P(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^4V5P=&5M
M8F5R(#,P+#PO8CX\+W`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9"<^
M#0H@("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`U+CAP="`P(#`[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^/&(^4VEX($UO;G1H<SPO8CX\+W`^#0H@
M("`@("`@(#QP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`U+CAP="`P(#`[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^/&(^16YD960\+V(^/"]P/@T*("`@("`@("`\
M<"!S='EL93TS1"=F;VYT.B`X<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@-2XX<'0@,"`P.R!T97AT+6%L:6=N
M.B!C96YT97(G/CQB/E-E<'1E;6)E<B`S,"P\+V(^/"]P/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+7)I9VAT.B`P+CAP=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N
M=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@,2XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,2XX<'0[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@<&%D9&EN9RUR:6=H=#H@,2XX<'0[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,SPO
M8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H
M=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@<&%D9&EN
M9RUR:6=H=#H@,2XX<'0[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M;&5F=#H@,3!P=#L@
M=&5X="UI;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY%>'!E8W1E9"!L:69E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@<&%D
M9&EN9RUR:6=H=#H@,2XX<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C@Y('EE87)S/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I
M;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!P861D:6YG+7)I9VAT.B`Q+CAP=#L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N.#4@
M>65A<G,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M<FEG:'0Z
M(#$N.'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^-2XX.2!Y96%R<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@<&%D9&EN9RUR:6=H=#H@,2XX<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C@U('EE87)S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VED=&@Z(#,V)3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)I
M<VLM9G)E92!I;G1E<F5S="!R871E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T
M:#H@,24[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@=VED=&@Z(#$S)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ+C0R)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!W:61T:#H@,24[('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#$E.R!P861D:6YG
M+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H
M.B`Q)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!W:61T:#H@,3,E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C`N-S,E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@,24[('!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z
M(#$E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[('=I9'1H.B`Q,R4[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,2XT,B4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@=VED=&@Z(#$E.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`Q)3L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@
M,24[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M('1O<#L@=VED=&@Z(#$S)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP
M+C<S)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!W:61T:#H@,24[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6QE9G0Z(#$P
M<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^1&EV:61E;F0@>6EE;&0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT
M.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,"XP,"4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H
M=#H@,"XX<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXP+C`P)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT
M.B`P+CAP=#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C`N,#`E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P
M+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,"XP,"4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6QE9G0Z(#$P
M<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5F]L871I;&ET>3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXX-B4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXX."4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXX-B4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXX."4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&
M86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I
M9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BXQ,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P
M861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT
M+C<V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P
M+CAP=#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(N,3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT.B`P+CAP=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('!A9&1I
M;F<M<FEG:'0Z(#`N.'!T.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-"XW-CPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!P861D:6YG+7)I9VAT
M.B`P+CAP=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&]P=&EO;B!A8W1I=FET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#AP="!#86QI8G)I
M+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/DYU
M;6)E<B8C,38P.V]F/"]B/CPO9F]N=#X\8G(@+SX-"CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^
M4VAA<F5S(#PO8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/BAI;B!T
M:&]U<V%N9',I/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CY796EG:'1E9"T\+V(^/"]F;VYT/CQB<B`O/@T*/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CY!=F5R86=E/"]B/CPO9F]N=#X\8G(@+SX-"CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&(^17AE<F-I<V4F(S$V,#M0<FEC93PO8CX\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^5V5I9VAT960M/"]B/CPO
M9F]N=#X\8G(@+SX-"CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^079E<F%G93PO8CX\+V9O;G0^
M/&)R("\^#0H\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQB/D-O;G1R86-T=6%L)B,Q-C`[(#PO8CX\
M+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/E1E<FT\+V(^/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D%G9W)E9V%T
M93PO8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/DEN=')I;G-I8SPO
M8CX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/E9A;'5E/"]B/CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,S8E.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3W5T<W1A;F1I;F<@870@36%R8V@F(S$V,#LS,2P@,C`Q,SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^.3<U/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,34N
M,#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS(&=R86YT
M960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,S,U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR+CDU/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-%145%144G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3W!T:6]N<R!E>&5R8VES
M960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-3`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$U,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3W!T:6]N<R!F;W)F
M96ET960@;W(@97AP:7)E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#@Q/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$U+C@V/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T5%145%12<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/
M=71S=&%N9&EN9R!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXQ+#(R.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C$Q+C<R/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXW+C0R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-3`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P
M<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^17AE<F-I<V%B;&4@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P
M,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.#$V/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,34N,S(\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C8N,S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$U,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C145%145%)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D]P=&EO;G,@879A:6QA8FQE(&9O<B!G<F%N
M="!A<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXX-#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C@N(%-E
M9VUE;G0@86YD($=E;V=R87!H:6,@26YF;W)M871I;VX@*%1A8FQE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M96=M96YT(%)E<&]R=&EN9R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396=M96YT(&%N9"!'96]G<F%P
M:&EC($EN9F]R;6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y
M;&4],T0G9F]N=#H@.'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I
M9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^5&AR964F
M(S$V,#M-;VYT:',\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY3:7@F(S$V,#M-;VYT:',\
M+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\8CY%;F1E9#PO8CX\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D5N
M9&5D/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CY397!T96UB97(F(S$V,#LS,"P\+V(^/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/E-E<'1E;6)E<B8C
M,38P.S,P+#PO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,CPO8CX\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,SPO8CX\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q
M,CPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C145%145%
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#,V)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^52Y3+CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L.#DX+#`P,#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C$L.#DX+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,L,C(Q+#`P,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C,L.3,Q+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY-97AI8V\\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PS-3(L,#`P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#@V,BPP
M,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(L-S<V+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,RPR-#`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T5%145%12<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5U<F]P92!A;F0@3W1H97(\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`X<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C8P,RPP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,#0L
M,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PP,3`L,#`P/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#AP="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^.3`Y+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+#@U
M,RPP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXT+#(V-"PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXW+#`P-RPP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@.'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXX+#`X,"PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P131,04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^,2X@4&]T96YT
M:6%L;'D@1&EL=71I=F4@4V5C=7)I=&5S(%1A8FQE("A$971A:6QS*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-E
M8W5R:71I97,@97AC;'5D960@9G)O;2!C;VUP=71A=&EO;B!O9B!B87-I8R!N
M970@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L-30W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-3$W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-E8W5R:71I97,@
M97AC;'5D960@9G)O;2!C;VUP=71A=&EO;B!O9B!B87-I8R!N970@;&]S<R!P
M97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C(Y
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDX."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@<V5C=7)I=&EE<R!E>&-L=61E9"!F<F]M(&-O
M;7!U=&%T:6]N(&]F(&)A<VEC(&YE="!L;W-S('!E<B!S:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,3@L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,CDL,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P131!04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^,2X@3W)G86YI>F%T:6]N(&%N9"!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$YA
M<G)A=&EV92D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N<V]L
M:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE
M;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R('5N8V]L;&5C=&EB;&4@86-C
M;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S97)V92!F;W(@97AC97-S(&%N9"!O8G-O;&5T92!I
M;G9E;G1O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.#9D8S)F,V-?-3=D-U\T,3@Y7V(V-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X
M7S,T.38T9#<Q83$U-B]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4T1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SXR+B!,:7%U:61I='D@86YD
M($9I;F%N8VEA;"!#;VYD:71I;VX@*$YA<G)A=&EV92D@*%531"`D*3QB<CY)
M;B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQI<75I9&ET>2!!;F0@1FEN86YC:6%L($-O;F1I=&EO;CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=O<FMI;F<@
M8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#$W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-BPT,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%5E!!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SXS+B!);G9E;G1O
M<FEE<R`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GDL(&=R;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@R-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PQ-C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,Z
M(&EN=F5N=&]R>2!A;&QO=V%N8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,L(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DR/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y287<@36%T97)I86QS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y+"!G
M<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M:6YI<VAE9"!';V]D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=F5N=&]R>2P@9W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%1T=!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXS
M+B!.;W1E<R!087EA8FQE("A.87)R871I=F4I("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N
M+6-A<V@@:6YT97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,S`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y63$PU($%G<F5E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T('!A>6UE
M;G1S(&UA9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<FEN8VEP86P@<&%Y;65N=',@;6%D93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9,3#4@5V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H(&EN
M=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F]T92!P87EA8FQE(&)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y63$PV($%G<F5E;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T
M('!A>6UE;G1S(&UA9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!P87EM96YT<R!M861E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9,3#8@5V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO
M;BUC87-H(&EN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E('!A>6%B;&4@8F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M:7-C;W5N="!O;B!L;V%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#0W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%6EE!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXT+B!#
M;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H3F%R<F%T:79E*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&]T96YT:6%L('-E=F5R86YC92!U;F1E<B!C97)T86EN(&5M
M<&QO>6UE;G0@86=R965M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#@T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$L.#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T960@86YN=6%L('-A
M;&%R:65S('5N9&5R(&-E<G1A:6X@96UP;&]Y;65N="!A9W)E96UE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,Q,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]D=6-T(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L-#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPX.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<L-C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YN;W9A8WEN/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V1U8W0@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L,#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPS-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;W)E(%!H87)M83PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I
M=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]D=6-T(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y7V(V
M-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K<VAE
M971S+U-H965T,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+54%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/C4N(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$971A:6QS($YA
M<G)A=&EV92D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R
M92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#DT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061V;V-O<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@<V5R
M=FEC97,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M."PQ,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#<R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,X+#0T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T+#,Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@<V5R
M=FEC97,L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y7:6YD<V]R($-O<G!O<F%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&9O<B!S97)V
M:6-E<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#`Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R('-E<G9I8V5S+"!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14Q/044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^-BX@4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS*2`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#@S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@
M;V8@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E;&QI;F<@9V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S0Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%3$-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SXV+B!/<'1I;VX@07-S
M=6UP=&EO;G,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D+"!!9&1I=&EO;F%L($=E;F5R86P@1&ES
M8VQO<W5R97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,@,3`@;6]N=&AS(#(P(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-2!Y96%R<R`Q,"!M;VYT:',@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,@,3`@;6]N=&AS
M(#(P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-2!Y96%R<R`Q,"!M;VYT:',@-B!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@
M:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XT,B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C<S)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$N-#(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XW,R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED96YD('EI96QD/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&]P=&EO;G,@
M9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0N-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-"XW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?.#9D8S)F,V-?-3=D-U\T,3@Y7V(V-3A?,S0Y-C1D-S%A
M,34V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@V9&,R9C-C7S4W
M9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-B]7;W)K<VAE971S+U-H965T,S`N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$532$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C8N
M($]P=&EO;G,@3W5T<W1A;F1I;F<@*$1E=&%I;',I("A54T0@)"D\8G(^26X@
M5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D]P=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG(&%T(&)E9VEN;FEN9R!O9B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S-2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F]R9F5I=&5D(&]R(&5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#@Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD:6YG(&%T(&5N9"!O9B!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C(Y+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AE<F-I<V%B;&4@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!A=F%I;&%B;&4@9F]R
M(&=R86YT+"!E;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@T."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W5T<W1A;F1I;F<@870@8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2XP.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+CDU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960@
M;W(@97AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-2XX-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XW,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V%B;&4@870@
M96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-2XS,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!!=F5R86=E($-O;G1R86-T=6%L
M(%1E<FT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]U='-T86YD:6YG(&%T(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S(#4@;6]N=&AS(#$@9&%Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES86)L92!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-B!Y96%R<R`T(&UO;G1H<R`V(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^06=G<F5G871E($EN=')I;G-I8R!686QU93PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@870@96YD
M(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES86)L92!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4$E!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SXV+B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$YA<G)A=&EV92D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96-O
M9VYI>F5D(&-O;7!E;G-A=&EO;B!C;W-T<R!R96QA=&5D('1O('-T;V-K(&]P
M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PT,#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D+6%V97)A9V4@86UO<G1I>F%T:6]N('!E<FEO9"!O9B!U;G)E
M8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,B!Y96%R<R`V(&UO;G1H<R`Q-"!D87ES/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%<W1I;6%T960@9F]R9F5I='5R92!R871E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2XV,R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!F;W)F96ET
M=7)E(')A=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C<W
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#9D
M8S)F,V-?-3=D-U\T,3@Y7V(V-3A?,S0Y-C1D-S%A,34V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S@V9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T
M.38T9#<Q83$U-B]7;W)K<VAE971S+U-H965T,S(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,
M3T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/C@N(%-E9VUE;G0@86YD($=E
M;V=R87!H:6,@26YF;W)M871I;VX@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y386QE<R!R979E;G5E(&9R;VT@9V5O9W)A<&AI8V%L('1E<G)I=&]R
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L.#4S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-"PR-C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`W+#`P-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,#@P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3+CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L97,@<F5V96YU
M92!F<F]M(&=E;V=R87!H:6-A;"!T97)R:71O<FEE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PX.3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX.3@L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,C$L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPY,S$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y-97AI8V\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-A;&5S(')E=F5N=64@9G)O;2!G96]G<F%P:&EC86P@=&5R
M<FET;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S4R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L.#8R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-S<V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C0P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^175R;W!E(&%N9"!/
M=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L
M97,@<F5V96YU92!F<F]M(&=E;V=R87!H:6-A;"!T97)R:71O<FEE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,#,L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,#0L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#`Q,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#DP.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2DA!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SXX+B!396=M96YT(&%N9"!'96]G<F%P:&EC($EN9F]R;6%T:6]N("A.87)R
M871I=F4I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY396=M96YT(%)E<&]R=&EN
M9R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y397)V:6-E(')E=F5N=65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Y-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O9'5C
M="!L:6-E;G-I;F<@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#@S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#`V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%*04<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^.2X@4VEG;FEF:6-A;G0@0W5S=&]M97(@0V]N8V5N=')A=&EO
M;G,@*$YA<G)A=&EV92D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]N92!#=7-T;VUE<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:6=N:69I8V%N="!C=7-T;VUE<B!C;VYC96YT<F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RXP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RXP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S(%)E8V5I=F%B;&4\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I
M8V%N="!C=7-T;VUE<B!C;VYC96YT<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S,N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5C;VYD($-U
M<W1O;65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY2979E;G5E<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT(&-U<W1O;65R(&-O;F-E
M;G1R871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT<R!296-E:79A8FQE/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG
M;FEF:6-A;G0@8W5S=&]M97(@8V]N8V5N=')A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H:7)D
M($-U<W1O;65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT<R!296-E:79A8FQE/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@
M8W5S=&]M97(@8V]N8V5N=')A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M/3-$(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S0N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S@V
F9&,R9C-C7S4W9#=?-#$X.5]B-C4X7S,T.38T9#<Q83$U-BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>91</ContextCount>
  <ElementCount>165</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - 1. Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>1. Organization and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - 2. Liquidity and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/LiquidityAndFinancialCondition</Role>
      <ShortName>2. Liquidity and Financial Condition</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 3. Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>3. Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 4. Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/CommitmentsAndContingencies</Role>
      <ShortName>4. Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 5. Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/StockholdersEquity</Role>
      <ShortName>5. Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 6. Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/Stock-BasedCompensation</Role>
      <ShortName>6. Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 7. Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/IncomeTaxes</Role>
      <ShortName>7. Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 8. Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SegmentAndGeographicInformation</Role>
      <ShortName>8. Segment and Geographic Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 9. Significant Customer Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SignificantCustomerConcentrations</Role>
      <ShortName>9. Significant Customer Concentrations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 10. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SubsequentEvents</Role>
      <ShortName>10. Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>1. Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>1. Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 3. Condensed Consolidated Balance Sheets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/CondensedConsolidatedBalanceSheetsTables</Role>
      <ShortName>3. Condensed Consolidated Balance Sheets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 6. Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/Stock-BasedCompensationTables</Role>
      <ShortName>6. Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 8. Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SegmentAndGeographicInformationTables</Role>
      <ShortName>8. Segment and Geographic Information (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 1. Potentially Dilutive Securites Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/PotentiallyDilutiveSecuritesTableDetails</Role>
      <ShortName>1. Potentially Dilutive Securites Table (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 1. Organization and Summary of Significant Accounting Policies (Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrative</Role>
      <ShortName>1. Organization and Summary of Significant Accounting Policies (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 2. Liquidity and Financial Condition (Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/LiquidityAndFinancialConditionNarrative</Role>
      <ShortName>2. Liquidity and Financial Condition (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 3. Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/InventoriesDetails</Role>
      <ShortName>3. Inventories (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 3. Notes Payable (Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://oculus.com/role/NotesPayableNarrative</Role>
      <ShortName>3. Notes Payable (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 4. Commitments and Contingencies (Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/CommitmentsAndContingenciesNarrative</Role>
      <ShortName>4. Commitments and Contingencies (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 5. Stockholders' Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>5. Stockholders' Equity (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 6. Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/Stock-BasedCompensationDetails</Role>
      <ShortName>6. Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 6. Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/OptionAssumptionsDetails</Role>
      <ShortName>6. Option Assumptions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - 6. Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/OptionsOutstandingDetails</Role>
      <ShortName>6. Options Outstanding (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - 6. Stock-Based Compensation (Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/Stock-BasedCompensationNarrative</Role>
      <ShortName>6. Stock-Based Compensation (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - 8. Segment and Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SegmentAndGeographicInformationDetails</Role>
      <ShortName>8. Segment and Geographic Information (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - 8. Segment and Geographic Information (Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SegmentAndGeographicInformationNarrative</Role>
      <ShortName>8. Segment and Geographic Information (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 9. Significant Customer Concentrations (Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oculus.com/role/SignificantCustomerConcentrationsNarrative</Role>
      <ShortName>9. Significant Customer Concentrations (Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 00000002 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>ocls-20130930.xml</File>
    <File>ocls-20130930.xsd</File>
    <File>ocls-20130930_cal.xml</File>
    <File>ocls-20130930_def.xml</File>
    <File>ocls-20130930_lab.xml</File>
    <File>ocls-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_DebtDiscountCurrentPortionOfLongtermDebt', window );">Debt discount, current portion of long-term debt</a></td>
        <td class="nump">$ 430<span></span></td>
        <td class="nump">$ 521<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_DebtDiscountLongtermPortionOfLongtermDebt', window );">Debt discount, long-term portion of long-term debt</a></td>
        <td class="nump">$ 45<span></span></td>
        <td class="nump">$ 248<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock par value (in Dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
        <td class="nump">$ 0.0001<span></span></td>
        <td class="nump">$ 0.0001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
        <td class="nump">14,285,715<span></span></td>
        <td class="nump">14,285,715<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
        <td class="nump">6,633,694<span></span></td>
        <td class="nump">6,583,150<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
        <td class="nump">6,633,694<span></span></td>
        <td class="nump">6,583,150<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_DebtDiscountCurrentPortionOfLongtermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt discount, current portion of long-term debt</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_DebtDiscountCurrentPortionOfLongtermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_DebtDiscountLongtermPortionOfLongtermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt discount long term portion of long term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_DebtDiscountLongtermPortionOfLongtermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>9. Significant Customer Concentrations<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">9. Significant Customer Concentrations</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September
30, 2013, one customer represented 33% of net revenue and one customer represented 32% of net revenue. For the three months ended
September 30, 2012, one customer represented 27% of net revenue.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ended September 30,
2013, one customer represented 37% of net revenue and one customer represented 27% of net revenue. For the six months ended September
30, 2012, one customer represented 28% of net revenue.&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2013, one customer represented
33%, one customer represented 30%, and one customer represented 11% of the net accounts receivable balance. At March 31, 2013,
one customer represented 34%, one customer represented 26%, and one customer represented 15% of the net accounts receivable balance.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RisksAndUncertaintiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELSAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (3,111)<span></span></td>
        <td class="num">$ (1,074)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">136<span></span></td>
        <td class="nump">136<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">666<span></span></td>
        <td class="nump">941<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(850)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_GainLossDueToChangeInFairValueOfCommonStock', window );">Loss due to change in fair value of common stock (See Note 3)</a></td>
        <td class="nump">210<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
        <td class="nump">294<span></span></td>
        <td class="nump">303<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign currency transaction gains</a></td>
        <td class="num">(5)<span></span></td>
        <td class="nump">7<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
        <td class="num">(738)<span></span></td>
        <td class="num">(705)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
        <td class="nump">215<span></span></td>
        <td class="nump">70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">369<span></span></td>
        <td class="nump">84<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">225<span></span></td>
        <td class="num">(28)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
        <td class="nump">76<span></span></td>
        <td class="num">(71)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(791)<span></span></td>
        <td class="nump">4,479<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
        <td class="num">(2,454)<span></span></td>
        <td class="nump">3,292<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(338)<span></span></td>
        <td class="num">(62)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Long-term deposits</a></td>
        <td class="nump">26<span></span></td>
        <td class="num">(143)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(312)<span></span></td>
        <td class="num">(205)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,925<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of convertible preferred stock, net of offering costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">907<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the exercise of common stock options and warrants</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_DeferredOfferingCosts1', window );">Deferred offering costs</a></td>
        <td class="num">(780)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
        <td class="num">(1,138)<span></span></td>
        <td class="num">(974)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
        <td class="num">(1,918)<span></span></td>
        <td class="nump">1,874<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
        <td class="num">(26)<span></span></td>
        <td class="num">(2)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase cash and cash equivalents</a></td>
        <td class="num">(4,710)<span></span></td>
        <td class="nump">4,959<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">7,900<span></span></td>
        <td class="nump">3,351<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">3,190<span></span></td>
        <td class="nump">8,310<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">143<span></span></td>
        <td class="nump">265<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash operating and financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering', window );">Warrants issued as derivative liabilities in connection with registered direct offering</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 2,347<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_DeferredOfferingCosts1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred offering costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_DeferredOfferingCosts1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_GainLossDueToChangeInFairValueOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) due to change in fair value of common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_GainLossDueToChangeInFairValueOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued as derivative liabilities in connection with registered direct offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_WarrantsIssuedAsDerivativeLiabilitiesInConnectionWithRegisteredDirectOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6477933&amp;loc=d3e60009-112784<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeposits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 3,190<span></span></td>
        <td class="nump">$ 7,900<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
        <td class="nump">2,424<span></span></td>
        <td class="nump">1,707<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
        <td class="nump">749<span></span></td>
        <td class="nump">992<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">549<span></span></td>
        <td class="nump">935<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">6,912<span></span></td>
        <td class="nump">11,534<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">987<span></span></td>
        <td class="nump">800<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
        <td class="nump">824<span></span></td>
        <td class="nump">44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">159<span></span></td>
        <td class="nump">187<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">8,882<span></span></td>
        <td class="nump">12,565<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,027<span></span></td>
        <td class="nump">808<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">699<span></span></td>
        <td class="nump">703<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_CashSettlementLiabilityCurrent', window );">Current portion of cash settlement liability (See Note 3)</a></td>
        <td class="nump">116<span></span></td>
        <td class="nump">37<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">2,322<span></span></td>
        <td class="nump">2,320<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of debt discount of $430 (unaudited) and $521 at September 30, 2013 and March 31, 2013, respectively</a></td>
        <td class="nump">573<span></span></td>
        <td class="nump">1,259<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">4,737<span></span></td>
        <td class="nump">5,127<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
        <td class="nump">1,883<span></span></td>
        <td class="nump">2,619<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of debt discount of $45 (unaudited) and $248 at September 30, 2013 and March 31, 2013, respectively, less current portion</a></td>
        <td class="nump">519<span></span></td>
        <td class="nump">676<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_CashSettlementLiabilityNoncurrent', window );">Cash settlement liability, less current portion (See Note 3)</a></td>
        <td class="nump">193<span></span></td>
        <td class="nump">62<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">7,332<span></span></td>
        <td class="nump">8,484<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized, none issued and outstanding at September 30, 2013 (unaudited) and March 31, 2013, respectively</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 14,285,715 shares authorized, 6,633,694 and 6,583,150 shares issued and outstanding at September 30, 2013 (unaudited) and March 31, 2013, respectively</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">145,482<span></span></td>
        <td class="nump">144,816<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num">(3,077)<span></span></td>
        <td class="num">(2,991)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(140,856)<span></span></td>
        <td class="num">(137,745)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">1,550<span></span></td>
        <td class="nump">4,081<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 8,882<span></span></td>
        <td class="nump">$ 12,565<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_CashSettlementLiabilityCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash settlement liability, current portion</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_CashSettlementLiabilityCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_CashSettlementLiabilityNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash settlement liability, noncurrent portion</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_CashSettlementLiabilityNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of liabilities incurred and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndOtherAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredOfferingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. Option Assumptions (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
        <td class="text">5 years 10 months 20 days<span></span></td>
        <td class="text">5 years 10 months 6 days<span></span></td>
        <td class="text">5 years 10 months 20 days<span></span></td>
        <td class="text">5 years 10 months 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.42%<span></span></td>
        <td class="nump">0.73%<span></span></td>
        <td class="nump">1.42%<span></span></td>
        <td class="nump">0.73%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">86.00%<span></span></td>
        <td class="nump">88.00%<span></span></td>
        <td class="nump">86.00%<span></span></td>
        <td class="nump">88.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of options granted</a></td>
        <td class="nump">$ 2.10<span></span></td>
        <td class="nump">$ 4.76<span></span></td>
        <td class="nump">$ 2.10<span></span></td>
        <td class="nump">$ 4.76<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4G">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>2. Liquidity and Financial Condition (Narrative) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_LiquidityAndFinancialConditionAbstract', window );"><strong>Liquidity And Financial Condition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_WorkingCapital', window );">Working capital</a></td>
        <td class="nump">$ 2,175<span></span></td>
        <td class="nump">$ 6,407<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_LiquidityAndFinancialConditionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_LiquidityAndFinancialConditionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_WorkingCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Working capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_WorkingCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>8. Segment and Geographic Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">8. Segment and Geographic Information</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates revenues from tissue
care products which are sold into the human and animal healthcare markets and the Company also generates revenues from laboratory
testing services which are provided to medical device manufacturers. The Company operates a single segment business for product
sales which consists of three geographical sales territories as follows:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three&#160;Months</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six&#160;Months</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September&#160;30,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September&#160;30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">U.S.</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,898,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,898,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,221,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,931,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Mexico</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,352,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,862,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,776,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,240,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Europe and Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">603,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">504,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,010,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">909,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,853,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4,264,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7,007,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8,080,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September
30, 2013 and 2012, the Company received licensing revenues of $397,000 and $374,000, respectively. Such revenues are included in
the Company&#146;s calculation of product revenues and are reflected in the table above under the respective geographic region
where such licensing revenues were earned. For the six months ended September 30, 2013 and 2012, the Company received licensing
revenues of $830,000 and $406,000, respectively. Such revenues are included in the Company&#146;s calculation of product revenues
and are reflected in the table above under the respective geographic region where such licensing revenues were earned.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s service revenues
amounted to $236,000 and $262,000 for the three months ended September 30, 2013 and 2012, respectively, and the Company&#146;s
service revenues amounted to $454,000 and $497,000 for the six months ended September 30, 2012 and 2011, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. Options Outstanding (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_StockOptionsAbstract', window );"><strong>Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
        <td class="nump">975,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump">335,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired</a></td>
        <td class="num">(81,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
        <td class="nump">1,229,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period</a></td>
        <td class="nump">816,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for grant, ending</a></td>
        <td class="nump">848,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
        <td class="nump">$ 15.08<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 2.95<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired</a></td>
        <td class="nump">$ 15.86<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
        <td class="nump">$ 11.72<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period</a></td>
        <td class="nump">$ 15.32<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
        <td class="text">7 years 5 months 1 day<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
        <td class="text">6 years 4 months 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_AggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_AggregateIntrinsicValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_StockOptionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_StockOptionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>1. Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_OrganizationTextBlock', window );">Organization</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Organization</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Oculus Innovative Sciences, Inc. (the
&#147;Company&#148;) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the
laws of the State of Delaware in December 2006. The Company&#146;s principal office is located in Petaluma, California. The Company
is a global healthcare company that designs, produces, and markets prescription and non-prescription products in 27 countries.
It is pioneering innovative products for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets.
The Company&#146;s primary focus is on its proprietary technology platform called Microcyn&#174; Technology. This technology is
based on electrically charged oxychlorine small molecules designed to target a wide range of organisms that cause disease (pathogens).
Several Microcyn&#174; Technology tissue care products are designed to treat infections and enhance healing while reducing the need
for antibiotics.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_ReverseStockSplitTextBlock', window );">Reverse Stock Split</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective as of the open of business
on April 1, 2013, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every 7 shares of
common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the
reverse stock split. Instead, each resulting fractional share of common stock was rounded up to one whole share. The reverse stock
split reduced the number of shares of the Company&#146;s common stock outstanding from 46,080,513 to 6,583,150. The total number
of authorized shares of common stock was also proportionally decreased by a ratio of 1:7 and the par value per share of the common
stock continued to be $0.0001.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All common shares and per share amounts
contained in the condensed consolidated financial statements have been retroactively adjusted to reflect a 1 for 7 reverse stock
split, effective April 1, 2013.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_BasisOfPresentationPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-size: 8pt"><b><i>Basis of Presentation</i></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">The accompanying
unaudited condensed consolidated financial statements as of September 30, 2013 and for the three and six months then ended have
been prepared in accordance with the accounting principles generally accepted in the United States of America for interim financial
information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission
(&#147;SEC&#148;) and on the same basis as the Company prepares its annual audited consolidated financial statements. The unaudited
condensed consolidated balance sheet as of September 30, 2013, the condensed consolidated statements of comprehensive loss for
the three and six months ended September 30, 2013 and 2012, and the condensed consolidated statements of cash flows for the six
months ended September 30, 2013 and 2012 are unaudited, but include all adjustments, consisting only of normal recurring adjustments,
which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for
the periods presented. The results for the three and six months ended September 30, 2013 are not necessarily indicative of results
to be expected for the year ending March 31, 2014 or for any future interim period. The condensed consolidated balance sheet at
March 31, 2013 has been derived from audited consolidated financial statements. However, it does not include all of the information
and notes required by accounting principles generally accepted in the United States of America for complete consolidated financial
statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements for the year ended March 31, 2013, and notes thereto included in the Company&#146;s annual report on Form 10-K, which
was filed with the SEC on June 25, 2013.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries, Aquamed Technologies, Inc. (&#147;Aquamed&#148;),
Oculus Technologies of Mexico S.A. de C.V. and Oculus Innovative Sciences Netherlands, B.V. and Ruthigen, Inc. (&#147;Ruthigen&#148;).
All significant intercompany accounts and transactions have been eliminated in consolidation. Aquamed has no current operations.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Use of Estimates</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed consolidated
financial statements in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities
at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs
related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company&#146;s
deferred taxes,&#160;the valuation of equity and derivative instruments, and debt discounts and the estimated amortization periods
of upfront licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly. The allowance
for uncollectible accounts receivable balances amounted to $9,000 and $22,000, which are included in accounts receivable, net in
the accompanying September 30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively. The reserve for excess
and obsolete inventory balances amounted to $76,000 and $170,000, which are included in inventories, net in the accompanying September
30, 2013 and March 31, 2013 condensed consolidated balance sheets, respectively.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassifications</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Reclassifications</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been
reclassified for comparative purposes to conform to the fiscal 2014 presentation. These reclassifications have no impact on the
Company&#146;s previously reported net loss.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss per Share</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per
share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding
for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would
include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock
using the &#147;treasury stock&#148; and/or &#147;if converted&#148; methods as applicable. The computation of basic net loss
per share for the three and six months ended September 30, 2013 and 2012 (adjusted if applicable for the reverse stock split effective
April 1, 2013) excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; padding-left: 9pt; text-indent: -9pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options to purchase common stock</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,229</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">988</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Warrants to purchase common stock</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,318</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,529</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,547</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,517</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Common Stock Purchase Warrants and Other Derivative Financial Instruments</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Common Stock Purchase Warrants and Other Derivative
Financial Instruments</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies common stock purchase
warrants and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or
net-share settlement, or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement
or net-share settlement). The Company classifies any contracts that (i) require net-cash settlement (including a requirement to
net cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty
a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions
as either an asset or a liability. The Company assesses classification of its freestanding derivatives at each reporting date to
determine whether a change in classification between assets and liabilities is required. The Company determined that its freestanding
derivatives, which principally consist of warrants to purchase common stock, satisfied the criteria for classification as equity
instruments at September 30, 2013, other than certain warrants that contain reset provisions and certain warrants that require
net-cash settlement that the Company classified as derivative liabilities.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fair Value of Financial Assets
and Liabilities</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including cash
and cash equivalents, accounts receivable, inventory, accounts payable and accrued liabilities are carried at cost, which management
believes approximates fair value due to the short-term nature of these instruments. The fair value of capital lease obligations
and equipment loans approximates their carrying amounts as a market rate of interest is attached to their repayment. The Company
measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or
paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes
the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair
value:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&#160;1&#160;&#151; quoted
prices in active markets for identical assets or liabilities</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&#160;2&#160;&#151; quoted
prices for similar assets and liabilities in active markets or inputs that are observable</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level&#160;3&#160;&#151; inputs
that are unobservable (for example, cash flow modeling inputs based on assumptions)</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Financial liabilities measured at fair value on a recurring
basis are summarized below:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 liabilities are valued using
unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities.
For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company&#146;s accounting and finance
department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination
of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company&#146;s
accounting and finance department and are approved by the Chief Financial Officer.&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr>
    <td style="width: 100%">&#160;</td></tr>
<tr>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Level 3 Valuation Techniques</u>:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 financial liabilities consist
of the derivative liabilities for which there is no current market for these securities such that the determination of fair value
requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy
are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option
valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates
transaction details such as the Company&#146;s stock price, contractual terms, maturity, risk free rates, as well as volatility.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A significant decrease in the volatility
or a significant decrease in the Company&#146;s stock price, in isolation, would result in a significantly lower fair value measurement.
Changes in the values of the derivative liabilities are recorded in &#147;(Loss) gain due to change in fair value of derivative
instruments&#148; in the Company&#146;s condensed consolidated statements of comprehensive loss.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2013, there were
no transfers in or out of Level 3 from other levels in the fair value hierarchy.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Subsequent Events</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events
or transactions occurring through the date the condensed consolidated financial statements were issued (Note 10).</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt"><b><i>Recent
Accounting Pronouncements</i></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">In June 2011,
the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. 2011-05,
<i>Comprehensive Income (Topic 220): Presentation of Comprehensive Income</i>. This guidance improves the comparability, consistency
and transparency of financial reporting and increases the prominence of items reported in other comprehensive income.&#160; In
December 2011, the FASB issued ASU No. 2011-12, <i>Deferral of the Effective Date for Amendments to the Presentation of Reclassifications
of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05</i>. ASU 2011-12 defers the requirement that companies present
reclassification adjustments for each component of Accumulated Other Comprehensive Income in both net income and Other Comprehensive
Income on the face of the financial statements. All other requirements in ASU No. 2011-05 are not affected by ASU No. 2011-12,
including the requirement to report comprehensive income either in a single continuous financial statement or in two separate
but consecutive financial statements.&#160; While the adoption of this standard required the Company to change the format of its
condensed consolidated financial statements, it did not have a material impact on the Company&#146;s consolidated financial position
and results of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 8pt">The FASB
has issued ASU No. 2013-11, <i>Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss
Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</i> (a consensus of the FASB Emerging Issues Task Force).
The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented
in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss,
or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax
credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional
income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not
require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax
benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The
amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after <font style="color: black">December
15, 2013</font>. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years,
beginning after <font style="color: black">December 15, 2014</font>. Early adoption is permitted. The amendments should be applied
prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption
of this standard is not expected to have a material impact on the Company&#146;s condensed consolidated financial position and
results of operations.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">Accounting standards
that have been issued or proposed by the FASB, SEC and/or other standards-setting bodies that do not require adoption until a
future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_BasisOfPresentationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Basis of presentation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_BasisOfPresentationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_OrganizationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Organization text block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_OrganizationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_ReverseStockSplitTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reverse Stock Split</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_ReverseStockSplitTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -URI http://asc.fasb.org/section&amp;trid=2229173<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(7))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesReportingOfDerivativeActivity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Reclassifications</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>7. Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">7. Income Taxes</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company completed a study during
the year ended March 31, 2013 to assess whether a change in control had occurred or whether there have been multiple changes of
control since the Company&#146;s formation.&#160; The Company determined, based on the results of the study, no change in control
occurred for purposes of Internal Revenue Code section 382. &#160;In addition, the Company is not aware of any changes in ownership
during the six months ended September 30, 2013 that would result in a change in control under Internal Revenue Code section 382.&#160;
The Company, after considering all available evidence, fully reserved against its deferred tax assets since it is more likely than
not that such benefits will not be realized in future periods. The Company incurred losses for both financial reporting and income
tax purposes for the six months ended September 30, 2013. Accordingly, the Company is continuing to fully reserve for its deferred
tax assets. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could
affect the realization of their future benefit. If it is determined in future periods that portions of the Company&#146;s deferred
income tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of certain realization requirements
of Accounting Standards Codification Topic 718, the Company&#146;s deferred tax assets and liabilities do not include certain
deferred tax assets at September 30, 2013 that arose directly from tax deductions related to equity compensation in excess of compensation
recognized for financial reporting purposes.&#160;&#160;Equity will be increased by approximately $533,000 if and when such deferred
tax assets are ultimately realized.&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>2. Liquidity and Financial Condition<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_LiquidityAndFinancialConditionAbstract', window );"><strong>Liquidity And Financial Condition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">2. Liquidity and Financial Condition</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">The Company reported
a net loss of $3,111,000 for the six months ended September 30, 2013. At September 30, 2013 and March 31, 2013, the Company&#146;s
accumulated deficit amounted to $140,856,000 and $137,745,000, respectively. The Company had working capital of $2,175,000 and
$6,407,000 as of September 30, 2013 and March 31, 2013, respectively. The Company expects the need to raise additional capital
from external sources in order to continue the longer term efforts contemplated under its business plan and repay its outstanding
notes payable obligations. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional
capital to pursue its product development initiatives, penetrate markets for the sale of its products and continue as a going
concern. Upon the closing of the intended initial public offering by the Company&#146;s subsidiary, Ruthigen, Inc., the Company
will be repaid for certain costs incurred and advanced related to Ruthigen&#146;s initial public offering and certain other agreed-upon
expenses, pursuant to the terms of the separation agreement the Company entered into with Ruthigen (See Note 4). At September
30, 2013, these costs amounted to $911,000, of which $824,000 is reported as deferred offering costs in the accompanying condensed
consolidated balance sheet and $87,000 was reported as selling, general and administrative expense.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">The Company currently
anticipates that its cash and cash equivalents will be sufficient to meet its working capital requirements to continue its sales
and marketing and research and development efforts through at least October 1, 2014. However, in order to execute the Company&#146;s
long-term Microcyn&#174; product development strategy and to penetrate new and existing markets, the Company may need to raise
additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially
reduce operating expenditures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-size: 8pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 8pt">Management believes
that the Company has access to capital resources through possible public or private equity offerings, debt financings, corporate
collaborations or other means; however, the Company has not secured any commitment for new financing at this time, nor can it
provide any assurance that the Ruthigen initial public offering will be completed or that other new financings will be available
on commercially acceptable terms, if needed. If the Company is unable to secure additional capital, it may be required to curtail
its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_LiquidityAndFinancialConditionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_LiquidityAndFinancialConditionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>8. Segment and Geographic Information (Narrative) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenues</a></td>
        <td class="nump">$ 236<span></span></td>
        <td class="nump">$ 262<span></span></td>
        <td class="nump">$ 454<span></span></td>
        <td class="nump">$ 497<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Product licensing revenues</a></td>
        <td class="nump">$ 397<span></span></td>
        <td class="nump">$ 374<span></span></td>
        <td class="nump">$ 830<span></span></td>
        <td class="nump">$ 406<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueServicesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>6. Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Employee stock-based compensation expense</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three&#160;Months</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six Months</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September 30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Cost of service revenue</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">30</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">34</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">56</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">66</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">45</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">63</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">78</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">130</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Selling, general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">221</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">275</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">349</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">484</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Total stock-based compensation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">296</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">372</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">483</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">680</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Weighted-average assumptions of fair value of employee stock options</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Three&#160;Months</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Ended</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>September 30,</b></p></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Six Months</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>Ended</b></p>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 5.8pt 0 0; text-align: center"><b>September 30,</b></p></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 0.8pt; padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 1.8pt; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Expected life</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.89 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.85 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.89 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">5.85 years</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: bottom; width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1.42%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.73%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1.42%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 13%; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.73%</font></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Volatility</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">86%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">88%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">86%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">88%</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Fair value of options granted</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2.10</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2.10</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4.76</font></td>
    <td style="vertical-align: top; padding-right: 0.8pt; line-height: 115%">&#160;</td></tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Summary of option activity</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number&#160;of</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Shares </b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Average</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Exercise&#160;Price</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Average</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Contractual&#160; </b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Term</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Aggregate</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Intrinsic</b></font><br />
<font style="font: 8pt Times New Roman, Times, Serif"><b>Value</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at March&#160;31, 2013</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">975</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">15.08</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: right; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">335</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2.95</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options forfeited or expired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">(81</font></td>
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">15.86</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding at September&#160;30, 2013</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,229</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">11.72</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7.42</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable at September&#160;30, 2013</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">816</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">15.32</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">6.35</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">&#150;</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Options available for grant as of September&#160;30, 2013</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">848</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e1928-114920<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the changes in other outstanding share-based compensation awards other than stock options or nonvested awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>10. Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">10. Subsequent Events</a></td>
        <td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock Issued to Non-Employee
For Services</i></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 2, 2013, the Company issued
11,070 shares of common stock, with a value of $30,000, to Windsor Corporation in consideration for services provided during the
three months ended September 30, 2013. The Company registered the issuance under its previously filed and currently effective shelf
registration statement on Form S-3 (File No. 333-171411) and the related prospectus supplement dated and filed on October 2, 2013.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><i>Amendments No. 1 and No. 2 to the License and Supply Agreement
with Ruthigen, Inc.</i></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 9, 2013, the Company
entered into Amendment No. 1 to the License and Supply Agreement with the Company&#146;s wholly owned subsidiary, Ruthigen,
Inc. Pursuant to the terms of the License and Supply Agreement, Ruthigen is required to make milestone payments to the
Company upon certain milestone events. Amendment No. 1 amended the second milestone event set forth in Section 7.1 of
the License and Supply Agreement. On November 6, 2013, the Company entered into Amendment No. 2 to the License and
Supply Agreement with Ruthigen to further amend the certain milestone events set forth in Section 7.1 of the License and
Supply Agreement and to amend the terms of the manufacturing equipment purchases set forth in Section 6.13 of the License and
Supply Agreement. Pursuant to the terms of Amendment No. 2, Ruthigen will be required to make a total of $5,000,000 in
milestone payments to the Company for the first product only, as follows: upon completion of Ruthigen&#146;s first meeting
with the U.S. Food and Drug Administration (FDA) following completion of Ruthigen&#146;s first pivotal clinical trial and
upon first patient enrollment in Ruthigen&#146;s second pivotal clinical trial. Ruthigen also agreed to purchase certain
research and development and manufacturing equipment from the Company for approximately $3 million following the completion
of Ruthigen&#146;s intended initial public offering. All other terms and conditions of the License and Supply Agreement
remain unmodified and in full force and effect.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>1. Organization and Summary of Significant Accounting Policies (Narrative) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for uncollectible accounts receivable</a></td>
        <td class="nump">$ 9<span></span></td>
        <td class="nump">$ 22<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for excess and obsolete inventory</a></td>
        <td class="nump">$ 76<span></span></td>
        <td class="nump">$ 170<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of valuation reserve for inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SX 210.12-09)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryValuationReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>8. Segment and Geographic Information (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Segment and Geographic Information</a></td>
        <td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three&#160;Months</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Six&#160;Months</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Ended</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September&#160;30,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>September&#160;30,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2012</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 36%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">U.S.</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,898,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,898,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,221,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,931,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Mexico</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,352,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,862,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">2,776,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,240,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">Europe and Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">603,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">504,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">1,010,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">909,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">3,853,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">4,264,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">7,007,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 8pt Times New Roman, Times, Serif">8,080,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8721-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8813-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 22<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8736-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 15, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocls_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Oculus Innovative Sciences, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001367083<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--03-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,644,764<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocls_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ocls_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ocls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>1. Potentially Dilutive Securites Table (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total securities excluded from computation of basic net loss per share</a></td>
        <td class="nump">2,547,000<span></span></td>
        <td class="nump">2,517,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total securities excluded from computation of basic net loss per share</a></td>
        <td class="nump">1,229,000<span></span></td>
        <td class="nump">988,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total securities excluded from computation of basic net loss per share</a></td>
        <td class="nump">1,318,000<span></span></td>
        <td class="nump">1,529,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
